2.7.4.8 付録

2.7.4 Summary of Clinical Safety

9. APPENDIX

9.1. Study Designs of Healthy Volunteer Studies

Table 66: Designs of Healthy Volunteer Studies Included in the Summary of Safety

Study Type Study Number	Study Design
Food Effect	
201-FG-PK-02/02	A randomized, open-label, 2–period crossover study to investigate the effects of a standard breakfast on the PK of BG00012 in 12 healthy male volunteers who received BG00012 240 mg while fasting or with food (low-fat diet).
C-1903	A randomized, single-center, 2–period crossover study to investigate possible food effects on the PK and safety of BG00012 in 36 healthy male and female volunteers who received BG00012 240 mg while fasting or with food (high-fat diet); each treatment period was 2 days.
Dose-Ascending	
201-FG-PK-03/04	A randomized, open-label, 2-period, dose-ascending study to investigate the effect of multiple oral dosing on the PK of BG00012 in 18 healthy male volunteers, who received BG00012 120 mg TID for 2 days followed by a 7-day washout period and treatment with BG00012 240 mg TID for 2 days.
IKP/ID32	A randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of increasing multiple doses of BG00012 in healthy male volunteers. This study was planned to include total doses of 720, 1080, or 1440 mg over a 6-day period. However, after dosing with BG00012 120 mg QD for 6 days (total dose of 720 mg), subjects experienced AEs of flushing and pruritus that increased in severity and the study was discontinued after the first cohort was completed (8 subjects, including 2 placebo and 6 BG00012).
IKP/ID33	A randomized, open-label, crossover, dose-ascending study to investigate the PK and safety of single ascending oral doses of BG00012 (120, 240, 360, and 480 mg, with 1-week washout periods between administrations) in healthy male volunteers. Dose escalation was halted at 360 mg due to flushing, and no subject received the 480 mg dose (study treatment was administered to 2 subjects during the prestudy and to 13 subjects during the main study with ascending doses).
Thorough QTc	
109HV101	A single-center, randomized, blinded, placebo- and active-controlled (moxifloxacin 400 mg), 4-way crossover study to evaluate the effect of BG00012 on the QTc interval and safety following a single dose of 240 or 360 mg administered to 54 healthy male and female volunteers.
Absorption, Metabolism, and Excretion	
109HV102	A single-center, open-label study designed to characterize the absorption, metabolism, excretion, and safety of a single dose of ^{14}C-BG00012 240 mg in 8 healthy male volunteers.

2.7.4 Summary of Clinical Safety

Study Type **Study Number**	**Study Design**
Effect of Co-Medications	
109HV103	A Phase 1, single-center, open-label, randomized, 2-period, crossover study to investigate the potential impact of drug interactions of BG00012 with Avonex in 26 healthy volunteers; BG00012 240 mg TID for 3 days as monotherapy was compared with a combination of BG00012 240 mg TID for 3 days and a single dose of Avonex.
109HV104	A Phase 1, single-center, open-label, randomized, 2-period, crossover study to investigate the potential impact of drug interactions of BG00012 with GA in 26 healthy volunteers; BG00012 240 mg TID for 2 days as monotherapy was compared with a combination of BG00012 240 mg TID for 2 days and a single dose of GA.
Formulation Comparison	
109HV105	An open-label, single-center, 2-period crossover, 2-formulation pharmacokinetic profile study to determine the pharmacokinetic profiles of the standard formulation of BG00012 and the active pharmaceutical ingredient formulation in 14 healthy male volunteers after a 240 mg oral dose of BG00012.
Acetylsalicylic Acid Mitigation of Flushing	
109HV106	A randomized, double-blind, placebo-controlled study of the safety, tolerability, and PK of repeated doses of BG00012 (total daily doses ranging from 480 to 720 mg) administered with and without 325 mg acetylsalicylic acid (also known as aspirin) in 56 healthy volunteers (6 placebo and 48 BG00012).
Bioequivalence	
109HV107	An open-label, single-center, 2-period crossover, pharmacokinetic profile study to demonstrate the bioequivalence of BG00012 240 mg given as a single 240 mg capsule and given as two 120 mg capsules in 81 healthy volunteers.
Oral Contraceptives	
109HV113	A randomized, two-way crossover with a lead-in period drug-drug interaction study to assess the effect of BG00012 on the pharmacokinetics (PK of norelgestromin and ethinyl estradiol) of Ortho Cyclen® given once daily in 46 healthy female subjects.

AE = adverse event; GA = glatiramer acetate; PK = pharmacokinetics; QD = once a day; QTc = corrected QT; TID = 3 times a day

2.7.4 Summary of Clinical Safety

9.2. Investigator's Assessment of the Severity of Adverse Events

Table 67: Severity of Adverse Events Classification - BG00012 MS

MS Studies	
Severity Grade	**Definition**
Mild	Symptoms(s) barely noticeable to subject or does not make subject uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for relief of symptom(s) but may be given because of personality of subject.
Moderate	Symptom(s) of a sufficient severity to make subject uncomfortable; performance of daily activity is influenced; subject is able to continue in study; treatment for symptom(s) may be needed.
Severe	Symptom(s) cause severe discomfort; symptoms cause incapacitation or significant impact on subject's daily life; severity may cause cessation of treatment with the study treatment; treatment for symptom(s) may be given and/or subject hospitalized.
Extreme	Not applicable.

MS = multiple sclerosis.

2.7.4 Summary of Clinical Safety

9.3. Assessment of an Adverse Event's Relationship to Study Treatment

Table 68: Relationship of Adverse Events to Investigational Drug Classification - BG00012 MS Studies

MS Studies	
Relationship to Study Treatment	**Definition**
Not related (C-1900); Unrelated (301, 302, 303)	Any event that does not follow a reasonable temporal sequence from administration of investigational drug AND that is likely to have been produced by the subject's clinical state or other modes of therapy administered to the subject
Unlikely	Any event that does not follow a reasonable temporal sequence from administration of study treatment *OR* that is likely to have been produced by the subject's clinical state or other modes of therapy administered to the subject.
Likely (C-1900); Possibly (301, 302, 303)	Any reaction that follows a reasonable temporal sequence from administration of study treatment *OR* that follows a known response pattern to the suspected drug *AND* that could not be reasonably explained by the known characteristics of the subject's clinical state or other modes of therapy administered to the subject.
Definitely (C-1900); Related (301, 302, 303)	Any reaction that follows a reasonable temporal sequence from administration of study treatment *AND* that follows a known response pattern to the suspected drug *AND* that recurs with re-challenge, *AND/OR* is improved by stopping the drug or reducing the dose.

MS = multiple sclerosis.

9.4 Criteria Used to Determine Potentially Clinically Significant Hematology Values

Table 69: NCI-CTC Grade Definitions and Criteria Used to Determine Potentially Clinically Significant Hematology Values - BG00012 MS Studies

Parameter	CTC Grade[a]	Potentially Clinically Significant Criteria
WBC	Grade 1: <LLN - 3.0 × 10^9/L Grade 2: <3.0 - 2.0 × 10^9/L Grade 3: <2.0 - 1.0 × 10^9/L Grade 4: <1.0 × 10^9/L	<3.0 × 10^9/L ≥16 × 10^9/L
Lymphocyte	Grade 1: <LLN - 0.8 × 10^9/L Grade 2: <0.8 - 0.5 × 10^9/L Grade 3: <0.5 - 0.2 × 10^9/L Grade 4: <0.2 × 10^9/L	<0.8 × 10^9/L <0.5 × 10^9/L >12 × 10^9/L
Neutrophils	Grade 1: <LLN - 1.5 × 10^9/L Grade 2: <1.5 - 1.0 × 10^9/L Grade 3: <1.0 - 0.5 × 10^9/L Grade 4: <0.5 × 10^9/L	≤1.0 × 10^9/L <1.5 × 10^9/L ≥12 × 10^9/L
RBC	NA	≤3.3 × 10^{12}/L ≥6.8 × 10^{12}/L
Hemoglobin	Not used in analysis	≤100 g/L
Platelets	Not used in analysis	≤100 × 10^9/L ≥600 × 10^9/L

a CTC version 4.0 (published May 2009)

CTC = Common Toxicity Criteria; LLN = lower limit of normal; MS = multiple sclerosis; NA = not applicable; NCI = National Cancer Institute; RBC = red blood cells; WBC = white blood cells

9.5. Analysis of Adverse Events of Special Interest: Definitions of terms

特に注目すべき有害事象の分析

以下の特に注目すべき有害事象の分析を実施した：

- 潮紅及びその関連症状
- 消化管忍容性事象
- 感染（日和見感染の疑いを含む）
- 心臓血管障害
- 肝障害と関連している可能性のある事象
- 腎障害
- 悪性疾患の可能性のある事象
- 悪性疾患

2.7.4 Summary of Clinical Safety

独立行政法人 医薬品医療機器総合機構より追加された特に注目すべき有害事象：

- 網膜変性
- 脳組織
- 膵臓組織
- 眼障害
- 皮膚組織

上記の特に注目すべき事象は、MedDRA 標準検索式（SMQ）、器官別大分類（SOC）、高位グループ語（HLGT）、高位語（HLT）、及び／又は該当する場合、基本語（PT）に基づき定義した。

以下の表に特に注目すべき有害事象の定義を示す。

潮紅及びその他の関連症状	
潮紅：	
定義レベル	**詳細**
PT	潮紅（SOC：血管障害の下層語）
PT	ほてり（SOC：血管障害の下層語）
その他の関連症状：	
定義レベル	**詳細**
PT	紅斑（SOC：皮膚および皮下組織障害の下層語）
PT	全身紅斑（SOC：皮膚および皮下組織障害の下層語）
PT	灼熱感（SOC：神経系障害の下層語）
PT	皮膚灼熱感（SOC：皮膚および皮下組織障害の下層語）
PT	熱感（SOC：一般・全身障害および投与部位の状態の下層語）
PT	充血（SOC：血管障害の下層語）

消化管忍容性事象	
定義レベル	**詳細**
サブ SMQ（レベル 2）	消化管の非特異的炎症（SMQ レベル 1：消化管の非特異的炎症および機能障害）
サブ SMQ（レベル 2）	消化管の非特異的症状および処置（SMQ レベル 1：消化管の非特異的炎症および機能障害）
サブ SMQ（レベル 2）	消化管の非特異的機能障害（SMQ レベル 1：消化管の非特異的炎症および機能障害）
消化管の非特異的炎症（SMQ）［20000138］ 十二指腸瘢痕、十二指腸炎、びらん性十二指腸炎、びらん性食道炎、胃炎、びらん性胃炎、胃十二指腸炎、消化管びらん、胃腸粘膜剥脱、胃食道炎、出血性びらん性胃炎、食道炎、逆流性胃炎、逆流性食道炎、残胃炎、小腸血管浮腫、アレルギー性大腸炎、肛門の炎症、びらん性大腸炎、結腸内視鏡検査異常、憩室炎、超音波内視鏡検査異常、内視鏡検査異常、消化管内視鏡検査異常、大腸内視鏡検査異常、上部消化管内視鏡検査異常、軟性Ｓ状結腸鏡、萎縮性胃炎、胃腸の炎症、回腸炎、内因子抗体異常、内因子抗体陽性、空腸炎、食道刺激症状、化学物質性食道炎、食道鏡検査異常、慢性膵炎、ペプシノーゲン１減少、ペプシノーゲン１増加、肛門周囲炎、直腸炎、直腸結腸炎、直腸鏡検査異常、直腸Ｓ状結腸鏡検査異常、Ｓ状結腸炎、Ｓ状結腸鏡検査異常、胃スキャン異常、下部消化管Ｘ線造影異常	
消化管の非特異的症状および処置（SMQ）［20000140］ 腹部不快感、腹部膨満、腹痛、下腹部痛、上腹部痛、腹部症状、腹部圧痛、異常便、空気嚥下、肛門直腸不快感、便通不規則、便習慣変化、便秘、便意切迫、下痢、心窩部不快感、おくび、便量減少、便量増加、鼓腸、排便回数増加、消化器痛、胃腸音異常、胃腸毒性、排便回数減少、悪心、非心臓性胸痛、食道不快感、食道痛、嘔吐、制酸薬療法、止瀉薬による補助療法、制吐薬による補助療法、呼気臭、胸痛、嚥下障害、早期満腹、胃炎予防、胃腸障害治療、消化管刺激症状、胃食道逆流予防、グリコーゲンアカントーシス、血液量減少症、緩下薬による補助療法、吸収不良、粘液便、食道内ポリマー埋込み、悪性貧血、処置後便秘、処置後下痢、咳嗽後嘔吐、プロバイオティクス療法、処置による悪心、処置による嘔吐、下痢予防、悪心・嘔吐の予防、吐き戻し、レッチング、脂肪便、噴出性嘔吐	
消化管の非特異的機能障害（SMQ）［20000139］ 十二指腸胃逆流、消化不良、胃食道逆流性疾患、胃食道括約筋機能不全、噴門痙攣、腸憩室、排便障害、食道ジスキネジー、胃アトニー、胃拡張、胃排出検査、胃液検査異常、胃運動過剰、胃緊張亢進、胃運動低下、胃内ｐＨ低下、胃内ｐＨ上昇、消化管運動過剰、消化管運動障害、胃排出不全、腸管拡張症、ミオコーシス、食道アカラシア、食道拡張、食道運動低下、食道内圧測定、食道内ｐＨ上昇、膵酵素異常、膵機能不全、老人性食道、幽門拡張、中毒性腸拡張	

感染	
定義レベル	**詳細**
SOC	SOC 中の全ての PT：感染症および寄生虫症
注：以下の PT には日和見感染の疑いも含まれるが、それに限定されない： 抗酸性桿菌感染、放線菌症、放線菌性腹部感染、放線菌性肺感染、放線菌性皮膚感染、急性肺ヒストプラスマ症、副腎結核、アレシェリア症、アルテルナリア感染、真菌性関節炎、アスペルギルス症、非定型マイコバクテリア感染、非定型マイコバクテリア性リンパ節炎、非定型マイコバクテリウム性心膜炎、クリプトスポリジウム性胆道感染、真菌性胆道感染、ＢＫウイルス感染、ブラストミセス症、骨結核、ウシ結核、真菌性気管支炎、気管支肺アスペルギルス症、バークホルデリア・セパシア菌群感染、カンピロバクター性敗血症、カンジダ性眼内炎、カンジダ性骨髄炎、カンジダ性肺炎、カンジダ性網膜炎、カンジダ性敗血症、脳アスペルギルス症、脳真菌感染、脳トキソプラズマ症、コクシジオイデス性脳炎、コクシジオイデス症、ヘルペス性大腸炎、結核性結膜炎、クリプトコッカス性真菌血症、クリプトコッカス症、クリプトスポリジウム感染、皮膚コクシジオイデス症、皮膚結核、サイトメガロウイルス性脈絡網膜炎、サイトメガロウイルス性大腸炎、サイトメガロウイルス性十二指腸炎、サイトメガロウイルス性小腸炎、サイトメガロウイルス性腸炎、サイトメガロウイルス性胃炎、サイトメガロウイルス性胃腸炎、サイトメガロウイルス性消化管感染、サイトメガロウイルス肝炎、サイトメガロウイルス感染、サイトメガロウイルス性脊髄髄膜神経根炎、サイトメガロウイルス性心筋炎、サイトメガロウイルス性食道炎、サイトメガロウイルス性膵炎、サイトメガロウイルス性心膜炎、サイトメガロウイルス性直腸結腸炎、サイトメガロウイルス性尿路感染、サイトメガロウイルス血症、播種性クリプトコッカス症、播種性サイトメガロウイルス感染、播種性結核、耳結核、オーストラリア脳炎、カリフォルニア脳炎、サイトメガロウイルス性脳炎、東部ウマ脳炎、エンテロウイルス性脳炎、真菌性脳炎、ヘルペス脳炎、インフルエンザ脳炎、日本脳炎Ｂ型、髄膜炎菌性脳炎、ムンプス脳炎、原虫性脳炎、リケッチア性脳炎、ベネズエラウマ脳炎、ウイルス性脳炎、西部ウマ脳炎、風疹性脳脊髄炎、カンジダ性心内膜炎、腸球菌性心内膜炎、ヒストプラスマ性心内膜炎、ウイルス性心内膜炎、真菌性腸炎、ウイルス性腸炎、精巣上体結核、肺外結核、トキソプラズマ性眼感染、女性生殖器結核、真菌血症、中枢神経系真菌性膿瘍、真菌性心内膜炎、真菌性迷路炎、真菌性食道炎、真菌性腹膜炎、真菌性網膜炎、真菌性敗血症、真菌性気管炎、フサリウム感染、真菌性胃炎、ヘルペス性胃炎、クリプトコッカス胃腸炎、クリプトスポリジウム性胃腸炎、消化器カンジダ症、真菌性消化管感染、肝カンジダ症、真菌性肝感染、トキソプラズマ性肝炎、肝脾カンジダ症、ヘルペス性食道炎、ヘルペス性敗血症、単純ヘルペス肝炎、内臓単純ヘルペス、播種性帯状疱疹、神経合併症を伴う帯状疱疹感染、多神経分節性帯状疱疹、ヒストプラスマ症、播種性ヒストプラスマ症、ヒトポリオーマウイルス感染、ＪＣウイルス感染、関節結核、カポジ肉腫、真菌性喉頭炎、白質脳症、リステリア性脳炎、リステリア性敗血症、リステリア症、真菌性下気道感染、リンパ節結核、男性生殖器結核、カンジダ性髄膜炎、コクシジオイデス性髄膜炎、クリプトコッカス性髄膜炎、真菌性髄膜炎、ヘルペス性髄膜炎、ヒストプラスマ性髄膜炎、リステリア菌性髄膜炎、トキソプラズマ性髄膜炎、結核性髄膜炎、ヘルペス性髄膜脳炎、粟粒肺炎、ムコール症、マレー渓谷脳炎、マイコバクテリア感染、マイコバクテリウム・アプセスス感染、マイコバクテリウム・アビウムコンプレックス免疫再構築疾患、マイコバクテリウム・アビウムコンプレックス感染、'マイコバクテリウム・ケロネイ感染、マイコバクテリウム・フォルチュイツム感染、マイコバクテリウム・カンサシイ感染、マイコバクテリウム・カンサシイ肺炎、マイコバクテリウム・	

2.7.4 Summary of Clinical Safety

感染
マリヌム感染、マイコバクテリウム・ウルセランス感染、真菌性動脈瘤、真菌性心筋炎、トキソプラズマ性心筋炎、真菌性壊死性筋膜炎、壊死性ヘルペス性網膜症、神経クリプトコッカス症、ノカルジア性敗血症、ノカルジア症、食道カンジダ症、食道結核、日和見感染、ブラストミセス菌性骨髄炎、真菌性骨髄炎、真菌性膵炎、パラコクシジオイデス感染、ペニシリウム症、真菌性心膜炎、ヒストプラスマ性心膜炎、結核性心膜炎、腹膜カンジダ症、結核性腹膜炎、褐色糸状菌症、ニューモシスティスジロヴェシ感染、ニューモシスティスジロヴェシ肺炎、アデノウイルス性肺炎、ブラストミセス菌性肺炎、クリプトコッカス性肺炎、サイトメガロウイルス性肺炎、真菌性肺炎、ヘルペスウイルス肺炎、ＲＳウイルス肺炎、トキソプラズマ性肺炎、ポリオーマウイルス関連腎症、推定眼ヒストプラスマ症候群、真菌性直腸炎、ヘルペス性直腸炎、モニリア性直腸炎、進行性多巣性白質脳症、結核性前立腺炎、肺真菌症、肺トリコスポロン症、肺結核、真菌性腎盂腎炎、腎結核、ヒストプラスマ性網膜炎、ウイルス性網膜炎、ロシア春夏脳炎、結核性卵管炎、セドスポリウム感染、アスペルギルス性副鼻腔炎、真菌性副鼻腔炎、脾臓結核、脾カンジダ症、真菌性脾感染、セントルイス脳炎、糞線虫症、全身性カンジダ、全身性真菌症、甲状腺結核、トルロプシス感染、トキソプラズマ症、ハンセン病、類結核型、結核、膀胱結核、消化器結核、肝結核、中枢神経系結核、眼結核、泌尿生殖器結核、胸腔内リンパ節結核、末梢リンパ節結核、尿管結核、中枢神経系結核性膿瘍、結核性喉頭炎、結核性胸膜炎、結核性腱鞘炎、ウイルス性心筋炎、ウイルス性食道炎、ウイルス性心膜炎.

心血管障害	
定義レベル	**詳細**
SMQ（レベル 1）	虚血性心疾患（レベル 2 の SMQ 心筋梗塞及びその他の虚血性心疾患からなる）
サブ SMQ（レベル 3）	虚血性脳血管障害（レベル 1 の SMQ 脳血管障害、レベル 2 の SMQ 中枢神経系出血および脳血管性疾患）
CMQ	心臓の SOC 下位のプライマリーPT 及びレベル 1 の SMQ 虚血性心疾患にリストされていない注目すべきセカンダリーPT の心臓の個別対応検索式
HLGT	重複を避けるため SMQ 虚血性心疾患のリストにも入っている PT を除く心血管系検査（酵素検査を除く）

虚血性心疾患（SMQ）［20000043］レベル 2 の SMQ 心筋梗塞およびその他の虚血性心疾患：

心筋梗塞（SMQ）［20000047］
急性冠動脈症候群、急性心筋梗塞、血中クレアチンホスホキナーゼＭＢ異常、血中クレアチンホスホキナーゼＭＢ増加、冠動脈塞栓症、冠動脈閉塞、冠動脈再閉塞、冠動脈血栓症、冠動脈バイパス血栓症、コーニス症候群、心筋梗塞、心筋再潅流障害、乳頭筋梗塞、処置後心筋梗塞、梗塞後狭心症、無症候性心筋梗塞、トロポニンＩ増加、トロポニン増加、トロポニンＴ増加、血中クレアチンホスホキナーゼ異常、血中クレアチンホスホキナーゼ増加、心筋酵素増加、心電図異常Q波、心電図ＳＴ部分異常、心電図ＳＴ部分上昇、心電図ＳＴ－Ｔ部分上昇、梗塞、心筋血流スキャン異常、移植血管閉塞

その他の虚血性心疾患（SMQ）［20000168］
狭心症、不安定狭心症、冠動脈硬化症、冠動脈攣縮、冠動脈形成、冠動脈ステント挿入、冠動脈バイパス、冠動脈疾患、冠動脈解離、冠動脈不全、冠動脈再狭窄、冠動脈狭窄、冠動脈内膜摘除、冠動脈ノーリフロー現象、冠状動脈入口部狭窄、冠動脈再建、解離性冠動脈瘤、心筋虚血の心電図所見、体外カウンターパルセーション、冠動脈出血、ステント内冠動脈再狭窄、虚血性心筋症、微小血管性狭心症、心筋虚血、経皮的冠インターベンション、プリンツメタル狭心症、ストレス心筋症、鎖骨下冠動脈スチール症候群、心内膜下虚血、冠血管造影異常、心臓負荷試験異常、冠動脈コンピュータ断層撮影異常、心電図ＳＴ部分下降、心電図ＳＴ－Ｔ部分異常、心電図ＳＴ－Ｔ部分下降、心電図異常Ｔ波、心電図Ｔ波逆転、運動負荷心電図異常、運動試験異常、負荷心エコー像異常

心血管障害
虚血性脳血管障害（SMQ）［20000063］ 大脳基底核梗塞、脳底動脈閉塞、脳底動脈狭窄、脳底動脈血栓症、腕頭動脈閉塞、脳幹梗塞、脳幹部虚血、脳幹卒中、脳幹血栓症、内包性前兆症候群、頚動脈塞栓、頚動脈硬化症、頚動脈バイパス、頚動脈疾患、頚動脈不全、頚動脈閉塞、頚動脈狭窄、頚動脈ステント挿入、頚動脈ステント除去、頚動脈血栓症、頚動脈内膜摘除、小脳動脈閉塞、小脳動脈血栓症、小脳塞栓症、小脳梗塞、小脳虚血、脳動脈硬化症、大脳動脈塞栓症、大脳動脈閉塞、大脳動脈狭窄、大脳動脈血栓症、脳ガス塞栓症、脳梗塞、胎児脳梗塞、脳虚血、血管癒合術による脳血行再建、敗血症性脳梗塞、大脳血栓症、脳血管収縮、大脳静脈血栓症、脳血管発作、脳血管障害、脳血管不全、脳血管攣縮、脳血管狭窄、塞栓性脳梗塞、塞栓性脳卒中、内耳梗塞、虚血性脳梗塞、虚血性脳卒中、ラクナ梗塞、外側髄症候群、ミラール・ギュブレ症候群、もやもや病、処置後脳卒中、脳実質外動脈閉塞、回復性虚血性神経脱落症候、脊髄動脈塞栓症、進行性脳卒中、視床梗塞、血栓性脳梗塞、血栓性脳卒中、一過性脳虚血発作、血管性脳症、椎骨動脈閉塞、椎骨動脈狭窄、椎骨動脈血栓症、椎骨脳底動脈不全、ワレンベルグ症候群
心臓の個別対応検索式（CMQ） 頻脈性固有心室調律、心臓副伝導路、後天性心中隔欠損症、急性左室不全、急性肺水腫、急性右室不全、アダムス・ストークス症候群、死戦調律、房室興奮の異常、大動脈弁石灰化、大動脈弁疾患、混合性大動脈弁疾患、大動脈弁閉鎖不全症、大動脈弁逸脱、大動脈弁硬化症、大動脈弁狭窄、不整脈、新生児不整脈、上室性不整脈、冠動脈炎、スポーツ心臓症候群、心房内伝導時間遅延、心房細動、心房粗動、心房肥大、心房破裂、後天性心房中隔欠損症、心房頻脈、心房血栓症、房室ブロック、完全房室ブロック、第一度房室ブロック、第二度房室ブロック、房室伝導時間短縮、房室解離、房室性期外収縮、自己免疫性心筋炎、二束ブロック、徐脈性不整脈、徐脈、胎児徐脈、新生児徐脈、ブルガダ症候群、脚ブロック、両側性脚ブロック、左脚ブロック、右脚ブロック、カルチノイド心疾患、心アミロイドーシス、心臓瘤、心停止、新生児心停止、心臓性喘息、心臓死、心不快感、心障害、心不全、急性心不全、慢性心不全、うっ血性心不全、高拍出性心不全、心細動、心粗動、心肉芽腫、心肥大、心穿孔、心偽動脈瘤、心サルコイドーシス、心鉄沈着症、心タンポナーデ、心臓弁膜疾患、心臓弁硬化症、心室障害、心原性ショック、心拡大、心筋症、急性心筋症、アルコール性心筋症、新生児心筋症、心肺不全、心腎症候群、心肺停止、新生児心肺停止、心肺機能窮迫、心毒性、心血管系デコンディショニング、心血管障害、心血管不全、心炎、腱索断裂、慢性左室不全、慢性右室不全、変時性応答不全、伝導障害、うっ血性心筋症、肺性心、急性肺性心、慢性肺性心、冠状動脈瘤、冠動脈拡張、冠動脈穿孔、チアノーゼ、細胞毒性心筋症、糖尿病性心筋症、拡張機能障害、心房拡張、心室拡張、労作性めまい、体位性めまい、ドレスラー症候群、呼吸困難、安静時呼吸困難、労作性呼吸困難、発作性夜間呼吸困難、電気収縮解離、心内膜疾患、心内膜線維症、心内膜静脈瘤、線維性心内膜炎、非感染性心内膜炎、リウマチ性心内膜炎、好酸球性心筋炎、期外収縮、水分過負荷、胎児不整脈、胎児一過性徐脈、胎児心拍障害、胃心臓症候群、新生児灰白症候群、交互脈、心臓弁石灰化、心臓弁閉鎖不全、心臓弁狭窄、肝頚静脈逆流、左室過剰収縮、過動心症候群、高血圧性心拡大、高血圧性心筋症、高血圧性心疾患、肥大型心筋症、心室中隔破裂、心臓内腫瘤、心臓内血栓、心嚢内血栓、脊柱後側弯性心疾患、左房拡張、左房肥大、左室機能不全、左室不全、左室肥大、心房中隔の脂肪腫性肥大、ＱＴ延長症候群、低心拍出量症候群、ループス心内膜炎、ループス心筋炎、悪性高血圧性心疾患、僧帽弁穿孔、僧帽弁石灰化、僧帽弁疾患、混合性僧帽弁疾患、僧帽弁閉鎖不全症、僧帽弁逸脱、僧帽弁硬化症、僧

心血管障害
帽弁狭窄症、心筋石灰化、心筋抑制、心筋線維症、心筋出血、心筋浮腫、心筋断裂、心筋炎、感染後心筋炎、心筋心膜炎、陰性心筋変力作用、新生児心不全、新生児頻脈、夜間呼吸困難、結節性不整脈、結節性調律、非閉塞性心筋症、心疾患による浮腫、末梢性浮腫、起坐呼吸、起立不耐性、ペースメーカー症候群、動悸、乳頭筋障害、乳頭筋出血、乳頭筋断裂、副収縮、発作性不整脈、心膜石灰化、心膜嚢胞、心膜疾患、心嚢液貯留、心膜線維症、心嚢内出血、心膜摩擦音、心膜炎、癒着性心膜炎、収縮性心膜炎、ループス心膜炎、リウマチ性心膜炎、尿毒症性心膜炎、扁平呼吸、胸膜心膜炎、心膜気腫、陽性心筋変力作用、起立性頻脈症候群、肺うっ血、肺水腫、肺動脈弁石灰化、肺動脈弁疾患、肺動脈弁閉鎖不全症、肺動脈弁硬化症、肺動脈弁狭窄、リバウンド頻脈、再潅流性不整脈、拘束性心筋症、リウマチ性心疾患、固有心室調律、右房拡張、右房肥大、右室機能不全、右室不全、右室肥大、脚気衝心、洞不全症候群、洞房ブロック、洞停止、洞性不整脈、洞性徐脈、洞性頻脈、線状出血、大動脈弁下狭窄、心突然死、大動脈弁上狭窄、上室性期外収縮、上室性頻脈性不整脈、上室性頻脈、失神、頻脈性不整脈、頻脈、胎児頻脈、発作性頻脈、トルサード　ド　ポアント、三尖弁石灰化、三尖弁疾患、三尖弁閉鎖不全症、三尖弁逸脱、三尖弁硬化症、三尖弁狭窄、三束ブロック、心室破裂、心室性不整脈、心室無収縮、心室機能不全、心室奇異性壁運動、心室性期外収縮、心室不全、心室細動、心室粗動、心室壁運動亢進、心室肥大、心室壁運動低下、心室早期興奮、心室リモデリング、後天性心室中隔欠損症、心室性頻脈性不整脈、心室性頻脈、移動性ペースメーカー、離脱性不整脈、ウォルフ・パーキンソン・ホワイト症候群
心血管系検査（酵素検査を除く）（HLGT） 腹部ブルイ、アレン試験、血管造影、血管造影異常、血管造影正常、末梢血管造影、末梢血管造影異常、末梢血管造影正常、アンギオスコープ検査、足関節／上腕血圧指数、足関節／上腕血圧指数減少、足関節／上腕血圧指数正常、大動脈雑音、大動脈造影、大動脈造影異常、大動脈造影正常、動脈雑音、動脈カテーテル、動脈カテーテル異常、動脈カテーテル正常、動脈造影、動脈造影異常、頚動脈造影、頚動脈血管造影異常、頚動脈血管造影正常、冠血管造影、冠血管造影正常、動脈造影正常、心房圧、心房圧上昇、動脈生検、動脈生検異常、動脈生検正常、血管生検、血管生検異常、血管生検正常、心臓生検、心臓生検異常、心臓生検正常、心膜生検、心膜生検異常、心膜生検正常、血圧、血圧異常、外来血圧、外来血圧異常、外来血圧低下、外来血圧上昇、外来血圧正常、血圧低下、拡張期血圧、拡張期血圧異常、拡張期血圧低下、拡張期血圧上昇、拡張期血圧正常、血圧測定不能、血圧上昇、血圧正常、起立血圧、起立血圧異常、起立血圧低下、起立血圧上昇、起立血圧正常、収縮期血圧、収縮期血圧異常、収縮期血圧低下、収縮期血圧上昇、吸気時収縮期血圧低下、吸気時収縮期血圧正常、収縮期血圧正常、上腕動脈脈拍、上腕動脈脈拍異常、上腕動脈脈拍減少、上腕動脈脈拍増加、上腕動脈脈拍正常、爪毛細血管再充満検査、爪毛細血管再充満検査異常、心臓電気生理学的検査、心臓電気生理学的検査異常、心臓電気生理学的検査正常、心機能検査、心機能検査異常、心機能検査正常、心臓画像検査、心臓画像検査異常、心臓画像検査正常、心指数、心指数異常、心指数減少、心指数増加、心指数正常、心モニタリング、心モニタリング異常、心モニタリング正常、心雑音、機能性心雑音、心拍出量、心拍出量低下、拍出量増加、心臓ペースメーカー機能評価、薬理学的心負荷試験、心臓負荷試験、心臓負荷試験正常、心電図テレメトリー、心電図テレメトリー異常、心電図テレメトリー正常、心室造影、心室造影異常、左室造影、左室造影異常、左室造影正常、心室造影正常、右室造影、右室造影異常、右室造影正常、心胸郭比、心胸郭比増加、心血管評価、心血管機能検査、心血管機能検査異常、心血管機能検査正常、頚動脈

心血管障害
雑音、頚動脈内膜中膜肥厚度増加、頚動脈脈拍、頚動脈脈拍異常、頚動脈脈拍減少、頚動脈脈拍増加、頚動脈脈拍正常、心カテーテル、心カテーテル異常、心カテーテル正常、中心静脈圧、中心静脈圧異常、中心静脈圧低下、中心静脈圧上昇、中心静脈圧正常、冠動脈コンピュータ断層撮影、冠動脈コンピュータ断層撮影正常、心室後負荷減少、心室前負荷減少、方向性ドップラー法血流量試験、方向性ドップラー法血流量試験異常、方向性ドップラー法血流量試験正常、心電図Ｐ波逆転、心室肥大の心電図所見、心エコー像、心エコー像異常、心エコー像正常、駆出率、駆出率異常、駆出率減少、駆出率正常、心電図、心電図異常、外来心電図、外来心電図異常、外来心電図正常、心電図変化、心電図 δ 波異常、心電図低電位、心電図正常、心電図肺性Ｐ波、心電図異常Ｐ波、心電図２相性Ｐ波、心電図正常Ｐ波、心電図ペースメーカースパイク、心電図Ｒ波上昇不良、心電図ＰＱ間隔、心電図ＰＱ間隔延長、心電図ＰＲ間隔、心電図ＰＲ延長、心電図ＰＲ短縮、心電図Ｑ波、心電図正常Ｑ波、心電図ＱＲＳ群、心電図異常ＱＲＳ群、心電図正常ＱＲＳ群、心電図ＱＲＳ群延長、心電図ＱＲＳ群短縮、心電図ＱＴ間隔、心電図ＱＴ間隔異常、心電図ＱＴ間隔正常、心電図ＱＴ延長、心電図ＱＴ短縮、心電図Ｒｏｎ Ｔ現象、心電図再分極異常、心電図ＲＲ間隔延長、心電図ＳＴ部分、心電図ＳＴ部分正常、心電図ＳＴ－Ｔ変化、心電図Ｔ波振幅減少、心電図Ｔ波振幅増加、心電図２相性Ｔ波、心電図正常Ｔ波、心電図Ｔ波、心電図Ｕ波逆転、心電図Ｕ波異常、心電図２相性Ｕ波、運動負荷心電図、運動負荷心電図正常、運動試験、運動試験正常、大腿動脈雑音、大腿動脈脈拍、大腿動脈脈拍異常、大腿動脈脈拍減少、大腿動脈脈拍増加、大腿動脈脈拍正常、ギャロップ・リズム陽性、血行力学検査、血行力学検査異常、血行力学検査正常、心拍数、心拍数異常、心拍数減少、心拍数増加、心拍数不整、心拍数正常、心音、心音異常、心音正常、ホーマンズ徴候、腸骨動脈雑音、心室後負荷増加、心室前負荷増加、左室拡張終期圧、左室拡張終期圧低下、左室拡張終期圧上昇、リンパ管造影、リンパ管造影異常、リンパ管造影正常、最大心拍数、平均動脈圧、平均動脈圧低下、平均動脈圧上昇、ＭＵＧＡスキャン、ＭＵＧＡスキャン異常、ＭＵＧＡスキャン正常、心筋ストレイン、起立時心拍数増加、足脈拍異常、足脈拍減少、心嚢排液検査、心嚢排液検査異常、心嚢排液検査正常、膝窩動脈脈拍、膝窩動脈脈拍異常、膝窩動脈脈拍減少、膝窩動脈脈拍増加、膝窩動脈脈拍正常、肺動脈圧、肺動脈圧異常、肺動脈圧低下、肺動脈圧上昇、肺動脈圧正常、肺動脈楔入圧、肺動脈楔入圧異常、肺動脈楔入圧低下、肺動脈楔入圧上昇、肺動脈楔入圧正常、脈拍異常、脈拍欠損、脈圧異常、脈圧低下、脈圧上昇、脈圧正常、容積脈波低下、脈波形、脈波形異常、脈波形正常、ＱＲＳ軸、ＱＲＳ軸異常、ＱＲＳ軸正常、橈骨動脈脈拍、橈骨動脈脈拍異常、橈骨動脈脈拍減少、橈骨動脈脈拍増加、橈骨動脈脈拍正常、腎雑音、右房圧上昇、右室収縮期圧、右室収縮期圧低下、右室収縮期圧上昇、心筋血流スキャン、心筋血流スキャン正常、シェロング試験、ＳＩ　ＱＩＩＩ　ＴＩＩＩパターン、洞調律、負荷心エコー像、負荷心エコー像正常、一回拍出量、一回拍出量減少、一回拍出量増加、一回拍出量正常、傾斜試験、超音波血管造影、超音波血管造影異常、超音波血管造影正常、ドップラー超音波、ドップラー超音波異常、ドップラー超音波正常、血管画像、肺血管抵抗減少、肺血管抵抗増加、肺血管抵抗正常、全身性血管抵抗、全身性血管抵抗減少、全身性血管抵抗増加、全身性血管抵抗正常、血管検査、血管検査異常、血管検査正常、静脈造影、静脈造影異常、静脈造影正常、静脈雑音、静脈圧、静脈圧異常、静脈圧低下、静脈圧上昇、頚静脈圧、頚静脈圧異常、頚静脈圧低下、頚静脈圧上昇、頚静脈圧正常、静脈圧正常、心室内径、心室内径異常、心室内径正常

肝障害と関連している可能性のある事象	
定義レベル	**詳細**
サブ SMQ（レベル 2）	薬剤に関連する肝障害－包括的検索（肝障害のレベル 1 の SMQ）

薬剤に関連する肝障害－包括的検索（SMQ）［20000006］レベル 3 の SMQ、4 事象からなる：肝臓に起因する胆汁うっ滞および黄疸；薬剤に関連する肝障害－重症事象のみ；肝臓に関連する凝固および出血障害；肝臓関連臨床検査、徴候および症状

肝臓に起因する胆汁うっ滞および黄疸（SMQ）［20000009］

ビリルビン排泄障害、胆血症、胆汁うっ滞、胆汁うっ滞性肝損傷、胆汁うっ滞性そう痒症、胆汁うっ滞性肝炎、高ビリルビン血症、黄疸指数上昇、黄疸、胆汁うっ滞性黄疸、肝細胞性黄疸、混合型肝損傷、黄疸眼、黄色皮膚

薬剤に関連する肝障害－重症事象のみ（SMQ）［20000007］レベル 4 の SMQ、4 事象からなる：肝不全、肝線維症、肝硬変およびその他の肝細胞障害；非感染性肝炎；良性肝新生物（嚢胞およびポリープを含む）；および悪性または詳細不明な肝新生物.

肝不全、肝線維症、肝硬変およびその他の肝細胞障害（SMQ）［20000013］

急性肝不全、急性黄色肝萎縮、腹水、固定姿勢保持困難、細菌感染腹水、胆汁性肝硬変、原発性胆汁性肝硬変、胆管線維症、胆汁うっ滞性肝損傷、慢性肝不全、肝性昏睡、特発性肝硬変、十二指腸静脈瘤、胃静脈瘤、胃静脈瘤出血、肝切除、肝萎縮、肝石灰化、肝硬変、肝性脳症、肝性脳症予防、肝不全、肝線維症、肝性胸水、肝好酸球浸潤、肝病変、肝壊死、脂肪肝、劇症肝炎、肝胆道系疾患、肝細胞泡沫細胞症候群、肝細胞損傷、肝肺症候群、肝腎不全、肝腎症候群、肝毒性、肝小腸移植、肝障害、肝損傷、肝臓手術、肝移植、ルポイド肝硬変症、混合型肝損傷、結節性再生性過形成、肝疾患による浮腫、食道静脈瘤出血、門脈圧亢進症、門脈圧亢進性腸症、門脈圧亢進性胃障害、門脈三分岐炎、門脈肺高血圧症、肝腎移植、門脈逆流、ライ症候群、亜急性肝不全、食道静脈瘤、肛門直腸静脈瘤、肛門直腸静脈瘤出血、門脈シャント、肝過小グラフト症候群、くも状母斑

非感染性肝炎（SMQ）［20000010］

急性肝移植片対宿主病、自己免疫性肝炎、慢性肝炎、肝細胞融解性肝炎、肝炎、急性肝炎、胆汁うっ滞性肝炎、慢性活動性肝炎、慢性持続性肝炎、劇症肝炎、中毒性肝炎、虚血性肝炎、ループス肝炎、放射線肝炎、肉芽腫性肝疾患、肝サルコイドーシス

良性肝新生物（嚢胞およびポリープを含む）（SMQ）［20000012］

肝の良性新生物、限局性結節性過形成、肝臓血管腫、出血性肝嚢胞、肝腺腫、肝嚢胞、肝嚢胞破裂、肝臓血管腫破裂

悪性または詳細不明な肝新生物（SMQ）［20000011］

肝血管肉腫、転移性肝癌、肝癌第１期、肝癌第２期、肝癌第３期、肝癌第４期、肝新生物、肝の悪性新生物、切除不能な肝臓悪性新生物、再発肝臓悪性新生物、切除可能な肝臓悪性新生物、肝胆道系上皮内癌、肝胆道系新生物、肝芽腫、再発肝芽腫、肝癌破裂、肝胆道系の悪性新

肝障害と関連している可能性のある事象
生物、肝細胞癌・胆管細胞癌の混合型
肝臓関連臨床検査、徴候および症状（SMQ）［20000008］ アラニン・アミノトランスフェラーゼ異常、アラニン・アミノトランスフェラーゼ増加、アンモニア異常、アンモニア増加、腹水、アスパラギン酸アミノトランスフェラーゼ異常、アスパラギン酸アミノトランスフェラーゼ増加、細菌感染腹水、胆汁量異常、胆汁量減少、抱合ビリルビン異常、抱合ビリルビン増加、肝生検異常、血中ビリルビン異常、血中ビリルビン増加、血中非抱合ビリルビン増加、ブロモスルフォフタレイン検査異常、メズサ頭、チャイルド・ピュー・ターコットスコア増加、肝性口臭、ガラクトース排泄能検査異常、ガラクトース排泄能検査値減少、γ－グルタミルトランスフェラーゼ異常、γ－グルタミルトランスフェラーゼ増加、グアナーゼ増加、ヘパプラスチン異常、ヘパプラスチン減少、肝動脈血流減少、肝臓うっ血、肝酵素異常、肝酵素低下、肝酵素上昇、肝機能異常、肝性胸水、肝腫瘤、肝臓痛、肝分離、肝血管抵抗増加、肝胆道スキャン異常、肝腫大、肝脾腫大、高アンモニア血症、高ビリルビン血症、胆汁過多、高トランスアミナーゼ血症、ハイの法則例、カイザー・フライシャー輪、肝機能検査異常、肝硬結、季肋下肝触知、肝スキャン異常、肝圧痛、ｍ－ＡＳＴ増加、総分岐鎖アミノ酸／チロシンモル比、肝疾患による浮腫、肝周囲不快感、門脈逆流、総胆汁酸増加、トランスアミナーゼ異常、トランスアミナーゼ上昇、肝超音波検査異常、尿中ビリルビン増加、肝胆道Ｘ線異常、５－ヌクレオチダーゼ上昇、血中アルカリホスファターゼ異常、血中アルカリホスファターゼ増加、血中コリンエステラーゼ異常、血中コリンエステラーゼ減少、グルタミン酸脱水素酵素増加、血性腹水、低アルブミン血症、ロイシンアミノペプチダーゼ上昇、門脈周囲浮腫、腹腔液蛋白異常、腹腔液蛋白減少、腹腔液蛋白増加、胆道気腫、門脈血流減少、門脈圧上昇、レチノール結合蛋白減少、尿中ウロビリノーゲン減少、尿中ウロビリノーゲン増加
肝臓に関連する凝固および出血障害（SMQ）［20000015］ アンチトロンビンＩＩＩ減少、血中フィブリノゲン異常、血中フィブリノゲン減少、血中トロンビン異常、血中トロンビン減少、血中トロンボプラスチン異常、血中トロンボプラスチン減少、凝固因子減少、凝固第ＩＸ因子量異常、凝固第ＩＸ因子量減少、凝固第Ｖ因子量異常、凝固第Ｖ因子量減少、凝固第ＶＩＩ因子量異常、凝固第ＶＩＩ因子量減少、凝固第Ｘ因子量異常、凝固第Ｘ因子量減少、ＩＮＲ異常、ＩＮＲ増加、プロテインＣ減少、プロテインＳ異常、プロテインＳ減少、プロトロンビン量異常、プロトロンビン量減少、プロトロンビン時間異常、プロトロンビン時間延長、プロトロンビン時間比異常、プロトロンビン時間比増加、トロンビン時間異常、トロンビン時間延長

2.7.4 Summary of Clinical Safety

腎障害	
定義レベル	**詳細**
治験依頼者によって医学的に重要であると考えられる腎臓の有害事象及び腎機能に関する臨床検査値のパラメータ	SOC：腎および尿路障害及び臨床検査の有害事象のサブセット、並びに治験依頼者によって医学的に重要であると考えられる腎機能に関する臨床検査値のパラメータ（BUN、クレアチニン、β2 ミクログロブリン、及び微量アルブミン）

悪性疾患と関連している可能性のある事象	
定義レベル	詳細
サブ SMQ（レベル 2）	悪性または詳細不明の腫瘍（悪性疾患のレベル 1 の SMQ）

悪性または詳細不明の腫瘍（SMQ）［20000091］

５ｑマイナス症候群、腹部新生物、腹壁新生物、末端部黒子様黒色腫第１期、末端部黒子様黒色腫第２期、末端部黒子様黒色腫第３期、末端部黒子様黒色腫第４期、末端部黒子様黒色腫、病期不明、ＡＣＴＨ産生性下垂体腫瘍、急性混合性白血病、急性白血病、急性白血病、寛解期、急性リンパ性白血病、急性リンパ性白血病（寛解期）、再発急性リンパ性白血病、急性巨核芽球性白血病、急性巨核芽球性白血病（寛解期）、急性単球性白血病、急性単球性白血病（寛解期）、急性骨髄性白血病、急性骨髄性白血病（寛解期）、再発急性骨髄性白血病、急性骨髄単球性白血病、急性前骨髄球性白血病、腺癌、子宮頚部腺癌、膵腺癌、腺様嚢胞癌、子宮頚部腺扁平上皮癌、腺扁平上皮癌、肺腺扁平上皮癌、再発肺腺扁平上皮癌、肺腺扁平上皮癌第０期、肺腺扁平上皮癌第１期、肺腺扁平上皮癌第２期、肺腺扁平上皮癌第３期、肺腺扁平上皮癌第４期、副腎癌、転移性副腎癌、副腎新生物、副腎皮質癌、成人Ｔ細胞リンパ腫・白血病、再発成人Ｔ細胞リンパ腫・白血病、治療抵抗性成人Ｔ細胞リンパ腫・白血病、成人Ｔ細胞リンパ腫・白血病第１期、成人Ｔ細胞リンパ腫・白血病第２期、成人Ｔ細胞リンパ腫・白血病第３期、成人Ｔ細胞リンパ腫・白血病第４期、感覚神経芽腫、無白血病性白血病、胞巣状軟部肉腫、転移性胞巣状軟部肉腫、限局性胞巣状軟部肉腫、再発胞巣状軟部肉腫、アミロイドーマ、肛門癌、転移性肛門癌、再発肛門癌、肛門癌第０期、肛門癌第１期、肛門癌第２期、肛門癌第３期、肛門癌第４期、肛門新生物、退形成星細胞腫、未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型、再発未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型、治療抵抗性未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型、未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型第１期、未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型第２期、未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型第３期、未分化大細胞型リンパ腫、Ｔ細胞およびヌル細胞型第４期、血管中心性リンパ腫、再発血管中心性リンパ腫、治療抵抗性血管中心性リンパ腫、血管中心性リンパ腫第１期、血管中心性リンパ腫第２期、血管中心性リンパ腫第３期、血管中心性リンパ腫第４期、血管免疫芽球性Ｔ細胞性リンパ腫、再発血管免疫芽球性Ｔ細胞性リンパ腫、治療抵抗性血管免疫芽球性Ｔ細胞性リンパ腫、血管免疫芽球性Ｔ細胞性リンパ腫第１期、血管免疫芽球性Ｔ細胞性リンパ腫第２期、血管免疫芽球性Ｔ細胞性リンパ腫第３期、血管免疫芽球性Ｔ細胞性リンパ腫第４期、血管肉腫、転移性血管肉腫、限局性血管肉腫、再発血管肉腫、アプドーマ、星細胞腫、悪性星細胞腫、異型線維黄色腫、前駆Ｂ細胞型急性白血病、基底細胞癌、基底扁平上皮癌、皮膚基底有棘細胞癌、Ｂ細胞性リンパ腫、再発Ｂ細胞性リンパ腫、治療抵抗性Ｂ細胞性リンパ腫、Ｂ細胞性リンパ腫第１期、Ｂ細胞性リンパ腫第２期、Ｂ細胞性リンパ腫第３期、Ｂ細胞性リンパ腫第４期、Ｂ細胞性小リンパ球性リンパ腫、再発Ｂ細胞性小リンパ球性リンパ腫、治療抵抗性Ｂ細胞性小リンパ球性リンパ腫、Ｂ細胞性小リンパ球性リンパ腫第１期、Ｂ細胞性小リンパ球性リンパ腫第２期、Ｂ細胞性小リンパ球性リンパ腫第３期、Ｂ細胞性小リンパ球性リンパ腫第４期、Ｂ細胞型急性白血病、分類不能なＢ細胞性リンパ腫ハイグレード、分類不能なＢ細胞性リンパ腫ローグレード、胆管癌、切除不能な胆管癌、再発胆管癌、切除可能な胆管癌、胆管癌第０期、胆管癌第１期、胆管癌第２期、胆管癌第３期、胆管癌第４期、転移性胆道癌、胆道新生物、再発膀胱腺癌、膀胱腺癌第０期、膀胱腺癌第１期、膀胱腺癌第２期、膀胱腺癌第３期、膀胱腺癌第４期、膀胱腺癌、病期不明、膀胱癌、再発膀胱癌、膀胱癌第０期、

上皮内癌を伴う、膀胱癌第０期、上皮内癌を除く、膀胱癌第１期、上皮内癌を伴う、膀胱癌第１期、上皮内癌を除く、膀胱癌第２期、膀胱癌第３期、膀胱癌第４期、膀胱新生物、再発膀胱扁平上皮癌、膀胱扁平上皮癌第０期、膀胱扁平上皮癌第１期、膀胱扁平上皮癌第２期、膀胱扁平上皮癌第３期、膀胱扁平上皮癌第４期、膀胱扁平上皮癌、病期不明、膀胱移行上皮癌、再発膀胱移行上皮癌、膀胱移行上皮癌第０期、膀胱移行上皮癌第１期、膀胱移行上皮癌第２期、膀胱移行上皮癌第３期、膀胱移行上皮癌第４期、芽球発症、骨髄性白血病の芽球発症、転移性骨癌、骨巨細胞腫瘍、白血病細胞の骨髄浸潤、腫瘍細胞の骨髄浸潤、骨新生物、骨の悪性新生物、骨肉腫、境界悪性卵巣腫瘍、ボーエン病、転移性脳悪性腫瘍、脳新生物、脳の悪性新生物、脳幹神経膠腫、脳奇形腫、乳癌、女性乳癌、乳房の上皮内癌、男性乳癌、転移性乳癌、再発乳癌、乳癌第１期、乳癌第２期、乳癌第３期、乳癌第４期、乳房新生物、乳房肉腫、転移性乳房肉腫、再発乳房肉腫、気管支癌、気管支新生物、細気管支肺胞上皮癌、バーキット白血病、バーキットリンパ腫、再発バーキットリンパ腫、治療抵抗性バーキットリンパ腫、バーキットリンパ腫第１期、バーキットリンパ腫第２期、バーキットリンパ腫第３期、バーキットリンパ腫第４期、ブシュケ・レーベンシュタイン腫瘍、癌、寛解期、カルチノイド腫瘍、虫垂のカルチノイド腫瘍、盲腸のカルチノイド腫瘍、十二指腸のカルチノイド腫瘍、消化管のカルチノイド腫瘍、膵のカルチノイド腫瘍、前立腺のカルチノイド腫瘍、小腸のカルチノイド腫瘍、胃のカルチノイド腫瘍、肺カルチノイド腫瘍、上皮内癌、眼の上皮内癌、陰茎上皮内癌、皮膚上皮内癌、気管の上皮内癌、心臓の悪性新生物、詳細不明の心臓新生物、心奇形腫、頚動脈球腫瘍、軟骨新生物、中枢神経系類皮腫、中枢神経系リンパ腫、中枢神経系新生物、小脳腫瘍、小脳橋角部腫瘍、大脳神経芽腫、転移性子宮頚部癌、子宮頚部癌、再発子宮頚部癌、子宮頚部癌第０期、子宮頚部癌第１期、子宮頚部癌第２期、子宮頚部癌第３期、子宮頚部癌第４期、子宮頚部新生物、緑色腫、緑色腫（寛解期）、軟骨肉腫、転移性軟骨肉腫、再発軟骨肉腫、脊索腫、絨毛癌、脈絡膜黒色腫、脈絡膜新生物、脈絡叢癌、慢性好酸球性白血病、慢性白血病、慢性白血病、寛解期、慢性リンパ性白血病、慢性リンパ性白血病（寛解期）、再発慢性リンパ性白血病、治療抵抗性慢性リンパ性白血病、慢性リンパ性白血病第０期、慢性リンパ性白血病第１期、慢性リンパ性白血病第２期、慢性リンパ性白血病第３期、慢性リンパ性白血病第４期、慢性リンパ性白血病急性転化、慢性骨髄性白血病、慢性骨髄性白血病（寛解期）、慢性骨髄性白血病急性転化、慢性骨髄単球性白血病、慢性骨髄単球性白血病（寛解期）、子宮内膜明細胞癌、腎臓明細胞肉腫、中枢神経系胚腫、結腸癌、転移性結腸癌、再発結腸癌、結腸癌第０期、結腸癌第１期、結腸癌第２期、結腸癌第３期、結腸癌第４期、結腸新生物、結腸直腸癌、転移性結腸直腸癌、再発結腸直腸癌、結腸直腸癌第１期、結腸直腸癌第２期、結腸直腸癌第３期、結腸直腸癌第４期、結腸直腸癌第０期、先天性線維肉腫、先天性奇形腫、結膜黒色腫、結膜新生物、原発性後天性結膜メラノーシス、対側乳癌、頭蓋咽頭腫、葉状肉腫、皮膚線維肉腫、線維形成性小円形細胞腫瘍、横隔膜新生物、びまん性大細胞型Ｂ細胞性リンパ腫、再発びまん性大細胞型Ｂ細胞性リンパ腫、治療抵抗性びまん性大細胞型Ｂ細胞性リンパ腫、びまん性大細胞型Ｂ細胞性リンパ腫第１期、びまん性大細胞型Ｂ細胞性リンパ腫第２期、びまん性大細胞型Ｂ細胞性リンパ腫第３期、びまん性大細胞型Ｂ細胞性リンパ腫第４期、播種性大細胞型リンパ腫、十二指腸新生物、異形成母斑症候群、耳新生物、耳の悪性新生物、エクリン腺癌、内分泌腺新生物、内分泌腺の悪性新生物、子宮内膜癌、転移性子宮内膜癌、再発子宮内膜癌、子宮内膜癌第０期、子宮内膜癌第１期、子宮内膜癌第２期、子宮内膜癌第３期、子宮内膜癌第４期、子宮内膜新生物、子宮内膜肉腫、転移性子宮内膜肉腫、子宮内膜肉腫再発、好酸球性白血病、脳室上衣細胞腫、悪性上衣細胞腫、精巣上体新生物、喉頭蓋癌、類上皮肉腫、転移性類上皮肉腫、限局性類上皮肉腫、再発類上皮肉腫、エプスタイン・バーウイルス関連リンパ増殖性障害、赤血

病性骨髄症（寛解期）、赤白血病、紅色肥厚症、口唇の紅色肥厚症、陰茎の紅色肥厚症、外陰の紅色肥厚症、ユーイング肉腫、転移性ユーイング肉腫、再発ユーイング肉腫、性腺外原発性胎児性癌、性腺外原発性胚細胞癌、性腺外原発性混合胚細胞腫瘍第１期、性腺外原発性混合胚細胞腫瘍第２期、性腺外原発性混合胚細胞腫瘍第３期、性腺外原発性悪性奇形腫、性腺外原発性非セミノーマ、性腺外原発性非セミノーマ第１期、性腺外原発性非セミノーマ第２期、性腺外原発性非セミノーマ第３期、性腺外原発性非セミノーマ第４期、性腺外原発性（純）セミノーマ第１期、性腺外原発性（純）セミノーマ第２期、性腺外原発性（純）セミノーマ第３期、性腺外原発性（純）セミノーマ第４期、乳房外パジェット病、節外周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型)、再発性節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型)、治療抵抗性節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型)、節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型）第１期、節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型）第２期、節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型）第３期、節外性周辺帯Ｂ細胞リンパ腫（ＭＡＬＴ型）第４期、節外性ＮＫ・Ｔ細胞性リンパ腫、鼻型、眼球外網膜芽細胞腫、骨外性ユーイング肉腫、転移性骨外性ユーイング肉腫、限局性骨外性ユーイング肉腫、再発骨外性ユーイング肉腫、骨外性軟骨肉腫、転移性骨外性軟骨肉腫、限局性骨外性軟骨肉腫、再発骨外性軟骨肉腫、骨外性骨肉腫、転移性骨外性骨肉腫、限局性骨外性骨肉腫、再発骨外性骨肉腫、眼瞼腫瘍、卵管癌、転移性卵管癌、卵管癌第１期、卵管癌第２期、卵管癌第３期、卵管癌第４期、卵管新生物、女性生殖器新生物、女性生殖器上皮内癌、線維肉腫、転移性線維肉腫、限局性線維肉腫、小細胞型濾胞中心リンパ腫びまん性、再発性小細胞型濾胞中心リンパ腫びまん性、治療抵抗性小細胞型濾胞中心リンパ腫びまん性、小細胞型濾胞中心リンパ腫びまん性第１期、小細胞型濾胞中心リンパ腫びまん性第２期、小細胞型濾胞中心リンパ腫びまん性第３期、小細胞型濾胞中心リンパ腫びまん性第４期、濾胞中心リンパ腫、濾胞グレード１、２、３、再発濾胞中心リンパ腫、濾胞グレード１、２、３、治療抵抗性濾胞中心リンパ腫、濾胞グレード１、２、３、濾胞中心リンパ腫、濾胞グレード１、２、３第１期、濾胞中心リンパ腫、濾胞グレード１、２、３第２期、濾胞中心リンパ腫、濾胞グレード１、２、３第３期、濾胞中心リンパ腫、濾胞グレード１、２、３第４期、胆嚢癌、転移性胆嚢癌、切除不能な胆嚢癌、再発胆嚢癌、胆嚢癌第０期、胆嚢癌第１期、胆嚢癌第２期、胆嚢癌第３期、胆嚢癌第４期、神経節細胞芽腫、胃癌、再発胃癌、胃癌第０期、胃癌第１期、胃癌第２期、胃癌第３期、胃癌第４期、胃新生物、胃肉腫、ガストリノーマ、悪性ガストリノーマ、転移性消化器癌、消化器癌、消化器上皮内癌、消化器新生物、胃腸間質性腫瘍、胃食道癌、女性生殖器の悪性新生物、男性生殖器の悪性新生物、泌尿生殖器新生物、胚細胞癌、転移性胚細胞癌、妊娠性絨毛性腫瘍、腱鞘の巨細胞腫瘍、歯肉癌、神経膠芽細胞腫、多形性神経膠芽細胞腫、神経膠腫、大脳神経膠腫症、膠細胞神経細胞腫瘍、神経膠肉腫、声門癌、グルカゴン産生腫瘍、顆粒細胞腫、成長ホルモン産生性下垂体腫瘍、血管周囲細胞腫、髄膜血管外皮腫、血液学的悪性疾患、造血器新生物、毛様細胞白血病、頭頚部癌、重鎖病、肝血管肉腫、転移性肝癌、肝癌第１期、肝癌第２期、肝癌第３期、肝癌第４期、肝新生物、肝の悪性新生物、切除不能な肝臓悪性新生物、再発肝臓悪性新生物、切除可能な肝臓悪性新生物、肝胆道系上皮内癌、肝胆道系新生物、肝芽腫、再発肝芽腫、肝脾Ｔ細胞リンパ腫、遺伝性平滑筋腫様腎細胞癌、遺伝性乳頭状腎癌、ハイグレードＢ細胞性バーキット様リンパ腫、再発ハイグレードＢ細胞性バーキット様リンパ腫、治療抵抗性ハイグレードＢ細胞性バーキット様リンパ腫、ハイグレードＢ細胞性バーキット様リンパ腫第１期、ハイグレードＢ細胞性バーキット様リンパ腫第２期、ハイグレードＢ細胞性バーキット様リンパ腫第３期、ハイグレードＢ細胞性バーキット様リンパ腫第４期、組織球性髄様細網症、ホジキン病、リンパ球減少型ホジキン病第１期、部位不明、横隔膜下リンパ球減少型ホジキン病第１期、横隔膜上リンパ球減少型ホジキン病第１期、リンパ球減少型

ホジキン病第２期、部位不明、横隔膜下リンパ球減少型ホジキン病第２期、横隔膜上リンパ球減少型ホジキン病第２期、再発リンパ球減少型ホジキン病、治療抵抗性リンパ球減少型ホジキン病、リンパ球減少型ホジキン病第３期、リンパ球減少型ホジキン病第４期、リンパ球減少型ホジキン病、病期不明、リンパ球優位型ホジキン病第１期、部位不明、横隔膜下リンパ球優位型ホジキン病第１期、横隔膜上リンパ球優位型ホジキン病第１期、リンパ球優位型ホジキン病第２期、部位不明、横隔膜下リンパ球優位型ホジキン病第２期、横隔膜上リンパ球優位型ホジキン病第２期、再発リンパ球優位型ホジキン病、治療抵抗性リンパ球優位型ホジキン病、リンパ球優位型ホジキン病第３期、リンパ球優位型ホジキン病第４期、リンパ球優位型ホジキン病、病期不明、再発混合細胞型ホジキン病、治療抵抗性混合細胞型ホジキン病、混合細胞型ホジキン病第１期、部位不明、横隔膜下混合細胞型ホジキン病第１期、横隔膜上混合細胞型ホジキン病第１期、横隔膜下混合細胞型ホジキン病第２期、横隔膜上混合細胞型ホジキン病第２期、混合細胞型ホジキン病第３期、混合細胞型ホジキン病第４期、混合細胞型ホジキン病、病期不明、再発結節性硬化症型ホジキン病、治療抵抗性結節性硬化症型ホジキン病、結節性硬化症型ホジキン病第１期、部位不明、横隔膜下結節硬化型ホジキン病第１期、横隔膜上結節硬化型ホジキン病第１期、横隔膜下結節硬化型ホジキン病第２期、横隔膜上結節硬化型ホジキン病第２期、結節性硬化症型ホジキン病第３期、結節性硬化症型ホジキン病第４期、結節性硬化症型ホジキン病、病期不明、再発ホジキン病、治療抵抗性ホジキン病、ホジキン病第１期、ホジキン病第２期、ホジキン病第３期、ホジキン病第４期、分類不能のホジキン病、ホルモン産生卵巣腫瘍、下咽頭癌、再発下咽頭癌、下咽頭癌第０期、下咽頭癌第１期、下咽頭癌第２期、下咽頭癌第３期、下咽頭癌第４期、下咽頭新生物、免疫芽球性リンパ腫、再発炎症性乳癌、炎症性乳癌第３期、炎症性乳癌第４期、炎症性乳癌、炎症性筋線維芽細胞性腫瘍、インスリノーマ、腸管腺癌、腸管Ｔ細胞性リンパ腫、再発腸管Ｔ細胞性リンパ腫、治療抵抗性腸管Ｔ細胞性リンパ腫、腸管Ｔ細胞性リンパ腫第１期、腸管Ｔ細胞性リンパ腫第２期、腸管Ｔ細胞性リンパ腫第３期、腸管Ｔ細胞性リンパ腫第４期、頭蓋内悪性髄膜腫、眼球内黒色腫、眼球内網膜芽細胞腫、骨内血管腫、虹彩新生物、虹彩黒色腫、若年性慢性骨髄単球性白血病、カポジ肉腫、エイズ関連カポジ肉腫、古典的カポジ肉腫、ケラトアカントーマ、涙管新生物、ランゲルハンス細胞組織球症、呼吸器大細胞癌、病期不明、転移性肺大細胞癌、再発肺大細胞癌、肺大細胞癌第０期、肺大細胞癌第１期、肺大細胞癌第２期、肺大細胞癌第３期、肺大細胞癌第４期、大顆粒性リンパ球増多症、大腸癌、喉頭癌、再発喉頭癌、喉頭癌第０期、喉頭癌第１期、喉頭癌第２期、喉頭癌第３期、喉頭癌第４期、喉頭新生物、平滑筋肉腫、転移性平滑筋肉腫、限局性平滑筋肉腫、再発平滑筋肉腫、再発悪性黒子、悪性黒子第１期、悪性黒子第２期、悪性黒子第３期、悪性黒子第４期、悪性黒子、病期不明、白血病、好塩基球性白血病、皮膚白血病、顆粒球白血病、白血病、寛解期、単球性白血病、形質細胞性白血病、形質細胞性白血病（寛解期）、白血病再発、白血病浸潤、白血病脳浸潤、白血病髄外浸潤、白血病歯肉浸潤、白血病肝浸潤、白血病肺浸潤、白血病腎浸潤、白血性リンパ腫、白血病性網膜症、Ｌ鎖病、形成性胃組織炎、口唇および口腔内癌、再発口唇および口腔内癌、口唇および口腔内癌第０期、口唇および口腔内癌第１期、口唇および口腔内癌第２期、口唇および口腔内癌第３期、口唇および口腔内癌第４期、口唇新生物、口唇の悪性新生物、病期不明、脂肪肉腫、転移性脂肪肉腫、、再発脂肪肉腫、肝癌破裂、肺腺癌、転移性肺腺癌、再発肺腺癌、肺腺癌第０期、肺腺癌第１期、肺腺癌第２期、肺腺癌第３期、肺腺癌第４期、転移性肺癌、再発肺癌、細胞タイプ不明、肺癌第０期、細胞タイプ不明、肺癌第１期、細胞タイプ不明、肺癌第２期、細胞タイプ不明、肺癌第３期、細胞タイプ不明、肺癌第４期、細胞タイプ不明、悪性肺浸潤、肺新生物、肺の悪性新生物、再発肺扁平上皮癌、肺扁平上皮癌第０期、肺扁平上皮癌第１期、肺扁平上皮癌第２期、肺扁平上皮

癌第３期、肺扁平上皮癌第４期、肺扁平上皮癌、病期不明、転移性リンパ節癌、リンパ管肉腫、癌性リンパ管症、リンパ系新生物、リンパ性白血病、リンパ球性リンパ腫、リンパ性白血病（寛解期）、リンパ腫、エイズ関連リンパ腫、皮膚型リンパ腫、リンパ腫の転化、リンパ形質細胞様リンパ腫・免疫細胞腫、再発リンパ形質細胞様リンパ腫・免疫細胞腫、治療抵抗性リンパ形質細胞様リンパ腫・免疫細胞腫、リンパ形質細胞様リンパ腫・免疫細胞腫第１期、リンパ形質細胞様リンパ腫・免疫細胞腫第２期、リンパ形質細胞様リンパ腫・免疫細胞腫第３期、リンパ形質細胞様リンパ腫・免疫細胞腫第４期、リンパ増殖性障害、リンパ増殖性障害、寛解期、男性生殖器上皮内癌、男性生殖器新生物、肛門直腸の悪性新生物、脳神経の悪性新生物、悪性線維性組織球腫、転移性悪性線維性組織球腫、限局性悪性線維性組織球腫、再発悪性線維性組織球腫、悪性神経膠腫、悪性血管周囲細胞腫、転移性悪性血管周囲細胞腫、限局性悪性血管周囲細胞腫、再発悪性血管周囲細胞腫、肝胆道系の悪性新生物、悪性組織球増殖症、悪性胞状奇胎、悪性リンパ様新生物、分類不能なハイグレードの悪性リンパ腫、分類不能なローグレードの悪性リンパ腫、肥満細胞の悪性新生物、縦隔の悪性新生物、悪性黒色腫、表皮内悪性黒色腫、眼瞼の悪性黒色腫、皮膚以外の悪性黒色腫、悪性黒色腫第１期、悪性黒色腫第２期、悪性黒色腫第３期、悪性黒色腫第４期、悪性間葉腫、転移性悪性間葉腫、限局性悪性間葉腫、再発悪性間葉腫、腸間膜の悪性新生物、中耳の悪性新生物、筋の悪性新生物、ファーター膨大部の悪性新生物、耳介軟骨の悪性新生物、脈絡膜の悪性新生物、結膜の悪性新生物、角膜の悪性新生物、精巣上体の悪性新生物、眼の悪性新生物、眼瞼の悪性新生物、ランゲルハンス島の悪性新生物、涙管の悪性新生物、涙腺の悪性新生物、眼窩の悪性新生物、尿道傍腺の悪性新生物、胎盤の悪性新生物、胸膜の悪性新生物、腎盂の悪性新生物、網膜の悪性新生物、精嚢の悪性新生物、精索の悪性新生物、脊髄の悪性新生物、胸部の悪性新生物、子宮付属器の悪性新生物、悪性新生物進行、神経系の悪性新生物、乳頭の悪性新生物、女性乳頭の悪性新生物、男性乳頭の悪性新生物、悪性乏突起神経膠腫、悪性卵巣嚢腫、口蓋の悪性新生物、心膜の悪性新生物、腹膜の悪性新生物、下垂体の悪性腫瘍、気道の悪性新生物、軟部組織の悪性新生物、脾臓の悪性新生物、悪性転換、尿路の悪性新生物、マントル細胞リンパ腫、再発マントル細胞リンパ腫、治療抵抗性マントル細胞リンパ腫、マントル細胞リンパ腫第１期、マントル細胞リンパ腫第２期、マントル細胞リンパ腫第３期、マントル細胞リンパ腫第４期、肥満細胞性白血病、肥満細胞腫、成熟Ｂ細胞型急性白血病、上顎顔面洞新生物、縦隔新生物、髄芽腫、再発髄芽腫、再発黒色腫、黒色腫性髄膜炎、髄膜新生物、髄膜腫、悪性髄膜腫、中皮腫、中皮腫、悪性度不明、悪性中皮腫、進行した悪性中皮腫、再発悪性中皮腫、腹腔内転移、腹壁転移、副腎転移、胆道転移、膀胱転移、骨転移、骨髄転移、乳房転移、中枢神経系転移、胸壁転移、横隔膜転移、耳管転移、眼転移、卵管転移、胆嚢転移、胃腸管転移、心転移、腎転移、大腸転移、喉頭転移、肝転移、肺転移、リンパ節転移、髄膜転移、口腔転移、筋転移、副鼻腔転移、頚部転移、神経系転移、食道転移、卵巣転移、膵転移、陰茎転移、会陰転移、末梢神経系転移、末梢血管系転移、腹膜転移、咽頭転移、下垂体転移、胎盤転移、胸膜転移、前立腺転移、直腸転移、生殖器転移、後腹膜転移、唾液腺転移、皮膚転移、小腸転移、軟部組織転移、脊椎転移、脾臓転移、胃転移、精巣転移、縦隔転移、呼吸器系転移、胸部転移、甲状腺転移、気管転移、尿路転移、子宮転移、転移、転移性気管支癌、転移性カルチノイド腫瘍、膀胱の転移性癌、転移性胃癌、転移性神経膠腫、転移性悪性黒色腫、転移性新生物、転移性眼球黒色腫、転移性腎細胞癌、転移性唾液腺癌、転移性扁平上皮癌、転移性子宮癌、混合星状・上衣細胞腫、肝細胞癌・胆管細胞癌の混合型、混合乏突起星細胞腫、唾液腺混合腫瘍、単球性白血病、寛解期、粘液性子宮内膜癌、粘液性類表皮癌、ミュラー管混合腫瘍、多発性骨髄腫、菌状息肉症、再発菌状息肉症、治療抵抗性菌状息肉症、菌状息肉症第１期、菌状息肉症第２期、菌状息肉症第３

期、菌状息肉症第４期、骨髄芽球腫、骨髄異形成症候群、骨髄異形成症候群の転化、分類不能な骨髄異形成症候群、骨髄性白血病、骨髄性白血病、寛解期、再発ミエローマ、鼻腔癌、鼻新生物、副鼻腔癌、上咽頭癌、再発上咽頭癌、上咽頭癌第０期、上咽頭癌第１期、上咽頭癌第２期、上咽頭癌第３期、上咽頭癌第４期、ナチュラルキラー細胞白血病、ナチュラルキラー細胞リンパ芽球性リンパ腫、新生児白血病、新生児神経芽腫、新生物、悪性新生物、虫垂新生物、角膜新生物、悪性度不明、眼窩新生物、胸腺新生物、新生物進行、前立腺新生物、新生物再発、皮膚の新生物、腎芽細胞腫、神経系新生物、神経鞘腫、悪性神経線維鞘腫、神経芽腫、再発神経芽腫、神経外胚葉新生物、神経内分泌癌、皮膚神経内分泌癌、神経内分泌腫瘍、神経線維肉腫、転移性神経線維肉腫、限局性神経線維肉腫、再発神経線維肉腫、ニューロテンシノーマ、乳頭新生物、リンパ節周辺帯Ｂ細胞性リンパ腫、再発リンパ節周辺帯Ｂ細胞性リンパ腫、治療抵抗性リンパ節周辺帯Ｂ細胞性リンパ腫、リンパ節周辺帯Ｂ細胞性リンパ腫第１期、リンパ節周辺帯Ｂ細胞性リンパ腫第２期、リンパ節周辺帯Ｂ細胞性リンパ腫第３期、リンパ節周辺帯Ｂ細胞性リンパ腫第４期、中枢神経系非胚腫性胚細胞腫瘍、非ホジキンリンパ腫、再発非ホジキンリンパ腫、治療抵抗性非ホジキンリンパ腫、非ホジキンリンパ腫第１期、非ホジキンリンパ腫第２期、非ホジキンリンパ腫第３期、非ホジキンリンパ腫第４期、トランスフォームした再発非ホジキンリンパ腫、組織型不明の侵襲性非ホジキンリンパ腫、組織型不明の侵襲性再発非ホジキンリンパ腫、組織型不明の侵襲性治療抵抗性非ホジキンリンパ腫、組織型不明の侵襲性非ホジキンリンパ腫第１期、組織型不明の侵襲性非ホジキンリンパ腫第２期、組織型不明の侵襲性非ホジキンリンパ腫第３期、組織型不明の侵襲性非ホジキンリンパ腫第４期、組織型不明の無症候性非ホジキンリンパ腫、組織型不明の無症候性非ホジキンリンパ腫第１期、組織型不明の無症候性非ホジキンリンパ腫第２期、組織型不明の無症候性非ホジキンリンパ腫第３期、組織型不明の無症候性非ホジキンリンパ腫第４期、非腎細胞性腎癌、非分泌型下垂体腺腫、非小細胞肺癌、転移性非小細胞肺癌、再発非小細胞肺癌、非小細胞肺癌第０期、非小細胞肺癌第１期、非小細胞肺癌第２期、非小細胞肺癌第３期、非小細胞肺癌第３Ａ期、非小細胞肺癌第３Ｂ期、非小細胞肺癌第４期、転移性眼悪性腫瘍、眼部血管外皮腫、眼部新生物、食道腺癌、転移性食道腺癌、再発食道腺癌、食道腺癌第０期、食道腺癌第１期、食道腺癌第２期、食道腺癌第３期、食道腺癌第４期、転移性食道癌、食道癌、再発食道癌、食道癌第０期、食道新生物、食道扁平上皮癌、転移性食道扁平上皮癌、再発食道扁平上皮癌、食道扁平上皮癌第０期、食道扁平上皮癌第１期、食道扁平上皮癌第２期、食道扁平上皮癌第３期、食道扁平上皮癌第４期、希突起神経膠腫、大網新生物、視神経膠腫、視神経新生物、視索神経膠腫、転移性口腔内癌、口腔新生物、再発中咽頭癌、中咽頭癌第０期、中咽頭癌第１期、中咽頭癌第２期、中咽頭癌第３期、中咽頭癌第４期、中咽頭癌、病期不明、中咽頭新生物、限局性骨肉腫、転移性骨肉腫、再発骨肉腫、転移性耳悪性腫瘍、卵巣癌、転移性卵巣癌、再発卵巣癌、卵巣未分化胚細胞腫第１期、卵巣未分化胚細胞腫第２期、卵巣未分化胚細胞腫第３期、卵巣未分化胚細胞腫第４期、卵巣未分化胚細胞腫、病期不明、卵巣胎芽性癌、卵巣上皮癌、転移性卵巣上皮癌、再発卵巣上皮癌、卵巣上皮癌第１期、卵巣上皮癌第２期、卵巣上皮癌第３期、卵巣上皮癌第４期、卵巣胚細胞癌、卵巣胚細胞癌第１期、卵巣胚細胞癌第２期、卵巣胚細胞癌第３期、卵巣胚細胞癌第４期、卵巣胚細胞絨毛癌第１期、卵巣胚細胞絨毛癌第２期、卵巣胚細胞絨毛癌第３期、卵巣胚細胞絨毛癌第４期、卵巣胚細胞胎芽性癌第１期、卵巣胚細胞胎芽性癌第２期、卵巣胚細胞胎芽性癌第３期、卵巣胚細胞胎芽性癌第４期、卵巣胚細胞内胚葉洞腫瘍第１期、卵巣胚細胞内胚葉洞腫瘍第２期、卵巣胚細胞内胚葉洞腫瘍第３期、卵巣胚細胞内胚葉洞腫瘍第４期、卵巣胚細胞多胎芽腫第１期、卵巣胚細胞多胎芽腫第２期、卵巣胚細胞多胎芽腫第３期、卵巣胚細胞多胎芽腫第４期、卵巣胚細胞奇形腫第１期、卵巣胚細胞奇形腫第２期、卵巣胚細胞奇形腫

第３期、卵巣胚細胞奇形腫第４期、卵巣顆粒卵胞膜細胞腫、低悪性度卵巣腫瘍、卵巣新生物、間質性卵巣癌、陰茎パジェット病、皮膚パジェット病、乳房パジェット病、外陰部パジェット病、パンコースト腫瘍、膵癌、転移性膵癌、切除不能な膵癌、再発膵癌、切除可能な膵癌、膵癌第０期、膵癌第１期、膵癌第２期、膵癌第３期、膵癌第４期、膵新生物、膵神経内分泌腫瘍、転移性膵神経内分泌腫瘍、膵肉腫、乳頭状漿液性子宮内膜癌、傍神経節新生物、傍神経節の悪性新生物、副鼻腔および鼻腔の悪性新生物、再発副鼻腔および鼻腔悪性新生物、副鼻腔および鼻腔悪性新生物第０期、副鼻腔および鼻腔悪性新生物第１期、副鼻腔および鼻腔悪性新生物第２期、副鼻腔および鼻腔悪性新生物第３期、副鼻腔および鼻腔悪性新生物第４期、副鼻腔新生物、パラプロテイン血症、副甲状腺腫瘍、悪性副甲状腺腫瘍、骨盤新生物、陰茎の悪性新生物、陰茎新生物、陰茎癌、転移性陰茎癌、再発陰茎癌、陰茎癌第１期、陰茎癌第２期、陰茎癌第３期、陰茎癌第４期、進行した心膜悪性中皮腫、限局性心膜悪性中皮腫、再発心膜悪性中皮腫、心膜新生物、末梢神経系新生物、末梢性神経上皮腫、骨末梢神経上皮腫、転移性骨末梢神経上皮腫、再発骨末梢神経上皮腫、軟部組織末梢神経上皮腫、末梢性Ｔ細胞性リンパ腫、組織型不明、再発組織型不明の末梢性Ｔ細胞性リンパ腫、治療抵抗性組織型不明の末梢性Ｔ細胞性リンパ腫、組織型不明の末梢性Ｔ細胞性リンパ腫第１期、組織型不明の末梢性Ｔ細胞性リンパ腫第２期、組織型不明の末梢性Ｔ細胞性リンパ腫第３期、組織型不明の末梢性Ｔ細胞性リンパ腫第４期、転移性腹膜癌、腹膜悪性中皮腫、進行した腹膜悪性中皮腫、再発腹膜悪性中皮腫、腹膜新生物、腹膜肉腫、褐色細胞腫、悪性褐色細胞腫、転移性咽頭癌、再発咽頭癌、咽頭癌第０期、咽頭癌第１期、咽頭癌第２期、咽頭癌第３期、咽頭癌第４期、咽頭癌、病期不明、咽頭新生物、松果体胚腫、松果体新生物、松果体実質部の悪性新生物、松果体芽腫、松果体腫、松果体細胞腫、転移性下垂体癌、再発悪性下垂体新生物、下垂体腫瘍、再発下垂体腫瘍、胎盤新生物、形質芽球性リンパ腫、形質細胞腫、胸膜癌、胸膜中皮腫、胸膜悪性中皮腫、進行した胸膜悪性中皮腫、再発胸膜悪性中皮腫、胸膜新生物、胸膜肉腫、汗孔癌、輪状後部癌、前駆Ｂリンパ芽球性リンパ腫、再発前駆Ｂリンパ芽球性リンパ腫、治療抵抗性前駆Ｂリンパ芽球性リンパ腫、前駆Ｂリンパ芽球性リンパ腫第１期、前駆Ｂリンパ芽球性リンパ腫第２期、前駆Ｂリンパ芽球性リンパ腫第３期、前駆Ｂリンパ芽球性リンパ腫第４期、前駆Ｔリンパ芽球性リンパ腫・白血病、再発前駆Ｔリンパ芽球性リンパ腫・白血病、治療抵抗性前駆Ｔリンパ芽球性リンパ腫・白血病、前駆Ｔリンパ芽球性リンパ腫・白血病第１期、前駆Ｔリンパ芽球性リンパ腫・白血病第２期、前駆Ｔリンパ芽球性リンパ腫・白血病第３期、前駆Ｔリンパ芽球性リンパ腫・白血病第４期、原発性体腔性リンパ腫、縦隔原発Ｂ細胞性大細胞型リンパ腫、再発縦隔原発Ｂ細胞性大細胞型リンパ腫、治療抵抗性縦隔原発Ｂ細胞性大細胞型リンパ腫、縦隔原発Ｂ細胞性大細胞型リンパ腫第１期、縦隔原発Ｂ細胞性大細胞型リンパ腫第２期、縦隔原発Ｂ細胞性大細胞型リンパ腫第３期、縦隔原発Ｂ細胞性大細胞型リンパ腫第４期、未分化神経外胚葉性腫瘍、転移性未分化神経外胚葉性腫瘍、プロラクチン産生性下垂体腫瘍、前リンパ性白血病、前立腺癌、転移性前立腺癌、再発前立腺癌、前立腺癌第０期、前立腺癌第１期、前立腺癌第２期、前立腺癌第３期、前立腺癌第４期、偽リンパ腫、偽肉腫、ケーラー紅色肥厚症、直腸癌、転移性直腸癌、再発直腸癌、直腸癌第０期、直腸癌第１期、直腸癌第２期、直腸癌第３期、直腸癌第４期、直腸新生物、直腸Ｓ状結腸癌、転移性直腸Ｓ状結腸癌、再発直腸Ｓ状結腸癌、直腸Ｓ状結腸癌第０期、直腸Ｓ状結腸癌第１期、直腸Ｓ状結腸癌第２期、直腸Ｓ状結腸癌第３期、直腸Ｓ状結腸癌第４期、再発癌、不応性貧血、芽球増加を伴う不応性貧血、環状鉄芽球を伴う不応性貧血、難治性癌、多血球系異形成を伴う不応性血球減少症、多血球系異形成と環状鉄芽球を伴う不応性血球減少症、腎癌、転移性腎癌、再発腎癌、腎癌第１期、腎癌第２期、腎癌第３期、腎癌第４期、腎細胞癌、再発腎細胞癌、腎細胞癌第１期、腎細胞癌第２期、腎細胞

癌第３期、腎細胞癌第４期、腎新生物、気道の上皮内癌、気道新生物、網膜メラノーマ、網膜新生物、網膜芽腫、両側性網膜芽細胞腫、片側性網膜芽細胞腫、後眼窩新生物、後腹膜癌、後腹膜新生物、転移性後腹膜新生物、腎臓杆状細胞腫、横紋筋肉腫、再発横紋筋肉腫、唾液腺癌、再発唾液腺癌、唾液腺癌第０期、唾液腺癌第１期、唾液腺癌第２期、唾液腺癌第３期、唾液腺癌第４期、唾液腺新生物、肉腫、転移性肉腫、皮膚の肉腫、子宮肉腫、肉腫症、陰嚢癌、脂腺癌、分泌型下垂体腺腫、セミノーマ、印環細胞癌、転移性副鼻腔癌、皮膚癌、転移性皮膚癌、皮膚新生物出血、小細胞癌、子宮頚部小細胞癌、進展型小細胞肺癌、限局型小細胞肺癌、転移性小細胞肺癌、再発小細胞肺癌、小細胞肺癌、病期不明、小腸癌、転移性小腸癌、切除不能な小腸癌、再発小腸癌、切除可能な小腸癌、小腸癌第０期、小腸癌第１期、小腸癌第２期、小腸癌第３期、小腸癌第４期、小腸平滑筋肉腫、平滑筋細胞新生物、軟部組織新生物、膵の充実性偽乳頭状腫瘍、ソマトスタチノーマ、脊髄新生物、悪性脊髄髄膜腫、紡錘細胞肉腫、脾臓周辺帯リンパ腫、再発性脾臓周辺帯リンパ腫、治療抵抗性脾臓周辺帯リンパ腫、脾臓周辺帯リンパ腫第１期、脾臓周辺帯リンパ腫第２期、脾臓周辺帯リンパ腫第３期、脾臓周辺帯リンパ腫第４期、悪性度不明の脾臓新生物、扁平上皮癌、皮膚有棘細胞癌、子宮頚部扁平上皮癌、子宮内膜扁平上皮癌、スチュアート・トリーヴェス症候群、表在拡大型黒色腫第１期、表在拡大型黒色腫第２期、表在拡大型黒色腫第３期、表在拡大型黒色腫第４期、表在拡大型黒色腫、病期不明、滑膜肉腫、転移性滑膜肉腫、限局性滑膜肉腫、再発滑膜肉腫、Ｔ細胞性慢性リンパ性白血病、Ｔ細胞性リンパ腫、再発Ｔ細胞性リンパ腫、治療抵抗性Ｔ細胞性リンパ腫、Ｔ細胞性リンパ腫第１期、Ｔ細胞性リンパ腫第２期、Ｔ細胞性リンパ腫第３期、Ｔ細胞性リンパ腫第４期、Ｔ細胞性前リンパ性白血病、Ｔ細胞型急性白血病、分類不能なＴ細胞性リンパ腫、ハイグレード、分類不能なＴ細胞性リンパ腫、ローグレード、腱新生物、奇形腫、精巣奇形腫、転移性精巣癌、精巣絨毛癌、再発精巣絨毛癌、精巣絨毛癌第１期、精巣絨毛癌第２期、精巣絨毛癌第３期、精巣胎芽性癌、精巣胎芽性癌第１期、精巣胎芽性癌第２期、精巣胎芽性癌第３期、精巣胚細胞性癌、転移性精巣胚細胞性癌、精巣胚細胞性混合腫瘍第１期、精巣胚細胞性混合腫瘍第２期、精巣胚細胞性混合腫瘍第３期、精巣平滑筋肉腫、精巣悪性奇形腫第１期、精巣悪性奇形腫第２期、精巣悪性奇形腫第３期、精巣新生物、精巣（純粋）セミノーマ、精巣（純粋）セミノーマ第１期、精巣（純粋）セミノーマ第２期、精巣（純粋）セミノーマ第３期、精巣卵黄嚢腫瘍第１期、精巣卵黄嚢腫瘍第２期、精巣卵黄嚢腫瘍第３期、精巣癌、再発精巣癌、咽喉癌、転移性胸腺癌、胸腺腫、悪性胸腺腫、再発悪性胸腺腫、甲状腺癌、転移性甲状腺癌、甲状腺癌第０期、甲状腺新生物、甲状腺刺激ホルモン産生性下垂体腫瘍、転移性舌癌、舌癌第０期、舌癌第１期、舌癌第２期、舌癌第３期、舌癌第４期、舌新生物、舌の悪性新生物、病期不明、扁桃癌、扁桃新生物、気管癌、気管新生物、腎盂および尿管の転移性移行上皮癌、腎盂および尿管移行上皮癌、腎盂および尿管の限局性移行上皮癌、腎盂および尿管の再発移行上皮癌、腎盂および尿管の局所性移行上皮癌、移行上皮癌、未分化型肉腫、尿管新生物、尿管癌、限局性尿管癌、転移性尿管癌、再発尿管癌、局所性尿管癌、尿道癌、限局性尿道癌、転移性尿道癌、再発尿道癌、局所性尿道癌、尿道新生物、膀胱肉腫、尿路上皮内癌、尿路新生物、子宮癌、子宮上皮内癌、子宮平滑筋肉腫、子宮新生物、腟癌、転移性腟癌、再発腟癌、腟癌第０期、腟癌第１期、腟癌第２期、腟癌第３期、腟癌第４Ａ期、腟癌第４Ｂ期、腟新生物、血管新生物、ビポーマ、声帯新生物、外陰部癌、転移性外陰部癌、再発外陰部癌、外陰部癌第０期、外陰部癌第１期、外陰部癌第２期、外陰部癌第３期、外陰部癌第４期、外陰新生物、ワルデンストローム・マクログロブリン血症、再発ワルデンストローム・マクログロブリン血症、治療抵抗性ワルデンストローム・マクログロブリン血症、ワルデンストローム・マクログロブリン血症第１期、ワルデンストローム・マクログロブリン血症第２期、ワルデンストローム・マク

2.7.4 Summary of Clinical Safety

ログロブリン血症第３期、ワルデンストローム・マクログロブリン血症第４期、卵黄嚢腫瘍、部位不明

悪性疾患	
定義レベル	**詳細**
治験依頼者による医学的評価により分類された悪性疾患	悪性腫瘍（悪性新生物）に分類されるかどうか同定するために治験依頼者による医学的評価を受けた、上記の SMQ 検索に基づく悪性疾患の可能性のある事象。特に、悪性腫瘍の可能性があると同定された良性腫瘍を悪性腫瘍から排除するよう求めた医学的評価。

2.7.4 Summary of Clinical Safety

網膜変性	
定義レベル	詳細
PT	網膜変性を含めて、定義に「網膜」を含む全ての PT
網膜血管造影、網膜血管造影異常、網膜血管造影正常、網膜の良性新生物、網膜生検、網膜生検異常、網膜生検正常、網脈絡膜萎縮、先天性脈絡網膜変性、脈絡網膜障害、脈絡網膜瘢痕、網膜色素上皮剥離、糖尿病性網膜浮腫、網膜血管腫、遺伝性網膜ジストロフィー、網膜脂血症、網膜の悪性新生物、網膜血管瘤、先天性網膜異常、網膜動静脈奇形、網膜動脈塞栓症、網膜動脈閉塞、網膜動脈攣縮、網膜動脈狭窄、網膜動脈血栓症、網膜欠損、網膜嚢胞、網膜嚢胞切除、網膜変性、網膜色素脱失、網膜沈着物、網膜剥離、網膜障害、網膜ジストロフィー、網膜滲出物、網膜機能検査異常、網膜機能検査正常、網膜出血、人工網膜植込み、網膜梗塞、網膜滲出斑、網膜損傷、網膜虚血、網膜レーザー凝固、網膜色素細胞腫、網膜メラノーマ、網膜性片頭痛、網膜新生物、網膜血管新生、網膜浮腫、網膜手術、網膜蒼白、網膜光毒性、網膜色素上皮裂孔、網膜色素上皮症、網膜色素沈着、網膜瘢痕、網膜裂孔、網膜末梢血管拡張、網膜毒性、網膜移植、網膜腫瘍摘除、網膜血管障害、網膜血管閉塞、網膜血管血栓症、網膜血管炎、網膜静脈閉塞、網膜静脈血栓症、網膜下線維症	

脳組織	
定義レベル	**詳細**
SOC	SOC：神経系障害および精神障害中の全ての PT（プライマリー及びセカンダリー）

神経系障害（SOC）の下位の PT：

１８ｑマイナス症候群、歩行不能、異常な夢、睡眠関連異常事象、無為、失算症、副神経障害、聴神経炎、聴神経腫、後天性てんかん性失語症、肢端疼痛症、先端栄養性疼痛症、アクティベーション症候群、急性散在性脳脊髄炎、急性出血性白質脳炎、急性多発ニューロパチー、喘息後急性筋萎縮症、急性前庭症候群、アダムス・ストークス症候群、声帯内転筋無力、脂肪性器性ジストロフィー、アドレナリン作動性症候群、副腎脳白質ジストロフィー、抗アドレナリン作動性症候群、進行睡眠期、感覚神経芽腫、味覚消失、激越性うつ病、激越、新生児不穏、術後激越、失認症、失書症、アイカルディ症候群、エイズ認知症複合、エイズ脳症、アカシジア、運動感覚消失、無動、アルコール性持続性認知症、アルコール性痙攣、失読、異痛症、アルパース病、意識変容状態、深径覚の変化、一過性黒内障、家族性黒内障白痴、無表情、健忘、健忘障害、アメーバ性脳膿瘍、断端痛、失音楽症、筋萎縮性側索硬化症、筋萎縮症、無感覚、有痛性感覚消失、麻酔による神経系合併症、肛門括約筋無緊張症、肛門括約筋過緊張、退形成星細胞腫、無脳症、アンゲルマン症候群、住血線虫感染、無嗅覚、病態失認、前骨間神経症候群、前脊髄動脈症候群、前向性健忘、抗コリン作動性症候群、失外套症候群、失語症、失声症、心因性失声症、無呼吸発作、乳幼児突発性危急事態、適用部位知覚消失、適用部位知覚過敏、適用部位異常感覚、失行症、失韻症、中脳水道狭窄、くも膜嚢胞、くも膜炎、反射消失、アーガイルロバートソン瞳孔、アーノルド・キアリ奇形、固定姿勢保持困難、星細胞腫、悪性星細胞腫、ローグレード星細胞腫、運動失調、毛細血管拡張運動失調、アテトーゼ、脱力発作、無緊張性膀胱、非定型良性部分てんかん、前兆、耳介側頭神経症候群、自閉症、自己免疫性ニューロパチー、てんかん性自動症、自律神経異常反射、自律神経機能不全症候群、自律神経失調、自律神経ニューロパチー、自律神経発作、腋窩神経損傷、軸索型ニューロパチー、中枢神経系細菌性膿瘍、バラムチア感染、平衡障害、バリント症候群、バリズム、バルト型ミオクローヌスてんかん、帯状感、基底細胞母斑症候群、大脳基底核出血、大脳基底核梗塞、大脳基底核変性、脳底動脈閉塞、脳底動脈狭窄、脳底動脈血栓症、脳底動脈型片頭痛、ベッカー型筋ジストロフィー、良性先天性筋緊張低下、良性家族性新生児痙攣、良性頭蓋内圧亢進、松果体の良性新生物、脊髄の良性新生物、良性ローランドてんかん、両眼球運動障害、膀胱括約筋無緊張症、眼瞼痙攣、失明、皮質盲、一過性失明、片側失明、血液脳関門欠損、境界線級精神的機能障害、腕神経叢障害、腕神経叢損傷、運動緩慢、精神緩慢、脳膿瘍、転移性脳悪性腫瘍、脳圧迫、脳挫傷、脳死、脳ヘルニア、脳損傷、脳奇形、脳腫瘤、脳正中線偏位、脳新生物、脳の良性新生物、脳の悪性新生物、脳浮腫、脳幹神経膠腫、良性脳幹神経膠腫、脳幹出血、脳幹梗塞、脳幹部虚血、脳幹卒中、脳幹症候群、脳幹血栓症、脳奇形腫、呼吸関連睡眠障害、ブラウン・セカール症候群、ブルジンスキー徴候、頬舌症候群、球麻痺、延髄灰白髄炎、先天性球脊髄性筋萎縮症、灼熱足症候群、口腔灼熱感症候群、灼熱感、粘膜の灼熱感、体幹前屈症、カナバン病、内包性前兆症候群、心臓自律神経ニューロパチー、頚動脈瘤破裂、頚動脈塞栓、頚動脈硬化症、頚動脈瘤、頚動脈疾患、頚動脈解離、頚動脈不全、頚動脈閉塞、頚動脈狭窄、頚動脈血栓症、頚動脈球腫瘍、頚動脈洞症候群、手根管症候群、カタプレキシー、馬尾症候群、尾部退行症候群、海綿静脈洞血栓症、中枢性聴覚情報処理障害、中央ヨーロッパ脳炎、中枢神経系膿瘍、中枢神経系類皮腫、中枢神経系エンテロウイルス感染、中枢神

脳組織
経系感染、中枢神経系の炎症、中枢神経系病変、中枢神経系腫瘤、中枢神経系壊死、中枢神経系新生物、中枢神経系ウイルス感染、中枢痛症候群、中枢性肺胞性低換気、小脳動脈閉塞、小脳動脈血栓症、小脳性運動失調、小脳萎縮、小脳性認知感情症候群、小脳塞栓症、小脳血管腫、小脳血腫、小脳出血、小脳低形成、小脳梗塞、小脳虚血、小脳性無言症、小脳症候群、小脳腫瘍、小脳橋角部腫瘍、脳アミロイド血管障害、梅毒性脳動脈瘤破裂、脳動脈硬化症、出血性脳動静脈奇形、脳動脈炎、大脳動脈塞栓症、大脳動脈閉塞、大脳動脈狭窄、大脳動脈血栓症、脳アスペルギルス症、大脳性運動失調、大脳萎縮、先天性大脳萎縮、皮質下梗塞および白質脳症を伴う常染色体優性脳動脈症、大脳石灰化、脳循環不全、脳嚢胞、大脳障害、大脳形成異常、脳真菌感染、脳ガス塞栓症、脳血管腫、脳血腫、脳出血、胎児脳出血、新生児脳出血、外傷性脳出血、脳ヒグローマ、脳過潅流症候群、脳低潅流、脳梗塞、胎児脳梗塞、脳虚血、脳マラリア、脳微小血管症、脳微小出血、大脳神経芽腫、脳性麻痺、中枢性塩類喪失症候群、脳サルコイドーシス、敗血症性脳梗塞、大脳血栓症、脳トキソプラズマ症、脳血管収縮、大脳静脈血栓症、脳室拡張、脳肝腎症候群、脳硬化症、脳脊髄癆、髄液貯留、髄液鼻漏、脳脊髄血栓性タンポナーデ、脳血管発作、脳血管動静脈奇形、脳血管障害、脳血管不全、脳血管攣縮、脳血管狭窄、頚髄圧迫、頚髄症、頚椎症性神経炎、頚神経叢病変、頚髄神経根痛、頚部脊柱管狭窄症、頚腕症候群、頚原性頭痛、シャルコ・ブシャール微小動脈瘤、ＣＨＡＲＧＥ症候群、視交差症候群、コリン作動性症候群、コリンエステラーゼ阻害、舞踏病、舞踏病アテトーゼ、リンパ性脈絡髄膜炎、脈絡叢癌、脈絡叢乳頭腫、慢性乳児期発症神経皮膚関節症候群、慢性炎症性脱髄性多発根ニューロパチー、慢性発作性片側頭痛、毛様体筋痙攣、概日リズム睡眠障害、間代性痙攣、間代、不器用、不器用な子症候群、群発頭痛、中枢神経系胚腫、中枢神経系脳室炎、コブ症候群、コクシジオイデス性脳炎、コケーン症候群、認知障害、歯車様固縮、コーエン症候群、偽性結腸閉塞、昏睡、アシドーシス性昏睡、昏睡性水疱、肝性昏睡、新生児昏睡、尿毒症性昏睡、複雑部分発作、複合性局所疼痛症候群、複雑型片頭痛、同心円性硬化症、脳振盪、術後錯乱、錯乱性覚醒、錯乱状態、先天性中脳水道狭窄、先天性脳損傷、先天性中枢性低換気症候群、先天性中枢神経系異常、先天性小脳無形成、先天性脳嚢胞、先天性脳血管腫、先天性脳血管異常、先天性脈絡叢嚢胞、先天性脳神経麻痺、先天性顔面神経形成不全、先天性弛緩麻痺、先天性筋緊張低下児、先天性水頭症、先天性神経変性、先天性神経学的障害、先天性ニューロパチー、先天性眼振、先天性眼球運動失行、先天性視神経異常、先天性脊髄異常、先天性梅毒性脳炎、先天性梅毒性髄膜炎、先天性斜頚、先天性視力低下、意識変動、脊髄円錐症候群、痙攣、小児痙攣、新生児痙攣、局在性痙攣、痙攣閾値低下、協調運動異常、汚言症、皮質異形成、皮質層状壊死、脳神経障害、脳神経感染、脳神経損傷、分娩時外傷による脳神経損傷、脳神経の良性新生物、多発性脳神経麻痺、脳神経麻痺、良性頭蓋咽頭腫、頭蓋脊椎披裂、クロイツフェルト・ヤコブ病、ネコ泣き症候群、重症疾患多発ニューロパチー、ワニの涙症候群、泣き、肘部管症候群、毛様体筋麻痺、サイトメガロウイルス性脊髄髄膜神経根炎、細胞毒性浮腫、ダンディーウォーカー症候群、ド・ランゲ症候群、ろう唖、感音性難聴、永久難聴、一過性難聴、除脳、アイコンタクト減少、振動覚低下、既視感、麻酔からの覚醒遅延、遅延睡眠期、認知症、アルツハイマー型認知症、アルツハイマー型認知症、合併症を伴わない、アルツハイマー型認知症、譫妄を伴う、アルツハイマー型認知症、妄想を伴う、アルツハイマー型認知症、抑うつを伴う、レヴィ小体型認知症、脱髄性多発ニューロパチー、脱髄、意識レベルの低下、協調運動発達障害、糖尿病性筋萎縮、糖尿病性自律神経ニューロパチー、糖尿病性昏睡、糖尿病性脳症、糖尿病性足病変、糖尿病性足感染、糖尿病性胃不全麻痺、糖尿病性高血糖昏睡、糖尿病性高浸透圧性昏睡、糖尿病性ケトアシドーシス性高血糖昏睡、糖尿病性単ニュー

脳組織
ロパチー、糖尿病性神経障害性潰瘍、糖尿病性ニューロパチー、糖尿病性眼筋麻痺、透析不均衡症候群、横隔膜筋力低下、横隔膜麻痺、分裂脊髄、乳児間脳症候群、びまん性軸索損傷、両麻痺、複視、失見当識、注意力障害、浮動性めまい、労作性めまい、体位性めまい、ドーパミン調節障害症候群、夢幻状態、よだれ、転倒発作、薬物離脱性痙攣、薬物離脱性頭痛、デュアン症候群、デュボヴィッツ症候群、デュシェンヌ型筋ジストロフィー、硬膜膿瘍、硬膜瘻、硬膜裂傷、異常感覚、咽頭知覚不全、構語障害、計算力障害、味覚異常、書字障害、ジスキネジー、新生児ジスキネジー、食道ジスキネジー、構音障害、失読症、視測障害、髄鞘形成異常、ディスフェミア、発声障害、心因性発声障害、神経性錯誤対応、統合運動障害、韻律障害、睡眠異常、起立障害、ジストニー、イーグル症候群、反響言語、子癇、塞栓性脳梗塞、塞栓性脳卒中、前弯痙攣、感染性脳炎、脳炎、アレルギー性脳炎、オーストラリア脳炎、脳幹脳炎、カリフォルニア脳炎、サイトメガロウイルス性脳炎、東部ウマ脳炎、エンテロウイルス性脳炎、真菌性脳炎、出血性脳炎、ヘルペス脳炎、インフルエンザ脳炎、日本脳炎Ｂ型、嗜眠性脳炎、髄膜炎菌性脳炎、ムンプス脳炎、びまん性軸索周囲性脳炎、免疫処置後脳炎、麻疹後脳炎、水痘後脳炎、原虫性脳炎、リケッチア性脳炎、中毒性脳炎、ベネズエラウマ脳炎、ウイルス性脳炎、西部ウマ脳炎、脳瘤、脳石、脳軟化、脳脊髄炎、風疹性脳脊髄炎、脳症、アレルギー性脳症、新生児脳症、脳血管周囲腔拡大、上衣炎、脳室上衣細胞腫、良性上衣腫、悪性上衣細胞腫、髄膜外脂肪腫症、硬膜外腔炎症、てんかん、先天性てんかん、てんかんの前兆、てんかん精神病、エルプ麻痺、本態性振戦、過剰驚愕反応、瞬目過多、眼の輻輳過多、労作性頭痛、伸展性足底反応、硬膜外膿瘍、硬膜外血腫、外眼筋不全麻痺、錐体外路障害、眼運動障害、眼瞼下垂、先天性眼瞼下垂、眼瞼知覚障害、ファブリ病、椎間関節症候群、顔面神経障害、顔面部神経痛、顔面不全麻痺、顔面痙攣、顔面肩甲上腕型筋ジストロフィー、便失禁、ファール病、家族性アミロイドーシス、家族性片麻痺性片頭痛、家族性周期性麻痺、家族性振戦、熱性痙攣、大腿神経損傷、大腿神経麻痺、微細運動遅延、筋緊張低下児、虹彩緊張低下症候群、口腔内泡沫、胎児性アルコール症候群、胎児脳血管障害、泉門膨隆、泉門陥没、蟻走感、フォスター・ケネディー症候群、脆弱Ｘ症候群、すくみ現象、フリードライヒ運動失調症、前頭葉てんかん、前頭側頭型認知症、ファンブル、中枢神経系真菌性膿瘍、歩行失行、歩行偏位、歩行障害、痙性歩行、ガラクトース血症、神経節細胞芽腫、神経節腫、あえぎ症候群、ゴーシェ病、注視麻痺、非痙攣性全般てんかん、膝神経節炎、性器感覚鈍麻、ゲルストマン症候群、眉間反射異常、神経膠瘢痕、神経膠芽細胞腫、多形性神経膠芽細胞腫、神経膠腫、大脳神経膠腫症、膠細胞神経細胞腫瘍、神経膠肉腫、グリオーシス、頚静脈グロムス腫瘍、舌咽神経障害、舌咽神経麻痺、舌咽神経痛、２型糖原貯蔵障害、３型糖原貯蔵障害、５型糖原貯蔵障害、７型糖原貯蔵障害、グラデニーゴ症候群、大発作痙攣、グレイグ症候群、しかめ面、粗大運動遅延、ギラン・バレー症候群、湾岸戦争症候群、血管芽腫、髄膜血管外皮腫、頭蓋内出血、出血性脳梗塞、出血性卒中、卒中の出血性変化、手腕振動症候群、橋本脳症、頭部不快感、頭部動揺、頭痛、半盲、異名性半盲、同名性半盲、片側失行症、片側頭痛、不全片麻痺、片麻痺、半側無視、肝性脳症、肝レンズ核変性症、遺伝性無反射性起立障害、遺伝性脳変性疾患、遺伝性神経障害性アミロイドーシス、遺伝性圧脆弱性ニューロパチー、遺伝性痙性対麻痺、神経合併症を伴う帯状疱疹感染、眼帯状疱疹、耳帯状疱疹、眼球斜位、海馬硬化症、瞳孔動揺、ＨＩＶ末梢性ニューロパチー、ホフマン徴候、ホイグネ症候群、ホームズ振戦、ホームズ・アディー瞳孔、全前脳胞症、ホルネル症候群、ハンチントン病、水頭症、水脊髄症、聴覚過敏、知覚過敏、高アンモニア血性脳症、新生児高ビリルビン血症、高炭酸ガス血性脳症、過度驚愕、味覚過敏、高血糖性高浸透圧性非ケトン性症候群、運動過多、新生児運動過多、ヒペルパチー、反

脳組織
射亢進、過眠症、高血圧性脳症、高圧性水頭症、筋緊張亢進、新生児筋緊張亢進、緊張性膀胱、感覚鈍麻、眼の知覚低下、顔面感覚鈍麻、口の感覚鈍麻、歯の感覚鈍麻、味覚減退、舌下神経障害、舌下神経麻痺、舌下神経不全麻痺、低血糖昏睡、低血糖性脳症、低血糖性痙攣、低血糖性意識消失、運動低下、新生児運動減退、低ナトリウム血性脳症、反射減弱、嗅覚減退、短時間睡眠、筋緊張低下、新生児筋緊張低下、低緊張性膀胱、筋緊張低下－反応性低下発作、低酸素性虚血性脳症、特殊言語症、第３脳神経障害、第３神経損傷、第３脳神経麻痺、第３脳神経不全麻痺、埋込み部位異常感覚、はい歩き不能、切開部位知覚低下、思考散乱、失禁、ハンセン病、未定型群、点頭てんかん、注入部位知覚消失、注入部位異常感覚、後頭孔脳脱出症、初期不眠症、注射部位知覚消失、注射部位知覚不全、注射部位知覚異常、分娩時外傷による脊髄損傷、内耳梗塞、不眠症、知能増進、企図振戦、肋間神経痛、頭蓋内動脈瘤、頭蓋内血管腫、頭蓋内血腫、脳圧低下、頭蓋内悪性髄膜腫、頭蓋内圧上昇、頭蓋内腫瘍出血、頭蓋内静脈洞血栓症、鼻腔内感覚鈍麻、鼻腔内異常感覚、神経内嚢胞、術中大脳動脈閉塞、脊髄内膿瘍、脳室内出血、新生児脳室内出血、虹彩麻痺、不規則睡眠期、虚血性脳梗塞、虚血性ニューロパチー、虚血性脳卒中、第４脳神経障害、第４神経損傷、第４脳神経麻痺、第４脳神経不全麻痺、判断力低下、歌舞伎メーキャップ症候群、ケアーンズ・セイヤー症候群、核黄疸、ケルニッヒ徴候、クルンプケ麻痺、クリューバー・ビューシー症候群、アルコール性コルサコフ精神病、非アルコール性コルサコフ精神病、クラッベ病、クール一病、ラクナ梗塞、ラフォラ・ミオクローヌスてんかん、ランガー・ギーディオン症候群、潜伏テタニー、外側髄症候群、ローレンス・ムーン・バルデー・ビードル症候群、レノックス・ガストー症候群、ハンセン病、らい腫型、嗜眠、白血病脳浸潤、白質病変、白質ジストロフィー、白質脳脊髄炎、白質脳症、ルイス・サムナー症候群、レルミット徴候、閉眼遅延、脂肪髄膜瘤、脳回欠損、リステリア性脳炎、閉じ込め症候群、言葉もれ、長胸神経麻痺、意識消失、夢欠如、固有感覚の欠如、跳躍病、下位運動ニューロンの病変、ローリー・ウッド症候群、腰髄神経根障害、腰部脊柱管狭窄症、腰仙神経叢損傷、腰仙部神経叢病変、ループス脳炎、ライム病、脳神経の悪性新生物、悪性神経膠腫、脊髄の悪性新生物、神経系の悪性新生物、悪性乏突起神経膠腫、マンーインーザーバレル症候群、マールブルグ型多発性硬化症、マルキアファーヴァ・ビニャミ病、マーカス・ガン症候群、仮面状顔貌、咀嚼障害、正中神経損傷、髄芽腫、再発髄芽腫、メージ症候群、黒色腫性髄膜炎、ＭＥＬＡＳ症候群、メルカーソン・ロゼンタール症候群、膜性リポジストロフィー、記憶障害、メニエール病、髄膜障害、髄膜新生物、髄膜腫、良性髄膜腫、悪性髄膜腫、髄膜症、髄膜炎、無菌性髄膜炎、細菌性髄膜炎、ボレリア性髄膜炎、カンジダ性髄膜炎、化学性髄膜炎、コクシジオイデス性髄膜炎、コクサッキーウイルス性髄膜炎、クロノバクター性髄膜炎、クリプトコッカス性髄膜炎、エコーウイルス性髄膜炎、腸球菌性髄膜炎、エンテロウイルス性髄膜炎、好酸球性髄膜炎、真菌性髄膜炎、淋菌性髄膜炎、ヘモフィルス性髄膜炎、ヘルペス性髄膜炎、ヒストプラスマ性髄膜炎、レプトスピラ性髄膜炎、リステリア菌性髄膜炎、髄膜炎菌性髄膜炎、ムンプス性髄膜炎、新生児髄膜炎、非感染性髄膜炎、肺炎球菌性髄膜炎、サルモネラ菌性髄膜炎、ブドウ球菌性髄膜炎、レンサ球菌性髄膜炎、トキソプラズマ性髄膜炎、トリパノソーマ性髄膜炎、結核性髄膜炎、ウイルス性髄膜炎、髄膜瘤、後天性髄膜瘤、アデノウイルス性髄膜脳炎、アメーバ性髄膜脳炎、細菌性髄膜脳炎、ヘルペス性髄膜脳炎、髄膜脊髄瘤、髄膜神経根炎、髄膜出血、メンケス症候群、精神的機能障害、精神遅滞、感覚異常性大腿神経痛、代謝性脳症、代謝性ミオパチー、異染性白質ジストロフィー、変視症、中枢神経系転移、髄膜転移、神経系転移、末梢神経系転移、転移性神経膠腫、メチレンテトラヒドロ葉酸還元酵素欠損症、小脳症、小字症、中期不眠症、片頭痛、前兆を伴う片頭痛、前兆

脳組織
を伴わない片頭痛、軽度精神遅滞、ミラール・ギュブレ症候群、ミラー・フィッシャー症候群、軽度認知運動障害、縮瞳、ミトコンドリア脳筋症、ミトコンドリア神経胃腸脳症、混合星状・上衣細胞腫、混合性難聴、混合乏突起星細胞腫、運動性低下、中等度精神遅滞、メービウス２型症候群、モリブデン補因子欠損症、単肢筋萎縮症、単神経炎、単ニューロパチー、多発性単ニューロパチー、不全単麻痺、単麻痺、朝顔症候群、モートン神経痛、モートン神経腫、乗物酔い、運動発達遅滞、運動機能障害、運動ニューロン疾患、マウント・リーバック症候群、運動障害、もやもや病、ムコ多糖症ＩＨ、多巣性運動ニューロパチー、多発性硬化症、多発性硬化症再発、多系統萎縮症、マレー渓谷脳炎、筋萎縮、不随意性筋収縮、筋固縮、筋痙直、筋ジストロフィー、筋力低下、筋皮神経損傷、無言症、重症筋無力症、重症筋無力症クリーゼ、新生児重症筋無力症、筋無力症候群、散瞳、脊髄炎、横断性脊髄炎、脊髄軟化症、脊髄症、ミオクローヌス性てんかん、赤色ぼろ線維・ミオクローヌスてんかん症候群、ミオクローヌス、筋膜攣縮、ミオトニー、先天性筋緊張症、筋強直性ジストロフィー、粘液水腫性昏睡、ネグレリア感染、ナルコレプシー、言語新作、新生児神経芽腫、新生児過鎮静、神経圧迫、神経変性、神経損傷、神経根圧迫、神経根損傷、頚椎神経根損傷、腰椎神経根損傷、仙椎神経根損傷、胸椎神経根損傷、神経根病変、神経系障害、神経系新生物、神経系の良性新生物、神経管欠損、神経痛、神経痛性筋萎縮症、神経鞘腫、良性神経鞘腫、悪性神経線維鞘腫、神経炎、脳神経炎、神経芽腫、再発神経芽腫、神経ボレリア症、神経クリプトコッカス症、神経嚢虫症、神経変性障害、神経発達障害、神経外胚葉新生物、神経線維腫、神経線維腫症、神経因性膀胱、神経因性腸、神経性高血圧、神経原性ショック、神経低糖症、悪性症候群、神経学的無視症候群、医療機器関連神経系合併症、神経学的代償不全、神経性眼瞼障害、神経系感染、神経学的症状、神経腫、神経筋ブロック遷延、神経筋ブロック、神経筋毒性、視神経脊髄炎、ニューロミオパチー、神経障害性関節症、神経障害性潰瘍、末梢性ニューロパチー、ビタミンＢ６欠乏性ニューロパチー、ＮＡＲＰ症候群、神経精神ループス、感音性聴力低下、神経梅毒、神経毒性、神経栄養性角膜症、ニーマン・ピック病、中枢神経系非胚腫性胚細胞腫瘍、非ケトン性高グリシン血症、非分泌型下垂体腺腫、正常圧水頭症、ノリエ病、項部硬直、おとがいしびれ症候群、眼振、閉鎖神経ニューロパチー、後頭神経痛、眼球運動失調、眼筋無力症、眼頭回転反射欠如、眼脳腎症候群、眼球運動顔面麻痺、眼球回転発作、嗅脳性器異形成、嗅神経障害、希突起神経膠腫、良性乏突起膠腫、オンオフ現象、眼筋麻痺、眼筋麻痺性片頭痛、弓なり緊張、眼球クローヌスミオクローヌス、視神経乳頭辺縁不鮮明、虚血性視神経症、視神経障害、視神経膠腫、視神経損傷、視神経炎、髄膜炎菌性視神経炎、視神経症、視覚路損傷、口腔知覚不全、眼窩先端部症候群、口下顎ジストニー、起立不耐性、起立時振戦、オルトナー症候群、浸透圧性脱髄症候群、骨粗鬆症・偽性神経膠腫症候群、大回脳症、硬膜炎、手掌・足底発赤知覚不全症候群、手掌おとがい反射、パンコースト症候群、汎脳炎、視神経乳頭浮腫、逆説疼痛、錯感覚、粘膜異常感覚、女性性器感覚異常、男性性器感覚異常、口の錯感覚、麻痺、弛緩性麻痺、麻痺性兎眼、腫瘍随伴性小脳変性症、腫瘍随伴性脳脊髄炎、不全対麻痺、対麻痺、寄生虫性脳炎、傍脊椎膿瘍、不全麻痺、肛門括約筋不全麻痺、脳神経不全麻痺、パーキンソン発症、パーキンソン歩行、パーキンソン病安静時振戦、パーキンソニズム、パーキンソン病、嗅覚錯誤、発作性舞踏病アテトーゼ、部分発作、二次性全般化を伴う部分発作、ペリツェウス・メルツバッハー病、周産期脳損傷、神経周囲嚢胞、周期性四肢運動障害、末梢性運動ニューロパチー、末梢神経感染、末梢神経損傷、末梢神経病変、末梢神経麻痺、末梢神経系新生物、末梢性麻痺、末梢性感覚運動ニューロパチー、末梢性感覚ニューロパチー、脳室周囲白質軟化症、脳室周囲結節性異所性灰白質、腓骨部筋萎縮症、腓骨神経損傷、腓骨神経麻痺、術後

脳組織
腓骨神経麻痺、人格変化、小発作てんかん、ＰＨＡＣＥＳ症候群、母斑症、幻痛、咽頭感覚鈍麻、フェニルケトン尿症、羞明、光視症、横隔神経麻痺、ピックウィック症候群、松果体胚腫、松果体嚢胞、松果体新生物、松果体実質部の悪性新生物、松果体芽腫、松果体腫、松果体細胞腫、梨状筋症候群、下垂体出血、下垂体梗塞、髄液細胞増加症、側反弓、気脳体、ＰＯＥＭＳ症候群、灰白脳炎、灰白髄炎、ワクチン接種後の灰白髄炎、多発ニューロパチー、アルコール性多発ニューロパチー、慢性多発ニューロパチー、特発性進行性多発ニューロパチー、悪性疾患に伴う多発ニューロパチー、ムンプス性多発ニューロパチー、睡眠の質低下、吸啜反射不良、孔脳症、急性ポルフィリン症、脳振盪後症候群、ヘルペス後神経痛、椎弓切除後症候群、腰椎穿刺後症候群、ポリオ後症候群、処置後脳卒中、脳卒中後うつ病、ウイルス感染後疲労症候群、無酸素後ミオクローヌス、後頭蓋窩症候群、後骨間神経症候群、後脛骨神経損傷、発作後頭痛、発作後麻痺、発作後精神病、発作後状態、蘇生後脳症、開胸術後疼痛症候群、外傷後健忘障害、外傷後てんかん、外傷後頭痛、姿勢反射障害、姿勢異常、不自然な姿勢、プラダーウィリ症候群、脳実質外動脈閉塞、初老期認知症、失神寸前の状態、原発性小脳変性症、一次性進行型多発性硬化症、未分化神経外胚葉性腫瘍、転移性未分化神経外胚葉性腫瘍、処置によるめまい、処置による頭痛、肛門括約筋麻痺、最重度精神遅滞、進行性球麻痺、進行性小脳変性症、進行性外眼筋麻痺、進行性多巣性白質脳症、進行性多発性硬化症、進行性筋萎縮症、進行再発型多発性硬化症、進行性核上性麻痺、プロラクチン産生腫瘍、舌突出、偽眼瞼下垂、仮性球麻痺、偽性髄膜瘤、偽乳頭浮腫、偽性麻痺、偽性根症候群、精神運動亢進、精神運動発作、精神運動機能障害、陰部神経管症候群、固定瞳孔、瞳孔障害、瞳孔反射障害、瞳孔緊張、瞳孔不同、脳紫斑、被殻出血、錐体路症候群、四肢不全麻痺、四肢麻痺、兎の口症候群、狂犬病、橈骨神経損傷、橈骨神経麻痺、橈骨神経管症候群、放射線脊髄症、放射線ニューロパチー、神経根痛、根症候群、神経根炎、上腕の神経根炎、頚髄神経根炎、腰仙部神経根炎、神経根障害、レム睡眠異常、ラトケ嚢胞、レイモン・セスタン症候群、原始反射再出現、再発神経筋ブロック、反射異常、レフサム病、再発寛解型多発性硬化症、反復言語、呼吸器ジスキネジー、呼吸筋力低下、呼吸麻痺、下肢静止不能症候群、落ち着きのなさ、網膜性片頭痛、逆行性健忘、レット障害、回復性虚血性神経脱落症候、可逆性後白質脳症症候群、ライ症候群、ライリー・デイ症候群、筋さざ波病、痙笑、ロス症候群、神経合併症を伴う風疹感染、ルビンシュタイン・テイビ症候群、破裂性脳動脈瘤、ロシア春夏脳炎、衝動性眼球運動、サンディファー症候群、シンツェル・ギーディオン症候群、坐骨神経損傷、坐骨神経ニューロパチー、坐骨神経麻痺、坐骨神経痛、閃輝暗点、暗点、二次性進行型多発性硬化症、分泌型下垂体腺腫、鎮静、無酸素性発作、選択的緘黙症、老年認知症、感覚運動障害、感覚障害、感覚神経節炎、感覚統合機能障害、感覚消失、遺伝性感覚ニューロパチー、敗血症性脳症、視神経中隔形成異常、透明中隔欠損、セロトニン症候群、重度精神遅滞、単純部分発作、副鼻腔炎に伴う頭痛、シェーグレン・ラルソン症候群、皮膚灼熱感、睡眠時無呼吸症候群、睡眠慣性、睡眠時麻痺、睡眠期リズム障害、睡眠時性行為、ねごと、睡眠時驚愕、睡眠関連摂食障害、すべり肋骨症候群、刺激反応遅滞、スネドン症候群、身体表現性心血管系障害、身体表現性神経障害、夢遊症、傾眠、新生児傾眠、昏眠、痙攣性発声障害、痙性両麻痺、痙性麻痺、痙性対麻痺、会話障害、発達性会話障害、翼口蓋神経痛、二分脊椎、潜在性二分脊椎、脊髄動脈塞栓症、脊髄性跛行症、脊柱管狭窄症、脊髄圧迫、脊髄障害、脊髄出血、脊髄ヘルニア、脊髄梗塞、脊髄感染、脊髄損傷、馬尾損傷、頚椎部脊髄損傷、腰椎部脊髄損傷、仙髄損傷、胸髄損傷、脊髄虚血、脊髄新生物、脊髄浮腫、脊髄麻痺、脊髄硬膜外出血、脊髄血管腫、脊髄血腫、脊髄髄膜嚢胞、良性脊髄髄膜腫、悪性脊髄髄膜腫、脊髄性筋萎縮症、脊髄ショック、脊髄血管障害、先天性脊椎

脳組織
血管異常、脊髄小脳失調症、脊髄小脳障害、脊椎炎性脊髄症、セントルイス脳炎、てんかん重積状態、片頭痛発作重積、常同症、斜視、先天性斜視、進行性脳卒中、昏迷、スタージ・ウェーバー症候群、亜急性脊髄連合変性症、亜急性脊髄視神経ニューロパチー、亜急性硬化性全脳炎、くも膜下膿瘍、くも膜下出血、新生児くも膜下出血、鎖骨下動脈スチール症候群、硬膜下滲出液、硬膜下蓄膿症、硬膜下血腫、硬膜下出血、新生児硬膜下出血、硬膜下ヒグローマ、突発的睡眠、てんかんにおける原因不明の突然死、突然視力消失、ＳＵＮＣＴ症候群、脳表ヘモジデリン沈着症、上矢状洞血栓症、核上性麻痺、シデナム舞踏病、象徴機能障害、交感神経損傷、交感神経性後頚部症候群、交感神経緊張、交感神経作動作用、失神、脊髄空洞症、精神活動過多、寡黙、遅発性ジスキネジー、足根管症候群、ティサックス病、側頭動脈炎、側頭葉てんかん、顎関節症候群、緊張性頭痛、早朝覚醒型不眠症、破傷風、新生児破傷風、脊髄係留症候群、テトラヒドロビオプテリン欠損症、視床梗塞、視床出血、温度覚消失、温度覚過敏、温度覚鈍麻、思考異常、胸郭出口症候群、血栓性脳梗塞、血栓性脳卒中、甲状腺中毒性周期性四肢麻痺、チック、ティネル徴候、耳鳴、爪先歩行、トロサ・ハント症候群、咬舌、舌の麻痺、強直性間代性運動、強直性痙攣、斜頚、トゥレット病、中毒性脳症、中毒性ニューロパチー、トキシックオイル症候群、中毒性視神経症、一過性全健忘、一過性脳虚血発作、横静脈洞血栓症、外傷性脳損傷、外傷性昏睡、外傷性頭蓋内出血、外傷性脊髄圧迫、振戦、新生児振戦、トレンデレンブルグ症状、三叉神経障害、三叉神経不全麻痺、三叉神経痛、三叉神経麻痺、三叉神経心臓反射、開口障害、１３トリソミー、１７トリソミー、１８トリソミー、２１トリソミー、２２トリソミー、熱帯性痙性不全麻痺、ハンセン病、類結核型、中枢神経系結核腫、中枢神経系結核、中枢神経系結核性膿瘍、結節性硬化症、トンネル状視野、１型らい反応、ウートホフ現象、尺骨神経損傷、尺骨神経麻痺、尺骨ニューラプラキシー、尺骨神経炎、尺骨神経管症候群、鉤発作、刺激無反応、アップダウン現象、上気道抵抗症候群、上位運動ニューロンの病変、尿毒症性脳症、尿毒症性ニューロパチー、尿失禁、口蓋垂痙攣、ワクチン接種部位知覚異常、迷走神経障害、迷走神経麻痺、異型クロイツフェルト・ヤコブ病、血管性認知症、血管性脳症、血管性頭痛、血管性パーキンソニズム、脳血管炎、血管原性脳浮腫、口蓋心臓顔面症候群、脳静脈性血管腫、語唱、ヴェルネ症候群、椎骨動脈形成不全、椎骨動脈閉塞、椎骨動脈狭窄、椎骨動脈血栓症、椎間孔狭窄、椎骨脳底動脈不全、回転性めまい、中枢神経系に起因する回転性めまい、迷路性回転性めまい、頭位性回転性めまい、血管穿刺部位知覚消失、血管穿刺部位知覚異常、前庭性運動失調、前庭障害、前庭神経炎、前庭眼振、振動覚亢進、第８神経損傷、第８脳神経病変、第７神経損傷、第７脳神経麻痺、霧視、視力低下、一過性視力低下、視覚の明るさ、視野欠損、視覚正中線偏位症候群、視覚路障害、第６脳神経障害、第６神経損傷、第６脳神経麻痺、声帯麻痺、声帯不全麻痺、フォンヒッペル・リンダウ病、第５神経損傷、ワレンベルグ症候群、ウェルニッケ・コルサコフ症候群、ウェルニッケ脳症、ウエストナイルウイルス感染、むち打ち損傷、ウィリアムス症候群、ウォルフ・ヒルシュホーン症候群、ワイバーン・メーソン症候群、第１２神経損傷、第１１神経損傷、第１１脳神経麻痺、黄熱ワクチン関連神経向性疾患
精神障害（SOC）の下位の PT：
異常行動、異常な夢、睡眠関連異常事象、無為、失算症、高所恐怖症、アクティベーション症候群、急性精神病、急性ストレス反応、脂肪性器性ジストロフィー、適応障害、不安を伴う適応障害、抑うつ気分を伴う適応障害、行為障害を伴う適応障害、混合性不安抑うつを伴う適応障害、情動障害および行為障害を伴う適応障害、進行睡眠期、感情不安定、感情障害、攻撃

脳組織
性、激越性うつ病、激越、新生児不穏、術後激越、失認症、広場恐怖症、失書症、エイズ認知症複合、アカシジア、アルコール乱用、アルコール性持続性認知症、アルコールに関連する問題、アルコール離脱症候群、アルコールによる宿酔、アルコール精神病、アルコール症、失読、不思議の国のアリス症候群、意識変容状態、健忘、健忘障害、失音楽症、怒り、快感消失、動物恐怖症、無食欲および大食症候群、神経性無食欲症、無オルガズム症、病態失認、前向性健忘、予期不安、反社会的行動、反社会性人格障害、不安、不安障害、身体疾患による不安障害、術後不安、無感情、嚥下不能、失語症、失声症、心因性失声症、食欲障害、失行症、くも恐怖症、非社会的行動、アスペルガー障害、注意欠陥多動性障害、注意喚起行動、非定型的注意欠陥障害、自閉症、自閉症スペクトラム障害、自動症、てんかん性自動症、命令自動、嫌悪、回避的人格障害、バルト型ミオクローヌスてんかん、認知症の行動と心理症状、好戦的態度、気晴らし食い、双極性障害、双極１型障害、双極２型障害、ヒステリー盲、情動鈍麻、身体醜形障害、境界線級精神的機能障害、境界性人格障害、退屈感、精神緩慢、脳損傷、息こらえ、呼吸関連睡眠障害、著明なストレッサーを伴う短期精神病性障害、著明なストレッサーを伴わない短期精神病性障害、短期精神病性障害、産後発症、歯ぎしり、神経性過食症、燃え尽き症候群、心臓神経症、カタプレキシー、カタトニー、中枢性聴覚情報処理障害、小脳性認知感情症候群、小脳性無言症、注意力維持の変化、ＣＨＡＲＧＥ症候群、シャルル・ボネ症候群、小児うつ病、小児期崩壊性障害、小児精神病、息詰まり感、概日リズム睡眠障害、迂遠、音連合、閉所恐怖症、早口、認知障害、コーエン症候群、心因性結腸炎、コミュニケーション障害、賠償神経症、自殺既遂、強迫行為、強迫的ためこみ、強迫性咬唇、強迫性性行動、強迫性購買、行為障害、作話、術後錯乱、錯乱性覚醒、錯乱状態、先天性脳損傷、情動抑制、転換性障害、汚言症、コタール症候群、クロイツフェルト・ヤコブ病、ネコ泣き症候群、泣き、クッシング様、クッシング症候群、気分循環性障害、白日夢、ろう唖、活動性低下、アイコンタクト減少、興味の減少、既視感、遅延睡眠期、譫妄、熱性譫妄、振戦譫妄、妄想、誇大妄想、関連妄想、替え玉妄想、妄想性障害、色情型、妄想性障害、誇大型、妄想性障害、嫉妬型、妄想性障害、混合型、妄想性障害、被害型、妄想性障害、身体型、妄想性障害、詳細不明、妄想知覚、混合性妄想、認知症、アルツハイマー型認知症、アルツハイマー型認知症、合併症を伴わない、アルツハイマー型認知症、譫妄を伴う、アルツハイマー型認知症、妄想を伴う、アルツハイマー型認知症、抑うつを伴う、レヴィ小体型認知症、依存、依存性人格障害、離人症、抑うつ気分、うつ病、術後うつ病、希死念慮を有するうつ病、うつ病性妄想、抑うつ症状、脱線、現実感消失、自傷性皮膚症、協調運動発達障害、医療機器による心因性合併症、乳児間脳症候群、脱抑制、失見当識、解離、解離性健忘、解離性障害、解離性遁走、解離性同一性障害、転導性、注意力障害、性的興奮障害、社会的行為障害、ドーパミン調節障害症候群、薬物乱用、薬物依存、薬物依存、分娩前、薬物依存、分娩後、薬剤離脱症候群、新生児薬物離脱症候群、デュボヴィッツ症候群、構語障害、計算力障害、構音障害、失読症、論理障害、醜形恐怖症、性交困難、ディスフェミア、発声障害、心因性発声障害、不快気分、韻律障害、睡眠異常、気分変調性障害、摂食障害、摂食障害症状、反響言語、反響動作、高揚状態、嘔吐恐怖症、情動障害、小児期の感情障害、感情的苦悩、遺糞、遺尿、てんかん精神病、勃起不全、勃起増強、色情妄想、多幸気分、過剰驚愕反応、自慰過剰、性的空想過剰、遂行機能障害、露出症、表出性言語障害、虚偽性障害、ファール病、成長障害、恐怖、動物恐怖、閉所恐怖、群集恐怖、死の恐怖、疾病恐怖、食事恐怖、転倒の恐怖、針恐怖、広場恐怖、妊娠恐怖、体重増加恐怖、栄養補給障害、乳児および小児期早期の哺育障害、罪責感、絶望感、自己否定気分、女性オルガズム障害、女性の性的興奮障害、女性性機能不全、フェチシスム、微細運動遅延、フ

脳組織
ラッシュバック、感情の平板化、観念奔逸、食物嫌悪、食物渇望、食物のためこみ、蟻走感、脆弱X症候群、前頭側頭型認知症、窃触症、欲求不満、ガラクトース血症、性同一性障害、全般性不安障害、ゲルストマン症候群、誇大的態度、グレイグ症候群、悲嘆反応、粗大運動遅延、湾岸戦争症候群、幻覚、幻聴、幻味、幻嗅、共感覚性幻覚、触覚性幻覚、幻視、混合性幻覚、接触恐怖症、頭を激しくぶっつける、片側失行症、演技性人格障害、殺人念慮、敵意、恐水病、過食、性欲過剰、過眠症、他の精神疾患に関連する過眠症、過眠・大食症候群、過換気、過覚醒、入眠時幻覚、傾眠時幻覚、心気症、軽躁、過小食、短時間睡眠、ヒステリー性精神病、関連念慮、特殊言語症、非論理的思考、錯覚、セルフケア障害、せっかち、衝動制御障害、衝動行為、不十分な膣の潤滑、不相応な情動、無関心、劣等コンプレックス、初期不眠症、不眠症、他の精神疾患に関連する不眠症、知性化、企図的薬剤誤用、企図的過量投与、故意の自傷行為、間欠性爆発性障害、不規則睡眠期、易刺激性、過敏性腸症候群、未視感、嫉妬妄想、判断力低下、歌舞伎メーキャップ症候群、窃盗癖、クリューバー・ビューシー症候群、アルコール性コルサコフ精神病、非アルコール性コルサコフ精神病、クールー病、満腹感欠如、自発発語の減少、ランガー・ギーディオン症候群、ローレンス・ムーン・バルデー・ビードル症候群、怠惰、学習障害、レノックス・ガストー症候群、嗜眠、白質病変、リビドー減退、性欲障害、リビドー亢進、症状限定パニック発作、気力低下、言葉もれ、連合弛緩、夢欠如、リビドー消失、呪術的思考、大うつ病、男性オルガズム障害、男性性機能不全、躁病、マゾヒズム、膜性リポジストロフィー、記憶障害、閉経期うつ病、精神障害、身体疾患による精神障害、精神的機能障害、精神遅滞、精神状態変化、術後精神状態変化、反すう、中期不眠症、軽度精神遅滞、軽度認知運動障害、受容・表出混合性言語障害、呻吟、中等度精神遅滞、気分変化、身体疾患による気分障害、気分動揺、病的思考、陰気、運動発達遅滞、企図的多剤過量投与、ミュンヒハウゼン症候群、無言症、爪摘み取り、自己愛性人格障害、ナルコレプシー、死体狂、消極的思考、拒絶症、外見に対する無関心、言語新作、母体の物質乱用による新生児合併症、神経過敏、神経発達障害、神経学的無視症候群、神経精神ループス、神経症、小児期の神経症性障害、ニコチン依存、悪夢、暗夜恐怖症、夜間恐怖、ノリエ病、疾病恐怖症、強迫反すう症、強迫観念、強迫性障害、強迫性人格障害、群集恐怖症、眼脳腎症候群、爪咬癖、反抗挑戦性障害、器質性勃起機能不全、オルガズム異常、オルガズム感減少、臭気恐怖症、骨粗鬆症・偽性神経膠腫症候群、自信過剰、小児性愛、パニック発作、パニック障害、広場恐怖症を伴うパニック障害、広場恐怖症を伴わないパニック障害、パニック反応、記憶錯誤、妄想症、妄想性人格障害、性嗜好異常、睡眠時随伴症、知覚変容発作、排尿恐怖症、病的賭博、行為恐怖、周産期脳損傷、周期性四肢運動障害、被害妄想、保続、人格変化、身体疾患による人格変化、人格障害、小児の人格障害、恐食症、薬物恐怖症、フェニルケトン尿症、恐怖症、運転恐怖症、試験恐怖症、飛行機恐怖症、恐怖回避、音韻障害、音恐怖症、眩輝恐怖症、異食症、ピックウィック症候群、ピチアチスム、心因性多飲症、多物質依存、睡眠の質低下、徘徊癖、急性ポルフィリン症、脳振盪後症候群、脳卒中後うつ病、後頭蓋窩症候群、発作後精神病、産後うつ病、産褥神経症、出産後ストレス障害、外傷後健忘障害、外傷後ストレス障害、不自然な姿勢、発語の乏しさ、思考内容の貧困さ、プラダーウィリ症候群、早漏、月経前症候群、初老期認知症、談話促迫、最重度精神遅滞、偽性狭心症、仮性認知症、虚言症、偽神経学的症状、精神的機能代償不全、精神症状、心因性排尿困難、心因性勃起機能不全、心因性疼痛障害、身体疾患に影響を与える精神的要因、精神運動亢進、精神運動制止遅滞、精神運動機能障害、精神病質人格、精神性的障害、術後精神病、心身症、精神病的行動、精神病性障害、身体疾患による精神病性障害、浄化行動、放火癖、レム睡眠異常、幼児もしくは小児期初

脳組織
期の反応性愛情障害、反応性精神病、読字障害、退行行動、反復言語、落ち着きのなさ、逆行性健忘、レット障害、ルビンシュタイン・テイビ症候群、サディズム、シンツェル・ギーディオン症候群、統合失調感情障害、双極型統合失調感情障害、うつ病型統合失調感情障害、統合失調質人格障害、統合失調症、単純型統合失調症、統合失調症、緊張型、統合失調症、解体型、統合失調症、妄想型、統合失調症、残遺型、統合失調症、鑑別不能型、統合失調症様障害、統合失調型人格障害、登校拒否、絶叫、季節性感情障害、選択的緘黙症、自尊心低下、自尊心肥大、自傷行動、自己誘発性嘔吐、自傷念慮、老年認知症、老人性精神病、重度精神遅滞、性的嫌悪障害、性機能不全、性的抑制、不適切な性的行動、共有精神病性障害、シェーグレン・ラルソン症候群、睡眠時無呼吸症候群、睡眠発作、睡眠障害、身体疾患による睡眠障害、身体疾患による睡眠障害、過眠症型、身体疾患による睡眠障害、不眠症型、身体疾患による睡眠障害、混合型、身体疾患による睡眠障害、睡眠時随伴症型、睡眠慣性、睡眠時麻痺、睡眠期リズム障害、睡眠時性行為、ねごと、睡眠時驚愕、睡眠関連摂食障害、スネドン症候群、社会逃避行動、社会的恐怖、社会恐怖症、独語、身体妄想、体感幻覚、身体化障害、身体表現性障害、身体表現性心血管系障害、身体表現性消化管系障害、身体表現性神経障害、身体表現性妊娠、身体表現性皮膚障害、夢遊症、傾眠、新生児傾眠、昏眠、会話障害、発達性会話障害、凝視、常同症、ステロイド離脱症候群、ストレス、頑固、昏迷、物質乱用、被暗示性、自殺行為、自殺念慮、自殺企図、疑い深さ、象徴機能障害、精神活動過多、寡黙、脱線思考、涙ぐむ、緊張、早朝覚醒型不眠症、テトラヒドロビオプテリン欠損症、死恐怖症、思考異常、思考途絶、思考伝播、思考吹入、思考奪取、咽喉絞扼感、甲状腺中毒クリーゼ、チック、タバコ乱用、タバコ離脱症状、爪先歩行、心因性斜頚、トゥレット病、トランス、一過性全健忘、一過性精神病、服装倒錯、抜毛癖、１７トリソミー、１８トリソミー、２１トリソミー、２２トリソミー、上気道抵抗症候群、腟痙、異型クロイツフェルト・ヤコブ病、血管性認知症、血管性脳症、口蓋心臓顔面症候群、語唱、暴力関連症状、心因性嘔吐、窃視症、水中毒、ろう屈症、ウェルニッケ・コルサコフ症候群、ウィリアムス症候群、離脱症候群、ウォルフ・ヒルシュホーン症候群

膵臓組織	
定義レベル	詳細
HLGT	HLGT：膵外分泌障害の下位の全ての PT（プライマリー及びセカンダリー）
HLT	HLT：膵新生物の下位の全ての PT（プライマリー及びセカンダリー）
HLT	HLT：消化酵素の下位の全ての PT（プライマリー及びセカンダリー）
HLT	HLT：膵治療手技の下位の全ての PT（プライマリー及びセカンダリー）
HLT	HLT：膵放射線療法の下位の全ての PT（プライマリー及びセカンダリー）
HLT	HLT：消化管、膵臓およびＡＰＵＤホルモン検査の下位の全ての PT（プライマリー及びセカンダリー）
膵新生物（HLGT）の下位の PT： アルコール性膵炎、ファーター膨大部狭窄、膵胆管合流異常、自己免疫性膵炎、移植膵の合併症、先天性異所性膵、先天性膵臓異常、嚢胞性線維症、膵嚢胞性線維症、サイトメガロウイルス性膵炎、遺伝性膵炎、虚血性膵炎、肝膵移植拒絶反応、ループス膵炎、浮腫性膵炎、分割膵、膵感染、膵脂肪腫症、膵移植拒絶反応、膵膿瘍、膵萎縮、膵石灰化、膵臓障害、膵管拡張、膵管閉塞、膵管狭窄、膵腫大、膵酵素異常、膵臓出血、膵梗塞、膵損傷、膵機能不全、膵島過形成、膵液漏出、膵腫瘤、膵壊死、膵フレグモーネ、膵仮性嚢胞、膵炎、急性膵炎、細菌性膵炎、慢性膵炎、真菌性膵炎、出血性膵炎、蠕虫性膵炎、ムンプス性膵炎、壊死性膵炎、再発性膵炎、ウイルス性膵炎、膵石症、膵腎症候群、ピアソン症候群、腎膵移植拒絶反応、シュワッハマン・ダイアモンド症候群、オッディ括約筋機能不全	
膵新生物（HLT）の下位の PT： 膵腺癌、膵のカルチノイド腫瘍、悪性ガストリノーマ、グルカゴン産生腫瘍、インスリノーマ、ランゲルハンス島の悪性新生物、膵転移、ニューロテンシノーマ、膵癌、転移性膵癌、切除不能な膵癌、再発膵癌、切除可能な膵癌、膵癌第０期、膵癌第１期、膵癌第２期、膵癌第３期、膵癌第４期、膵嚢胞、膵新生物、膵神経内分泌腫瘍、転移性膵神経内分泌腫瘍、膵肉腫、膵の充実性偽乳頭状腫瘍、ソマトスタチノーマ、ビポーマ	

膵臓組織
消化酵素（HLT）の下位の PT（LLT）: 血中アミラーゼ（Amylase）、血中アミラーゼ減少（Amylase decreased）、血中アミラーゼ増加（Amylase high）、血中アミラーゼ増加（Amylase increased）、血中アミラーゼ減少（Amylase low）、血中アミラーゼ増加（Amylase serum increased）、血中アミラーゼ（Blood alpha amylase）、血中アミラーゼ減少（Blood alpha amylase decreased）、血中アミラーゼ増加（Blood alpha amylase increased）、血中アミラーゼ、血中アミラーゼ異常、血中アミラーゼ減少、血中アミラーゼ増加、血中アミラーゼ正常、血中エラスターゼ、血中エラスターゼ減少、血中エラスターゼ増加、血中アミラーゼ（Blood gamma amylase）、血中アミラーゼ減少（Blood gamma amylase decreased）、血中アミラーゼ増加（Blood gamma amylase increased）、血中アミラーゼ（Blood pancreatic amylase）、血中アミラーゼ減少（Blood pancreatic amylase decreased）、血中アミラーゼ増加（Blood pancreatic amylase increased）、血中アミラーゼ（Blood salivary amylase）、血中アミラーゼ減少（Blood salivary amylase decreased）、血中アミラーゼ増加（Blood salivary amylase increased）、血中トリプシン減少、血中トリプシン増加、消化酵素（Digestive enzymes）、膵外分泌機能検査、膵外分泌機能検査異常、膵外分泌機能検査正常、リパーゼ、リパーゼ異常、リパーゼ減少、リパーゼ増加、リパーゼ正常、尿中リパーゼ、尿中リパーゼ減少、尿中リパーゼ増加、膵酵素減少（Pancreas enzymes decreased）、膵酵素増加（Pancreas enzymes increased）、膵酵素減少（Pancreatic enzyme decreased）、膵酵素、膵酵素検査異常、膵酵素減少、膵酵素増加、膵酵素検査正常、膵酵素（Pancreatic enzymes NOS）、膵酵素検査異常（Pancreatic enzymes NOS abnormal）、膵酵素減少（Pancreatic enzymes NOS decreased）、膵酵素増加（Pancreatic enzymes NOS increased）、膵酵素検査正常（Pancreatic enzymes NOS normal）、膵外分泌機能検査（Pancreatic exocrine secretion test）、膵外分泌機能検査異常（Pancreatic exocrine secretion test abnormal）、膵外分泌機能検査正常（Pancreatic exocrine secretion test normal）、膵酵素減少（Pancreatic secretion decreased）、膵酵素増加（Pancreatic secretion increased）、膵酵素減少（Pancreatic-secretion decreased）、膵酵素増加（Pancreatic-secretion increased）、ペプシノーゲン１減少、ペプシノーゲン１増加、ペプシノーゲン検査陽性、血中アミラーゼ（Plasma amylase）、血中アミラーゼ減少（Plasma amylase decreased）、血中アミラーゼ増加（Plasma amylase increased）、血中アミラーゼ（Serum amylase）、血中アミラーゼ減少（Serum amylase decreased）、血中アミラーゼ増加（Serum amylase increased）、便中キモトリプシン減少、尿中アミラーゼ、尿中アミラーゼ異常、尿中アミラーゼ減少、尿中アミラーゼ増加、尿中アミラーゼ正常
膵治療手技（HLT）の下位の PT: 総胆管括約筋切開、膵移植、膵切除、膵石除去、膵瘻修復、膵病変部切除、膵臓手術、膵仮性嚢胞ドレナージ、膵管括約筋切除、膵管括約筋切開、膵管ステント装着、膵管ステント除去、膵胃吻合、膵空腸吻合、胆膵管膨大部括約筋切開
膵放射線療法（HLT）の下位の PT: 膵臓近距離照射療法、膵臓電子照射療法、膵臓 γ 線療法、膵臓光子照射療法、膵臓放射線療法、膵臓レントゲン照射療法
消化管、膵臓および APUD ホルモン検査（HLT）の下位の PT: 血中カルシトニン、血中カルシトニン異常、血中カルシトニン減少、血中カルシトニン増加、血中カルシトニン正常、血中ガストリン、血中ガストリン減少、血中ガストリン増加、血中ガストリン正常、血中グルカゴン、血中グルカゴン異常、血中グルカゴン減少、血中グルカゴン増加、血中グルカゴン正常、血中インスリン、血中インスリン異常、血中インスリン減少、血

膵臓組織
中インスリン増加、血中インスリン正常、血中プロインスリン、血中プロインスリン異常、血中プロインスリン減少、血中プロインスリン増加、血中プロインスリン正常、グルカゴン負荷試験、インスリンＣペプチド、インスリンＣペプチド異常、インスリンＣペプチド減少、インスリンＣペプチド増加、インスリンＣペプチド正常、インスリン耐性試験、インスリン耐性試験異常、インスリン耐性試験正常、セクレチン試験、セクレチン試験値増加、血管作動性腸ポプリペプチド検査

眼障害	
定義レベル	**詳細**
SOC	SOC：眼障害の下位の全ての PT（プライマリー及びセカンダリー）
眼の異常感、眼瞼膿瘍、アカントアメーバ角膜炎、調節障害、後天性角膜ジストロフィー、後天性眼瞼贅皮、後天性円錐水晶体、後天性色素性網膜症、急性出血性結膜炎、アデノウイルス結膜炎、エイズ網膜症、アレルギー性角膜炎、アルストレム症候群、深径覚の変化、黒内障、一過性黒内障、弱視、アルコール性弱視、先天性弱視、斜視弱視、タバコ性弱視、閉塞隅角緑内障、無虹彩症、不等像視、不同視、先天性眼窩異常、無眼球症、前嚢収縮、前房内細胞、前房分離不全症候群、前眼房結晶形成、前眼房の変性、前眼房障害、前房のフィブリン、前房のフレア、前房の炎症、前眼房混濁、前房色素沈着、異種不同視、無水晶体眼、先天性無水晶体眼、房水のフィブリン、房水漏出、角膜リポイド環、アーガイルロバートソン瞳孔、動脈硬化性網膜症、眼精疲労、乱視、アトピー性白内障、アトピー性角結膜炎、眼球萎縮、細菌性涙嚢炎、細菌性虹彩炎、バリント症候群、基底細胞母斑症候群、バセドウ病、脈絡膜の良性新生物、結膜の良性新生物、角膜の良性新生物、眼の良性新生物、眼瞼の良性新生物、涙管の良性新生物、涙腺の良性新生物、視神経の良性新生物、眼窩の良性新生物、網膜の良性新生物、両眼球運動障害、濾過胞炎、眼瞼乳頭腫、眼瞼色素沈着、眼瞼炎、アレルギー性眼瞼炎、眼瞼皮膚弛緩症、眼瞼肥厚症、瞼裂狭小、先天性瞼裂狭小、眼瞼痙攣、眼瞼癒着、失明、先天性失明、皮質盲、昼盲、ヒステリー盲、一過性失明、外傷性失明、片側失明、境界域緑内障、ボーマン膜障害、カンジダ性眼内炎、カンジダ性網膜炎、嚢ブロック症候群、眼の上皮内癌、白内障、先天性白内障、皮質白内障、糖尿病性白内障、核性白内障、白内障手術合併症、嚢下白内障、外傷性白内障、眼窩蜂巣炎、霰粒腫、ＣＨＡＲＧＥ症候群、シャルル・ボネ症候群、眼部化学熱傷、眼部化学的損傷、視交差症候群、緑視症、網脈絡膜萎縮、先天性脈絡網膜変性、脈絡網膜障害、脈絡網膜瘢痕、脈絡網膜炎、網脈絡膜症、脈絡膜黒色腫、脈絡膜新生物、脈絡膜結節、脈絡膜欠損、脈絡膜剥離、脈絡膜ジストロフィー、脈絡膜滲出、脈絡膜血腫、脈絡膜出血、脈絡膜梗塞、脈絡膜血管新生、脈絡膜破裂、脈絡膜硬化症、脈絡膜炎、色視症、毛様体変性、毛様体障害、毛様体出血、毛様体充血、毛様体筋痙攣、毛様小帯断裂、コケーン症候群、コーガン症候群、コーエン症候群、眼欠損症、色盲、後天性色盲、コンピュータ視覚症候群、先天性脈絡膜異常、先天性角膜異常、先天性眼瞼贅皮、先天性眼障害、眼の先天性母斑、先天性眼瞼奇形、先天性虹彩異常、先天性涙腺異常、先天性涙道異常、先天性円錐水晶体、先天性近視、先天性夜盲、先天性眼振、先天性視神経異常、先天性強膜障害、先天性視力低下、先天性硝子体異常、結膜擦過傷、結膜癒着、結膜濾過胞、結膜嚢胞、結膜変性、結膜沈着物、結膜変色、結膜障害、結膜びらん、結膜濾過胞漏出、結膜濾胞、結膜肉芽、結膜出血、結膜充血、結膜刺激、結膜黒色腫、結膜新生物、結膜浮腫、結膜の混濁、結膜蒼白、結膜色素沈着、原発性後天性結膜メラノーシス、結膜瘢痕、結膜潰瘍、結膜血管障害、結膜炎、アレルギー性結膜炎、細菌性結膜炎、クラミジア性結膜炎、新生児淋菌性結膜炎、感染性結膜炎、結核性結膜炎、ウイルス性結膜炎、結膜弛緩症、コンタクトレンズ不耐性、瞳孔偏位、角膜擦過傷、角膜膿瘍、角膜出血、角膜嚢胞、角膜代償不全、角膜欠損、角膜変性、角膜沈着物、角膜障害、角膜ジストロフィー、角膜内皮炎、角膜上皮小嚢胞、角膜上皮欠損、角膜びらん、角膜落屑、角膜移植片拒絶反応、角膜肥厚、角膜感染、角膜浸潤、角膜病変、角膜白斑、角膜血管新生、角膜浮腫、角膜混濁、先天性角膜混濁、角膜穿孔、角膜色素沈着、角膜瘢痕、角膜ブドウ腫、角膜線条、角膜菲薄化、角膜接触、ネコ泣き症候群、ワニの涙症候群、潜在眼球症、青視症、毛	

眼障害
様体膜、毛様体炎、単眼症、毛様体筋麻痺、先天性嚢胞性眼球、嚢胞様黄斑浮腫、サイトメガロウイルス性脈絡網膜炎、後天性涙腺炎、涙小管炎、涙嚢炎、涙石、後天性涙道狭窄、先天性涙道狭窄、眼の隈、眼窩変形、角膜縁凹窩、眼沈着物、デスメ膜剥離、網膜色素上皮剥離、発達緑内障、糖尿病性失明、糖尿病性眼病変、糖尿病性緑内障、糖尿病性角膜症、糖尿病性眼筋麻痺、糖尿病性網膜浮腫、糖尿病性網膜症、糖尿病性ブドウ膜炎、複視、眼球障害、眼窩障害、睫毛重生、眼乾燥、デュアン症候群、視測障害、イールズ病、眼瞼外反、眼瞼湿疹、内分泌性眼症、眼内炎、眼球陥入、外傷による眼球陥入、眼瞼内反、先天性眼瞼内反症、上強膜充血、上強膜炎、眼瞼紅斑、赤視症、涙点外転、瞬目過多、眼の輻輳過多、眼球突出症、先天性眼球突出症、外眼筋障害、外眼筋不全麻痺、眼球外網膜芽細胞腫、滲出性網膜症、眼膿瘍、眼のアレルギー、先天性前眼房異常、眼の熱傷、医療機器関連眼合併症、眼変性障害、眼脂、眼の障害、眼出血、眼感染、細菌性眼感染、クラミジア性眼感染、真菌性眼感染、淋菌性眼感染、蠕虫性眼感染、眼内感染、ブドウ球菌性眼感染、梅毒性眼感染、トキソプラズマ性眼感染、ウイルス性眼感染、眼の炎症、眼外傷、眼刺激、眼レーザー瘢痕、眼の脱臼、眼運動障害、眼筋絞扼、眼の母斑、眼球浮腫、眼部手術合併症、眼痛、眼の貫通性外傷、眼そう痒症、眼球回旋、眼部腫脹、眼球裂離、眼球破裂、睫毛変色、睫毛剛毛化、眼瞼出血、眼瞼せつ、眼瞼嚢胞、眼瞼変性障害、眼瞼障害、眼瞼びらん、眼瞼落屑、眼瞼毛包炎、眼瞼機能障害、眼瞼感染、眼瞼損傷、眼瞼刺激、眼瞼縁痂皮、眼瞼浮腫、眼瞼痛、眼瞼下垂、先天性眼瞼下垂、眼瞼後退、眼瞼知覚障害、眼瞼腫瘍、眼瞼血管障害、眼瞼そう痒症、くぼんだ眼、顔面指性器異形成、術後水晶体のフィブリン沈着、糸状虫症、浅前眼房、フロッピー眼瞼症候群、虹彩緊張低下症候群、眼内異物、眼の異物感、フォスター・ケネディー症候群、フックス症候群、真菌性網膜炎、注視麻痺、巨大乳頭結膜炎、グレア、緑内障、外傷性緑内障、緑内障性毛様体炎発症、緑内障性視神経乳頭萎縮、睫毛の成長、網膜血管腫、光輪視、ヘールフォルト症候群、半盲、異名性半盲、同名性半盲、肝レンズ核変性症、遺伝性脈絡膜形成異常、遺伝性視神経萎縮、遺伝性網膜ジストロフィー、ヘルペス眼感染、眼部単純ヘルペス、新生児単純ヘルペスウイルス結膜炎、眼帯状疱疹、虹彩異色、眼球斜位、瞳孔動揺、ホームズ・アディー瞳孔、麦粒腫、ホルネル症候群、星状硝子体症、遠視、前房出血、眼の知覚低下、前房蓄膿、低眼圧、第３脳神経障害、第３神経損傷、第３脳神経麻痺、第３脳神経不全麻痺、封入体結膜炎、新生児封入体結膜炎、感染性結晶状角膜症、感染性虹彩毛様体炎、涙道の炎症、角膜損傷、中間部ブドウ膜炎、眼球内黒色腫、眼球内網膜芽細胞腫、虹彩脱出、虹彩角膜内皮症候群、虹彩毛様体炎、虹彩離断、虹彩振盪、虹彩麻痺、虹彩分離、虹彩癒着、虹彩萎縮、膨隆虹彩、虹彩欠損、凸虹彩、虹彩嚢腫、虹彩障害、虹彩落屑、虹彩出血、虹彩色素過剰、虹彩色素減少、虹彩嵌頓、虹彩損傷、虹彩新生物、虹彩血管新生、虹彩徹照異常、虹彩血管障害、虹彩黒色腫、虹彩炎、第４脳神経障害、第４神経損傷、第４脳神経麻痺、カイザー・フライシャー輪、ケアーンズ・セイヤー症候群、角膜炎、細菌性角膜炎、真菌性角膜炎、ヘルペス性角膜炎、角膜実質炎、硬化性角膜炎、ウイルス性角膜炎、角膜炎・魚鱗癬・難聴症候群、麻疹性角結膜炎、乾性角結膜炎、円錐角膜、角膜軟化症、角膜症、角膜破裂、淋菌性角化症、ケッペ結節、涙腺萎縮、涙腺嚢胞、涙器障害、涙管新生物、涙管色素沈着、涙腺癆、涙腺肥大、涙器出血、涙腺粘液嚢胞、涙道肉芽腫、涙点欠損、涙嚢蜂巣炎、涙液分泌低下、流涙増加、兎眼、ローレンス・ムーン・バルデー・ビードル症候群、レーバー先天性黒内障、先天性水晶体異常、水晶体変色、水晶体脱臼、水晶体障害、水晶体混濁、水晶体色素沈着、白血病性網膜症、白色瞳孔、閉眼遅延、眼瞼縁分泌物、角膜輪部充血、網膜脂血症、視覚コントラスト感度低下、巨大角膜、黄斑嚢胞、黄斑変性、黄斑円孔、黄斑虚血、黄斑浮腫、黄斑部混濁、黄斑偽円孔、黄斑破裂、

眼障害
黄斑部瘢痕、黄斑部血管痙攣、黄斑症、睫毛眉毛脱落症、眼瞼の悪性黒色腫、悪性近視、脈絡膜の悪性新生物、結膜の悪性新生物、角膜の悪性新生物、眼の悪性新生物、眼瞼の悪性新生物、涙管の悪性新生物、涙腺の悪性新生物、眼窩の悪性新生物、網膜の悪性新生物、マーカス・ガン症候群、マルファン症候群、マイボーム腺分泌物、マイボーム腺機能不全、瞼板腺炎、眼球金属症、変視症、眼転移、転移性眼球黒色腫、小角膜、小眼球症、ミクリッツ病、ミクリッツ症候群、ミラール・ギュブレ症候群、ミラー・フィッシャー症候群、縮瞳、朝顔症候群、真菌性角膜潰瘍、散瞳、近視、近視乳頭、前房狭隅角、壊死性ヘルペス性網膜症、壊死性網膜炎、壊死性強膜炎、角膜新生物、悪性度不明、眼窩新生物、神経性眼瞼障害、視神経脊髄炎、ＮＡＲＰ症候群、神経栄養性角膜症、夜盲、正常眼圧緑内障、ノリエ病、眼振、眼白子症、転移性眼悪性腫瘍、眼部不快感、眼球運動失調、眼球癆、眼部血管外皮腫、眼充血、高眼圧症、黄疸眼、眼虚血症候群、眼筋無力症、眼部新生物、眼類天疱瘡、眼球後出血、眼サルコイドーシス、オキュラーサーフェス疾患、眼毒性、眼血管障害、眼血管炎、眼脳腎症候群、眼歯指形成異常、眼球回転発作、皮膚粘膜眼症候群、眼咽頭筋ジストロフィー、眼呼吸器症候群、オンコセルカ症、開放隅角緑内障、新生児眼炎、結節性眼炎、眼筋麻痺、眼筋麻痺性片頭痛、眼球クローヌスミオクローヌス、視神経萎縮、視神経乳頭障害、視神経乳頭ドルーゼン、視神経乳頭出血、視神経乳頭毛細血管拡張、視神経乳頭血管障害、視神経乳頭辺縁不鮮明、虚血性視神経症、視神経乳頭陥凹、視神経障害、視神経低形成、視神経梗塞、視神経損傷、視神経新生物、視神経鞘出血、視神経炎、髄膜炎菌性視神経炎、視神経症、視覚路損傷、視索神経膠腫、眼窩萎縮、眼窩先端部症候群、眼窩嚢胞、眼窩肉芽腫、眼窩感染、眼窩浮腫、眼窩偽腫瘍、動揺視、骨粗鬆症・偽性神経膠腫症候群、太田母斑、全眼球炎、視神経乳頭浮腫、結膜乳頭腫、視神経乳頭血管炎、麻痺性兎眼、腫瘍随伴性網膜症、眼傍結合織炎、毛様体扁平部嚢胞、眼窩周囲膿瘍、眼窩周囲蜂巣炎、眼窩周囲障害、眼窩脂肪ヘルニア、眼窩周囲血腫、眼窩周囲感染、眼窩周囲浮腫、ＰＨＡＣＥＳ症候群、水晶体融解性緑内障、母斑症、光視、光痛、電気性結膜炎、光線角膜炎、羞明、光視症、色素散乱症候群、色素性緑内障、瞼裂斑、瞼裂斑炎、ポリープ状脈絡膜血管症、後嚢部混濁、後嚢破裂、後眼房異常、先天性後眼房異常、老視、推定眼ヒストプラスマ症候群、進行性外眼筋麻痺、内眼角贅皮、原虫性角膜潰瘍、偽眼瞼下垂、偽眼内炎、水晶体嚢の偽落屑、偽乳頭浮腫、偽翼状片、弾性線維性仮性黄色腫、翼状片、点状角膜炎、固定瞳孔、瞳孔変形、瞳孔障害、瞳孔反射障害、瞳孔緊張、瞳孔不同、放射線性白内障、放射線角膜損傷、放射線網膜症、レイモン・セスタン症候群、隅角離開、屈折障害、屈折弱視、網膜血管瘤、先天性網膜異常、網膜動静脈奇形、網膜動脈塞栓症、網膜動脈閉塞、網膜動脈攣縮、網膜動脈狭窄、網膜動脈血栓症、網膜欠損、網膜嚢胞、網膜変性、網膜色素脱失、網膜沈着物、網膜剥離、網膜障害、網膜ジストロフィー、網膜滲出物、網膜出血、網膜梗塞、網膜滲出斑、網膜損傷、網膜虚血、網膜色素細胞腫、網膜メラノーマ、網膜性片頭痛、網膜新生物、網膜血管新生、網膜浮腫、網膜蒼白、網膜光毒性、網膜色素上皮裂孔、網膜色素上皮症、網膜色素沈着、網膜瘢痕、網膜裂孔、網膜末梢血管拡張、網膜毒性、網膜血管障害、網膜血管閉塞、網膜血管血栓症、網膜血管炎、網膜静脈閉塞、網膜静脈血栓症、網膜炎、ヒストプラスマ性網膜炎、色素性網膜炎、ウイルス性網膜炎、網膜芽腫、両側性網膜芽細胞腫、片側性網膜芽細胞腫、網膜症、先天性網膜症、出血性網膜症、高血圧性網膜症、粘度亢進網膜症、未熟児網膜症、増殖性網膜症、鎌状赤血球網膜症、日光網膜症、網膜分離症、先天性網膜分離症、後眼窩新生物、リウマトイド強膜炎、ロス症候群、衝動性眼球運動、閃輝暗点、強膜嚢胞、強膜変性、強膜変色、強膜障害、強膜出血、強膜充血、強膜浮腫、強膜色素沈着、強膜菲薄化、強膜炎、アレルギー性強膜炎、強膜軟化症、暗点、乾燥症候群、シェーグレン症

眼障害
候群、球状水晶体、ブドウ腫、スタルガルト病、スティックラー症候群、斜視、先天性斜視、スタージ・ウェーバー症候群、亜急性脊髄視神経ニューロパチー、結膜下嚢胞、網膜下線維症、突然視力消失、眼の擦過傷、涙管腫脹、瞼球癒着、交感性眼炎、閃輝性融解、涙液変色、テノン嚢胞、テリエン周辺角膜変性、眼部熱性熱傷、甲状腺中毒クリーゼ、トロサ・ハント症候群、中毒性前眼部症候群、中毒性白内障、中毒性視神経症、トキソカラ症、トラコーマ、睫毛乱生、長睫毛症、１３トリソミー、２２トリソミー、眼結核、結節性硬化症、尿細管間質性腎炎ブドウ膜炎症候群、トンネル状視野、ウートホフ現象、潰瘍性角膜炎、アッシャー症候群、ブドウ膜脱出、ブドウ膜炎、ブドウ膜炎－緑内障－前房出血症候群、静脈うっ滞網膜症、前庭眼振、ウイルス性角膜潰瘍、ウイルス性虹彩炎、新生児視覚異常、霧視、視力低下、一過性視力低下、視覚の明るさ、視野欠損、視力障害、視覚路障害、ビタミンＡ欠乏性眼障害、ビタミンＡ欠乏性結膜障害、ビタミンＡ欠乏性角膜障害、第６脳神経障害、第６神経損傷、第６脳神経麻痺、硝子体細胞、硝子体膿瘍、硝子体癒着、硝子体変性、硝子体剥離、硝子体障害、硝子体のフィブリン、硝子体浮遊物、硝子体出血、硝子体損傷、硝子体脱失、硝子体混濁、硝子体脱出、硝子体炎、フォークト・小柳・原田症候群、ワールデンブルグ症候群、ワグナー病、ヴァイル・マルケサーニ症候群、ウィルダーバンク症候群、ワイバーン・メーソン症候群、黄視症、眼球乾燥

皮膚組織	
定義レベル	詳細
SOC	SOC：皮膚および皮下組織障害の下位の全ての PT（プライマリー及びセカンダリー）
手掌／足底皮線異常、外耳道膿瘍、眼瞼膿瘍、汗腺膿瘍、棘融解、棘細胞腫、表皮肥厚、黒色表皮腫、ダニ症、ダニ皮膚炎、後天性毛髪色素欠乏症、先天性毛髪色素欠乏症、ざ瘡、集簇性ざ瘡、化粧品性ざ瘡、嚢胞性ざ瘡、電撃性ざ瘡、乳児性ざ瘡、職業性ざ瘡、膿疱性ざ瘡、痘瘡状ざ瘡、後天性指被角線維症、後天性表皮水疱症、末端部黒子様黒色腫第１期、末端部黒子様黒色腫第２期、末端部黒子様黒色腫第３期、末端部黒子様黒色腫第４期、末端部黒子様黒色腫、病期不明、アクロコルドン、慢性萎縮性先端皮膚炎、腸性先端皮膚炎、肢端疼痛症、腫瘍随伴性肢端角化症、疣贅状肢端角化症、光線性弾性線維症、日光性角化症、放線菌性皮膚感染、急性熱性好中球性皮膚症、急性汎発性発疹性膿疱症、急性皮膚移植片対宿主病、乳児急性出血性浮腫、有痛性脂肪症、白子症、オールブライト病、脱毛症、円形脱毛症、休止期脱毛、瘢痕性脱毛症、梅毒性脱毛症、全頭脱毛症、汎発性脱毛症、アメーバ性皮膚潰瘍、肛門カンジダ症、真菌性肛門感染、肛門白癬、アンドロゲン性脱毛症、血管皮膚炎、血管浮腫、被角血管腫、好酸球増多を伴う血管リンパ組織過形成、無汗症、肛門性器疣贅、肛門直腸蜂巣炎、先天性皮膚形成不全、アポクリン汗疹、適用部位脱毛、適用部位熱傷、適用部位蜂巣炎、適用部位皮膚炎、適用部位分泌物、適用部位乾燥、適用部位湿疹、適用部位紅斑、適用部位皮膚剥脱、適用部位毛包炎、適用部位結節、適用部位蒼白、適用部位丘疹、適用部位光線過敏反応、適用部位そう痒感、適用部位膿疱、適用部位発疹、適用部位痂皮、適用部位瘢痕、適用部位蕁麻疹、適用部位小水疱、水原性そう痒症、銀皮症、砒素角化症、動脈硬化性壊疽、節足動物寄生、皮脂欠乏症、毛細血管拡張運動失調、白色萎縮、パッシーニ・ピエリーニ型皮膚萎縮症、異型線維黄色腫、外耳道びらん、腋窩カンジダ症、細菌性血管腫症、基底細胞癌、基底細胞母斑症候群、皮膚基底有棘細胞癌、ベッカー母斑、トコジラミ寄生、ベーチェット症候群、良性家族性天疱瘡、皮膚良性新生物、あざ、バート・ホッグ・デュベ症候群、黒色砂毛、眼瞼色素沈着、眼瞼炎、眼瞼皮膚弛緩症、眼瞼肥厚症、水疱、感染性水疱、血性水疱、体部白癬、ハンセン病、境界群、ボタン熱、ウシ膿庖性口内炎ウイルス感染、ボーエン病様丘疹症、ボーエン病、乳房変色、臭汗症、臭素疹、水疱性膿痂疹、熱傷部感染、灼熱足症候群、蝶形皮疹、カフェ・オ・レ斑、キャンベル・ドゥ・モルガン斑、カンジダ性おむつ皮疹、毛細血管炎、毛細血管脆弱、癬、皮膚上皮内癌、カテーテル留置部位蜂巣炎、カテーテル留置部位そう痒感、カテーテル留置部位発疹、カテーテル留置部位蕁麻疹、蜂巣炎、腸球菌性蜂巣炎、壊疽性蜂巣炎、パスツレラ菌性蜂巣炎、ブドウ球菌性蜂巣炎、レンサ球菌性蜂巣炎、子宮頚部水疱、口唇炎、肉芽腫性口唇炎、口唇症、皮膚化学熱傷、肝斑、クロールざ瘡、胆汁うっ滞性そう痒症、慢性乳児期発症神経皮膚関節症候群、口周囲浮腫、コブ症候群、冷汗、昏睡性水疱、代償性発汗、扁平コンジローマ、融合性細網状乳頭腫症、先天性アクロコルドン、先天性皮膚弛緩症、先天性皮膚洞、先天性角化異常症、先天性外胚葉形成不全、先天性眼瞼奇形、先天性全身性リポジストロフィー、先天性毛髪障害、先天性多毛症、先天性黒色症、先天性母斑、先天性爪障害、先天性色素沈着障害、先天性多形皮膚萎縮症、先天性皮膚障害、挫傷、牛痘、クレスト症候群、クロンカイト・カナダ症候群、クリプトコッカス皮膚感染、カレン徴候、皮膚アミロイドーシス、皮膚炭疽、皮膚コクシジオイデス症、皮膚輪郭変形、皮膚幼虫移行症、皮膚リーシュマニア症、皮膚イトグモ刺咬症、皮膚エリテマトーデス、皮膚サルコイドーシス、皮膚スポロトリコーシス、皮膚結核、皮膚血管炎、血小板減少症を伴う皮膚内臓血管腫症、皮膚弛緩症、	

皮膚組織
項部菱形皮膚、サイトメガロウイルス性皮膚粘膜潰瘍、頭部粃糠疹、ダプソン症候群、褥瘡性潰瘍、デング熱、デニー・モルガン皺襞、循環不全性充血、皮膚嚢腫、皮膚洞、自傷性皮膚症、皮膚炎、ざ瘡様皮膚炎、アレルギー性皮膚炎、人工皮膚炎、アトピー性皮膚炎、水疱性皮膚炎、接触性皮膚炎、おむつ皮膚炎、剥脱性皮膚炎、全身性剥脱性皮膚炎、疱疹状皮膚炎、感染性皮膚炎、頭部乳頭状皮膚炎、乾癬様皮膚炎、播種性皮膚線維腫症、先天性皮膚掌紋異常、皮膚筋炎、皮膚糸状菌症、皮膚症、皮膚皮下組織炎、糖尿病性水疱、糖尿病性手障害、糖尿病性皮膚障害、糖尿病性足病変、糖尿病性足感染、糖尿病性壊疽、糖尿病性神経障害性潰瘍、糖尿病性潰瘍、びまん性皮膚肥満細胞症、ダウリング・デゴス病、薬疹、好酸球増加と全身症状を伴う薬疹、乾性壊疽、皮膚乾燥、発汗障害、異形成母斑症候群、外耳道紅斑、耳垂感染、斑状出血、エクリン腺癌、膿瘡、眼瞼外反、湿疹、皮脂欠乏性湿疹、眼瞼湿疹、ヘルペス性状湿疹、膿痂疹性湿疹、乳児湿疹、感染性湿疹、貨幣状湿疹、種痘性湿疹、小水疱性湿疹、湿潤性湿疹、エーラース・ダンロス症候群、穿孔性弾性線維症、腸管皮膚瘻、眼瞼内反、好酸球性蜂巣炎、好酸球性膿疱性毛包炎、好酸球性膿疱症、雀卵斑、表皮壊死、疣贅状表皮発育異常症、表皮融解、表皮水疱症、嚢状腺様上皮腫、発疹性偽血管腫症、丹毒、類丹毒、紅斑、ヒダコ、環状紅斑、色素異常性固定紅斑、持続性隆起性紅斑、硬結性紅斑、伝染性紅斑、辺縁紅斑、遊走性紅斑、多形紅斑、結節性紅斑、眼瞼紅斑、新生児中毒性紅斑、紅色陰癬、紅色チアノーゼ、乾癬性紅皮症、変異性紅斑角皮症、紅痛症、紅色症、焼痂、過剰肉芽組織、過剰皮膚、擦過傷、剥脱性発疹、乳房外パジェット病、眼瞼出血、眼瞼せつ、眼瞼嚢胞、眼瞼変性障害、眼瞼障害、眼瞼びらん、眼瞼落屑、眼瞼毛包炎、眼瞼感染、眼瞼損傷、眼瞼刺激、眼瞼縁痂皮、眼瞼浮腫、眼瞼痛、眼瞼血管障害、眼瞼そう痒症、ファブリ病、顔面浮腫、顔面片側萎縮、顔のやせ、家族性感冒自己炎症性症候群、女性生殖器瘻、線維性組織球腫、指紋消失、固定疹、ノミ寄生、フロッピー眼瞼症候群、潮紅、毛包性ムチン沈着症、毛包炎、口蹄疫、異物反応、真菌性爪囲炎、皮膚真菌感染、腫瘍自潰創、せつ、壊疽、新生児壊疽、ガス壊疽、全身紅斑、全身性ワクシニア、性器紅斑、性器潰瘍形成、ジアノッティ・クロスティ症候群、グライヒ症候群、顎口虫症、痛風結節、肉芽腫、環状肉芽腫、皮膚肉芽腫、滴状乾癬、皮膚血管腫、血管腫・血小板減少症候群、血汗症、皮下出血、表皮下出血、出血性蕁麻疹、毛髪変色、毛髪障害、良性毛包腫瘍、毛髪成長異常、毛質異常、ＨＡＩＲ－ＡＮ症候群、鎌状赤血球貧血による手足症候群、手足口病、逆むけ、ハーレキン胎児、ハートナップ病、紅色汗疹、ヘノッホ・シェーンライン紫斑病、ヘノッホ・シェーンライン紫斑病性腎炎、遺伝性血管浮腫、遺伝性出血性毛細血管拡張症、ヘルペス性皮膚炎、妊娠ヘルペス、単純ヘルペス、単純ヘルペス性外耳炎、帯状疱疹、多神経分節性帯状疱疹、耳帯状疱疹、汗腺炎、男性型多毛症、蛭寄生、皮膚ヒストプラスマ症、ハッチンソン夏期痒疹、高カロチン血症、多汗症、過角化、毛包毛包傍角化症、掌蹠角化症、多毛症、肥厚性瘢痕、顔面感覚鈍麻、乏汗症、貧毛症、魚鱗癬、後天性魚鱗癬、特発性滴状色素減少症、特発性黒子様皮膚粘膜色素沈着、特発性血小板減少性紫斑病、特発性蕁麻疹、膿痂疹、疱疹状膿痂疹、埋込み部位蜂巣炎、埋込み部位皮膚炎、埋込み部位変色、埋込み部位皮膚剥脱、埋込み部位丘疹、埋込み部位そう痒感、埋込み部位膿疱、埋込み部位発疹、埋込み部位瘢痕、埋込み部位蕁麻疹、埋込み部位小水疱、切開部位水疱、切開部位蜂巣炎、切開部位紅斑、切開部位そう痒感、内出血発生の増加傾向、感染性腱膜瘤、感染性表皮嚢胞、感染性母斑、感染性皮脂嚢腫、感染性皮膚潰瘍、寄生、注入部位蜂巣炎、注入部位皮膚炎、注入部位びらん、注入部位皮膚剥脱、注入部位光線過敏反応、注入部位そう痒感、注入部位膿疱、注入部位発疹、注入部位痂皮、注入部位瘢痕、注入部位潰瘍、注入部位蕁麻疹、注入部位小水疱、嵌入爪、内方発育毛、注射部位蜂巣炎、注射部位皮膚炎、注射部位乾燥、注射部

皮膚組織
位湿疹、注射部位びらん、注射部位皮膚剥脱、注射部位斑、注射部位結節、注射部位蒼白、注射部位丘疹、注射部位光線過敏反応、注射部位そう痒感、注射部位膿疱、注射部位発疹、注射部位痂皮、注射部位瘢痕、注射部位潰瘍、注射部位蕁麻疹、注射部位小水疱、滴下投与部位紅斑、滴下投与部位そう痒感、間質性肉芽腫性皮膚炎、間擦疹、カンジダ性間擦疹、ヨードざ瘡、瘢痕そう痒感、日本紅斑熱、黄疸、ジェスナーリンパ球浸潤、良性若年性黒色腫、若年性春期丘疹、カポジ水痘様発疹、ケロイド瘢痕、角膜炎・魚鱗癬・難聴症候群、ケラトアカントーマ、膿漏性角皮症、後天性剥脱性角質剥離、先天性剥脱性角質剥離、毛包性角化症、淋菌性角化症、毛孔性角化症、禿瘡、ケブナー現象、さじ状爪、喉頭浮腫、喉頭爪皮膚症候群、喉頭気管浮腫、ラッサ熱、ラテックスアレルギー、黒子、再発悪性黒子、悪性黒子第１期、悪性黒子第２期、悪性黒子第３期、悪性黒子第４期、悪性黒子、病期不明、ハンセン病、らい腫型、レーザー・トレラ徴候、白血球破砕性血管炎、白斑、白斑症、シラミ寄生、粘液水腫性苔癬、光沢苔癬、扁平苔癬、硬化性苔癬、棘状苔癬、線状苔癬、苔癬化、苔癬様角化症、リニアＩｇＡ病、口唇水疱、口唇浮腫、口唇腫脹、脂肪組織萎縮症、後天性リポジストロフィー、脂肪肥大症、網状皮斑、青藍色状態、顔面播種状粟粒性狼瘡、尋常性狼瘡、ループス様症候群、ライム病、皮膚型リンパ腫、リンパ腫様丘疹症、斑、睫毛眉毛脱落症、マヨッキ紫斑病、悪性萎縮性丘疹症、悪性黒色腫、表皮内悪性黒色腫、悪性黒色腫第１期、悪性黒色腫第２期、悪性黒色腫第３期、悪性黒色腫第４期、肥満細胞腫、マゾッティ反応、麻疹、ワクチン接種後の麻疹、機械的ざ瘡、機械性蕁麻疹、メラノサイト性母斑、黒皮症、再発黒色腫、メラノーシス、メルカーソン・ロゼンタール症候群、メンケス症候群、皮膚転移、転移性悪性黒色腫、稗粒腫、搾乳者結節、伝染性軟属腫、モルフェア、マックル・ウェルズ症候群、粘膜皮膚カンジダ症、粘膜皮膚リーシュマニア症、皮膚粘膜発疹、皮膚粘膜潰瘍形成、ムア・トレ症候群、多中心性細網組織球症、多発性黒子症候群、マイコバクテリウム・ウルセランス感染、粘液水腫、貧血母斑、火炎状母斑、母斑出血、先天性くも状母斑、爪萎縮、爪裂離、爪床出血、爪床障害、爪床感染、細菌性爪床感染、真菌性爪床感染、ウイルス性爪床感染、爪床の炎症、爪床圧痛、爪カンジダ症、爪変色、爪の不快感、爪の障害、爪ジストロフィー、爪成長異常、爪肥厚、爪感染、爪損傷、爪摘み取り、爪色素沈着、爪甲点状凹窩、爪乾癬、翼状爪、爪毒性、爪膝蓋骨症候群、糖尿病性脂肪類壊死症、壊死融解性遊走性紅斑、壊死性脂肪織炎、注射痕、新生児エリテマトーデス、皮膚の新生物、腎原性全身性線維症、ネザートン症候群、神経皮膚炎、皮膚神経内分泌癌、神経障害性潰瘍、好中球性脂肪織炎、ニコチン酸欠乏、寝汗、ニコルスキー現象、乳頭潰瘍形成、結節性脈管炎、組織黒変症、眼類天疱瘡、皮膚粘膜眼症候群、眼呼吸器症候群、口腔浮腫、油性ざ瘡、オルムステッド症候群、オンコセルカ症、爪痛、爪破損、爪甲鉤弯症、爪甲離床症、爪甲脱落症、爪軟化症、爪真菌症、爪咬癖、口腔扁平苔癬、ヒツジ鶩口瘡、オスラー結節、皮膚骨腫、太田母斑、カンジダ性外耳炎、真菌性外耳炎、オーバーラップ症候群、皮膚パジェット病、皮膚疼痛、蒼白、手掌紅斑、手掌・足底発赤知覚不全症候群、触知可能紫斑病、脂肪織炎、小葉性脂肪織炎、丘疹、丘疹－紅皮症（太藤）、不全角化、腫瘍随伴性皮膚筋炎、腫瘍随伴性天疱瘡、類乾癬、パラワクシニア、爪囲炎、部分的リポジストロフィー、ポードレンジ、類天疱瘡、天疱瘡、陰茎水疱、陰茎潰瘍形成、肛門周囲紅斑、会陰紅斑、会陰潰瘍、眼窩周囲浮腫、ブドウ球菌性汗孔周囲炎、臍帯周囲膿瘍、血管周囲細胞浸潤性皮膚炎、点状出血、ポイツ・イェガース症候群、褐色糸状菌症、母斑症、光線性皮膚症、光線性爪甲離床症、アレルギー性光線過敏性反応、光線過敏性反応、色素沈着障害、口唇色素沈着、立毛、毛巣嚢胞、先天性毛巣嚢胞、ピンタ、点状角質融解症、粃糠疹、白色粃糠疹、急性痘瘡状苔癬状粃糠疹、ばら色粃糠疹、毛孔性紅色粃糠疹、足底紅斑、胸膜皮膚癆、ポゴスタ病、多形

皮膚組織
皮膚萎縮症、多形妊娠疹、多形日光疹、汗孔癌、汗孔角化症、非急性ポルフィリン症、炎症後色素沈着変化、処置後蜂巣炎、ワクチン接種後自家接種、耳後部瘻、前癌性皮膚病変、早老、進行性ワクシニア、痒疹、そう痒症、アレルギー性そう痒症、全身性そう痒症、陰部そう痒症、偽須毛包炎、偽性ポルフィリン症、弾性線維性仮性黄色腫、乾癬、乾癬性関節症、点状角化症、紫斑、電撃性紫斑病、新生児紫斑、老人性紫斑、膿疱性乾癬、膿皮症、壊疽性膿皮症、レンサ球菌性膿皮症、化膿性肉芽腫、クインスランドダニ性チフス、放射線宿酔症候群、放射線皮膚損傷、発疹、紅斑性皮疹、毛孔性皮疹、全身性皮疹、斑状皮疹、斑状丘疹状皮疹、斑水疱性皮疹、麻疹様発疹、新生児発疹、丘疹性皮疹、丘疹落屑性皮疹、そう痒性皮疹、膿疱性皮疹、風疹状皮疹、猩紅熱様発疹、小水疱性皮疹、反応性穿孔性膠原線維症、リバウンド乾癬、リコール現象、再発性せつ、レッドマン症候群、網状紅斑性ムチン沈着症、リウマトイド結節、リケッチア痘症、ロッキー山紅斑熱、酒さ、ロス症候群、ＳＡＰＨＯ症候群、皮膚の肉腫、里吉症候群、痂皮、瘢痕、瘢痕痛、猩紅熱、シャンバーグ病、皮膚住血吸虫症、シュニッツラー症候群、皮膚硬化症、肢端硬化症、強皮症、浮腫性硬化症、硬化性胼胝腫、引っかき傷、陰嚢嚢胞、陰嚢紅斑、陰嚢壊疽、陰嚢潰瘍、脂腺腺腫、脂腺癌、脂腺障害、脂腺感染、脂腺機能亢進、脂腺過形成、脂腺母斑、脂漏、脂漏性皮膚炎、脂漏性角化症、分節ヒアリン血管炎、老人性そう痒症、中隔性脂肪組織炎、敗血疹、シリコン肉芽腫、シェーグレン・ラルソン症候群、皮膚萎縮、皮膚細菌感染、皮膚灼熱感、皮膚癌、転移性皮膚癌、皮膚カンジダ、ひび・あかぎれ、皮膚変性障害、皮膚色素脱失、皮膚変色、皮膚不快感、皮膚障害、皮膚ジストロフィー、皮膚びらん、皮膚剥脱、皮膚線維症、皮膚亀裂、皮弁壊死、皮膚脆弱性、植皮生着不全、植皮感染、皮膚移植片拒絶反応、皮膚出血、皮膚色素過剰、皮膚肥厚、皮膚色素減少、皮膚低形成、皮膚硬結、皮膚感染、皮膚蠕虫感染、皮膚損傷、皮膚刺激、皮膚裂傷、皮膚病変、皮膚軟化、皮膚奇形、皮膚腫瘤、皮膚壊死、皮膚新生物出血、皮膚小結節、皮膚異常臭、皮膚浮腫、皮膚乳頭腫、皮膚局面、皮膚反応、皮膚感作、皮膚線条、皮膚腫脹、皮膚のつっぱり感、皮膚毒性、皮膚潰瘍、出血性皮膚潰瘍、皮膚熱感、皮膚しわ、小腸血管浮腫、痘瘡、スネドン症候群、日光蕁麻疹、身体表現性皮膚障害、くも状母斑、くも状静脈、線状出血、皮膚有棘細胞癌、ブドウ球菌性膿痂疹、ブドウ球菌性熱傷様皮膚症候群、ブドウ球菌皮膚感染、うっ滞性皮膚炎、多発性脂腺嚢腫、スティーブンス・ジョンソン症候群、皮膚のべとつき感、レンサ球菌性膿痂疹、スタージ・ウェーバー症候群、角層下膿疱性皮膚症、皮下組織膿瘍、皮下気腫、皮下血腫、皮下結節、サンバーン、表在拡大型黒色腫第１期、表在拡大型黒色腫第２期、表在拡大型黒色腫第３期、表在拡大型黒色腫第４期、表在拡大型黒色腫、病期不明、多乳頭、術後皮膚裂傷、汗の変色、汗腺障害、汗腺感染、汗腺腫瘍、顔面腫脹、須毛瘡、全身性エリテマトーデス、全身性エリテマトーデス皮疹、全身性硬化症、毛細血管拡張症、先天性毛細血管拡張症、血小板減少性紫斑病、血栓性血小板減少性紫斑病、甲状腺性皮膚障害、須毛白癬、白色癬、頭部白癬、股部白癬、顔面白癬、渦状癬、白癬感染、手白癬、黒癬、足部白癬、癜風、舌浮腫、中毒性表皮壊死融解症、中毒性皮疹、一過性棘融解性皮膚症、ざんごう熱、睫毛乱生、長睫毛症、白癬性肉芽腫、トリコフィトン感染症、裂毛、棘状毛貯留症、裂毛症、抜毛癖、熱帯性潰瘍、結核疹、ハンセン病、類結核型、結節性硬化症、腫瘍壊死因子受容体関連周期性症候群、１型らい反応、２型らい反応、臍帯出血、臍紅斑、臍肉芽腫、臍出血、臍奇形、尿毒症性そう痒症、尿汗症、蕁麻疹、水性蕁麻疹、コリン性蕁麻疹、慢性蕁麻疹、接触蕁麻疹、丘疹状蕁麻疹、物理的蕁麻疹、色素性蕁麻疹、圧迫性蕁麻疹、温熱蕁麻疹、小水疱性蕁麻疹、振動性蕁麻疹、ワクチン接種部位蜂巣炎、ワクチン接種部位皮膚炎、ワクチン接種部位変色、ワクチン接種部位皮膚剥脱、ワクチン接種部位結節、ワクチン接種部位蒼白、ワクチン

皮膚組織
接種部位丘疹、ワクチン接種部位そう痒感、ワクチン接種部位膿疱、ワクチン接種部位発疹、ワクチン接種部位痂皮、ワクチン接種部位瘢痕、ワクチン接種部位潰瘍、ワクチン接種部位蕁麻疹、ワクチン接種部位小水疱、腟潰瘍、水痘、ワクチン接種後の水痘、静脈瘤性潰瘍、血管性紫斑病、皮膚血管障害、血管炎性皮疹、血管収縮、血管拡張、静脈性潰瘍痛、血管穿刺部位そう痒感、ウイルス性発疹、皮膚ウイルス感染、尋常性白斑、女性外陰部潰瘍、外陰腟そう痒症、外陰腟潰瘍、ワールデンブルグ症候群、疣贅状異常角化腫、ウェーバー・クリスチャン病、ウィスコット・オルドリック症候群、黄色板腫、黄色腫、黄色腫症、乾皮症、色素性乾皮症、いちご腫、皮膚いちご腫、黄色爪症候群、黄色皮膚

2.7.4 Summary of Clinical Safety

9.6. List of Tables and Figures

Table 70: Cumulative Subject Exposure to BG00012 From Clinical Trials

Cumulative subject exposure to BG00012 from clinical trials
Page 1 of 3

Indication Study	Number of Subjects Exposed	Person-Years
Multiple Sclerosis (MS)		
109MS301	826	
109MS302	703	
109MS303 (a)	734 (c)	
109MS305 Part 1	111	
C-1900 Part 1	191	
C-1900 Part 2 (b)	59 (c)	
109MS201	104	
109MS101	48	
Total MS subjects exposed	2776	
Total number of person-years		8383.99

Note: Total number of person-years exposed to BG00012 is calculated as the sum of number of days exposed to BG00012/365.25.
(a) Ongoing safety extension study of the parent studies 109MS301 and 109MS302. April 15, 2015 interim cut.
(b) Safety extension phase.
(c) Number of subjects calculation does not include subjects who have been previously exposed to BG00012 and counted in the parent phase or study. However, the continued exposure to BG00012 of such subjects will contribute to the cumulative person-year calculation.
(d) Studies with no electronic data do not contribute to the person-year calculation.

SOURCE: BG12MS/JAPAN/ISS/T-EX-SUM-PYRS.SAS DATE: 05NOV2015

Cumulative subject exposure to BG00012 from clinical trials
Page 2 of 3

Indication Study	Number of Subjects Exposed	Person-Years
Healthy Volunteers		
109HV101	51	
109HV102	8	
109HV103	26	
109HV104	26	
109HV105	14	
109HV106	42	
109HV107	81	
109HV108	71	
109HV109	80	
109HV113	34	
C-1903	36	
201-FG-PK-02/02 (d)	12	
201-FG-PK-03/04 (d)	18	
IKP/ID32 (d)	6	
IKP/ID33 (d)	15	
Total Healthy Volunteers exposed	520	
Total number of person-years (d)		10.77

Note: Total number of person-years exposed to BG00012 is calculated as the sum of number of days exposed to BG00012/365.25.
(a) Ongoing safety extension study of the parent studies 109MS301 and 109MS302. April 15, 2015 interim cut.
(b) Safety extension phase.
(c) Number of subjects calculation does not include subjects who have been previously exposed to BG00012 and counted in the parent phase or study. However, the continued exposure to BG00012 of such subjects will contribute to the cumulative person-year calculation.
(d) Studies with no electronic data do not contribute to the person-year calculation.

SOURCE: BG12MS/JAPAN/ISS/T-EX-SUM-PYRS.SAS DATE: 05NOV2015

Cumulative subject exposure to BG00012 from clinical trials
Page 3 of 3

Indication Study	Number of Subjects Exposed	Person-Years
Total subjects exposed across all indications	3296	
Total number of person-years across all indications		8394.77
Total number of person-years exposed to BG00012 among those subjects who were exposed to BG00012 for		
<12 weeks	830	36.00
>=12 weeks	2415	8358.76
>=48 weeks	1868	8060.40
>=96 weeks	1601	7723.33
>=144 weeks	1388	7283.18
>=192 weeks	1289	6962.92
>=240 weeks	898	5394.50
>=288 weeks	696	4372.47
>=336 weeks	246	1699.08
>=384 weeks	34	254.40
No electronic data (d)	51	N/A

Note: Total number of person-years exposed to BG00012 is calculated as the sum of number of days exposed to BG00012/365.25.
(a) Ongoing safety extension study of the parent studies 109MS301 and 109MS302. April 15, 2015 interim cut.
(b) Safety extension phase.
(c) Number of subjects calculation does not include subjects who have been previously exposed to BG00012 and counted in the parent phase or study. However, the continued exposure to BG00012 of such subjects will contribute to the cumulative person-year calculation.
(d) Studies with no electronic data do not contribute to the person-year calculation.

SOURCE: BG12MS/JAPAN/ISS/T-EX-SUM-PYRS.SAS DATE: 05NOV2015

Table 71: Concomitant Medications - Alternative MS Treatment: Studies 109MS301 and 109MS302

Concomitant medications - alternative MS treatment: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects taking any alternative MS medication	95 (12)	50 (7)	49 (6)	99 (6)	22 (6)
GA	4 (<1)	10 (1)	5 (<1)	15 (<1)	0
Interferon Beta-1a IM	67 (9)	31 (4)	31 (4)	62 (4)	19 (5)
Interferon Beta-1a SC	10 (1)	3 (<1)	4 (<1)	7 (<1)	2 (<1)
Interferon Beta-1b	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
Natalizumab	11 (1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
Any of the above MS therapies	93 (12)	47 (6)	47 (6)	94 (6)	22 (6)
Other	2 (<1)	3 (<1)	2 (<1)	5 (<1)	0
MITOXANTRONE	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
AZATHIOPRINE	0	0	1 (<1)	1 (<1)	0
FINGOLIMOD	0	1 (<1)	0	1 (<1)	0
MYCOPHENOLIC ACID	0	1 (<1)	0	1 (<1)	0
PLASMAPHERESIS	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages. The table presents alternative MS treatments for subjects in Studies 109MS301 and 109MS302 who switched to an alternative MS treatment.
2: The first alternative MS medication was counted for subjects who received more than one alternative MS medication.

SOURCE: BG12MS/ISS/CSR/T-CONMEDS-ALTMS-A.SAS DATE: 14NOV2011

Table 73: Demographics: Studies 109MS301 and 109MS302

Demographics: Studies 109MS301 and 109MS302
Page 1 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Age (yrs)					
<40	419 (54)	432 (56)	406 (53)	838 (55)	216 (62)
>=40	352 (46)	337 (44)	354 (47)	691 (45)	135 (38)
n	771	769	760	1529	351
Mean	37.7	37.9	38.3	38.1	36.7
SD	9.22	9.22	9.11	9.16	9.05
Median	38.0	38.0	39.0	38.0	36.0
Min, Max	18, 56	18, 55	18, 56	18, 56	18, 55
Sex					
Male	214 (28)	228 (30)	204 (27)	432 (28)	104 (30)
Female	557 (72)	541 (70)	556 (73)	1097 (72)	247 (70)

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western European countries (Austria, Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and United Kingdom), Australia, Canada, Costa Rica, Israel, New Zealand, and South Africa. Region 3 includes Eastern European countries (Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, Turkey, and Ukraine), Guatemala, India, and Mexico.

SOURCE: BG12MS/JAPAN/ISS/T-DEMOG-A.SAS DATE: 28SEP2015

Demographics: Studies 109MS301 and 109MS302
Page 2 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Race					
White	623 (81)	625 (81)	621 (82)	1246 (81)	291 (83)
Other	115 (15)	112 (15)	109 (14)	221 (14)	49 (14)
Unknown	33 (4)	32 (4)	30 (4)	62 (4)	11 (3)
Height (cm)					
n	767	766	757	1523	350
Mean	168.0	168.0	167.6	167.8	168.2
SD	9.25	9.84	9.32	9.58	9.82
Median	167.0	167.0	167.0	167.0	167.5
Min, Max	142, 194	135, 200	132, 195	132, 200	142, 198

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western European countries (Austria, Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and United Kingdom), Australia, Canada, Costa Rica, Israel, New Zealand, and South Africa. Region 3 includes Eastern European countries (Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, Turkey, and Ukraine), Guatemala, India, and Mexico.

SOURCE: BG12MS/JAPAN/ISS/T-DEMOG-A.SAS DATE: 28SEP2015

Demographics: Studies 109MS301 and 109MS302
Page 3 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Weight (kg)					
n	764	766	757	1523	351
Mean	71.85	71.24	71.82	71.53	71.37
SD	16.960	18.236	17.334	17.790	19.110
Median	70.00	68.00	69.00	68.00	67.30
25th, 75th percentiles	60.0, 81.3	58.0, 81.8	59.0, 82.0	58.1, 82.0	57.0, 82.0
10th, 90th percentiles	52.3, 93.5	51.5, 96.0	52.3, 95.4	52.0, 95.5	51.0, 96.6
Min, Max	37.0, 152.3	34.0, 162.3	40.0, 151.0	34.0, 162.3	35.2, 143.5
Body mass index (kg/m^2)					
n	764	764	755	1519	350
Mean	25.439	25.137	25.530	25.332	25.123
SD	5.6849	5.6608	5.6804	5.6721	5.9602
Median	24.401	24.167	24.539	24.375	23.998
Min, Max	15.62, 57.03	13.80, 70.25	15.42, 55.98	13.80, 70.25	15.24, 56.05

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western European countries (Austria, Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and United Kingdom), Australia, Canada, Costa Rica, Israel, New Zealand, and South Africa. Region 3 includes Eastern European countries (Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, Turkey, and Ukraine), Guatemala, India, and Mexico.

SOURCE: BG12MS/JAPAN/ISS/T-DEMOG-A.SAS DATE: 28SEP2015

Demographics: Studies 109MS301 and 109MS302
Page 4 of 4

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Region (a)					
Region 1	137 (18)	130 (17)	136 (18)	266 (17)	66 (19)
Region 2	227 (29)	229 (30)	225 (30)	454 (30)	50 (14)
Region 3	407 (53)	410 (53)	399 (53)	809 (53)	235 (67)

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western European countries (Austria, Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, and United Kingdom), Australia, Canada, Costa Rica, Israel, New Zealand, and South Africa. Region 3 includes Eastern European countries (Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Macedonia, Moldova, Poland, Romania, Russia, Serbia, Slovakia, Turkey, and Ukraine), Guatemala, India, and Mexico.

SOURCE: BG12MS/JAPAN/ISS/T-DEMOG-A.SAS DATE: 28SEP2015

Table 74: Baseline Disease Characteristics: Studies 109MS301 and 109MS302

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 1 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Time since first MS symptoms (years)					
n	771	769	760	1529	351
Mean	8.1	8.3	7.8	8.1	7.1
SD	6.46	6.84	6.49	6.67	5.91
Median	7.0	7.0	6.0	6.0	6.0
Min, Max	0, 33	0, 42	0, 33	0, 42	0, 29
Time since diagnosis of MS (years)					
n	771	769	760	1529	351
Mean	5.3	5.3	4.9	5.1	4.4
SD	5.45	5.27	5.27	5.27	4.69
Median	4.0	4.0	3.0	3.0	3.0
Min, Max	0, 33	0, 32	0, 27	0, 32	0, 24

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 2 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of relapses within the previous 3 years					
0	6 (<1)	5 (<1)	5 (<1)	10 (<1)	2 (<1)
1	168 (22)	158 (21)	168 (22)	326 (21)	76 (22)
2	281 (36)	311 (40)	292 (38)	603 (39)	143 (41)
3	198 (26)	168 (22)	167 (22)	335 (22)	80 (23)
>=4	116 (15)	127 (17)	127 (17)	254 (17)	50 (14)
Unknown	2 (<1)	0	1 (<1)	1 (<1)	0
n	769	769	759	1528	351
Mean	2.5	2.5	2.5	2.5	2.4
SD	1.52	1.36	1.38	1.37	1.32
Median	2.0	2.0	2.0	2.0	2.0
Min, Max	0, 12	0, 11	0, 12	0, 12	0, 10

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 3 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of relapses within the prior 12 months					
0	27 (4)	26 (3)	22 (3)	48 (3)	7 (2)
1	519 (67)	515 (67)	504 (66)	1019 (67)	231 (66)
2	190 (25)	191 (25)	193 (25)	384 (25)	98 (28)
3	23 (3)	33 (4)	33 (4)	66 (4)	12 (3)
>=4	11 (1)	4 (<1)	7 (<1)	11 (<1)	3 (<1)
Unknown	1 (<1)	0	1 (<1)	1 (<1)	0
n	770	769	759	1528	351
Mean	1.3	1.3	1.3	1.3	1.4
SD	0.73	0.65	0.66	0.66	0.64
Median	1.0	1.0	1.0	1.0	1.0
Min, Max	0, 8	0, 6	0, 5	0, 6	0, 5

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 4 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
EDSS Score (a)					
0.0	34 (4)	44 (6)	39 (5)	83 (5)	18 (5)
1.0	63 (8)	69 (9)	64 (8)	133 (9)	25 (7)
1.5	120 (16)	125 (16)	124 (16)	249 (16)	52 (15)
2.0	145 (19)	135 (18)	156 (21)	291 (19)	61 (17)
2.5	78 (10)	75 (10)	83 (11)	158 (10)	36 (10)
3.0	103 (13)	97 (13)	92 (12)	189 (12)	42 (12)
3.5	92 (12)	90 (12)	92 (12)	182 (12)	57 (16)
4.0	69 (9)	65 (8)	53 (7)	118 (8)	29 (8)
4.5	37 (5)	38 (5)	31 (4)	69 (5)	17 (5)
5.0	29 (4)	28 (4)	25 (3)	53 (3)	14 (4)
>5	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
Unknown	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 5 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
n	771	768	760	1528	351
Mean	2.53	2.48	2.43	2.46	2.57
SD	1.208	1.251	1.190	1.221	1.222
Median	2.50	2.50	2.00	2.50	2.50
Min, Max	0.0, 6.0	0.0, 6.5	0.0, 6.0	0.0, 6.5	0.0, 5.0
McDonald criteria					
1(b)	647 (84)	627 (82)	609 (80)	1236 (81)	295 (84)
2(c)	91 (12)	90 (12)	102 (13)	192 (13)	32 (9)
3(d)	21 (3)	38 (5)	38 (5)	76 (5)	19 (5)
4(e)	12 (2)	14 (2)	11 (1)	25 (2)	5 (1)
Number of subjects who took any prior MS medication	374 (49)	371 (48)	368 (48)	739 (48)	139 (40)
INTERFERON BETA-1A : IM	112 (15)	106 (14)	109 (14)	215 (14)	38 (11)
INTERFERON BETA-1A : SC	86 (11)	76 (10)	82 (11)	158 (10)	35 (10)
INTERFERON BETA-1B	98 (13)	99 (13)	99 (13)	198 (13)	33 (9)
INTERFERON BETA-1A : Unknown	9 (1)	13 (2)	12 (2)	25 (2)	7 (2)
NATALIZUMAB	14 (2)	10 (1)	24 (3)	34 (2)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 6 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
GLATIRAMER ACETATE	76 (10)	53 (7)	63 (8)	116 (8)	1 (<1)
Any of the above MS therapies	283 (37)	263 (34)	268 (35)	531 (35)	103 (29)
Other	144 (19)	162 (21)	165 (22)	327 (21)	50 (14)
CORTICOSTEROIDS	55 (7)	58 (8)	58 (8)	116 (8)	26 (7)
PLASMAPHERESIS OR CYTAPHERESIS	10 (1)	14 (2)	15 (2)	29 (2)	8 (2)
MITOXANTRONE	21 (3)	26 (3)	15 (2)	41 (3)	7 (2)
INTERFERON ALFA	14 (2)	12 (2)	11 (1)	23 (2)	4 (1)
AZATHIOPRINE	24 (3)	30 (4)	37 (5)	67 (4)	3 (<1)
METHYLPREDNISOLONE	6 (<1)	6 (<1)	10 (1)	16 (1)	3 (<1)
INVESTIGATIONAL DRUG	8 (1)	7 (<1)	8 (1)	15 (<1)	2 (<1)
CICLOSPORIN	0	0	1 (<1)	1 (<1)	1 (<1)
CORTISONE	0	1 (<1)	0	1 (<1)	1 (<1)
FAMPRIDINE	2 (<1)	3 (<1)	4 (<1)	7 (<1)	1 (<1)
FINGOLIMOD	0	0	0	0	1 (<1)
LASER THERAPY	0	0	0	0	1 (<1)
METHOTREXATE	9 (1)	9 (1)	6 (<1)	15 (<1)	1 (<1)
ALL OTHER THERAPEUTIC PRODUCTS	1 (<1)	6 (<1)	5 (<1)	11 (<1)	0
BX 471	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 7 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
CORTICOTROPIN	1 (<1)	0	0	0	0
CYCLOPHOSPHAMIDE	4 (<1)	2 (<1)	5 (<1)	7 (<1)	0
DACLIXIMAB	1 (<1)	1 (<1)	0	1 (<1)	0
ELETRIPTAN	0	0	1 (<1)	1 (<1)	0
GABAPENTIN	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
GUSPERIMUS	1 (<1)	0	0	0	0
IBUDILAST	1 (<1)	1 (<1)	0	1 (<1)	0
IMMUNOGLOBULIN	1 (<1)	0	0	0	0
IMMUNOGLOBULIN G HUMAN	13 (2)	16 (2)	16 (2)	32 (2)	0
IMMUNOSTIMULANTS	1 (<1)	0	0	0	0
LAQUINIMOD	0	1 (<1)	2 (<1)	3 (<1)	0
MONOCLONAL ANTIBODIES	1 (<1)	0	0	0	0
MYCOPHENOLIC ACID	0	0	1 (<1)	1 (<1)	0
NALTREXONE	1 (<1)	0	2 (<1)	2 (<1)	0
PREDNISOLONE	1 (<1)	1 (<1)	0	1 (<1)	0
PREDNISONE	0	3 (<1)	1 (<1)	4 (<1)	0
ROQUINIMEX	1 (<1)	0	1 (<1)	1 (<1)	0
SELECTIVE IMMUNOSUPPRESSIVE AGENTS	0	0	1 (<1)	1 (<1)	0
TEMSIROLIMUS	2 (<1)	0	1 (<1)	1 (<1)	0
TERIFLUNOMIDE	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Baseline disease characteristics: Studies 109MS301 and 109MS302
Page 8 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
TRIMETAZIDINE	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Baseline is defined as the latest available value prior to first exposure to study treatment.
(a) EDSS ranges from 0 to 10 (no score of 0.5); (b) 2 or more relapses, 2 or more objective lesions.
(c) 2 or more relapses, 1 objective lesion, and dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS or further clinical attack involving different site.
(d) 1 relapse, 2 or more objective lesions, and dissemination in time by MRI or second clinical attack.
(e) 1 (mono-symptomatic) relapse, 1 objective lesion, dissemination in space by MRI or positive CSF and 2 or more MRI lesions consistent with MS, and dissemination in time by MRI or second clinical attack.

SOURCE: BG12MS/JAPAN/ISS/T-BL-DC-A.SAS DATE: 29SEP2015

Table 76: Concomitant Medications - Alternative MS Treatment: 24 Weeks of Studies 109MS301 and 109MS302

Concomitant medications - Alternative MS treatment: 24 weeks of studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects taking any concomitant medication	9 (1)	8 (1)	11 (1)	19 (1)	2 (<1)
INTERFERON BETA-1A	7 (<1)	4 (<1)	8 (1)	12 (<1)	2 (<1)
GLATIRAMER	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0
MITOXANTRONE	0	0	1 (<1)	1 (<1)	0
NATALIZUMAB	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages. The table presents alternative MS treatments for subjects who switched to an alternative MS treatment.
2: The first alternative MS medication was counted for subjects who received more than one alternative MS medication.

SOURCE: BG12MS/JAPAN/ISS/T-CONMEDS-ALTMS-A-24W.SAS DATE: 07OCT2015

Table 77: Demography - ITT Population – Part I (Placebo-Controlled Period)

Demography - ITT population
-Part I (placebo-controlled period)
Page 1 of 3

	Placebo	BG00012 240 mg BID	Total
Number of subjects in ITT population	113 (100)	111 (100)	224 (100)
Age (yrs)			
18-19	0	0	0
20-29	23 (20)	20 (18)	43 (19)
30-39	57 (50)	45 (41)	102 (46)
40-49	29 (26)	37 (33)	66 (29)
50-55	3 (3)	9 (8)	12 (5)
>55	1 (<1)	0	1 (<1)
n	113	111	224
Mean	36.0	37.3	36.7
SD	7.46	8.27	7.88
Median	36.0	37.0	36.0
Min, Max	20, 56	20, 55	20, 56
<40	80 (71)	65 (59)	145 (65)
>=40	33 (29)	46 (41)	79 (35)
Gender			
Male	29 (26)	33 (30)	62 (28)
Female	84 (74)	78 (70)	162 (72)

NOTE: Numbers in parentheses are percentages.

SOURCE: BG12MS/109MS305/PART1/T-DEMO-ITT.SAS DATE: 25SEP2015

Demography - ITT population
-Part I (placebo-controlled period)
Page 2 of 3

	Placebo	BG00012 240 mg BID	Total
Country			
Czech Republic	21 (19)	21 (19)	42 (19)
Japan	58 (51)	56 (50)	114 (51)
Korea	10 (9)	10 (9)	20 (9)
Poland	20 (18)	20 (18)	40 (18)
Taiwan	4 (4)	4 (4)	8 (4)
Region			
Asia-Pacific Region	72 (64)	70 (63)	142 (63)
Eastern Europe	41 (36)	41 (37)	82 (37)
Region			
Japan	58 (51)	56 (50)	114 (51)
Non-Japan	55 (49)	55 (50)	110 (49)
Height (cm)			
n	111	110	221
Mean	165.5	165.5	165.5
SD	10.24	9.77	9.99
Median	164.0	164.8	164.0
Min, Max	145, 197	146, 198	145, 198

NOTE: Numbers in parentheses are percentages.

SOURCE: BG12MS/109MS305/PART1/T-DEMO-ITT.SAS DATE: 25SEP2015

Demography - ITT population
-Part I (placebo-controlled period)
Page 3 of 3

	Placebo	BG00012 240 mg BID	Total
Weight (kg)			
n	113	111	224
Mean	63.42	64.30	63.86
SD	15.510	15.641	15.546
Median	61.00	59.80	60.00
Min, Max	41.7, 116.0	36.7, 110.0	36.7, 116.0
Body mass index (kg/m^2)			
n	111	110	221
Mean	22.99	23.21	23.10
SD	4.293	4.097	4.189
Median	22.11	22.36	22.21
Min, Max	16.0, 37.9	14.6, 39.0	14.6, 39.0

NOTE: Numbers in parentheses are percentages.

SOURCE: BG12MS/109MS305/PART1/T-DEMO-ITT.SAS DATE: 25SEP2015

Table 79: Concomitant Alternative MS Medications - ITT Population –Part I (Placebo-Controlled Period)

Concomitant alternative MS medications - ITT population - Part I (placebo-controlled period)

	Placebo	BG00012 240 mg BID	Total
Number of subjects in ITT population	113 (100)	111 (100)	224 (100)
Number of subjects taking any alternative MS medication	2 (2)	0	2 (<1)
GLATIRAMER ACETATE	0	0	0
INTERFERON BETA-1A	0	0	0
INTERFERON BETA-1B	1 (<1)	0	1 (<1)
NATALIZUMAB	0	0	0
Any of the above MS medications	1 (<1)	0	1 (<1)
Other	1 (<1)	0	1 (<1)
FINGOLIMOD HYDROCHLORIDE	1 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: The first alternative MS medication was counted for subjects who received more than one alternative MS medication.

SOURCE: BG12MS/109MS305/PART1/T-CM-ALTMS.SAS DATE: 25SEP2015

Table 81: Demography - ITT Population

Demography - ITT population
Page 1 of 10

	301 or 302 -> 303					
	BG00012 240 mg BID -> 240 mg BID	BG00012 240 mg TID -> 240 mg TID	Placebo -> BG00012 240 mg BID	Placebo -> BG00012 240 mg TID	GA -> BG00012 240 mg BID	GA -> BG00012 240 mg TID
Number of subjects in ITT population	501 (100)	502 (100)	249 (100)	248 (100)	118 (100)	118 (100)
Age (yrs)						
18-19	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)	0
20-29	85 (17)	70 (14)	39 (16)	40 (16)	17 (14)	20 (17)
30-39	151 (30)	162 (32)	80 (32)	73 (29)	50 (42)	36 (31)
40-49	185 (37)	185 (37)	95 (38)	85 (34)	36 (31)	43 (36)
50-55	68 (14)	63 (13)	32 (13)	42 (17)	12 (10)	15 (13)
>55	11 (2)	21 (4)	3 (1)	7 (3)	2 (2)	4 (3)
n	501	502	249	248	118	118
Mean	39.8	40.0	39.9	40.5	38.2	39.5
SD	9.08	9.10	8.82	9.39	8.50	9.46
Median	40.0	40.0	40.0	41.0	38.0	40.0
Min, Max	19, 57	19, 58	20, 57	19, 57	19, 57	20, 57

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 2 of 10

	303		
	Total BG00012 240 mg BID	Total BG00012 240 mg TID	Total
Number of subjects in ITT population	868 (100)	868 (100)	1736 (100)
Age (yrs)			
18-19	2 (<1)	2 (<1)	4 (<1)
20-29	141 (16)	130 (15)	271 (16)
30-39	281 (32)	271 (31)	552 (32)
40-49	316 (36)	313 (36)	629 (36)
50-55	112 (13)	120 (14)	232 (13)
>55	16 (2)	32 (4)	48 (3)
n	868	868	1736
Mean	39.6	40.1	39.8
SD	8.93	9.23	9.08
Median	40.0	40.0	40.0
Min, Max	19, 57	19, 58	19, 58

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 3 of 10

	301 or 302 -> 303					
	BG00012 240 mg BID -> 240 mg BID	BG00012 240 mg TID -> 240 mg TID	Placebo -> BG00012 240 mg BID	Placebo -> BG00012 240 mg TID	GA -> BG00012 240 mg BID	GA -> BG00012 240 mg TID
Age (yrs)						
<40	237 (47)	233 (46)	119 (48)	114 (46)	68 (58)	56 (47)
>=40	264 (53)	269 (54)	130 (52)	134 (54)	50 (42)	62 (53)
Sex						
Female	352 (70)	354 (71)	178 (71)	166 (67)	86 (73)	76 (64)
Male	149 (30)	148 (29)	71 (29)	82 (33)	32 (27)	42 (36)

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 4 of 10

	303		
	Total BG00012 240 mg BID	Total BG00012 240 mg TID	Total
Age (yrs)			
<40	424 (49)	403 (46)	827 (48)
>=40	444 (51)	465 (54)	909 (52)
Sex			
Female	616 (71)	596 (69)	1212 (70)
Male	252 (29)	272 (31)	524 (30)

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 5 of 10

	301 or 302 -> 303					
	BG00012 240 mg BID -> 240 mg BID	BG00012 240 mg TID -> 240 mg TID	Placebo -> BG00012 240 mg BID	Placebo -> BG00012 240 mg TID	GA -> BG00012 240 mg BID	GA -> BG00012 240 mg TID
Race						
White	403 (80)	413 (82)	202 (81)	198 (80)	98 (83)	103 (87)
Asian	51 (10)	45 (9)	21 (8)	28 (11)	10 (8)	7 (6)
Unknown	20 (4)	16 (3)	14 (6)	10 (4)	4 (3)	3 (3)
Other	23 (5)	19 (4)	9 (4)	7 (3)	3 (3)	3 (3)
Black or African American	4 (<1)	9 (2)	3 (1)	5 (2)	3 (3)	2 (2)
American Indian or Alaska Native	0	0	0	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 6 of 10

	303		
	Total BG00012 240 mg BID	Total BG00012 240 mg TID	Total
Race			
White	703 (81)	714 (82)	1417 (82)
Asian	82 (9)	80 (9)	162 (9)
Unknown	38 (4)	29 (3)	67 (4)
Other	35 (4)	29 (3)	64 (4)
Black or African American	10 (1)	16 (2)	26 (1)
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 7 of 10

	301 or 302 -> 303					
	BG00012 240 mg BID -> 240 mg BID	BG00012 240 mg TID -> 240 mg TID	Placebo -> BG00012 240 mg BID	Placebo -> BG00012 240 mg TID	GA -> BG00012 240 mg BID	GA -> BG00012 240 mg TID
Region (a)						
Region 1	72 (14)	76 (15)	36 (14)	45 (18)	19 (16)	23 (19)
Region 2	150 (30)	151 (30)	80 (32)	60 (24)	15 (13)	14 (12)
Region 3	279 (56)	275 (55)	133 (53)	143 (58)	84 (71)	81 (69)
MRI cohort						
Yes	211 (42)	221 (44)	104 (42)	101 (41)	48 (41)	60 (51)
No	290 (58)	281 (56)	145 (58)	147 (59)	70 (59)	58 (49)
Height (cm)						
n	501	502	249	248	118	118
Mean	167.9	167.9	167.7	168.2	167.5	168.7
SD	10.08	9.32	10.06	9.01	10.12	9.79
Median	167.0	167.0	168.0	167.0	166.0	167.5
Min, Max	137, 200	138, 195	132, 192	148, 194	144, 196	142, 188

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 8 of 10

	303		
	Total BG00012 240 mg BID	Total BG00012 240 mg TID	Total
Region (a)			
Region 1	127 (15)	144 (17)	271 (16)
Region 2	245 (28)	225 (26)	470 (27)
Region 3	496 (57)	499 (57)	995 (57)
MRI cohort			
Yes	363 (42)	382 (44)	745 (43)
No	505 (58)	486 (56)	991 (57)
Height (cm)			
n	868	868	1736
Mean	167.8	168.1	167.9
SD	10.07	9.29	9.69
Median	167.0	167.0	167.0
Min, Max	132, 200	138, 195	132, 200

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 9 of 10

	301 or 302 -> 303					
	BG00012 240 mg BID -> 240 mg BID	BG00012 240 mg TID -> 240 mg TID	Placebo -> BG00012 240 mg BID	Placebo -> BG00012 240 mg TID	GA -> BG00012 240 mg BID	GA -> BG00012 240 mg TID
Weight (kg)						
n	501	502	249	248	118	118
Mean	70.60	71.82	70.92	73.75	73.35	72.00
SD	17.822	17.027	16.488	16.918	21.534	17.889
Median	66.90	70.00	68.00	72.00	68.95	68.55
Min, Max	39.0, 158.6	40.0, 166.5	40.0, 130.1	45.0, 152.3	38.0, 158.2	42.0, 131.8
Body mass index (kg/m^2)						
n	501	502	249	248	118	118
Mean	24.92	25.42	25.19	26.05	26.01	25.21
SD	5.242	5.548	5.434	5.750	7.067	5.602
Median	24.01	24.38	24.44	24.65	24.87	24.07
Min, Max	15.4, 49.4	16.1, 57.6	15.4, 52.8	16.4, 57.6	16.7, 61.3	17.0, 45.6

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Demography - ITT population
Page 10 of 10

	303		
	Total BG00012 240 mg BID	Total BG00012 240 mg TID	Total
Weight (kg)			
n	868	868	1736
Mean	71.06	72.40	71.73
SD	18.010	17.117	17.577
Median	67.10	70.00	69.00
Min, Max	38.0, 158.6	40.0, 166.5	38.0, 166.5
Body mass index (kg/m^2)			
n	868	868	1736
Mean	25.14	25.57	25.36
SD	5.582	5.616	5.601
Median	24.15	24.44	24.30
Min, Max	15.4, 61.3	16.1, 57.6	15.4, 61.3

NOTE 1: Numbers in parentheses are percentages.
2: Age, weight, height, and BMI are summarized based on Study 109MS303 baseline.
(a) Region 1 includes United States (including Puerto Rico). Region 2 includes Western Europe, Australia, Canada, Costa Rica, New Zealand, Israel, and South Africa. Region 3 includes Eastern Europe, India, Guatemala, and Mexico.

SOURCE: BG12MS/109MS303/INTERIM6/T-DM-DEMOG.SAS DATE: 08JUL2015

Table 84: Summary Analysis of Adverse Events: 24 Weeks of Studies 109MS301 and 109MS302

Summary analysis of adverse events: 24 weeks of studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	1308 (86)	246 (70)
Number of subjects with a moderate or severe event	344 (45)	396 (51)	412 (54)	808 (53)	136 (39)
Number of subjects with a severe event	60 (8)	56 (7)	74 (10)	130 (9)	17 (5)
Number of subjects with an unlikely, possibly or related event	426 (55)	566 (74)	561 (74)	1127 (74)	175 (50)
Number of subjects with a possibly or related event	247 (32)	484 (63)	486 (64)	970 (63)	128 (36)
Number of subjects with a related event	40 (5)	195 (25)	204 (27)	399 (26)	84 (24)
Number of subjects with a serious event	67 (9)	55 (7)	51 (7)	106 (7)	25 (7)
Number of subjects discontinuing treatment due to an adverse event	37 (5)	75 (10)	79 (10)	154 (10)	19 (5)
Number of subjects withdrawing from study due to an adverse event	17 (2)	48 (6)	49 (6)	97 (6)	6 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SUM-A-24W.SAS DATE: 17FEB2016

Table 85: Incidence of Adverse Events by System Organ Class: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class: 24 weeks of Studies 109MS301 and 109MS302
Page 1 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	1308 (86)	246 (70)
感染症および寄生虫症	269 (35)	289 (38)	274 (36)	563 (37)	87 (25)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (<1)	8 (1)	9 (1)	17 (1)	2 (<1)
血液およびリンパ系障害	11 (1)	24 (3)	22 (3)	46 (3)	5 (1)
免疫系障害	4 (<1)	14 (2)	12 (2)	26 (2)	5 (1)
内分泌障害	5 (<1)	1 (<1)	5 (<1)	6 (<1)	1 (<1)
代謝および栄養障害	29 (4)	23 (3)	25 (3)	48 (3)	10 (3)
精神障害	84 (11)	58 (8)	64 (8)	122 (8)	29 (8)
神経系障害	312 (40)	260 (34)	253 (33)	513 (34)	105 (30)
眼障害	46 (6)	22 (3)	38 (5)	60 (4)	10 (3)
耳および迷路障害	31 (4)	21 (3)	22 (3)	43 (3)	12 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class: 24 weeks of Studies 109MS301 and 109MS302
Page 2 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓障害	21 (3)	14 (2)	17 (2)	31 (2)	10 (3)
血管障害	51 (7)	276 (36)	246 (32)	522 (34)	14 (4)
呼吸器、胸郭および縦隔障害	60 (8)	57 (7)	64 (8)	121 (8)	15 (4)
胃腸障害	192 (25)	286 (37)	304 (40)	590 (39)	30 (9)
肝胆道系障害	1 (<1)	4 (<1)	12 (2)	16 (1)	0
皮膚および皮下組織障害	98 (13)	176 (23)	183 (24)	359 (23)	35 (10)
筋骨格系および結合組織障害	138 (18)	127 (17)	125 (16)	252 (16)	41 (12)
腎および尿路障害	69 (9)	73 (9)	95 (13)	168 (11)	24 (7)
妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
生殖系および乳房障害	38 (5)	40 (5)	40 (5)	80 (5)	14 (4)
先天性、家族性および遺伝性障害	0	1 (<1)	0	1 (<1)	1 (<1)
一般・全身障害および投与部位の状態	103 (13)	102 (13)	118 (16)	220 (14)	108 (31)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class: 24 weeks of Studies 109MS301 and 109MS302
Page 3 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
臨床検査	98 (13)	129 (17)	117 (15)	246 (16)	57 (16)
傷害、中毒および処置合併症	44 (6)	33 (4)	38 (5)	71 (5)	18 (5)
外科および内科処置	4 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
社会環境	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A-24W.SAS DATE: 02DEC2015

Table 86: Incidence of Adverse Events by System Organ Class and Preferred Term: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 1 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (1)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	1308 (86)	246 (70)
感染症および寄生虫症	269 (35)	289 (38)	274 (36)	563 (37)	87 (25)
鼻咽頭炎	70 (9)	71 (9)	80 (11)	151 (10)	24 (7)
尿路感染	40 (5)	61 (8)	43 (6)	104 (7)	22 (6)
上気道感染	44 (6)	43 (6)	46 (6)	89 (6)	8 (2)
インフルエンザ	27 (4)	27 (4)	29 (4)	56 (4)	2 (<1)
気管支炎	10 (1)	17 (2)	17 (2)	34 (2)	7 (2)
胃腸炎	10 (1)	18 (2)	13 (2)	31 (2)	1 (<1)
副鼻腔炎	7 (<1)	11 (1)	16 (2)	27 (2)	2 (<1)
咽頭炎	13 (2)	15 (2)	9 (1)	24 (2)	6 (2)
鼻炎	10 (1)	12 (2)	8 (1)	20 (1)	3 (<1)
ウイルス性胃腸炎	5 (<1)	6 (<1)	10 (1)	16 (1)	1 (<1)
気道感染	5 (<1)	7 (<1)	9 (1)	16 (1)	2 (<1)
口腔ヘルペス	8 (1)	11 (1)	4 (<1)	15 (<1)	2 (<1)
膀胱炎	8 (1)	5 (<1)	6 (<1)	11 (<1)	1 (<1)
ウイルス感染	7 (<1)	5 (<1)	6 (<1)	11 (<1)	2 (<1)
耳感染	3 (<1)	0	10 (1)	10 (<1)	0
喉頭炎	2 (<1)	4 (<1)	5 (<1)	9 (<1)	1 (<1)
感染性結膜炎	0	3 (<1)	5 (<1)	8 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 2 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
消化管感染	2 (<1)	2 (<1)	6 (<1)	8 (<1)	0
扁桃炎	3 (<1)	4 (<1)	3 (<1)	7 (<1)	1 (<1)
帯状疱疹	2 (<1)	1 (<1)	5 (<1)	6 (<1)	2 (<1)
麦粒腫	1 (<1)	3 (<1)	3 (<1)	6 (<1)	0
ウイルス性消化管感染	3 (<1)	3 (<1)	2 (<1)	5 (<1)	0
ウイルス性気道感染	3 (<1)	4 (<1)	1 (<1)	5 (<1)	0
外陰腟真菌感染	4 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
中耳炎	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
ウイルス性上気道感染	8 (1)	3 (<1)	1 (<1)	4 (<1)	0
蜂巣炎	0	1 (<1)	2 (<1)	3 (<1)	0
毛包炎	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
せつ	0	2 (<1)	1 (<1)	3 (<1)	0
単純ヘルペス	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
下気道感染	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
歯膿瘍	4 (<1)	3 (<1)	0	3 (<1)	1 (<1)
外陰部腟カンジダ症	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
細菌尿	0	0	2 (<1)	2 (<1)	1 (<1)
性器カンジダ症	0	2 (<1)	0	2 (<1)	0
ヘリコバクター感染	0	1 (<1)	1 (<1)	2 (<1)	0
爪真菌症	0	2 (<1)	0	2 (<1)	0
レンサ球菌性咽頭炎	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
咽頭扁桃炎	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 3 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肺炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)
皮下組織膿瘍	0	1 (<1)	1 (<1)	2 (<1)	0
癜風	0	1 (<1)	1 (<1)	2 (<1)	0
歯感染	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
腟感染	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ダニ症	0	0	1 (<1)	1 (<1)	0
急性副鼻腔炎	0	0	1 (<1)	1 (<1)	0
虫垂炎	0	1 (<1)	0	1 (<1)	1 (<1)
細菌感染	1 (<1)	1 (<1)	0	1 (<1)	0
気管支肺炎	0	1 (<1)	0	1 (<1)	0
カンジダ症	0	1 (<1)	0	1 (<1)	0
ウイルス性結膜炎	0	0	1 (<1)	1 (<1)	0
感染性皮膚炎	0	0	1 (<1)	1 (<1)	0
憩室炎	0	0	1 (<1)	1 (<1)	0
熱性感染症	0	0	1 (<1)	1 (<1)	0
ロタウイルス胃腸炎	0	1 (<1)	0	1 (<1)	0
陰部ヘルペス	1 (<1)	1 (<1)	0	1 (<1)	0
細菌性性器感染	0	1 (<1)	0	1 (<1)	0
泌尿生殖器感染	0	1 (<1)	0	1 (<1)	0
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	1 (<1)	0
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
切開部位感染	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 4 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
咬傷感染	0	1 (<1)	0	1 (<1)	0
伝染性単核症	0	1 (<1)	0	1 (<1)	0
シラミ寄生	0	1 (<1)	0	1 (<1)	0
限局性感染	1 (<1)	1 (<1)	0	1 (<1)	0
乳腺炎	0	1 (<1)	0	1 (<1)	0
口腔カンジダ症	1 (<1)	0	1 (<1)	1 (<1)	0
口腔真菌感染	0	0	1 (<1)	1 (<1)	0
急性中耳炎	0	0	1 (<1)	1 (<1)	0
腎盂腎炎	0	1 (<1)	0	1 (<1)	0
卵管卵巣炎	1 (<1)	1 (<1)	0	1 (<1)	0
細菌性副鼻腔炎	0	1 (<1)	0	1 (<1)	0
気管炎	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
気管気管支炎	0	1 (<1)	0	1 (<1)	1 (<1)
腸チフス熱	0	0	1 (<1)	1 (<1)	0
細菌性上気道感染	0	1 (<1)	0	1 (<1)	0
水痘	0	1 (<1)	0	1 (<1)	0
ウイルス性鼻炎	0	0	1 (<1)	1 (<1)	0
外陰部膿瘍	0	0	1 (<1)	1 (<1)	0
外陰部炎	0	1 (<1)	0	1 (<1)	0
顎膿瘍	1 (<1)	0	0	0	0
急性扁桃炎	2 (<1)	0	0	0	0
無症候性細菌尿	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 5 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ボレリア感染	1 (<1)	0	0	0	0
ウイルス性気管支炎	0	0	0	0	1 (<1)
慢性副鼻腔炎	0	0	0	0	1 (<1)
デング熱	0	0	0	0	1 (<1)
細菌性心内膜炎	1 (<1)	0	0	0	0
眼感染	2 (<1)	0	0	0	0
真菌感染	1 (<1)	0	0	0	1 (<1)
歯肉感染	1 (<1)	0	0	0	0
Ｈ１Ｎ１インフルエンザ	0	0	0	0	1 (<1)
感染性皮脂嚢腫	1 (<1)	0	0	0	0
寄生虫感染	0	0	0	0	1 (<1)
迷路炎	0	0	0	0	1 (<1)
乳様突起炎	0	0	0	0	1 (<1)
外耳炎	1 (<1)	0	0	0	0
パラインフルエンザウイルス感染	1 (<1)	0	0	0	0
子宮傍組織炎	0	0	0	0	1 (<1)
耳下腺炎	0	0	0	0	1 (<1)
細菌性咽頭炎	2 (<1)	0	0	0	0
猩紅熱	1 (<1)	0	0	0	0
白癬感染	1 (<1)	0	0	0	0
腟膿瘍	1 (<1)	0	0	0	0
細菌性腟炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 6 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
創傷感染	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (<1)	8 (1)	9 (1)	17 (1)	2 (<1)
皮膚乳頭腫	0	2 (<1)	3 (<1)	5 (<1)	0
メラノサイト性母斑	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
線維腫	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
脂肪腫	0	2 (<1)	0	2 (<1)	1 (<1)
肺新生物	0	1 (<1)	1 (<1)	2 (<1)	0
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
血管腫	1 (<1)	0	1 (<1)	1 (<1)	0
肝臓血管腫	0	0	1 (<1)	1 (<1)	0
子宮平滑筋腫	1 (<1)	0	1 (<1)	1 (<1)	0
良性副甲状腺腫瘍	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	11 (1)	24 (3)	22 (3)	46 (3)	5 (1)
貧血	5 (<1)	5 (<1)	8 (1)	13 (<1)	2 (<1)
リンパ球減少症	1 (<1)	6 (<1)	5 (<1)	11 (<1)	0
好酸球増加症	0	3 (<1)	4 (<1)	7 (<1)	0
白血球増加症	2 (<1)	5 (<1)	1 (<1)	6 (<1)	0
白血球減少症	0	2 (<1)	4 (<1)	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 7 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
好中球増加症	1 (<1)	3 (<1)	3 (<1)	6 (<1)	0
リンパ節症	1 (<1)	2 (<1)	1 (<1)	3 (<1)	3 (<1)
好中球減少症	0	1 (<1)	2 (<1)	3 (<1)	0
鉄欠乏性貧血	1 (<1)	1 (<1)	0	1 (<1)	0
血小板増加症	1 (<1)	0	0	0	0
免疫系障害	4 (<1)	14 (2)	12 (2)	26 (2)	5 (1)
過敏症	0	7 (<1)	6 (<1)	13 (<1)	1 (<1)
食物アレルギー	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
季節性アレルギー	3 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
薬物過敏症	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
造影剤アレルギー	0	1 (<1)	0	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)
内分泌障害	5 (<1)	1 (<1)	5 (<1)	6 (<1)	1 (<1)
甲状腺腫	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
甲状腺機能低下症	2 (<1)	0	2 (<1)	2 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	1 (<1)	0
副腎腫瘤	1 (<1)	0	0	0	0
副甲状腺機能亢進症	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 8 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
甲状腺機能亢進症	1 (<1)	0	0	0	0
代謝および栄養障害	29 (4)	23 (3)	25 (3)	48 (3)	10 (3)
食欲減退	7 (<1)	12 (2)	12 (2)	24 (2)	2 (<1)
高コレステロール血症	2 (<1)	4 (<1)	1 (<1)	5 (<1)	2 (<1)
脱水	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
高血糖	3 (<1)	0	3 (<1)	3 (<1)	0
糖尿病	3 (<1)	0	2 (<1)	2 (<1)	0
高脂血症	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
食欲亢進	3 (<1)	2 (<1)	0	2 (<1)	0
ビタミンD欠乏	0	0	2 (<1)	2 (<1)	1 (<1)
異常体重減少	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	2 (<1)	0	1 (<1)	1 (<1)	0
脂質異常症	0	0	1 (<1)	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	1 (<1)	0
高尿酸血症	0	1 (<1)	0	1 (<1)	1 (<1)
低カリウム血症	0	1 (<1)	0	1 (<1)	0
鉄欠乏	1 (<1)	0	1 (<1)	1 (<1)	0
痛風	1 (<1)	0	0	0	0
高カルシウム血症	1 (<1)	0	0	0	0
高カリウム血症	1 (<1)	0	0	0	1 (<1)
高トリグリセリド血症	1 (<1)	0	0	0	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 9 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ビタミン欠乏症	1 (<1)	0	0	0	0
肥満	0	0	0	0	1 (<1)
精神障害	84 (11)	58 (8)	64 (8)	122 (8)	29 (8)
うつ病	33 (4)	23 (3)	19 (3)	42 (3)	13 (4)
不安	16 (2)	16 (2)	14 (2)	30 (2)	4 (1)
不眠症	16 (2)	10 (1)	13 (2)	23 (2)	6 (2)
睡眠障害	5 (<1)	6 (<1)	5 (<1)	11 (<1)	1 (<1)
抑うつ気分	7 (<1)	5 (<1)	4 (<1)	9 (<1)	2 (<1)
感情障害	3 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
気分変化	0	1 (<1)	2 (<1)	3 (<1)	0
気分動揺	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
感情不安定	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
抑うつ症状	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
初期不眠症	0	0	2 (<1)	2 (<1)	0
リビドー減退	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ストレス	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
異常行動	0	1 (<1)	0	1 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	1 (<1)	0
情動障害	0	0	1 (<1)	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	1 (<1)	0
幻聴	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 10 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
大うつ病	0	0	1 (<1)	1 (<1)	0
躁病	0	1 (<1)	0	1 (<1)	0
神経過敏	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
人格変化	0	1 (<1)	0	1 (<1)	0
精神症状	0	1 (<1)	0	1 (<1)	0
落ち着きのなさ	0	1 (<1)	0	1 (<1)	0
自殺念慮	1 (<1)	1 (<1)	0	1 (<1)	2 (<1)
攻撃性	1 (<1)	0	0	0	0
激越	1 (<1)	0	0	0	0
気晴らし食い	1 (<1)	0	0	0	0
精神緩慢	1 (<1)	0	0	0	0
歯ぎしり	1 (<1)	0	0	0	0
錯乱状態	1 (<1)	0	0	0	0
幻覚	1 (<1)	0	0	0	0
精神障害	0	0	0	0	1 (<1)
中期不眠症	1 (<1)	0	0	0	0
悪夢	1 (<1)	0	0	0	0
緊張	1 (<1)	0	0	0	0
神経系障害	312 (40)	260 (34)	253 (33)	513 (34)	105 (30)
多発性硬化症再発	165 (21)	104 (14)	96 (13)	200 (13)	56 (16)
頭痛	88 (11)	84 (11)	80 (11)	164 (11)	33 (9)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 11 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
錯感覚	27 (4)	29 (4)	28 (4)	57 (4)	4 (1)
感覚鈍麻	20 (3)	15 (2)	15 (2)	30 (2)	8 (2)
灼熱感	5 (<1)	14 (2)	14 (2)	28 (2)	0
浮動性めまい	17 (2)	13 (2)	15 (2)	28 (2)	7 (2)
片頭痛	10 (1)	10 (1)	11 (1)	21 (1)	3 (<1)
筋痙直	12 (2)	7 (<1)	5 (<1)	12 (<1)	3 (<1)
異常感覚	2 (<1)	9 (1)	2 (<1)	11 (<1)	0
傾眠	4 (<1)	5 (<1)	6 (<1)	11 (<1)	2 (<1)
振戦	5 (<1)	7 (<1)	2 (<1)	9 (<1)	1 (<1)
平衡障害	2 (<1)	3 (<1)	4 (<1)	7 (<1)	2 (<1)
味覚異常	1 (<1)	2 (<1)	5 (<1)	7 (<1)	2 (<1)
神経痛	3 (<1)	3 (<1)	3 (<1)	6 (<1)	0
坐骨神経痛	2 (<1)	3 (<1)	3 (<1)	6 (<1)	0
感覚障害	8 (1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
前兆を伴う片頭痛	0	4 (<1)	1 (<1)	5 (<1)	0
構語障害	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
多発性硬化症	5 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
緊張性頭痛	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
三叉神経痛	5 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
過眠症	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
記憶障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
失神	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 12 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ウートホフ現象	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
運動失調	1 (<1)	0	2 (<1)	2 (<1)	0
帯状感	0	0	2 (<1)	2 (<1)	0
手根管症候群	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
頚髄神経根痛	0	0	2 (<1)	2 (<1)	0
認知障害	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
知覚過敏	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
肋間神経痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
レルミット徴候	4 (<1)	0	2 (<1)	2 (<1)	1 (<1)
意識消失	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
運動機能障害	0	1 (<1)	1 (<1)	2 (<1)	0
眼振	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
味覚消失	0	1 (<1)	0	1 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0
自律神経失調	0	0	1 (<1)	1 (<1)	0
頚原性頭痛	0	0	1 (<1)	1 (<1)	0
概日リズム睡眠障害	0	1 (<1)	0	1 (<1)	0
痙攣	2 (<1)	0	1 (<1)	1 (<1)	0
泣き	0	0	1 (<1)	1 (<1)	0
振動覚低下	0	1 (<1)	0	1 (<1)	0
注意力障害	0	1 (<1)	0	1 (<1)	1 (<1)
体位性めまい	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 13 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
よだれ	0	0	1 (<1)	1 (<1)	0
ジスキネジー	0	1 (<1)	0	1 (<1)	0
てんかん	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
てんかんの前兆	0	1 (<1)	0	1 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)	0
頭部動揺	0	1 (<1)	0	1 (<1)	0
片側頭痛	2 (<1)	1 (<1)	0	1 (<1)	0
不全片麻痺	0	0	1 (<1)	1 (<1)	0
反射亢進	2 (<1)	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
嗜眠	0	0	1 (<1)	1 (<1)	0
腰髄神経根障害	1 (<1)	1 (<1)	0	1 (<1)	0
感覚異常性大腿神経痛	0	1 (<1)	0	1 (<1)	0
神経圧迫	0	0	1 (<1)	1 (<1)	0
視神経炎	0	1 (<1)	0	1 (<1)	0
腓骨神経麻痺	0	1 (<1)	0	1 (<1)	0
睡眠の質低下	0	1 (<1)	0	1 (<1)	0
頚髄神経根炎	0	1 (<1)	0	1 (<1)	0
下肢静止不能症候群	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
鎮静	0	0	1 (<1)	1 (<1)	0
副鼻腔炎に伴う頭痛	2 (<1)	0	1 (<1)	1 (<1)	0
会話障害	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 14 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
舌の麻痺	0	1 (<1)	0	1 (<1)	0
健忘	3 (<1)	0	0	0	0
失語症	1 (<1)	0	0	0	1 (<1)
中枢神経系病変	1 (<1)	0	0	0	0
中枢痛症候群	1 (<1)	0	0	0	0
小脳症候群	1 (<1)	0	0	0	0
脳血管発作	1 (<1)	0	0	0	0
頚腕症候群	1 (<1)	0	0	0	0
複雑部分発作	1 (<1)	0	0	0	0
顔面不全麻痺	1 (<1)	0	0	0	0
顔面痙攣	1 (<1)	0	0	0	1 (<1)
筋緊張亢進	1 (<1)	0	0	0	0
仮面状顔貌	0	0	0	0	1 (<1)
末梢性ニューロパチー	0	0	0	0	1 (<1)
後頭神経痛	1 (<1)	0	0	0	0
嗅覚錯誤	1 (<1)	0	0	0	0
部分発作	0	0	0	0	1 (<1)
失神寸前の状態	2 (<1)	0	0	0	0
温度覚鈍麻	1 (<1)	0	0	0	0
振動覚亢進	1 (<1)	0	0	0	0
第７脳神経麻痺	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 15 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼障害	46 (6)	22 (3)	38 (5)	60 (4)	10 (3)
霧視	7 (<1)	6 (<1)	8 (1)	14 (<1)	3 (<1)
眼痛	5 (<1)	1 (<1)	10 (1)	11 (<1)	2 (<1)
眼瞼痙攣	4 (<1)	3 (<1)	3 (<1)	6 (<1)	0
視力障害	3 (<1)	3 (<1)	3 (<1)	6 (<1)	0
眼乾燥	3 (<1)	4 (<1)	1 (<1)	5 (<1)	0
複視	5 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
結膜炎	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
視力低下	5 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
白内障	0	0	2 (<1)	2 (<1)	0
アレルギー性結膜炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
緑内障	0	0	2 (<1)	2 (<1)	0
ブドウ膜炎	0	0	2 (<1)	2 (<1)	1 (<1)
眼瞼炎	0	0	1 (<1)	1 (<1)	0
眼出血	0	0	1 (<1)	1 (<1)	0
眼刺激	0	0	1 (<1)	1 (<1)	0
眼運動障害	0	0	1 (<1)	1 (<1)	0
眼そう痒症	2 (<1)	0	1 (<1)	1 (<1)	0
角膜炎	0	0	1 (<1)	1 (<1)	0
開放隅角緑内障	0	0	1 (<1)	1 (<1)	0
眼筋麻痺	0	1 (<1)	0	1 (<1)	0
光視症	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 16 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
強膜炎	0	1 (<1)	0	1 (<1)	0
硝子体浮遊物	0	1 (<1)	0	1 (<1)	0
霰粒腫	1 (<1)	0	0	0	0
結膜出血	1 (<1)	0	0	0	0
結膜刺激	1 (<1)	0	0	0	0
眼瞼紅斑	2 (<1)	0	0	0	0
眼のアレルギー	0	0	0	0	1 (<1)
眼瞼そう痒症	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
遠視	1 (<1)	0	0	0	0
流涙増加	1 (<1)	0	0	0	1 (<1)
黄斑浮腫	1 (<1)	0	0	0	0
近視	1 (<1)	0	0	0	0
眼充血	1 (<1)	0	0	0	0
耳および迷路障害	31 (4)	21 (3)	22 (3)	43 (3)	12 (3)
回転性めまい	24 (3)	13 (2)	14 (2)	27 (2)	6 (2)
耳鳴	4 (<1)	3 (<1)	2 (<1)	5 (<1)	0
耳痛	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
頭位性回転性めまい	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
難聴	2 (<1)	1 (<1)	0	1 (<1)	0
耳閉	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 17 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
耳不快感	0	0	1 (<1)	1 (<1)	2 (<1)
耳そう痒症	0	1 (<1)	0	1 (<1)	0
聴力低下	0	0	1 (<1)	1 (<1)	0
乗物酔い	1 (<1)	1 (<1)	0	1 (<1)	0
耳垢栓塞	0	0	0	0	1 (<1)
外耳道紅斑	1 (<1)	0	0	0	0
耳管機能障害	0	0	0	0	1 (<1)
前庭障害	1 (<1)	0	0	0	0
心臓障害	21 (3)	14 (2)	17 (2)	31 (2)	10 (3)
動悸	10 (1)	7 (<1)	4 (<1)	11 (<1)	1 (<1)
頻脈	2 (<1)	3 (<1)	4 (<1)	7 (<1)	4 (1)
第一度房室ブロック	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
徐脈	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
期外収縮	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
洞性徐脈	0	1 (<1)	1 (<1)	2 (<1)	0
洞性頻脈	2 (<1)	0	2 (<1)	2 (<1)	0
上室性期外収縮	1 (<1)	2 (<1)	0	2 (<1)	0
心室性期外収縮	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
狭心症	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	1 (<1)	1 (<1)	1 (<1)
心不全	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 18 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
右脚ブロック	0	0	0	0	1 (<1)
伝導障害	0	0	0	0	1 (<1)
心筋虚血	1 (<1)	0	0	0	0
心筋炎	0	0	0	0	1 (<1)
上室性頻脈	1 (<1)	0	0	0	0
発作性頻脈	1 (<1)	0	0	0	0
血管障害	51 (7)	276 (36)	246 (32)	522 (34)	14 (4)
潮紅	27 (4)	231 (30)	199 (26)	430 (28)	3 (<1)
ほてり	10 (1)	39 (5)	41 (5)	80 (5)	5 (1)
高血圧	7 (<1)	5 (<1)	11 (1)	16 (1)	6 (2)
充血	0	2 (<1)	6 (<1)	8 (<1)	0
低血圧	1 (<1)	4 (<1)	0	4 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
起立性低血圧	1 (<1)	0	1 (<1)	1 (<1)	0
静脈炎	1 (<1)	0	1 (<1)	1 (<1)	0
レイノー現象	1 (<1)	1 (<1)	0	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0	0
血腫	2 (<1)	0	0	0	0
腹腔内血腫	0	0	0	0	1 (<1)
呼吸器、胸郭および縦隔障害	60 (8)	57 (7)	64 (8)	121 (8)	15 (4)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 19 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
口腔咽頭痛	13 (2)	15 (2)	18 (2)	33 (2)	5 (1)
咳嗽	18 (2)	18 (2)	11 (1)	29 (2)	3 (<1)
鼻漏	5 (<1)	9 (1)	7 (<1)	16 (1)	0
呼吸困難	5 (<1)	4 (<1)	3 (<1)	7 (<1)	4 (1)
鼻閉	5 (<1)	4 (<1)	2 (<1)	6 (<1)	0
副鼻腔うっ血	0	1 (<1)	5 (<1)	6 (<1)	0
アレルギー性鼻炎	2 (<1)	1 (<1)	4 (<1)	5 (<1)	0
上気道咳症候群	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
喘息	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
鼻出血	3 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
気道うっ血	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
咽喉刺激感	2 (<1)	3 (<1)	0	3 (<1)	0
息詰まり	1 (<1)	0	2 (<1)	2 (<1)	0
湿性咳嗽	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	2 (<1)	0
上気道うっ血	2 (<1)	0	2 (<1)	2 (<1)	0
喘鳴	1 (<1)	2 (<1)	0	2 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	1 (<1)	0
咽喉乾燥	1 (<1)	1 (<1)	0	1 (<1)	0
発声障害	0	0	1 (<1)	1 (<1)	1 (<1)
労作性呼吸困難	0	1 (<1)	0	1 (<1)	0
しゃっくり	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 20 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
過換気	0	0	1 (<1)	1 (<1)	0
呼吸時疼痛	0	0	1 (<1)	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	1 (<1)	0
咽頭紅斑	0	1 (<1)	0	1 (<1)	0
咽頭腫瘤	0	0	1 (<1)	1 (<1)	0
胸膜炎	0	0	1 (<1)	1 (<1)	0
ラ音	0	0	1 (<1)	1 (<1)	0
アレルギー性咽頭炎	2 (<1)	0	0	0	0
慢性気管支炎	1 (<1)	0	0	0	0
低換気	0	0	0	0	1 (<1)
上気道分泌増加	1 (<1)	0	0	0	0
鼻部不快感	1 (<1)	0	0	0	0
鼻乾燥	2 (<1)	0	0	0	0
低音性連続性ラ音	1 (<1)	0	0	0	0
副鼻腔障害	1 (<1)	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0	1 (<1)
くしゃみ	1 (<1)	0	0	0	1 (<1)
声帯の炎症	1 (<1)	0	0	0	0
胃腸障害	192 (25)	286 (37)	304 (40)	590 (39)	30 (9)
下痢	49 (6)	78 (10)	102 (13)	180 (12)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 21 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
悪心	51 (7)	75 (10)	86 (11)	161 (11)	10 (3)
上腹部痛	29 (4)	58 (8)	61 (8)	119 (8)	2 (<1)
腹痛	26 (3)	55 (7)	44 (6)	99 (6)	2 (<1)
嘔吐	16 (2)	44 (6)	36 (5)	80 (5)	2 (<1)
消化不良	15 (2)	22 (3)	30 (4)	52 (3)	3 (<1)
胃腸障害	5 (<1)	17 (2)	30 (4)	47 (3)	1 (<1)
便秘	18 (2)	15 (2)	19 (3)	34 (2)	3 (<1)
胃炎	5 (<1)	11 (1)	11 (1)	22 (1)	0
胃食道逆流性疾患	9 (1)	12 (2)	10 (1)	22 (1)	1 (<1)
口内乾燥	3 (<1)	15 (2)	6 (<1)	21 (1)	0
腹部不快感	6 (<1)	9 (1)	11 (1)	20 (1)	0
歯痛	7 (<1)	8 (1)	11 (1)	19 (1)	2 (<1)
鼓腸	6 (<1)	7 (<1)	8 (1)	15 (<1)	2 (<1)
腹部膨満	7 (<1)	3 (<1)	10 (1)	13 (<1)	0
齲歯	2 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
下腹部痛	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
おくび	0	2 (<1)	3 (<1)	5 (<1)	0
便失禁	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
痔核	1 (<1)	4 (<1)	1 (<1)	5 (<1)	0
便意切迫	0	1 (<1)	3 (<1)	4 (<1)	0
歯周炎	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
嚥下障害	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 22 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心窩部不快感	0	1 (<1)	2 (<1)	3 (<1)	0
食中毒	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
胃障害	0	1 (<1)	2 (<1)	3 (<1)	0
流涎過多	0	3 (<1)	0	3 (<1)	0
腹部圧痛	0	0	2 (<1)	2 (<1)	1 (<1)
異常便	1 (<1)	2 (<1)	0	2 (<1)	0
排便回数増加	0	0	2 (<1)	2 (<1)	0
歯肉炎	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
裂孔ヘルニア	0	1 (<1)	1 (<1)	2 (<1)	0
胃酸過多	1 (<1)	2 (<1)	0	2 (<1)	0
口の感覚鈍麻	0	1 (<1)	1 (<1)	2 (<1)	0
過敏性腸症候群	0	1 (<1)	1 (<1)	2 (<1)	0
食道炎	0	2 (<1)	0	2 (<1)	0
腹部硬直	0	0	1 (<1)	1 (<1)	0
唾液欠乏	0	1 (<1)	0	1 (<1)	0
便習慣変化	0	0	1 (<1)	1 (<1)	0
口唇炎	0	1 (<1)	0	1 (<1)	0
大腸炎	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
クローン病	0	1 (<1)	0	1 (<1)	0
十二指腸ポリープ	0	1 (<1)	0	1 (<1)	0
十二指腸潰瘍	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 23 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
小腸炎	0	1 (<1)	0	1 (<1)	0
腸炎	0	0	1 (<1)	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)	1 (<1)
出血性胃炎	0	1 (<1)	0	1 (<1)	0
胃十二指腸炎	0	0	1 (<1)	1 (<1)	0
胃腸出血	0	0	1 (<1)	1 (<1)	0
歯肉出血	0	1 (<1)	0	1 (<1)	0
歯肉痛	1 (<1)	0	1 (<1)	1 (<1)	0
歯肉腫脹	0	1 (<1)	0	1 (<1)	0
舌炎	0	1 (<1)	0	1 (<1)	0
舌痛	1 (<1)	1 (<1)	0	1 (<1)	0
吐血	0	1 (<1)	0	1 (<1)	0
胃排出不全	0	1 (<1)	0	1 (<1)	0
弛緩歯	0	1 (<1)	0	1 (<1)	0
腰ヘルニア	0	0	1 (<1)	1 (<1)	0
嚥下痛	0	1 (<1)	0	1 (<1)	0
食道出血	0	1 (<1)	0	1 (<1)	0
食道痙攣	0	0	1 (<1)	1 (<1)	0
口腔内痛	0	0	1 (<1)	1 (<1)	0
膵臓障害	0	0	1 (<1)	1 (<1)	0
膵機能不全	0	0	1 (<1)	1 (<1)	0
膵炎	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 24 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
口の錯感覚	0	1 (<1)	0	1 (<1)	0
消化性潰瘍	0	0	1 (<1)	1 (<1)	0
歯周病	0	1 (<1)	0	1 (<1)	0
舌腫脹	0	1 (<1)	0	1 (<1)	0
舌苔	0	0	1 (<1)	1 (<1)	0
歯の脱落	1 (<1)	1 (<1)	0	1 (<1)	0
呼気臭	1 (<1)	0	0	0	0
口唇のひび割れ	1 (<1)	0	0	0	0
胃ポリープ	1 (<1)	0	0	0	0
歯肉紅斑	0	0	0	0	1 (<1)
痔出血	0	0	0	0	1 (<1)
口唇乾燥	1 (<1)	0	0	0	0
口腔内潰瘍形成	2 (<1)	0	0	0	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
直腸出血	1 (<1)	0	0	0	0
直腸攣縮	0	0	0	0	1 (<1)
逆流性食道炎	1 (<1)	0	0	0	0
口内炎	1 (<1)	0	0	0	0
脆弱歯	1 (<1)	0	0	0	0
歯の障害	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 25 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝胆道系障害	1 (<1)	4 (<1)	12 (2)	16 (1)	0
肝障害	0	2 (<1)	5 (<1)	7 (<1)	0
肝細胞融解性肝炎	0	0	2 (<1)	2 (<1)	0
肝嚢胞	0	1 (<1)	1 (<1)	2 (<1)	0
胆管結石	0	0	1 (<1)	1 (<1)	0
胆石症	1 (<1)	0	1 (<1)	1 (<1)	0
胆嚢浮腫	0	0	1 (<1)	1 (<1)	0
肝炎	0	0	1 (<1)	1 (<1)	0
高ビリルビン血症	0	0	1 (<1)	1 (<1)	0
高トランスアミナーゼ血症	0	1 (<1)	0	1 (<1)	0
皮膚および皮下組織障害	98 (13)	176 (23)	183 (24)	359 (23)	35 (10)
そう痒症	18 (2)	45 (6)	41 (5)	86 (6)	2 (<1)
発疹	16 (2)	41 (5)	37 (5)	78 (5)	5 (1)
紅斑	3 (<1)	24 (3)	40 (5)	64 (4)	4 (1)
多汗症	6 (<1)	9 (1)	15 (2)	24 (2)	3 (<1)
脱毛症	11 (1)	13 (2)	7 (<1)	20 (1)	5 (1)
蕁麻疹	5 (<1)	9 (1)	9 (1)	18 (1)	1 (<1)
寝汗	7 (<1)	9 (1)	8 (1)	17 (1)	1 (<1)
全身性そう痒症	3 (<1)	5 (<1)	9 (1)	14 (<1)	2 (<1)
皮膚灼熱感	0	4 (<1)	6 (<1)	10 (<1)	0
そう痒性皮疹	2 (<1)	6 (<1)	3 (<1)	9 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 26 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚乾燥	3 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
ざ瘡	10 (1)	4 (<1)	3 (<1)	7 (<1)	2 (<1)
アレルギー性皮膚炎	2 (<1)	4 (<1)	3 (<1)	7 (<1)	0
斑状皮疹	0	1 (<1)	6 (<1)	7 (<1)	0
全身性皮疹	0	2 (<1)	4 (<1)	6 (<1)	0
皮膚炎	3 (<1)	1 (<1)	4 (<1)	5 (<1)	0
全身紅斑	0	2 (<1)	3 (<1)	5 (<1)	0
光線過敏性反応	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
酒さ	0	5 (<1)	0	5 (<1)	0
湿疹	4 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
紅斑性皮疹	0	1 (<1)	3 (<1)	4 (<1)	0
薬疹	0	1 (<1)	2 (<1)	3 (<1)	0
痒疹	0	2 (<1)	1 (<1)	3 (<1)	0
皮膚反応	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)
ざ瘡様皮膚炎	1 (<1)	2 (<1)	0	2 (<1)	0
斑状出血	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
顔面感覚鈍麻	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
皮膚疼痛	0	0	2 (<1)	2 (<1)	0
アレルギー性そう痒症	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
乾癬	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
皮膚剥脱	0	1 (<1)	1 (<1)	2 (<1)	0
皮膚色素過剰	1 (<1)	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 27 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
皮膚刺激	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
皮膚のつっぱり感	0	0	2 (<1)	2 (<1)	0
皮膚熱感	0	1 (<1)	1 (<1)	2 (<1)	0
水疱	0	1 (<1)	0	1 (<1)	0
皮膚嚢腫	1 (<1)	0	1 (<1)	1 (<1)	0
紅色症	0	0	1 (<1)	1 (<1)	0
剥脱性発疹	1 (<1)	1 (<1)	0	1 (<1)	0
紅色汗疹	0	1 (<1)	0	1 (<1)	0
過角化	0	0	1 (<1)	1 (<1)	0
掌蹠角化症	0	1 (<1)	0	1 (<1)	0
内出血発生の増加傾向	0	0	1 (<1)	1 (<1)	0
毛孔性角化症	0	0	1 (<1)	1 (<1)	0
網状皮斑	0	0	1 (<1)	1 (<1)	1 (<1)
爪変色	0	1 (<1)	0	1 (<1)	0
爪破損	0	1 (<1)	0	1 (<1)	0
丘疹性皮疹	0	1 (<1)	0	1 (<1)	0
脂腺障害	0	0	1 (<1)	1 (<1)	0
皮膚色素脱失	0	0	1 (<1)	1 (<1)	0
皮膚色素減少	0	1 (<1)	0	1 (<1)	0
皮下結節	0	1 (<1)	0	1 (<1)	1 (<1)
乾皮症	1 (<1)	0	1 (<1)	1 (<1)	0
冷汗	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 28 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
接触性皮膚炎	1 (<1)	0	0	0	2 (<1)
皮下出血	0	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0	0
黒子	1 (<1)	0	0	0	0
爪床障害	1 (<1)	0	0	0	0
光線性皮膚症	1 (<1)	0	0	0	0
色素沈着障害	1 (<1)	0	0	0	0
ばら色粃糠疹	2 (<1)	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0	0
猩紅熱様発疹	1 (<1)	0	0	0	0
脂漏性皮膚炎	0	0	0	0	1 (<1)
皮膚障害	1 (<1)	0	0	0	0
皮膚硬結	0	0	0	0	2 (<1)
皮膚病変	1 (<1)	0	0	0	0
皮膚小結節	0	0	0	0	1 (<1)
顔面腫脹	1 (<1)	0	0	0	2 (<1)
裂毛	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	138 (18)	127 (17)	125 (16)	252 (16)	41 (12)
背部痛	39 (5)	44 (6)	33 (4)	77 (5)	13 (4)
関節痛	25 (3)	28 (4)	23 (3)	51 (3)	4 (1)
四肢痛	28 (4)	25 (3)	23 (3)	48 (3)	10 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 29 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋痙縮	17 (2)	10 (1)	18 (2)	28 (2)	4 (1)
筋肉痛	16 (2)	7 (<1)	10 (1)	17 (1)	3 (<1)
筋力低下	18 (2)	6 (<1)	9 (1)	15 (<1)	5 (1)
頚部痛	9 (1)	8 (1)	6 (<1)	14 (<1)	2 (<1)
筋骨格痛	12 (2)	5 (<1)	8 (1)	13 (<1)	3 (<1)
関節炎	0	2 (<1)	3 (<1)	5 (<1)	0
筋骨格硬直	3 (<1)	2 (<1)	3 (<1)	5 (<1)	4 (1)
滑液包炎	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
筋骨格系胸痛	2 (<1)	1 (<1)	3 (<1)	4 (<1)	0
重感	2 (<1)	4 (<1)	0	4 (<1)	0
腱炎	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
側腹部痛	1 (<1)	0	3 (<1)	3 (<1)	0
関節腫脹	1 (<1)	3 (<1)	0	3 (<1)	0
骨痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
関節硬直	0	0	2 (<1)	2 (<1)	0
筋緊張	0	1 (<1)	1 (<1)	2 (<1)	0
腱鞘炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
関節障害	0	1 (<1)	0	1 (<1)	0
腋窩腫瘤	0	1 (<1)	0	1 (<1)	0
尾骨痛	0	0	1 (<1)	1 (<1)	0
成長痛	0	0	1 (<1)	1 (<1)	1 (<1)
椎間板変性症	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 30 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
四肢不快感	0	0	1 (<1)	1 (<1)	0
筋拘縮	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
筋骨格不快感	2 (<1)	0	1 (<1)	1 (<1)	0
ミオキミア	0	0	1 (<1)	1 (<1)	0
筋炎	0	0	1 (<1)	1 (<1)	0
変形性関節症	2 (<1)	1 (<1)	0	1 (<1)	0
骨端症	0	0	1 (<1)	1 (<1)	0
骨減少症	0	0	1 (<1)	1 (<1)	0
骨粗鬆症	0	1 (<1)	0	1 (<1)	0
関節周囲炎	1 (<1)	1 (<1)	0	1 (<1)	0
変形性脊椎症	0	0	1 (<1)	1 (<1)	0
外骨腫	0	0	0	0	1 (<1)
筋肉疲労	1 (<1)	0	0	0	0
筋攣縮	1 (<1)	0	0	0	0
顎痛	1 (<1)	0	0	0	0
足底筋膜炎	1 (<1)	0	0	0	0
関節リウマチ	1 (<1)	0	0	0	0
肩回旋筋腱板症候群	2 (<1)	0	0	0	0
脊柱変形	1 (<1)	0	0	0	0
斜頚	1 (<1)	0	0	0	0
腎および尿路障害	69 (9)	73 (9)	95 (13)	168 (11)	24 (7)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 31 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
蛋白尿	31 (4)	31 (4)	43 (6)	74 (5)	11 (3)
血尿	17 (2)	15 (2)	23 (3)	38 (2)	4 (1)
ミクロアルブミン尿	10 (1)	14 (2)	14 (2)	28 (2)	5 (1)
ケトン尿	4 (<1)	3 (<1)	10 (1)	13 (<1)	0
排尿困難	3 (<1)	2 (<1)	6 (<1)	8 (<1)	1 (<1)
尿意切迫	4 (<1)	4 (<1)	4 (<1)	8 (<1)	3 (<1)
尿失禁	1 (<1)	4 (<1)	2 (<1)	6 (<1)	0
頻尿	5 (<1)	2 (<1)	3 (<1)	5 (<1)	3 (<1)
腎結石症	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
膀胱機能障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
糖尿	4 (<1)	1 (<1)	2 (<1)	3 (<1)	0
白血球尿	1 (<1)	0	3 (<1)	3 (<1)	1 (<1)
腎臓痛	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
切迫性尿失禁	0	0	3 (<1)	3 (<1)	1 (<1)
非感染性膀胱炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
排尿躊躇	1 (<1)	0	2 (<1)	2 (<1)	0
尿臭異常	0	1 (<1)	1 (<1)	2 (<1)	0
出血性膀胱炎	0	1 (<1)	0	1 (<1)	0
緊張性膀胱	0	1 (<1)	0	1 (<1)	0
失禁	0	0	1 (<1)	1 (<1)	0
排尿異常	0	1 (<1)	0	1 (<1)	0
神経因性膀胱	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 32 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
起立性蛋白尿症	0	1 (<1)	0	1 (<1)	0
腎仙痛	0	0	1 (<1)	1 (<1)	0
慢性腎不全	0	0	1 (<1)	1 (<1)	0
有痛性排尿困難	0	1 (<1)	0	1 (<1)	0
尿閉	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
アルブミン尿	0	0	0	0	1 (<1)
膀胱憩室	1 (<1)	0	0	0	0
夜間頻尿	1 (<1)	0	0	0	0
'妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
自然流産	1 (<1)	0	0	0	0
生殖系および乳房障害	38 (5)	40 (5)	40 (5)	80 (5)	14 (4)
月経困難症	6 (<1)	8 (1)	10 (1)	18 (1)	2 (<1)
無月経	3 (<1)	3 (<1)	4 (<1)	7 (<1)	2 (<1)
不正子宮出血	2 (<1)	4 (<1)	3 (<1)	7 (<1)	3 (<1)
不規則月経	4 (<1)	2 (<1)	4 (<1)	6 (<1)	3 (<1)
勃起不全	4 (<1)	2 (<1)	3 (<1)	5 (<1)	0
腟出血	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
卵巣嚢胞	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)
月経障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
月経遅延	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 33 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
頻発月経	0	2 (<1)	1 (<1)	3 (<1)	1 (<1)
乳房痛	0	1 (<1)	1 (<1)	2 (<1)	0
乳房圧痛	0	0	2 (<1)	2 (<1)	0
月経過多	4 (<1)	1 (<1)	1 (<1)	2 (<1)	0
骨盤痛	2 (<1)	0	2 (<1)	2 (<1)	0
腺筋症	0	0	1 (<1)	1 (<1)	0
萎縮性外陰腟炎	0	0	1 (<1)	1 (<1)	0
乳房嚢胞	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
乳房障害	0	1 (<1)	0	1 (<1)	0
乳房出血	0	1 (<1)	0	1 (<1)	0
子宮頚部上皮異形成	0	1 (<1)	0	1 (<1)	0
射精障害	0	1 (<1)	0	1 (<1)	0
子宮内膜増殖症	0	1 (<1)	0	1 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
閉経期症状	1 (<1)	1 (<1)	0	1 (<1)	0
乳頭障害	0	1 (<1)	0	1 (<1)	0
希発月経	1 (<1)	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	1 (<1)	1 (<1)	0	1 (<1)	0
多嚢胞性卵巣	0	1 (<1)	0	1 (<1)	0
閉経後出血	1 (<1)	0	1 (<1)	1 (<1)	0
性機能不全	0	1 (<1)	0	1 (<1)	0
精巣障害	0	0	1 1 <1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 34 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
子宮出血	1 (<1)	0	1 (<1)	1 (<1)	0
子宮ポリープ	1 (<1)	1 (<1)	0	1 (<1)	0
外陰腟乾燥	0	0	1 (<1)	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0	0
乳房腫大	0	0	0	0	1 (<1)
乳房腫瘤	1 (<1)	0	0	0	0
子宮頚管ポリープ	0	0	0	0	1 (<1)
生殖器病変	1 (<1)	0	0	0	0
機能性子宮出血	0	0	0	0	1 (<1)
子宮頚部びらん	1 (<1)	0	0	0	0
外陰腟痛	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	0	1 (<1)	0	1 (<1)	1 (<1)
異形成母斑症候群	0	1 (<1)	0	1 (<1)	0
過誤腫	0	0	0	0	1 (<1)
一般・全身障害および投与部位の状態	103 (13)	102 (13)	118 (16)	220 (14)	108 (31)
疲労	42 (5)	52 (7)	51 (7)	103 (7)	19 (5)
発熱	10 (1)	11 (1)	22 (3)	33 (2)	7 (2)
無力症	9 (1)	17 (2)	10 (1)	27 (2)	7 (2)
熱感	2 (<1)	11 (1)	9 (1)	20 (1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 35 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
疼痛	1 (<1)	8 (1)	5 (<1)	13 (<1)	2 (<1)
末梢性浮腫	11 (1)	3 (<1)	9 (1)	12 (<1)	2 (<1)
胸痛	7 (<1)	4 (<1)	6 (<1)	10 (<1)	2 (<1)
インフルエンザ様疾患	7 (<1)	2 (<1)	4 (<1)	6 (<1)	3 (<1)
胸部不快感	3 (<1)	2 (<1)	3 (<1)	5 (<1)	0
易刺激性	3 (<1)	3 (<1)	2 (<1)	5 (<1)	2 (<1)
倦怠感	0	2 (<1)	3 (<1)	5 (<1)	1 (<1)
非心臓性胸痛	1 (<1)	1 (<1)	4 (<1)	5 (<1)	2 (<1)
悪寒	3 (<1)	1 (<1)	3 (<1)	4 (<1)	3 (<1)
歩行障害	6 (<1)	2 (<1)	2 (<1)	4 (<1)	3 (<1)
顔面痛	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
嚢胞	0	0	2 (<1)	2 (<1)	0
冷感	1 (<1)	0	2 (<1)	2 (<1)	0
粘膜乾燥	0	1 (<1)	1 (<1)	2 (<1)	0
腫脹	0	2 (<1)	0	2 (<1)	0
圧痛	0	0	2 (<1)	2 (<1)	0
不快感	0	0	1 (<1)	1 (<1)	0
脂肪壊死	0	1 (<1)	0	1 (<1)	0
異常感	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
びくびく感	0	0	1 (<1)	1 (<1)	0
重力性浮腫	0	0	1 (<1)	1 (<1)	0
高熱	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 36 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位血腫	0	0	1 (<1)	1 (<1)	5 (1)
医療機器による疼痛	0	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	1 (<1)	0
浮腫	0	1 (<1)	0	1 (<1)	1 (<1)
温度変化不耐症	0	1 (<1)	0	1 (<1)	0
口渇	0	0	1 (<1)	1 (<1)	0
血管穿刺部位血腫	0	0	1 (<1)	1 (<1)	0
嚢胞破裂	0	0	0	0	1 (<1)
全身症状	1 (<1)	0	0	0	0
空腹	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	2 (<1)
注射部位変色	0	0	0	0	1 (<1)
注射部位乾燥	0	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	30 (9)
注射部位血管外漏出	0	0	0	0	1 (<1)
注射部位出血	0	0	0	0	2 (<1)
注射部位過敏反応	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	1 (<1)
注射部位硬結	0	0	0	0	7 (2)
注射部位炎症	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	7 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 37 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位結節	0	0	0	0	1 (<1)
注射部位浮腫	0	0	0	0	3 (<1)
注射部位疼痛	0	0	0	0	29 (8)
注射部位そう痒感	0	0	0	0	12 (3)
注射部位発疹	0	0	0	0	3 (<1)
注射部位反応	0	0	0	0	3 (<1)
注射部位瘢痕	0	0	0	0	1 (<1)
注射部位腫脹	0	0	0	0	9 (3)
注射部位蕁麻疹	0	0	0	0	3 (<1)
注射部位熱感	0	0	0	0	3 (<1)
足のもつれ	1 (<1)	0	0	0	0
微石症	0	0	0	0	1 (<1)
ワクチン接種部位疼痛	1 (<1)	0	0	0	0
臨床検査	98 (13)	129 (17)	117 (15)	246 (16)	57 (16)
アラニン・アミノトランスフェラーゼ増加	9 (1)	32 (4)	30 (4)	62 (4)	10 (3)
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	21 (3)	19 (3)	40 (3)	6 (2)
尿中アルブミン陽性	11 (1)	20 (3)	15 (2)	35 (2)	5 (1)
尿中蛋白陽性	6 (<1)	14 (2)	10 (1)	24 (2)	10 (3)
体重減少	2 (<1)	8 (1)	8 (1)	16 (1)	1 (<1)
γ－グルタミルトランスフェラーゼ増加	5 (<1)	7 (<1)	7 (<1)	14 (<1)	4 (1)
尿中血陽性	1 (<1)	7 (<1)	6 (<1)	13 (<1)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 38 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球数減少	1 (<1)	7 (<1)	6 (<1)	13 (<1)	0
肝酵素上昇	4 (<1)	7 (<1)	5 (<1)	12 (<1)	3 (<1)
尿中β２ミクログロブリン増加	4 (<1)	8 (1)	2 (<1)	10 (<1)	2 (<1)
血中ブドウ糖増加	3 (<1)	4 (<1)	6 (<1)	10 (<1)	2 (<1)
尿中ケトン体陽性	0	4 (<1)	6 (<1)	10 (<1)	1 (<1)
尿中赤血球陽性	2 (<1)	5 (<1)	4 (<1)	9 (<1)	1 (<1)
尿中白血球陽性	6 (<1)	4 (<1)	5 (<1)	9 (<1)	7 (2)
血中副甲状腺ホルモン増加	3 (<1)	5 (<1)	3 (<1)	8 (<1)	1 (<1)
血中トリグリセリド増加	4 (<1)	4 (<1)	3 (<1)	7 (<1)	5 (1)
ヘモグロビン減少	2 (<1)	4 (<1)	2 (<1)	6 (<1)	0
リンパ球数減少	0	4 (<1)	2 (<1)	6 (<1)	1 (<1)
体重増加	9 (1)	2 (<1)	4 (<1)	6 (<1)	3 (<1)
白血球数増加	6 (<1)	4 (<1)	2 (<1)	6 (<1)	3 (<1)
体温上昇	1 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
好中球数増加	5 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
血中コレステロール増加	1 (<1)	0	4 (<1)	4 (<1)	1 (<1)
血中クレアチニン増加	1 (<1)	2 (<1)	2 (<1)	4 (<1)	3 (<1)
好中球数減少	1 (<1)	4 (<1)	0	4 (<1)	1 (<1)
好酸球数増加	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
ヘマトクリット減少	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
β２ミクログロブリン増加	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 39 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中ビリルビン増加	5 (<1)	1 (<1)	1 (<1)	2 (<1)	0
血中乳酸脱水素酵素増加	1 (<1)	2 (<1)	0	2 (<1)	0
血中カリウム増加	0	1 (<1)	1 (<1)	2 (<1)	0
血圧上昇	0	1 (<1)	1 (<1)	2 (<1)	0
血中尿酸増加	0	0	2 (<1)	2 (<1)	0
心電図ＳＴ部分下降	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
心拍数増加	1 (<1)	2 (<1)	0	2 (<1)	0
肝機能検査異常	0	2 (<1)	0	2 (<1)	0
リンパ球形態異常	0	1 (<1)	1 (<1)	2 (<1)	0
赤血球数減少	2 (<1)	2 (<1)	0	2 (<1)	0
ビタミンＤ増加	1 (<1)	0	2 (<1)	2 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	1 (<1)	0
細菌検査陽性	1 (<1)	0	1 (<1)	1 (<1)	0
血中アルカリホスファターゼ増加	1 (<1)	1 (<1)	0	1 (<1)	0
血中重炭酸塩減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中カルシウム増加	1 (<1)	0	1 (<1)	1 (<1)	0
血中クレアチン増加	0	1 (<1)	0	1 (<1)	0
血中クレアチニン異常	0	1 (<1)	0	1 (<1)	0
血中ブドウ糖減少	0	0	1 (<1)	1 (<1)	1 (<1)
血中ケトン体増加	0	0	1 (<1)	1 (<1)	0
血中カリウム減少	2 (<1)	0	1 (<1)	1 (<1)	0
血圧低下	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 40 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中ナトリウム減少	0	0	1 (<1)	1 (<1)	0
血中ナトリウム増加	0	1 (<1)	0	1 (<1)	0
血中尿素増加	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
心雑音	0	1 (<1)	0	1 (<1)	0
尿中結晶陽性	3 (<1)	0	1 (<1)	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	1 (<1)	0
心電図ＱＴ延長	0	1 (<1)	0	1 (<1)	2 (<1)
心電図Ｔ波逆転	0	1 (<1)	0	1 (<1)	0
好酸球数異常	0	0	1 (<1)	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	1 (<1)	0
大腸菌検査陽性	0	1 (<1)	0	1 (<1)	0
胃内ｐＨ上昇	0	0	1 (<1)	1 (<1)	0
尿中ブドウ糖陽性	2 (<1)	1 (<1)	0	1 (<1)	0
血液学的検査異常	0	1 (<1)	0	1 (<1)	0
心拍数減少	0	0	1 (<1)	1 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	1 (<1)	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	1 (<1)	0
眼圧上昇	0	1 (<1)	0	1 (<1)	0
リンパ球数増加	1 (<1)	1 (<1)	0	1 (<1)	0
単球数増加	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 41 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脳核磁気共鳴画像異常	0	1 (<1)	0	1 (<1)	0
血小板数	0	1 (<1)	0	1 (<1)	0
血小板数減少	1 (<1)	1 (<1)	0	1 (<1)	2 (<1)
血小板数増加	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
腎機能検査異常	0	1 (<1)	0	1 (<1)	0
残尿量増加	0	1 (<1)	0	1 (<1)	0
呼吸数増加	0	0	1 (<1)	1 (<1)	0
血清フェリチン減少	0	0	1 (<1)	1 (<1)	0
尿円柱	0	0	1 (<1)	1 (<1)	0
ビタミンＢ１２減少	1 (<1)	1 (<1)	0	1 (<1)	0
ビタミンD減少	0	1 (<1)	0	1 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	0	0	0	2 (<1)
動脈雑音	1 (<1)	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	0	0	0	1 (<1)
血中アルカリホスファターゼ異常	0	0	0	0	1 (<1)
血中ビリルビン異常	0	0	0	0	1 (<1)
血中鉄減少	1 (<1)	0	0	0	0
血中乳酸脱水素酵素異常	0	0	0	0	1 (<1)
血中副甲状腺ホルモン減少	1 (<1)	0	0	0	0
血中リン減少	1 (<1)	0	0	0	0
心電図異常	2 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 42 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心電図ＰＲ延長	1 (<1)	0	0	0	0
心電図Ｔ波振幅減少	0	0	0	0	1 (<1)
心音異常	1 (<1)	0	0	0	0
リンパ球数異常	0	0	0	0	1 (<1)
好中球数異常	0	0	0	0	1 (<1)
ＱＲＳ軸異常	2 (<1)	0	0	0	0
トランスアミナーゼ上昇	1 (<1)	0	0	0	0
尿細胞診異常	1 (<1)	0	0	0	0
白血球数異常	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	44 (6)	33 (4)	38 (5)	71 (5)	18 (5)
転倒	8 (1)	5 (<1)	9 (1)	14 (<1)	6 (2)
挫傷	7 (<1)	4 (<1)	7 (<1)	11 (<1)	4 (1)
関節捻挫	3 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
四肢損傷	1 (<1)	3 (<1)	3 (<1)	6 (<1)	3 (<1)
肉離れ	1 (<1)	3 (<1)	2 (<1)	5 (<1)	0
節足動物咬傷	2 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
サンバーン	0	1 (<1)	3 (<1)	4 (<1)	0
擦過傷	2 (<1)	0	3 (<1)	3 (<1)	1 (<1)
足骨折	0	2 (<1)	1 (<1)	3 (<1)	0
関節損傷	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 43 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
交通事故	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
動物咬傷	1 (<1)	2 (<1)	0	2 (<1)	0
足関節部骨折	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
橈骨骨折	0	0	2 (<1)	2 (<1)	1 (<1)
皮膚裂傷	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
歯牙破折	0	1 (<1)	1 (<1)	2 (<1)	0
偶発的過量投与	0	1 (<1)	0	1 (<1)	0
節足動物刺傷	0	1 (<1)	0	1 (<1)	0
鎖骨骨折	0	1 (<1)	0	1 (<1)	0
造影剤反応	0	0	1 (<1)	1 (<1)	0
顔面損傷	0	0	1 (<1)	1 (<1)	1 (<1)
切開部位痛	0	1 (<1)	0	1 (<1)	0
関節脱臼	0	1 (<1)	0	1 (<1)	0
靭帯損傷	0	0	1 (<1)	1 (<1)	0
靭帯断裂	3 (<1)	1 (<1)	0	1 (<1)	0
処置後出血	0	1 (<1)	0	1 (<1)	0
肋骨骨折	0	0	1 (<1)	1 (<1)	0
熱傷	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
舌損傷	0	1 (<1)	0	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
ワクチン接種合併症	1 (<1)	0	1 (<1)	1 (<1)	0
手首関節骨折	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 44 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
第２度熱傷	1 (<1)	0	0	0	0
眼部化学的損傷	1 (<1)	0	0	0	0
凍瘡	1 (<1)	0	0	0	0
角膜擦過傷	1 (<1)	0	0	0	0
大腿骨骨折	0	0	0	0	1 (<1)
手骨折	1 (<1)	0	0	0	2 (<1)
頭部損傷	1 (<1)	0	0	0	1 (<1)
半月板障害	1 (<1)	0	0	0	1 (<1)
筋損傷	1 (<1)	0	0	0	0
頚部損傷	0	0	0	0	1 (<1)
外傷後疼痛	0	0	0	0	2 (<1)
処置による疼痛	1 (<1)	0	0	0	0
骨格損傷	3 (<1)	0	0	0	1 (<1)
腱損傷	1 (<1)	0	0	0	0
腱断裂	1 (<1)	0	0	0	0
有毒性刺傷	1 (<1)	0	0	0	0
むち打ち損傷	1 (<1)	0	0	0	1 (<1)
創傷	1 (<1)	0	0	0	0
外科および内科処置	4 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
子宮摘出	0	0	1 (<1)	1 (<1)	0
治療食	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 45 of 45

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
抜歯	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
子宮頚部円錐切除	1 (<1)	0	0	0	0
嚢胞ドレナージ	1 (<1)	0	0	0	0
色素性母斑切除	1 (<1)	0	0	0	0
不妊手術	0	0	0	0	1 (<1)
社会環境	1 (<1)	1 (<1)	0	1 (<1)	0
閉経	0	1 (<1)	0	1 (<1)	0
元タバコ使用者	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A-24W.SAS DATE: 02DEC2015

Table 88: Incidence of Adverse Events At Least 2% Higher for Any BG00012 Group or GA Relative to Placebo - by System Organ Class and Preferred Term: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo - by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 1 of 2

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	1308 (86)	246 (70)
感染症および寄生虫症	269 (35)	289 (38)	274 (36)	563 (37)	87 (25)
尿路感染	40 (5)	61 (8)	43 (6)	104 (7)	22 (6)
血管障害	51 (7)	276 (36)	246 (32)	522 (34)	14 (4)
潮紅	27 (4)	231 (30)	199 (26)	430 (28)	3 (<1)
ほてり	10 (1)	39 (5)	41 (5)	80 (5)	5 (1)
胃腸障害	192 (25)	286 (37)	304 (40)	590 (39)	30 (9)
下痢	49 (6)	78 (10)	102 (13)	180 (12)	4 (1)
悪心	51 (7)	75 (10)	86 (11)	161 (11)	10 (3)
上腹部痛	29 (4)	58 (8)	61 (8)	119 (8)	2 (<1)
腹痛	26 (3)	55 (7)	44 (6)	99 (6)	2 (<1)
嘔吐	16 (2)	44 (6)	36 (5)	80 (5)	2 (<1)
消化不良	15 (2)	22 (3)	30 (4)	52 (3)	3 (<1)
胃腸障害	5 (<1)	17 (2)	30 (4)	47 (3)	1 (<1)
皮膚および皮下組織障害	98 (13)	176 (23)	183 (24)	359 (23)	35 (10)
そう痒症	18 (2)	45 (6)	41 (5)	86 (6)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-HTPL2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo - by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 2 of 2

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
発疹	16 (2)	41 (5)	37 (5)	78 (5)	5 (1)
紅斑	3 (<1)	24 (3)	40 (5)	64 (4)	4 (1)
腎および尿路障害	69 (9)	73 (9)	95 (13)	168 (11)	24 (7)
一般・全身障害および投与部位の状態	103 (13)	102 (13)	118 (16)	220 (14)	108 (31)
注射部位紅斑	0	0	0	0	30 (9)
注射部位疼痛	0	0	0	0	29 (8)
注射部位そう痒感	0	0	0	0	12 (3)
注射部位腫脹	0	0	0	0	9 (3)
臨床検査	98 (13)	129 (17)	117 (15)	246 (16)	57 (16)
アラニン・アミノトランスフェラーゼ増加	9 (1)	32 (4)	30 (4)	62 (4)	10 (3)
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	21 (3)	19 (3)	40 (3)	6 (2)
尿中蛋白陽性	6 (<1)	14 (2)	10 (1)	24 (2)	10 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-HTPL2-A-24W.SAS DATE: 02DEC2015

Table 92: Incidence of Flushing and Other Related Symptoms by System Organ Class and Preferred Term by 3-Months Intervals: Studies 109MS301 and 109MS302

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 1 of 20

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	771 (100)	751 (100)	715 (100)	675 (100)	632 (100)	587 (100)
Number of subjects with an event	40 (5)	5 (<1)	10 (1)	3 (<1)	2 (<1)	3 (<1)
Number of subjects with flushing (a)	34 (4)	4 (<1)	5 (<1)	2 (<1)	1 (<1)	2 (<1)
Number of subjects with an other related symptom (b)	8 (1)	1 (<1)	5 (<1)	2 (<1)	1 (<1)	1 (<1)
神経系障害	4 (<1)	1 (<1)	4 (<1)	1 (<1)	1 (<1)	1 (<1)
灼熱感	4 (<1)	1 (<1)	4 (<1)	1 (<1)	1 (<1)	1 (<1)
血管障害	34 (4)	4 (<1)	5 (<1)	2 (<1)	1 (<1)	2 (<1)
潮紅	24 (3)	4 (<1)	3 (<1)	2 (<1)	0	1 (<1)
ほてり	10 (1)	0	2 (<1)	0	1 (<1)	1 (<1)
充血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Flushing consists of the preferred terms of Flushing and Hot Flush.

(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 2 of 20

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	556 (100)	542 (100)	382 (100)
Number of subjects with an event	5 (<1)	7 (1)	0
Number of subjects with flushing (a)	3 (<1)	3 (<1)	0
Number of subjects with an other related symptom (b)	2 (<1)	4 (<1)	0
神経系障害	1 (<1)	1 (<1)	0
灼熱感	1 (<1)	1 (<1)	0
血管障害	3 (<1)	3 (<1)	0
潮紅	2 (<1)	2 (<1)	0
ほてり	1 (<1)	1 (<1)	0
充血	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 3 of 20

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
皮膚および皮下組織障害	3 (<1)	0	2 (<1)	1 (<1)	0	0
紅斑	3 (<1)	0	2 (<1)	1 (<1)	0	0
皮膚灼熱感	0	0	0	0	0	0
全身紅斑	0	0	0	0	0	0
一般・全身障害および投与部位の状態	2 (<1)	0	0	0	0	0
熱感	2 (<1)	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 4 of 20

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
皮膚および皮下組織障害	1 (<1)	3 (<1)	0
紅斑	1 (<1)	3 (<1)	0
皮膚灼熱感	0	0	0
全身紅斑	0	0	0
一般・全身障害および投与部位の状態	0	0	0
熱感	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 5 of 20

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	769 (100)	719 (100)	682 (100)	652 (100)	628 (100)	611 (100)
Number of subjects with an event	280 (36)	52 (7)	31 (5)	37 (6)	27 (4)	29 (5)
Number of subjects with flushing (a)	246 (32)	44 (6)	25 (4)	31 (5)	20 (3)	21 (3)
Number of subjects with an other related symptom (b)	48 (6)	9 (1)	7 (1)	6 (<1)	7 (1)	8 (1)
神経系障害	14 (2)	0	2 (<1)	3 (<1)	1 (<1)	1 (<1)
灼熱感	14 (2)	0	2 (<1)	3 (<1)	1 (<1)	1 (<1)
血管障害	248 (32)	45 (6)	25 (4)	31 (5)	20 (3)	21 (3)
潮紅	212 (28)	40 (6)	23 (3)	28 (4)	18 (3)	17 (3)
ほてり	35 (5)	5 (<1)	2 (<1)	3 (<1)	2 (<1)	4 (<1)
充血	2 (<1)	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 6 of 20

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	596 (100)	585 (100)	405 (100)
Number of subjects with an event	12 (2)	10 (2)	1 (<1)
Number of subjects with flushing (a)	9 (2)	6 (1)	1 (<1)
Number of subjects with an other related symptom (b)	4 (<1)	5 (<1)	0
神経系障害	0	2 (<1)	0
灼熱感	0	2 (<1)	0
血管障害	9 (2)	6 (1)	1 (<1)
潮紅	8 (1)	6 (1)	1 (<1)
ほてり	1 (<1)	0	0
充血	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 7 of 20

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
皮膚および皮下組織障害	27 (4)	6 (<1)	3 (<1)	0	5 (<1)	6 (<1)
紅斑	21 (3)	6 (<1)	2 (<1)	0	3 (<1)	5 (<1)
皮膚灼熱感	4 (<1)	0	0	0	1 (<1)	1 (<1)
全身紅斑	2 (<1)	0	1 (<1)	0	1 (<1)	0
一般・全身障害および投与部位の状態	9 (1)	2 (<1)	2 (<1)	3 (<1)	1 (<1)	1 (<1)
熱感	9 (1)	2 (<1)	2 (<1)	3 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 8 of 20

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
皮膚および皮下組織障害	4 (<1)	2 (<1)	0
紅斑	4 (<1)	1 (<1)	0
皮膚灼熱感	0	1 (<1)	0
全身紅斑	0	0	0
一般・全身障害および投与部位の状態	0	1 (<1)	0
熱感	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 9 of 20

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	760 (100)	695 (100)	666 (100)	639 (100)	626 (100)	608 (100)
Number of subjects with an event	260 (34)	46 (7)	31 (5)	23 (4)	16 (3)	21 (3)
Number of subjects with 潮紅 (a)	216 (28)	36 (5)	25 (4)	17 (3)	13 (2)	14 (2)
Number of subjects with an other related symptom (b)	63 (8)	13 (2)	7 (1)	6 (<1)	5 (<1)	7 (1)
神経系障害	12 (2)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	3 (<1)
灼熱感	12 (2)	2 (<1)	3 (<1)	1 (<1)	1 (<1)	3 (<1)
血管障害	222 (29)	36 (5)	25 (4)	17 (3)	14 (2)	15 (2)
潮紅	185 (24)	31 (4)	23 (3)	14 (2)	11 (2)	13 (2)
ほてり	36 (5)	7 (1)	3 (<1)	3 (<1)	2 (<1)	1 (<1)
充血	6 (<1)	0	0	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 10 of 20

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	586 (100)	573 (100)	416 (100)
Number of subjects with an event	20 (3)	14 (2)	1 (<1)
Number of subjects with flushing (a)	13 (2)	9 (2)	1 (<1)
Number of subjects with an other related symptom (b)	7 (1)	6 (1)	0
神経系障害	4 (<1)	0	0
灼熱感	4 (<1)	0	0
血管障害	13 (2)	9 (2)	1 (<1)
潮紅	10 (2)	7 (1)	1 (<1)
ほてり	3 (<1)	2 (<1)	0
充血	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 11 of 20

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
皮膚および皮下組織障害	41 (5)	10 (1)	3 (<1)	5 (<1)	3 (<1)	3 (<1)
紅斑	34 (4)	9 (1)	2 (<1)	5 (<1)	3 (<1)	3 (<1)
皮膚灼熱感	6 (<1)	0	1 (<1)	0	0	0
全身紅斑	2 (<1)	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	7 (<1)	2 (<1)	1 (<1)	0	0	1 (<1)
熱感	7 (<1)	2 (<1)	1 (<1)	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 12 of 20

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
皮膚および皮下組織障害	3 (<1)	5 (<1)	0
紅斑	3 (<1)	4 (<1)	0
皮膚灼熱感	0	0	0
全身紅斑	0	1 (<1)	0
一般・全身障害および投与部位の状態	0	1 (<1)	0
熱感	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 13 of 20

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	1529 (100)	1414 (100)	1348 (100)	1291 (100)	1254 (100)	1219 (100)
Number of subjects with an event	540 (35)	98 (7)	62 (5)	60 (5)	43 (3)	50 (4)
Number of subjects with flushing (a)	462 (30)	80 (6)	50 (4)	48 (4)	33 (3)	35 (3)
Number of subjects with an other related symptom (b)	111 (7)	22 (2)	14 (1)	12 (<1)	12 (<1)	15 (1)
神経系障害	26 (2)	2 (<1)	5 (<1)	4 (<1)	2 (<1)	4 (<1)
灼熱感	26 (2)	2 (<1)	5 (<1)	4 (<1)	2 (<1)	4 (<1)
血管障害	470 (31)	81 (6)	50 (4)	48 (4)	34 (3)	36 (3)
潮紅	397 (26)	71 (5)	46 (3)	42 (3)	29 (2)	30 (2)
ほてり	71 (5)	12 (<1)	5 (<1)	6 (<1)	4 (<1)	5 (<1)
充血	8 (<1)	1 (<1)	0	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 14 of 20

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	1182 (100)	1158 (100)	821 (100)
Number of subjects with an event	32 (3)	24 (2)	2 (<1)
Number of subjects with flushing (a)	22 (2)	15 (1)	2 (<1)
Number of subjects with an other related symptom (b)	11 (<1)	11 (<1)	0
神経系障害	4 (<1)	2 (<1)	0
灼熱感	4 (<1)	2 (<1)	0
血管障害	22 (2)	15 (1)	2 (<1)
潮紅	18 (2)	13 (1)	2 (<1)
ほてり	4 (<1)	2 (<1)	0
充血	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 15 of 20

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
皮膚および皮下組織障害	68 (4)	16 (1)	6 (<1)	5 (<1)	8 (<1)	9 (<1)
紅斑	55 (4)	15 (1)	4 (<1)	5 (<1)	6 (<1)	8 (<1)
皮膚灼熱感	10 (<1)	0	1 (<1)	0	1 (<1)	1 (<1)
全身紅斑	4 (<1)	1 (<1)	1 (<1)	0	1 (<1)	0
一般・全身障害および投与部位の状態	16 (1)	4 (<1)	3 (<1)	3 (<1)	1 (<1)	2 (<1)
熱感	16 (1)	4 (<1)	3 (<1)	3 (<1)	1 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 16 of 20

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
皮膚および皮下組織障害	7 (<1)	7 (<1)	0
紅斑	7 (<1)	5 (<1)	0
皮膚灼熱感	0	1 (<1)	0
全身紅斑	0	1 (<1)	0
一般・全身障害および投与部位の状態	0	2 (<1)	0
熱感	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 17 of 20

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	351 (100)	338 (100)	327 (100)	322 (100)	307 (100)	298 (100)
Number of subjects with an event	10 (3)	5 (1)	3 (<1)	1 (<1)	0	1 (<1)
Number of subjects with flushing (a)	6 (2)	2 (<1)	2 (<1)	1 (<1)	0	1 (<1)
Number of subjects with an other related symptom (b)	4 (1)	3 (<1)	1 (<1)	1 (<1)	0	0
神経系障害	0	0	0	0	0	0
灼熱感	0	0	0	0	0	0
血管障害	6 (2)	2 (<1)	2 (<1)	1 (<1)	0	1 (<1)
潮紅	1 (<1)	2 (<1)	2 (<1)	1 (<1)	0	1 (<1)
ほてり	5 (1)	0	0	0	0	0
充血	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 18 of 20

	GA		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	291 (100)	282 (100)	217 (100)
Number of subjects with an event	1 (<1)	2 (<1)	0
Number of subjects with flushing (a)	1 (<1)	0	0
Number of subjects with an other related symptom (b)	0	2 (<1)	0
神経系障害	0	0	0
灼熱感	0	0	0
血管障害	1 (<1)	0	0
潮紅	1 (<1)	0	0
ほてり	0	0	0
充血	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 19 of 20

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
皮膚および皮下組織障害	3 (<1)	1 (<1)	1 (<1)	0	0	0
紅斑	3 (<1)	1 (<1)	1 (<1)	0	0	0
皮膚灼熱感	0	0	0	0	0	0
全身紅斑	0	0	0	0	0	0
一般・全身障害および投与部位の状態	1 (<1)	3 (<1)	0	1 (<1)	0	0
熱感	1 (<1)	3 (<1)	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Incidence of flushing and other related symptoms by system organ class and preferred term by 3-months intervals:
Studies 109MS301 and 109MS302
Page 20 of 20

	GA		
	>18-21 Months	>21-24 Months	>24 Months
皮膚および皮下組織障害	0	1 (<1)	0
紅斑	0	1 (<1)	0
皮膚灼熱感	0	0	0
全身紅斑	0	0	0
一般・全身障害および投与部位の状態	0	1 (<1)	0
熱感	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Flushing consists of the preferred terms of Flushing and Hot Flush.
(b) Other related symptoms consist of the preferred terms of Erythema, Generalised Erythema, Burning Sensation, Skin Burning, Feeling Hot, and Hyperaemia.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-FLUSH-INT3-A.SAS DATE: 02DEC2015

Table 93: Incidence of Gastrointestinal Tolerability Adverse Events Symptoms by System Organ Class and Preferred Term by 3-Months Intervals: Studies 109MS301 and 109MS302

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 1 of 40

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	771 (100)	751 (100)	715 (100)	675 (100)	632 (100)	587 (100)
Number of subjects with a gastrointestinal tolerability event (a)	147 (19)	47 (6)	44 (6)	36 (5)	27 (4)	25 (4)
感染症および寄生虫症	0	0	0	0	0	0
憩室炎	0	0	0	0	0	0
胃腸障害	143 (19)	46 (6)	43 (6)	36 (5)	26 (4)	24 (4)
下痢	37 (5)	13 (2)	14 (2)	8 (1)	9 (1)	9 (2)
悪心	41 (5)	11 (1)	7 (<1)	4 (<1)	3 (<1)	5 (<1)
上腹部痛	26 (3)	3 (<1)	5 (<1)	5 (<1)	1 (<1)	1 (<1)
腹痛	24 (3)	4 (<1)	6 (<1)	6 (<1)	2 (<1)	1 (<1)
嘔吐	13 (2)	3 (<1)	4 (<1)	5 (<1)	3 (<1)	5 (<1)
消化不良	10 (1)	6 (<1)	4 (<1)	1 (<1)	0	1 (<1)
便秘	14 (2)	5 (<1)	2 (<1)	5 (<1)	3 (<1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 2 of 40

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	556 (100)	542 (100)	382 (100)
Number of subjects with a gastrointestinal tolerability event (a)	23 (4)	26 (5)	6 (2)
感染症および寄生虫症	0	0	0
憩室炎	0	0	0
胃腸障害	23 (4)	25 (5)	6 (2)
下痢	6 (1)	7 (1)	3 (<1)
悪心	2 (<1)	8 (1)	0
上腹部痛	4 (<1)	4 (<1)	0
腹痛	2 (<1)	1 (<1)	1 (<1)
嘔吐	3 (<1)	4 (<1)	2 (<1)
消化不良	0	0	0
便秘	3 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 3 of 40

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
胃炎	2 (<1)	4 (<1)	1 (<1)	2 (<1)	0	1 (<1)
腹部不快感	5 (<1)	1 (<1)	2 (<1)	1 (<1)	0	1 (<1)
胃食道逆流性疾患	8 (1)	1 (<1)	0	1 (<1)	2 (<1)	2 (<1)
鼓腸	6 (<1)	0	3 (<1)	1 (<1)	1 (<1)	2 (<1)
腹部膨満	7 (<1)	1 (<1)	2 (<1)	0	1 (<1)	1 (<1)
下腹部痛	1 (<1)	1 (<1)	0	0	1 (<1)	0
嚥下障害	1 (<1)	1 (<1)	1 (<1)	1 (<1)	0	1 (<1)
心窩部不快感	0	0	0	0	1 (<1)	1 (<1)
おくび	0	0	0	0	0	0
便意切迫	0	0	0	0	0	0
逆流性食道炎	1 (<1)	0	0	0	0	1 (<1)
腹部圧痛	0	0	1 (<1)	1 (<1)	0	0
排便回数増加	0	0	0	0	0	0
異常便	1 (<1)	0	0	1 (<1)	0	0
腸憩室	0	0	0	0	0	0
食道炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 4 of 40

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
胃炎	1 (<1)	2 (<1)	0
腹部不快感	2 (<1)	0	0
胃食道逆流性疾患	1 (<1)	0	0
鼓腸	1 (<1)	1 (<1)	0
腹部膨満	0	0	0
下腹部痛	0	0	0
嚥下障害	0	1 (<1)	0
心窩部不快感	0	0	0
おくび	0	0	0
便意切迫	0	0	0
逆流性食道炎	0	0	0
腹部圧痛	0	0	0
排便回数増加	0	0	0
異常便	0	0	0
腸憩室	0	0	0
食道炎	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 5 of 40

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
便通不規則	0	0	0	0	0	0
便習慣変化	0	0	0	0	0	0
十二指腸炎	0	0	0	0	0	0
胃十二指腸炎	0	0	0	0	0	0
消化器痛	0	0	3 (<1)	0	0	0
胃排出不全	0	0	0	0	0	0
膵機能不全	0	0	0	0	0	0
逆流性胃炎	0	0	0	0	1 (<1)	0
呼気臭	0	1 (<1)	0	0	0	0
十二指腸胃逆流	0	0	0	0	0	0
一般・全身障害および投与部位の状態	7 (<1)	1 (<1)	2 (<1)	0	1 (<1)	0
胸痛	6 (<1)	1 (<1)	1 (<1)	0	1 (<1)	0
非心臓性胸痛	1 (<1)	0	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 6 of 40

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
便通不規則	0	1 (<1)	0
便習慣変化	0	0	0
十二指腸炎	0	0	0
胃十二指腸炎	0	0	0
消化器痛	0	0	0
胃排出不全	0	0	0
膵機能不全	0	0	0
逆流性胃炎	0	0	0
呼気臭	0	0	0
十二指腸胃逆流	0	1 (<1)	0
一般・全身障害および投与部位の状態	0	1 (<1)	0
胸痛	0	1 (<1)	0
非心臓性胸痛	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 7 of 40

	Placebo					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
臨床検査	0	0	0	0	0	0
胃内ｐＨ上昇	0	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	1 (<1)
処置による悪心	0	0	0	0	0	1 (<1)
処置による嘔吐	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 8 of 40

	Placebo		
	>18-21 Months	>21-24 Months	>24 Months
臨床検査	0	0	0
胃内ｐＨ上昇	0	0	0
傷害、中毒および処置合併症	0	0	0
処置による悪心	0	0	0
処置による嘔吐	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 9 of 40

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	769 (100)	719 (100)	682 (100)	652 (100)	628 (100)	611 (100)
Number of subjects with a gastrointestinal tolerability event (a)	223 (29)	60 (8)	54 (8)	48 (7)	29 (5)	19 (3)
感染症および寄生虫症	0	0	0	0	0	0
憩室炎	0	0	0	0	0	0
胃腸障害	223 (29)	59 (8)	54 (8)	47 (7)	29 (5)	18 (3)
下痢	69 (9)	14 (2)	10 (1)	9 (1)	6 (<1)	4 (<1)
悪心	70 (9)	7 (<1)	12 (2)	9 (1)	2 (<1)	3 (<1)
上腹部痛	54 (7)	9 (1)	11 (2)	7 (1)	7 (1)	0
腹痛	50 (7)	7 (<1)	8 (1)	11 (2)	2 (<1)	2 (<1)
嘔吐	39 (5)	5 (<1)	10 (1)	7 (1)	4 (<1)	2 (<1)
消化不良	18 (2)	6 (<1)	5 (<1)	5 (<1)	2 (<1)	1 (<1)
便秘	13 (2)	3 (<1)	2 (<1)	0	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 10 of 40

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	596 (100)	585 (100)	405 (100)
Number of subjects with a gastrointestinal tolerability event (a)	27 (5)	23 (4)	3 (<1)
感染症および寄生虫症	0	0	0
憩室炎	0	0	0
胃腸障害	24 (4)	22 (4)	3 (<1)
下痢	6 (1)	7 (1)	1 (<1)
悪心	6 (1)	5 (<1)	1 (<1)
上腹部痛	6 (1)	2 (<1)	0
腹痛	3 (<1)	2 (<1)	0
嘔吐	1 (<1)	3 (<1)	2 (<1)
消化不良	2 (<1)	1 (<1)	0
便秘	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 11 of 40

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
胃炎	6 (<1)	5 (<1)	1 (<1)	4 (<1)	1 (<1)	3 (<1)
腹部不快感	8 (1)	2 (<1)	2 (<1)	5 (<1)	3 (<1)	2 (<1)
胃食道逆流性疾患	10 (1)	4 (<1)	2 (<1)	1 (<1)	1 (<1)	0
鼓腸	7 (<1)	1 (<1)	1 (<1)	0	0	2 (<1)
腹部膨満	3 (<1)	0	1 (<1)	0	0	0
下腹部痛	1 (<1)	1 (<1)	0	0	0	0
嚥下障害	0	1 (<1)	0	2 (<1)	2 (<1)	0
心窩部不快感	0	1 (<1)	1 (<1)	1 (<1)	0	0
おくび	1 (<1)	1 (<1)	0	0	0	0
便意切迫	1 (<1)	0	0	0	0	0
逆流性食道炎	0	0	1 (<1)	1 (<1)	0	0
腹部圧痛	0	0	0	0	1 (<1)	0
排便回数増加	0	0	1 (<1)	0	0	0
異常便	2 (<1)	0	0	0	0	0
腸憩室	0	0	0	0	0	0
食道炎	1 (<1)	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 12 of 40

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
胃炎	2 (<1)	1 (<1)	0
腹部不快感	1 (<1)	1 (<1)	0
胃食道逆流性疾患	0	1 (<1)	0
鼓腸	1 (<1)	1 (<1)	0
腹部膨満	1 (<1)	0	0
下腹部痛	0	1 (<1)	0
嚥下障害	0	1 (<1)	0
心窩部不快感	0	0	0
おくび	0	0	0
便意切迫	0	0	0
逆流性食道炎	1 (<1)	0	0
腹部圧痛	0	0	0
排便回数増加	0	0	0
異常便	0	0	0
腸憩室	0	0	0
食道炎	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 13 of 40

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
便通不規則	0	0	0	0	0	0
便習慣変化	0	0	0	0	0	0
十二指腸炎	0	0	0	0	0	0
胃十二指腸炎	0	0	0	0	0	0
消化器痛	0	0	0	0	0	0
胃排出不全	1 (<1)	0	0	0	0	0
膵機能不全	0	0	0	0	0	0
逆流性胃炎	0	0	0	0	0	0
呼気臭	0	0	0	0	0	0
十二指腸胃逆流	0	0	0	0	0	0
一般・全身障害および投与部位の状態	3 (<1)	2 (<1)	0	2 (<1)	0	1 (<1)
胸痛	2 (<1)	2 (<1)	0	2 (<1)	0	0
非心臓性胸痛	1 (<1)	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 14 of 40

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
便通不規則	0	0	0
便習慣変化	0	0	0
十二指腸炎	0	0	0
胃十二指腸炎	0	0	0
消化器痛	1 (<1)	0	0
胃排出不全	0	0	0
膵機能不全	0	0	0
逆流性胃炎	0	0	0
呼気臭	0	0	0
十二指腸胃逆流	0	0	0
一般・全身障害および投与部位の状態	3 (<1)	1 (<1)	0
胸痛	2 (<1)	1 (<1)	0
非心臓性胸痛	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 15 of 40

	BG00012 240 mg BID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
臨床検査	0	0	0	0	0	0
胃内ｐＨ上昇	0	0	0	0	0	0
傷害、中毒および処置合併症	0	0	1 (<1)	0	0	0
処置による悪心	0	0	1 (<1)	0	0	0
処置による嘔吐	0	0	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 16 of 40

	BG00012 240 mg BID		
	>18-21 Months	>21-24 Months	>24 Months
臨床検査	0	0	0
胃内ｐＨ上昇	0	0	0
傷害、中毒および処置合併症	0	0	0
処置による悪心	0	0	0
処置による嘔吐	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 17 of 40

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	760 (100)	695 (100)	666 (100)	639 (100)	626 (100)	608 (100)
Number of subjects with a gastrointestinal tolerability event (a)	239 (31)	67 (10)	41 (6)	49 (8)	36 (6)	32 (5)
感染症および寄生虫症	1 (<1)	0	0	0	0	0
憩室炎	1 (<1)	0	0	0	0	0
胃腸障害	237 (31)	63 (9)	40 (6)	46 (7)	35 (6)	32 (5)
下痢	94 (12)	19 (3)	13 (2)	12 (2)	7 (1)	7 (1)
悪心	75 (10)	11 (2)	8 (1)	3 (<1)	4 (<1)	3 (<1)
上腹部痛	54 (7)	8 (1)	6 (<1)	10 (2)	9 (1)	5 (<1)
腹痛	38 (5)	7 (1)	2 (<1)	7 (1)	5 (<1)	3 (<1)
嘔吐	35 (5)	1 (<1)	6 (<1)	5 (<1)	4 (<1)	2 (<1)
消化不良	22 (3)	10 (1)	5 (<1)	2 (<1)	1 (<1)	7 (1)
便秘	14 (2)	5 (<1)	2 (<1)	4 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 18 of 40

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	586 (100)	573 (100)	416 (100)
Number of subjects with a gastrointestinal tolerability event (a)	30 (5)	25 (4)	3 (<1)
感染症および寄生虫症	0	0	0
憩室炎	0	0	0
胃腸障害	27 (5)	23 (4)	3 (<1)
下痢	6 (1)	2 (<1)	0
悪心	7 (1)	5 (<1)	1 (<1)
上腹部痛	2 (<1)	6 (1)	0
腹痛	3 (<1)	3 (<1)	0
嘔吐	3 (<1)	2 (<1)	0
消化不良	2 (<1)	3 (<1)	0
便秘	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 19 of 40

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
胃炎	9 (1)	4 (<1)	1 (<1)	0	2 (<1)	2 (<1)
腹部不快感	11 (1)	0	2 (<1)	1 (<1)	2 (<1)	0
胃食道逆流性疾患	7 (<1)	3 (<1)	3 (<1)	4 (<1)	1 (<1)	1 (<1)
鼓腸	8 (1)	0	0	1 (<1)	0	0
腹部膨満	7 (<1)	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
下腹部痛	1 (<1)	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
嚥下障害	2 (<1)	0	0	0	2 (<1)	1 (<1)
心窩部不快感	1 (<1)	1 (<1)	0	0	0	1 (<1)
おくび	3 (<1)	0	0	0	0	0
便意切迫	2 (<1)	1 (<1)	0	0	0	0
逆流性食道炎	0	0	1 (<1)	0	0	0
腹部圧痛	2 (<1)	0	0	0	0	1 (<1)
排便回数増加	2 (<1)	0	0	0	0	0
異常便	0	0	0	0	0	0
腸憩室	0	0	0	2 (<1)	0	0
食道炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 20 of 40

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
胃炎	4 (<1)	1 (<1)	0
腹部不快感	0	0	0
胃食道逆流性疾患	0	0	1 (<1)
鼓腸	0	1 (<1)	0
腹部膨満	1 (<1)	0	0
下腹部痛	0	1 (<1)	0
嚥下障害	0	0	0
心窩部不快感	0	0	0
おくび	0	0	0
便意切迫	0	0	0
逆流性食道炎	2 (<1)	0	0
腹部圧痛	0	0	1 (<1)
排便回数増加	1 (<1)	0	0
異常便	0	0	0
腸憩室	0	0	0
食道炎	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 21 of 40

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
便通不規則	0	0	0	1 (<1)	0	0
便習慣変化	1 (<1)	0	0	0	0	0
十二指腸炎	1 (<1)	0	0	0	0	0
胃十二指腸炎	1 (<1)	0	0	0	0	0
消化器痛	0	0	0	0	0	0
胃排出不全	0	0	0	0	0	0
膵機能不全	1 (<1)	0	0	0	0	0
逆流性胃炎	0	0	0	0	0	1 (<1)
呼気臭	0	0	0	0	0	0
十二指腸胃逆流	0	0	0	0	0	0
一般・全身障害および投与部位の状態	6 (<1)	4 (<1)	1 (<1)	3 (<1)	1 (<1)	0
胸痛	5 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)	0
非心臓性胸痛	2 (<1)	2 (<1)	0	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.
(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 22 of 40

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
便通不規則	0	0	0
便習慣変化	0	0	0
十二指腸炎	0	0	0
胃十二指腸炎	0	0	0
消化器痛	0	0	0
胃排出不全	0	0	0
膵機能不全	0	0	0
逆流性胃炎	0	0	0
呼気臭	0	0	0
十二指腸胃逆流	0	0	0
一般・全身障害および投与部位の状態	4 (<1)	2 (<1)	0
胸痛	3 (<1)	2 (<1)	0
非心臓性胸痛	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 23 of 40

	BG00012 240 mg TID					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
臨床検査	1 (<1)	0	0	0	0	0
胃内ｐＨ上昇	1 (<1)	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
処置による悪心	0	0	0	0	0	0
処置による嘔吐	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 24 of 40

	BG00012 240 mg TID		
	>18-21 Months	>21-24 Months	>24 Months
臨床検査	0	0	0
胃内ｐＨ上昇	0	0	0
傷害、中毒および処置合併症	0	0	0
処置による悪心	0	0	0
処置による嘔吐	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 25 of 40

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	1529 (100)	1414 (100)	1348 (100)	1291 (100)	1254 (100)	1219 (100)
Number of subjects with a gastrointestinal tolerability event (a)	462 (30)	127 (9)	95 (7)	97 (8)	65 (5)	51 (4)
感染症および寄生虫症	1 (<1)	0	0	0	0	0
憩室炎	1 (<1)	0	0	0	0	0
胃腸障害	460 (30)	122 (9)	94 (7)	93 (7)	64 (5)	50 (4)
下痢	163 (11)	33 (2)	23 (2)	21 (2)	13 (1)	11 (<1)
悪心	145 (9)	18 (1)	20 (1)	12 (<1)	6 (<1)	6 (<1)
上腹部痛	108 (7)	17 (1)	17 (1)	17 (1)	16 (1)	5 (<1)
腹痛	88 (6)	14 (<1)	10 (<1)	18 (1)	7 (<1)	5 (<1)
嘔吐	74 (5)	6 (<1)	16 (1)	12 (<1)	8 (<1)	4 (<1)
消化不良	40 (3)	16 (1)	10 (<1)	7 (<1)	3 (<1)	8 (<1)
便秘	27 (2)	8 (<1)	4 (<1)	4 (<1)	7 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 26 of 40

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	1182 (100)	1158 (100)	821 (100)
Number of subjects with a gastrointestinal tolerability event (a)	57 (5)	48 (4)	6 (<1)
感染症および寄生虫症	0	0	0
憩室炎	0	0	0
胃腸障害	51 (4)	45 (4)	6 (<1)
下痢	12 (1)	9 (<1)	1 (<1)
悪心	13 (1)	10 (<1)	2 (<1)
上腹部痛	8 (<1)	8 (<1)	0
腹痛	6 (<1)	5 (<1)	0
嘔吐	4 (<1)	5 (<1)	2 (<1)
消化不良	4 (<1)	4 (<1)	0
便秘	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 27 of 40

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
胃炎	15 (<1)	9 (<1)	2 (<1)	4 (<1)	3 (<1)	5 (<1)
腹部不快感	19 (1)	2 (<1)	4 (<1)	6 (<1)	5 (<1)	2 (<1)
胃食道逆流性疾患	17 (1)	7 (<1)	5 (<1)	5 (<1)	2 (<1)	1 (<1)
鼓腸	15 (<1)	1 (<1)	1 (<1)	1 (<1)	0	2 (<1)
腹部膨満	10 (<1)	3 (<1)	1 (<1)	1 (<1)	1 (<1)	1 (<1)
下腹部痛	2 (<1)	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
嚥下障害	2 (<1)	1 (<1)	0	2 (<1)	4 (<1)	1 (<1)
心窩部不快感	1 (<1)	2 (<1)	1 (<1)	1 (<1)	0	1 (<1)
おくび	4 (<1)	1 (<1)	0	0	0	0
便意切迫	3 (<1)	1 (<1)	0	0	0	0
逆流性食道炎	0	0	2 (<1)	1 (<1)	0	0
腹部圧痛	2 (<1)	0	0	0	1 (<1)	1 (<1)
排便回数増加	2 (<1)	0	1 (<1)	0	0	0
異常便	2 (<1)	0	0	0	0	0
腸憩室	0	0	0	2 (<1)	0	0
食道炎	1 (<1)	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 28 of 40

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
胃炎	6 (<1)	2 (<1)	0
腹部不快感	1 (<1)	1 (<1)	0
胃食道逆流性疾患	0	1 (<1)	1 (<1)
鼓腸	1 (<1)	2 (<1)	0
腹部膨満	2 (<1)	0	0
下腹部痛	0	2 (<1)	0
嚥下障害	0	1 (<1)	0
心窩部不快感	0	0	0
おくび	0	0	0
便意切迫	0	0	0
逆流性食道炎	3 (<1)	0	0
腹部圧痛	0	0	1 (<1)
排便回数増加	1 (<1)	0	0
異常便	0	0	0
腸憩室	0	0	0
食道炎	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 29 of 40

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
便通不規則	0	0	0	1 (<1)	0	0
便習慣変化	1 (<1)	0	0	0	0	0
十二指腸炎	1 (<1)	0	0	0	0	0
胃十二指腸炎	1 (<1)	0	0	0	0	0
消化器痛	0	0	0	0	0	0
胃排出不全	1 (<1)	0	0	0	0	0
膵機能不全	1 (<1)	0	0	0	0	0
逆流性胃炎	0	0	0	0	0	1 (<1)
呼気臭	0	0	0	0	0	0
十二指腸胃逆流	0	0	0	0	0	0
一般・全身障害および投与部位の状態	9 (<1)	6 (<1)	1 (<1)	5 (<1)	1 (<1)	1 (<1)
胸痛	7 (<1)	4 (<1)	1 (<1)	3 (<1)	1 (<1)	0
非心臓性胸痛	3 (<1)	2 (<1)	0	2 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 30 of 40

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
便通不規則	0	0	0
便習慣変化	0	0	0
十二指腸炎	0	0	0
胃十二指腸炎	0	0	0
消化器痛	1 (<1)	0	0
胃排出不全	0	0	0
膵機能不全	0	0	0
逆流性胃炎	0	0	0
呼気臭	0	0	0
十二指腸胃逆流	0	0	0
一般・全身障害および投与部位の状態	7 (<1)	3 (<1)	0
胸痛	5 (<1)	3 (<1)	0
非心臓性胸痛	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 31 of 40

	Total BG00012					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
臨床検査	1 (<1)	0	0	0	0	0
胃内ｐＨ上昇	1 (<1)	0	0	0	0	0
傷害、中毒および処置合併症	0	0	1 (<1)	0	0	0
処置による悪心	0	0	1 (<1)	0	0	0
処置による嘔吐	0	0	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 32 of 40

	Total BG00012		
	>18-21 Months	>21-24 Months	>24 Months
臨床検査	0	0	0
胃内ｐＨ上昇	0	0	0
傷害、中毒および処置合併症	0	0	0
処置による悪心	0	0	0
処置による嘔吐	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 33 of 40

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
Number of subjects followed in the interval	351 (100)	338 (100)	327 (100)	322 (100)	307 (100)	298 (100)
Number of subjects with a gastrointestinal tolerability event (a)	18 (5)	10 (3)	10 (3)	10 (3)	7 (2)	8 (3)
感染症および寄生虫症	0	0	0	0	0	0
憩室炎	0	0	0	0	0	0
胃腸障害	16 (5)	8 (2)	10 (3)	10 (3)	6 (2)	7 (2)
下痢	3 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)	0
悪心	9 (3)	1 (<1)	3 (<1)	1 (<1)	1 (<1)	2 (<1)
上腹部痛	1 (<1)	1 (<1)	0	2 (<1)	0	0
腹痛	2 (<1)	0	1 (<1)	1 (<1)	0	1 (<1)
嘔吐	2 (<1)	0	1 (<1)	2 (<1)	3 (<1)	0
消化不良	1 (<1)	2 (<1)	1 (<1)	1 (<1)	0	0
便秘	2 (<1)	1 (<1)	2 (<1)	2 (<1)	0	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 34 of 40

	GA		
	>18-21 Months	>21-24 Months	>24 Months
Number of subjects followed in the interval	291 (100)	282 (100)	217 (100)
Number of subjects with a gastrointestinal tolerability event (a)	6 (2)	4 (1)	0
感染症および寄生虫症	0	0	0
憩室炎	0	0	0
胃腸障害	5 (2)	4 (1)	0
下痢	4 (1)	1 (<1)	0
悪心	1 (<1)	0	0
上腹部痛	0	0	0
腹痛	0	0	0
嘔吐	1 (<1)	0	0
消化不良	1 (<1)	0	0
便秘	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 35 of 40

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
胃炎	0	0	1 (<1)	0	1 (<1)	0
腹部不快感	0	0	0	0	0	1 (<1)
胃食道逆流性疾患	1 (<1)	0	0	0	0	1 (<1)
鼓腸	1 (<1)	1 (<1)	0	0	0	0
腹部膨満	0	0	0	0	0	0
下腹部痛	0	0	0	0	0	0
嚥下障害	0	0	1 (<1)	0	0	0
心窩部不快感	0	0	0	0	0	0
おくび	0	0	0	0	0	0
便意切迫	0	0	1 (<1)	1 (<1)	0	0
逆流性食道炎	0	0	0	0	0	1 (<1)
腹部圧痛	0	1 (<1)	0	0	0	0
排便回数増加	0	0	0	0	0	0
異常便	0	0	0	0	0	0
腸憩室	0	0	0	0	1 (<1)	0
食道炎	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 36 of 40

	GA		
	>18-21 Months	>21-24 Months	>24 Months
胃炎	0	2 (<1)	0
腹部不快感	0	0	0
胃食道逆流性疾患	0	0	0
鼓腸	0	0	0
腹部膨満	0	0	0
下腹部痛	0	0	0
嚥下障害	0	1 (<1)	0
心窩部不快感	0	0	0
おくび	0	0	0
便意切迫	0	0	0
逆流性食道炎	0	0	0
腹部圧痛	0	0	0
排便回数増加	0	0	0
異常便	0	0	0
腸憩室	0	0	0
食道炎	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 37 of 40

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
便通不規則	0	0	0	0	0	0
便習慣変化	0	0	0	0	0	0
十二指腸炎	0	0	0	0	0	0
胃十二指腸炎	0	0	0	0	0	0
消化器痛	0	0	0	1 (<1)	0	0
胃排出不全	0	0	0	0	0	0
膵機能不全	0	0	0	0	0	0
逆流性胃炎	0	0	0	0	0	0
呼気臭	0	0	0	0	0	0
十二指腸胃逆流	0	0	0	0	0	0
一般・全身障害および投与部位の状態	2 (<1)	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
胸痛	1 (<1)	1 (<1)	0	1 (<1)	0	0
非心臓性胸痛	1 (<1)	1 (<1)	0	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 38 of 40

	GA		
	>18-21 Months	>21-24 Months	>24 Months
便通不規則	0	0	0
便習慣変化	0	0	0
十二指腸炎	0	0	0
胃十二指腸炎	0	0	0
消化器痛	0	0	0
胃排出不全	0	0	0
膵機能不全	0	0	0
逆流性胃炎	0	0	0
呼気臭	0	0	0
十二指腸胃逆流	0	0	0
一般・全身障害および投与部位の状態	1 (<1)	0	0
胸痛	1 (<1)	0	0
非心臓性胸痛	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 39 of 40

	GA					
	0-3 Months	>3-6 Months	>6-9 Months	>9-12 Months	>12-15 Months	>15-18 Months
臨床検査	0	0	0	0	0	0
胃内ｐＨ上昇	0	0	0	0	0	0
傷害、中毒および処置合併症	0	0	0	0	0	0
処置による悪心	0	0	0	0	0	0
処置による嘔吐	0	0	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Incidence of gastrointestinal tolerability adverse events symptoms by system organ class and preferred term by 3-months intervals: Studies 109MS301 and 109MS302
Page 40 of 40

	GA		
	>18-21 Months	>21-24 Months	>24 Months
臨床検査	0	0	0
胃内ｐＨ上昇	0	0	0
傷害、中毒および処置合併症	0	0	0
処置による悪心	0	0	0
処置による嘔吐	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence of Total BG00012 incidence (not shown) within each system organ class.

(a) Gastrointestinal tolerability events were defined as those preferred terms in the Level 2 subordinate Standardised MedDRA Queries 'Gastrointestinal nonspecific inflammations', 'Gastrointestinal nonspecific symptoms and therapeutic procedures', or 'Gastrointestinal nonspecific dysfunction' (under the Level 1 SMQ 'Gastrointestinal nonspecific inflammation and dysfunctional conditions').

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-GI-INT3-A.SAS DATE: 02DEC2015

Table 94: Incidence of Adverse Events At Least 2% Higher for Any BG00012 Group or GA Relative to Placebo by Preferred Term During 1-3 Months: Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo by preferred term during 1-3 Months: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG0001 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	514 (67)	603 (78)	608 (80)	1211 (79)	200 (57)
潮紅	24 (3)	212 (28)	185 (24)	397 (26)	1 (<1)
下痢	37 (5)	69 (9)	94 (12)	163 (11)	3 (<1)
悪心	41 (5)	70 (9)	75 (10)	145 (9)	9 (3)
上腹部痛	26 (3)	54 (7)	54 (7)	108 (7)	1 (<1)
腹痛	24 (3)	50 (7)	38 (5)	88 (6)	2 (<1)
疲労	23 (3)	42 (5)	37 (5)	79 (5)	9 (3)
そう痒症	17 (2)	38 (5)	37 (5)	75 (5)	2 (<1)
嘔吐	13 (2)	39 (5)	35 (5)	74 (5)	2 (<1)
ほてり	10 (1)	35 (5)	36 (5)	71 (5)	5 (1)
発疹	13 (2)	33 (4)	33 (4)	66 (4)	4 (1)
紅斑	3 (<1)	21 (3)	34 (4)	55 (4)	3 (<1)
蛋白尿	16 (2)	19 (2)	34 (4)	53 (3)	9 (3)
アラニン・アミノトランスフェラーゼ増加	3 (<1)	25 (3)	26 (3)	51 (3)	5 (1)
胃腸障害	5 (<1)	17 (2)	28 (4)	45 (3)	0
注射部位紅斑	0	0	0	0	29 (8)
注射部位疼痛	0	0	0	0	27 (8)
注射部位そう痒感	0	0	0	0	12 (3)
注射部位腫脹	0	0	0	0	9 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A-24W.SAS DATE: 02DEC2015

Table 95: Incidence of Adverse Events At Least 2% Higher for Any BG00012 Group or GA Relative to Placebo by Preferred Term During 4-6 Months: Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo by preferred term during 4-6 Months: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	751 (100)	719 (100)	695 (100)	1414 (100)	338 (100)
Number of subjects with an event	434 (58)	400 (56)	396 (57)	796 (56)	163 (48)
鼻咽頭炎	32 (4)	37 (5)	44 (6)	81 (6)	16 (5)
潮紅	4 (<1)	40 (6)	31 (4)	71 (5)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-HTPL2-6M-A.SAS DATE: 02DEC2015

Table 96: Incidence of Severe Adverse Events by System Organ Class and Preferred Term: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 1 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with a severe event	60 (8)	56 (7)	74 (10)	130 (9)	17 (5)
感染症および寄生虫症	6 (<1)	8 (1)	9 (1)	17 (1)	2 (<1)
胃腸炎	1 (<1)	4 (<1)	0	4 (<1)	0
ウイルス性胃腸炎	0	0	2 (<1)	2 (<1)	0
インフルエンザ	1 (<1)	2 (<1)	0	2 (<1)	0
尿路感染	1 (<1)	0	2 (<1)	2 (<1)	0
蜂巣炎	0	0	1 (<1)	1 (<1)	0
せつ	0	1 (<1)	0	1 (<1)	0
消化管感染	0	0	1 (<1)	1 (<1)	0
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
中耳炎	0	0	1 (<1)	1 (<1)	0
鼻炎	0	0	1 (<1)	1 (<1)	0
副鼻腔炎	0	1 (<1)	0	1 (<1)	0
歯感染	1 (<1)	0	1 (<1)	1 (<1)	0
気管支炎	0	0	0	0	1 (<1)
細菌性心内膜炎	1 (<1)	0	0	0	0
鼻咽頭炎	1 (<1)	0	0	0	0
咽頭炎	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 2 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (<1)	2 (<1)	0	2 (<1)	0
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
脂肪腫	0	1 (<1)	0	1 (<1)	0
肺新生物	0	1 (<1)	0	1 (<1)	0
線維腫	1 (<1)	0	0	0	0
血液およびリンパ系障害	1 (<1)	0	0	0	0
貧血	1 (<1)	0	0	0	0
免疫系障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
過敏症	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
食物アレルギー	1 (<1)	0	0	0	0
内分泌障害	0	0	1 (<1)	1 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
代謝および栄養障害	1 (<1)	0	1 (<1)	1 (<1)	0
脱水	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 3 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
精神障害	1 (<1)	1 (<1)	0	1 (<1)	3 (<1)
うつ病	0	1 (<1)	0	1 (<1)	1 (<1)
不眠症	1 (<1)	1 (<1)	0	1 (<1)	0
不安	1 (<1)	0	0	0	1 (<1)
自殺念慮	0	0	0	0	1 (<1)
神経系障害	27 (4)	15 (2)	20 (3)	35 (2)	4 (1)
多発性硬化症再発	19 (2)	6 (<1)	7 (<1)	13 (<1)	4 (1)
頭痛	4 (<1)	6 (<1)	6 (<1)	12 (<1)	0
片頭痛	3 (<1)	1 (<1)	3 (<1)	4 (<1)	0
帯状感	0	0	1 (<1)	1 (<1)	0
灼熱感	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
前兆を伴う片頭痛	0	0	1 (<1)	1 (<1)	0
筋痙直	1 (<1)	1 (<1)	0	1 (<1)	0
錯感覚	0	0	1 (<1)	1 (<1)	0
感覚障害	0	0	1 (<1)	1 (<1)	0
失神	0	1 (<1)	0	1 (<1)	0
脳血管発作	1 (<1)	0	0	0	0
痙攣	1 (<1)	0	0	0	0
眼障害	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 4 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼運動障害	0	0	1 (<1)	1 (<1)	0
眼痛	0	0	1 (<1)	1 (<1)	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
耳および迷路障害	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
頭位性回転性めまい	0	0	1 (<1)	1 (<1)	0
耳痛	0	0	0	0	1 (<1)
回転性めまい	1 (<1)	0	0	0	0
前庭障害	1 (<1)	0	0	0	0
心臓障害	0	0	1 (<1)	1 (<1)	1 (<1)
狭心症	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	0	1 (<1)
心筋炎	0	0	0	0	1 (<1)
血管障害	1 (<1)	9 (1)	10 (1)	19 (1)	0
潮紅	0	7 (<1)	7 (<1)	14 (<1)	0
ほてり	0	2 (<1)	3 (<1)	5 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
静脈炎	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	2 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 5 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
息詰まり	0	0	1 (<1)	1 (<1)	0
過換気	0	0	1 (<1)	1 (<1)	0
鼻閉	1 (<1)	0	0	0	0
口腔咽頭痛	1 (<1)	0	0	0	0
胃腸障害	7 (<1)	22 (3)	24 (3)	46 (3)	0
上腹部痛	1 (<1)	5 (<1)	6 (<1)	11 (<1)	0
下痢	0	3 (<1)	8 (1)	11 (<1)	0
腹痛	0	4 (<1)	5 (<1)	9 (<1)	0
胃腸障害	0	4 (<1)	3 (<1)	7 (<1)	0
悪心	2 (<1)	3 (<1)	3 (<1)	6 (<1)	0
嘔吐	1 (<1)	4 (<1)	2 (<1)	6 (<1)	0
消化不良	0	1 (<1)	1 (<1)	2 (<1)	0
胃食道逆流性疾患	1 (<1)	2 (<1)	0	2 (<1)	0
腹部不快感	0	1 (<1)	0	1 (<1)	0
腹部膨満	0	0	1 (<1)	1 (<1)	0
便秘	1 (<1)	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
胃障害	0	1 (<1)	0	1 (<1)	0
胃炎	0	0	1 (<1)	1 (<1)	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 6 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝胆道系障害	1 (<1)	0	1 (<1)	1 (<1)	0
胆管結石	0	0	1 (<1)	1 (<1)	0
胆石症	1 (<1)	0	0	0	0
皮膚および皮下組織障害	4 (<1)	1 (<1)	7 (<1)	8 (<1)	1 (<1)
多汗症	0	1 (<1)	1 (<1)	2 (<1)	0
そう痒症	0	0	2 (<1)	2 (<1)	0
脱毛症	1 (<1)	0	1 (<1)	1 (<1)	0
紅斑	0	0	1 (<1)	1 (<1)	0
全身紅斑	0	0	1 (<1)	1 (<1)	0
発疹	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
寝汗	1 (<1)	0	0	0	0
乾癬	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	8 (1)	3 (<1)	6 (<1)	9 (<1)	1 (<1)
背部痛	2 (<1)	0	3 (<1)	3 (<1)	0
関節痛	0	1 (<1)	1 (<1)	2 (<1)	0
筋痙縮	0	1 (<1)	1 (<1)	2 (<1)	0
四肢痛	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
筋肉痛	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
筋拘縮	1 (<1)	0	0	0	0
頚部痛	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 7 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腎および尿路障害	1 (<1)	0	0	0	2 (<1)
ミクロアルブミン尿	0	0	0	0	1 (<1)
腎結石症	0	0	0	0	1 (<1)
尿閉	1 (<1)	0	0	0	0
妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
自然流産	1 (<1)	0	0	0	0
生殖系および乳房障害	1 (<1)	2 (<1)	3 (<1)	5 (<1)	0
月経困難症	0	0	2 (<1)	2 (<1)	0
勃起不全	0	0	1 (<1)	1 (<1)	0
閉経期症状	0	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
月経過多	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	5 (<1)	6 (<1)	7 (<1)	13 (<1)	2 (<1)
疲労	1 (<1)	2 (<1)	4 (<1)	6 (<1)	0
無力症	0	2 (<1)	0	2 (<1)	0
発熱	0	0	2 (<1)	2 (<1)	1 (<1)
胸痛	2 (<1)	0	1 (<1)	1 (<1)	0
脂肪壊死	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 8 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
易刺激性	0	1 (<1)	0	1 (<1)	0
疼痛	0	1 (<1)	0	1 (<1)	0
インフルエンザ様疾患	1 (<1)	0	0	0	0
注射部位紅斑	0	0	0	0	1 (<1)
末梢性浮腫	1 (<1)	0	0	0	0
臨床検査	2 (<1)	3 (<1)	1 (<1)	4 (<1)	2 (<1)
アラニン・アミノトランスフェラーゼ増加	0	2 (<1)	0	2 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	0	2 (<1)	0	2 (<1)	0
肝機能検査異常	0	1 (<1)	0	1 (<1)	0
尿中蛋白陽性	0	0	1 (<1)	1 (<1)	0
血中トリグリセリド増加	0	0	0	0	1 (<1)
肝酵素上昇	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	1 (<1)	0	0	0	0
尿中白血球陽性	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	1 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
交通事故	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
手首関節骨折	0	0	1 (<1)	1 (<1)	0
手骨折	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A-24W.SAS DATE: 02DEC2015

Table 99: Incidence of Adverse Events by System Organ Class and Preferred Term and Causal Association to Study Drug: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 1 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	246 (70)
感染症および寄生虫症	269 (35)	289 (38)	274 (36)	87 (25)
鼻咽頭炎	70 (9)	71 (9)	80 (11)	24 (7)
尿路感染	40 (5)	61 (8)	43 (6)	22 (6)
胃腸炎	10 (1)	18 (2)	13 (2)	1 (<1)
インフルエンザ	27 (4)	27 (4)	29 (4)	2 (<1)
気管支炎	10 (1)	17 (2)	17 (2)	7 (2)
膀胱炎	8 (1)	5 (<1)	6 (<1)	1 (<1)
ウイルス性胃腸炎	5 (<1)	6 (<1)	10 (1)	1 (<1)
消化管感染	2 (<1)	2 (<1)	6 (<1)	0
気道感染	5 (<1)	7 (<1)	9 (1)	2 (<1)
鼻炎	10 (1)	12 (2)	8 (1)	3 (<1)
憩室炎	0	0	1 (<1)	0
熱性感染症	0	0	1 (<1)	0
毛包炎	1 (<1)	2 (<1)	1 (<1)	1 (<1)
単純ヘルペス	1 (<1)	1 (<1)	2 (<1)	1 (<1)
口腔真菌感染	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 2 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	247 (32)	484 (63)	486 (64)	128 (36)
感染症および寄生虫症	26 (3)	41 (5)	44 (6)	9 (3)
鼻咽頭炎	8 (1)	8 (1)	12 (2)	1 (<1)
尿路感染	3 (<1)	7 (<1)	6 (<1)	3 (<1)
胃腸炎	2 (<1)	4 (<1)	5 (<1)	0
インフルエンザ	3 (<1)	1 (<1)	5 (<1)	0
気管支炎	2 (<1)	0	2 (<1)	0
膀胱炎	0	1 (<1)	2 (<1)	0
ウイルス性胃腸炎	0	1 (<1)	2 (<1)	0
消化管感染	0	1 (<1)	2 (<1)	0
気道感染	0	0	2 (<1)	0
鼻炎	2 (<1)	2 (<1)	2 (<1)	2 (<1)
憩室炎	0	0	1 (<1)	0
熱性感染症	0	0	1 (<1)	0
毛包炎	1 (<1)	0	1 (<1)	0
単純ヘルペス	0	1 (<1)	1 (<1)	0
口腔真菌感染	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 3 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
口腔ヘルペス	8 (1)	11 (1)	4 (<1)	2 (<1)
中耳炎	1 (<1)	1 (<1)	3 (<1)	0
咽頭炎	13 (2)	15 (2)	9 (1)	6 (2)
副鼻腔炎	7 (<1)	11 (1)	16 (2)	2 (<1)
癪風	0	1 (<1)	1 (<1)	0
上気道感染	44 (6)	43 (6)	46 (6)	8 (2)
ウイルス感染	7 (<1)	5 (<1)	6 (<1)	2 (<1)
外陰部膿瘍	0	0	1 (<1)	0
外陰腟真菌感染	4 (<1)	2 (<1)	3 (<1)	2 (<1)
顎膿瘍	1 (<1)	0	0	0
ダニ症	0	0	1 (<1)	0
急性副鼻腔炎	0	0	1 (<1)	0
急性扁桃炎	2 (<1)	0	0	0
虫垂炎	0	1 (<1)	0	1 (<1)
無症候性細菌尿	1 (<1)	0	0	0
細菌感染	1 (<1)	1 (<1)	0	0
細菌尿	0	0	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 4 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
口腔ヘルペス	4 (<1)	3 (<1)	1 (<1)	0
中耳炎	0	0	1 (<1)	0
咽頭炎	1 (<1)	1 (<1)	1 (<1)	1 (<1)
副鼻腔炎	0	0	1 (<1)	0
癪風	0	0	1 (<1)	0
上気道感染	4 (<1)	9 (1)	1 (<1)	1 (<1)
ウイルス感染	0	0	1 (<1)	0
外陰部膿瘍	0	0	1 (<1)	0
外陰腟真菌感染	1 (<1)	0	1 (<1)	0
顎膿瘍	0	0	0	0
ダニ症	0	0	0	0
急性副鼻腔炎	0	0	0	0
急性扁桃炎	0	0	0	0
虫垂炎	0	0	0	0
無症候性細菌尿	0	0	0	0
細菌感染	0	0	0	0
細菌尿	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 5 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ボレリア感染	1 (<1)	0	0	0
ウイルス性気管支炎	0	0	0	1 (<1)
気管支肺炎	0	1 (<1)	0	0
カンジダ症	0	1 (<1)	0	0
蜂巣炎	0	1 (<1)	2 (<1)	0
慢性副鼻腔炎	0	0	0	1 (<1)
感染性結膜炎	0	3 (<1)	5 (<1)	0
ウイルス性結膜炎	0	0	1 (<1)	0
デング熱	0	0	0	1 (<1)
感染性皮膚炎	0	0	1 (<1)	0
耳感染	3 (<1)	0	10 (1)	0
細菌性心内膜炎	1 (<1)	0	0	0
眼感染	2 (<1)	0	0	0
真菌感染	1 (<1)	0	0	1 (<1)
せつ	0	2 (<1)	1 (<1)	0
ロタウイルス胃腸炎	0	1 (<1)	0	0
ウイルス性消化管感染	3 (<1)	3 (<1)	2 (<1)	0
性器カンジダ症	0	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 6 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ボレリア感染	0	0	0	0
ウイルス性気管支炎	0	0	0	0
気管支肺炎	0	0	0	0
カンジダ症	0	0	0	0
蜂巣炎	0	0	0	0
慢性副鼻腔炎	0	0	0	0
感染性結膜炎	0	1 (<1)	0	0
ウイルス性結膜炎	0	0	0	0
デング熱	0	0	0	0
感染性皮膚炎	0	0	0	0
耳感染	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0
眼感染	0	0	0	0
真菌感染	0	0	0	0
せつ	0	0	0	0
ロタウイルス胃腸炎	0	0	0	0
ウイルス性消化管感染	0	0	0	0
性器カンジダ症	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 7 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
陰部ヘルペス	1 (<1)	1 (<1)	0	0
細菌性性器感染	0	1 (<1)	0	0
泌尿生殖器感染	0	1 (<1)	0	0
歯肉感染	1 (<1)	0	0	0
Ｈ１Ｎ１インフルエンザ	0	0	0	1 (<1)
ヘリコバクター感染	0	1 (<1)	1 (<1)	0
帯状疱疹	2 (<1)	1 (<1)	5 (<1)	2 (<1)
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	0
眼帯状疱疹	0	0	1 (<1)	0
麦粒腫	1 (<1)	3 (<1)	3 (<1)	0
切開部位感染	0	1 (<1)	0	0
咬傷感染	0	1 (<1)	0	0
感染性皮脂嚢腫	1 (<1)	0	0	0
寄生虫感染	0	0	0	1 (<1)
伝染性単核症	0	1 (<1)	0	0
迷路炎	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 8 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
陰部ヘルペス	1 (<1)	1 (<1)	0	0
細菌性性器感染	0	1 (<1)	0	0
泌尿生殖器感染	0	0	0	0
歯肉感染	0	0	0	0
Ｈ１Ｎ１インフルエンザ	0	0	0	0
ヘリコバクター感染	0	0	0	0
帯状疱疹	1 (<1)	0	0	0
神経合併症を伴う帯状疱疹感染	0	0	0	0
眼帯状疱疹	0	0	0	0
麦粒腫	0	0	0	0
切開部位感染	0	0	0	0
咬傷感染	0	0	0	0
感染性皮脂嚢腫	0	0	0	0
寄生虫感染	0	0	0	0
伝染性単核症	0	0	0	0
迷路炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 9 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
喉頭炎	2 (<1)	4 (<1)	5 (<1)	1 (<1)
シラミ寄生	0	1 (<1)	0	0
限局性感染	1 (<1)	1 (<1)	0	0
下気道感染	1 (<1)	1 (<1)	2 (<1)	1 (<1)
乳腺炎	0	1 (<1)	0	0
乳様突起炎	0	0	0	1 (<1)
爪真菌症	0	2 (<1)	0	0
口腔カンジダ症	1 (<1)	0	1 (<1)	0
外耳炎	1 (<1)	0	0	0
急性中耳炎	0	0	1 (<1)	0
パラインフルエンザウイルス感染	1 (<1)	0	0	0
子宮傍組織炎	0	0	0	1 (<1)
耳下腺炎	0	0	0	1 (<1)
細菌性咽頭炎	2 (<1)	0	0	0
レンサ球菌性咽頭炎	2 (<1)	1 (<1)	1 (<1)	0
咽頭扁桃炎	0	1 (<1)	1 (<1)	1 (<1)
肺炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 10 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
喉頭炎	0	0	0	0
シラミ寄生	0	0	0	0
限局性感染	0	1 (<1)	0	0
下気道感染	0	1 (<1)	0	0
乳腺炎	0	0	0	0
乳様突起炎	0	0	0	0
爪真菌症	0	1 (<1)	0	0
口腔カンジダ症	1 (<1)	0	0	0
外耳炎	0	0	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0
子宮傍組織炎	0	0	0	0
耳下腺炎	0	0	0	0
細菌性咽頭炎	2 (<1)	0	0	0
レンサ球菌性咽頭炎	0	0	0	0
咽頭扁桃炎	0	0	0	1 (<1)
肺炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 11 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
腎盂腎炎	0	1 (<1)	0	0
ウイルス性気道感染	3 (<1)	4 (<1)	1 (<1)	0
卵管卵巣炎	1 (<1)	1 (<1)	0	0
猩紅熱	1 (<1)	0	0	0
細菌性副鼻腔炎	0	1 (<1)	0	0
皮下組織膿瘍	0	1 (<1)	1 (<1)	0
白癬感染	1 (<1)	0	0	0
扁桃炎	3 (<1)	4 (<1)	3 (<1)	1 (<1)
歯膿瘍	4 (<1)	3 (<1)	0	1 (<1)
歯感染	1 (<1)	1 (<1)	1 (<1)	1 (<1)
気管炎	1 (<1)	1 (<1)	0	1 (<1)
気管気管支炎	0	1 (<1)	0	1 (<1)
腸チフス熱	0	0	1 (<1)	0
細菌性上気道感染	0	1 (<1)	0	0
膣膿瘍	1 (<1)	0	0	0
膣感染	1 (<1)	2 (<1)	0	1 (<1)
細菌性膣炎	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 12 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
腎盂腎炎	0	1 (<1)	0	0
ウイルス性気道感染	0	0	0	0
卵管卵巣炎	0	0	0	0
猩紅熱	0	0	0	0
細菌性副鼻腔炎	0	0	0	0
皮下組織膿瘍	0	0	0	0
白癬感染	0	0	0	0
扁桃炎	0	0	0	0
歯膿瘍	0	0	0	0
歯感染	0	0	0	0
気管炎	0	0	0	1 (<1)
気管気管支炎	0	0	0	0
腸チフス熱	0	0	0	0
細菌性上気道感染	0	0	0	0
膣膿瘍	0	0	0	0
膣感染	1 (<1)	0	0	0
細菌性膣炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 13 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
水痘	0	1 (<1)	0	0
ウイルス性鼻炎	0	0	1 (<1)	0
ウイルス性上気道感染	8 (1)	3 (<1)	1 (<1)	0
外陰部炎	0	1 (<1)	0	0
外陰部腟カンジダ症	2 (<1)	1 (<1)	2 (<1)	0
創傷感染	1 (<1)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (<1)	8 (1)	9 (1)	2 (<1)
メラノサイト性母斑	1 (<1)	2 (<1)	2 (<1)	0
肺の良性新生物	0	1 (<1)	0	0
線維腫	1 (<1)	1 (<1)	1 (<1)	0
血管腫	1 (<1)	0	1 (<1)	0
肝臓血管腫	0	0	1 (<1)	0
脂肪腫	0	2 (<1)	0	1 (<1)
肺新生物	0	1 (<1)	1 (<1)	0
良性副甲状腺腫瘍	1 (<1)	0	0	0
皮膚乳頭腫	0	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 14 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
水痘	0	0	0	0
ウイルス性鼻炎	0	0	0	0
ウイルス性上気道感染	0	0	0	0
外陰部炎	0	0	0	0
外陰部腟カンジダ症	0	0	0	0
創傷感染	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (<1)	0
メラノサイト性母斑	0	0	1 (<1)	0
肺の良性新生物	0	0	0	0
線維腫	0	0	0	0
血管腫	0	0	0	0
肝臓血管腫	0	0	0	0
脂肪腫	0	0	0	0
肺新生物	0	0	0	0
良性副甲状腺腫瘍	0	0	0	0
皮膚乳頭腫	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 15 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
転移性甲状腺癌	0	0	0	1 (<1)
子宮平滑筋腫	1 (<1)	0	1 (<1)	0
血液およびリンパ系障害	11 (1)	24 (3)	22 (3)	5 (1)
リンパ球減少症	1 (<1)	6 (<1)	5 (<1)	0
好酸球増加症	0	3 (<1)	4 (<1)	0
貧血	5 (<1)	5 (<1)	8 (1)	2 (<1)
白血球減少症	0	2 (<1)	4 (<1)	0
好中球減少症	0	1 (<1)	2 (<1)	0
好中球増加症	1 (<1)	3 (<1)	3 (<1)	0
鉄欠乏性貧血	1 (<1)	1 (<1)	0	0
白血球増加症	2 (<1)	5 (<1)	1 (<1)	0
リンパ節症	1 (<1)	2 (<1)	1 (<1)	3 (<1)
血小板増加症	1 (<1)	0	0	0
免疫系障害	4 (<1)	14 (2)	12 (2)	5 (1)
過敏症	0	7 (<1)	6 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	0
アナフィラキシー反応	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 16 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
転移性甲状腺癌	0	0	0	0
子宮平滑筋腫	0	0	0	0
血液およびリンパ系障害	3 (<1)	12 (2)	12 (2)	2 (<1)
リンパ球減少症	1 (<1)	4 (<1)	5 (<1)	0
好酸球増加症	0	3 (<1)	4 (<1)	0
貧血	0	1 (<1)	3 (<1)	0
白血球減少症	0	1 (<1)	2 (<1)	0
好中球減少症	0	1 (<1)	2 (<1)	0
好中球増加症	1 (<1)	2 (<1)	1 (<1)	0
鉄欠乏性貧血	0	0	0	0
白血球増加症	1 (<1)	2 (<1)	0	0
リンパ節症	0	0	0	2 (<1)
血小板増加症	1 (<1)	0	0	0
免疫系障害	0	7 (<1)	6 (<1)	2 (<1)
過敏症	0	7 (<1)	5 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	0
アナフィラキシー反応	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 17 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
造影剤アレルギー	0	1 (<1)	0	0
薬物過敏症	0	1 (<1)	2 (<1)	1 (<1)
食物アレルギー	1 (<1)	3 (<1)	1 (<1)	0
季節性アレルギー	3 (<1)	2 (<1)	2 (<1)	2 (<1)
内分泌障害	5 (<1)	1 (<1)	5 (<1)	1 (<1)
副腎腫瘤	1 (<1)	0	0	0
間脳性内分泌障害	0	0	1 (<1)	0
甲状腺腫	0	1 (<1)	1 (<1)	1 (<1)
副甲状腺機能亢進症	1 (<1)	0	0	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	0
甲状腺機能亢進症	1 (<1)	0	0	0
甲状腺機能低下症	2 (<1)	0	2 (<1)	0
代謝および栄養障害	29 (4)	23 (3)	25 (3)	10 (3)
食欲減退	7 (<1)	12 (2)	12 (2)	2 (<1)
異常体重減少	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 18 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
造影剤アレルギー	0	0	0	0
薬物過敏症	0	0	0	0
食物アレルギー	0	0	0	0
季節性アレルギー	0	0	0	0
内分泌障害	1 (<1)	0	0	0
副腎腫瘤	0	0	0	0
間脳性内分泌障害	0	0	0	0
甲状腺腫	0	0	0	0
副甲状腺機能亢進症	0	0	0	0
原発性副甲状腺機能亢進症	0	0	0	0
甲状腺機能亢進症	0	0	0	0
甲状腺機能低下症	1 (<1)	0	0	0
代謝および栄養障害	7 (<1)	14 (2)	10 (1)	3 (<1)
食欲減退	4 (<1)	10 (1)	6 (<1)	2 (<1)
異常体重減少	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 19 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脱水	1 (<1)	2 (<1)	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	0
ビタミンD欠乏	0	0	2 (<1)	1 (<1)
糖尿病	3 (<1)	0	2 (<1)	0
糖尿病性ケトアシドーシス	2 (<1)	0	1 (<1)	0
脂質異常症	0	0	1 (<1)	0
痛風	1 (<1)	0	0	0
高カルシウム血症	1 (<1)	0	0	0
高コレステロール血症	2 (<1)	4 (<1)	1 (<1)	2 (<1)
高血糖	3 (<1)	0	3 (<1)	0
高カリウム血症	1 (<1)	0	0	1 (<1)
高脂血症	2 (<1)	1 (<1)	1 (<1)	0
高トリグリセリド血症	1 (<1)	0	0	4 (1)
高尿酸血症	0	1 (<1)	0	1 (<1)
低カリウム血症	0	1 (<1)	0	0
ビタミン欠乏症	1 (<1)	0	0	0
食欲亢進	3 (<1)	2 (<1)	0	0
鉄欠乏	1 (<1)	0	1 (<1)	0
肥満	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 20 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脱水	0	0	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	0
ビタミンD欠乏	0	0	1 (<1)	0
糖尿病	0	0	0	0
糖尿病性ケトアシドーシス	0	0	0	0
脂質異常症	0	0	0	0
痛風	0	0	0	0
高カルシウム血症	0	0	0	0
高コレステロール血症	1 (<1)	1 (<1)	0	0
高血糖	0	0	0	0
高カリウム血症	0	0	0	1 (<1)
高脂血症	0	0	0	0
高トリグリセリド血症	1 (<1)	0	0	0
高尿酸血症	0	0	0	0
低カリウム血症	0	1 (<1)	0	0
ビタミン欠乏症	0	0	0	0
食欲亢進	1 (<1)	2 (<1)	0	0
鉄欠乏	0	0	0	0
肥満	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 21 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
精神障害	84 (11)	58 (8)	64 (8)	29 (8)
不眠症	16 (2)	10 (1)	13 (2)	6 (2)
うつ病	33 (4)	23 (3)	19 (3)	13 (4)
感情不安定	2 (<1)	0	2 (<1)	1 (<1)
初期不眠症	0	0	2 (<1)	0
気分変化	0	1 (<1)	2 (<1)	0
異常行動	0	1 (<1)	0	0
感情障害	3 (<1)	2 (<1)	2 (<1)	1 (<1)
攻撃性	1 (<1)	0	0	0
激越	1 (<1)	0	0	0
不安	16 (2)	16 (2)	14 (2)	4 (1)
気晴らし食い	1 (<1)	0	0	0
精神緩慢	1 (<1)	0	0	0
歯ぎしり	1 (<1)	0	0	0
錯乱状態	1 (<1)	0	0	0
抑うつ気分	7 (<1)	5 (<1)	4 (<1)	2 (<1)
抑うつ症状	1 (<1)	1 (<1)	1 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 22 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
精神障害	12 (2)	12 (2)	14 (2)	2 (<1)
不眠症	2 (<1)	2 (<1)	6 (<1)	1 (<1)
うつ病	4 (<1)	3 (<1)	4 (<1)	1 (<1)
感情不安定	0	0	2 (<1)	0
初期不眠症	0	0	1 (<1)	0
気分変化	0	0	1 (<1)	0
異常行動	0	1 (<1)	0	0
感情障害	1 (<1)	0	0	0
攻撃性	0	0	0	0
激越	0	0	0	0
不安	1 (<1)	4 (<1)	0	0
気晴らし食い	0	0	0	0
精神緩慢	0	0	0	0
歯ぎしり	0	0	0	0
錯乱状態	0	0	0	0
抑うつ気分	0	0	0	0
抑うつ症状	0	0	0	0
性的興奮障害	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 23 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
情動障害	0	0	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	0
幻覚	1 (<1)	0	0	0
幻聴	0	1 (<1)	0	0
リビドー減退	1 (<1)	1 (<1)	1 (<1)	0
大うつ病	0	0	1 (<1)	0
躁病	0	1 (<1)	0	0
精神障害	0	0	0	1 (<1)
中期不眠症	1 (<1)	0	0	0
気分動揺	2 (<1)	2 (<1)	1 (<1)	1 (<1)
神経過敏	1 (<1)	0	1 (<1)	1 (<1)
悪夢	1 (<1)	0	0	0
人格変化	0	1 (<1)	0	0
精神症状	0	1 (<1)	0	0
落ち着きのなさ	0	1 (<1)	0	0
睡眠障害	5 (<1)	6 (<1)	5 (<1)	1 (<1)
ストレス	1 (<1)	0	2 (<1)	1 (<1)
自殺念慮	1 (<1)	1 (<1)	0	2 (<1)
緊張	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 24 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
情動障害	0	0	0	0
多幸気分	0	1 (<1)	0	0
幻覚	1 (<1)	0	0	0
幻聴	0	0	0	0
リビドー減退	0	0	0	0
大うつ病	0	0	0	0
躁病	0	0	0	0
精神障害	0	0	0	0
中期不眠症	0	0	0	0
気分動揺	0	1 (<1)	0	0
神経過敏	1 (<1)	0	0	1 (<1)
悪夢	1 (<1)	0	0	0
人格変化	0	0	0	0
精神症状	0	1 (<1)	0	0
落ち着きのなさ	0	0	0	0
睡眠障害	0	3 (<1)	0	0
ストレス	0	0	0	0
自殺念慮	0	0	0	0
緊張	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 25 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
神経系障害	312 (40)	260 (34)	253 (33)	105 (30)
頭痛	88 (11)	84 (11)	80 (11)	33 (9)
錯感覚	27 (4)	29 (4)	28 (4)	4 (1)
灼熱感	5 (<1)	14 (2)	14 (2)	0
多発性硬化症再発	165 (21)	104 (14)	96 (13)	56 (16)
浮動性めまい	17 (2)	13 (2)	15 (2)	7 (2)
片頭痛	10 (1)	10 (1)	11 (1)	3 (<1)
傾眠	4 (<1)	5 (<1)	6 (<1)	2 (<1)
味覚異常	1 (<1)	2 (<1)	5 (<1)	2 (<1)
帯状感	0	0	2 (<1)	0
異常感覚	2 (<1)	9 (1)	2 (<1)	0
蟻走感	0	0	1 (<1)	0
不全片麻痺	0	0	1 (<1)	0
知覚過敏	3 (<1)	1 (<1)	1 (<1)	1 (<1)
感覚鈍麻	20 (3)	15 (2)	15 (2)	8 (2)
嗜眠	0	0	1 (<1)	0
意識消失	1 (<1)	0	2 (<1)	1 (<1)
感覚障害	8 (1)	3 (<1)	3 (<1)	1 (<1)
ウートホフ現象	1 (<1)	1 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 26 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
神経系障害	66 (9)	86 (11)	76 (10)	18 (5)
頭痛	34 (4)	40 (5)	34 (4)	6 (2)
錯感覚	4 (<1)	8 (1)	13 (2)	1 (<1)
灼熱感	2 (<1)	9 (1)	8 (1)	0
多発性硬化症再発	7 (<1)	6 (<1)	6 (<1)	1 (<1)
浮動性めまい	8 (1)	8 (1)	5 (<1)	4 (1)
片頭痛	3 (<1)	3 (<1)	5 (<1)	0
傾眠	0	4 (<1)	3 (<1)	2 (<1)
味覚異常	0	1 (<1)	2 (<1)	0
帯状感	0	0	1 (<1)	0
異常感覚	1 (<1)	5 (<1)	1 (<1)	0
蟻走感	0	0	1 (<1)	0
不全片麻痺	0	0	1 (<1)	0
知覚過敏	2 (<1)	1 (<1)	1 (<1)	0
感覚鈍麻	2 (<1)	1 (<1)	1 (<1)	2 (<1)
嗜眠	0	0	1 (<1)	0
意識消失	0	0	1 (<1)	0
感覚障害	1 (<1)	0	1 (<1)	0
ウートホフ現象	0	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 27 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
味覚消失	0	1 (<1)	0	0
意識変容状態	0	0	1 (<1)	0
健忘	3 (<1)	0	0	0
失語症	1 (<1)	0	0	1 (<1)
運動失調	1 (<1)	0	2 (<1)	0
自律神経失調	0	0	1 (<1)	0
平衡障害	2 (<1)	3 (<1)	4 (<1)	2 (<1)
手根管症候群	1 (<1)	1 (<1)	1 (<1)	1 (<1)
中枢神経系病変	1 (<1)	0	0	0
中枢痛症候群	1 (<1)	0	0	0
小脳症候群	1 (<1)	0	0	0
脳血管発作	1 (<1)	0	0	0
頚髄神経根痛	0	0	2 (<1)	0
頚腕症候群	1 (<1)	0	0	0
頚原性頭痛	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 28 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
味覚消失	0	1 (<1)	0	0
意識変容状態	0	0	0	0
健忘	1 (<1)	0	0	0
失語症	0	0	0	0
運動失調	0	0	0	0
自律神経失調	0	0	0	0
平衡障害	0	0	0	0
手根管症候群	0	0	0	0
中枢神経系病変	1 (<1)	0	0	0
中枢痛症候群	0	0	0	0
小脳症候群	0	0	0	0
脳血管発作	0	0	0	0
頚髄神経根痛	0	0	0	0
頚腕症候群	0	0	0	0
頚原性頭痛	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 29 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
概日リズム睡眠障害	0	1 (<1)	0	0
認知障害	0	1 (<1)	1 (<1)	1 (<1)
複雑部分発作	1 (<1)	0	0	0
痙攣	2 (<1)	0	1 (<1)	0
泣き	0	0	1 (<1)	0
振動覚低下	0	1 (<1)	0	0
注意力障害	0	1 (<1)	0	1 (<1)
体位性めまい	0	1 (<1)	0	0
よだれ	0	0	1 (<1)	0
構語障害	1 (<1)	2 (<1)	2 (<1)	0
ジスキネジー	0	1 (<1)	0	0
てんかん	1 (<1)	0	1 (<1)	1 (<1)
てんかんの前兆	0	1 (<1)	0	0
顔面不全麻痺	1 (<1)	0	0	0
顔面痙攣	1 (<1)	0	0	1 (<1)
頭部動揺	0	1 (<1)	0	0
片側頭痛	2 (<1)	1 (<1)	0	0
反射亢進	2 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 30 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
概日リズム睡眠障害	0	0	0	0
認知障害	0	0	0	0
複雑部分発作	1 (<1)	0	0	0
痙攣	0	0	0	0
泣き	0	0	0	0
振動覚低下	0	0	0	0
注意力障害	0	0	0	0
体位性めまい	0	0	0	0
よだれ	0	0	0	0
構語障害	0	0	0	0
ジスキネジー	0	0	0	0
てんかん	0	0	0	1 (<1)
てんかんの前兆	0	1 (<1)	0	0
顔面不全麻痺	1 (<1)	0	0	0
顔面痙攣	0	0	0	0
頭部動揺	0	0	0	0
片側頭痛	0	1 (<1)	0	0
反射亢進	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 31 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過眠症	2 (<1)	2 (<1)	1 (<1)	0
筋緊張亢進	1 (<1)	0	0	0
肋間神経痛	1 (<1)	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	0
レルミット徴候	4 (<1)	0	2 (<1)	1 (<1)
腰髄神経根障害	1 (<1)	1 (<1)	0	0
仮面状顔貌	0	0	0	1 (<1)
記憶障害	1 (<1)	2 (<1)	1 (<1)	2 (<1)
感覚異常性大腿神経痛	0	1 (<1)	0	0
前兆を伴う片頭痛	0	4 (<1)	1 (<1)	0
運動機能障害	0	1 (<1)	1 (<1)	0
多発性硬化症	5 (<1)	3 (<1)	1 (<1)	1 (<1)
筋痙直	12 (2)	7 (<1)	5 (<1)	3 (<1)
神経圧迫	0	0	1 (<1)	0
神経痛	3 (<1)	3 (<1)	3 (<1)	0
末梢性ニューロパチー	0	0	0	1 (<1)
眼振	1 (<1)	1 (<1)	1 (<1)	0
後頭神経痛	1 (<1)	0	0	0
視神経炎	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 32 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過眠症	0	1 (<1)	0	0
筋緊張亢進	1 (<1)	0	0	0
肋間神経痛	0	0	0	0
虚血性脳卒中	0	0	0	0
レルミット徴候	1 (<1)	0	0	0
腰髄神経根障害	0	0	0	0
仮面状顔貌	0	0	0	1 (<1)
記憶障害	0	0	0	0
感覚異常性大腿神経痛	0	0	0	0
前兆を伴う片頭痛	0	0	0	0
運動機能障害	0	0	0	0
多発性硬化症	2 (<1)	0	0	0
筋痙直	1 (<1)	1 (<1)	0	0
神経圧迫	0	0	0	0
神経痛	1 (<1)	1 (<1)	0	0
末梢性ニューロパチー	0	0	0	0
眼振	0	1 (<1)	0	0
後頭神経痛	0	0	0	0
視神経炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 33 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嗅覚錯誤	1 (<1)	0	0	0
部分発作	0	0	0	1 (<1)
腓骨神経麻痺	0	1 (<1)	0	0
睡眠の質低下	0	1 (<1)	0	0
失神寸前の状態	2 (<1)	0	0	0
頚髄神経根炎	0	1 (<1)	0	0
下肢静止不能症候群	1 (<1)	0	1 (<1)	1 (<1)
坐骨神経痛	2 (<1)	3 (<1)	3 (<1)	0
鎮静	0	0	1 (<1)	0
副鼻腔炎に伴う頭痛	2 (<1)	0	1 (<1)	0
会話障害	0	1 (<1)	0	0
失神	2 (<1)	1 (<1)	2 (<1)	1 (<1)
緊張性頭痛	3 (<1)	2 (<1)	2 (<1)	0
温度覚鈍麻	1 (<1)	0	0	0
舌の麻痺	0	1 (<1)	0	0
振戦	5 (<1)	7 (<1)	2 (<1)	1 (<1)
三叉神経痛	5 (<1)	2 (<1)	2 (<1)	1 (<1)
振動覚亢進	1 (<1)	0	0	0
第７脳神経麻痺	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 34 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嗅覚錯誤	0	0	0	0
部分発作	0	0	0	0
腓骨神経麻痺	0	0	0	0
睡眠の質低下	0	1 (<1)	0	0
失神寸前の状態	2 (<1)	0	0	0
頚髄神経根炎	0	0	0	0
下肢静止不能症候群	0	0	0	0
坐骨神経痛	0	0	0	0
鎮静	0	0	0	0
副鼻腔炎に伴う頭痛	1 (<1)	0	0	0
会話障害	0	0	0	0
失神	0	0	0	1 (<1)
緊張性頭痛	0	1 (<1)	0	0
温度覚鈍麻	1 (<1)	0	0	0
舌の麻痺	0	0	0	0
振戦	0	2 (<1)	0	1 (<1)
三叉神経痛	0	0	0	0
振動覚亢進	0	0	0	0
第７脳神経麻痺	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 35 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼障害	46 (6)	22 (3)	38 (5)	10 (3)
霧視	7 (<1)	6 (<1)	8 (1)	3 (<1)
眼瞼痙攣	4 (<1)	3 (<1)	3 (<1)	0
眼痛	5 (<1)	1 (<1)	10 (1)	2 (<1)
眼そう痒症	2 (<1)	0	1 (<1)	0
眼瞼炎	0	0	1 (<1)	0
白内障	0	0	2 (<1)	0
霰粒腫	1 (<1)	0	0	0
結膜出血	1 (<1)	0	0	0
結膜刺激	1 (<1)	0	0	0
結膜炎	3 (<1)	1 (<1)	2 (<1)	0
アレルギー性結膜炎	1 (<1)	1 (<1)	1 (<1)	0
複視	5 (<1)	1 (<1)	3 (<1)	2 (<1)
眼乾燥	3 (<1)	4 (<1)	1 (<1)	0
眼瞼紅斑	2 (<1)	0	0	0
眼のアレルギー	0	0	0	1 (<1)
眼出血	0	0	1 (<1)	0
眼刺激	0	0	1 (<1)	0
眼運動障害	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 36 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼障害	8 (1)	2 (<1)	4 (<1)	0
霧視	2 (<1)	0	2 (<1)	0
眼瞼痙攣	0	0	1 (<1)	0
眼痛	0	0	1 (<1)	0
眼そう痒症	0	0	1 (<1)	0
眼瞼炎	0	0	0	0
白内障	0	0	0	0
霰粒腫	0	0	0	0
結膜出血	0	0	0	0
結膜刺激	0	0	0	0
結膜炎	1 (<1)	0	0	0
アレルギー性結膜炎	0	0	0	0
複視	0	1 (<1)	0	0
眼乾燥	1 (<1)	1 (<1)	0	0
眼瞼紅斑	2 (<1)	0	0	0
眼のアレルギー	0	0	0	0
眼出血	0	0	0	0
眼刺激	0	0	0	0
眼運動障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 37 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼瞼そう痒症	1 (<1)	0	0	0
緑内障	0	0	2 (<1)	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0
遠視	1 (<1)	0	0	0
角膜炎	0	0	1 (<1)	0
流涙増加	1 (<1)	0	0	1 (<1)
黄斑浮腫	1 (<1)	0	0	0
近視	1 (<1)	0	0	0
眼充血	1 (<1)	0	0	0
開放隅角緑内障	0	0	1 (<1)	0
眼筋麻痺	0	1 (<1)	0	0
光視症	0	1 (<1)	0	0
強膜炎	0	1 (<1)	0	0
ブドウ膜炎	0	0	2 (<1)	1 (<1)
視力低下	5 (<1)	1 (<1)	2 (<1)	1 (<1)
視力障害	3 (<1)	3 (<1)	3 (<1)	0
硝子体浮遊物	0	1 (<1)	0	0
耳および迷路障害	31 (4)	21 (3)	22 (3)	12 (3)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 38 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼瞼そう痒症	1 (<1)	0	0	0
緑内障	0	0	0	0
ホームズ・アディー瞳孔	0	0	0	0
遠視	0	0	0	0
角膜炎	0	0	0	0
流涙増加	0	0	0	0
黄斑浮腫	0	0	0	0
近視	0	0	0	0
眼充血	1 (<1)	0	0	0
開放隅角緑内障	0	0	0	0
眼筋麻痺	0	0	0	0
光視症	0	0	0	0
強膜炎	0	0	0	0
ブドウ膜炎	0	0	0	0
視力低下	0	0	0	0
視力障害	1 (<1)	0	0	0
硝子体浮遊物	0	0	0	0
耳および迷路障害	4 (<1)	6 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 39 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
回転性めまい	24 (3)	13 (2)	14 (2)	6 (2)
耳不快感	0	0	1 (<1)	2 (<1)
耳鳴	4 (<1)	3 (<1)	2 (<1)	0
耳垢栓塞	0	0	0	1 (<1)
難聴	2 (<1)	1 (<1)	0	0
外耳道紅斑	1 (<1)	0	0	0
耳閉	1 (<1)	0	1 (<1)	0
耳痛	0	1 (<1)	3 (<1)	1 (<1)
耳そう痒症	0	1 (<1)	0	0
耳管機能障害	0	0	0	1 (<1)
聴力低下	0	0	1 (<1)	0
乗物酔い	1 (<1)	1 (<1)	0	0
頭位性回転性めまい	1 (<1)	1 (<1)	1 (<1)	1 (<1)
前庭障害	1 (<1)	0	0	0
心臓障害	21 (3)	14 (2)	17 (2)	10 (3)
頻脈	2 (<1)	3 (<1)	4 (<1)	4 (1)
動悸	10 (1)	7 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 40 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
回転性めまい	3 (<1)	4 (<1)	4 (<1)	0
耳不快感	0	0	1 (<1)	0
耳鳴	1 (<1)	0	1 (<1)	0
耳垢栓塞	0	0	0	0
難聴	0	0	0	0
外耳道紅斑	0	0	0	0
耳閉	0	0	0	0
耳痛	0	1 (<1)	0	0
耳そう痒症	0	0	0	0
耳管機能障害	0	0	0	0
聴力低下	0	0	0	0
乗物酔い	0	1 (<1)	0	0
頭位性回転性めまい	0	0	0	0
前庭障害	0	0	0	0
心臓障害	6 (<1)	7 (<1)	9 (1)	7 (2)
頻脈	1 (<1)	2 (<1)	4 (<1)	4 (1)
動悸	5 (<1)	4 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 41 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
狭心症	0	0	1 (<1)	0
徐脈	1 (<1)	0	2 (<1)	1 (<1)
期外収縮	1 (<1)	1 (<1)	1 (<1)	0
心房細動	0	0	1 (<1)	1 (<1)
第一度房室ブロック	0	1 (<1)	1 (<1)	1 (<1)
右脚ブロック	0	0	0	1 (<1)
心不全	0	0	1 (<1)	0
伝導障害	0	0	0	1 (<1)
心筋虚血	1 (<1)	0	0	0
心筋炎	0	0	0	1 (<1)
洞性徐脈	0	1 (<1)	1 (<1)	0
洞性頻脈	2 (<1)	0	2 (<1)	0
上室性期外収縮	1 (<1)	2 (<1)	0	0
上室性頻脈	1 (<1)	0	0	0
発作性頻脈	1 (<1)	0	0	0
心室性期外収縮	2 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 42 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
狭心症	0	0	1 (<1)	0
徐脈	0	0	1 (<1)	1 (<1)
期外収縮	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	1 (<1)
第一度房室ブロック	0	0	0	0
右脚ブロック	0	0	0	0
心不全	0	0	0	0
伝導障害	0	0	0	0
心筋虚血	0	0	0	0
心筋炎	0	0	0	1 (<1)
洞性徐脈	0	0	0	0
洞性頻脈	0	0	0	0
上室性期外収縮	0	1 (<1)	0	0
上室性頻脈	0	0	0	0
発作性頻脈	0	0	0	0
心室性期外収縮	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 43 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血管障害	51 (7)	276 (36)	246 (32)	14 (4)
潮紅	27 (4)	231 (30)	199 (26)	3 (<1)
ほてり	10 (1)	39 (5)	41 (5)	5 (1)
充血	0	2 (<1)	6 (<1)	0
高血圧	7 (<1)	5 (<1)	11 (1)	6 (2)
起立性低血圧	1 (<1)	0	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0
深部静脈血栓症	0	0	1 (<1)	0
血腫	2 (<1)	0	0	0
低血圧	1 (<1)	4 (<1)	0	0
腹腔内血腫	0	0	0	1 (<1)
静脈炎	1 (<1)	0	1 (<1)	0
レイノー現象	1 (<1)	1 (<1)	0	0
呼吸器、胸郭および縦隔障害	60 (8)	57 (7)	64 (8)	15 (4)
鼻漏	5 (<1)	9 (1)	7 (<1)	0
呼吸困難	5 (<1)	4 (<1)	3 (<1)	4 (1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 44 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血管障害	38 (5)	261 (34)	227 (30)	6 (2)
潮紅	25 (3)	224 (29)	190 (25)	3 (<1)
ほてり	10 (1)	35 (5)	38 (5)	3 (<1)
充血	0	2 (<1)	6 (<1)	0
高血圧	1 (<1)	2 (<1)	1 (<1)	0
起立性低血圧	1 (<1)	0	1 (<1)	0
毛細血管脆弱	0	0	0	0
深部静脈血栓症	0	0	0	0
血腫	0	0	0	0
低血圧	0	1 (<1)	0	0
腹腔内血腫	0	0	0	1 (<1)
静脈炎	1 (<1)	0	0	0
レイノー現象	0	0	0	0
呼吸器、胸郭および縦隔障害	7 (<1)	18 (2)	14 (2)	5 (1)
鼻漏	1 (<1)	8 (1)	5 (<1)	0
呼吸困難	3 (<1)	1 (<1)	2 (<1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 45 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
上気道咳症候群	2 (<1)	2 (<1)	2 (<1)	0
咳嗽	18 (2)	18 (2)	11 (1)	3 (<1)
発声障害	0	0	1 (<1)	1 (<1)
鼻出血	3 (<1)	1 (<1)	2 (<1)	1 (<1)
鼻閉	5 (<1)	4 (<1)	2 (<1)	0
口腔咽頭痛	13 (2)	15 (2)	18 (2)	5 (1)
気道うっ血	3 (<1)	1 (<1)	2 (<1)	0
副鼻腔うっ血	0	1 (<1)	5 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	0
アレルギー性咽頭炎	2 (<1)	0	0	0
喘息	1 (<1)	2 (<1)	1 (<1)	0
慢性気管支炎	1 (<1)	0	0	0
息詰まり	1 (<1)	0	2 (<1)	0
咽喉乾燥	1 (<1)	1 (<1)	0	0
労作性呼吸困難	0	1 (<1)	0	0
しゃっくり	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 46 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
上気道咳症候群	0	1 (<1)	2 (<1)	0
咳嗽	1 (<1)	2 (<1)	1 (<1)	0
発声障害	0	0	1 (<1)	0
鼻出血	1 (<1)	0	1 (<1)	0
鼻閉	1 (<1)	1 (<1)	1 (<1)	0
口腔咽頭痛	0	1 (<1)	1 (<1)	1 (<1)
気道うっ血	1 (<1)	0	1 (<1)	0
副鼻腔うっ血	0	1 (<1)	1 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	0
アレルギー性気管支炎	0	0	0	0
アレルギー性咽頭炎	0	0	0	0
喘息	0	2 (<1)	0	0
慢性気管支炎	0	0	0	0
息詰まり	1 (<1)	0	0	0
咽喉乾燥	1 (<1)	0	0	0
労作性呼吸困難	0	0	0	0
しゃっくり	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 47 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過換気	0	0	1 (<1)	0
低換気	0	0	0	1 (<1)
上気道分泌増加	1 (<1)	0	0	0
鼻部不快感	1 (<1)	0	0	0
鼻乾燥	2 (<1)	0	0	0
呼吸時疼痛	0	0	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	0
咽頭紅斑	0	1 (<1)	0	0
咽頭腫瘤	0	0	1 (<1)	0
胸膜炎	0	0	1 (<1)	0
湿性咳嗽	3 (<1)	1 (<1)	1 (<1)	0
ラ音	0	0	1 (<1)	0
アレルギー性鼻炎	2 (<1)	1 (<1)	4 (<1)	0
低音性連続性ラ音	1 (<1)	0	0	0
副鼻腔障害	1 (<1)	0	0	0
睡眠時無呼吸症候群	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 48 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過換気	0	0	0	0
低換気	0	0	0	1 (<1)
上気道分泌増加	0	0	0	0
鼻部不快感	1 (<1)	0	0	0
鼻乾燥	2 (<1)	0	0	0
呼吸時疼痛	0	0	0	0
副鼻腔嚢胞	0	0	0	0
副鼻腔分泌過多	0	0	0	0
咽頭紅斑	0	0	0	0
咽頭腫瘤	0	0	0	0
胸膜炎	0	0	0	0
湿性咳嗽	0	0	0	0
ラ音	0	0	0	0
アレルギー性鼻炎	1 (<1)	1 (<1)	0	0
低音性連続性ラ音	0	0	0	0
副鼻腔障害	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 49 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
くしゃみ	1 (<1)	0	0	1 (<1)
咽喉刺激感	2 (<1)	3 (<1)	0	0
上気道うっ血	2 (<1)	0	2 (<1)	0
声帯の炎症	1 (<1)	0	0	0
喘鳴	1 (<1)	2 (<1)	0	0
胃腸障害	192 (25)	286 (37)	304 (40)	30 (9)
下痢	49 (6)	78 (10)	102 (13)	4 (1)
悪心	51 (7)	75 (10)	86 (11)	10 (3)
上腹部痛	29 (4)	58 (8)	61 (8)	2 (<1)
腹痛	26 (3)	55 (7)	44 (6)	2 (<1)
嘔吐	16 (2)	44 (6)	36 (5)	2 (<1)
胃腸障害	5 (<1)	17 (2)	30 (4)	1 (<1)
消化不良	15 (2)	22 (3)	30 (4)	3 (<1)
胃炎	5 (<1)	11 (1)	11 (1)	0
胃食道逆流性疾患	9 (1)	12 (2)	10 (1)	1 (<1)
腹部膨満	7 (<1)	3 (<1)	10 (1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 50 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
くしゃみ	0	0	0	0
咽喉刺激感	0	2 (<1)	0	0
上気道うっ血	0	0	0	0
声帯の炎症	0	0	0	0
喘鳴	0	0	0	0
胃腸障害	108 (14)	217 (28)	230 (30)	11 (3)
下痢	25 (3)	56 (7)	75 (10)	1 (<1)
悪心	35 (5)	66 (9)	74 (10)	7 (2)
上腹部痛	22 (3)	55 (7)	56 (7)	2 (<1)
腹痛	19 (2)	41 (5)	35 (5)	1 (<1)
嘔吐	7 (<1)	29 (4)	29 (4)	2 (<1)
胃腸障害	4 (<1)	16 (2)	27 (4)	0
消化不良	9 (1)	18 (2)	22 (3)	0
胃炎	3 (<1)	7 (<1)	8 (1)	0
胃食道逆流性疾患	4 (<1)	8 (1)	8 (1)	0
腹部膨満	5 (<1)	3 (<1)	7 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 51 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
便秘	18 (2)	15 (2)	19 (3)	3 (<1)
鼓腸	6 (<1)	7 (<1)	8 (1)	2 (<1)
腹部不快感	6 (<1)	9 (1)	11 (1)	0
口内乾燥	3 (<1)	15 (2)	6 (<1)	0
便意切迫	0	1 (<1)	3 (<1)	0
おくび	0	2 (<1)	3 (<1)	0
便失禁	1 (<1)	2 (<1)	3 (<1)	0
排便回数増加	0	0	2 (<1)	0
腹部硬直	0	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	0
心窩部不快感	0	1 (<1)	2 (<1)	0
食中毒	1 (<1)	1 (<1)	2 (<1)	0
胃障害	0	1 (<1)	2 (<1)	0
胃腸出血	0	0	1 (<1)	0
歯肉痛	1 (<1)	0	1 (<1)	0
歯肉炎	2 (<1)	0	2 (<1)	1 (<1)
舌苔	0	0	1 (<1)	0
下腹部痛	2 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 52 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
便秘	7 (<1)	9 (1)	7 (<1)	0
鼓腸	5 (<1)	6 (<1)	7 (<1)	1 (<1)
腹部不快感	5 (<1)	9 (1)	6 (<1)	0
口内乾燥	0	9 (1)	3 (<1)	0
便意切迫	0	0	2 (<1)	0
おくび	0	2 (<1)	2 (<1)	0
便失禁	1 (<1)	1 (<1)	2 (<1)	0
排便回数増加	0	0	2 (<1)	0
腹部硬直	0	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	0
心窩部不快感	0	1 (<1)	1 (<1)	0
食中毒	0	0	1 (<1)	0
胃障害	0	1 (<1)	1 (<1)	0
胃腸出血	0	0	1 (<1)	0
歯肉痛	1 (<1)	0	1 (<1)	0
歯肉炎	1 (<1)	0	1 (<1)	0
舌苔	0	0	1 (<1)	0
下腹部痛	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 53 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
腹部圧痛	0	0	2 (<1)	1 (<1)
異常便	1 (<1)	2 (<1)	0	0
唾液欠乏	0	1 (<1)	0	0
呼気臭	1 (<1)	0	0	0
便習慣変化	0	0	1 (<1)	0
口唇のひび割れ	1 (<1)	0	0	0
口唇炎	0	1 (<1)	0	0
大腸炎	2 (<1)	1 (<1)	0	1 (<1)
クローン病	0	1 (<1)	0	0
齲歯	2 (<1)	3 (<1)	3 (<1)	1 (<1)
十二指腸ポリープ	0	1 (<1)	0	0
十二指腸潰瘍	0	1 (<1)	0	0
嚥下障害	2 (<1)	1 (<1)	2 (<1)	0
小腸炎	0	1 (<1)	0	0
腸炎	0	0	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)
胃ポリープ	1 (<1)	0	0	0
出血性胃炎	0	1 (<1)	0	0
胃十二指腸炎	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 54 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
腹部圧痛	0	0	0	0
異常便	1 (<1)	2 (<1)	0	0
唾液欠乏	0	1 (<1)	0	0
呼気臭	0	0	0	0
便習慣変化	0	0	0	0
口唇のひび割れ	1 (<1)	0	0	0
口唇炎	0	0	0	0
大腸炎	2 (<1)	0	0	1 (<1)
クローン病	0	0	0	0
齲歯	0	0	0	0
十二指腸ポリープ	0	0	0	0
十二指腸潰瘍	0	1 (<1)	0	0
嚥下障害	0	0	0	0
小腸炎	0	1 (<1)	0	0
腸炎	0	0	0	0
変色便	0	0	0	0
胃ポリープ	0	0	0	0
出血性胃炎	0	0	0	0
胃十二指腸炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 55 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯肉出血	0	1 (<1)	0	0
歯肉紅斑	0	0	0	1 (<1)
歯肉腫脹	0	1 (<1)	0	0
舌炎	0	1 (<1)	0	0
舌痛	1 (<1)	1 (<1)	0	0
吐血	0	1 (<1)	0	0
痔出血	0	0	0	1 (<1)
痔核	1 (<1)	4 (<1)	1 (<1)	0
裂孔ヘルニア	0	1 (<1)	1 (<1)	0
胃酸過多	1 (<1)	2 (<1)	0	0
口の感覚鈍麻	0	1 (<1)	1 (<1)	0
胃排出不全	0	1 (<1)	0	0
過敏性腸症候群	0	1 (<1)	1 (<1)	0
口唇乾燥	1 (<1)	0	0	0
弛緩歯	0	1 (<1)	0	0
腰ヘルニア	0	0	1 (<1)	0
口腔内潰瘍形成	2 (<1)	0	0	0
嚥下痛	0	1 (<1)	0	0
食道出血	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 56 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯肉出血	0	0	0	0
歯肉紅斑	0	0	0	0
歯肉腫脹	0	0	0	0
舌炎	0	0	0	0
舌痛	0	0	0	0
吐血	0	0	0	0
痔出血	0	0	0	0
痔核	0	0	0	0
裂孔ヘルニア	0	0	0	0
胃酸過多	1 (<1)	0	0	0
口の感覚鈍麻	0	1 (<1)	0	0
胃排出不全	0	1 (<1)	0	0
過敏性腸症候群	0	0	0	0
口唇乾燥	1 (<1)	0	0	0
弛緩歯	0	0	0	0
腰ヘルニア	0	0	0	0
口腔内潰瘍形成	0	0	0	0
嚥下痛	0	1 (<1)	0	0
食道出血	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 57 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
食道痙攣	0	0	1 (<1)	0
食道炎	0	2 (<1)	0	0
口腔内痛	0	0	1 (<1)	0
膵臓障害	0	0	1 (<1)	0
膵機能不全	0	0	1 (<1)	0
膵炎	1 (<1)	1 (<1)	0	0
急性膵炎	1 (<1)	0	0	0
口の錯感覚	0	1 (<1)	0	0
消化性潰瘍	0	0	1 (<1)	0
歯周病	0	1 (<1)	0	0
歯周炎	2 (<1)	1 (<1)	3 (<1)	0
腹膜出血	1 (<1)	0	0	0
直腸出血	1 (<1)	0	0	0
直腸攣縮	0	0	0	1 (<1)
逆流性食道炎	1 (<1)	0	0	0
流涎過多	0	3 (<1)	0	0
口内炎	1 (<1)	0	0	0
舌腫脹	0	1 (<1)	0	0
脆弱歯	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 58 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
食道痙攣	0	0	0	0
食道炎	0	0	0	0
口腔内痛	0	0	0	0
膵臓障害	0	0	0	0
膵機能不全	0	0	0	0
膵炎	0	1 (<1)	0	0
急性膵炎	0	0	0	0
口の錯感覚	0	0	0	0
消化性潰瘍	0	0	0	0
歯周病	0	0	0	0
歯周炎	0	0	0	0
腹膜出血	0	0	0	0
直腸出血	0	0	0	0
直腸攣縮	0	0	0	0
逆流性食道炎	1 (<1)	0	0	0
流涎過多	0	2 (<1)	0	0
口内炎	1 (<1)	0	0	0
舌腫脹	0	0	0	0
脆弱歯	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 59 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯の障害	1 (<1)	0	0	0
歯の脱落	1 (<1)	1 (<1)	0	0
歯痛	7 (<1)	8 (1)	11 (1)	2 (<1)
肝胆道系障害	1 (<1)	4 (<1)	12 (2)	0
肝障害	0	2 (<1)	5 (<1)	0
肝細胞融解性肝炎	0	0	2 (<1)	0
胆管結石	0	0	1 (<1)	0
肝炎	0	0	1 (<1)	0
胆石症	1 (<1)	0	1 (<1)	0
胆嚢浮腫	0	0	1 (<1)	0
肝嚢胞	0	1 (<1)	1 (<1)	0
高ビリルビン血症	0	0	1 (<1)	0
高トランスアミナーゼ血症	0	1 (<1)	0	0
皮膚および皮下組織障害	98 (13)	176 (23)	183 (24)	35 (10)
紅斑	3 (<1)	24 (3)	40 (5)	4 (1)
そう痒症	18 (2)	45 (6)	41 (5)	2 (<1)
発疹	16 (2)	41 (5)	37 (5)	5 (1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 60 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯の障害	0	0	0	0
歯の脱落	0	0	0	0
歯痛	1 (<1)	0	0	0
肝胆道系障害	0	2 (<1)	8 (1)	0
肝障害	0	1 (<1)	4 (<1)	0
肝細胞融解性肝炎	0	0	2 (<1)	0
胆管結石	0	0	1 (<1)	0
肝炎	0	0	1 (<1)	0
胆石症	0	0	0	0
胆嚢浮腫	0	0	0	0
肝嚢胞	0	0	0	0
高ビリルビン血症	0	0	0	0
高トランスアミナーゼ血症	0	1 (<1)	0	0
皮膚および皮下組織障害	48 (6)	137 (18)	139 (18)	16 (5)
紅斑	2 (<1)	23 (3)	37 (5)	4 (1)
そう痒症	13 (2)	41 (5)	32 (4)	2 (<1)
発疹	6 (<1)	34 (4)	26 (3)	3 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 61 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
多汗症	6 (<1)	9 (1)	15 (2)	3 (<1)
全身性そう痒症	3 (<1)	5 (<1)	9 (1)	2 (<1)
蕁麻疹	5 (<1)	9 (1)	9 (1)	1 (<1)
皮膚灼熱感	0	4 (<1)	6 (<1)	0
寝汗	7 (<1)	9 (1)	8 (1)	1 (<1)
全身性皮疹	0	2 (<1)	4 (<1)	0
脱毛症	11 (1)	13 (2)	7 (<1)	5 (1)
アレルギー性皮膚炎	2 (<1)	4 (<1)	3 (<1)	0
全身紅斑	0	2 (<1)	3 (<1)	0
光線過敏性反応	1 (<1)	2 (<1)	3 (<1)	0
紅斑性皮疹	0	1 (<1)	3 (<1)	0
斑状皮疹	0	1 (<1)	6 (<1)	0
そう痒性皮疹	2 (<1)	6 (<1)	3 (<1)	0
皮膚炎	3 (<1)	1 (<1)	4 (<1)	0
皮膚乾燥	3 (<1)	4 (<1)	4 (<1)	1 (<1)
皮膚反応	0	1 (<1)	2 (<1)	2 (<1)
ざ瘡	10 (1)	4 (<1)	3 (<1)	2 (<1)
紅色症	0	0	1 (<1)	0
毛孔性角化症	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 62 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
多汗症	4 (<1)	6 (<1)	11 (1)	3 (<1)
全身性そう痒症	3 (<1)	5 (<1)	8 (1)	1 (<1)
蕁麻疹	0	7 (<1)	7 (<1)	0
皮膚灼熱感	0	4 (<1)	6 (<1)	0
寝汗	3 (<1)	6 (<1)	4 (<1)	0
全身性皮疹	0	2 (<1)	4 (<1)	0
脱毛症	5 (<1)	7 (<1)	3 (<1)	1 (<1)
アレルギー性皮膚炎	1 (<1)	3 (<1)	3 (<1)	0
全身紅斑	0	2 (<1)	3 (<1)	0
光線過敏性反応	1 (<1)	1 (<1)	3 (<1)	0
紅斑性皮疹	0	1 (<1)	3 (<1)	0
斑状皮疹	0	0	3 (<1)	0
そう痒性皮疹	1 (<1)	4 (<1)	3 (<1)	0
皮膚炎	2 (<1)	0	2 (<1)	0
皮膚乾燥	1 (<1)	4 (<1)	2 (<1)	0
皮膚反応	0	1 (<1)	2 (<1)	1 (<1)
ざ瘡	4 (<1)	1 (<1)	1 (<1)	0
紅色症	0	0	1 (<1)	0
毛孔性角化症	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 63 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
皮膚疼痛	0	0	2 (<1)	0
痒疹	0	2 (<1)	1 (<1)	0
アレルギー性そう痒症	2 (<1)	1 (<1)	1 (<1)	0
乾癬	2 (<1)	0	2 (<1)	1 (<1)
皮膚色素脱失	0	0	1 (<1)	0
皮膚のつっぱり感	0	0	2 (<1)	0
皮膚熱感	0	1 (<1)	1 (<1)	0
水疱	0	1 (<1)	0	0
冷汗	1 (<1)	0	0	0
皮膚嚢腫	1 (<1)	0	1 (<1)	0
ざ瘡様皮膚炎	1 (<1)	2 (<1)	0	0
接触性皮膚炎	1 (<1)	0	0	2 (<1)
薬疹	0	1 (<1)	2 (<1)	0
斑状出血	2 (<1)	0	2 (<1)	1 (<1)
湿疹	4 (<1)	2 (<1)	2 (<1)	1 (<1)
剥脱性発疹	1 (<1)	1 (<1)	0	0
皮下出血	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0
紅色汗疹	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 64 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
皮膚疼痛	0	0	1 (<1)	0
痒疹	0	1 (<1)	1 (<1)	0
アレルギー性そう痒症	1 (<1)	1 (<1)	1 (<1)	0
乾癬	1 (<1)	0	1 (<1)	1 (<1)
皮膚色素脱失	0	0	1 (<1)	0
皮膚のつっぱり感	0	0	1 (<1)	0
皮膚熱感	0	1 (<1)	1 (<1)	0
水疱	0	0	0	0
冷汗	0	0	0	0
皮膚嚢腫	0	0	0	0
ざ瘡様皮膚炎	0	1 (<1)	0	0
接触性皮膚炎	0	0	0	0
薬疹	0	1 (<1)	0	0
斑状出血	1 (<1)	0	0	0
湿疹	1 (<1)	1 (<1)	0	0
剥脱性発疹	1 (<1)	0	0	0
皮下出血	0	0	0	0
毛質異常	1 (<1)	0	0	0
紅色汗疹	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 65 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過角化	0	0	1 (<1)	0
掌蹠角化症	0	1 (<1)	0	0
顔面感覚鈍麻	2 (<1)	1 (<1)	1 (<1)	0
内出血発生の増加傾向	0	0	1 (<1)	0
黒子	1 (<1)	0	0	0
網状皮斑	0	0	1 (<1)	1 (<1)
爪床障害	1 (<1)	0	0	0
爪変色	0	1 (<1)	0	0
爪破損	0	1 (<1)	0	0
光線性皮膚症	1 (<1)	0	0	0
色素沈着障害	1 (<1)	0	0	0
ばら色粃糠疹	2 (<1)	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0
丘疹性皮疹	0	1 (<1)	0	0
猩紅熱様発疹	1 (<1)	0	0	0
酒さ	0	5 (<1)	0	0
脂腺障害	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 66 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
過角化	0	0	0	0
掌蹠角化症	0	0	0	0
顔面感覚鈍麻	0	0	0	0
内出血発生の増加傾向	0	0	0	0
黒子	0	0	0	0
網状皮斑	0	0	0	0
爪床障害	0	0	0	0
爪変色	0	0	0	0
爪破損	0	1 (<1)	0	0
光線性皮膚症	1 (<1)	0	0	0
色素沈着障害	0	0	0	0
ばら色粃糠疹	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0
丘疹性皮疹	0	1 (<1)	0	0
猩紅熱様発疹	0	0	0	0
酒さ	0	1 (<1)	0	0
脂腺障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 67 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脂漏性皮膚炎	0	0	0	1 (<1)
皮膚障害	1 (<1)	0	0	0
皮膚剥脱	0	1 (<1)	1 (<1)	0
皮膚色素過剰	1 (<1)	2 (<1)	0	0
皮膚色素減少	0	1 (<1)	0	0
皮膚硬結	0	0	0	2 (<1)
皮膚刺激	1 (<1)	1 (<1)	1 (<1)	1 (<1)
皮膚病変	1 (<1)	0	0	0
皮膚小結節	0	0	0	1 (<1)
皮下結節	0	1 (<1)	0	1 (<1)
顔面腫脹	1 (<1)	0	0	2 (<1)
裂毛	1 (<1)	0	0	0
乾皮症	1 (<1)	0	1 (<1)	0
筋骨格系および結合組織障害	138 (18)	127 (17)	125 (16)	41 (12)
関節痛	25 (3)	28 (4)	23 (3)	4 (1)
背部痛	39 (5)	44 (6)	33 (4)	13 (4)
筋痙縮	17 (2)	10 (1)	18 (2)	4 (1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 68 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脂漏性皮膚炎	0	0	0	0
皮膚障害	1 (<1)	0	0	0
皮膚剥脱	0	0	0	0
皮膚色素過剰	0	2 (<1)	0	0
皮膚色素減少	0	0	0	0
皮膚硬結	0	0	0	1 (<1)
皮膚刺激	1 (<1)	0	0	0
皮膚病変	1 (<1)	0	0	0
皮膚小結節	0	0	0	1 (<1)
皮下結節	0	1 (<1)	0	1 (<1)
顔面腫脹	1 (<1)	0	0	2 (<1)
裂毛	1 (<1)	0	0	0
乾皮症	0	0	0	0
筋骨格系および結合組織障害	17 (2)	15 (2)	24 (3)	5 (1)
関節痛	2 (<1)	5 (<1)	5 (<1)	0
背部痛	3 (<1)	1 (<1)	5 (<1)	1 (<1)
筋痙縮	2 (<1)	4 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 69 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
筋肉痛	16 (2)	7 (<1)	10 (1)	3 (<1)
四肢痛	28 (4)	25 (3)	23 (3)	10 (3)
頚部痛	9 (1)	8 (1)	6 (<1)	2 (<1)
関節炎	0	2 (<1)	3 (<1)	0
骨痛	1 (<1)	1 (<1)	1 (<1)	0
側腹部痛	1 (<1)	0	3 (<1)	0
四肢不快感	0	0	1 (<1)	0
筋緊張	0	1 (<1)	1 (<1)	0
筋力低下	18 (2)	6 (<1)	9 (1)	5 (1)
筋骨格系胸痛	2 (<1)	1 (<1)	3 (<1)	0
関節障害	0	1 (<1)	0	0
腋窩腫瘤	0	1 (<1)	0	0
滑液包炎	1 (<1)	2 (<1)	2 (<1)	0
尾骨痛	0	0	1 (<1)	0
外骨腫	0	0	0	1 (<1)
成長痛	0	0	1 (<1)	1 (<1)
椎間板変性症	0	0	1 (<1)	0
関節硬直	0	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 70 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
筋肉痛	5 (<1)	2 (<1)	4 (<1)	1 (<1)
四肢痛	2 (<1)	3 (<1)	4 (<1)	0
頚部痛	0	0	2 (<1)	0
関節炎	0	0	1 (<1)	0
骨痛	0	0	1 (<1)	0
側腹部痛	1 (<1)	0	1 (<1)	0
四肢不快感	0	0	1 (<1)	0
筋緊張	0	0	1 (<1)	0
筋力低下	2 (<1)	0	1 (<1)	1 (<1)
筋骨格系胸痛	0	0	1 (<1)	0
関節障害	0	0	0	0
腋窩腫瘤	0	0	0	0
滑液包炎	0	0	0	0
尾骨痛	0	0	0	0
外骨腫	0	0	0	0
成長痛	0	0	0	1 (<1)
椎間板変性症	0	0	0	0
関節硬直	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 71 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
関節腫脹	1 (<1)	3 (<1)	0	0
筋拘縮	1 (<1)	0	1 (<1)	1 (<1)
筋肉疲労	1 (<1)	0	0	0
筋攣縮	1 (<1)	0	0	0
筋骨格不快感	2 (<1)	0	1 (<1)	0
筋骨格痛	12 (2)	5 (<1)	8 (1)	3 (<1)
筋骨格硬直	3 (<1)	2 (<1)	3 (<1)	4 (1)
ミオキミア	0	0	1 (<1)	0
筋炎	0	0	1 (<1)	0
変形性関節症	2 (<1)	1 (<1)	0	0
骨端症	0	0	1 (<1)	0
骨減少症	0	0	1 (<1)	0
骨粗鬆症	0	1 (<1)	0	0
顎痛	1 (<1)	0	0	0
関節周囲炎	1 (<1)	1 (<1)	0	0
足底筋膜炎	1 (<1)	0	0	0
関節リウマチ	1 (<1)	0	0	0
肩回旋筋腱板症候群	2 (<1)	0	0	0
重感	2 (<1)	4 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 72 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
関節腫脹	0	1 (<1)	0	0
筋拘縮	1 (<1)	0	0	0
筋肉疲労	0	0	0	0
筋攣縮	1 (<1)	0	0	0
筋骨格不快感	0	0	0	0
筋骨格痛	0	0	0	0
筋骨格硬直	0	0	0	0
ミオキミア	0	0	0	0
筋炎	0	0	0	0
変形性関節症	0	0	0	0
骨端症	0	0	0	0
骨減少症	0	0	0	0
骨粗鬆症	0	0	0	0
顎痛	0	0	0	0
関節周囲炎	0	0	0	0
足底筋膜炎	0	0	0	0
関節リウマチ	0	0	0	0
肩回旋筋腱板症候群	0	0	0	0
重感	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 73 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脊柱変形	1 (<1)	0	0	0
変形性脊椎症	0	0	1 (<1)	0
腱炎	2 (<1)	2 (<1)	2 (<1)	0
腱鞘炎	1 (<1)	1 (<1)	1 (<1)	0
斜頚	1 (<1)	0	0	0
腎および尿路障害	69 (9)	73 (9)	95 (13)	24 (7)
蛋白尿	31 (4)	31 (4)	43 (6)	11 (3)
ミクロアルブミン尿	10 (1)	14 (2)	14 (2)	5 (1)
血尿	17 (2)	15 (2)	23 (3)	4 (1)
ケトン尿	4 (<1)	3 (<1)	10 (1)	0
排尿困難	3 (<1)	2 (<1)	6 (<1)	1 (<1)
頻尿	5 (<1)	2 (<1)	3 (<1)	3 (<1)
慢性腎不全	0	0	1 (<1)	0
腎臓痛	1 (<1)	1 (<1)	2 (<1)	0
アルブミン尿	0	0	0	1 (<1)
膀胱憩室	1 (<1)	0	0	0
膀胱機能障害	1 (<1)	2 (<1)	1 (<1)	0
出血性膀胱炎	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 74 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脊柱変形	0	0	0	0
変形性脊椎症	0	0	0	0
腱炎	0	0	0	0
腱鞘炎	0	0	0	0
斜頚	0	0	0	0
腎および尿路障害	25 (3)	27 (4)	29 (4)	4 (1)
蛋白尿	13 (2)	11 (1)	16 (2)	2 (<1)
ミクロアルブミン尿	4 (<1)	8 (1)	6 (<1)	2 (<1)
血尿	6 (<1)	3 (<1)	5 (<1)	0
ケトン尿	2 (<1)	3 (<1)	4 (<1)	0
排尿困難	0	0	1 (<1)	0
頻尿	1 (<1)	0	1 (<1)	0
慢性腎不全	0	0	1 (<1)	0
腎臓痛	1 (<1)	0	1 (<1)	0
アルブミン尿	0	0	0	0
膀胱憩室	0	0	0	0
膀胱機能障害	0	0	0	0
出血性膀胱炎	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 75 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
非感染性膀胱炎	1 (<1)	1 (<1)	1 (<1)	0
糖尿	4 (<1)	1 (<1)	2 (<1)	0
緊張性膀胱	0	1 (<1)	0	0
失禁	0	0	1 (<1)	0
白血球尿	1 (<1)	0	3 (<1)	1 (<1)
排尿異常	0	1 (<1)	0	0
尿意切迫	4 (<1)	4 (<1)	4 (<1)	3 (<1)
腎結石症	1 (<1)	2 (<1)	2 (<1)	1 (<1)
神経因性膀胱	0	0	1 (<1)	0
夜間頻尿	1 (<1)	0	0	0
起立性蛋白尿症	0	1 (<1)	0	0
腎仙痛	0	0	1 (<1)	0
有痛性排尿困難	0	1 (<1)	0	0
切迫性尿失禁	0	0	3 (<1)	1 (<1)
排尿躊躇	1 (<1)	0	2 (<1)	0
尿失禁	1 (<1)	4 (<1)	2 (<1)	0
尿閉	2 (<1)	1 (<1)	0	1 (<1)
尿臭異常	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 76 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
非感染性膀胱炎	0	0	0	0
糖尿	2 (<1)	0	0	0
緊張性膀胱	0	0	0	0
失禁	0	0	0	0
白血球尿	1 (<1)	0	0	0
排尿異常	0	0	0	0
尿意切迫	0	0	0	0
腎結石症	0	0	0	0
神経因性膀胱	0	0	0	0
夜間頻尿	0	0	0	0
起立性蛋白尿症	0	0	0	0
腎仙痛	0	0	0	0
有痛性排尿困難	0	0	0	0
切迫性尿失禁	0	0	0	0
排尿躊躇	0	0	0	0
尿失禁	0	1 (<1)	0	0
尿閉	0	0	0	0
尿臭異常	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 77 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
妊娠、産褥および周産期の状態	1 (<1)	0	0	0
自然流産	1 (<1)	0	0	0
生殖系および乳房障害	38 (5)	40 (5)	40 (5)	14 (4)
無月経	3 (<1)	3 (<1)	4 (<1)	2 (<1)
勃起不全	4 (<1)	2 (<1)	3 (<1)	0
月経障害	1 (<1)	1 (<1)	2 (<1)	1 (<1)
不規則月経	4 (<1)	2 (<1)	4 (<1)	3 (<1)
月経過多	4 (<1)	1 (<1)	1 (<1)	0
月経遅延	2 (<1)	2 (<1)	1 (<1)	1 (<1)
頻発月経	0	2 (<1)	1 (<1)	1 (<1)
閉経後出血	1 (<1)	0	1 (<1)	0
腺筋症	0	0	1 (<1)	0
萎縮性外陰腟炎	0	0	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0
乳房嚢胞	1 (<1)	1 (<1)	0	1 (<1)
乳房障害	0	1 (<1)	0	0
乳房腫大	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 78 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
妊娠、産褥および周産期の状態	0	0	0	0
自然流産	0	0	0	0
生殖系および乳房障害	12 (2)	9 (1)	12 (2)	4 (1)
無月経	2 (<1)	0	3 (<1)	0
勃起不全	3 (<1)	0	2 (<1)	0
月経障害	0	0	2 (<1)	0
不規則月経	1 (<1)	0	2 (<1)	0
月経過多	0	0	1 (<1)	0
月経遅延	0	1 (<1)	1 (<1)	1 (<1)
頻発月経	0	2 (<1)	1 (<1)	1 (<1)
閉経後出血	1 (<1)	0	1 (<1)	0
腺筋症	0	0	0	0
萎縮性外陰腟炎	0	0	0	0
バルトリン嚢腫	0	0	0	0
乳房嚢胞	0	0	0	0
乳房障害	0	0	0	0
乳房腫大	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 79 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房出血	0	1 (<1)	0	0
乳房腫瘤	1 (<1)	0	0	0
乳房痛	0	1 (<1)	1 (<1)	0
乳房圧痛	0	0	2 (<1)	0
子宮頚部上皮異形成	0	1 (<1)	0	0
子宮頚管ポリープ	0	0	0	1 (<1)
月経困難症	6 (<1)	8 (1)	10 (1)	2 (<1)
射精障害	0	1 (<1)	0	0
子宮内膜増殖症	0	1 (<1)	0	0
子宮内膜症	0	1 (<1)	0	0
生殖器病変	1 (<1)	0	0	0
機能性子宮出血	0	0	0	1 (<1)
閉経期症状	1 (<1)	1 (<1)	0	0
不正子宮出血	2 (<1)	4 (<1)	3 (<1)	3 (<1)
乳頭障害	0	1 (<1)	0	0
希発月経	1 (<1)	1 (<1)	0	0
卵巣嚢胞	0	3 (<1)	1 (<1)	1 (<1)
卵巣嚢胞破裂	1 (<1)	1 (<1)	0	0
骨盤痛	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 80 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房出血	0	0	0	0
乳房腫瘤	0	0	0	0
乳房痛	0	1 (<1)	0	0
乳房圧痛	0	0	0	0
子宮頚部上皮異形成	0	0	0	0
子宮頚管ポリープ	0	0	0	0
月経困難症	2 (<1)	2 (<1)	0	0
射精障害	0	1 (<1)	0	0
子宮内膜増殖症	0	0	0	0
子宮内膜症	0	0	0	0
生殖器病変	1 (<1)	0	0	0
機能性子宮出血	0	0	0	0
閉経期症状	0	0	0	0
不正子宮出血	0	1 (<1)	0	2 (<1)
乳頭障害	0	0	0	0
希発月経	1 (<1)	1 (<1)	0	0
卵巣嚢胞	0	0	0	0
卵巣嚢胞破裂	0	0	0	0
骨盤痛	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 81 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
多嚢胞性卵巣	0	1 (<1)	0	0
性機能不全	0	1 (<1)	0	0
精巣障害	0	0	1 (<1)	0
子宮頚部びらん	1 (<1)	0	0	0
子宮出血	1 (<1)	0	1 (<1)	0
子宮ポリープ	1 (<1)	1 (<1)	0	0
腟出血	2 (<1)	2 (<1)	3 (<1)	0
外陰腟乾燥	0	0	1 (<1)	0
外陰腟痛	1 (<1)	0	0	0
先天性、家族性および遺伝性障害	0	1 (<1)	0	1 (<1)
異形成母斑症候群	0	1 (<1)	0	0
過誤腫	0	0	0	1 (<1)
一般・全身障害および投与部位の状態	103 (13)	102 (13)	118 (16)	108 (31)
疲労	42 (5)	52 (7)	51 (7)	19 (5)
熱感	2 (<1)	11 (1)	9 (1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 82 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
多嚢胞性卵巣	0	0	0	0
性機能不全	0	0	0	0
精巣障害	0	0	0	0
子宮頚部びらん	0	0	0	0
子宮出血	0	0	0	0
子宮ポリープ	0	0	0	0
腟出血	0	1 (<1)	0	0
外陰腟乾燥	0	0	0	0
外陰腟痛	0	0	0	0
先天性、家族性および遺伝性障害	0	0	0	0
異形成母斑症候群	0	0	0	0
過誤腫	0	0	0	0
一般・全身障害および投与部位の状態	26 (3)	46 (6)	45 (6)	91 (26)
疲労	11 (1)	20 (3)	18 (2)	5 (1)
熱感	2 (<1)	8 (1)	8 (1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 83 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
発熱	10 (1)	11 (1)	22 (3)	7 (2)
胸痛	7 (<1)	4 (<1)	6 (<1)	2 (<1)
無力症	9 (1)	17 (2)	10 (1)	7 (2)
胸部不快感	3 (<1)	2 (<1)	3 (<1)	0
悪寒	3 (<1)	1 (<1)	3 (<1)	3 (<1)
インフルエンザ様疾患	7 (<1)	2 (<1)	4 (<1)	3 (<1)
倦怠感	0	2 (<1)	3 (<1)	1 (<1)
不快感	0	0	1 (<1)	0
顔面痛	2 (<1)	1 (<1)	2 (<1)	0
冷感	1 (<1)	0	2 (<1)	0
びくびく感	0	0	1 (<1)	0
歩行障害	6 (<1)	2 (<1)	2 (<1)	3 (<1)
重力性浮腫	0	0	1 (<1)	0
易刺激性	3 (<1)	3 (<1)	2 (<1)	2 (<1)
粘膜乾燥	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	0
圧痛	0	0	2 (<1)	0
口渇	0	0	1 (<1)	0
嚢胞	0	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 84 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
発熱	2 (<1)	2 (<1)	5 (<1)	5 (1)
胸痛	0	1 (<1)	3 (<1)	2 (<1)
無力症	3 (<1)	8 (1)	2 (<1)	5 (1)
胸部不快感	1 (<1)	2 (<1)	2 (<1)	0
悪寒	0	1 (<1)	2 (<1)	2 (<1)
インフルエンザ様疾患	2 (<1)	1 (<1)	2 (<1)	2 (<1)
倦怠感	0	1 (<1)	2 (<1)	0
不快感	0	0	1 (<1)	0
顔面痛	0	0	1 (<1)	0
冷感	0	0	1 (<1)	0
びくびく感	0	0	1 (<1)	0
歩行障害	1 (<1)	1 (<1)	1 (<1)	0
重力性浮腫	0	0	1 (<1)	0
易刺激性	1 (<1)	0	1 (<1)	1 (<1)
粘膜乾燥	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	0
圧痛	0	0	1 (<1)	0
口渇	0	0	1 (<1)	0
嚢胞	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 85 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嚢胞破裂	0	0	0	1 (<1)
脂肪壊死	0	1 (<1)	0	0
異常感	1 (<1)	0	1 (<1)	1 (<1)
全身症状	1 (<1)	0	0	0
空腹	1 (<1)	0	0	0
高熱	1 (<1)	1 (<1)	0	0
注射直後反応	0	0	0	2 (<1)
注射部位変色	0	0	0	1 (<1)
注射部位乾燥	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	1 (<1)
注射部位紅斑	0	0	0	30 (9)
注射部位血管外漏出	0	0	0	1 (<1)
注射部位血腫	0	0	1 (<1)	5 (1)
注射部位出血	0	0	0	2 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 86 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嚢胞破裂	0	0	0	0
脂肪壊死	0	0	0	0
異常感	1 (<1)	0	0	0
全身症状	0	0	0	0
空腹	1 (<1)	0	0	0
高熱	0	1 (<1)	0	0
注射直後反応	0	0	0	2 (<1)
注射部位変色	0	0	0	1 (<1)
注射部位乾燥	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	1 (<1)
注射部位紅斑	0	0	0	29 (8)
注射部位血管外漏出	0	0	0	1 (<1)
注射部位血腫	0	0	0	5 (1)
注射部位出血	0	0	0	2 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 87 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位過敏反応	0	0	0	1 (<1)
注射部位肥厚	0	0	0	1 (<1)
注射部位硬結	0	0	0	7 (2)
注射部位炎症	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	7 (2)
注射部位結節	0	0	0	1 (<1)
注射部位浮腫	0	0	0	3 (<1)
注射部位疼痛	0	0	0	29 (8)
注射部位そう痒感	0	0	0	12 (3)
注射部位発疹	0	0	0	3 (<1)
注射部位反応	0	0	0	3 (<1)
注射部位瘢痕	0	0	0	1 (<1)
注射部位腫脹	0	0	0	9 (3)
注射部位蕁麻疹	0	0	0	3 (<1)
注射部位熱感	0	0	0	3 (<1)
足のもつれ	1 (<1)	0	0	0
医療機器による疼痛	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 88 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位過敏反応	0	0	0	1 (<1)
注射部位肥厚	0	0	0	1 (<1)
注射部位硬結	0	0	0	7 (2)
注射部位炎症	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	6 (2)
注射部位結節	0	0	0	1 (<1)
注射部位浮腫	0	0	0	3 (<1)
注射部位疼痛	0	0	0	27 (8)
注射部位そう痒感	0	0	0	12 (3)
注射部位発疹	0	0	0	3 (<1)
注射部位反応	0	0	0	3 (<1)
注射部位瘢痕	0	0	0	1 (<1)
注射部位腫脹	0	0	0	9 (3)
注射部位蕁麻疹	0	0	0	3 (<1)
注射部位熱感	0	0	0	3 (<1)
足のもつれ	0	0	0	0
医療機器による疼痛	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 89 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
微石症	0	0	0	1 (<1)
非心臓性胸痛	1 (<1)	1 (<1)	4 (<1)	2 (<1)
浮腫	0	1 (<1)	0	1 (<1)
末梢性浮腫	11 (1)	3 (<1)	9 (1)	2 (<1)
疼痛	1 (<1)	8 (1)	5 (<1)	2 (<1)
腫脹	0	2 (<1)	0	0
温度変化不耐症	0	1 (<1)	0	0
ワクチン接種部位疼痛	1 (<1)	0	0	0
血管穿刺部位血腫	0	0	1 (<1)	0
臨床検査	98 (13)	129 (17)	117 (15)	57 (16)
アラニン・アミノトランスフェラーゼ増加	9 (1)	32 (4)	30 (4)	10 (3)
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	21 (3)	19 (3)	6 (2)
尿中アルブミン陽性	11 (1)	20 (3)	15 (2)	5 (1)
尿中蛋白陽性	6 (<1)	14 (2)	10 (1)	10 (3)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 90 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
微石症	0	0	0	0
非心臓性胸痛	0	0	0	1 (<1)
浮腫	0	0	0	1 (<1)
末梢性浮腫	3 (<1)	2 (<1)	0	1 (<1)
疼痛	0	1 (<1)	0	2 (<1)
腫脹	0	2 (<1)	0	0
温度変化不耐症	0	0	0	0
ワクチン接種部位疼痛	0	0	0	0
血管穿刺部位血腫	0	0	0	0
臨床検査	39 (5)	60 (8)	75 (10)	14 (4)
アラニン・アミノトランスフェラーゼ増加	7 (<1)	18 (2)	24 (3)	5 (1)
アスパラギン酸アミノトランスフェラーゼ増加	4 (<1)	10 (1)	13 (2)	5 (1)
尿中アルブミン陽性	5 (<1)	8 (1)	8 (1)	1 (<1)
尿中蛋白陽性	6 (<1)	5 (<1)	8 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 91 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
白血球数減少	1 (<1)	7 (<1)	6 (<1)	0
γ－グルタミルトランスフェラーゼ増加	5 (<1)	7 (<1)	7 (<1)	4 (1)
肝酵素上昇	4 (<1)	7 (<1)	5 (<1)	3 (<1)
体重減少	2 (<1)	8 (1)	8 (1)	1 (<1)
尿中血陽性	1 (<1)	7 (<1)	6 (<1)	4 (1)
体温上昇	1 (<1)	2 (<1)	3 (<1)	1 (<1)
尿中ケトン体陽性	0	4 (<1)	6 (<1)	1 (<1)
体重増加	9 (1)	2 (<1)	4 (<1)	3 (<1)
血中コレステロール増加	1 (<1)	0	4 (<1)	1 (<1)
リンパ球数減少	0	4 (<1)	2 (<1)	1 (<1)
抗痙攣剤濃度減少	0	0	1 (<1)	0
β２ミクログロブリン増加	0	1 (<1)	1 (<1)	0
尿中β２ミクログロブリン増加	4 (<1)	8 (1)	2 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 92 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
白血球数減少	0	2 (<1)	6 (<1)	0
γ－グルタミルトランスフェラーゼ増加	2 (<1)	4 (<1)	5 (<1)	2 (<1)
肝酵素上昇	3 (<1)	4 (<1)	4 (<1)	1 (<1)
体重減少	1 (<1)	5 (<1)	4 (<1)	0
尿中血陽性	1 (<1)	2 (<1)	3 (<1)	0
体温上昇	0	1 (<1)	3 (<1)	0
尿中ケトン体陽性	0	2 (<1)	3 (<1)	0
体重増加	2 (<1)	1 (<1)	3 (<1)	1 (<1)
血中コレステロール増加	0	0	2 (<1)	0
リンパ球数減少	0	3 (<1)	2 (<1)	1 (<1)
抗痙攣剤濃度減少	0	0	1 (<1)	0
β２ミクログロブリン増加	0	0	1 (<1)	0
尿中β２ミクログロブリン増加	1 (<1)	4 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 93 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中クレアチニン増加	1 (<1)	2 (<1)	2 (<1)	3 (<1)
血中ブドウ糖減少	0	0	1 (<1)	1 (<1)
血中ブドウ糖増加	3 (<1)	4 (<1)	6 (<1)	2 (<1)
血中副甲状腺ホルモン増加	3 (<1)	5 (<1)	3 (<1)	1 (<1)
血圧上昇	0	1 (<1)	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	0
血中尿素増加	1 (<1)	0	1 (<1)	1 (<1)
尿中結晶陽性	3 (<1)	0	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	0
好酸球数異常	0	0	1 (<1)	0
ヘマトクリット減少	1 (<1)	2 (<1)	1 (<1)	0
ヘモグロビン減少	2 (<1)	4 (<1)	2 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 94 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中クレアチニン増加	0	0	1 (<1)	1 (<1)
血中ブドウ糖減少	0	0	1 (<1)	0
血中ブドウ糖増加	1 (<1)	0	1 (<1)	0
血中副甲状腺ホルモン増加	2 (<1)	2 (<1)	1 (<1)	0
血圧上昇	0	0	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	0
血中尿素増加	0	0	1 (<1)	0
尿中結晶陽性	1 (<1)	0	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	0
好酸球数異常	0	0	1 (<1)	0
ヘマトクリット減少	0	0	1 (<1)	0
ヘモグロビン減少	0	0	1 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	0
低比重リポ蛋白増加	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 95 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
リンパ球形態異常	0	1 (<1)	1 (<1)	0
呼吸数増加	0	0	1 (<1)	0
尿円柱	0	0	1 (<1)	0
尿中白血球陽性	6 (<1)	4 (<1)	5 (<1)	7 (2)
アラニン・アミノトランスフェラーゼ異常	0	0	0	2 (<1)
動脈雑音	1 (<1)	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	0	0	1 (<1)
細菌検査陽性	1 (<1)	0	1 (<1)	0
血中アルカリホスファターゼ異常	0	0	0	1 (<1)
血中アルカリホスファターゼ増加	1 (<1)	1 (<1)	0	0
血中重炭酸塩減少	1 (<1)	1 (<1)	0	0
血中ビリルビン異常	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 96 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
リンパ球形態異常	0	0	1 (<1)	0
呼吸数増加	0	0	1 (<1)	0
尿円柱	0	0	1 (<1)	0
尿中白血球陽性	0	0	1 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	0	0	1 (<1)
動脈雑音	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	0	0	0
細菌検査陽性	0	0	0	0
血中アルカリホスファターゼ異常	0	0	0	1 (<1)
血中アルカリホスファターゼ増加	1 (<1)	0	0	0
血中重炭酸塩減少	1 (<1)	0	0	0
血中ビリルビン異常	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 97 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中ビリルビン増加	5 (<1)	1 (<1)	1 (<1)	0
血中カルシウム増加	1 (<1)	0	1 (<1)	0
血中クレアチン増加	0	1 (<1)	0	0
血中クレアチニン異常	0	1 (<1)	0	0
血中鉄減少	1 (<1)	0	0	0
血中ケトン体増加	0	0	1 (<1)	0
血中乳酸脱水素酵素異常	0	0	0	1 (<1)
血中乳酸脱水素酵素増加	1 (<1)	2 (<1)	0	0
血中副甲状腺ホルモン減少	1 (<1)	0	0	0
血中リン減少	1 (<1)	0	0	0
血中カリウム減少	2 (<1)	0	1 (<1)	0
血中カリウム増加	0	1 (<1)	1 (<1)	0
血圧低下	0	1 (<1)	0	0
血中ナトリウム増加	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 98 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中ビリルビン増加	2 (<1)	0	0	0
血中カルシウム増加	1 (<1)	0	0	0
血中クレアチン増加	0	1 (<1)	0	0
血中クレアチニン異常	0	0	0	0
血中鉄減少	0	0	0	0
血中ケトン体増加	0	0	0	0
血中乳酸脱水素酵素異常	0	0	0	0
血中乳酸脱水素酵素増加	1 (<1)	1 (<1)	0	0
血中副甲状腺ホルモン減少	0	0	0	0
血中リン減少	1 (<1)	0	0	0
血中カリウム減少	0	0	0	0
血中カリウム増加	0	0	0	0
血圧低下	0	0	0	0
血中ナトリウム増加	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 99 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中トリグリセリド増加	4 (<1)	4 (<1)	3 (<1)	5 (1)
血中尿酸増加	0	0	2 (<1)	0
心雑音	0	1 (<1)	0	0
心電図異常	2 (<1)	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0
心電図ＱＴ延長	0	1 (<1)	0	2 (<1)
心電図ＳＴ部分下降	0	1 (<1)	1 (<1)	1 (<1)
心電図Ｔ波振幅減少	0	0	0	1 (<1)
心電図Ｔ波逆転	0	1 (<1)	0	0
好酸球数増加	1 (<1)	2 (<1)	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	0
大腸菌検査陽性	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 100 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中トリグリセリド増加	0	0	0	0
血中尿酸増加	0	0	0	0
心雑音	0	0	0	0
心電図異常	0	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0
心電図ＱＴ延長	0	1 (<1)	0	1 (<1)
心電図ＳＴ部分下降	0	0	0	0
心電図Ｔ波振幅減少	0	0	0	0
心電図Ｔ波逆転	0	0	0	0
好酸球数増加	1 (<1)	1 (<1)	0	0
好酸球百分率増加	0	1 (<1)	0	0
大腸菌検査陽性	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 101 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
胃内ｐＨ上昇	0	0	1 (<1)	0
尿中ブドウ糖陽性	2 (<1)	1 (<1)	0	0
血液学的検査異常	0	1 (<1)	0	0
心拍数減少	0	0	1 (<1)	0
心拍数増加	1 (<1)	2 (<1)	0	0
心音異常	1 (<1)	0	0	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	0
眼圧上昇	0	1 (<1)	0	0
肝機能検査異常	0	2 (<1)	0	0
リンパ球数異常	0	0	0	1 (<1)
リンパ球数増加	1 (<1)	1 (<1)	0	0
単球数増加	0	0	1 (<1)	0
好中球数異常	0	0	0	1 (<1)
好中球数減少	1 (<1)	4 (<1)	0	1 (<1)
好中球数増加	5 (<1)	3 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 102 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
胃内ｐＨ上昇	0	0	0	0
尿中ブドウ糖陽性	1 (<1)	0	0	0
血液学的検査異常	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	1 (<1)	1 (<1)	0	0
心音異常	1 (<1)	0	0	0
ヒト乳頭腫ウイルス検査陽性	0	0	0	0
眼圧上昇	0	0	0	0
肝機能検査異常	0	2 (<1)	0	0
リンパ球数異常	0	0	0	0
リンパ球数増加	0	1 (<1)	0	0
単球数増加	0	0	0	0
好中球数異常	0	0	0	0
好中球数減少	0	2 (<1)	0	0
好中球数増加	0	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 103 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脳核磁気共鳴画像異常	0	1 (<1)	0	0
血小板数	0	1 (<1)	0	0
血小板数減少	1 (<1)	1 (<1)	0	2 (<1)
血小板数増加	1 (<1)	0	1 (<1)	1 (<1)
ＱＲＳ軸異常	2 (<1)	0	0	0
赤血球数減少	2 (<1)	2 (<1)	0	0
尿中赤血球陽性	2 (<1)	5 (<1)	4 (<1)	1 (<1)
腎機能検査異常	0	1 (<1)	0	0
残尿量増加	0	1 (<1)	0	0
血清フェリチン減少	0	0	1 (<1)	0
トランスアミナーゼ上昇	1 (<1)	0	0	0
尿細胞診異常	1 (<1)	0	0	0
ビタミンＢ１２減少	1 (<1)	1 (<1)	0	0
ビタミンD減少	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 104 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脳核磁気共鳴画像異常	0	0	0	0
血小板数	0	1 (<1)	0	0
血小板数減少	0	0	0	0
血小板数増加	0	0	0	0
ＱＲＳ軸異常	0	0	0	0
赤血球数減少	0	1 (<1)	0	0
尿中赤血球陽性	0	2 (<1)	0	0
腎機能検査異常	0	1 (<1)	0	0
残尿量増加	0	0	0	0
血清フェリチン減少	0	0	0	0
トランスアミナーゼ上昇	0	0	0	0
尿細胞診異常	0	0	0	0
ビタミンＢ１２減少	0	0	0	0
ビタミンＤ減少	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 105 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ビタミンD増加	1 (<1)	0	2 (<1)	0
白血球数異常	0	0	0	1 (<1)
白血球数増加	6 (<1)	4 (<1)	2 (<1)	3 (<1)
傷害、中毒および処置合併症	44 (6)	33 (4)	38 (5)	18 (5)
サンバーン	0	1 (<1)	3 (<1)	0
偶発的過量投与	0	1 (<1)	0	0
動物咬傷	1 (<1)	2 (<1)	0	0
足関節部骨折	0	1 (<1)	1 (<1)	1 (<1)
節足動物咬傷	2 (<1)	1 (<1)	3 (<1)	1 (<1)
節足動物刺傷	0	1 (<1)	0	0
第２度熱傷	1 (<1)	0	0	0
眼部化学的損傷	1 (<1)	0	0	0
凍瘡	1 (<1)	0	0	0
鎖骨骨折	0	1 (<1)	0	0
造影剤反応	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 106 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ビタミンD増加	0	0	0	0
白血球数異常	0	0	0	0
白血球数増加	1 (<1)	2 (<1)	0	0
傷害、中毒および処置合併症	1 (<1)	1 (<1)	1 (<1)	0
サンバーン	0	0	1 (<1)	0
偶発的過量投与	0	1 (<1)	0	0
動物咬傷	0	0	0	0
足関節部骨折	0	0	0	0
節足動物咬傷	0	0	0	0
節足動物刺傷	0	0	0	0
第２度熱傷	0	0	0	0
眼部化学的損傷	0	0	0	0
凍瘡	0	0	0	0
鎖骨骨折	0	0	0	0
造影剤反応	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 107 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
挫傷	7 (<1)	4 (<1)	7 (<1)	4 (1)
角膜擦過傷	1 (<1)	0	0	0
擦過傷	2 (<1)	0	3 (<1)	1 (<1)
顔面損傷	0	0	1 (<1)	1 (<1)
転倒	8 (1)	5 (<1)	9 (1)	6 (2)
大腿骨骨折	0	0	0	1 (<1)
足骨折	0	2 (<1)	1 (<1)	0
手骨折	1 (<1)	0	0	2 (<1)
頭部損傷	1 (<1)	0	0	1 (<1)
切開部位痛	0	1 (<1)	0	0
関節脱臼	0	1 (<1)	0	0
関節損傷	1 (<1)	1 (<1)	2 (<1)	0
関節捻挫	3 (<1)	3 (<1)	3 (<1)	1 (<1)
靱帯損傷	0	0	1 (<1)	0
靱帯断裂	3 (<1)	1 (<1)	0	0
四肢損傷	1 (<1)	3 (<1)	3 (<1)	3 (<1)
半月板障害	1 (<1)	0	0	1 (<1)
筋損傷	1 (<1)	0	0	0
肉離れ	1 (<1)	3 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 108 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
挫傷	0	0	0	0
角膜擦過傷	0	0	0	0
擦過傷	0	0	0	0
顔面損傷	0	0	0	0
転倒	1 (<1)	0	0	0
大腿骨骨折	0	0	0	0
足骨折	0	0	0	0
手骨折	0	0	0	0
頭部損傷	0	0	0	0
切開部位痛	0	0	0	0
関節脱臼	0	0	0	0
関節損傷	0	0	0	0
関節捻挫	0	0	0	0
靭帯損傷	0	0	0	0
靭帯断裂	0	0	0	0
四肢損傷	0	0	0	0
半月板障害	0	0	0	0
筋損傷	0	0	0	0
肉離れ	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 109 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頚部損傷	0	0	0	1 (<1)
処置後出血	0	1 (<1)	0	0
外傷後疼痛	0	0	0	2 (<1)
処置による疼痛	1 (<1)	0	0	0
橈骨骨折	0	0	2 (<1)	1 (<1)
肋骨骨折	0	0	1 (<1)	0
交通事故	2 (<1)	1 (<1)	2 (<1)	1 (<1)
骨格損傷	3 (<1)	0	0	1 (<1)
皮膚裂傷	1 (<1)	1 (<1)	1 (<1)	0
腱損傷	1 (<1)	0	0	0
腱断裂	1 (<1)	0	0	0
熱傷	3 (<1)	1 (<1)	0	1 (<1)
舌損傷	0	1 (<1)	0	0
歯牙破折	0	1 (<1)	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	0
ワクチン接種合併症	1 (<1)	0	1 (<1)	0
有毒性刺傷	1 (<1)	0	0	0
むち打ち損傷	1 (<1)	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 110 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頚部損傷	0	0	0	0
処置後出血	0	0	0	0
外傷後疼痛	0	0	0	0
処置による疼痛	0	0	0	0
橈骨骨折	0	0	0	0
肋骨骨折	0	0	0	0
交通事故	0	0	0	0
骨格損傷	0	0	0	0
皮膚裂傷	0	0	0	0
腱損傷	0	0	0	0
腱断裂	0	0	0	0
熱傷	0	0	0	0
舌損傷	0	0	0	0
歯牙破折	0	0	0	0
外傷性脳損傷	0	0	0	0
ワクチン接種合併症	0	0	0	0
有毒性刺傷	0	0	0	0
むち打ち損傷	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 111 of 112

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
創傷	1 (<1)	0	0	0
手首関節骨折	1 (<1)	0	1 (<1)	0
外科および内科処置	4 (<1)	2 (<1)	1 (<1)	2 (<1)
子宮頚部円錐切除	1 (<1)	0	0	0
嚢胞ドレナージ	1 (<1)	0	0	0
子宮摘出	0	0	1 (<1)	0
治療食	0	1 (<1)	0	0
色素性母斑切除	1 (<1)	0	0	0
不妊手術	0	0	0	1 (<1)
抜歯	1 (<1)	1 (<1)	0	1 (<1)
社会環境	1 (<1)	1 (<1)	0	0
元タバコ使用者	1 (<1)	0	0	0
閉経	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
24 Weeks of Studies 109MS301 and 109MS302
Page 112 of 112

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
創傷	0	0	0	0
手首関節骨折	0	0	0	0
外科および内科処置	0	0	0	0
子宮頚部円錐切除	0	0	0	0
嚢胞ドレナージ	0	0	0	0
子宮摘出	0	0	0	0
治療食	0	0	0	0
色素性母斑切除	0	0	0	0
不妊手術	0	0	0	0
抜歯	0	0	0	0
社会環境	0	0	0	0
元タバコ使用者	0	0	0	0
閉経	0	0	0	0

NOTE 1: Numbers in parentheses are percentages
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A-24W.SAS DATE: 02DEC2015

Table 100: Incidence of Adverse Events At Least 2% Higher in Any Treatment Group by System Organ Class and Preferred Term and Causal Association to Study Drug: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 1 of 10

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	614 (80)	650 (85)	658 (87)	246 (70)
感染症および寄生虫症	184 (24)	212 (28)	209 (28)	61 (17)
鼻咽頭炎	70 (9)	71 (9)	80 (11)	24 (7)
尿路感染	40 (5)	61 (8)	43 (6)	22 (6)
胃腸炎	10 (1)	18 (2)	13 (2)	1 (<1)
インフルエンザ	27 (4)	27 (4)	29 (4)	2 (<1)
気管支炎	10 (1)	17 (2)	17 (2)	7 (2)
副鼻腔炎	7 (<1)	11 (1)	16 (2)	2 (<1)
上気道感染	44 (6)	43 (6)	46 (6)	8 (2)
精神障害	56 (7)	43 (6)	43 (6)	21 (6)
不眠症	16 (2)	10 (1)	13 (2)	6 (2)
うつ病	33 (4)	23 (3)	19 (3)	13 (4)
不安	16 (2)	16 (2)	14 (2)	4 (1)
神経系障害	257 (33)	201 (26)	200 (26)	90 (26)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term
and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 2 of 10

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	247 (32)	484 (63)	486 (64)	128 (36)
感染症および寄生虫症	19 (2)	26 (3)	29 (4)	5 (1)
鼻咽頭炎	8 (1)	8 (1)	12 (2)	1 (<1)
尿路感染	3 (<1)	7 (<1)	6 (<1)	3 (<1)
胃腸炎	2 (<1)	4 (<1)	5 (<1)	0
インフルエンザ	3 (<1)	1 (<1)	5 (<1)	0
気管支炎	2 (<1)	0	2 (<1)	0
副鼻腔炎	0	0	1 (<1)	0
上気道感染	4 (<1)	9 (1)	1 (<1)	1 (<1)
精神障害	7 (<1)	8 (1)	10 (1)	2 (<1)
不眠症	2 (<1)	2 (<1)	6 (<1)	1 (<1)
うつ病	4 (<1)	3 (<1)	4 (<1)	1 (<1)
不安	1 (<1)	4 (<1)	0	0
神経系障害	49 (6)	58 (8)	55 (7)	12 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 3 of 10

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頭痛	88 (11)	84 (11)	80 (11)	33 (9)
錯感覚	27 (4)	29 (4)	28 (4)	4 (1)
多発性硬化症再発	165 (21)	104 (14)	96 (13)	56 (16)
浮動性めまい	17 (2)	13 (2)	15 (2)	7 (2)
感覚鈍麻	20 (3)	15 (2)	15 (2)	8 (2)
耳および迷路障害	24 (3)	13 (2)	14 (2)	6 (2)
回転性めまい	24 (3)	13 (2)	14 (2)	6 (2)
血管障害	37 (5)	267 (35)	232 (31)	8 (2)
潮紅	27 (4)	231 (30)	199 (26)	3 (<1)
ほてり	10 (1)	39 (5)	41 (5)	5 (1)
呼吸器、胸郭および縦隔障害	30 (4)	30 (4)	28 (4)	8 (2)
咳嗽	18 (2)	18 (2)	11 (1)	3 (<1)
口腔咽頭痛	13 (2)	15 (2)	18 (2)	5 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term
and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 4 of 10

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頭痛	34 (4)	40 (5)	34 (4)	6 (2)
錯感覚	4 (<1)	8 (1)	13 (2)	1 (<1)
多発性硬化症再発	7 (<1)	6 (<1)	6 (<1)	1 (<1)
浮動性めまい	8 (1)	8 (1)	5 (<1)	4 (1)
感覚鈍麻	2 (<1)	1 (<1)	1 (<1)	2 (<1)
耳および迷路障害	3 (<1)	4 (<1)	4 (<1)	0
回転性めまい	3 (<1)	4 (<1)	4 (<1)	0
血管障害	35 (5)	257 (33)	221 (29)	6 (2)
潮紅	25 (3)	224 (29)	190 (25)	3 (<1)
ほてり	10 (1)	35 (5)	38 (5)	3 (<1)
呼吸器、胸郭および縦隔障害	1 (<1)	3 (<1)	2 (<1)	1 (<1)
咳嗽	1 (<1)	2 (<1)	1 (<1)	0
口腔咽頭痛	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 5 of 10

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
胃腸障害	150 (19)	240 (31)	259 (34)	20 (6)
下痢	49 (6)	78 (10)	102 (13)	4 (1)
悪心	51 (7)	75 (10)	86 (11)	10 (3)
上腹部痛	29 (4)	58 (8)	61 (8)	2 (<1)
腹痛	26 (3)	55 (7)	44 (6)	2 (<1)
嘔吐	16 (2)	44 (6)	36 (5)	2 (<1)
胃腸障害	5 (<1)	17 (2)	30 (4)	1 (<1)
消化不良	15 (2)	22 (3)	30 (4)	3 (<1)
便秘	18 (2)	15 (2)	19 (3)	3 (<1)
皮膚および皮下組織障害	35 (5)	104 (14)	108 (14)	10 (3)
紅斑	3 (<1)	24 (3)	40 (5)	4 (1)
そう痒症	18 (2)	45 (6)	41 (5)	2 (<1)
発疹	16 (2)	41 (5)	37 (5)	5 (1)
筋骨格系および結合組織障害	114 (15)	102 (13)	99 (13)	33 (9)
関節痛	25 (3)	28 (4)	23 (3)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 6 of 10

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
胃腸障害	91 (12)	186 (24)	211 (28)	10 (3)
下痢	25 (3)	56 (7)	75 (10)	1 (<1)
悪心	35 (5)	66 (9)	74 (10)	7 (2)
上腹部痛	22 (3)	55 (7)	56 (7)	2 (<1)
腹痛	19 (2)	41 (5)	35 (5)	1 (<1)
嘔吐	7 (<1)	29 (4)	29 (4)	2 (<1)
胃腸障害	4 (<1)	16 (2)	27 (4)	0
消化不良	9 (1)	18 (2)	22 (3)	0
便秘	7 (<1)	9 (1)	7 (<1)	0
皮膚および皮下組織障害	20 (3)	92 (12)	87 (11)	8 (2)
紅斑	2 (<1)	23 (3)	37 (5)	4 (1)
そう痒症	13 (2)	41 (5)	32 (4)	2 (<1)
発疹	6 (<1)	34 (4)	26 (3)	3 (<1)
筋骨格系および結合組織障害	14 (2)	14 (2)	19 (3)	4 (1)
関節痛	2 (<1)	5 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term
and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 7 of 10

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
背部痛	39 (5)	44 (6)	33 (4)	13 (4)
筋痙縮	17 (2)	10 (1)	18 (2)	4 (1)
筋肉痛	16 (2)	7 (<1)	10 (1)	3 (<1)
四肢痛	28 (4)	25 (3)	23 (3)	10 (3)
筋力低下	18 (2)	6 (<1)	9 (1)	5 (1)
腎および尿路障害	44 (6)	43 (6)	55 (7)	14 (4)
蛋白尿	31 (4)	31 (4)	43 (6)	11 (3)
血尿	17 (2)	15 (2)	23 (3)	4 (1)
一般・全身障害および投与部位の状態	59 (8)	73 (9)	77 (10)	76 (22)
疲労	42 (5)	52 (7)	51 (7)	19 (5)
発熱	10 (1)	11 (1)	22 (3)	7 (2)
無力症	9 (1)	17 (2)	10 (1)	7 (2)
注射部位紅斑	0	0	0	30 (9)
注射部位疼痛	0	0	0	29 (8)
注射部位そう痒感	0	0	0	12 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term
and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 8 of 10

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
背部痛	3 (<1)	1 (<1)	5 (<1)	1 (<1)
筋痙縮	2 (<1)	4 (<1)	4 (<1)	1 (<1)
筋肉痛	5 (<1)	2 (<1)	4 (<1)	1 (<1)
四肢痛	2 (<1)	3 (<1)	4 (<1)	0
筋力低下	2 (<1)	0	1 (<1)	1 (<1)
腎および尿路障害	19 (2)	14 (2)	18 (2)	2 (<1)
蛋白尿	13 (2)	11 (1)	16 (2)	2 (<1)
血尿	6 (<1)	3 (<1)	5 (<1)	0
一般・全身障害および投与部位の状態	15 (2)	30 (4)	24 (3)	64 (18)
疲労	11 (1)	20 (3)	18 (2)	5 (1)
発熱	2 (<1)	2 (<1)	5 (<1)	5 (1)
無力症	3 (<1)	8 (1)	2 (<1)	5 (1)
注射部位紅斑	0	0	0	29 (8)
注射部位疼痛	0	0	0	27 (8)
注射部位そう痒感	0	0	0	12 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 9 of 10

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位腫脹	0	0	0	9 (3)
臨床検査	26 (3)	60 (8)	53 (7)	24 (7)
アラニン・アミノトランスフェラーゼ増加	9 (1)	32 (4)	30 (4)	10 (3)
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	21 (3)	19 (3)	6 (2)
尿中アルブミン陽性	11 (1)	20 (3)	15 (2)	5 (1)
尿中蛋白陽性	6 (<1)	14 (2)	10 (1)	10 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher in any treatment group by system organ class and preferred term and causal association to study drug: 24 Weeks of Studies 109MS301 and 109MS302
Page 10 of 10

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位腫脹	0	0	0	9 (3)
臨床検査	19 (2)	30 (4)	37 (5)	8 (2)
アラニン・アミノトランスフェラーゼ増加	7 (<1)	18 (2)	24 (3)	5 (1)
アスパラギン酸アミノトランスフェラーゼ増加	4 (<1)	10 (1)	13 (2)	5 (1)
尿中アルブミン陽性	5 (<1)	8 (1)	8 (1)	1 (<1)
尿中蛋白陽性	6 (<1)	5 (<1)	8 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS2-A-24W.SAS DATE: 02DEC2015

Table 101: Incidence of Serious Adverse Events by System Organ Class and Preferred Term: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 1 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with a serious event	67 (9)	55 (7)	51 (7)	106 (7)	25 (7)
感染症および寄生虫症	5 (<1)	5 (<1)	8 (1)	13 (<1)	2 (<1)
胃腸炎	0	4 (<1)	2 (<1)	6 (<1)	0
尿路感染	0	0	2 (<1)	2 (<1)	0
虫垂炎	0	1 (<1)	0	1 (<1)	1 (<1)
蜂巣炎	0	0	1 (<1)	1 (<1)	0
ウイルス性胃腸炎	0	0	1 (<1)	1 (<1)	0
副鼻腔炎	0	0	1 (<1)	1 (<1)	0
ウイルス感染	0	0	1 (<1)	1 (<1)	1 (<1)
外陰部膿瘍	0	0	1 (<1)	1 (<1)	0
ボレリア感染	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0
鼻咽頭炎	1 (<1)	0	0	0	0
肺炎	1 (<1)	0	0	0	0
気管炎	1 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
肺の良性新生物	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 2 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
線維腫	1 (<1)	0	0	0	0
血管腫	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	1 (<1)	0	0	0	0
貧血	1 (<1)	0	0	0	0
免疫系障害	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)
過敏症	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)
内分泌障害	0	0	2 (<1)	2 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
甲状腺腫	0	0	1 (<1)	1 (<1)	0
代謝および栄養障害	1 (<1)	0	1 (<1)	1 (<1)	0
脱水	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0
精神障害	3 (<1)	1 (<1)	0	1 (<1)	2 (<1)
躁病	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 3 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
不安	1 (<1)	0	0	0	0
うつ病	1 (<1)	0	0	0	1 (<1)
自殺念慮	1 (<1)	0	0	0	1 (<1)
神経系障害	48 (6)	37 (5)	28 (4)	65 (4)	16 (5)
多発性硬化症再発	45 (6)	37 (5)	26 (3)	63 (4)	14 (4)
頭痛	0	0	2 (<1)	2 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
片頭痛	1 (<1)	0	1 (<1)	1 (<1)	0
失語症	0	0	0	0	1 (<1)
脳血管発作	1 (<1)	0	0	0	0
痙攣	2 (<1)	0	0	0	0
意識消失	0	0	0	0	1 (<1)
部分発作	0	0	0	0	1 (<1)
眼障害	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
耳および迷路障害	0	0	1 (<1)	1 (<1)	0
頭位性回転性めまい	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 4 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓障害	0	0	1 (<1)	1 (<1)	1 (<1)
心不全	0	0	1 (<1)	1 (<1)	0
心筋炎	0	0	0	0	1 (<1)
血管障害	0	1 (<1)	2 (<1)	3 (<1)	0
潮紅	0	1 (<1)	1 (<1)	2 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
胃腸障害	4 (<1)	3 (<1)	4 (<1)	7 (<1)	0
胃炎	0	0	2 (<1)	2 (<1)	0
腹痛	0	1 (<1)	0	1 (<1)	0
便秘	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
胃腸障害	0	1 (<1)	0	1 (<1)	0
胃腸出血	0	0	1 (<1)	1 (<1)	0
大腸炎	1 (<1)	0	0	0	0
悪心	1 (<1)	0	0	0	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
嘔吐	1 (<1)	0	0	0	0
肝胆道系障害	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 5 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胆管結石	0	0	1 (<1)	1 (<1)	0
胆石症	0	0	1 (<1)	1 (<1)	0
皮膚および皮下組織障害	0	0	1 (<1)	1 (<1)	0
そう痒症	0	0	1 (<1)	1 (<1)	0
筋骨格系および結合組織障害	0	0	1 (<1)	1 (<1)	0
背部痛	0	0	1 (<1)	1 (<1)	0
妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
自然流産	1 (<1)	0	0	0	0
生殖系および乳房障害	2 (<1)	2 (<1)	0	2 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
バルトリン嚢腫	1 (<1)	0	0	0	0
子宮出血	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	1 (<1)	0	3 (<1)	3 (<1)	0
発熱	0	0	2 (<1)	2 (<1)	0
非心臓性胸痛	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Incidence of serious adverse events by system organ class and preferred term:
24 weeks of studies 109MS301 and 109MS302
Page 6 of 6

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
無力症	1 (<1)	0	0	0	0
臨床検査	0	0	1 (<1)	1 (<1)	0
血中ブドウ糖増加	0	0	1 (<1)	1 (<1)	0
傷害、中毒および処置合併症	1 (<1)	3 (<1)	3 (<1)	6 (<1)	2 (<1)
交通事故	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
転倒	0	1 (<1)	0	1 (<1)	0
足骨折	0	1 (<1)	0	1 (<1)	0
靭帯断裂	0	1 (<1)	0	1 (<1)	0
橈骨骨折	0	0	1 (<1)	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
手首関節骨折	0	0	1 (<1)	1 (<1)	0
大腿骨骨折	0	0	0	0	1 (<1)
腱断裂	1 (<1)	0	0	0	0
外科および内科処置	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
治療食	0	1 (<1)	0	1 (<1)	0
子宮頚部円錐切除	1 (<1)	0	0	0	0
不妊手術	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SER-A-24.SAS DATE: 02DEC2015

Table 104: Incidence of Adverse Events That Led to Discontinuation of Study Drug by System Organ Class and Preferred Term: 24 Weeks of Studies 109MS301 and 109MS302

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 1 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	37 (5)	75 (10)	79 (10)	154 (10)	19 (5)
感染症および寄生虫症	3 (<1)	1 (<1)	5 (<1)	6 (<1)	0
憩室炎	0	0	1 (<1)	1 (<1)	0
胃腸炎	0	1 (<1)	0	1 (<1)	0
消化管感染	0	0	1 (<1)	1 (<1)	0
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
気道感染	0	0	1 (<1)	1 (<1)	0
尿路感染	0	0	1 (<1)	1 (<1)	0
細菌性心内膜炎	1 (<1)	0	0	0	0
帯状疱疹	1 (<1)	0	0	0	0
細菌性咽頭炎	1 (<1)	0	0	0	0
血液およびリンパ系障害	0	1 (<1)	0	1 (<1)	0
好中球増加症	0	1 (<1)	0	1 (<1)	0
免疫系障害	0	4 (<1)	5 (<1)	9 (<1)	2 (<1)
過敏症	0	4 (<1)	4 (<1)	8 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 2 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
代謝および栄養障害	1 (<1)	0	1 (<1)	1 (<1)	0
高血糖	0	0	1 (<1)	1 (<1)	0
食欲亢進	1 (<1)	0	0	0	0
精神障害	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
異常行動	0	1 (<1)	0	1 (<1)	0
気分変化	0	0	1 (<1)	1 (<1)	0
うつ病	0	0	0	0	1 (<1)
性的興奮障害	1 (<1)	0	0	0	0
神経系障害	19 (2)	13 (2)	10 (1)	23 (2)	5 (1)
頭痛	1 (<1)	5 (<1)	2 (<1)	7 (<1)	2 (<1)
多発性硬化症再発	15 (2)	3 (<1)	4 (<1)	7 (<1)	1 (<1)
灼熱感	0	1 (<1)	1 (<1)	2 (<1)	0
浮動性めまい	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
平衡障害	0	0	1 (<1)	1 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
多発性硬化症	0	1 (<1)	0	1 (<1)	0
傾眠	0	1 (<1)	0	1 (<1)	0
振戦	0	1 (<1)	0	1 (<1)	1 (<1)
脳血管発作	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 3 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
感覚鈍麻	1 (<1)	0	0	0	0
筋痙直	1 (<1)	0	0	0	0
眼障害	0	0	1 (<1)	1 (<1)	0
霧視	0	0	1 (<1)	1 (<1)	0
耳および迷路障害	0	1 (<1)	2 (<1)	3 (<1)	0
回転性めまい	0	1 (<1)	1 (<1)	2 (<1)	0
耳不快感	0	0	1 (<1)	1 (<1)	0
耳鳴	0	0	1 (<1)	1 (<1)	0
心臓障害	1 (<1)	0	1 (<1)	1 (<1)	3 (<1)
狭心症	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	0	1 (<1)
心筋炎	0	0	0	0	1 (<1)
動悸	1 (<1)	0	0	0	0
頻脈	0	0	0	0	2 (<1)
血管障害	0	18 (2)	10 (1)	28 (2)	0
潮紅	0	16 (2)	10 (1)	26 (2)	0
ほてり	0	1 (<1)	1 (<1)	2 (<1)	0
高血圧	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 4 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
呼吸器、胸郭および縦隔障害	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
咳嗽	0	1 (<1)	1 (<1)	2 (<1)	0
呼吸困難	0	0	0	0	1 (<1)
胃腸障害	4 (<1)	26 (3)	38 (5)	64 (4)	3 (<1)
下痢	1 (<1)	6 (<1)	15 (2)	21 (1)	0
悪心	0	6 (<1)	11 (1)	17 (1)	2 (<1)
嘔吐	0	8 (1)	8 (1)	16 (1)	1 (<1)
上腹部痛	1 (<1)	5 (<1)	9 (1)	14 (<1)	1 (<1)
腹痛	0	4 (<1)	9 (1)	13 (<1)	0
胃腸障害	0	2 (<1)	4 (<1)	6 (<1)	0
腹部不快感	0	2 (<1)	2 (<1)	4 (<1)	0
腹部膨満	1 (<1)	0	3 (<1)	3 (<1)	0
消化不良	0	2 (<1)	0	2 (<1)	0
胃炎	0	1 (<1)	1 (<1)	2 (<1)	0
下腹部痛	0	1 (<1)	0	1 (<1)	0
腹部硬直	0	0	1 (<1)	1 (<1)	0
便秘	0	1 (<1)	0	1 (<1)	0
便失禁	0	1 (<1)	0	1 (<1)	0
鼓腸	0	0	1 (<1)	1 (<1)	0
齲歯	0	0	0	0	1 (<1)
歯肉炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 5 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
肝胆道系障害	0	0	1 (<1)	1 (<1)	0
肝障害	0	0	1 (<1)	1 (<1)	0
皮膚および皮下組織障害	2 (<1)	16 (2)	13 (2)	29 (2)	3 (<1)
発疹	1 (<1)	5 (<1)	1 (<1)	6 (<1)	0
そう痒症	1 (<1)	4 (<1)	1 (<1)	5 (<1)	0
アレルギー性皮膚炎	0	2 (<1)	2 (<1)	4 (<1)	0
蕁麻疹	0	2 (<1)	2 (<1)	4 (<1)	0
全身紅斑	0	2 (<1)	1 (<1)	3 (<1)	0
全身性皮疹	0	1 (<1)	2 (<1)	3 (<1)	0
紅斑	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
全身性そう痒症	0	2 (<1)	0	2 (<1)	0
脱毛症	0	0	1 (<1)	1 (<1)	0
ざ瘡様皮膚炎	0	1 (<1)	0	1 (<1)	0
多汗症	0	0	1 (<1)	1 (<1)	0
アレルギー性そう痒症	0	1 (<1)	0	1 (<1)	0
そう痒性皮疹	0	0	1 (<1)	1 (<1)	0
皮膚灼熱感	0	0	1 (<1)	1 (<1)	0
皮膚硬結	0	0	0	0	1 (<1)
顔面腫脹	0	0	0	0	2 (<1)
筋骨格系および結合組織障害	1 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 6 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
背部痛	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
四肢痛	0	1 (<1)	1 (<1)	2 (<1)	0
側腹部痛	0	0	1 (<1)	1 (<1)	0
筋力低下	0	0	0	0	1 (<1)
腎および尿路障害	2 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
血尿	1 (<1)	1 (<1)	0	1 (<1)	0
蛋白尿	1 (<1)	0	1 (<1)	1 (<1)	0
慢性腎不全	0	0	1 (<1)	1 (<1)	0
腎臓痛	0	0	1 (<1)	1 (<1)	0
ミクロアルブミン尿	0	0	0	0	1 (<1)
頻尿	0	0	0	0	1 (<1)
生殖系および乳房障害	0	0	1 (<1)	1 (<1)	0
腟出血	0	0	1 (<1)	1 (<1)	0
一般・全身障害および投与部位の状態	1 (<1)	5 (<1)	4 (<1)	9 (<1)	11 (3)
胸痛	0	0	2 (<1)	2 (<1)	1 (<1)
疲労	0	1 (<1)	1 (<1)	2 (<1)	0
発熱	0	1 (<1)	1 (<1)	2 (<1)	0
胸部不快感	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 7 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
悪寒	0	0	1 (<1)	1 (<1)	0
不快感	0	0	1 (<1)	1 (<1)	0
高熱	0	1 (<1)	0	1 (<1)	0
粘膜乾燥	0	1 (<1)	0	1 (<1)	0
腫脹	0	1 (<1)	0	1 (<1)	0
無力症	0	0	0	0	3 (<1)
インフルエンザ様疾患	1 (<1)	0	0	0	0
注射部位紅斑	0	0	0	0	3 (<1)
注射部位硬結	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	1 (<1)
注射部位結節	0	0	0	0	1 (<1)
注射部位疼痛	0	0	0	0	4 (1)
注射部位そう痒感	0	0	0	0	3 (<1)
注射部位反応	0	0	0	0	1 (<1)
注射部位腫脹	0	0	0	0	2 (<1)
注射部位熱感	0	0	0	0	1 (<1)
臨床検査	6 (<1)	8 (1)	4 (<1)	12 (<1)	1 (<1)
アラニン・アミノトランスフェラーゼ増加	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
肝機能検査異常	0	2 (<1)	0	2 (<1)	0
体重減少	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Incidence of adverse events that led to discontinuation of study drug by system organ class and preferred term: 24 weeks of studies 109MS301 and 109MS302
Page 8 of 8

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿中アルブミン陽性	0	1 (<1)	0	1 (<1)	0
好酸球数増加	0	1 (<1)	0	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	1 (<1)	0
γ－グルタミルトランスフェラーゼ増加	0	1 (<1)	0	1 (<1)	1 (<1)
肝酵素上昇	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
尿中蛋白陽性	0	0	1 (<1)	1 (<1)	0
白血球数減少	0	0	1 (<1)	1 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	0	0	0	1 (<1)
血中アルカリホスファターゼ異常	0	0	0	0	1 (<1)
心電図ＰＲ延長	1 (<1)	0	0	0	0
トランスアミナーゼ上昇	1 (<1)	0	0	0	0
傷害、中毒および処置合併症	0	1 (<1)	1 (<1)	2 (<1)	0
交通事故	0	1 (<1)	1 (<1)	2 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-DISC-A-24W.SAS DATE: 02DEC2015

Table 108: Summary Analysis of Adverse Events: Studies 109MS301 and 109MS302

Summary analysis of adverse events: Studies 109MS301 and 109MS302

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	720 (93)	733 (95)	712 (94)	1445 (95)	304 (87)
Number of subjects with a moderate or severe event	536 (70)	544 (71)	554 (73)	1098 (72)	210 (60)
Number of subjects with a severe event	118 (15)	115 (15)	111 (15)	226 (15)	45 (13)
Number of subjects with an unlikely, possibly or related event	537 (70)	633 (82)	627 (83)	1260 (82)	221 (63)
Number of subjects with a possibly or related event	350 (45)	536 (70)	538 (71)	1074 (70)	153 (44)
Number of subjects with a related event	53 (7)	222 (29)	221 (29)	443 (29)	92 (26)
Number of subjects with a serious event	165 (21)	135 (18)	119 (16)	254 (17)	60 (17)
Number of subjects discontinuing treatment due to an adverse event	93 (12)	109 (14)	109 (14)	218 (14)	35 (10)
Number of subjects withdrawing from study due to an adverse event	31 (4)	61 (8)	63 (8)	124 (8)	11 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SUM-A.SAS DATE: 02DEC2015

Table 109: Incidence of Adverse Events by System Organ Class: Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class: Studies 109MS301 and 109MS302
Page 1 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	720 (93)	733 (95)	712 (94)	1445 (95)	304 (87)
感染症および寄生虫症	447 (58)	463 (60)	472 (62)	935 (61)	175 (50)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	17 (2)	21 (3)	24 (3)	45 (3)	9 (3)
血液およびリンパ系障害	37 (5)	51 (7)	56 (7)	107 (7)	11 (3)
免疫系障害	17 (2)	23 (3)	22 (3)	45 (3)	8 (2)
内分泌障害	8 (1)	7 (<1)	10 (1)	17 (1)	3 (<1)
代謝および栄養障害	60 (8)	50 (7)	51 (7)	101 (7)	20 (6)
精神障害	163 (21)	131 (17)	131 (17)	262 (17)	60 (17)
神経系障害	511 (66)	414 (54)	389 (51)	803 (53)	178 (51)
眼障害	95 (12)	72 (9)	80 (11)	152 (10)	29 (8)
耳および迷路障害	56 (7)	45 (6)	65 (9)	110 (7)	24 (7)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class: Studies 109MS301 and 109MS302
Page 2 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心臓障害	37 (5)	40 (5)	47 (6)	87 (6)	19 (5)
血管障害	84 (11)	322 (42)	277 (36)	599 (39)	25 (7)
呼吸器、胸郭および縦隔障害	120 (16)	117 (15)	125 (16)	242 (16)	41 (12)
胃腸障害	289 (37)	366 (48)	398 (52)	764 (50)	65 (19)
肝胆道系障害	11 (1)	10 (1)	15 (2)	25 (2)	6 (2)
皮膚および皮下組織障害	157 (20)	245 (32)	247 (33)	492 (32)	60 (17)
筋骨格系および結合組織障害	261 (34)	246 (32)	246 (32)	492 (32)	82 (23)
腎および尿路障害	151 (20)	146 (19)	176 (23)	322 (21)	58 (17)
妊娠、産褥および周産期の状態	3 (<1)	1 (<1)	0	1 (<1)	0
生殖系および乳房障害	76 (10)	76 (10)	76 (10)	152 (10)	26 (7)
先天性、家族性および遺伝性障害	1 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
一般・全身障害および投与部位の状態	194 (25)	178 (23)	216 (28)	394 (26)	133 (38)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class: Studies 109MS301 and 109MS302
Page 3 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
臨床検査	200 (26)	212 (28)	216 (28)	428 (28)	106 (30)
傷害、中毒および処置合併症	140 (18)	103 (13)	119 (16)	222 (15)	41 (12)
外科および内科処置	7 (<1)	9 (1)	4 (<1)	13 (<1)	4 (1)
社会環境	3 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOC-A.SAS DATE: 02DEC2015

Table 110: Incidence of Adverse Events by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 1 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	720 (93)	733 (95)	712 (94)	1445 (95)	304 (87)
感染症および寄生虫症	447 (58)	463 (60)	472 (62)	935 (61)	175 (50)
鼻咽頭炎	159 (21)	170 (22)	172 (23)	342 (22)	51 (15)
尿路感染	95 (12)	107 (14)	95 (13)	202 (13)	46 (13)
上気道感染	87 (11)	99 (13)	98 (13)	197 (13)	27 (8)
インフルエンザ	61 (8)	54 (7)	73 (10)	127 (8)	15 (4)
副鼻腔炎	31 (4)	35 (5)	52 (7)	87 (6)	11 (3)
気管支炎	32 (4)	35 (5)	48 (6)	83 (5)	16 (5)
胃腸炎	28 (4)	42 (5)	34 (4)	76 (5)	5 (1)
咽頭炎	31 (4)	31 (4)	27 (4)	58 (4)	14 (4)
鼻炎	26 (3)	26 (3)	23 (3)	49 (3)	8 (2)
気道感染	14 (2)	17 (2)	20 (3)	37 (2)	9 (3)
口腔ヘルペス	26 (3)	23 (3)	13 (2)	36 (2)	6 (2)
ウイルス性胃腸炎	16 (2)	15 (2)	20 (3)	35 (2)	6 (2)
ウイルス感染	15 (2)	18 (2)	13 (2)	31 (2)	5 (1)
膀胱炎	21 (3)	11 (1)	19 (3)	30 (2)	5 (1)
耳感染	12 (2)	5 (<1)	18 (2)	23 (2)	2 (<1)
喉頭炎	5 (<1)	11 (1)	12 (2)	23 (2)	1 (<1)
ウイルス性上気道感染	12 (2)	13 (2)	9 (1)	22 (1)	7 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 2 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
帯状疱疹	10 (1)	8 (1)	12 (2)	20 (1)	2 (<1)
外陰腟真菌感染	11 (1)	8 (1)	12 (2)	20 (1)	5 (1)
中耳炎	1 (<1)	10 (1)	9 (1)	19 (1)	1 (<1)
扁桃炎	9 (1)	9 (1)	9 (1)	18 (1)	2 (<1)
腟感染	3 (<1)	10 (1)	7 (<1)	17 (1)	5 (1)
消化管感染	8 (1)	5 (<1)	11 (1)	16 (1)	2 (<1)
歯膿瘍	11 (1)	9 (1)	7 (<1)	16 (1)	4 (1)
感染性結膜炎	2 (<1)	7 (<1)	8 (1)	15 (<1)	0
麦粒腫	4 (<1)	6 (<1)	5 (<1)	11 (<1)	0
ウイルス性消化管感染	4 (<1)	6 (<1)	4 (<1)	10 (<1)	1 (<1)
下気道感染	6 (<1)	2 (<1)	7 (<1)	9 (<1)	1 (<1)
歯感染	4 (<1)	3 (<1)	6 (<1)	9 (<1)	6 (2)
蜂巣炎	2 (<1)	5 (<1)	3 (<1)	8 (<1)	1 (<1)
レンサ球菌性咽頭炎	10 (1)	3 (<1)	5 (<1)	8 (<1)	1 (<1)
肺炎	3 (<1)	4 (<1)	4 (<1)	8 (<1)	6 (2)
ウイルス性気道感染	4 (<1)	6 (<1)	2 (<1)	8 (<1)	0
気管炎	2 (<1)	6 (<1)	2 (<1)	8 (<1)	2 (<1)
外陰部腟カンジダ症	5 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
せつ	2 (<1)	5 (<1)	2 (<1)	7 (<1)	0
爪真菌症	2 (<1)	7 (<1)	0	7 (<1)	0
咽頭扁桃炎	1 (<1)	4 (<1)	2 (<1)	6 (<1)	1 (<1)
細菌尿	1 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 3 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Ｈ１Ｎ１インフルエンザ	2 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
口腔カンジダ症	2 (<1)	1 (<1)	4 (<1)	5 (<1)	0
急性扁桃炎	4 (<1)	3 (<1)	1 (<1)	4 (<1)	2 (<1)
毛包炎	4 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
陰部ヘルペス	3 (<1)	4 (<1)	0	4 (<1)	1 (<1)
単純ヘルペス	2 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
外耳炎	1 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
細菌性副鼻腔炎	0	3 (<1)	1 (<1)	4 (<1)	0
皮下組織膿瘍	0	2 (<1)	2 (<1)	4 (<1)	0
癜風	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
細菌性膣炎	2 (<1)	4 (<1)	0	4 (<1)	2 (<1)
急性副鼻腔炎	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
細菌性結膜炎	0	1 (<1)	2 (<1)	3 (<1)	0
遊走性紅斑	0	1 (<1)	2 (<1)	3 (<1)	0
ヘリコバクター性胃炎	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
咬傷感染	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
シラミ寄生	0	2 (<1)	1 (<1)	3 (<1)	0
歯周感染	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
無症候性細菌尿	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
細菌感染	1 (<1)	2 (<1)	0	2 (<1)	0
眼感染	3 (<1)	2 (<1)	0	2 (<1)	0
真菌感染	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 4 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
性器カンジダ症	0	2 (<1)	0	2 (<1)	0
ヘリコバクター感染	0	1 (<1)	1 (<1)	2 (<1)	0
切開部位感染	0	2 (<1)	0	2 (<1)	0
伝染性単核症	0	1 (<1)	1 (<1)	2 (<1)	0
限局性感染	3 (<1)	2 (<1)	0	2 (<1)	0
口腔真菌感染	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
爪囲炎	1 (<1)	2 (<1)	0	2 (<1)	0
骨盤内炎症性疾患	1 (<1)	0	2 (<1)	2 (<1)	0
術後創感染	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
歯髄炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
陰嚢膿瘍	0	0	2 (<1)	2 (<1)	0
ブドウ球菌感染	0	0	2 (<1)	2 (<1)	0
気管気管支炎	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
腸チフス熱	0	0	2 (<1)	2 (<1)	0
細菌性上気道感染	1 (<1)	2 (<1)	0	2 (<1)	0
外陰部炎	0	2 (<1)	0	2 (<1)	0
腹壁膿瘍	0	0	1 (<1)	1 (<1)	0
ダニ症	0	0	1 (<1)	1 (<1)	0
虫垂炎	0	1 (<1)	0	1 (<1)	1 (<1)
ボレリア感染	3 (<1)	1 (<1)	0	1 (<1)	0
乳房膿瘍	0	0	1 (<1)	1 (<1)	0
乳房蜂巣炎	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 5 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ウイルス性気管支炎	0	0	1 (<1)	1 (<1)	1 (<1)
気管支肺炎	0	1 (<1)	0	1 (<1)	0
カンジダ症	0	1 (<1)	0	1 (<1)	1 (<1)
子宮頚管炎	0	1 (<1)	0	1 (<1)	1 (<1)
ウイルス性結膜炎	1 (<1)	0	1 (<1)	1 (<1)	0
デング熱	0	1 (<1)	0	1 (<1)	1 (<1)
感染性皮膚炎	0	0	1 (<1)	1 (<1)	0
憩室炎	0	0	1 (<1)	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
感染性湿疹	0	0	1 (<1)	1 (<1)	0
エプスタイン・バーウイルス感染	0	0	1 (<1)	1 (<1)	0
大腸菌性尿路感染	0	1 (<1)	0	1 (<1)	0
熱性感染症	1 (<1)	0	1 (<1)	1 (<1)	0
ノロウイルス性胃腸炎	1 (<1)	1 (<1)	0	1 (<1)	0
ロタウイルス胃腸炎	0	1 (<1)	0	1 (<1)	0
細菌性性器感染	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
泌尿生殖器感染	1 (<1)	1 (<1)	0	1 (<1)	0
ジアルジア症	0	1 (<1)	0	1 (<1)	0
歯肉感染	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	1 (<1)	0
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
膿痂疹	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 6 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
感染性嚢腫	1 (<1)	1 (<1)	0	1 (<1)	0
感染性皮脂嚢腫	1 (<1)	0	1 (<1)	1 (<1)	0
感染	0	0	1 (<1)	1 (<1)	1 (<1)
カンジダ性間擦疹	0	0	1 (<1)	1 (<1)	0
迷路炎	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
ライム病	0	0	1 (<1)	1 (<1)	1 (<1)
乳腺炎	1 (<1)	1 (<1)	0	1 (<1)	0
マイコプラズマ感染	0	0	1 (<1)	1 (<1)	0
爪感染	0	0	1 (<1)	1 (<1)	0
精巣炎	0	0	1 (<1)	1 (<1)	0
急性中耳炎	0	0	1 (<1)	1 (<1)	0
扁桃周囲膿瘍	0	0	1 (<1)	1 (<1)	0
ウイルス感染後疲労症候群	1 (<1)	1 (<1)	0	1 (<1)	0
腎盂腎炎	2 (<1)	1 (<1)	0	1 (<1)	1 (<1)
急性腎盂腎炎	0	0	1 (<1)	1 (<1)	0
膿皮症	0	1 (<1)	0	1 (<1)	0
膿疱性皮疹	0	1 (<1)	0	1 (<1)	1 (<1)
卵管卵巣炎	2 (<1)	1 (<1)	0	1 (<1)	0
皮膚細菌感染	0	0	1 (<1)	1 (<1)	0
皮膚感染	0	1 (<1)	0	1 (<1)	0
軟部組織感染	0	1 (<1)	0	1 (<1)	0
足部白癬	4 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 7 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
細菌性尿路感染	3 (<1)	0	1 (<1)	1 (<1)	0
真菌性尿路感染	0	1 (<1)	0	1 (<1)	0
泌尿生殖器真菌感染	0	0	1 (<1)	1 (<1)	0
ガードネレラ菌性膣炎	0	1 (<1)	0	1 (<1)	0
水痘	0	1 (<1)	0	1 (<1)	1 (<1)
ウイルス性咽頭炎	1 (<1)	1 (<1)	0	1 (<1)	0
ウイルス性鼻炎	0	0	1 (<1)	1 (<1)	0
外陰部膿瘍	1 (<1)	0	1 (<1)	1 (<1)	0
膿瘍	1 (<1)	0	0	0	0
顎膿瘍	1 (<1)	0	0	0	0
四肢膿瘍	1 (<1)	0	0	0	0
肛門膿瘍	1 (<1)	0	0	0	0
熱傷部感染	1 (<1)	0	0	0	0
慢性副鼻腔炎	0	0	0	0	1 (<1)
医療機器関連感染	1 (<1)	0	0	0	0
感染性下痢	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0
皮膚真菌感染	1 (<1)	0	0	0	1 (<1)
真菌性消化管感染	1 (<1)	0	0	0	0
ヘルペスウイルス感染	1 (<1)	0	0	0	1 (<1)
寄生虫感染	0	0	0	0	1 (<1)
乳様突起炎	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 8 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ムンプス	1 (<1)	0	0	0	0
パラインフルエンザウイルス感染	1 (<1)	0	0	0	0
子宮傍組織炎	0	0	0	0	1 (<1)
耳下腺炎	0	0	0	0	1 (<1)
細菌性咽頭炎	3 (<1)	0	0	0	1 (<1)
毛巣嚢胞	1 (<1)	0	0	0	0
術後膿瘍	1 (<1)	0	0	0	0
膿胸	0	0	0	0	1 (<1)
ライター症候群	1 (<1)	0	0	0	0
猩紅熱	1 (<1)	0	0	0	0
敗血症	2 (<1)	0	0	0	0
レンサ球菌感染	1 (<1)	0	0	0	0
白癬感染	1 (<1)	0	0	0	0
消化器結核	1 (<1)	0	0	0	0
尿路性敗血症	2 (<1)	0	0	0	0
腟膿瘍	1 (<1)	0	0	0	0
創傷感染	2 (<1)	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	17 (2)	21 (3)	24 (3)	45 (3)	9 (3)
皮膚乳頭腫	1 (<1)	5 (<1)	4 (<1)	9 (<1)	0
脂肪腫	0	3 (<1)	4 (<1)	7 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 9 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
メラノサイト性母斑	3 (<1)	2 (<1)	4 (<1)	6 (<1)	2 (<1)
子宮平滑筋腫	2 (<1)	2 (<1)	4 (<1)	6 (<1)	2 (<1)
線維腫	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
乳腺線維腺腫	0	1 (<1)	1 (<1)	2 (<1)	0
肺新生物	0	1 (<1)	1 (<1)	2 (<1)	0
甲状腺新生物	1 (<1)	2 (<1)	0	2 (<1)	0
基底細胞癌	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
乳癌	1 (<1)	0	1 (<1)	1 (<1)	0
子宮頚部癌	0	0	1 (<1)	1 (<1)	1 (<1)
泌尿生殖器新生物	0	0	1 (<1)	1 (<1)	0
血管腫	1 (<1)	0	1 (<1)	1 (<1)	0
肝臓血管腫	0	0	1 (<1)	1 (<1)	0
神経鞘腫	0	1 (<1)	0	1 (<1)	0
乳頭腫	0	0	1 (<1)	1 (<1)	0
腎新生物	0	1 (<1)	0	1 (<1)	0
脂漏性角化症	0	0	1 (<1)	1 (<1)	0
移行上皮癌	0	1 (<1)	0	1 (<1)	0
外陰腟ヒト乳頭腫ウイルス感染	0	1 (<1)	0	1 (<1)	0
アクロコルドン	1 (<1)	0	0	0	0
リンパ節の良性新生物	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 10 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
甲状腺の良性新生物	1 (<1)	0	0	0	0
乳房新生物	1 (<1)	0	0	0	0
子宮内膜癌	0	0	0	0	1 (<1)
線維性組織球腫	0	0	0	0	1 (<1)
モートン神経腫	1 (<1)	0	0	0	0
皮膚の新生物	1 (<1)	0	0	0	0
口腔新生物	1 (<1)	0	0	0	0
良性副甲状腺腫瘍	1 (<1)	0	0	0	0
転移性甲状腺癌	0	0	0	0	1 (<1)
血液およびリンパ系障害	37 (5)	51 (7)	56 (7)	107 (7)	11 (3)
リンパ球減少症	2 (<1)	18 (2)	17 (2)	35 (2)	0
貧血	15 (2)	13 (2)	21 (3)	34 (2)	4 (1)
白血球減少症	1 (<1)	7 (<1)	11 (1)	18 (1)	0
リンパ節症	6 (<1)	4 (<1)	6 (<1)	10 (<1)	4 (1)
好中球増加症	5 (<1)	4 (<1)	6 (<1)	10 (<1)	1 (<1)
白血球増加症	4 (<1)	8 (1)	1 (<1)	9 (<1)	0
好酸球増加症	1 (<1)	3 (<1)	5 (<1)	8 (<1)	0
鉄欠乏性貧血	3 (<1)	3 (<1)	2 (<1)	5 (<1)	0
好中球減少症	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
血小板減少症	0	2 (<1)	0	2 (<1)	1 (<1)
正色素性正球性貧血	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 11 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脾腫	0	0	1 (<1)	1 (<1)	0
妊娠貧血	1 (<1)	0	0	0	0
低色素性貧血	1 (<1)	0	0	0	1 (<1)
リンパ節炎	1 (<1)	0	0	0	0
小球性貧血	1 (<1)	0	0	0	0
血小板増加症	1 (<1)	0	0	0	0
免疫系障害	17 (2)	23 (3)	22 (3)	45 (3)	8 (2)
過敏症	2 (<1)	11 (1)	9 (1)	20 (1)	1 (<1)
季節性アレルギー	9 (1)	6 (<1)	7 (<1)	13 (<1)	3 (<1)
食物アレルギー	1 (<1)	5 (<1)	2 (<1)	7 (<1)	1 (<1)
薬物過敏症	3 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
造影剤アレルギー	0	1 (<1)	1 (<1)	2 (<1)	0
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
家塵アレルギー	2 (<1)	0	1 (<1)	1 (<1)	0
免疫不全症	0	0	1 (<1)	1 (<1)	0
続発性免疫不全症	0	0	1 (<1)	1 (<1)	0
化学物質アレルギー	1 (<1)	0	0	0	0
アナフィラキシー反応	0	0	0	0	2 (<1)
内分泌障害	8 (1)	7 (<1)	10 (1)	17 (1)	3 (<1)
甲状腺腫	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 12 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
甲状腺機能低下症	4 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
副甲状腺機能亢進症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
自己免疫性甲状腺炎	0	1 (<1)	0	1 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	1 (<1)	0
続発性副甲状腺機能亢進症	0	1 (<1)	0	1 (<1)	0
甲状腺機能亢進症	2 (<1)	0	1 (<1)	1 (<1)	0
エストロゲン欠乏症	0	0	1 (<1)	1 (<1)	0
甲状腺腫瘤	0	0	1 (<1)	1 (<1)	0
副腎腫瘤	1 (<1)	0	0	0	0
代謝および栄養障害	60 (8)	50 (7)	51 (7)	101 (7)	20 (6)
食欲減退	14 (2)	17 (2)	14 (2)	31 (2)	4 (1)
高コレステロール血症	4 (<1)	7 (<1)	7 (<1)	14 (<1)	2 (<1)
ビタミンD欠乏	7 (<1)	5 (<1)	8 (1)	13 (<1)	3 (<1)
高血糖	7 (<1)	3 (<1)	5 (<1)	8 (<1)	1 (<1)
脱水	1 (<1)	3 (<1)	3 (<1)	6 (<1)	0
高脂血症	5 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
耐糖能障害	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
糖尿病	3 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
脂質異常症	0	0	3 (<1)	3 (<1)	0
鉄欠乏	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 13 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ビタミンＢ１２欠乏	0	0	3 (<1)	3 (<1)	0
高トリグリセリド血症	4 (<1)	1 (<1)	1 (<1)	2 (<1)	4 (1)
低カリウム血症	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミン欠乏症	2 (<1)	2 (<1)	0	2 (<1)	0
食欲亢進	3 (<1)	2 (<1)	0	2 (<1)	0
２型糖尿病	0	2 (<1)	0	2 (<1)	0
異常体重減少	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	2 (<1)	0	1 (<1)	1 (<1)	0
痛風	1 (<1)	1 (<1)	0	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	1 (<1)	0
高尿酸血症	0	1 (<1)	0	1 (<1)	3 (<1)
低血糖症	0	0	1 (<1)	1 (<1)	0
過小食	0	0	1 (<1)	1 (<1)	0
低リン酸血症	0	0	1 (<1)	1 (<1)	0
ケトーシス	0	0	1 (<1)	1 (<1)	0
１型糖尿病	0	1 (<1)	0	1 (<1)	0
亜鉛欠乏	0	0	1 (<1)	1 (<1)	0
電解質失調	1 (<1)	0	0	0	0
葉酸欠乏	1 (<1)	0	0	0	0
妊娠糖尿病	1 (<1)	0	0	0	0
高カルシウム血症	1 (<1)	0	0	0	0
高カリウム血症	1 (<1)	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 14 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ビタミンD過剰症	1 (<1)	0	0	0	0
低ナトリウム血症	1 (<1)	0	0	0	0
肥満	1 (<1)	0	0	0	1 (<1)
多飲症	1 (<1)	0	0	0	0
精神障害	163 (21)	131 (17)	131 (17)	262 (17)	60 (17)
うつ病	68 (9)	53 (7)	48 (6)	101 (7)	30 (9)
不眠症	38 (5)	35 (5)	30 (4)	65 (4)	13 (4)
不安	27 (4)	31 (4)	26 (3)	57 (4)	7 (2)
抑うつ気分	17 (2)	12 (2)	7 (<1)	19 (1)	4 (1)
睡眠障害	12 (2)	8 (1)	7 (<1)	15 (<1)	2 (<1)
気分動揺	5 (<1)	2 (<1)	5 (<1)	7 (<1)	1 (<1)
感情障害	3 (<1)	3 (<1)	3 (<1)	6 (<1)	1 (<1)
ストレス	4 (<1)	3 (<1)	3 (<1)	6 (<1)	4 (1)
気分変化	0	2 (<1)	3 (<1)	5 (<1)	0
パニック発作	1 (<1)	0	5 (<1)	5 (<1)	0
リビドー減退	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
抑うつ症状	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
初期不眠症	0	0	3 (<1)	3 (<1)	0
神経過敏	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
神経症	0	2 (<1)	1 (<1)	3 (<1)	0
自殺念慮	1 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 15 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
感情不安定	5 (<1)	0	2 (<1)	2 (<1)	2 (<1)
大うつ病	0	0	2 (<1)	2 (<1)	0
落ち着きのなさ	0	2 (<1)	0	2 (<1)	0
身体表現性障害	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
異常行動	0	1 (<1)	0	1 (<1)	0
異常な夢	1 (<1)	0	1 (<1)	1 (<1)	0
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
不安障害	2 (<1)	1 (<1)	0	1 (<1)	0
双極１型障害	0	1 (<1)	0	1 (<1)	0
歯ぎしり	1 (<1)	0	1 (<1)	1 (<1)	0
燃え尽き症候群	0	1 (<1)	0	1 (<1)	0
転換性障害	0	0	1 (<1)	1 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	1 (<1)	0
情動障害	0	0	1 (<1)	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	1 (<1)	0
全般性不安障害	0	1 (<1)	0	1 (<1)	0
幻聴	0	1 (<1)	0	1 (<1)	0
リビド消失	0	1 (<1)	0	1 (<1)	0
躁病	1 (<1)	1 (<1)	0	1 (<1)	0
自己愛性人格障害	0	1 (<1)	0	1 (<1)	0
パニック障害	0	1 (<1)	0	1 (<1)	0
人格変化	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 16 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
人格障害	0	1 (<1)	0	1 (<1)	0
精神症状	0	1 (<1)	0	1 (<1)	0
精神病性障害	0	0	1 (<1)	1 (<1)	0
睡眠発作	0	0	1 (<1)	1 (<1)	0
自殺企図	0	0	1 (<1)	1 (<1)	1 (<1)
適応障害	0	0	0	0	1 (<1)
攻撃性	1 (<1)	0	0	0	0
激越	1 (<1)	0	0	0	0
怒り	1 (<1)	0	0	0	0
気晴らし食い	1 (<1)	0	0	0	0
精神緩慢	1 (<1)	0	0	0	0
閉所恐怖症	0	0	0	0	1 (<1)
自殺既遂	0	0	0	0	1 (<1)
錯乱状態	1 (<1)	0	0	0	0
不快気分	1 (<1)	0	0	0	0
幻覚	1 (<1)	0	0	0	0
故意の自傷行為	0	0	0	0	1 (<1)
精神障害	0	0	0	0	1 (<1)
中期不眠症	1 (<1)	0	0	0	0
悪夢	1 (<1)	0	0	0	0
強迫性障害	1 (<1)	0	0	0	0
緊張	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 17 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
タバコ乱用	1 (<1)	0	0	0	0
神経系障害	511 (66)	414 (54)	389 (51)	803 (53)	178 (51)
多発性硬化症再発	344 (45)	221 (29)	199 (26)	420 (27)	119 (34)
頭痛	130 (17)	133 (17)	126 (17)	259 (17)	46 (13)
錯感覚	69 (9)	56 (7)	59 (8)	115 (8)	15 (4)
感覚鈍麻	48 (6)	31 (4)	43 (6)	74 (5)	16 (5)
浮動性めまい	38 (5)	33 (4)	31 (4)	64 (4)	9 (3)
灼熱感	13 (2)	21 (3)	25 (3)	46 (3)	0
片頭痛	21 (3)	21 (3)	22 (3)	43 (3)	6 (2)
筋痙直	27 (4)	17 (2)	16 (2)	33 (2)	7 (2)
平衡障害	9 (1)	10 (1)	11 (1)	21 (1)	2 (<1)
感覚障害	10 (1)	9 (1)	9 (1)	18 (1)	1 (<1)
異常感覚	5 (<1)	12 (2)	4 (<1)	16 (1)	0
多発性硬化症	15 (2)	8 (1)	8 (1)	16 (1)	7 (2)
坐骨神経痛	8 (1)	9 (1)	7 (<1)	16 (1)	2 (<1)
振戦	11 (1)	11 (1)	5 (<1)	16 (1)	4 (1)
傾眠	8 (1)	6 (<1)	8 (1)	14 (<1)	2 (<1)
緊張性頭痛	7 (<1)	5 (<1)	8 (1)	13 (<1)	2 (<1)
レルミット徴候	8 (1)	3 (<1)	9 (1)	12 (<1)	1 (<1)
神経痛	6 (<1)	7 (<1)	4 (<1)	11 (<1)	1 (<1)
構語障害	1 (<1)	3 (<1)	6 (<1)	9 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 18 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
味覚異常	1 (<1)	4 (<1)	5 (<1)	9 (<1)	2 (<1)
失神	4 (<1)	2 (<1)	7 (<1)	9 (<1)	2 (<1)
前兆を伴う片頭痛	2 (<1)	7 (<1)	1 (<1)	8 (<1)	1 (<1)
三叉神経痛	8 (1)	5 (<1)	3 (<1)	8 (<1)	2 (<1)
ウートホフ現象	4 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
健忘	5 (<1)	4 (<1)	3 (<1)	7 (<1)	0
認知障害	0	1 (<1)	5 (<1)	6 (<1)	1 (<1)
注意力障害	0	3 (<1)	3 (<1)	6 (<1)	2 (<1)
下肢静止不能症候群	6 (<1)	2 (<1)	4 (<1)	6 (<1)	4 (1)
副鼻腔炎に伴う頭痛	3 (<1)	2 (<1)	4 (<1)	6 (<1)	2 (<1)
運動失調	2 (<1)	1 (<1)	4 (<1)	5 (<1)	0
知覚過敏	5 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
記憶障害	6 (<1)	4 (<1)	1 (<1)	5 (<1)	5 (1)
神経圧迫	1 (<1)	0	5 (<1)	5 (<1)	0
失神寸前の状態	4 (<1)	2 (<1)	3 (<1)	5 (<1)	2 (<1)
帯状感	0	1 (<1)	3 (<1)	4 (<1)	0
手根管症候群	6 (<1)	3 (<1)	1 (<1)	4 (<1)	2 (<1)
過眠症	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
不随意性筋収縮	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)
てんかん	2 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
反射亢進	5 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
眼振	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 19 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
視神経炎	0	2 (<1)	1 (<1)	3 (<1)	0
味覚消失	0	1 (<1)	1 (<1)	2 (<1)	0
頚髄神経根痛	1 (<1)	0	2 (<1)	2 (<1)	2 (<1)
頚原性頭痛	0	1 (<1)	1 (<1)	2 (<1)	0
不器用	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
痙攣	4 (<1)	1 (<1)	1 (<1)	2 (<1)	0
協調運動異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
振動覚低下	2 (<1)	2 (<1)	0	2 (<1)	0
顔面不全麻痺	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
大発作痙攣	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
頭部動揺	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
不全片麻痺	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
肋間神経痛	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
意識消失	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
腰髄神経根障害	1 (<1)	2 (<1)	0	2 (<1)	0
感覚異常性大腿神経痛	0	1 (<1)	1 (<1)	2 (<1)	0
運動機能障害	0	1 (<1)	1 (<1)	2 (<1)	0
神経学的症状	0	1 (<1)	1 (<1)	2 (<1)	0
後頭神経痛	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
一過性脳虚血発作	0	1 (<1)	1 (<1)	2 (<1)	0
失認症	0	1 (<1)	0	1 (<1)	0
意識変容状態	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 20 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
自律神経失調	0	0	1 (<1)	1 (<1)	0
良性頭蓋内圧亢進	0	0	1 (<1)	1 (<1)	0
小脳症候群	1 (<1)	0	1 (<1)	1 (<1)	0
概日リズム睡眠障害	0	1 (<1)	0	1 (<1)	0
泣き	0	0	1 (<1)	1 (<1)	0
体位性めまい	0	1 (<1)	0	1 (<1)	0
よだれ	1 (<1)	0	1 (<1)	1 (<1)	0
ジスキネジー	0	1 (<1)	0	1 (<1)	0
ジストニー	0	1 (<1)	0	1 (<1)	1 (<1)
てんかんの前兆	0	1 (<1)	0	1 (<1)	0
顔面神経障害	0	0	1 (<1)	1 (<1)	0
顔面部神経痛	0	1 (<1)	0	1 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)	1 (<1)
舌咽神経痛	0	1 (<1)	0	1 (<1)	0
片側頭痛	5 (<1)	1 (<1)	0	1 (<1)	1 (<1)
思考散乱	0	0	1 (<1)	1 (<1)	0
脳圧低下	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
嗜眠	0	0	1 (<1)	1 (<1)	0
末梢性ニューロパチー	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
部分発作	0	1 (<1)	0	1 (<1)	1 (<1)
腓骨神経麻痺	0	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 21 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
睡眠の質低下	0	1 (<1)	0	1 (<1)	1 (<1)
神経根痛	0	1 (<1)	0	1 (<1)	0
頚髄神経根炎	0	1 (<1)	0	1 (<1)	0
逆行性健忘	0	1 (<1)	0	1 (<1)	0
二次性進行型多発性硬化症	0	0	1 (<1)	1 (<1)	0
鎮静	0	0	1 (<1)	1 (<1)	0
感覚消失	0	1 (<1)	0	1 (<1)	1 (<1)
会話障害	0	1 (<1)	0	1 (<1)	0
舌の麻痺	0	1 (<1)	0	1 (<1)	0
一過性全健忘	0	0	1 (<1)	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
尺骨神経管症候群	0	1 (<1)	0	1 (<1)	0
血管性頭痛	0	0	1 (<1)	1 (<1)	0
第７脳神経麻痺	1 (<1)	1 (<1)	0	1 (<1)	0
視野欠損	1 (<1)	1 (<1)	0	1 (<1)	0
異痛症	1 (<1)	0	0	0	0
失語症	1 (<1)	0	0	0	2 (<1)
中枢神経系病変	2 (<1)	0	0	0	0
中枢痛症候群	1 (<1)	0	0	0	0
脳血管発作	1 (<1)	0	0	0	0
脳血管障害	0	0	0	0	1 (<1)
頚腕症候群	2 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 22 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
複雑部分発作	1 (<1)	0	0	0	0
脳症	1 (<1)	0	0	0	0
顔面痙攣	2 (<1)	0	0	0	2 (<1)
痙性歩行	1 (<1)	0	0	0	0
ホルネル症候群	1 (<1)	0	0	0	0
筋緊張亢進	1 (<1)	0	0	0	0
筋緊張低下	1 (<1)	0	0	0	0
仮面状顔貌	0	0	0	0	1 (<1)
不全単麻痺	1 (<1)	0	0	0	1 (<1)
単麻痺	1 (<1)	0	0	0	0
起立不耐性	0	0	0	0	1 (<1)
嗅覚錯誤	1 (<1)	0	0	0	0
周期性四肢運動障害	0	0	0	0	1 (<1)
錐体路症候群	1 (<1)	0	0	0	0
片頭痛発作重積	1 (<1)	0	0	0	0
足根管症候群	0	0	0	0	1 (<1)
温度覚鈍麻	1 (<1)	0	0	0	0
振動覚亢進	2 (<1)	0	0	0	1 (<1)
第６脳神経麻痺	0	0	0	0	1 (<1)
眼障害	95 (12)	72 (9)	80 (11)	152 (10)	29 (8)
霧視	22 (3)	13 (2)	18 (2)	31 (2)	6 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 23 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼痛	14 (2)	13 (2)	16 (2)	29 (2)	6 (2)
結膜炎	6 (<1)	8 (1)	7 (<1)	15 (<1)	3 (<1)
複視	12 (2)	5 (<1)	8 (1)	13 (<1)	4 (1)
視力障害	6 (<1)	7 (<1)	6 (<1)	13 (<1)	1 (<1)
眼瞼痙攣	7 (<1)	4 (<1)	6 (<1)	10 (<1)	0
眼乾燥	4 (<1)	7 (<1)	2 (<1)	9 (<1)	1 (<1)
視力低下	11 (1)	4 (<1)	4 (<1)	8 (<1)	4 (1)
アレルギー性結膜炎	2 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
眼充血	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
眼瞼炎	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
眼の異常感	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
失明	0	1 (<1)	2 (<1)	3 (<1)	0
白内障	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
霰粒腫	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
眼瞼下垂	0	1 (<1)	2 (<1)	3 (<1)	0
流涙増加	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
光視症	0	2 (<1)	1 (<1)	3 (<1)	0
ブドウ膜炎	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)
硝子体浮遊物	0	2 (<1)	1 (<1)	3 (<1)	0
眼出血	0	1 (<1)	1 (<1)	2 (<1)	0
眼刺激	1 (<1)	0	2 (<1)	2 (<1)	0
緑内障	1 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 24 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
眼筋麻痺	0	1 (<1)	1 (<1)	2 (<1)	0
羞明	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
屈折障害	1 (<1)	2 (<1)	0	2 (<1)	0
黒内障	0	1 (<1)	0	1 (<1)	0
眼精疲労	1 (<1)	0	1 (<1)	1 (<1)	0
両眼球運動障害	0	0	1 (<1)	1 (<1)	0
アレルギー性眼瞼炎	0	0	1 (<1)	1 (<1)	0
眼瞼湿疹	0	1 (<1)	0	1 (<1)	0
眼運動障害	0	0	1 (<1)	1 (<1)	0
眼そう痒症	2 (<1)	0	1 (<1)	1 (<1)	0
眼部腫脹	0	0	1 (<1)	1 (<1)	1 (<1)
眼瞼嚢胞	0	1 (<1)	0	1 (<1)	0
眼瞼障害	0	0	1 (<1)	1 (<1)	0
眼瞼浮腫	0	0	1 (<1)	1 (<1)	0
遠視	2 (<1)	1 (<1)	0	1 (<1)	0
角膜炎	0	0	1 (<1)	1 (<1)	0
瞼板腺炎	0	0	1 (<1)	1 (<1)	0
夜盲	0	0	1 (<1)	1 (<1)	0
眼球運動失調	0	1 (<1)	0	1 (<1)	0
開放隅角緑内障	0	0	1 (<1)	1 (<1)	0
視神経萎縮	0	0	1 (<1)	1 (<1)	0
動揺視	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 25 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
全眼球炎	0	1 (<1)	0	1 (<1)	0
老視	0	1 (<1)	0	1 (<1)	0
強膜炎	0	1 (<1)	0	1 (<1)	0
乾燥症候群	0	1 (<1)	0	1 (<1)	0
一過性失明	1 (<1)	0	0	0	1 (<1)
片側失明	0	0	0	0	1 (<1)
嚢下白内障	1 (<1)	0	0	0	0
結膜出血	1 (<1)	0	0	0	1 (<1)
結膜刺激	1 (<1)	0	0	0	0
眼瞼紅斑	2 (<1)	0	0	0	0
眼のアレルギー	0	0	0	0	1 (<1)
眼の障害	1 (<1)	0	0	0	0
眼瞼刺激	1 (<1)	0	0	0	0
眼瞼そう痒症	1 (<1)	0	0	0	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
虹彩毛様体炎	0	0	0	0	1 (<1)
黄斑浮腫	1 (<1)	0	0	0	0
近視	1 (<1)	0	0	0	1 (<1)
翼状片	1 (<1)	0	0	0	0
閃輝暗点	1 (<1)	0	0	0	0
硝子体出血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 26 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
耳および迷路障害	56 (7)	45 (6)	65 (9)	110 (7)	24 (7)
回転性めまい	37 (5)	22 (3)	42 (6)	64 (4)	15 (4)
耳痛	4 (<1)	6 (<1)	8 (1)	14 (<1)	1 (<1)
耳鳴	6 (<1)	6 (<1)	7 (<1)	13 (<1)	2 (<1)
頭位性回転性めまい	4 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
耳閉	1 (<1)	0	3 (<1)	3 (<1)	0
耳不快感	1 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
聴力低下	3 (<1)	0	3 (<1)	3 (<1)	1 (<1)
乗物酔い	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
聴覚過敏	0	1 (<1)	1 (<1)	2 (<1)	0
耳垢栓塞	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
難聴	2 (<1)	1 (<1)	0	1 (<1)	0
感音性難聴	0	1 (<1)	0	1 (<1)	0
耳出血	0	1 (<1)	0	1 (<1)	0
耳そう痒症	0	1 (<1)	0	1 (<1)	0
耳管障害	0	0	1 (<1)	1 (<1)	0
耳管機能障害	0	0	1 (<1)	1 (<1)	1 (<1)
外耳障害	0	0	1 (<1)	1 (<1)	0
外耳痛	0	1 (<1)	0	1 (<1)	0
鼓膜充血	0	1 (<1)	0	1 (<1)	0
外耳道紅斑	1 (<1)	0	0	0	0
中耳の炎症	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 27 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
前庭性運動失調	0	0	0	0	1 (<1)
前庭障害	1 (<1)	0	0	0	0
心臓障害	37 (5)	40 (5)	47 (6)	87 (6)	19 (5)
頻脈	6 (<1)	8 (1)	8 (1)	16 (1)	6 (2)
動悸	10 (1)	9 (1)	6 (<1)	15 (<1)	3 (<1)
上室性期外収縮	2 (<1)	5 (<1)	4 (<1)	9 (<1)	1 (<1)
心室性期外収縮	7 (<1)	2 (<1)	7 (<1)	9 (<1)	0
第一度房室ブロック	1 (<1)	5 (<1)	3 (<1)	8 (<1)	2 (<1)
狭心症	0	3 (<1)	2 (<1)	5 (<1)	0
徐脈	1 (<1)	0	5 (<1)	5 (<1)	2 (<1)
洞性徐脈	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
期外収縮	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
洞性頻脈	3 (<1)	0	4 (<1)	4 (<1)	0
左脚ブロック	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
右脚ブロック	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
心臓瘤	0	1 (<1)	1 (<1)	2 (<1)	0
心筋症	0	1 (<1)	1 (<1)	2 (<1)	0
僧帽弁逸脱	0	1 (<1)	1 (<1)	2 (<1)	0
ウォルフ・パーキンソン・ホワイト症候群	0	2 (<1)	0	2 (<1)	0
急性冠動脈症候群	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 28 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心不全	0	0	1 (<1)	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	1 (<1)	0
伝導障害	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
結節性調律	0	0	1 (<1)	1 (<1)	0
頻脈性不整脈	0	0	1 (<1)	1 (<1)	0
上室性不整脈	1 (<1)	0	0	0	0
心筋虚血	1 (<1)	0	0	0	0
心筋炎	0	0	0	0	1 (<1)
上室性頻脈	1 (<1)	0	0	0	0
発作性頻脈	1 (<1)	0	0	0	1 (<1)
血管障害	84 (11)	322 (42)	277 (36)	599 (39)	25 (7)
潮紅	33 (4)	265 (34)	215 (28)	480 (31)	6 (2)
ほてり	16 (2)	52 (7)	49 (6)	101 (7)	5 (1)
高血圧	24 (3)	12 (2)	20 (3)	32 (2)	13 (4)
充血	0	2 (<1)	7 (<1)	9 (<1)	0
低血圧	3 (<1)	6 (<1)	1 (<1)	7 (<1)	0
静脈瘤	0	4 (<1)	1 (<1)	5 (<1)	0
血腫	5 (<1)	2 (<1)	2 (<1)	4 (<1)	2 (<1)
起立性低血圧	2 (<1)	0	2 (<1)	2 (<1)	0
静脈炎	2 (<1)	0	2 (<1)	2 (<1)	0
レイノー現象	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 29 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
静脈不全	0	1 (<1)	1 (<1)	2 (<1)	0
血管障害	0	0	1 (<1)	1 (<1)	0
動脈障害	0	1 (<1)	0	1 (<1)	0
動脈硬化症	0	0	1 (<1)	1 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	1 (<1)
高血圧クリーゼ	1 (<1)	0	1 (<1)	1 (<1)	0
微小血管症	0	1 (<1)	0	1 (<1)	0
末梢冷感	3 (<1)	1 (<1)	0	1 (<1)	0
末梢性虚血	1 (<1)	1 (<1)	0	1 (<1)	0
静脈痛	0	1 (<1)	0	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0	0
腹腔内血腫	0	0	0	0	1 (<1)
蒼白	1 (<1)	0	0	0	0
静脈狭窄	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	120 (16)	117 (15)	125 (16)	242 (16)	41 (12)
口腔咽頭痛	33 (4)	37 (5)	42 (6)	79 (5)	15 (4)
咳嗽	36 (5)	38 (5)	37 (5)	75 (5)	9 (3)
鼻漏	8 (1)	15 (2)	11 (1)	26 (2)	1 (<1)
鼻閉	8 (1)	9 (1)	4 (<1)	13 (<1)	1 (<1)
呼吸困難	7 (<1)	6 (<1)	5 (<1)	11 (<1)	7 (2)
アレルギー性鼻炎	7 (<1)	3 (<1)	6 (<1)	9 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 30 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
副鼻腔うっ血	2 (<1)	1 (<1)	8 (1)	9 (<1)	0
喘息	2 (<1)	6 (<1)	2 (<1)	8 (<1)	2 (<1)
鼻出血	7 (<1)	4 (<1)	4 (<1)	8 (<1)	2 (<1)
上気道咳症候群	3 (<1)	2 (<1)	4 (<1)	6 (<1)	0
湿性咳嗽	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
上気道うっ血	3 (<1)	0	4 (<1)	4 (<1)	2 (<1)
喘鳴	1 (<1)	3 (<1)	1 (<1)	4 (<1)	0
息詰まり	2 (<1)	0	3 (<1)	3 (<1)	1 (<1)
口腔咽頭不快感	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
気道うっ血	5 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
咽喉刺激感	3 (<1)	3 (<1)	0	3 (<1)	0
アレルギー性咽頭炎	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
咽喉乾燥	2 (<1)	2 (<1)	0	2 (<1)	0
発声障害	3 (<1)	0	2 (<1)	2 (<1)	1 (<1)
しゃっくり	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
咽頭紅斑	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	2 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	1 (<1)	0
アレルギー性副鼻腔炎	1 (<1)	1 (<1)	0	1 (<1)	0
息詰まり感	0	1 (<1)	0	1 (<1)	0
労作性呼吸困難	1 (<1)	1 (<1)	0	1 (<1)	0
過換気	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 31 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
鼻乾燥	2 (<1)	0	1 (<1)	1 (<1)	0
鼻浮腫	0	0	1 (<1)	1 (<1)	0
鼻中隔弯曲	0	1 (<1)	0	1 (<1)	0
口腔咽頭プラーク	1 (<1)	1 (<1)	0	1 (<1)	0
口腔咽頭腫脹	0	0	1 (<1)	1 (<1)	0
呼吸時疼痛	0	0	1 (<1)	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	1 (<1)	0
咽頭嚢腫	0	1 (<1)	0	1 (<1)	0
咽頭腫瘤	0	0	1 (<1)	1 (<1)	0
胸水	0	1 (<1)	0	1 (<1)	0
胸膜炎	0	0	1 (<1)	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	1 (<1)	0
気胸	0	0	1 (<1)	1 (<1)	0
ラ音	2 (<1)	0	1 (<1)	1 (<1)	0
呼吸抑制	0	1 (<1)	0	1 (<1)	0
呼吸障害	0	0	1 (<1)	1 (<1)	0
気道の炎症	1 (<1)	0	1 (<1)	1 (<1)	0
低音性連続性ラ音	3 (<1)	1 (<1)	0	1 (<1)	0
副鼻腔障害	1 (<1)	0	1 (<1)	1 (<1)	0
睡眠時無呼吸症候群	0	0	1 (<1)	1 (<1)	2 (<1)
声帯の炎症	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 32 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
声帯ポリープ	0	0	1 (<1)	1 (<1)	0
アレルギー性咳嗽	1 (<1)	0	0	0	0
アレルギー性呼吸器疾患	1 (<1)	0	0	0	0
アレルギー性呼吸器症状	1 (<1)	0	0	0	0
慢性気管支炎	1 (<1)	0	0	0	0
喀血	1 (<1)	0	0	0	0
低換気	0	0	0	0	1 (<1)
上気道分泌増加	1 (<1)	0	0	0	0
鼻部不快感	1 (<1)	0	0	0	0
鼻茸	1 (<1)	0	0	0	0
鼻中隔穿孔	0	0	0	0	1 (<1)
口腔咽頭水疱形成	1 (<1)	0	0	0	0
咽頭の炎症	1 (<1)	0	0	0	0
季節性鼻炎	0	0	0	0	1 (<1)
くしゃみ	1 (<1)	0	0	0	1 (<1)
扁桃障害	1 (<1)	0	0	0	0
上気道の炎症	1 (<1)	0	0	0	0
胃腸障害	289 (37)	366 (48)	398 (52)	764 (50)	65 (19)
下痢	83 (11)	107 (14)	128 (17)	235 (15)	14 (4)
悪心	67 (9)	93 (12)	105 (14)	198 (13)	16 (5)
上腹部痛	45 (6)	76 (10)	85 (11)	161 (11)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 33 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腹痛	37 (5)	73 (9)	63 (8)	136 (9)	5 (1)
嘔吐	37 (5)	65 (8)	53 (7)	118 (8)	9 (3)
消化不良	20 (3)	35 (5)	40 (5)	75 (5)	6 (2)
便秘	33 (4)	23 (3)	29 (4)	52 (3)	9 (3)
胃腸障害	8 (1)	18 (2)	34 (4)	52 (3)	2 (<1)
歯痛	19 (2)	18 (2)	26 (3)	44 (3)	4 (1)
胃炎	11 (1)	22 (3)	20 (3)	42 (3)	4 (1)
腹部不快感	11 (1)	19 (2)	14 (2)	33 (2)	1 (<1)
胃食道逆流性疾患	15 (2)	15 (2)	18 (2)	33 (2)	2 (<1)
口内乾燥	6 (<1)	16 (2)	10 (1)	26 (2)	1 (<1)
鼓腸	13 (2)	11 (1)	9 (1)	20 (1)	2 (<1)
腹部膨満	11 (1)	4 (<1)	14 (2)	18 (1)	0
痔核	7 (<1)	8 (1)	8 (1)	16 (1)	1 (<1)
歯周炎	3 (<1)	2 (<1)	10 (1)	12 (<1)	0
下腹部痛	3 (<1)	3 (<1)	7 (<1)	10 (<1)	0
嚥下障害	6 (<1)	5 (<1)	5 (<1)	10 (<1)	2 (<1)
齲歯	2 (<1)	4 (<1)	5 (<1)	9 (<1)	3 (<1)
食中毒	2 (<1)	4 (<1)	5 (<1)	9 (<1)	1 (<1)
便失禁	2 (<1)	3 (<1)	4 (<1)	7 (<1)	0
心窩部不快感	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
おくび	0	2 (<1)	3 (<1)	5 (<1)	0
歯肉炎	3 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 34 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
裂孔ヘルニア	2 (<1)	4 (<1)	1 (<1)	5 (<1)	0
胃酸過多	2 (<1)	5 (<1)	0	5 (<1)	0
便意切迫	0	1 (<1)	3 (<1)	4 (<1)	2 (<1)
小腸炎	0	1 (<1)	3 (<1)	4 (<1)	0
口の感覚鈍麻	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
逆流性食道炎	2 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
腹部硬直	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
腹部圧痛	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
大腸炎	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
十二指腸潰瘍	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
排便回数増加	0	1 (<1)	2 (<1)	3 (<1)	0
胃障害	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
流涎過多	0	3 (<1)	0	3 (<1)	0
口内炎	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
埋伏歯	1 (<1)	0	3 (<1)	3 (<1)	1 (<1)
腹部ヘルニア	0	2 (<1)	0	2 (<1)	0
異常便	1 (<1)	2 (<1)	0	2 (<1)	0
結腸ポリープ	2 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
腸憩室	0	0	2 (<1)	2 (<1)	1 (<1)
歯肉出血	1 (<1)	2 (<1)	0	2 (<1)	1 (<1)
歯肉痛	1 (<1)	0	2 (<1)	2 (<1)	0
舌痛	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 35 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
吐血	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
過敏性腸症候群	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
口腔内潰瘍形成	4 (<1)	1 (<1)	1 (<1)	2 (<1)	0
嚥下痛	0	1 (<1)	1 (<1)	2 (<1)	0
食道炎	0	2 (<1)	0	2 (<1)	0
口腔内痛	0	1 (<1)	1 (<1)	2 (<1)	0
口の錯感覚	2 (<1)	2 (<1)	0	2 (<1)	0
アフタ性口内炎	1 (<1)	0	1 (<1)	1 (<1)	0
唾液欠乏	0	1 (<1)	0	1 (<1)	0
便通不規則	1 (<1)	0	1 (<1)	1 (<1)	0
口腔灼熱感症候群	0	0	1 (<1)	1 (<1)	0
便習慣変化	0	0	1 (<1)	1 (<1)	0
口唇炎	0	1 (<1)	0	1 (<1)	0
クローン病	0	1 (<1)	0	1 (<1)	0
憩室穿孔	0	1 (<1)	0	1 (<1)	0
十二指腸ポリープ	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
腸炎	1 (<1)	0	1 (<1)	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)	1 (<1)
胃潰瘍	0	0	1 (<1)	1 (<1)	0
出血性胃炎	0	1 (<1)	0	1 (<1)	1 (<1)
胃十二指腸炎	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 36 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
胃腸出血	1 (<1)	0	1 (<1)	1 (<1)	0
消化器痛	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
歯肉嚢胞	0	0	1 (<1)	1 (<1)	0
歯肉障害	0	0	1 (<1)	1 (<1)	0
歯肉腫脹	1 (<1)	1 (<1)	0	1 (<1)	0
舌炎	0	1 (<1)	0	1 (<1)	0
血便排泄	2 (<1)	0	1 (<1)	1 (<1)	0
胃排出不全	0	1 (<1)	0	1 (<1)	0
炎症性腸疾患	0	0	1 (<1)	1 (<1)	0
腸閉塞	0	0	1 (<1)	1 (<1)	0
腸管ポリープ	0	1 (<1)	0	1 (<1)	0
口唇水疱	0	1 (<1)	0	1 (<1)	0
弛緩歯	0	1 (<1)	0	1 (<1)	0
腰ヘルニア	0	0	1 (<1)	1 (<1)	0
マロリー・ワイス症候群	0	1 (<1)	0	1 (<1)	0
神経因性腸	0	0	1 (<1)	1 (<1)	0
食道出血	0	1 (<1)	0	1 (<1)	0
食道痙攣	0	0	1 (<1)	1 (<1)	0
食道潰瘍	0	0	1 (<1)	1 (<1)	0
膵脂肪腫症	0	1 (<1)	0	1 (<1)	0
膵臓障害	0	0	1 (<1)	1 (<1)	0
膵機能不全	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 37 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
膵炎	1 (<1)	1 (<1)	0	1 (<1)	0
消化性潰瘍	0	0	1 (<1)	1 (<1)	0
歯周病	0	1 (<1)	0	1 (<1)	0
肛門周囲痛	2 (<1)	1 (<1)	0	1 (<1)	0
直腸出血	1 (<1)	1 (<1)	0	1 (<1)	0
逆流性胃炎	1 (<1)	0	1 (<1)	1 (<1)	0
唾液管閉塞	0	0	1 (<1)	1 (<1)	0
舌腫脹	0	1 (<1)	0	1 (<1)	0
舌苔	0	0	1 (<1)	1 (<1)	0
舌障害	1 (<1)	0	1 (<1)	1 (<1)	0
地図状舌	0	1 (<1)	0	1 (<1)	0
歯の障害	1 (<1)	1 (<1)	0	1 (<1)	0
歯の磨耗	0	1 (<1)	0	1 (<1)	0
歯の脱落	1 (<1)	1 (<1)	0	1 (<1)	0
臍ヘルニア	1 (<1)	0	1 (<1)	1 (<1)	0
裂肛	1 (<1)	0	0	0	0
根尖肉芽腫	0	0	0	0	1 (<1)
呼気臭	1 (<1)	0	0	0	0
口唇のひび割れ	1 (<1)	0	0	0	0
潰瘍性大腸炎	1 (<1)	0	0	0	0
十二指腸胃逆流	1 (<1)	0	0	0	0
胃ポリープ	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 38 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯肉紅斑	0	0	0	0	1 (<1)
痔出血	0	0	0	0	1 (<1)
口唇乾燥	1 (<1)	0	0	0	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
直腸攣縮	0	0	0	0	1 (<1)
脆弱歯	1 (<1)	0	0	0	0
舌乾燥	1 (<1)	0	0	0	0
歯の発育障害	1 (<1)	0	0	0	0
肝胆道系障害	11 (1)	10 (1)	15 (2)	25 (2)	6 (2)
肝障害	1 (<1)	2 (<1)	6 (<1)	8 (<1)	2 (<1)
胆石症	3 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (<1)
肝細胞融解性肝炎	0	1 (<1)	2 (<1)	3 (<1)	0
胆道ジスキネジー	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
肝嚢胞	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
脂肪肝	1 (<1)	2 (<1)	0	2 (<1)	0
胆管結石	2 (<1)	0	1 (<1)	1 (<1)	0
胆嚢浮腫	0	0	1 (<1)	1 (<1)	0
肝炎	1 (<1)	0	1 (<1)	1 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
高ビリルビン血症	2 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 39 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
高トランスアミナーゼ血症	0	1 (<1)	0	1 (<1)	0
中毒性肝炎	1 (<1)	0	0	0	0
皮膚および皮下組織障害	157 (20)	245 (32)	247 (33)	492 (32)	60 (17)
そう痒症	30 (4)	62 (8)	58 (8)	120 (8)	7 (2)
発疹	26 (3)	58 (8)	55 (7)	113 (7)	9 (3)
紅斑	10 (1)	36 (5)	54 (7)	90 (6)	6 (2)
多汗症	10 (1)	17 (2)	26 (3)	43 (3)	5 (1)
脱毛症	19 (2)	17 (2)	11 (1)	28 (2)	7 (2)
寝汗	8 (1)	13 (2)	14 (2)	27 (2)	2 (<1)
蕁麻疹	9 (1)	11 (1)	13 (2)	24 (2)	2 (<1)
アレルギー性皮膚炎	5 (<1)	13 (2)	8 (1)	21 (1)	1 (<1)
全身性そう痒症	3 (<1)	10 (1)	9 (1)	19 (1)	3 (<1)
ざ瘡	13 (2)	7 (<1)	8 (1)	15 (<1)	4 (1)
皮膚乾燥	6 (<1)	7 (<1)	7 (<1)	14 (<1)	1 (<1)
そう痒性皮疹	2 (<1)	8 (1)	5 (<1)	13 (<1)	0
皮膚灼熱感	0	6 (<1)	7 (<1)	13 (<1)	0
湿疹	4 (<1)	7 (<1)	5 (<1)	12 (<1)	2 (<1)
皮膚炎	4 (<1)	4 (<1)	6 (<1)	10 (<1)	1 (<1)
斑状皮疹	1 (<1)	1 (<1)	9 (1)	10 (<1)	0
全身紅斑	0	4 (<1)	4 (<1)	8 (<1)	0
光線過敏性反応	1 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 40 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
全身性皮疹	0	4 (<1)	4 (<1)	8 (<1)	0
顔面感覚鈍麻	7 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
紅斑性皮疹	0	2 (<1)	4 (<1)	6 (<1)	0
酒さ	3 (<1)	6 (<1)	0	6 (<1)	0
過角化	0	2 (<1)	2 (<1)	4 (<1)	0
痒疹	0	3 (<1)	1 (<1)	4 (<1)	0
乾癬	5 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
丘疹性皮疹	0	1 (<1)	3 (<1)	4 (<1)	0
皮膚色素過剰	2 (<1)	3 (<1)	1 (<1)	4 (<1)	2 (<1)
皮膚刺激	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
皮膚のつっぱり感	0	1 (<1)	3 (<1)	4 (<1)	0
水疱	1 (<1)	3 (<1)	0	3 (<1)	0
接触性皮膚炎	3 (<1)	2 (<1)	1 (<1)	3 (<1)	3 (<1)
薬疹	0	1 (<1)	2 (<1)	3 (<1)	0
斑状出血	4 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
アレルギー性そう痒症	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
皮膚剥脱	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
皮膚病変	3 (<1)	3 (<1)	0	3 (<1)	0
皮膚反応	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)
顔面腫脹	1 (<1)	1 (<1)	2 (<1)	3 (<1)	4 (1)
皮膚嚢腫	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
ざ瘡様皮膚炎	1 (<1)	2 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 41 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
網状皮斑	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
爪破損	1 (<1)	2 (<1)	0	2 (<1)	0
皮膚疼痛	0	0	2 (<1)	2 (<1)	0
皮膚硬結	1 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)
皮膚熱感	0	1 (<1)	1 (<1)	2 (<1)	0
日光性角化症	0	0	1 (<1)	1 (<1)	0
冷汗	2 (<1)	0	1 (<1)	1 (<1)	0
皮膚弛緩症	0	1 (<1)	0	1 (<1)	0
アトピー性皮膚炎	1 (<1)	1 (<1)	0	1 (<1)	0
紅色症	0	0	1 (<1)	1 (<1)	0
剥脱性発疹	1 (<1)	1 (<1)	0	1 (<1)	0
紅色汗疹	1 (<1)	1 (<1)	0	1 (<1)	0
掌蹠角化症	0	1 (<1)	0	1 (<1)	0
特発性蕁麻疹	0	1 (<1)	0	1 (<1)	0
内出血発生の増加傾向	0	0	1 (<1)	1 (<1)	1 (<1)
嵌入爪	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
毛孔性角化症	0	0	1 (<1)	1 (<1)	0
睫毛眉毛脱落症	0	1 (<1)	0	1 (<1)	0
爪変色	1 (<1)	1 (<1)	0	1 (<1)	0
爪の障害	0	0	1 (<1)	1 (<1)	0
色素沈着障害	3 (<1)	1 (<1)	0	1 (<1)	0
瘢痕	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 42 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脂腺障害	0	0	1 (<1)	1 (<1)	0
脂漏	0	1 (<1)	0	1 (<1)	0
皮膚色素脱失	0	0	1 (<1)	1 (<1)	0
皮膚変色	1 (<1)	0	1 (<1)	1 (<1)	0
皮膚色素減少	0	1 (<1)	0	1 (<1)	0
皮膚潰瘍	0	0	1 (<1)	1 (<1)	0
スティーブンス・ジョンソン症候群	0	1 (<1)	0	1 (<1)	0
皮下結節	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
毛細血管拡張症	1 (<1)	1 (<1)	0	1 (<1)	0
一過性棘融解性皮膚症	0	0	1 (<1)	1 (<1)	0
乾皮症	1 (<1)	0	1 (<1)	1 (<1)	0
血管浮腫	0	0	0	0	1 (<1)
頭部粃糠疹	0	0	0	0	1 (<1)
発汗障害	1 (<1)	0	0	0	0
多形紅斑	1 (<1)	0	0	0	0
皮膚肉芽腫	1 (<1)	0	0	0	0
皮下出血	0	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0	0
黒子	1 (<1)	0	0	0	0
脂肪組織萎縮症	0	0	0	0	1 (<1)
後天性リポジストロフィー	0	0	0	0	1 (<1)
爪床障害	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 43 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
爪床の炎症	1 (<1)	0	0	0	0
神経皮膚炎	0	0	0	0	1 (<1)
点状出血	3 (<1)	0	0	0	0
光線性皮膚症	1 (<1)	0	0	0	0
ばら色粃糠疹	3 (<1)	0	0	0	0
前癌性皮膚病変	1 (<1)	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0	0
猩紅熱様発疹	1 (<1)	0	0	0	0
小水疱性皮疹	1 (<1)	0	0	0	0
脂漏性皮膚炎	0	0	0	0	1 (<1)
皮膚障害	1 (<1)	0	0	0	0
皮膚小結節	0	0	0	0	1 (<1)
裂毛	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	261 (34)	246 (32)	246 (32)	492 (32)	82 (23)
背部痛	90 (12)	94 (12)	82 (11)	176 (12)	32 (9)
関節痛	65 (8)	66 (9)	64 (8)	130 (9)	17 (5)
四肢痛	58 (8)	58 (8)	55 (7)	113 (7)	21 (6)
筋痙縮	34 (4)	27 (4)	50 (7)	77 (5)	8 (2)
頚部痛	22 (3)	27 (4)	20 (3)	47 (3)	5 (1)
筋力低下	36 (5)	18 (2)	24 (3)	42 (3)	6 (2)
筋骨格痛	26 (3)	14 (2)	21 (3)	35 (2)	8 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 44 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋肉痛	26 (3)	13 (2)	13 (2)	26 (2)	4 (1)
滑液包炎	3 (<1)	5 (<1)	6 (<1)	11 (<1)	0
筋骨格硬直	11 (1)	7 (<1)	4 (<1)	11 (<1)	9 (3)
関節炎	1 (<1)	4 (<1)	6 (<1)	10 (<1)	2 (<1)
関節腫脹	3 (<1)	5 (<1)	4 (<1)	9 (<1)	2 (<1)
筋骨格系胸痛	6 (<1)	4 (<1)	5 (<1)	9 (<1)	1 (<1)
重感	4 (<1)	7 (<1)	2 (<1)	9 (<1)	2 (<1)
変形性関節症	5 (<1)	4 (<1)	4 (<1)	8 (<1)	0
骨痛	4 (<1)	3 (<1)	4 (<1)	7 (<1)	0
関節硬直	0	2 (<1)	5 (<1)	7 (<1)	1 (<1)
腱炎	9 (1)	3 (<1)	3 (<1)	6 (<1)	0
椎間板突出	2 (<1)	3 (<1)	2 (<1)	5 (<1)	0
筋緊張	2 (<1)	2 (<1)	3 (<1)	5 (<1)	0
側腹部痛	1 (<1)	0	4 (<1)	4 (<1)	2 (<1)
骨減少症	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
骨粗鬆症	4 (<1)	3 (<1)	1 (<1)	4 (<1)	0
関節周囲炎	4 (<1)	1 (<1)	3 (<1)	4 (<1)	0
変形性脊椎症	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
滑液嚢腫	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
腱鞘炎	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
関節障害	0	1 (<1)	2 (<1)	3 (<1)	0
尾骨痛	2 (<1)	0	3 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 45 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
椎間板障害	0	2 (<1)	1 (<1)	3 (<1)	0
筋骨格不快感	3 (<1)	1 (<1)	2 (<1)	3 (<1)	0
骨壊死	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
尻径部痛	1 (<1)	2 (<1)	0	2 (<1)	0
関節滲出液	0	0	2 (<1)	2 (<1)	0
筋拘縮	1 (<1)	0	2 (<1)	2 (<1)	1 (<1)
筋攣縮	4 (<1)	2 (<1)	0	2 (<1)	1 (<1)
ミオキミア	0	1 (<1)	1 (<1)	2 (<1)	0
四肢の結節	0	0	2 (<1)	2 (<1)	0
膝蓋大腿部痛症候群	0	1 (<1)	1 (<1)	2 (<1)	0
肩回旋筋腱板症候群	2 (<1)	0	2 (<1)	2 (<1)	0
シェーグレン症候群	0	2 (<1)	0	2 (<1)	0
弾発指	0	1 (<1)	1 (<1)	2 (<1)	0
腋窩腫瘤	1 (<1)	1 (<1)	0	1 (<1)	0
軟骨炎	0	1 (<1)	0	1 (<1)	0
腱付着部症	0	1 (<1)	0	1 (<1)	0
外骨腫	0	0	1 (<1)	1 (<1)	2 (<1)
四肢拘縮	0	1 (<1)	0	1 (<1)	0
成長痛	0	0	1 (<1)	1 (<1)	1 (<1)
椎間板圧迫	0	1 (<1)	0	1 (<1)	0
椎間板変性症	0	0	1 (<1)	1 (<1)	0
四肢不快感	1 (<1)	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 46 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
下肢腫瘤	0	0	1 (<1)	1 (<1)	0
中足骨痛	0	1 (<1)	0	1 (<1)	0
筋肉内出血	0	0	1 (<1)	1 (<1)	0
筋腫脹	0	1 (<1)	0	1 (<1)	0
筋硬化症	1 (<1)	1 (<1)	0	1 (<1)	0
筋炎	1 (<1)	0	1 (<1)	1 (<1)	0
骨端症	0	0	1 (<1)	1 (<1)	0
顎痛	4 (<1)	1 (<1)	0	1 (<1)	1 (<1)
乾癬性関節症	0	0	1 (<1)	1 (<1)	0
足根洞症候群	0	1 (<1)	0	1 (<1)	0
脊椎障害	0	1 (<1)	0	1 (<1)	0
脊椎分離	0	1 (<1)	0	1 (<1)	0
滑膜障害	0	1 (<1)	0	1 (<1)	0
腱障害	1 (<1)	1 (<1)	0	1 (<1)	0
斜頚	1 (<1)	0	1 (<1)	1 (<1)	0
線維筋痛	2 (<1)	0	0	0	0
運動性低下	1 (<1)	0	0	0	1 (<1)
筋肉疲労	1 (<1)	0	0	0	0
筋固縮	0	0	0	0	1 (<1)
結節性変形性関節症	1 (<1)	0	0	0	0
回帰性リウマチ	1 (<1)	0	0	0	0
足底筋膜炎	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 47 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
多発性関節炎	1 (<1)	0	0	0	0
関節リウマチ	2 (<1)	0	0	0	0
脊柱変形	1 (<1)	0	0	0	0
滑膜炎	1 (<1)	0	0	0	0
腱痛	1 (<1)	0	0	0	0
腎および尿路障害	151 (20)	146 (19)	176 (23)	322 (21)	58 (17)
蛋白尿	59 (8)	67 (9)	85 (11)	152 (10)	30 (9)
血尿	34 (4)	33 (4)	41 (5)	74 (5)	10 (3)
ミクロアルブミン尿	24 (3)	35 (5)	36 (5)	71 (5)	15 (4)
ケトン尿	6 (<1)	7 (<1)	15 (2)	22 (1)	1 (<1)
排尿困難	11 (1)	7 (<1)	13 (2)	20 (1)	1 (<1)
尿意切迫	11 (1)	10 (1)	9 (1)	19 (1)	5 (1)
腎結石症	8 (1)	5 (<1)	8 (1)	13 (<1)	1 (<1)
頻尿	12 (2)	7 (<1)	6 (<1)	13 (<1)	3 (<1)
尿失禁	7 (<1)	8 (1)	5 (<1)	13 (<1)	3 (<1)
尿閉	4 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
糖尿	9 (1)	4 (<1)	3 (<1)	7 (<1)	2 (<1)
切迫性尿失禁	0	2 (<1)	4 (<1)	6 (<1)	1 (<1)
排尿躊躇	5 (<1)	1 (<1)	5 (<1)	6 (<1)	1 (<1)
アルブミン尿	0	2 (<1)	2 (<1)	4 (<1)	2 (<1)
腎臓痛	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 48 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿臭異常	1 (<1)	1 (<1)	3 (<1)	4 (<1)	0
膀胱機能障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
白血球尿	2 (<1)	0	3 (<1)	3 (<1)	1 (<1)
神経因性膀胱	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
腎仙痛	1 (<1)	1 (<1)	2 (<1)	3 (<1)	0
膀胱刺激症状	0	1 (<1)	1 (<1)	2 (<1)	0
非感染性膀胱炎	3 (<1)	1 (<1)	1 (<1)	2 (<1)	0
グロブリン尿	0	2 (<1)	0	2 (<1)	0
緊張性膀胱	0	1 (<1)	1 (<1)	2 (<1)	0
起立性蛋白尿症	0	1 (<1)	1 (<1)	2 (<1)	0
腎嚢胞	1 (<1)	2 (<1)	0	2 (<1)	0
膀胱痛	0	1 (<1)	0	1 (<1)	0
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
着色尿	0	0	1 (<1)	1 (<1)	0
出血性膀胱炎	0	1 (<1)	0	1 (<1)	0
失禁	0	0	1 (<1)	1 (<1)	1 (<1)
排尿異常	0	1 (<1)	0	1 (<1)	0
腎下垂症	1 (<1)	1 (<1)	0	1 (<1)	0
腎障害	0	1 (<1)	0	1 (<1)	0
慢性腎不全	0	0	1 (<1)	1 (<1)	0
腎機能障害	0	0	1 (<1)	1 (<1)	0
腎尿細管性アシドーシス	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 49 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
有痛性排尿困難	0	1 (<1)	0	1 (<1)	0
尿管瘤	0	1 (<1)	0	1 (<1)	0
尿路痛	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
膀胱憩室	1 (<1)	0	0	0	0
膀胱痙縮	1 (<1)	0	0	0	0
尿路結石	1 (<1)	0	0	0	0
肋骨脊柱角圧痛	1 (<1)	0	0	0	0
慢性糸球体腎炎	1 (<1)	0	0	0	0
高血圧性腎症	0	0	0	0	1 (<1)
ネフローゼ症候群	0	0	0	0	1 (<1)
夜間頻尿	1 (<1)	0	0	0	1 (<1)
膿尿	0	0	0	0	1 (<1)
腹圧性尿失禁	1 (<1)	0	0	0	0
尿路の炎症	1 (<1)	0	0	0	0
妊娠、産褥および周産期の状態	3 (<1)	1 (<1)	0	1 (<1)	0
妊娠	0	1 (<1)	0	1 (<1)	0
自然流産	2 (<1)	0	0	0	0
妊娠浮腫	1 (<1)	0	0	0	0
生殖系および乳房障害	76 (10)	76 (10)	76 (10)	152 (10)	26 (7)
月経困難症	9 (1)	12 (2)	11 (1)	23 (2)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 50 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
不規則月経	9 (1)	5 (<1)	10 (1)	15 (<1)	5 (1)
不正子宮出血	6 (<1)	8 (1)	7 (<1)	15 (<1)	5 (1)
卵巣嚢胞	5 (<1)	9 (1)	4 (<1)	13 (<1)	3 (<1)
月経過多	6 (<1)	5 (<1)	6 (<1)	11 (<1)	3 (<1)
勃起不全	4 (<1)	5 (<1)	5 (<1)	10 (<1)	0
無月経	6 (<1)	3 (<1)	5 (<1)	8 (<1)	3 (<1)
乳房痛	1 (<1)	2 (<1)	6 (<1)	8 (<1)	0
腟出血	3 (<1)	4 (<1)	3 (<1)	7 (<1)	0
骨盤痛	4 (<1)	3 (<1)	3 (<1)	6 (<1)	0
頻発月経	2 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
月経障害	2 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
子宮出血	2 (<1)	1 (<1)	3 (<1)	4 (<1)	1 (<1)
乳房嚢胞	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
月経遅延	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
性機能不全	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
萎縮性外陰腟炎	0	0	2 (<1)	2 (<1)	0
乳房腫瘤	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
乳房圧痛	0	0	2 (<1)	2 (<1)	0
子宮頚部上皮異形成	1 (<1)	2 (<1)	0	2 (<1)	0
閉経期症状	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
卵巣嚢胞破裂	1 (<1)	2 (<1)	0	2 (<1)	0
多嚢胞性卵巣	0	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 51 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
前立腺炎	0	1 (<1)	1 (<1)	2 (<1)	0
外陰腟乾燥	0	1 (<1)	1 (<1)	2 (<1)	0
外陰腟そう痒症	0	1 (<1)	1 (<1)	2 (<1)	0
腺筋症	0	0	1 (<1)	1 (<1)	0
バルトリン腺炎	0	0	1 (<1)	1 (<1)	0
良性前立腺肥大症	1 (<1)	1 (<1)	0	1 (<1)	0
乳房分泌	0	0	1 (<1)	1 (<1)	0
乳房不快感	0	1 (<1)	0	1 (<1)	0
乳房障害	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
乳房出血	0	1 (<1)	0	1 (<1)	0
子宮頚部の炎症	0	1 (<1)	0	1 (<1)	0
性交困難	0	0	1 (<1)	1 (<1)	0
射精障害	0	1 (<1)	0	1 (<1)	0
子宮内膜増殖症	0	1 (<1)	0	1 (<1)	0
子宮内膜症	0	1 (<1)	0	1 (<1)	0
線維嚢胞性乳腺疾患	3 (<1)	0	1 (<1)	1 (<1)	0
乳汁漏出症	0	1 (<1)	0	1 (<1)	0
乳頭障害	0	1 (<1)	0	1 (<1)	0
希発月経	1 (<1)	1 (<1)	0	1 (<1)	0
閉経後出血	2 (<1)	0	1 (<1)	1 (<1)	0
早発閉経	0	1 (<1)	0	1 (<1)	0
前立腺腫大	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 52 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
精巣障害	0	0	1 (<1)	1 (<1)	0
精巣痛	3 (<1)	1 (<1)	0	1 (<1)	0
子宮の炎症	0	1 (<1)	0	1 (<1)	0
子宮ポリープ	1 (<1)	1 (<1)	0	1 (<1)	0
子宮腟脱	0	1 (<1)	0	1 (<1)	0
腟分泌物	1 (<1)	0	1 (<1)	1 (<1)	0
バルトリン嚢腫	2 (<1)	0	0	0	0
乳房腫大	0	0	0	0	1 (<1)
乳房硬結	1 (<1)	0	0	0	0
子宮頚管ポリープ	0	0	0	0	1 (<1)
生殖器病変	1 (<1)	0	0	0	0
機能性子宮出血	1 (<1)	0	0	0	1 (<1)
子宮頚部びらん	1 (<1)	0	0	0	0
外陰腟痛	1 (<1)	0	0	0	0
先天性、家族性および遺伝性障害	1 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
異形成母斑症候群	0	1 (<1)	1 (<1)	2 (<1)	0
角膜ジストロフィー	0	0	1 (<1)	1 (<1)	0
先天性心臓疾患	0	1 (<1)	0	1 (<1)	0
陰嚢水瘤	0	0	1 (<1)	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	1 (<1)	0
ジルベール症候群	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 53 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
過誤腫	0	0	0	0	1 (<1)
一般・全身障害および投与部位の状態	194 (25)	178 (23)	216 (28)	394 (26)	133 (38)
疲労	87 (11)	94 (12)	98 (13)	192 (13)	30 (9)
発熱	40 (5)	27 (4)	44 (6)	71 (5)	17 (5)
無力症	20 (3)	24 (3)	17 (2)	41 (3)	15 (4)
疼痛	11 (1)	15 (2)	15 (2)	30 (2)	5 (1)
熱感	2 (<1)	15 (2)	12 (2)	27 (2)	4 (1)
インフルエンザ様疾患	11 (1)	10 (1)	15 (2)	25 (2)	3 (<1)
胸痛	10 (1)	9 (1)	14 (2)	23 (2)	3 (<1)
末梢性浮腫	19 (2)	7 (<1)	16 (2)	23 (2)	4 (1)
歩行障害	10 (1)	8 (1)	11 (1)	19 (1)	6 (2)
非心臓性胸痛	2 (<1)	3 (<1)	7 (<1)	10 (<1)	3 (<1)
胸部不快感	5 (<1)	4 (<1)	4 (<1)	8 (<1)	1 (<1)
悪寒	7 (<1)	4 (<1)	4 (<1)	8 (<1)	4 (1)
易刺激性	5 (<1)	4 (<1)	3 (<1)	7 (<1)	2 (<1)
倦怠感	1 (<1)	2 (<1)	5 (<1)	7 (<1)	2 (<1)
顔面痛	3 (<1)	2 (<1)	4 (<1)	6 (<1)	2 (<1)
嚢胞	1 (<1)	0	4 (<1)	4 (<1)	0
高熱	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
浮腫	1 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 54 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腫脹	0	2 (<1)	1 (<1)	3 (<1)	0
圧痛	0	0	3 (<1)	3 (<1)	0
冷感	1 (<1)	0	2 (<1)	2 (<1)	0
炎症	0	0	2 (<1)	2 (<1)	0
医療機器による疼痛	0	0	2 (<1)	2 (<1)	0
粘膜乾燥	0	1 (<1)	1 (<1)	2 (<1)	0
腋窩痛	0	0	1 (<1)	1 (<1)	0
医療機器不具合	0	1 (<1)	0	1 (<1)	0
不快感	0	0	1 (<1)	1 (<1)	0
医療機器関連眼合併症	1 (<1)	1 (<1)	0	1 (<1)	0
脂肪壊死	0	1 (<1)	0	1 (<1)	0
異常感	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
びくびく感	0	0	1 (<1)	1 (<1)	0
全身性浮腫	0	1 (<1)	0	1 (<1)	0
重力性浮腫	0	0	1 (<1)	1 (<1)	0
閉塞性ヘルニア	0	0	1 (<1)	1 (<1)	0
注入部位血腫	0	1 (<1)	0	1 (<1)	0
注射部位血腫	0	0	1 (<1)	1 (<1)	5 (1)
注射部位硬結	0	0	1 (<1)	1 (<1)	7 (2)
局所腫脹	0	1 (<1)	0	1 (<1)	0
足のもつれ	1 (<1)	1 (<1)	0	1 (<1)	0
腫瘤	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 55 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
粘膜の炎症	0	0	1 (<1)	1 (<1)	0
不活発	0	0	1 (<1)	1 (<1)	0
軟部組織の炎症	0	1 (<1)	0	1 (<1)	0
温度変化不耐症	0	1 (<1)	0	1 (<1)	0
口渇	1 (<1)	0	1 (<1)	1 (<1)	0
血管穿刺部位血腫	0	0	1 (<1)	1 (<1)	0
血管穿刺部位出血	0	1 (<1)	0	1 (<1)	0
血管穿刺部位疼痛	0	1 (<1)	0	1 (<1)	0
血管穿刺部位反応	0	1 (<1)	0	1 (<1)	0
適用部位浮腫	0	0	0	0	1 (<1)
嚢胞破裂	0	0	0	0	1 (<1)
体温変動感	1 (<1)	0	0	0	0
全身症状	1 (<1)	0	0	0	0
ヘルニア痛	1 (<1)	0	0	0	0
空腹	1 (<1)	0	0	0	0
注射直後反応	0	0	0	0	4 (1)
注射部位変色	0	0	0	0	1 (<1)
注射部位乾燥	0	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	0	1 (<1)
注射部位紅斑	0	0	0	0	31 (9)
注射部位血管外漏出	0	0	0	0	1 (<1)
注射部位出血	0	0	0	0	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 56 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
注射部位過敏反応	0	0	0	0	1 (<1)
注射部位肥厚	0	0	0	0	3 (<1)
注射部位炎症	0	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	0	7 (2)
注射部位結節	0	0	0	0	1 (<1)
注射部位浮腫	0	0	0	0	3 (<1)
注射部位疼痛	0	0	0	0	29 (8)
注射部位そう痒感	0	0	0	0	13 (4)
注射部位発疹	0	0	0	0	3 (<1)
注射部位反応	0	0	0	0	5 (1)
注射部位瘢痕	0	0	0	0	1 (<1)
注射部位腫脹	0	0	0	0	10 (3)
注射部位蕁麻疹	0	0	0	0	3 (<1)
注射部位熱感	0	0	0	0	3 (<1)
微石症	0	0	0	0	1 (<1)
壊死	0	0	0	0	1 (<1)
骨盤腔内腫瘤	1 (<1)	0	0	0	0
ワクチン接種部位疼痛	1 (<1)	0	0	0	0
臨床検査	200 (26)	212 (28)	216 (28)	428 (28)	106 (30)
アラニン・アミノトランスフェラーゼ増加	38 (5)	45 (6)	49 (6)	94 (6)	20 (6)
尿中アルブミン陽性	27 (4)	46 (6)	36 (5)	82 (5)	18 (5)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 57 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
アスパラギン酸アミノトランスフェラーゼ増加	18 (2)	33 (4)	29 (4)	62 (4)	14 (4)
尿中蛋白陽性	22 (3)	28 (4)	20 (3)	48 (3)	15 (4)
尿中血陽性	7 (<1)	16 (2)	18 (2)	34 (2)	4 (1)
血中副甲状腺ホルモン増加	6 (<1)	15 (2)	17 (2)	32 (2)	2 (<1)
γ－グルタミルトランスフェラーゼ増加	19 (2)	20 (3)	12 (2)	32 (2)	8 (2)
尿中白血球陽性	13 (2)	14 (2)	15 (2)	29 (2)	9 (3)
血中ブドウ糖増加	7 (<1)	10 (1)	18 (2)	28 (2)	7 (2)
尿中β２ミクログロブリン増加	14 (2)	12 (2)	15 (2)	27 (2)	5 (1)
白血球数減少	1 (<1)	13 (2)	12 (2)	25 (2)	1 (<1)
体重減少	3 (<1)	11 (1)	10 (1)	21 (1)	3 (<1)
リンパ球数減少	1 (<1)	9 (1)	8 (1)	17 (1)	1 (<1)
尿中ケトン体陽性	2 (<1)	7 (<1)	10 (1)	17 (1)	2 (<1)
体重増加	11 (1)	5 (<1)	11 (1)	16 (1)	4 (1)
ヘモグロビン減少	5 (<1)	8 (1)	6 (<1)	14 (<1)	1 (<1)
肝酵素上昇	10 (1)	7 (<1)	7 (<1)	14 (<1)	7 (2)
白血球数増加	14 (2)	8 (1)	6 (<1)	14 (<1)	5 (1)
好中球数増加	12 (2)	7 (<1)	6 (<1)	13 (<1)	2 (<1)
尿中赤血球陽性	6 (<1)	8 (1)	5 (<1)	13 (<1)	2 (<1)
β２ミクログロブリン増加	2 (<1)	4 (<1)	7 (<1)	11 (<1)	0
血中クレアチニン増加	5 (<1)	6 (<1)	5 (<1)	11 (<1)	6 (2)
血中トリグリセリド増加	5 (<1)	6 (<1)	3 (<1)	9 (<1)	6 (2)
ヘマトクリット減少	4 (<1)	6 (<1)	3 (<1)	9 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 58 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中カリウム増加	0	4 (<1)	3 (<1)	7 (<1)	1 (<1)
好中球数減少	2 (<1)	6 (<1)	1 (<1)	7 (<1)	1 (<1)
ビタミンＤ減少	2 (<1)	5 (<1)	2 (<1)	7 (<1)	1 (<1)
血中アルカリホスファターゼ増加	7 (<1)	4 (<1)	2 (<1)	6 (<1)	1 (<1)
血中コレステロール増加	2 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
心電図ＱＴ延長	7 (<1)	1 (<1)	5 (<1)	6 (<1)	5 (1)
尿中ブドウ糖陽性	3 (<1)	3 (<1)	3 (<1)	6 (<1)	3 (<1)
肝機能検査異常	2 (<1)	3 (<1)	3 (<1)	6 (<1)	0
赤血球数減少	3 (<1)	4 (<1)	2 (<1)	6 (<1)	0
血中ビリルビン増加	9 (1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
血中乳酸脱水素酵素増加	4 (<1)	5 (<1)	0	5 (<1)	0
体温上昇	1 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
血圧上昇	1 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)
血中尿素増加	2 (<1)	0	4 (<1)	4 (<1)	1 (<1)
好酸球数増加	2 (<1)	2 (<1)	2 (<1)	4 (<1)	0
血液学的検査異常	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
リンパ球形態異常	1 (<1)	2 (<1)	2 (<1)	4 (<1)	0
血小板数減少	2 (<1)	4 (<1)	0	4 (<1)	3 (<1)
ビタミンＤ増加	2 (<1)	0	4 (<1)	4 (<1)	0
血中クレアチン増加	0	2 (<1)	1 (<1)	3 (<1)	0
血中ナトリウム増加	0	1 (<1)	2 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 59 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心電図異常	4 (<1)	0	3 (<1)	3 (<1)	0
心電図ＳＴ部分下降	1 (<1)	2 (<1)	1 (<1)	3 (<1)	2 (<1)
高比重リポ蛋白増加	1 (<1)	0	3 (<1)	3 (<1)	0
リンパ球数増加	2 (<1)	2 (<1)	1 (<1)	3 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	1 (<1)	1 (<1)	2 (<1)	2 (<1)
細菌検査陽性	2 (<1)	0	2 (<1)	2 (<1)	2 (<1)
血中クロール増加	0	0	2 (<1)	2 (<1)	0
血中葉酸減少	0	1 (<1)	1 (<1)	2 (<1)	0
血中ケトン体増加	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
血中尿酸増加	2 (<1)	0	2 (<1)	2 (<1)	1 (<1)
尿中結晶陽性	6 (<1)	1 (<1)	1 (<1)	2 (<1)	0
γ－グルタミルトランスフェラーゼ異常	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
心拍数増加	2 (<1)	2 (<1)	0	2 (<1)	0
血小板数増加	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
赤血球数増加	1 (<1)	1 (<1)	1 (<1)	2 (<1)	0
ビタミンＢ１２減少	2 (<1)	2 (<1)	0	2 (<1)	0
アレルギー検査	0	0	1 (<1)	1 (<1)	0
抗ＳＳＡ抗体陽性	0	1 (<1)	0	1 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	1 (<1)	0
アスパラギン酸アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)	1 (<1)
血中アルカリホスファターゼ異常	0	1 (<1)	0	1 (<1)	1 (<1)
血中重炭酸塩減少	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 60 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
血中重炭酸塩増加	0	1 (<1)	0	1 (<1)	0
血中カルシウム減少	1 (<1)	1 (<1)	0	1 (<1)	1 (<1)
血中カルシウム増加	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
血中クレアチニン異常	0	1 (<1)	0	1 (<1)	0
血中ブドウ糖減少	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
血中免疫グロブリンM増加	0	0	1 (<1)	1 (<1)	0
血中鉄減少	1 (<1)	1 (<1)	0	1 (<1)	0
血中副甲状腺ホルモン異常	0	0	1 (<1)	1 (<1)	0
血中カリウム減少	2 (<1)	0	1 (<1)	1 (<1)	0
血圧低下	1 (<1)	1 (<1)	0	1 (<1)	0
拡張期血圧上昇	0	0	1 (<1)	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	1 (<1)	0
血中甲状腺刺激ホルモン増加	0	0	1 (<1)	1 (<1)	0
体温低下	0	1 (<1)	0	1 (<1)	0
呼吸音異常	0	1 (<1)	0	1 (<1)	0
心雑音	2 (<1)	1 (<1)	0	1 (<1)	0
結腸内視鏡検査	0	1 (<1)	0	1 (<1)	0
白血球百分率数異常	0	0	1 (<1)	1 (<1)	0
心筋虚血の心電図所見	0	1 (<1)	0	1 (<1)	0
心電図T波振幅減少	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 61 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
心電図Ｔ波逆転	1 (<1)	1 (<1)	0	1 (<1)	2 (<1)
好酸球数異常	1 (<1)	0	1 (<1)	1 (<1)	0
好酸球百分率増加	0	1 (<1)	0	1 (<1)	0
エプスタイン・バーウイルス抗体陽性	0	0	1 (<1)	1 (<1)	0
大腸菌検査陽性	0	1 (<1)	0	1 (<1)	0
γ－グルタミルトランスフェラーゼ減少	0	1 (<1)	0	1 (<1)	0
胃内ｐＨ上昇	0	0	1 (<1)	1 (<1)	0
心拍数減少	0	0	1 (<1)	1 (<1)	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	1 (<1)	0
ヒステロスコピー	0	1 (<1)	0	1 (<1)	0
眼圧上昇	0	1 (<1)	0	1 (<1)	0
検査	0	0	1 (<1)	1 (<1)	0
リンパ節触知	0	0	1 (<1)	1 (<1)	0
リンパ球百分率減少	1 (<1)	1 (<1)	0	1 (<1)	0
医学的観察	0	0	1 (<1)	1 (<1)	0
単球数減少	0	0	1 (<1)	1 (<1)	1 (<1)
単球数増加	0	0	1 (<1)	1 (<1)	0
神経学的検査異常	0	1 (<1)	0	1 (<1)	0
好中球百分率増加	1 (<1)	1 (<1)	0	1 (<1)	0
脳核磁気共鳴画像異常	1 (<1)	1 (<1)	0	1 (<1)	0
血小板数	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 62 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
ロンベルグ徴候陽性	0	1 (<1)	0	1 (<1)	0
腎機能検査異常	0	1 (<1)	0	1 (<1)	0
残尿量増加	0	1 (<1)	0	1 (<1)	0
呼吸数増加	0	0	1 (<1)	1 (<1)	0
血清フェリチン減少	0	0	1 (<1)	1 (<1)	0
子宮頚部スミア異常	1 (<1)	0	1 (<1)	1 (<1)	0
つぎ足歩行検査異常	0	1 (<1)	0	1 (<1)	0
尿円柱	0	0	1 (<1)	1 (<1)	0
抗甲状腺抗体陽性	1 (<1)	0	0	0	0
抗核抗体増加	1 (<1)	0	0	0	0
動脈雑音	1 (<1)	0	0	0	0
細菌検査	2 (<1)	0	0	0	0
血中ビリルビン異常	0	0	0	0	1 (<1)
血中ビリルビン減少	1 (<1)	0	0	0	0
血中クロール減少	1 (<1)	0	0	0	0
血中クレアチン異常	1 (<1)	0	0	0	0
血中乳酸脱水素酵素異常	0	0	0	0	1 (<1)
血中マグネシウム減少	1 (<1)	0	0	0	0
血中副甲状腺ホルモン減少	1 (<1)	0	0	0	0
血中リン減少	1 (<1)	0	0	0	0
血中リン増加	1 (<1)	0	0	0	0
収縮期血圧上昇	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 63 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
中枢神経系機能検査異常	1 (<1)	0	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0	0
心電図異常ＱＲＳ群	1 (<1)	0	0	0	0
心電図ＱＲＳ群延長	1 (<1)	0	0	0	0
心電図２相性Ｔ波	0	0	0	0	1 (<1)
全血球数異常	1 (<1)	0	0	0	0
握力低下	0	0	0	0	2 (<1)
心音異常	1 (<1)	0	0	0	0
Ａ型インフルエンザウイルス検査陽性	1 (<1)	0	0	0	0
リンパ球数異常	0	0	0	0	1 (<1)
後骨髄球百分率増加	1 (<1)	0	0	0	0
骨髄球数増加	1 (<1)	0	0	0	0
骨髄球百分率増加	1 (<1)	0	0	0	0
好中球数異常	0	0	0	0	1 (<1)
好中球百分率異常	1 (<1)	0	0	0	0
便潜血陽性	0	0	0	0	1 (<1)
ＱＲＳ軸異常	2 (<1)	0	0	0	0
トランスアミナーゼ上昇	2 (<1)	0	0	0	1 (<1)
膀胱超音波検査異常	1 (<1)	0	0	0	0
尿細胞診異常	1 (<1)	0	0	0	0
前庭機能検査異常	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 64 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
白血球数異常	0	0	0	0	1 (<1)
傷害、中毒および処置合併症	140 (18)	103 (13)	119 (16)	222 (15)	41 (12)
挫傷	19 (2)	21 (3)	25 (3)	46 (3)	5 (1)
転倒	22 (3)	22 (3)	22 (3)	44 (3)	14 (4)
関節捻挫	16 (2)	13 (2)	13 (2)	26 (2)	3 (<1)
足骨折	4 (<1)	7 (<1)	6 (<1)	13 (<1)	2 (<1)
肉離れ	5 (<1)	5 (<1)	8 (1)	13 (<1)	1 (<1)
節足動物咬傷	9 (1)	4 (<1)	7 (<1)	11 (<1)	2 (<1)
四肢損傷	5 (<1)	5 (<1)	6 (<1)	11 (<1)	3 (<1)
処置による疼痛	3 (<1)	4 (<1)	6 (<1)	10 (<1)	2 (<1)
擦過傷	4 (<1)	2 (<1)	6 (<1)	8 (<1)	2 (<1)
交通事故	5 (<1)	3 (<1)	5 (<1)	8 (<1)	3 (<1)
皮膚裂傷	7 (<1)	5 (<1)	3 (<1)	8 (<1)	1 (<1)
半月板障害	3 (<1)	4 (<1)	3 (<1)	7 (<1)	1 (<1)
熱傷	8 (1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
足関節部骨折	0	2 (<1)	3 (<1)	5 (<1)	1 (<1)
靭帯断裂	4 (<1)	1 (<1)	4 (<1)	5 (<1)	0
サンバーン	4 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
歯牙破折	2 (<1)	3 (<1)	2 (<1)	5 (<1)	0
節足動物刺傷	3 (<1)	2 (<1)	2 (<1)	4 (<1)	0
骨格損傷	6 (<1)	2 (<1)	2 (<1)	4 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 65 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
外傷性血腫	0	3 (<1)	1 (<1)	4 (<1)	1 (<1)
むち打ち損傷	2 (<1)	4 (<1)	0	4 (<1)	3 (<1)
上顆炎	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
関節脱臼	1 (<1)	3 (<1)	0	3 (<1)	0
関節損傷	6 (<1)	1 (<1)	2 (<1)	3 (<1)	0
橈骨骨折	1 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
創傷	3 (<1)	2 (<1)	1 (<1)	3 (<1)	0
動物咬傷	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
鎖骨骨折	0	1 (<1)	1 (<1)	2 (<1)	0
脳振盪	1 (<1)	2 (<1)	0	2 (<1)	2 (<1)
眼外傷	3 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
顔面損傷	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
大腿骨骨折	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
損傷	0	0	2 (<1)	2 (<1)	1 (<1)
筋断裂	0	2 (<1)	0	2 (<1)	0
頚部損傷	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
術後発熱	0	2 (<1)	0	2 (<1)	0
脊椎圧迫骨折	0	2 (<1)	0	2 (<1)	0
手首関節骨折	2 (<1)	0	2 (<1)	2 (<1)	0
偶発的過量投与	0	1 (<1)	0	1 (<1)	0
アルコール中毒	0	0	1 (<1)	1 (<1)	0
凍瘡	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 66 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
造影剤反応	0	0	1 (<1)	1 (<1)	0
眼瞼損傷	0	1 (<1)	0	1 (<1)	0
顔面骨骨折	0	1 (<1)	0	1 (<1)	0
尾骨骨折	1 (<1)	0	1 (<1)	1 (<1)	0
手骨折	2 (<1)	1 (<1)	0	1 (<1)	4 (1)
頭部損傷	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
腸脛靭帯症候群	0	0	1 (<1)	1 (<1)	0
切開部位痛	0	1 (<1)	0	1 (<1)	0
瘢痕ヘルニア	1 (<1)	1 (<1)	0	1 (<1)	0
閉塞性瘢痕ヘルニア	0	0	1 (<1)	1 (<1)	0
靭帯損傷	1 (<1)	0	1 (<1)	1 (<1)	0
靭帯捻挫	0	0	1 (<1)	1 (<1)	0
下肢骨折	0	0	1 (<1)	1 (<1)	0
神経損傷	0	0	1 (<1)	1 (<1)	0
過量投与	0	1 (<1)	0	1 (<1)	0
処置後出血	1 (<1)	1 (<1)	0	1 (<1)	0
処置後浮腫	0	0	1 (<1)	1 (<1)	0
処置による低血圧	0	1 (<1)	0	1 (<1)	0
処置による悪心	1 (<1)	1 (<1)	0	1 (<1)	0
処置による嘔吐	0	1 (<1)	0	1 (<1)	0
放射線皮膚損傷	0	0	1 (<1)	1 (<1)	0
反復性挫傷	1 (<1)	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 67 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
網膜損傷	1 (<1)	1 (<1)	0	1 (<1)	0
肋骨骨折	0	0	1 (<1)	1 (<1)	0
引っかき傷	0	0	1 (<1)	1 (<1)	0
軟部組織損傷	0	1 (<1)	0	1 (<1)	0
滑膜断裂	0	0	1 (<1)	1 (<1)	0
舌損傷	0	1 (<1)	0	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
外傷性骨折	0	0	1 (<1)	1 (<1)	0
上肢骨折	1 (<1)	0	1 (<1)	1 (<1)	1 (<1)
ワクチン接種合併症	1 (<1)	0	1 (<1)	1 (<1)	0
創し開	0	0	1 (<1)	1 (<1)	0
労働災害	1 (<1)	0	0	0	0
動物による引っかき傷	0	0	0	0	1 (<1)
気圧性中耳炎	0	0	0	0	1 (<1)
第２度熱傷	1 (<1)	0	0	0	0
眼部化学的損傷	1 (<1)	0	0	0	0
角膜擦過傷	1 (<1)	0	0	0	0
大腿骨頚部骨折	1 (<1)	0	0	0	0
腓骨骨折	1 (<1)	0	0	0	0
前腕骨折	0	0	0	0	1 (<1)
眼内異物	1 (<1)	0	0	0	0
口唇損傷	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 68 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
筋損傷	2 (<1)	0	0	0	0
処置後合併症	2 (<1)	0	0	0	1 (<1)
外傷後疼痛	2 (<1)	0	0	0	2 (<1)
術後創合併症	0	0	0	0	1 (<1)
ストレス骨折	0	0	0	0	1 (<1)
腱損傷	1 (<1)	0	0	0	0
腱断裂	3 (<1)	0	0	0	1 (<1)
治療薬毒性	1 (<1)	0	0	0	0
脛骨骨折	2 (<1)	0	0	0	0
歯の完全脱臼	1 (<1)	0	0	0	0
有毒性刺傷	2 (<1)	0	0	0	0
第７神経損傷	0	0	0	0	1 (<1)
創傷出血	1 (<1)	0	0	0	0
外科および内科処置	7 (<1)	9 (1)	4 (<1)	13 (<1)	4 (1)
抜歯	3 (<1)	4 (<1)	0	4 (<1)	2 (<1)
子宮摘出	0	1 (<1)	1 (<1)	2 (<1)	0
乳房腫瘤摘除	0	1 (<1)	0	1 (<1)	0
デンタルケア	0	0	1 (<1)	1 (<1)	0
女性不妊手術	0	1 (<1)	0	1 (<1)	0
ヘルニア修復	0	1 (<1)	0	1 (<1)	0
椎間板手術	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 69 of 69

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
治療食	0	1 (<1)	0	1 (<1)	0
静脈ステント挿入	0	0	1 (<1)	1 (<1)	0
子宮頚部円錐切除	1 (<1)	0	0	0	0
嚢胞ドレナージ	1 (<1)	0	0	0	0
入院	0	0	0	0	1 (<1)
色素性母斑切除	1 (<1)	0	0	0	0
不妊手術	0	0	0	0	1 (<1)
鼻甲介切除	1 (<1)	0	0	0	0
社会環境	3 (<1)	1 (<1)	0	1 (<1)	0
閉経	0	1 (<1)	0	1 (<1)	0
元タバコ使用者	1 (<1)	0	0	0	0
社会問題	1 (<1)	0	0	0	0
職場でのストレス	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-A.SAS DATE: 02DEC2015

Table 112: Incidence of Adverse Events At Least 2% Higher for Any BG00012 Group or GA Relative to Placebo - by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo - by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 1 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with an event	720 (93)	733 (95)	712 (94)	1445 (95)	304 (87)
感染症および寄生虫症	447 (58)	463 (60)	472 (62)	935 (61)	175 (50)
鼻咽頭炎	159 (21)	170 (22)	172 (23)	342 (22)	51 (15)
副鼻腔炎	31 (4)	35 (5)	52 (7)	87 (6)	11 (3)
気管支炎	32 (4)	35 (5)	48 (6)	83 (5)	16 (5)
血液およびリンパ系障害	37 (5)	51 (7)	56 (7)	107 (7)	11 (3)
リンパ球減少症	2 (<1)	18 (2)	17 (2)	35 (2)	0
血管障害	84 (11)	322 (42)	277 (36)	599 (39)	25 (7)
潮紅	33 (4)	265 (34)	215 (28)	480 (31)	6 (2)
ほてり	16 (2)	52 (7)	49 (6)	101 (7)	5 (1)
胃腸障害	289 (37)	366 (48)	398 (52)	764 (50)	65 (19)
下痢	83 (11)	107 (14)	128 (17)	235 (15)	14 (4)
悪心	67 (9)	93 (12)	105 (14)	198 (13)	16 (5)
上腹部痛	45 (6)	76 (10)	85 (11)	161 (11)	4 (1)
腹痛	37 (5)	73 (9)	63 (8)	136 (9)	5 (1)
嘔吐	37 (5)	65 (8)	53 (7)	118 (8)	9 (3)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-HTPL2-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo - by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 2 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
消化不良	20 (3)	35 (5)	40 (5)	75 (5)	6 (2)
胃腸障害	8 (1)	18 (2)	34 (4)	52 (3)	2 (<1)
皮膚および皮下組織障害	157 (20)	245 (32)	247 (33)	492 (32)	60 (17)
そう痒症	30 (4)	62 (8)	58 (8)	120 (8)	7 (2)
発疹	26 (3)	58 (8)	55 (7)	113 (7)	9 (3)
紅斑	10 (1)	36 (5)	54 (7)	90 (6)	6 (2)
多汗症	10 (1)	17 (2)	26 (3)	43 (3)	5 (1)
筋痙縮	34 (4)	27 (4)	50 (7)	77 (5)	8 (2)
腎および尿路障害	151 (20)	146 (19)	176 (23)	322 (21)	58 (17)
蛋白尿	59 (8)	67 (9)	85 (11)	152 (10)	30 (9)
一般・全身障害および投与部位の状態	194 (25)	178 (23)	216 (28)	394 (26)	133 (38)
注射部位紅斑	0	0	0	0	31 (9)
注射部位疼痛	0	0	0	0	29 (8)
注射部位そう痒感	0	0	0	0	13 (4)
注射部位腫脹	0	0	0	0	10 (3)
臨床検査	200 (26)	212 (28)	216 (28)	428 (28)	106 (30)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-HTPL2-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any BG00012 group or GA relative to placebo - by system organ class and preferred term:
Studies 109MS301 and 109MS302
Page 3 of 3

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
尿中アルブミン陽性	27 (4)	46 (6)	36 (5)	82 (5)	18 (5)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-HTPL2-A.SAS DATE: 02DEC2015

Table 114: Incidence of Adverse Events At Least 2% Higher for Any Treatment Group and the Entire Study Period by Preferred Term and 3-Months Interval: Studies 109MS301 and 109MS302

Incidence of adverse events at least 2% higher for any treatment group and the entire study period
by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 1 of 50

	Placebo				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
Number of subjects followed in the interval	771 (100)	751 (100)	714 (100)	674 (100)	629 (100)
Number of subjects with an event	507 (66)	434 (58)	381 (53)	346 (51)	298 (47)
Number of subjects with deaths	0	0	0	0	1 (<1)
Number of subjects with SAEs other than deaths	34 (4)	36 (5)	42 (6)	28 (4)	21 (3)
Number of subjects who discontinued	14 (2)	5 (<1)	3 (<1)	2 (<1)	4 (<1)
潮紅	23 (3)	4 (<1)	3 (<1)	2 (<1)	0
多発性硬化症再発	96 (12)	89 (12)	82 (11)	66 (10)	59 (9)
鼻咽頭炎	45 (6)	32 (4)	32 (4)	33 (5)	30 (5)
頭痛	76 (10)	20 (3)	29 (4)	18 (3)	17 (3)
下痢	36 (5)	13 (2)	14 (2)	8 (1)	9 (1)
尿路感染	23 (3)	24 (3)	14 (2)	16 (2)	15 (2)
悪心	41 (5)	11 (1)	7 (<1)	4 (<1)	3 (<1)
上気道感染	27 (4)	20 (3)	15 (2)	10 (1)	11 (2)
疲労	23 (3)	22 (3)	14 (2)	9 (1)	13 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 2 of 50

	Placebo			
	>15-18 months	>18-21 months	>21-24 months	>24 months
Number of subjects followed in the interval	584 (100)	554 (100)	541 (100)	381 (100)
Number of subjects with an event	287 (49)	284 (51)	243 (45)	47 (12)
Number of subjects with deaths	0	0	0	0
Number of subjects with SAEs other than deaths	22 (4)	17 (3)	23 (4)	2 (<1)
Number of subjects who discontinued	2 (<1)	2 (<1)	1 (<1)	0
潮紅	1 (<1)	2 (<1)	2 (<1)	0
多発性硬化症再発	42 (7)	47 (8)	39 (7)	4 (1)
鼻咽頭炎	30 (5)	24 (4)	23 (4)	2 (<1)
頭痛	13 (2)	8 (1)	10 (2)	2 (<1)
下痢	9 (2)	6 (1)	7 (1)	3 (<1)
尿路感染	17 (3)	17 (3)	14 (3)	0
悪心	5 (<1)	2 (<1)	8 (1)	0
上気道感染	13 (2)	7 (1)	12 (2)	1 (<1)
疲労	8 (1)	11 (2)	8 (1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 3 of 50

	Placebo				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
背部痛	17 (2)	24 (3)	17 (2)	11 (2)	9 (1)
上腹部痛	26 (3)	3 (<1)	5 (<1)	5 (<1)	1 (<1)
蛋白尿	15 (2)	20 (3)	10 (1)	8 (1)	8 (1)
腹痛	23 (3)	4 (<1)	6 (<1)	6 (<1)	2 (<1)
関節痛	16 (2)	11 (1)	13 (2)	10 (1)	8 (1)
インフルエンザ	19 (2)	12 (2)	11 (2)	10 (1)	8 (1)
そう痒症	17 (2)	2 (<1)	5 (<1)	0	3 (<1)
嘔吐	13 (2)	3 (<1)	4 (<1)	5 (<1)	3 (<1)
錯感覚	16 (2)	11 (1)	6 (<1)	15 (2)	8 (1)
四肢痛	18 (2)	14 (2)	10 (1)	10 (1)	5 (<1)
発疹	12 (2)	3 (<1)	0	8 (1)	0
うつ病	14 (2)	20 (3)	6 (<1)	10 (1)	3 (<1)
ほてり	10 (1)	0	2 (<1)	0	1 (<1)
アラニン・アミノトランスフェラーゼ増加	2 (<1)	6 (<1)	7 (<1)	8 (1)	3 (<1)
紅斑	3 (<1)	0	2 (<1)	1 (<1)	0
副鼻腔炎	1 (<1)	6 (<1)	4 (<1)	9 (1)	9 (1)
気管支炎	3 (<1)	7 (<1)	6 (<1)	5 (<1)	8 (1)
尿中アルブミン陽性	4 (<1)	6 (<1)	2 (<1)	4 (<1)	5 (<1)
口腔咽頭痛	7 (<1)	6 (<1)	7 (<1)	3 (<1)	2 (<1)
胃腸炎	5 (<1)	6 (<1)	6 (<1)	4 (<1)	5 (<1)
咳嗽	8 (1)	11 (1)	3 (<1)	7 (1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 4 of 50

	Placebo			
	>15-18 months	>18-21 months	>21-24 months	>24 months
背部痛	7 (1)	11 (2)	11 (2)	1 (<1)
上腹部痛	1 (<1)	4 (<1)	4 (<1)	0
蛋白尿	5 (<1)	7 (1)	5 (<1)	2 (<1)
腹痛	1 (<1)	2 (<1)	1 (<1)	1 (<1)
関節痛	7 (1)	5 (<1)	6 (1)	0
インフルエンザ	2 (<1)	5 (<1)	6 (1)	0
そう痒症	4 (<1)	3 (<1)	2 (<1)	0
嘔吐	5 (<1)	3 (<1)	4 (<1)	2 (<1)
錯感覚	7 (1)	11 (2)	7 (1)	0
四肢痛	3 (<1)	9 (2)	4 (<1)	0
発疹	1 (<1)	2 (<1)	1 (<1)	1 (<1)
うつ病	9 (2)	8 (1)	6 (1)	0
ほてり	1 (<1)	1 (<1)	1 (<1)	0
アラニン・アミノトランスフェラーゼ増加	6 (1)	6 (1)	2 (<1)	1 (<1)
紅斑	0	1 (<1)	3 (<1)	0
副鼻腔炎	6 (1)	5 (<1)	2 (<1)	0
気管支炎	7 (1)	5 (<1)	1 (<1)	0
尿中アルブミン陽性	3 (<1)	2 (<1)	6 (1)	2 (<1)
口腔咽頭痛	6 (1)	1 (<1)	4 (<1)	1 (<1)
胃腸炎	3 (<1)	1 (<1)	1 (<1)	0
咳嗽	3 (<1)	3 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 5 of 50

	Placebo				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
消化不良	10 (1)	6 (<1)	4 (<1)	1 (<1)	0
血尿	10 (1)	6 (<1)	9 (1)	4 (<1)	4 (<1)
感覚鈍麻	12 (2)	10 (1)	8 (1)	10 (1)	3 (<1)
筋痙縮	9 (1)	8 (1)	3 (<1)	6 (<1)	4 (<1)
ミクロアルブミン尿	4 (<1)	3 (<1)	3 (<1)	3 (<1)	5 (<1)
発熱	7 (<1)	5 (<1)	13 (2)	4 (<1)	9 (1)
不眠症	8 (1)	9 (1)	7 (<1)	5 (<1)	4 (<1)
回転性めまい	15 (2)	11 (1)	2 (<1)	2 (<1)	3 (<1)
浮動性めまい	11 (1)	6 (<1)	5 (<1)	1 (<1)	5 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	3 (<1)	2 (<1)	1 (<1)	6 (<1)	1 (<1)
咽頭炎	6 (<1)	8 (1)	4 (<1)	3 (<1)	7 (1)
不安	11 (1)	7 (<1)	3 (<1)	3 (<1)	0
便秘	14 (2)	5 (<1)	2 (<1)	5 (<1)	3 (<1)
胃腸障害	5 (<1)	1 (<1)	0	3 (<1)	0
鼻炎	5 (<1)	5 (<1)	6 (<1)	3 (<1)	1 (<1)
尿中蛋白陽性	4 (<1)	2 (<1)	2 (<1)	4 (<1)	6 (<1)
頚部痛	7 (<1)	3 (<1)	3 (<1)	3 (<1)	2 (<1)
灼熱感	4 (<1)	1 (<1)	4 (<1)	1 (<1)	1 (<1)
挫傷	5 (<1)	2 (<1)	2 (<1)	6 (<1)	1 (<1)
転倒	4 (<1)	5 (<1)	4 (<1)	4 (<1)	3 (<1)
歯痛	5 (<1)	2 (<1)	4 (<1)	1 (<1)	4 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 6 of 50

	Placebo			
	>15-18 months	>18-21 months	>21-24 months	>24 months
消化不良	1 (<1)	0	0	0
血尿	6 (1)	4 (<1)	4 (<1)	1 (<1)
感覚鈍麻	5 (<1)	8 (1)	2 (<1)	2 (<1)
筋痙縮	3 (<1)	6 (1)	0	0
ミクロアルブミン尿	4 (<1)	2 (<1)	2 (<1)	3 (<1)
発熱	3 (<1)	6 (1)	2 (<1)	1 (<1)
不眠症	4 (<1)	2 (<1)	4 (<1)	0
回転性めまい	6 (1)	5 (<1)	2 (<1)	0
浮動性めまい	1 (<1)	7 (1)	5 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	2 (<1)	0	0
咽頭炎	5 (<1)	2 (<1)	5 (<1)	1 (<1)
不安	3 (<1)	1 (<1)	1 (<1)	0
便秘	3 (<1)	3 (<1)	3 (<1)	0
胃腸障害	0	2 (<1)	1 (<1)	0
鼻炎	5 (<1)	4 (<1)	1 (<1)	0
尿中蛋白陽性	2 (<1)	1 (<1)	4 (<1)	0
頚部痛	5 (<1)	3 (<1)	1 (<1)	0
灼熱感	1 (<1)	1 (<1)	1 (<1)	0
挫傷	3 (<1)	1 (<1)	0	0
転倒	2 (<1)	4 (<1)	2 (<1)	0
歯痛	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 7 of 50

	Placebo				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
多汗症	5 (<1)	1 (<1)	2 (<1)	0	1 (<1)
片頭痛	5 (<1)	6 (<1)	2 (<1)	3 (<1)	3 (<1)
胃炎	2 (<1)	4 (<1)	1 (<1)	2 (<1)	0
筋力低下	8 (1)	10 (1)	4 (<1)	3 (<1)	1 (<1)
無力症	4 (<1)	5 (<1)	0	1 (<1)	3 (<1)
気道感染	1 (<1)	4 (<1)	1 (<1)	4 (<1)	3 (<1)
口腔ヘルペス	6 (<1)	2 (<1)	8 (1)	3 (<1)	6 (<1)
ウイルス性胃腸炎	4 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
リンパ球減少症	1 (<1)	0	1 (<1)	0	0
筋骨格痛	5 (<1)	7 (<1)	3 (<1)	4 (<1)	3 (<1)
貧血	3 (<1)	2 (<1)	3 (<1)	1 (<1)	2 (<1)
尿中血陽性	1 (<1)	0	1 (<1)	0	4 (<1)
腹部不快感	5 (<1)	1 (<1)	2 (<1)	1 (<1)	0
胃食道逆流性疾患	8 (1)	1 (<1)	0	1 (<1)	2 (<1)
筋痙直	9 (1)	4 (<1)	8 (1)	5 (<1)	2 (<1)
血中副甲状腺ホルモン増加	1 (<1)	0	0	2 (<1)	0
γ－グルタミルトランスフェラーゼ増加	3 (<1)	2 (<1)	3 (<1)	9 (1)	4 (<1)
高血圧	3 (<1)	4 (<1)	5 (<1)	2 (<1)	1 (<1)
食欲減退	5 (<1)	2 (<1)	3 (<1)	1 (<1)	0
ウイルス感染	5 (<1)	2 (<1)	3 (<1)	4 (<1)	3 (<1)
霧視	4 (<1)	3 (<1)	3 (<1)	4 (<1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 8 of 50

	Placebo			
	>15-18 months	>18-21 months	>21-24 months	>24 months
多汗症	0	0	1 (<1)	0
片頭痛	4 (<1)	1 (<1)	3 (<1)	0
胃炎	1 (<1)	1 (<1)	2 (<1)	0
筋力低下	6 (1)	3 (<1)	2 (<1)	0
無力症	5 (<1)	3 (<1)	2 (<1)	0
気道感染	2 (<1)	1 (<1)	0	0
口腔ヘルペス	6 (1)	7 (1)	3 (<1)	0
ウイルス性胃腸炎	2 (<1)	4 (<1)	2 (<1)	0
リンパ球減少症	0	0	0	0
筋骨格痛	4 (<1)	3 (<1)	1 (<1)	0
貧血	1 (<1)	1 (<1)	2 (<1)	0
尿中血陽性	1 (<1)	0	1 (<1)	0
腹部不快感	1 (<1)	2 (<1)	0	0
胃食道逆流性疾患	2 (<1)	1 (<1)	0	0
筋痙直	3 (<1)	2 (<1)	1 (<1)	0
血中副甲状腺ホルモン増加	0	0	1 (<1)	2 (<1)
γ－グルタミルトランスフェラーゼ増加	1 (<1)	1 (<1)	0	1 (<1)
高血圧	4 (<1)	2 (<1)	4 (<1)	0
食欲減退	0	1 (<1)	1 (<1)	0
ウイルス感染	1 (<1)	0	0	0
霧視	1 (<1)	4 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 9 of 50

	Placebo				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
膀胱炎	6 (<1)	2 (<1)	4 (<1)	1 (<1)	2 (<1)
眼痛	2 (<1)	3 (<1)	0	2 (<1)	1 (<1)
尿中白血球陽性	4 (<1)	2 (<1)	1 (<1)	3 (<1)	0
脱毛症	6 (<1)	5 (<1)	2 (<1)	3 (<1)	1 (<1)
血中ブドウ糖増加	3 (<1)	0	1 (<1)	3 (<1)	1 (<1)
口内乾燥	2 (<1)	1 (<1)	2 (<1)	0	0
関節捻挫	2 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
筋肉痛	11 (1)	5 (<1)	2 (<1)	2 (<1)	3 (<1)
耳感染	1 (<1)	2 (<1)	1 (<1)	3 (<1)	3 (<1)
末梢性浮腫	11 (1)	1 (<1)	3 (<1)	3 (<1)	2 (<1)
抑うつ気分	2 (<1)	5 (<1)	2 (<1)	1 (<1)	0
筋骨格硬直	1 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 10 of 50

	Placebo			
	>15-18 months	>18-21 months	>21-24 months	>24 months
膀胱炎	3 (<1)	1 (<1)	5 (<1)	1 (<1)
眼痛	2 (<1)	3 (<1)	1 (<1)	0
尿中白血球陽性	1 (<1)	1 (<1)	1 (<1)	1 (<1)
脱毛症	2 (<1)	0	0	0
血中ブドウ糖増加	0	3 (<1)	2 (<1)	0
口内乾燥	0	1 (<1)	0	0
関節捻挫	2 (<1)	0	5 (<1)	0
筋肉痛	3 (<1)	2 (<1)	1 (<1)	0
耳感染	4 (<1)	0	0	0
末梢性浮腫	0	1 (<1)	1 (<1)	0
抑うつ気分	5 (<1)	3 (<1)	1 (<1)	0
筋骨格硬直	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 11 of 50

	BG00012 240 mg BID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
Number of subjects followed in the interval	769 (100)	719 (100)	682 (100)	652 (100)	628 (100)
Number of subjects with an event	596 (78)	401 (56)	365 (54)	322 (49)	313 (50)
Number of subjects with deaths	0	1 (<1)	0	0	0
Number of subjects with SAEs other than deaths	37 (5)	23 (3)	20 (3)	24 (4)	19 (3)
Number of subjects who discontinued	45 (6)	3 (<1)	4 (<1)	0	1 (<1)
潮紅	212 (28)	40 (6)	23 (3)	28 (4)	18 (3)
多発性硬化症再発	63 (8)	51 (7)	38 (6)	34 (5)	36 (6)
鼻咽頭炎	40 (5)	37 (5)	37 (5)	34 (5)	30 (5)
頭痛	67 (9)	27 (4)	18 (3)	21 (3)	23 (4)
下痢	69 (9)	14 (2)	10 (1)	9 (1)	6 (<1)
尿路感染	31 (4)	32 (4)	16 (2)	15 (2)	13 (2)
悪心	70 (9)	7 (<1)	12 (2)	9 (1)	2 (<1)
上気道感染	30 (4)	20 (3)	20 (3)	22 (3)	21 (3)
疲労	41 (5)	13 (2)	18 (3)	11 (2)	8 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 12 of 50

	BG00012 240 mg BID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
Number of subjects followed in the interval	611 (100)	596 (100)	585 (100)	404 (100)
Number of subjects with an event	295 (48)	259 (43)	254 (43)	62 (15)
Number of subjects with deaths	0	0	0	0
Number of subjects with SAEs other than deaths	12 (2)	22 (4)	13 (2)	1 (<1)
Number of subjects who discontinued	3 (<1)	2 (<1)	3 (<1)	0
潮紅	17 (3)	8 (1)	6 (1)	1 (<1)
多発性硬化症再発	25 (4)	32 (5)	27 (5)	4 (<1)
鼻咽頭炎	37 (6)	24 (4)	32 (5)	1 (<1)
頭痛	18 (3)	15 (3)	13 (2)	5 (1)
下痢	4 (<1)	6 (1)	7 (1)	1 (<1)
尿路感染	17 (3)	15 (3)	14 (2)	2 (<1)
悪心	3 (<1)	6 (1)	5 (<1)	1 (<1)
上気道感染	10 (2)	17 (3)	14 (2)	0
疲労	12 (2)	6 (1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 13 of 50

	BG00012 240 mg BID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
背部痛	26 (3)	19 (3)	21 (3)	13 (2)	15 (2)
上腹部痛	54 (7)	9 (1)	11 (2)	7 (1)	7 (1)
蛋白尿	17 (2)	14 (2)	18 (3)	8 (1)	15 (2)
腹痛	50 (7)	7 (<1)	8 (1)	11 (2)	2 (<1)
関節痛	19 (2)	9 (1)	10 (1)	10 (2)	10 (2)
インフルエンザ	12 (2)	16 (2)	7 (1)	9 (1)	5 (<1)
そう痒症	38 (5)	10 (1)	12 (2)	6 (<1)	3 (<1)
嘔吐	39 (5)	5 (<1)	10 (1)	7 (1)	4 (<1)
錯感覚	20 (3)	9 (1)	10 (1)	7 (1)	3 (<1)
四肢痛	14 (2)	13 (2)	9 (1)	13 (2)	6 (<1)
発疹	33 (4)	13 (2)	8 (1)	6 (<1)	6 (<1)
うつ病	14 (2)	8 (1)	11 (2)	7 (1)	7 (1)
ほてり	35 (5)	5 (<1)	2 (<1)	3 (<1)	2 (<1)
アラニン・アミノトランスフェラーゼ増加	24 (3)	10 (1)	4 (<1)	5 (<1)	2 (<1)
紅斑	21 (3)	6 (<1)	2 (<1)	0	3 (<1)
副鼻腔炎	6 (<1)	5 (<1)	8 (1)	4 (<1)	4 (<1)
気管支炎	8 (1)	9 (1)	5 (<1)	5 (<1)	5 (<1)
尿中アルブミン陽性	8 (1)	10 (1)	12 (2)	4 (<1)	7 (1)
口腔咽頭痛	7 (<1)	8 (1)	4 (<1)	6 (<1)	4 (<1)
胃腸炎	14 (2)	5 (<1)	2 (<1)	6 (<1)	9 (1)
咳嗽	11 (1)	7 (<1)	4 (<1)	3 (<1)	4 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 14 of 50

	BG00012 240 mg BID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
背部痛	9 (1)	9 (2)	9 (2)	0
上腹部痛	0	6 (1)	2 (<1)	0
蛋白尿	9 (1)	8 (1)	7 (1)	4 (<1)
腹痛	2 (<1)	3 (<1)	2 (<1)	0
関節痛	7 (1)	7 (1)	8 (1)	0
インフルエンザ	6 (<1)	7 (1)	6 (1)	1 (<1)
そう痒症	3 (<1)	1 (<1)	3 (<1)	0
嘔吐	2 (<1)	1 (<1)	3 (<1)	2 (<1)
錯感覚	7 (1)	4 (<1)	6 (1)	0
四肢痛	7 (1)	5 (<1)	7 (1)	0
発疹	4 (<1)	0	2 (<1)	0
うつ病	3 (<1)	6 (1)	5 (<1)	2 (<1)
ほてり	4 (<1)	1 (<1)	0	0
アラニン・アミノトランスフェラーゼ増加	4 (<1)	2 (<1)	6 (1)	1 (<1)
紅斑	5 (<1)	4 (<1)	1 (<1)	0
副鼻腔炎	4 (<1)	7 (1)	3 (<1)	0
気管支炎	2 (<1)	4 (<1)	2 (<1)	1 (<1)
尿中アルブミン陽性	5 (<1)	4 (<1)	4 (<1)	4 (<1)
口腔咽頭痛	6 (<1)	5 (<1)	3 (<1)	0
胃腸炎	3 (<1)	4 (<1)	3 (<1)	0
咳嗽	6 (<1)	4 (<1)	4 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 15 of 50

	BG00012 240 mg BID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
消化不良	18 (2)	6 (<1)	5 (<1)	5 (<1)	2 (<1)
血尿	5 (<1)	9 (1)	5 (<1)	6 (<1)	5 (<1)
感覚鈍麻	11 (1)	4 (<1)	5 (<1)	5 (<1)	3 (<1)
筋痙縮	7 (<1)	1 (<1)	1 (<1)	6 (<1)	6 (<1)
ミクロアルブミン尿	3 (<1)	8 (1)	3 (<1)	4 (<1)	10 (2)
発熱	5 (<1)	6 (<1)	1 (<1)	3 (<1)	4 (<1)
不眠症	9 (1)	2 (<1)	7 (1)	7 (1)	3 (<1)
回転性めまい	6 (<1)	7 (<1)	4 (<1)	1 (<1)	2 (<1)
浮動性めまい	11 (1)	3 (<1)	6 (<1)	5 (<1)	5 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	17 (2)	5 (<1)	4 (<1)	3 (<1)	2 (<1)
咽頭炎	10 (1)	6 (<1)	3 (<1)	5 (<1)	6 (<1)
不安	9 (1)	8 (1)	11 (2)	3 (<1)	2 (<1)
便秘	13 (2)	3 (<1)	2 (<1)	0	6 (<1)
胃腸障害	17 (2)	1 (<1)	0	2 (<1)	0
鼻炎	5 (<1)	7 (<1)	3 (<1)	3 (<1)	3 (<1)
尿中蛋白陽性	8 (1)	6 (<1)	2 (<1)	3 (<1)	4 (<1)
頚部痛	1 (<1)	7 (<1)	4 (<1)	4 (<1)	2 (<1)
灼熱感	14 (2)	0	2 (<1)	3 (<1)	1 (<1)
挫傷	2 (<1)	2 (<1)	5 (<1)	4 (<1)	4 (<1)
転倒	0	5 (<1)	6 (<1)	3 (<1)	3 (<1)
歯痛	5 (<1)	3 (<1)	1 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 16 of 50

	BG00012 240 mg BID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
消化不良	1 (<1)	2 (<1)	1 (<1)	0
血尿	5 (<1)	7 (1)	11 (2)	3 (<1)
感覚鈍麻	1 (<1)	2 (<1)	3 (<1)	0
筋痙縮	4 (<1)	2 (<1)	4 (<1)	1 (<1)
ミクロアルブミン尿	4 (<1)	4 (<1)	4 (<1)	6 (1)
発熱	4 (<1)	6 (1)	2 (<1)	1 (<1)
不眠症	4 (<1)	6 (1)	2 (<1)	0
回転性めまい	3 (<1)	0	2 (<1)	0
浮動性めまい	4 (<1)	2 (<1)	4 (<1)	1 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	4 (<1)	0	2 (<1)	0
咽頭炎	7 (1)	3 (<1)	6 (1)	0
不安	1 (<1)	0	0	1 (<1)
便秘	0	0	1 (<1)	0
胃腸障害	1 (<1)	0	0	0
鼻炎	4 (<1)	2 (<1)	1 (<1)	0
尿中蛋白陽性	5 (<1)	1 (<1)	4 (<1)	2 (<1)
頚部痛	5 (<1)	1 (<1)	4 (<1)	0
灼熱感	1 (<1)	0	2 (<1)	0
挫傷	2 (<1)	3 (<1)	1 (<1)	1 (<1)
転倒	1 (<1)	2 (<1)	3 (<1)	0
歯痛	2 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 17 of 50

	BG00012 240 mg BID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
多汗症	7 (<1)	2 (<1)	4 (<1)	4 (<1)	0
片頭痛	7 (<1)	4 (<1)	4 (<1)	3 (<1)	2 (<1)
胃炎	6 (<1)	5 (<1)	1 (<1)	4 (<1)	1 (<1)
筋力低下	3 (<1)	3 (<1)	4 (<1)	0	4 (<1)
無力症	16 (2)	1 (<1)	1 (<1)	2 (<1)	1 (<1)
気道感染	4 (<1)	3 (<1)	3 (<1)	3 (<1)	1 (<1)
口腔ヘルペス	7 (<1)	4 (<1)	5 (<1)	4 (<1)	3 (<1)
ウイルス性胃腸炎	5 (<1)	1 (<1)	2 (<1)	0	0
リンパ球減少症	3 (<1)	3 (<1)	4 (<1)	1 (<1)	1 (<1)
筋骨格痛	3 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)
貧血	3 (<1)	2 (<1)	1 (<1)	1 (<1)	1 (<1)
尿中血陽性	3 (<1)	4 (<1)	1 (<1)	1 (<1)	3 (<1)
腹部不快感	8 (1)	2 (<1)	2 (<1)	5 (<1)	3 (<1)
胃食道逆流性疾患	10 (1)	4 (<1)	2 (<1)	1 (<1)	1 (<1)
筋痙直	2 (<1)	5 (<1)	2 (<1)	0	2 (<1)
血中副甲状腺ホルモン増加	1 (<1)	1 (<1)	0	6 (<1)	2 (<1)
γ－グルタミルトランスフェラーゼ増加	4 (<1)	3 (<1)	3 (<1)	0	3 (<1)
高血圧	4 (<1)	1 (<1)	0	1 (<1)	1 (<1)
食欲減退	8 (1)	4 (<1)	0	2 (<1)	1 (<1)
ウイルス感染	3 (<1)	3 (<1)	1 (<1)	1 (<1)	2 (<1)
霧視	5 (<1)	1 (<1)	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 18 of 50

	BG00012 240 mg BID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
多汗症	0	0	2 (<1)	0
片頭痛	2 (<1)	3 (<1)	1 (<1)	0
胃炎	3 (<1)	2 (<1)	1 (<1)	0
筋力低下	2 (<1)	1 (<1)	3 (<1)	0
無力症	1 (<1)	2 (<1)	1 (<1)	0
気道感染	2 (<1)	0	2 (<1)	0
口腔ヘルペス	4 (<1)	1 (<1)	3 (<1)	0
ウイルス性胃腸炎	5 (<1)	2 (<1)	2 (<1)	0
リンパ球減少症	3 (<1)	2 (<1)	4 (<1)	0
筋骨格痛	2 (<1)	1 (<1)	2 (<1)	0
貧血	3 (<1)	1 (<1)	3 (<1)	0
尿中血陽性	2 (<1)	4 (<1)	2 (<1)	0
腹部不快感	2 (<1)	1 (<1)	1 (<1)	0
胃食道逆流性疾患	0	0	1 (<1)	0
筋痙直	3 (<1)	3 (<1)	1 (<1)	0
血中副甲状腺ホルモン増加	0	0	1 (<1)	5 (1)
γ－グルタミルトランスフェラーゼ増加	1 (<1)	2 (<1)	6 (1)	0
高血圧	1 (<1)	3 (<1)	0	1 (<1)
食欲減退	1 (<1)	0	2 (<1)	0
ウイルス感染	2 (<1)	6 (1)	2 (<1)	0
霧視	3 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 19 of 50

	BG00012 240 mg BID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
膀胱炎	1 (<1)	5 (<1)	1 (<1)	0	1 (<1)
眼痛	0	1 (<1)	3 (<1)	4 (<1)	1 (<1)
尿中白血球陽性	0	4 (<1)	4 (<1)	3 (<1)	2 (<1)
脱毛症	9 (1)	4 (<1)	0	1 (<1)	2 (<1)
血中ブドウ糖増加	2 (<1)	4 (<1)	1 (<1)	1 (<1)	3 (<1)
口内乾燥	14 (2)	1 (<1)	1 (<1)	1 (<1)	0
関節捻挫	1 (<1)	2 (<1)	1 (<1)	4 (<1)	2 (<1)
筋肉痛	4 (<1)	3 (<1)	3 (<1)	0	2 (<1)
耳感染	0	0	1 (<1)	0	3 (<1)
末梢性浮腫	3 (<1)	0	1 (<1)	0	1 (<1)
抑うつ気分	5 (<1)	0	3 (<1)	0	1 (<1)
筋骨格硬直	1 (<1)	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 20 of 50

	BG00012 240 mg BID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
膀胱炎	1 (<1)	1 (<1)	2 (<1)	0
眼痛	5 (<1)	1 (<1)	1 (<1)	0
尿中白血球陽性	1 (<1)	2 (<1)	2 (<1)	0
脱毛症	0	1 (<1)	0	0
血中ブドウ糖増加	1 (<1)	2 (<1)	0	0
口内乾燥	0	0	0	0
関節捻挫	1 (<1)	1 (<1)	1 (<1)	0
筋肉痛	0	0	1 (<1)	0
耳感染	2 (<1)	0	1 (<1)	0
末梢性浮腫	2 (<1)	0	1 (<1)	0
抑うつ気分	2 (<1)	0	0	1 (<1)
筋骨格硬直	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 21 of 50

	BG00012 240 mg TID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
Number of subjects followed in the interval	760 (100)	695 (100)	665 (100)	638 (100)	625 (100)
Number of subjects with an event	605 (80)	396 (57)	366 (55)	340 (53)	302 (48)
Number of subjects with deaths	1 (<1)	0	1 (<1)	0	0
Number of subjects with SAEs other than deaths	29 (4)	22 (3)	18 (3)	12 (2)	13 (2)
Number of subjects who discontinued	46 (6)	4 (<1)	4 (<1)	2 (<1)	7 (1)
潮紅	185 (24)	31 (4)	23 (3)	14 (2)	11 (2)
多発性硬化症再発	61 (8)	43 (6)	41 (6)	41 (6)	22 (4)
鼻咽頭炎	49 (6)	44 (6)	43 (6)	35 (5)	27 (4)
頭痛	58 (8)	30 (4)	19 (3)	18 (3)	22 (4)
下痢	94 (12)	19 (3)	13 (2)	12 (2)	7 (1)
尿路感染	24 (3)	25 (4)	17 (3)	17 (3)	9 (1)
悪心	74 (10)	11 (2)	8 (1)	3 (<1)	4 (<1)
上気道感染	31 (4)	19 (3)	19 (3)	17 (3)	16 (3)
疲労	37 (5)	19 (3)	15 (2)	9 (1)	11 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 22 of 50

	BG00012 240 mg TID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
Number of subjects followed in the interval	608 (100)	586 (100)	573 (100)	412 (100)
Number of subjects with an event	299 (49)	282 (48)	252 (44)	55 (13)
Number of subjects with deaths	0	0	0	0
Number of subjects with SAEs other than deaths	21 (3)	16 (3)	16 (3)	3 (<1)
Number of subjects who discontinued	1 (<1)	2 (<1)	0	0
潮紅	13 (2)	10 (2)	7 (1)	1 (<1)
多発性硬化症再発	31 (5)	23 (4)	20 (3)	8 (2)
鼻咽頭炎	42 (7)	26 (4)	27 (5)	0
頭痛	10 (2)	6 (1)	13 (2)	1 (<1)
下痢	7 (1)	6 (1)	2 (<1)	0
尿路感染	10 (2)	18 (3)	17 (3)	2 (<1)
悪心	3 (<1)	7 (1)	5 (<1)	1 (<1)
上気道感染	11 (2)	19 (3)	11 (2)	1 (<1)
疲労	8 (1)	9 (2)	8 (1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 23 of 50

	BG00012 240 mg TID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
背部痛	16 (2)	18 (3)	13 (2)	11 (2)	9 (1)
上腹部痛	54 (7)	8 (1)	6 (<1)	10 (2)	9 (1)
蛋白尿	32 (4)	13 (2)	20 (3)	16 (3)	13 (2)
腹痛	38 (5)	7 (1)	2 (<1)	7 (1)	5 (<1)
関節痛	15 (2)	8 (1)	14 (2)	15 (2)	6 (<1)
インフルエンザ	24 (3)	6 (<1)	13 (2)	8 (1)	9 (1)
そう痒症	37 (5)	5 (<1)	4 (<1)	5 (<1)	3 (<1)
嘔吐	35 (5)	1 (<1)	6 (<1)	5 (<1)	4 (<1)
錯感覚	18 (2)	13 (2)	10 (2)	8 (1)	4 (<1)
四肢痛	13 (2)	11 (2)	9 (1)	13 (2)	5 (<1)
発疹	33 (4)	7 (1)	7 (1)	5 (<1)	2 (<1)
うつ病	12 (2)	7 (1)	7 (1)	10 (2)	4 (<1)
ほてり	35 (5)	7 (1)	3 (<1)	3 (<1)	2 (<1)
アラニン・アミノトランスフェラーゼ増加	26 (3)	5 (<1)	4 (<1)	4 (<1)	6 (<1)
紅斑	34 (4)	9 (1)	2 (<1)	5 (<1)	3 (<1)
副鼻腔炎	11 (1)	5 (<1)	12 (2)	10 (2)	13 (2)
気管支炎	12 (2)	7 (1)	4 (<1)	4 (<1)	9 (1)
尿中アルブミン陽性	8 (1)	8 (1)	2 (<1)	7 (1)	5 (<1)
口腔咽頭痛	7 (<1)	12 (2)	4 (<1)	7 (1)	6 (<1)
胃腸炎	11 (1)	2 (<1)	5 (<1)	5 (<1)	3 (<1)
咳嗽	6 (<1)	5 (<1)	7 (1)	7 (1)	8 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 24 of 50

	BG00012 240 mg TID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
背部痛	15 (2)	6 (1)	9 (2)	4 (<1)
上腹部痛	5 (<1)	2 (<1)	6 (1)	0
蛋白尿	9 (1)	8 (1)	8 (1)	3 (<1)
腹痛	3 (<1)	3 (<1)	3 (<1)	0
関節痛	3 (<1)	4 (<1)	5 (<1)	1 (<1)
インフルエンザ	9 (1)	9 (2)	10 (2)	1 (<1)
そう痒症	1 (<1)	3 (<1)	7 (1)	0
嘔吐	2 (<1)	3 (<1)	2 (<1)	0
錯感覚	5 (<1)	9 (2)	5 (<1)	0
四肢痛	3 (<1)	5 (<1)	7 (1)	2 (<1)
発疹	1 (<1)	5 (<1)	3 (<1)	1 (<1)
うつ病	2 (<1)	7 (1)	7 (1)	0
ほてり	1 (<1)	3 (<1)	2 (<1)	0
アラニン・アミノトランスフェラーゼ増加	3 (<1)	4 (<1)	5 (<1)	1 (<1)
紅斑	3 (<1)	3 (<1)	4 (<1)	0
副鼻腔炎	11 (2)	8 (1)	7 (1)	0
気管支炎	4 (<1)	7 (1)	5 (<1)	1 (<1)
尿中アルブミン陽性	4 (<1)	7 (1)	6 (1)	2 (<1)
口腔咽頭痛	2 (<1)	6 (1)	4 (<1)	0
胃腸炎	5 (<1)	3 (<1)	2 (<1)	0
咳嗽	5 (<1)	4 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 25 of 50

	BG00012 240 mg TID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
消化不良	22 (3)	10 (1)	5 (<1)	2 (<1)	1 (<1)
血尿	16 (2)	8 (1)	11 (2)	8 (1)	3 (<1)
感覚鈍麻	8 (1)	8 (1)	13 (2)	6 (<1)	5 (<1)
筋痙縮	11 (1)	7 (1)	6 (<1)	4 (<1)	11 (2)
ミクロアルブミン尿	6 (<1)	4 (<1)	10 (2)	3 (<1)	7 (1)
発熱	16 (2)	7 (1)	3 (<1)	4 (<1)	7 (1)
不眠症	9 (1)	4 (<1)	2 (<1)	5 (<1)	5 (<1)
回転性めまい	8 (1)	6 (<1)	6 (<1)	9 (1)	6 (<1)
浮動性めまい	12 (2)	4 (<1)	7 (1)	3 (<1)	4 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	16 (2)	3 (<1)	2 (<1)	1 (<1)	4 (<1)
咽頭炎	7 (<1)	2 (<1)	5 (<1)	4 (<1)	8 (1)
不安	7 (<1)	7 (1)	4 (<1)	4 (<1)	1 (<1)
便秘	14 (2)	5 (<1)	2 (<1)	4 (<1)	1 (<1)
胃腸障害	28 (4)	2 (<1)	2 (<1)	1 (<1)	0
鼻炎	7 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (<1)
尿中蛋白陽性	5 (<1)	6 (<1)	4 (<1)	1 (<1)	4 (<1)
頚部痛	4 (<1)	3 (<1)	3 (<1)	7 (1)	0
灼熱感	12 (2)	2 (<1)	3 (<1)	1 (<1)	1 (<1)
挫傷	3 (<1)	4 (<1)	5 (<1)	5 (<1)	3 (<1)
転倒	2 (<1)	7 (1)	5 (<1)	5 (<1)	3 (<1)
歯痛	6 (<1)	5 (<1)	3 (<1)	0	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 26 of 50

	BG00012 240 mg TID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
消化不良	7 (1)	2 (<1)	3 (<1)	0
血尿	2 (<1)	2 (<1)	2 (<1)	1 (<1)
感覚鈍麻	8 (1)	5 (<1)	3 (<1)	0
筋痙縮	3 (<1)	10 (2)	5 (<1)	0
ミクロアルブミン尿	5 (<1)	5 (<1)	6 (1)	1 (<1)
発熱	6 (<1)	3 (<1)	4 (<1)	0
不眠症	3 (<1)	4 (<1)	0	0
回転性めまい	6 (<1)	6 (1)	0	0
浮動性めまい	4 (<1)	3 (<1)	4 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (<1)	1 (<1)	2 (<1)	2 (<1)
咽頭炎	6 (<1)	4 (<1)	0	0
不安	2 (<1)	3 (<1)	2 (<1)	0
便秘	1 (<1)	1 (<1)	1 (<1)	0
胃腸障害	1 (<1)	0	0	0
鼻炎	6 (<1)	4 (<1)	0	0
尿中蛋白陽性	4 (<1)	1 (<1)	2 (<1)	0
頚部痛	4 (<1)	2 (<1)	2 (<1)	0
灼熱感	3 (<1)	4 (<1)	0	0
挫傷	6 (<1)	0	2 (<1)	0
転倒	5 (<1)	2 (<1)	0	0
歯痛	3 (<1)	3 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 27 of 50

	BG00012 240 mg TID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
多汗症	12 (2)	3 (<1)	3 (<1)	1 (<1)	4 (<1)
片頭痛	7 (<1)	4 (<1)	2 (<1)	3 (<1)	4 (<1)
胃炎	9 (1)	4 (<1)	1 (<1)	0	2 (<1)
筋力低下	7 (<1)	3 (<1)	6 (<1)	6 (<1)	1 (<1)
無力症	7 (<1)	3 (<1)	4 (<1)	2 (<1)	1 (<1)
気道感染	6 (<1)	3 (<1)	5 (<1)	5 (<1)	0
口腔ヘルペス	2 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)
ウイルス性胃腸炎	7 (<1)	3 (<1)	3 (<1)	2 (<1)	1 (<1)
リンパ球減少症	4 (<1)	0	5 (<1)	2 (<1)	3 (<1)
筋骨格痛	4 (<1)	6 (<1)	3 (<1)	3 (<1)	2 (<1)
貧血	5 (<1)	2 (<1)	3 (<1)	5 (<1)	1 (<1)
尿中血陽性	4 (<1)	2 (<1)	3 (<1)	2 (<1)	5 (<1)
腹部不快感	11 (1)	0	2 (<1)	1 (<1)	2 (<1)
胃食道逆流性疾患	7 (<1)	3 (<1)	3 (<1)	4 (<1)	1 (<1)
筋痙直	3 (<1)	2 (<1)	1 (<1)	2 (<1)	1 (<1)
血中副甲状腺ホルモン増加	2 (<1)	0	0	2 (<1)	8 (1)
γ－グルタミルトランスフェラーゼ増加	6 (<1)	1 (<1)	0	1 (<1)	1 (<1)
高血圧	5 (<1)	5 (<1)	4 (<1)	0	2 (<1)
食欲減退	7 (<1)	5 (<1)	0	1 (<1)	0
ウイルス感染	4 (<1)	3 (<1)	0	3 (<1)	2 (<1)
霧視	3 (<1)	6 (<1)	1 (<1)	3 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 28 of 50

	BG00012 240 mg TID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
多汗症	1 (<1)	4 (<1)	0	0
片頭痛	1 (<1)	4 (<1)	3 (<1)	0
胃炎	2 (<1)	4 (<1)	1 (<1)	0
筋力低下	4 (<1)	3 (<1)	1 (<1)	0
無力症	2 (<1)	1 (<1)	0	0
気道感染	1 (<1)	2 (<1)	2 (<1)	0
口腔ヘルペス	4 (<1)	3 (<1)	0	0
ウイルス性胃腸炎	2 (<1)	1 (<1)	3 (<1)	0
リンパ球減少症	1 (<1)	3 (<1)	2 (<1)	1 (<1)
筋骨格痛	3 (<1)	3 (<1)	4 (<1)	0
貧血	1 (<1)	2 (<1)	1 (<1)	1 (<1)
尿中血陽性	4 (<1)	3 (<1)	2 (<1)	0
腹部不快感	0	0	0	0
胃食道逆流性疾患	1 (<1)	0	0	1 (<1)
筋痙直	0	4 (<1)	3 (<1)	0
血中副甲状腺ホルモン増加	0	0	2 (<1)	3 (<1)
γ－グルタミルトランスフェラーゼ増加	2 (<1)	0	2 (<1)	0
高血圧	3 (<1)	1 (<1)	1 (<1)	1 (<1)
食欲減退	1 (<1)	0	0	0
ウイルス感染	2 (<1)	0	0	0
霧視	4 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 29 of 50

	BG00012 240 mg TID				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
膀胱炎	5 (<1)	1 (<1)	1 (<1)	1 (<1)	3 (<1)
眼痛	3 (<1)	7 (1)	1 (<1)	3 (<1)	1 (<1)
尿中白血球陽性	4 (<1)	1 (<1)	2 (<1)	2 (<1)	4 (<1)
脱毛症	4 (<1)	3 (<1)	1 (<1)	2 (<1)	0
血中ブドウ糖増加	1 (<1)	5 (<1)	4 (<1)	2 (<1)	2 (<1)
口内乾燥	5 (<1)	1 (<1)	1 (<1)	1 (<1)	0
関節捻挫	1 (<1)	2 (<1)	1 (<1)	1 (<1)	2 (<1)
筋肉痛	8 (1)	2 (<1)	0	1 (<1)	1 (<1)
耳感染	5 (<1)	5 (<1)	2 (<1)	2 (<1)	2 (<1)
末梢性浮腫	5 (<1)	4 (<1)	2 (<1)	4 (<1)	0
抑うつ気分	3 (<1)	1 (<1)	0	1 (<1)	2 (<1)
筋骨格硬直	2 (<1)	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 30 of 50

	BG00012 240 mg TID			
	>15-18 months	>18-21 months	>21-24 months	>24 months
膀胱炎	4 (<1)	0	4 (<1)	1 (<1)
眼痛	1 (<1)	1 (<1)	1 (<1)	0
尿中白血球陽性	2 (<1)	0	2 (<1)	0
脱毛症	1 (<1)	0	0	0
血中ブドウ糖増加	5 (<1)	5 (<1)	2 (<1)	1 (<1)
口内乾燥	2 (<1)	1 (<1)	0	0
関節捻挫	3 (<1)	2 (<1)	1 (<1)	1 (<1)
筋肉痛	0	2 (<1)	0	0
耳感染	4 (<1)	2 (<1)	1 (<1)	0
末梢性浮腫	2 (<1)	1 (<1)	2 (<1)	0
抑うつ気分	0	1 (<1)	0	0
筋骨格硬直	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 31 of 50

	Total BG00012				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
Number of subjects followed in the interval	1529 (100)	1414 (100)	1347 (100)	1290 (100)	1253 (100)
Number of subjects with an event	1201 (79)	797 (56)	731 (54)	662 (51)	615 (49)
Number of subjects with deaths	1 (<1)	1 (<1)	1 (<1)	0	0
Number of subjects with SAEs other than deaths	66 (4)	45 (3)	38 (3)	36 (3)	32 (3)
Number of subjects who discontinued	91 (6)	7 (<1)	8 (<1)	2 (<1)	8 (<1)
潮紅	397 (26)	71 (5)	46 (3)	42 (3)	29 (2)
多発性硬化症再発	124 (8)	94 (7)	79 (6)	75 (6)	58 (5)
鼻咽頭炎	89 (6)	81 (6)	80 (6)	69 (5)	57 (5)
頭痛	125 (8)	57 (4)	37 (3)	39 (3)	45 (4)
下痢	163 (11)	33 (2)	23 (2)	21 (2)	13 (1)
尿路感染	55 (4)	57 (4)	33 (2)	32 (2)	22 (2)
悪心	144 (9)	18 (1)	20 (1)	12 (<1)	6 (<1)
上気道感染	61 (4)	39 (3)	39 (3)	39 (3)	37 (3)
疲労	78 (5)	32 (2)	33 (2)	20 (2)	19 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 32 of 50

	Total BG00012			
	>15-18 months	>18-21 months	>21-24 months	>24 months
Number of subjects followed in the interval	1219 (100)	1182 (100)	1158 (100)	816 (100)
Number of subjects with an event	594 (49)	541 (46)	506 (44)	117 (14)
Number of subjects with deaths	0	0	0	0
Number of subjects with SAEs other than deaths	33 (3)	38 (3)	29 (3)	4 (<1)
Number of subjects who discontinued	4 (<1)	4 (<1)	3 (<1)	0
潮紅	30 (2)	18 (2)	13 (1)	2 (<1)
多発性硬化症再発	56 (5)	55 (5)	47 (4)	12 (1)
鼻咽頭炎	79 (6)	50 (4)	59 (5)	1 (<1)
頭痛	28 (2)	21 (2)	26 (2)	6 (<1)
下痢	11 (<1)	12 (1)	9 (<1)	1 (<1)
尿路感染	27 (2)	33 (3)	31 (3)	4 (<1)
悪心	6 (<1)	13 (1)	10 (<1)	2 (<1)
上気道感染	21 (2)	36 (3)	25 (2)	1 (<1)
疲労	20 (2)	15 (1)	11 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 33 of 50

	Total BG00012				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
背部痛	42 (3)	37 (3)	34 (3)	24 (2)	24 (2)
上腹部痛	108 (7)	17 (1)	17 (1)	17 (1)	16 (1)
蛋白尿	49 (3)	27 (2)	38 (3)	24 (2)	28 (2)
腹痛	88 (6)	14 (<1)	10 (<1)	18 (1)	7 (<1)
関節痛	34 (2)	17 (1)	24 (2)	25 (2)	16 (1)
インフルエンザ	36 (2)	22 (2)	20 (1)	17 (1)	14 (1)
そう痒症	75 (5)	15 (1)	16 (1)	11 (<1)	6 (<1)
嘔吐	74 (5)	6 (<1)	16 (1)	12 (<1)	8 (<1)
錯感覚	38 (2)	22 (2)	20 (1)	15 (1)	7 (<1)
四肢痛	27 (2)	24 (2)	18 (1)	26 (2)	11 (<1)
発疹	66 (4)	20 (1)	15 (1)	11 (<1)	8 (<1)
うつ病	26 (2)	15 (1)	18 (1)	17 (1)	11 (<1)
ほてり	70 (5)	12 (<1)	5 (<1)	6 (<1)	4 (<1)
アラニン・アミノトランスフェラーゼ増加	50 (3)	15 (1)	8 (<1)	9 (<1)	8 (<1)
紅斑	55 (4)	15 (1)	4 (<1)	5 (<1)	6 (<1)
副鼻腔炎	17 (1)	10 (<1)	20 (1)	14 (1)	17 (1)
気管支炎	20 (1)	16 (1)	9 (<1)	9 (<1)	14 (1)
尿中アルブミン陽性	16 (1)	18 (1)	14 (1)	11 (<1)	12 (<1)
口腔咽頭痛	14 (<1)	20 (1)	8 (<1)	13 (1)	10 (<1)
胃腸炎	25 (2)	7 (<1)	7 (<1)	11 (<1)	12 (<1)
咳嗽	17 (1)	12 (<1)	11 (<1)	10 (<1)	12 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 34 of 50

	Total BG00012			
	>15-18 months	>18-21 months	>21-24 months	>24 months
背部痛	24 (2)	15 (1)	18 (2)	4 (<1)
上腹部痛	5 (<1)	8 (<1)	8 (<1)	0
蛋白尿	18 (1)	16 (1)	15 (1)	7 (<1)
腹痛	5 (<1)	6 (<1)	5 (<1)	0
関節痛	10 (<1)	11 (<1)	13 (1)	1 (<1)
インフルエンザ	15 (1)	16 (1)	16 (1)	2 (<1)
そう痒症	4 (<1)	4 (<1)	10 (<1)	0
嘔吐	4 (<1)	4 (<1)	5 (<1)	2 (<1)
錯感覚	12 (<1)	13 (1)	11 (<1)	0
四肢痛	10 (<1)	10 (<1)	14 (1)	2 (<1)
発疹	5 (<1)	5 (<1)	5 (<1)	1 (<1)
うつ病	5 (<1)	13 (1)	12 (1)	2 (<1)
ほてり	5 (<1)	4 (<1)	2 (<1)	0
アラニン・アミノトランスフェラーゼ増加	7 (<1)	6 (<1)	11 (<1)	2 (<1)
紅斑	8 (<1)	7 (<1)	5 (<1)	0
副鼻腔炎	15 (1)	15 (1)	10 (<1)	0
気管支炎	6 (<1)	11 (<1)	7 (<1)	2 (<1)
尿中アルブミン陽性	9 (<1)	11 (<1)	10 (<1)	6 (<1)
口腔咽頭痛	8 (<1)	11 (<1)	7 (<1)	0
胃腸炎	8 (<1)	7 (<1)	5 (<1)	0
咳嗽	11 (<1)	8 (<1)	6 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 35 of 50

	Total BG00012				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
消化不良	40 (3)	16 (1)	10 (<1)	7 (<1)	3 (<1)
血尿	21 (1)	17 (1)	16 (1)	14 (1)	8 (<1)
感覚鈍麻	19 (1)	12 (<1)	18 (1)	11 (<1)	8 (<1)
筋痙縮	18 (1)	8 (<1)	7 (<1)	10 (<1)	17 (1)
ミクロアルブミン尿	9 (<1)	12 (<1)	13 (<1)	7 (<1)	17 (1)
発熱	21 (1)	13 (<1)	4 (<1)	7 (<1)	11 (<1)
不眠症	18 (1)	6 (<1)	9 (<1)	12 (<1)	8 (<1)
回転性めまい	14 (<1)	13 (<1)	10 (<1)	10 (<1)	8 (<1)
浮動性めまい	23 (2)	7 (<1)	13 (<1)	8 (<1)	9 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	33 (2)	8 (<1)	6 (<1)	4 (<1)	6 (<1)
咽頭炎	17 (1)	8 (<1)	8 (<1)	9 (<1)	14 (1)
不安	16 (1)	15 (1)	15 (1)	7 (<1)	3 (<1)
便秘	27 (2)	8 (<1)	4 (<1)	4 (<1)	7 (<1)
胃腸障害	45 (3)	3 (<1)	2 (<1)	3 (<1)	0
鼻炎	12 (<1)	8 (<1)	5 (<1)	6 (<1)	6 (<1)
尿中蛋白陽性	13 (<1)	12 (<1)	6 (<1)	4 (<1)	8 (<1)
頚部痛	5 (<1)	10 (<1)	7 (<1)	11 (<1)	2 (<1)
灼熱感	26 (2)	2 (<1)	5 (<1)	4 (<1)	2 (<1)
挫傷	5 (<1)	6 (<1)	10 (<1)	9 (<1)	7 (<1)
転倒	2 (<1)	12 (<1)	11 (<1)	8 (<1)	6 (<1)
歯痛	11 (<1)	8 (<1)	4 (<1)	3 (<1)	5 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 36 of 50

	Total BG00012			
	>15-18 months	>18-21 months	>21-24 months	>24 months
消化不良	8 (<1)	4 (<1)	4 (<1)	0
血尿	7 (<1)	9 (<1)	13 (1)	4 (<1)
感覚鈍麻	9 (<1)	7 (<1)	6 (<1)	0
筋痙縮	7 (<1)	12 (1)	9 (<1)	1 (<1)
ミクロアルブミン尿	9 (<1)	9 (<1)	10 (<1)	7 (<1)
発熱	10 (<1)	9 (<1)	6 (<1)	1 (<1)
不眠症	7 (<1)	10 (<1)	2 (<1)	0
回転性めまい	9 (<1)	6 (<1)	2 (<1)	0
浮動性めまい	8 (<1)	5 (<1)	8 (<1)	1 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	5 (<1)	1 (<1)	4 (<1)	2 (<1)
咽頭炎	13 (1)	7 (<1)	6 (<1)	0
不安	3 (<1)	3 (<1)	2 (<1)	1 (<1)
便秘	1 (<1)	1 (<1)	2 (<1)	0
胃腸障害	2 (<1)	0	0	0
鼻炎	10 (<1)	6 (<1)	1 (<1)	0
尿中蛋白陽性	9 (<1)	2 (<1)	6 (<1)	2 (<1)
頚部痛	9 (<1)	3 (<1)	6 (<1)	0
灼熱感	4 (<1)	4 (<1)	2 (<1)	0
挫傷	8 (<1)	3 (<1)	3 (<1)	1 (<1)
転倒	6 (<1)	4 (<1)	3 (<1)	0
歯痛	5 (<1)	4 (<1)	5 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 37 of 50

	Total BG00012				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
多汗症	19 (1)	5 (<1)	7 (<1)	5 (<1)	4 (<1)
片頭痛	14 (<1)	8 (<1)	6 (<1)	6 (<1)	6 (<1)
胃炎	15 (<1)	9 (<1)	2 (<1)	4 (<1)	3 (<1)
筋力低下	10 (<1)	6 (<1)	10 (<1)	6 (<1)	5 (<1)
無力症	23 (2)	4 (<1)	5 (<1)	4 (<1)	2 (<1)
気道感染	10 (<1)	6 (<1)	8 (<1)	8 (<1)	1 (<1)
口腔ヘルペス	9 (<1)	6 (<1)	7 (<1)	7 (<1)	5 (<1)
ウイルス性胃腸炎	12 (<1)	4 (<1)	5 (<1)	2 (<1)	1 (<1)
リンパ球減少症	7 (<1)	3 (<1)	9 (<1)	3 (<1)	4 (<1)
筋骨格痛	7 (<1)	8 (<1)	5 (<1)	6 (<1)	4 (<1)
貧血	8 (<1)	4 (<1)	4 (<1)	6 (<1)	2 (<1)
尿中血陽性	7 (<1)	6 (<1)	4 (<1)	3 (<1)	8 (<1)
腹部不快感	19 (1)	2 (<1)	4 (<1)	6 (<1)	5 (<1)
胃食道逆流性疾患	17 (1)	7 (<1)	5 (<1)	5 (<1)	2 (<1)
筋痙直	5 (<1)	7 (<1)	3 (<1)	2 (<1)	3 (<1)
血中副甲状腺ホルモン増加	3 (<1)	1 (<1)	0	8 (<1)	10 (<1)
γ－グルタミルトランスフェラーゼ増加	10 (<1)	4 (<1)	3 (<1)	1 (<1)	4 (<1)
高血圧	9 (<1)	6 (<1)	4 (<1)	1 (<1)	3 (<1)
食欲減退	15 (<1)	9 (<1)	0	3 (<1)	1 (<1)
ウイルス感染	7 (<1)	6 (<1)	1 (<1)	4 (<1)	4 (<1)
霧視	8 (<1)	7 (<1)	2 (<1)	5 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 38 of 50

	Total BG00012			
	>15-18 months	>18-21 months	>21-24 months	>24 months
多汗症	1 (<1)	4 (<1)	2 (<1)	0
片頭痛	3 (<1)	7 (<1)	4 (<1)	0
胃炎	5 (<1)	6 (<1)	2 (<1)	0
筋力低下	6 (<1)	4 (<1)	4 (<1)	0
無力症	3 (<1)	3 (<1)	1 (<1)	0
気道感染	3 (<1)	2 (<1)	4 (<1)	0
口腔ヘルペス	8 (<1)	4 (<1)	3 (<1)	0
ウイルス性胃腸炎	7 (<1)	3 (<1)	5 (<1)	0
リンパ球減少症	4 (<1)	5 (<1)	6 (<1)	1 (<1)
筋骨格痛	5 (<1)	4 (<1)	6 (<1)	0
貧血	4 (<1)	3 (<1)	4 (<1)	1 (<1)
尿中血陽性	6 (<1)	7 (<1)	4 (<1)	0
腹部不快感	2 (<1)	1 (<1)	1 (<1)	0
胃食道逆流性疾患	1 (<1)	0	1 (<1)	1 (<1)
筋痙直	3 (<1)	7 (<1)	4 (<1)	0
血中副甲状腺ホルモン増加	0	0	3 (<1)	8 (<1)
γ－グルタミルトランスフェラーゼ増加	3 (<1)	2 (<1)	8 (<1)	0
高血圧	4 (<1)	4 (<1)	1 (<1)	2 (<1)
食欲減退	2 (<1)	0	2 (<1)	0
ウイルス感染	4 (<1)	6 (<1)	2 (<1)	0
霧視	7 (<1)	3 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 39 of 50

	Total BG00012				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
膀胱炎	6 (<1)	6 (<1)	2 (<1)	1 (<1)	4 (<1)
眼痛	3 (<1)	8 (<1)	4 (<1)	7 (<1)	2 (<1)
尿中白血球陽性	4 (<1)	5 (<1)	6 (<1)	5 (<1)	6 (<1)
脱毛症	13 (<1)	7 (<1)	1 (<1)	3 (<1)	2 (<1)
血中ブドウ糖増加	3 (<1)	9 (<1)	5 (<1)	3 (<1)	5 (<1)
口内乾燥	19 (1)	2 (<1)	2 (<1)	2 (<1)	0
関節捻挫	2 (<1)	4 (<1)	2 (<1)	5 (<1)	4 (<1)
筋肉痛	12 (<1)	5 (<1)	3 (<1)	1 (<1)	3 (<1)
耳感染	5 (<1)	5 (<1)	3 (<1)	2 (<1)	5 (<1)
末梢性浮腫	8 (<1)	4 (<1)	3 (<1)	4 (<1)	1 (<1)
抑うつ気分	8 (<1)	1 (<1)	3 (<1)	1 (<1)	3 (<1)
筋骨格硬直	3 (<1)	2 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 40 of 50

	Total BG00012			
	>15-18 months	>18-21 months	>21-24 months	>24 months
膀胱炎	5 (<1)	1 (<1)	6 (<1)	1 (<1)
眼痛	6 (<1)	2 (<1)	2 (<1)	0
尿中白血球陽性	3 (<1)	2 (<1)	4 (<1)	0
脱毛症	1 (<1)	1 (<1)	0	0
血中ブドウ糖増加	6 (<1)	7 (<1)	2 (<1)	1 (<1)
口内乾燥	2 (<1)	1 (<1)	0	0
関節捻挫	4 (<1)	3 (<1)	2 (<1)	1 (<1)
筋肉痛	0	2 (<1)	1 (<1)	0
耳感染	6 (<1)	2 (<1)	2 (<1)	0
末梢性浮腫	4 (<1)	1 (<1)	3 (<1)	0
抑うつ気分	2 (<1)	1 (<1)	0	1 (<1)
筋骨格硬直	2 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 41 of 50

	GA				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
Number of subjects followed in the interval	351 (100)	338 (100)	327 (100)	322 (100)	307 (100)
Number of subjects with an event	197 (56)	163 (48)	138 (42)	131 (41)	120 (39)
Number of subjects with deaths	0	0	0	0	0
Number of subjects with SAEs other than deaths	14 (4)	14 (4)	12 (4)	8 (2)	6 (2)
Number of subjects who discontinued	6 (2)	0	3 (<1)	0	0
潮紅	1 (<1)	2 (<1)	2 (<1)	1 (<1)	0
多発性硬化症再発	33 (9)	30 (9)	32 (10)	22 (7)	17 (6)
鼻咽頭炎	9 (3)	16 (5)	13 (4)	7 (2)	7 (2)
頭痛	21 (6)	15 (4)	7 (2)	5 (2)	3 (<1)
下痢	3 (<1)	1 (<1)	1 (<1)	2 (<1)	2 (<1)
尿路感染	16 (5)	10 (3)	9 (3)	10 (3)	5 (2)
悪心	8 (2)	1 (<1)	3 (<1)	1 (<1)	1 (<1)
上気道感染	7 (2)	2 (<1)	3 (<1)	5 (2)	1 (<1)
疲労	9 (3)	11 (3)	6 (2)	3 (<1)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 42 of 50

	GA			
	>15-18 months	>18-21 months	>21-24 months	>24 months
Number of subjects followed in the interval	298 (100)	291 (100)	282 (100)	217 (100)
Number of subjects with an event	108 (36)	115 (40)	91 (32)	18 (8)
Number of subjects with deaths	0	1 (<1)	0	0
Number of subjects with SAEs other than deaths	2 (<1)	6 (2)	10 (4)	0
Number of subjects who discontinued	1 (<1)	2 (<1)	0	0
潮紅	1 (<1)	1 (<1)	0	0
多発性硬化症再発	17 (6)	17 (6)	12 (4)	2 (<1)
鼻咽頭炎	6 (2)	8 (3)	8 (3)	3 (1)
頭痛	6 (2)	4 (1)	2 (<1)	0
下痢	0	4 (1)	1 (<1)	0
尿路感染	5 (2)	6 (2)	5 (2)	1 (<1)
悪心	2 (<1)	1 (<1)	0	0
上気道感染	5 (2)	8 (3)	3 (1)	0
疲労	2 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 43 of 50

	GA				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
背部痛	9 (3)	5 (1)	7 (2)	3 (<1)	5 (2)
上腹部痛	1 (<1)	1 (<1)	0	2 (<1)	0
蛋白尿	8 (2)	4 (1)	7 (2)	10 (3)	5 (2)
腹痛	1 (<1)	0	1 (<1)	1 (<1)	0
関節痛	3 (<1)	2 (<1)	3 (<1)	3 (<1)	1 (<1)
インフルエンザ	1 (<1)	1 (<1)	4 (1)	3 (<1)	3 (<1)
そう痒症	2 (<1)	0	0	1 (<1)	1 (<1)
嘔吐	1 (<1)	0	1 (<1)	2 (<1)	3 (<1)
錯感覚	0	4 (1)	5 (2)	2 (<1)	1 (<1)
四肢痛	6 (2)	5 (1)	3 (<1)	3 (<1)	4 (1)
発疹	3 (<1)	1 (<1)	1 (<1)	0	1 (<1)
うつ病	9 (3)	4 (1)	4 (1)	2 (<1)	3 (<1)
ほてり	4 (1)	0	0	0	0
アラニン・アミノトランスフェラーゼ増加	5 (1)	5 (1)	3 (<1)	2 (<1)	5 (2)
紅斑	3 (<1)	1 (<1)	1 (<1)	0	0
副鼻腔炎	1 (<1)	1 (<1)	0	3 (<1)	2 (<1)
気管支炎	2 (<1)	5 (1)	2 (<1)	1 (<1)	0
尿中アルブミン陽性	1 (<1)	3 (<1)	1 (<1)	5 (2)	5 (2)
口腔咽頭痛	4 (1)	1 (<1)	2 (<1)	1 (<1)	0
胃腸炎	0	1 (<1)	1 (<1)	0	1 (<1)
咳嗽	0	3 (<1)	2 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 44 of 50

	GA			
	>15-18 months	>18-21 months	>21-24 months	>24 months
背部痛	4 (1)	2 (<1)	2 (<1)	0
上腹部痛	0	0	0	0
蛋白尿	1 (<1)	4 (1)	4 (1)	2 (<1)
腹痛	1 (<1)	0	0	0
関節痛	0	1 (<1)	6 (2)	0
インフルエンザ	3 (1)	2 (<1)	1 (<1)	0
そう痒症	1 (<1)	0	2 (<1)	0
嘔吐	0	1 (<1)	0	0
錯感覚	1 (<1)	4 (1)	0	0
四肢痛	5 (2)	4 (1)	2 (<1)	0
発疹	1 (<1)	0	2 (<1)	0
うつ病	4 (1)	4 (1)	1 (<1)	1 (<1)
ほてり	0	0	0	0
アラニン・アミノトランスフェラーゼ増加	1 (<1)	1 (<1)	3 (1)	0
紅斑	0	0	1 (<1)	0
副鼻腔炎	6 (2)	1 (<1)	0	0
気管支炎	3 (1)	2 (<1)	2 (<1)	0
尿中アルブミン陽性	4 (1)	2 (<1)	3 (1)	1 (<1)
口腔咽頭痛	5 (2)	1 (<1)	1 (<1)	0
胃腸炎	0	2 (<1)	1 (<1)	0
咳嗽	2 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 45 of 50

	GA				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
消化不良	1 (<1)	2 (<1)	1 (<1)	1 (<1)	0
血尿	2 (<1)	3 (<1)	0	3 (<1)	3 (<1)
感覚鈍麻	3 (<1)	5 (1)	2 (<1)	3 (<1)	3 (<1)
筋痙縮	2 (<1)	2 (<1)	2 (<1)	0	1 (<1)
ミクロアルブミン尿	3 (<1)	2 (<1)	2 (<1)	3 (<1)	3 (<1)
発熱	6 (2)	1 (<1)	2 (<1)	1 (<1)	3 (<1)
不眠症	4 (1)	2 (<1)	4 (1)	0	1 (<1)
回転性めまい	2 (<1)	4 (1)	1 (<1)	4 (1)	1 (<1)
浮動性めまい	7 (2)	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ増加	2 (<1)	4 (1)	2 (<1)	1 (<1)	3 (<1)
咽頭炎	2 (<1)	4 (1)	1 (<1)	3 (<1)	2 (<1)
不安	3 (<1)	1 (<1)	0	2 (<1)	0
便秘	2 (<1)	1 (<1)	2 (<1)	2 (<1)	0
胃腸障害	0	1 (<1)	0	0	0
鼻炎	1 (<1)	1 (<1)	4 (1)	1 (<1)	0
尿中蛋白陽性	3 (<1)	6 (2)	1 (<1)	3 (<1)	2 (<1)
頚部痛	0	2 (<1)	1 (<1)	1 (<1)	1 (<1)
挫傷	2 (<1)	2 (<1)	1 (<1)	1 (<1)	0
転倒	4 (1)	3 (<1)	2 (<1)	4 (1)	1 (<1)
歯痛	1 (<1)	1 (<1)	1 (<1)	1 (<1)	1 (<1)
多汗症	0	3 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 46 of 50

	GA			
	>15-18 months	>18-21 months	>21-24 months	>24 months
消化不良	0	1 (<1)	0	0
血尿	2 (<1)	0	3 (1)	0
感覚鈍麻	0	2 (<1)	2 (<1)	0
筋痙縮	1 (<1)	1 (<1)	0	0
ミクロアルブミン尿	0	5 (2)	1 (<1)	0
発熱	3 (1)	2 (<1)	1 (<1)	0
不眠症	2 (<1)	0	1 (<1)	0
回転性めまい	2 (<1)	2 (<1)	1 (<1)	0
浮動性めまい	0	1 (<1)	1 (<1)	0
アスパラギン酸アミノトランスフェラーゼ増加	1 (<1)	1 (<1)	1 (<1)	0
咽頭炎	2 (<1)	0	2 (<1)	0
不安	0	1 (<1)	1 (<1)	0
便秘	2 (<1)	0	0	0
胃腸障害	1 (<1)	0	0	0
鼻炎	1 (<1)	0	3 (1)	0
尿中蛋白陽性	2 (<1)	1 (<1)	1 (<1)	1 (<1)
頚部痛	1 (<1)	1 (<1)	0	0
挫傷	0	0	0	0
転倒	3 (1)	1 (<1)	1 (<1)	0
歯痛	0	0	0	0
多汗症	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 47 of 50

	GA				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
片頭痛	1 (<1)	2 (<1)	0	1 (<1)	3 (<1)
胃炎	0	0	1 (<1)	0	1 (<1)
筋力低下	3 (<1)	2 (<1)	2 (<1)	1 (<1)	1 (<1)
無力症	5 (1)	2 (<1)	2 (<1)	1 (<1)	2 (<1)
気道感染	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
口腔ヘルペス	1 (<1)	2 (<1)	2 (<1)	1 (<1)	1 (<1)
ウイルス性胃腸炎	1 (<1)	0	1 (<1)	2 (<1)	1 (<1)
筋骨格痛	0	3 (<1)	2 (<1)	1 (<1)	2 (<1)
貧血	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)
尿中血陽性	3 (<1)	1 (<1)	0	0	0
腹部不快感	0	0	0	0	0
胃食道逆流性疾患	1 (<1)	0	0	0	0
筋痙直	2 (<1)	1 (<1)	2 (<1)	0	0
血中副甲状腺ホルモン増加	0	0	0	0	1 (<1)
γ－グルタミルトランスフェラーゼ増加	3 (<1)	1 (<1)	0	1 (<1)	1 (<1)
高血圧	3 (<1)	3 (<1)	2 (<1)	1 (<1)	1 (<1)
食欲減退	1 (<1)	1 (<1)	1 (<1)	1 (<1)	0
ウイルス感染	0	2 (<1)	0	0	0
霧視	3 (<1)	0	0	0	1 (<1)
膀胱炎	0	1 (<1)	0	0	3 (<1)
眼痛	1 (<1)	2 (<1)	3 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 48 of 50

	GA			
	>15-18 months	>18-21 months	>21-24 months	>24 months
片頭痛	1 (<1)	0	1 (<1)	0
胃炎	0	0	2 (<1)	0
筋力低下	0	0	0	0
無力症	1 (<1)	1 (<1)	1 (<1)	1 (<1)
気道感染	0	1 (<1)	2 (<1)	0
口腔ヘルペス	0	1 (<1)	0	0
ウイルス性胃腸炎	1 (<1)	0	0	0
筋骨格痛	0	1 (<1)	0	0
貧血	0	1 (<1)	1 (<1)	0
尿中血陽性	0	0	0	0
腹部不快感	1 (<1)	0	0	0
胃食道逆流性疾患	1 (<1)	0	0	0
筋痙直	1 (<1)	1 (<1)	0	0
血中副甲状腺ホルモン増加	0	0	0	1 (<1)
γ－グルタミルトランスフェラーゼ増加	2 (<1)	0	1 (<1)	0
高血圧	3 (1)	2 (<1)	0	0
食欲減退	0	0	0	0
ウイルス感染	1 (<1)	1 (<1)	1 (<1)	0
霧視	0	1 (<1)	1 (<1)	0
膀胱炎	0	1 (<1)	1 (<1)	0
眼痛	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 49 of 50

	GA				
	0-3 months	>3-6 months	>6-9 months	>9-12 months	>12-15 months
尿中白血球陽性	3 (<1)	5 (1)	3 (<1)	0	1 (<1)
脱毛症	5 (1)	0	1 (<1)	0	0
血中ブドウ糖増加	1 (<1)	1 (<1)	0	2 (<1)	1 (<1)
口内乾燥	0	0	0	0	1 (<1)
関節捻挫	1 (<1)	0	1 (<1)	0	0
筋肉痛	3 (<1)	0	1 (<1)	0	0
耳感染	0	0	0	0	1 (<1)
末梢性浮腫	1 (<1)	1 (<1)	2 (<1)	1 (<1)	0
抑うつ気分	1 (<1)	1 (<1)	2 (<1)	0	0
筋骨格硬直	1 (<1)	3 (<1)	2 (<1)	2 (<1)	2 (<1)
注射部位紅斑	29 (8)	2 (<1)	0	1 (<1)	0
注射部位疼痛	27 (8)	3 (<1)	1 (<1)	0	0
注射部位そう痒感	12 (3)	0	0	0	1 (<1)
注射部位腫脹	9 (3)	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Incidence of adverse events at least 2% higher for any treatment group and the entire study period by preferred term and 3-months interval: Studies 109MS301 and 109MS302
Page 50 of 50

	GA			
	>15-18 months	>18-21 months	>21-24 months	>24 months
尿中白血球陽性	2 (<1)	0	0	0
脱毛症	0	1 (<1)	0	0
血中ブドウ糖増加	1 (<1)	2 (<1)	0	0
口内乾燥	0	0	0	0
関節捻挫	1 (<1)	0	0	0
筋肉痛	0	0	0	0
耳感染	0	0	1 (<1)	0
末梢性浮腫	1 (<1)	0	0	0
抑うつ気分	1 (<1)	0	0	0
筋骨格硬直	0	0	0	0
注射部位紅斑	0	0	0	0
注射部位疼痛	1 (<1)	0	0	0
注射部位そう痒感	0	0	0	0
注射部位腫脹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each interval for each preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column.

SOURCE: BG12MS/JAPAN/ISS/T-AE-PT-2PCT-3MON-A.SAS DATE: 02DEC2015

Table 115: Incidence of Severe Adverse Events by System Organ Class and Preferred Term: Studies 109MS301 and 109MS302

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 1 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
Number of subjects in safety population	771 (100)	769 (100)	760 (100)	1529 (100)	351 (100)
Number of subjects with a severe event	118 (15)	115 (15)	111 (15)	226 (15)	45 (13)
感染症および寄生虫症	17 (2)	15 (2)	16 (2)	31 (2)	4 (1)
胃腸炎	4 (<1)	6 (<1)	0	6 (<1)	0
インフルエンザ	1 (<1)	3 (<1)	2 (<1)	5 (<1)	1 (<1)
ウイルス性胃腸炎	2 (<1)	1 (<1)	2 (<1)	3 (<1)	0
尿路感染	2 (<1)	0	3 (<1)	3 (<1)	0
鼻咽頭炎	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
上気道感染	1 (<1)	2 (<1)	0	2 (<1)	0
気管支炎	0	1 (<1)	0	1 (<1)	1 (<1)
蜂巣炎	0	0	1 (<1)	1 (<1)	0
細菌性結膜炎	0	1 (<1)	0	1 (<1)	0
ダグラス窩膿瘍	0	0	1 (<1)	1 (<1)	0
せつ	0	1 (<1)	0	1 (<1)	0
消化管感染	0	0	1 (<1)	1 (<1)	0
眼帯状疱疹	0	0	1 (<1)	1 (<1)	0
中耳炎	0	0	1 (<1)	1 (<1)	0
扁桃周囲膿瘍	0	0	1 (<1)	1 (<1)	0
肺炎	0	1 (<1)	0	1 (<1)	0
鼻炎	0	0	1 (<1)	1 (<1)	0
副鼻腔炎	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 2 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
歯膿瘍	0	0	1 (<1)	1 (<1)	0
歯感染	1 (<1)	0	1 (<1)	1 (<1)	0
気管炎	0	1 (<1)	0	1 (<1)	0
肛門膿瘍	1 (<1)	0	0	0	0
膀胱炎	1 (<1)	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0	0
Ｈ１Ｎ１インフルエンザ	1 (<1)	0	0	0	0
帯状疱疹	1 (<1)	0	0	0	0
骨盤内炎症性疾患	1 (<1)	0	0	0	0
咽頭炎	0	0	0	0	1 (<1)
腎盂腎炎	0	0	0	0	1 (<1)
敗血症	1 (<1)	0	0	0	0
'良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	3 (<1)	4 (<1)	0	4 (<1)	1 (<1)
肺の良性新生物	0	1 (<1)	0	1 (<1)	0
脂肪腫	0	1 (<1)	0	1 (<1)	0
肺新生物	0	1 (<1)	0	1 (<1)	0
神経鞘腫	0	1 (<1)	0	1 (<1)	0
移行上皮癌	0	1 (<1)	0	1 (<1)	0
基底細胞癌	0	0	0	0	1 (<1)
乳癌	1 (<1)	0	0	0	0
線維腫	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 3 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
子宮平滑筋腫	1 (<1)	0	0	0	0
	1 (<1)	0	0	0	0
血液およびリンパ系障害					
貧血	1 (<1)	0	0	0	0
免疫系障害	1 (<1)	1 (<1)	2 (<1)	3 (<1)	2 (<1)
過敏症	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	1 (<1)	0
アナフィラキシー反応	0	0	0	0	1 (<1)
食物アレルギー	1 (<1)	0	0	0	0
内分泌障害	0	0	1 (<1)	1 (<1)	0
間脳性内分泌障害	0	0	1 (<1)	1 (<1)	0
代謝および栄養障害	2 (<1)	0	2 (<1)	2 (<1)	0
脱水	0	0	1 (<1)	1 (<1)	0
低血糖症	0	0	1 (<1)	1 (<1)	0
糖尿病性ケトアシドーシス	1 (<1)	0	0	0	0
ビタミンD欠乏	1 (<1)	0	0	0	0
精神障害	1 (<1)	6 (<1)	5 (<1)	11 (<1)	5 (1)
うつ病	0	2 (<1)	3 (<1)	5 (<1)	2 (<1)
不眠症	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 4 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
抑うつ気分を伴う適応障害	0	1 (<1)	0	1 (<1)	0
双極１型障害	0	1 (<1)	0	1 (<1)	0
自己愛性人格障害	0	1 (<1)	0	1 (<1)	0
自殺念慮	0	1 (<1)	0	1 (<1)	1 (<1)
自殺企図	0	0	1 (<1)	1 (<1)	1 (<1)
不安	1 (<1)	0	0	0	1 (<1)
自殺既遂	0	0	0	0	1 (<1)
神経系障害	60 (8)	39 (5)	32 (4)	71 (5)	18 (5)
多発性硬化症再発	43 (6)	22 (3)	12 (2)	34 (2)	12 (3)
頭痛	7 (<1)	9 (1)	7 (<1)	16 (1)	0
片頭痛	4 (<1)	1 (<1)	3 (<1)	4 (<1)	2 (<1)
構語障害	0	1 (<1)	2 (<1)	3 (<1)	0
浮動性めまい	0	1 (<1)	1 (<1)	2 (<1)	0
感覚障害	0	1 (<1)	1 (<1)	2 (<1)	0
失神	0	2 (<1)	0	2 (<1)	0
味覚消失	0	0	1 (<1)	1 (<1)	0
帯状感	0	0	1 (<1)	1 (<1)	0
灼熱感	0	0	1 (<1)	1 (<1)	0
手根管症候群	0	1 (<1)	0	1 (<1)	1 (<1)
てんかん	1 (<1)	1 (<1)	0	1 (<1)	0
舌咽神経痛	0	1 (<1)	0	1 (<1)	0
大発作痙攣	0	0	1 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 5 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
過眠症	0	0	1 (<1)	1 (<1)	0
感覚鈍麻	1 (<1)	0	1 (<1)	1 (<1)	0
思考散乱	0	0	1 (<1)	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	1 (<1)	0
意識消失	1 (<1)	0	1 (<1)	1 (<1)	0
前兆を伴う片頭痛	0	0	1 (<1)	1 (<1)	0
筋痙直	1 (<1)	1 (<1)	0	1 (<1)	0
後頭神経痛	0	0	1 (<1)	1 (<1)	0
錯感覚	0	0	1 (<1)	1 (<1)	0
部分発作	0	1 (<1)	0	1 (<1)	0
坐骨神経痛	0	0	1 (<1)	1 (<1)	0
緊張性頭痛	0	1 (<1)	0	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	1 (<1)	0
三叉神経痛	2 (<1)	0	1 (<1)	1 (<1)	0
脳血管発作	1 (<1)	0	0	0	0
痙攣	1 (<1)	0	0	0	0
多発性硬化症	1 (<1)	0	0	0	1 (<1)
失神寸前の状態	0	0	0	0	1 (<1)
片頭痛発作重積	1 (<1)	0	0	0	0
眼障害	3 (<1)	0	1 (<1)	1 (<1)	1 (<1)
眼運動障害	0	0	1 (<1)	1 (<1)	0
眼痛	0	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 6 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
一過性失明	1 (<1)	0	0	0	1 (<1)
ホームズ・アディー瞳孔	1 (<1)	0	0	0	0
視力低下	1 (<1)	0	0	0	0
耳および迷路障害	3 (<1)	0	2 (<1)	2 (<1)	1 (<1)
頭位性回転性めまい	0	0	2 (<1)	2 (<1)	0
耳痛	0	0	0	0	1 (<1)
回転性めまい	2 (<1)	0	0	0	0
前庭障害	1 (<1)	0	0	0	0
心臓障害	0	0	3 (<1)	3 (<1)	1 (<1)
急性冠動脈症候群	0	0	1 (<1)	1 (<1)	0
狭心症	0	0	1 (<1)	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	1 (<1)	0
心房細動	0	0	0	0	1 (<1)
心筋炎	0	0	0	0	1 (<1)
血管障害	4 (<1)	13 (2)	12 (2)	25 (2)	0
潮紅	1 (<1)	11 (1)	9 (1)	20 (1)	0
ほてり	0	2 (<1)	3 (<1)	5 (<1)	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)	0
末梢冷感	1 (<1)	0	0	0	0
末梢性虚血	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 7 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
静脈炎	1 (<1)	0	0	0	0
呼吸器、胸郭および縦隔障害	3 (<1)	2 (<1)	3 (<1)	5 (<1)	0
息詰まり	0	0	1 (<1)	1 (<1)	0
咳嗽	0	0	1 (<1)	1 (<1)	0
過換気	0	0	1 (<1)	1 (<1)	0
胸水	0	1 (<1)	0	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	1 (<1)	0
鼻閉	1 (<1)	0	0	0	0
口腔咽頭痛	2 (<1)	0	0	0	0
胃腸障害	14 (2)	28 (4)	31 (4)	59 (4)	0
上腹部痛	1 (<1)	5 (<1)	7 (<1)	12 (<1)	0
下痢	1 (<1)	3 (<1)	9 (1)	12 (<1)	0
腹痛	1 (<1)	5 (<1)	5 (<1)	10 (<1)	0
嘔吐	1 (<1)	6 (<1)	3 (<1)	9 (<1)	0
胃腸障害	0	4 (<1)	3 (<1)	7 (<1)	0
悪心	3 (<1)	4 (<1)	3 (<1)	7 (<1)	0
消化不良	0	2 (<1)	1 (<1)	3 (<1)	0
便秘	2 (<1)	1 (<1)	1 (<1)	2 (<1)	0
胃炎	0	0	2 (<1)	2 (<1)	0
胃食道逆流性疾患	1 (<1)	2 (<1)	0	2 (<1)	0
腹部不快感	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 8 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
腹部膨満	0	0	1 (<1)	1 (<1)	0
腹部ヘルニア	0	1 (<1)	0	1 (<1)	0
憩室穿孔	0	1 (<1)	0	1 (<1)	0
十二指腸炎	0	0	1 (<1)	1 (<1)	0
胃障害	0	1 (<1)	0	1 (<1)	0
胃潰瘍	0	0	1 (<1)	1 (<1)	0
腸閉塞	0	0	1 (<1)	1 (<1)	0
マロリー・ワイス症候群	0	1 (<1)	0	1 (<1)	0
嚥下障害	1 (<1)	0	0	0	0
急性膵炎	1 (<1)	0	0	0	0
腹膜出血	1 (<1)	0	0	0	0
歯痛	2 (<1)	0	0	0	0
肝胆道系障害	1 (<1)	2 (<1)	1 (<1)	3 (<1)	0
胆管結石	0	0	1 (<1)	1 (<1)	0
胆石症	1 (<1)	1 (<1)	0	1 (<1)	0
胆汁うっ滞性肝炎	0	1 (<1)	0	1 (<1)	0
皮膚および皮下組織障害	7 (<1)	6 (<1)	7 (<1)	13 (<1)	1 (<1)
多汗症	0	2 (<1)	1 (<1)	3 (<1)	0
紅斑	0	1 (<1)	1 (<1)	2 (<1)	0
そう痒症	0	0	2 (<1)	2 (<1)	0
発疹	1 (<1)	1 (<1)	1 (<1)	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 9 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
脱毛症	1 (<1)	0	1 (<1)	1 (<1)	0
アレルギー性皮膚炎	1 (<1)	1 (<1)	0	1 (<1)	0
全身紅斑	0	0	1 (<1)	1 (<1)	0
全身性皮疹	0	1 (<1)	0	1 (<1)	0
アトピー性皮膚炎	1 (<1)	0	0	0	0
多形紅斑	1 (<1)	0	0	0	0
寝汗	1 (<1)	0	0	0	0
乾癬	1 (<1)	0	0	0	0
筋骨格系および結合組織障害	14 (2)	9 (1)	11 (1)	20 (1)	7 (2)
背部痛	4 (<1)	2 (<1)	4 (<1)	6 (<1)	1 (<1)
関節痛	3 (<1)	1 (<1)	4 (<1)	5 (<1)	1 (<1)
四肢痛	3 (<1)	2 (<1)	1 (<1)	3 (<1)	1 (<1)
筋痙縮	0	1 (<1)	1 (<1)	2 (<1)	1 (<1)
筋肉痛	2 (<1)	2 (<1)	0	2 (<1)	1 (<1)
骨痛	1 (<1)	1 (<1)	0	1 (<1)	0
滑液包炎	0	1 (<1)	0	1 (<1)	0
筋攣縮	0	1 (<1)	0	1 (<1)	0
筋骨格痛	0	1 (<1)	0	1 (<1)	0
関節周囲炎	0	0	1 (<1)	1 (<1)	0
肩回旋筋腱板症候群	0	0	1 (<1)	1 (<1)	0
弾発指	0	0	1 (<1)	1 (<1)	0
側腹部痛	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 10 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
運動性低下	1 (<1)	0	0	0	0
筋拘縮	1 (<1)	0	0	0	0
頚部痛	1 (<1)	0	0	0	0
変形性関節症	1 (<1)	0	0	0	0
骨壊死	0	0	0	0	1 (<1)
滑液嚢腫	1 (<1)	0	0	0	0
腎および尿路障害	2 (<1)	1 (<1)	2 (<1)	3 (<1)	3 (<1)
膀胱穿孔	0	0	1 (<1)	1 (<1)	0
ミクロアルブミン尿	0	0	1 (<1)	1 (<1)	1 (<1)
腎結石症	0	1 (<1)	0	1 (<1)	1 (<1)
膀胱憩室	1 (<1)	0	0	0	0
ネフローゼ症候群	0	0	0	0	1 (<1)
尿閉	1 (<1)	0	0	0	0
妊娠、産褥および周産期の状態	1 (<1)	0	0	0	0
自然流産	1 (<1)	0	0	0	0
生殖系および乳房障害	3 (<1)	4 (<1)	4 (<1)	8 (<1)	0
月経困難症	0	0	2 (<1)	2 (<1)	0
勃起不全	0	0	1 (<1)	1 (<1)	0
線維嚢胞性乳腺疾患	0	0	1 (<1)	1 (<1)	0
閉経期症状	0	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 11 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
月経過多	1 (<1)	1 (<1)	0	1 (<1)	0
卵巣嚢胞破裂	0	1 (<1)	0	1 (<1)	0
子宮出血	0	1 (<1)	0	1 (<1)	0
月経障害	1 (<1)	0	0	0	0
卵巣嚢胞	1 (<1)	0	0	0	0
骨盤痛	1 (<1)	0	0	0	0
一般・全身障害および投与部位の状態	8 (1)	10 (1)	10 (1)	20 (1)	4 (1)
疲労	3 (<1)	5 (<1)	5 (<1)	10 (<1)	1 (<1)
無力症	0	2 (<1)	1 (<1)	3 (<1)	0
発熱	0	1 (<1)	2 (<1)	3 (<1)	1 (<1)
胸痛	2 (<1)	0	1 (<1)	1 (<1)	0
脂肪壊死	0	1 (<1)	0	1 (<1)	0
歩行障害	0	0	1 (<1)	1 (<1)	0
易刺激性	0	1 (<1)	0	1 (<1)	0
疼痛	0	1 (<1)	0	1 (<1)	0
インフルエンザ様疾患	1 (<1)	0	0	0	0
注射部位紅斑	0	0	0	0	1 (<1)
非心臓性胸痛	0	0	0	0	1 (<1)
末梢性浮腫	1 (<1)	0	0	0	0
骨盤腔内腫瘤	1 (<1)	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 12 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
臨床検査	7 (<1)	7 (<1)	5 (<1)	12 (<1)	4 (1)
アラニン・アミノトランスフェラーゼ増加	2 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
アスパラギン酸アミノトランスフェラーゼ増加	2 (<1)	3 (<1)	1 (<1)	4 (<1)	1 (<1)
肝機能検査異常	0	1 (<1)	1 (<1)	2 (<1)	0
血中乳酸脱水素酵素増加	0	1 (<1)	0	1 (<1)	0
ヘマトクリット減少	0	0	1 (<1)	1 (<1)	0
ヘモグロビン減少	0	0	1 (<1)	1 (<1)	0
血小板数減少	0	1 (<1)	0	1 (<1)	0
尿中蛋白陽性	0	0	1 (<1)	1 (<1)	0
白血球数減少	0	1 (<1)	0	1 (<1)	0
尿中白血球陽性	0	0	1 (<1)	1 (<1)	1 (<1)
血中クレアチニン増加	1 (<1)	0	0	0	0
血中ブドウ糖増加	1 (<1)	0	0	0	0
血中トリグリセリド増加	0	0	0	0	1 (<1)
γ－グルタミルトランスフェラーゼ増加	2 (<1)	0	0	0	0
肝酵素上昇	2 (<1)	0	0	0	1 (<1)
トランスアミナーゼ上昇	1 (<1)	0	0	0	0
傷害、中毒および処置合併症	5 (<1)	5 (<1)	9 (1)	14 (<1)	6 (2)
交通事故	1 (<1)	1 (<1)	2 (<1)	3 (<1)	1 (<1)
足関節部骨折	0	1 (<1)	1 (<1)	2 (<1)	0
大腿骨骨折	0	1 (<1)	1 (<1)	2 (<1)	0
肉離れ	1 (<1)	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Incidence of severe adverse events by system organ class and preferred term: Studies 109MS301 and 109MS302
Page 13 of 13

	Placebo	BG00012 240 mg BID	BG00012 240 mg TID	Total BG00012	GA
手首関節骨折	0	0	2 (<1)	2 (<1)	0
瘢痕ヘルニア	0	1 (<1)	0	1 (<1)	0
関節捻挫	0	0	1 (<1)	1 (<1)	1 (<1)
靭帯断裂	1 (<1)	0	1 (<1)	1 (<1)	0
過量投与	0	1 (<1)	0	1 (<1)	0
外傷性脳損傷	0	1 (<1)	0	1 (<1)	0
転倒	1 (<1)	0	0	0	1 (<1)
大腿骨頚部骨折	1 (<1)	0	0	0	0
足骨折	0	0	0	0	2 (<1)
手骨折	0	0	0	0	1 (<1)
橈骨骨折	0	0	0	0	1 (<1)
外科および内科処置	0	1 (<1)	0	1 (<1)	1 (<1)
女性不妊手術	0	1 (<1)	0	1 (<1)	0
抜歯	0	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS treatment are excluded.
3: A subject was counted only once within each system organ class/preferred term.
4: Preferred terms are presented by decreasing order of incidence in Total BG00012 column within each system organ class.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-SEV-A.SAS DATE: 02DEC2015

Table 117: Incidence of Adverse Events by System Organ Class and Preferred Term and Causal Association to Study Drug: Studies 109MS301 and 109MS302

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 1 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	720 (93)	733 (95)	712 (94)	304 (87)
感染症および寄生虫症	447 (58)	463 (60)	472 (62)	175 (50)
鼻咽頭炎	159 (21)	170 (22)	172 (23)	51 (15)
尿路感染	95 (12)	107 (14)	95 (13)	46 (13)
インフルエンザ	61 (8)	54 (7)	73 (10)	15 (4)
上気道感染	87 (11)	99 (13)	98 (13)	27 (8)
胃腸炎	28 (4)	42 (5)	34 (4)	5 (1)
気管支炎	32 (4)	35 (5)	48 (6)	16 (5)
鼻炎	26 (3)	26 (3)	23 (3)	8 (2)
副鼻腔炎	31 (4)	35 (5)	52 (7)	11 (3)
口腔ヘルペス	26 (3)	23 (3)	13 (2)	6 (2)
膀胱炎	21 (3)	11 (1)	19 (3)	5 (1)
消化管感染	8 (1)	5 (<1)	11 (1)	2 (<1)
耳感染	12 (2)	5 (<1)	18 (2)	2 (<1)
ウイルス性胃腸炎	16 (2)	15 (2)	20 (3)	6 (2)
帯状疱疹	10 (1)	8 (1)	12 (2)	2 (<1)
中耳炎	1 (<1)	10 (1)	9 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 2 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
Number of subjects with an event	348 (45)	535 (70)	538 (71)	153 (44)
感染症および寄生虫症	68 (9)	87 (11)	89 (12)	19 (5)
鼻咽頭炎	23 (3)	22 (3)	27 (4)	5 (1)
尿路感染	14 (2)	15 (2)	17 (2)	4 (1)
インフルエンザ	4 (<1)	2 (<1)	10 (1)	1 (<1)
上気道感染	9 (1)	17 (2)	9 (1)	2 (<1)
胃腸炎	5 (<1)	5 (<1)	8 (1)	1 (<1)
気管支炎	4 (<1)	5 (<1)	5 (<1)	0
鼻炎	4 (<1)	4 (<1)	5 (<1)	2 (<1)
副鼻腔炎	5 (<1)	2 (<1)	5 (<1)	0
口腔ヘルペス	10 (1)	9 (1)	4 (<1)	0
膀胱炎	1 (<1)	1 (<1)	3 (<1)	0
消化管感染	2 (<1)	2 (<1)	3 (<1)	0
耳感染	1 (<1)	0	2 (<1)	0
ウイルス性胃腸炎	1 (<1)	2 (<1)	2 (<1)	0
帯状疱疹	5 (<1)	3 (<1)	2 (<1)	0
中耳炎	0	2 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 3 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
気道感染	14 (2)	17 (2)	20 (3)	9 (3)
癜風	2 (<1)	2 (<1)	2 (<1)	0
外陰腟真菌感染	11 (1)	8 (1)	12 (2)	5 (1)
乳房膿瘍	0	0	1 (<1)	0
乳房蜂巣炎	0	0	1 (<1)	0
蜂巣炎	2 (<1)	5 (<1)	3 (<1)	1 (<1)
憩室炎	0	0	1 (<1)	0
熱性感染症	1 (<1)	0	1 (<1)	0
毛包炎	4 (<1)	3 (<1)	1 (<1)	1 (<1)
ヘリコバクター性胃炎	0	1 (<1)	2 (<1)	1 (<1)
単純ヘルペス	2 (<1)	2 (<1)	2 (<1)	1 (<1)
膿痂疹	0	0	1 (<1)	0
伝染性単核症	0	1 (<1)	1 (<1)	0
カンジダ性間擦疹	0	0	1 (<1)	0
喉頭炎	5 (<1)	11 (1)	12 (2)	1 (<1)
口腔カンジダ症	2 (<1)	1 (<1)	4 (<1)	0
口腔真菌感染	1 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 4 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
気道感染	0	1 (<1)	2 (<1)	0
癜風	0	1 (<1)	2 (<1)	0
外陰腟真菌感染	3 (<1)	2 (<1)	2 (<1)	0
乳房膿瘍	0	0	1 (<1)	0
乳房蜂巣炎	0	0	1 (<1)	0
蜂巣炎	1 (<1)	1 (<1)	1 (<1)	0
憩室炎	0	0	1 (<1)	0
熱性感染症	0	0	1 (<1)	0
毛包炎	2 (<1)	1 (<1)	1 (<1)	0
ヘリコバクター性胃炎	0	0	1 (<1)	0
単純ヘルペス	0	1 (<1)	1 (<1)	0
膿痂疹	0	0	1 (<1)	0
伝染性単核症	0	0	1 (<1)	0
カンジダ性間擦疹	0	0	1 (<1)	0
喉頭炎	0	0	1 (<1)	0
口腔カンジダ症	1 (<1)	0	1 (<1)	0
口腔真菌感染	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 5 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
咽頭炎	31 (4)	31 (4)	27 (4)	14 (4)
肺炎	3 (<1)	4 (<1)	4 (<1)	6 (2)
膣感染	3 (<1)	10 (1)	7 (<1)	5 (1)
ウイルス感染	15 (2)	18 (2)	13 (2)	5 (1)
ウイルス性上気道感染	12 (2)	13 (2)	9 (1)	7 (2)
外陰部膿瘍	1 (<1)	0	1 (<1)	0
外陰部膣カンジダ症	5 (<1)	4 (<1)	4 (<1)	1 (<1)
腹壁膿瘍	0	0	1 (<1)	0
膿瘍	1 (<1)	0	0	0
顎膿瘍	1 (<1)	0	0	0
四肢膿瘍	1 (<1)	0	0	0
ダニ症	0	0	1 (<1)	0
急性副鼻腔炎	1 (<1)	1 (<1)	2 (<1)	1 (<1)
急性扁桃炎	4 (<1)	3 (<1)	1 (<1)	2 (<1)
肛門膿瘍	1 (<1)	0	0	0
虫垂炎	0	1 (<1)	0	1 (<1)
無症候性細菌尿	1 (<1)	1 (<1)	1 (<1)	0
細菌感染	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 6 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
咽頭炎	2 (<1)	3 (<1)	1 (<1)	2 (<1)
肺炎	1 (<1)	1 (<1)	1 (<1)	0
膣感染	2 (<1)	0	1 (<1)	0
ウイルス感染	0	1 (<1)	1 (<1)	0
ウイルス性上気道感染	0	0	1 (<1)	0
外陰部膿瘍	0	0	1 (<1)	0
外陰部膣カンジダ症	2 (<1)	2 (<1)	1 (<1)	0
腹壁膿瘍	0	0	0	0
膿瘍	0	0	0	0
顎膿瘍	0	0	0	0
四肢膿瘍	0	0	0	0
ダニ症	0	0	0	0
急性副鼻腔炎	0	0	0	0
急性扁桃炎	0	1 (<1)	0	0
肛門膿瘍	1 (<1)	0	0	0
虫垂炎	0	0	0	0
無症候性細菌尿	0	0	0	0
細菌感染	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 7 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
細菌尿	1 (<1)	2 (<1)	3 (<1)	1 (<1)
ボレリア感染	3 (<1)	1 (<1)	0	0
ウイルス性気管支炎	0	0	1 (<1)	1 (<1)
気管支肺炎	0	1 (<1)	0	0
熱傷部感染	1 (<1)	0	0	0
カンジダ症	0	1 (<1)	0	1 (<1)
子宮頚管炎	0	1 (<1)	0	1 (<1)
慢性副鼻腔炎	0	0	0	1 (<1)
細菌性結膜炎	0	1 (<1)	2 (<1)	0
感染性結膜炎	2 (<1)	7 (<1)	8 (1)	0
ウイルス性結膜炎	1 (<1)	0	1 (<1)	0
デング熱	0	1 (<1)	0	1 (<1)
感染性皮膚炎	0	0	1 (<1)	0
医療機器関連感染	1 (<1)	0	0	0
感染性下痢	1 (<1)	0	0	0
ダグラス窩膿瘍	0	0	1 (<1)	0
感染性湿疹	0	0	1 (<1)	0
細菌性心内膜炎	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 8 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
細菌尿	0	0	0	0
ボレリア感染	0	0	0	0
ウイルス性気管支炎	0	0	0	0
気管支肺炎	0	0	0	0
熱傷部感染	0	0	0	0
カンジダ症	0	0	0	0
子宮頚管炎	0	0	0	0
慢性副鼻腔炎	0	0	0	0
細菌性結膜炎	0	1 (<1)	0	0
感染性結膜炎	0	1 (<1)	0	0
ウイルス性結膜炎	0	0	0	0
デング熱	0	0	0	0
感染性皮膚炎	0	0	0	0
医療機器関連感染	0	0	0	0
感染性下痢	0	0	0	0
ダグラス窩膿瘍	0	0	0	0
感染性湿疹	0	0	0	0
細菌性心内膜炎	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 9 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
エプスタイン・バーウイルス感染	0	0	1 (<1)	0
遊走性紅斑	0	1 (<1)	2 (<1)	0
大腸菌性尿路感染	0	1 (<1)	0	0
眼感染	3 (<1)	2 (<1)	0	0
真菌感染	2 (<1)	2 (<1)	0	1 (<1)
皮膚真菌感染	1 (<1)	0	0	1 (<1)
せつ	2 (<1)	5 (<1)	2 (<1)	0
ノロウイルス性胃腸炎	1 (<1)	1 (<1)	0	0
ロタウイルス胃腸炎	0	1 (<1)	0	0
真菌性消化管感染	1 (<1)	0	0	0
ウイルス性消化管感染	4 (<1)	6 (<1)	4 (<1)	1 (<1)
性器カンジダ症	0	2 (<1)	0	0
陰部ヘルペス	3 (<1)	4 (<1)	0	1 (<1)
細菌性性器感染	2 (<1)	1 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 10 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
エプスタイン・バーウイルス感染	0	0	0	0
遊走性紅斑	0	0	0	0
大腸菌性尿路感染	0	0	0	0
眼感染	0	0	0	0
真菌感染	0	0	0	0
皮膚真菌感染	0	0	0	0
せつ	0	1 (<1)	0	0
ノロウイルス性胃腸炎	1 (<1)	0	0	0
ロタウイルス胃腸炎	0	0	0	0
真菌性消化管感染	1 (<1)	0	0	0
ウイルス性消化管感染	0	0	0	0
性器カンジダ症	0	1 (<1)	0	0
陰部ヘルペス	2 (<1)	3 (<1)	0	0
細菌性性器感染	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 11 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
泌尿生殖器感染	1 (<1)	1 (<1)	0	0
ジアルジア症	0	1 (<1)	0	0
歯肉感染	2 (<1)	0	1 (<1)	1 (<1)
Ｈ１Ｎ１インフルエンザ	2 (<1)	2 (<1)	3 (<1)	2 (<1)
ヘリコバクター感染	0	1 (<1)	1 (<1)	0
ヘルペスウイルス感染	1 (<1)	0	0	1 (<1)
神経合併症を伴う帯状疱疹感染	0	1 (<1)	0	0
眼帯状疱疹	0	0	1 (<1)	0
麦粒腫	4 (<1)	6 (<1)	5 (<1)	0
切開部位感染	0	2 (<1)	0	0
咬傷感染	1 (<1)	2 (<1)	1 (<1)	0
感染性嚢腫	1 (<1)	1 (<1)	0	0
感染性皮脂嚢腫	1 (<1)	0	1 (<1)	0
感染	0	0	1 (<1)	1 (<1)
寄生虫感染	0	0	0	1 (<1)
迷路炎	2 (<1)	1 (<1)	0	1 (<1)
シラミ寄生	0	2 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 12 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
泌尿生殖器感染	0	0	0	0
ジアルジア症	0	0	0	0
歯肉感染	1 (<1)	0	0	1 (<1)
Ｈ１Ｎ１インフルエンザ	0	0	0	0
ヘリコバクター感染	0	0	0	0
ヘルペスウイルス感染	0	0	0	1 (<1)
神経合併症を伴う帯状疱疹感染	0	0	0	0
眼帯状疱疹	0	0	0	0
麦粒腫	1 (<1)	1 (<1)	0	0
切開部位感染	0	0	0	0
咬傷感染	0	0	0	0
感染性嚢腫	0	0	0	0
感染性皮脂嚢腫	0	0	0	0
感染	0	0	0	1 (<1)
寄生虫感染	0	0	0	0
迷路炎	0	0	0	0
シラミ寄生	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 13 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
限局性感染	3 (<1)	2 (<1)	0	0
下気道感染	6 (<1)	2 (<1)	7 (<1)	1 (<1)
ライム病	0	0	1 (<1)	1 (<1)
乳腺炎	1 (<1)	1 (<1)	0	0
乳様突起炎	0	0	0	1 (<1)
ムンプス	1 (<1)	0	0	0
マイコプラズマ感染	0	0	1 (<1)	0
爪感染	0	0	1 (<1)	0
爪真菌症	2 (<1)	7 (<1)	0	0
精巣炎	0	0	1 (<1)	0
外耳炎	1 (<1)	3 (<1)	1 (<1)	1 (<1)
急性中耳炎	0	0	1 (<1)	0
パラインフルエンザウイルス感染	1 (<1)	0	0	0
子宮傍組織炎	0	0	0	1 (<1)
爪囲炎	1 (<1)	2 (<1)	0	0
耳下腺炎	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 14 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
限局性感染	0	1 (<1)	0	0
下気道感染	0	2 (<1)	0	0
ライム病	0	0	0	0
乳腺炎	0	0	0	0
乳様突起炎	0	0	0	0
ムンプス	0	0	0	0
マイコプラズマ感染	0	0	0	0
爪感染	0	0	0	0
爪真菌症	0	2 (<1)	0	0
精巣炎	0	0	0	0
外耳炎	0	1 (<1)	0	0
急性中耳炎	0	0	0	0
パラインフルエンザウイルス感染	0	0	0	0
子宮傍組織炎	0	0	0	0
爪囲炎	0	0	0	0
耳下腺炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 15 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨盤内炎症性疾患	1 (<1)	0	2 (<1)	0
歯周感染	2 (<1)	1 (<1)	2 (<1)	1 (<1)
扁桃周囲膿瘍	0	0	1 (<1)	0
細菌性咽頭炎	3 (<1)	0	0	1 (<1)
レンサ球菌性咽頭炎	10 (1)	3 (<1)	5 (<1)	1 (<1)
咽頭扁桃炎	1 (<1)	4 (<1)	2 (<1)	1 (<1)
毛巣嚢胞	1 (<1)	0	0	0
ウイルス感染後疲労症候群	1 (<1)	1 (<1)	0	0
術後膿瘍	1 (<1)	0	0	0
術後創感染	1 (<1)	1 (<1)	1 (<1)	0
歯髄炎	1 (<1)	1 (<1)	1 (<1)	0
腎盂腎炎	2 (<1)	1 (<1)	0	1 (<1)
急性腎盂腎炎	0	0	1 (<1)	0
膿皮症	0	1 (<1)	0	0
膿胸	0	0	0	1 (<1)
膿疱性皮疹	0	1 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 16 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨盤内炎症性疾患	0	0	0	0
歯周感染	0	0	0	0
扁桃周囲膿瘍	0	0	0	0
細菌性咽頭炎	2 (<1)	0	0	0
レンサ球菌性咽頭炎	1 (<1)	0	0	0
咽頭扁桃炎	0	1 (<1)	0	1 (<1)
毛巣嚢胞	0	0	0	0
ウイルス感染後疲労症候群	0	0	0	0
術後膿瘍	0	0	0	0
術後創感染	0	0	0	0
歯髄炎	0	0	0	0
腎盂腎炎	0	1 (<1)	0	0
急性腎盂腎炎	0	0	0	0
膿皮症	0	0	0	0
膿胸	0	0	0	0
膿疱性皮疹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 17 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ライター症候群	1 (<1)	0	0	0
ウイルス性気道感染	4 (<1)	6 (<1)	2 (<1)	0
卵管卵巣炎	2 (<1)	1 (<1)	0	0
猩紅熱	1 (<1)	0	0	0
陰嚢膿瘍	0	0	2 (<1)	0
敗血症	2 (<1)	0	0	0
細菌性副鼻腔炎	0	3 (<1)	1 (<1)	0
皮膚細菌感染	0	0	1 (<1)	0
皮膚感染	0	1 (<1)	0	0
軟部組織感染	0	1 (<1)	0	0
ブドウ球菌感染	0	0	2 (<1)	0
レンサ球菌感染	1 (<1)	0	0	0
皮下組織膿瘍	0	2 (<1)	2 (<1)	0
白癬感染	1 (<1)	0	0	0
足部白癬	4 (<1)	0	1 (<1)	0
扁桃炎	9 (1)	9 (1)	9 (1)	2 (<1)
歯膿瘍	11 (1)	9 (1)	7 (<1)	4 (1)
歯感染	4 (<1)	3 (<1)	6 (<1)	6 (2)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 18 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ライター症候群	0	0	0	0
ウイルス性気道感染	0	0	0	0
卵管卵巣炎	1 (<1)	0	0	0
猩紅熱	0	0	0	0
陰嚢膿瘍	0	0	0	0
敗血症	2 (<1)	0	0	0
細菌性副鼻腔炎	0	1 (<1)	0	0
皮膚細菌感染	0	0	0	0
皮膚感染	0	0	0	0
軟部組織感染	0	0	0	0
ブドウ球菌感染	0	0	0	0
レンサ球菌感染	0	0	0	0
皮下組織膿瘍	0	0	0	0
白癬感染	0	0	0	0
足部白癬	0	0	0	0
扁桃炎	0	1 (<1)	0	0
歯膿瘍	0	0	0	0
歯感染	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 19 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
気管炎	2 (<1)	6 (<1)	2 (<1)	2 (<1)
気管気管支炎	1 (<1)	1 (<1)	1 (<1)	1 (<1)
消化器結核	1 (<1)	0	0	0
腸チフス熱	0	0	2 (<1)	0
細菌性上気道感染	1 (<1)	2 (<1)	0	0
細菌性尿路感染	3 (<1)	0	1 (<1)	0
真菌性尿路感染	0	1 (<1)	0	0
泌尿生殖器真菌感染	0	0	1 (<1)	0
尿路性敗血症	2 (<1)	0	0	0
膣膿瘍	1 (<1)	0	0	0
細菌性膣炎	2 (<1)	4 (<1)	0	2 (<1)
ガードネレラ菌性膣炎	0	1 (<1)	0	0
水痘	0	1 (<1)	0	1 (<1)
ウイルス性咽頭炎	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 20 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
気管炎	0	0	0	2 (<1)
気管気管支炎	0	0	0	0
消化器結核	1 (<1)	0	0	0
腸チフス熱	0	0	0	0
細菌性上気道感染	0	0	0	0
細菌性尿路感染	0	0	0	0
真菌性尿路感染	0	0	0	0
泌尿生殖器真菌感染	0	0	0	0
尿路性敗血症	1 (<1)	0	0	0
膣膿瘍	0	0	0	0
細菌性膣炎	0	1 (<1)	0	0
ガードネレラ菌性膣炎	0	1 (<1)	0	0
水痘	0	0	0	0
ウイルス性咽頭炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 21 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ウイルス性鼻炎	0	0	1 (<1)	0
外陰部炎	0	2 (<1)	0	0
創傷感染	2 (<1)	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	17 (2)	21 (3)	24 (3)	9 (3)
メラノサイト性母斑	3 (<1)	2 (<1)	4 (<1)	2 (<1)
乳頭腫	0	0	1 (<1)	0
子宮平滑筋腫	2 (<1)	2 (<1)	4 (<1)	2 (<1)
アクロコルドン	1 (<1)	0	0	0
基底細胞癌	1 (<1)	1 (<1)	0	1 (<1)
肺の良性新生物	0	1 (<1)	0	0
リンパ節の良性新生物	1 (<1)	0	0	0
甲状腺の良性新生物	1 (<1)	0	0	0
乳癌	1 (<1)	0	1 (<1)	0
乳房新生物	1 (<1)	0	0	0
子宮頚部癌	0	0	1 (<1)	1 (<1)
子宮内膜癌	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 22 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ウイルス性鼻炎	0	0	0	0
外陰部炎	0	0	0	0
創傷感染	0	0	0	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (<1)	3 (<1)	4 (<1)	0
メラノサイト性母斑	0	0	2 (<1)	0
乳頭腫	0	0	1 (<1)	0
子宮平滑筋腫	0	0	1 (<1)	0
アクロコルドン	0	0	0	0
基底細胞癌	0	1 (<1)	0	0
肺の良性新生物	0	0	0	0
リンパ節の良性新生物	0	0	0	0
甲状腺の良性新生物	0	0	0	0
乳癌	0	0	0	0
乳房新生物	0	0	0	0
子宮頚部癌	0	0	0	0
子宮内膜癌	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 23 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳腺線維腺腫	0	1 (<1)	1 (<1)	0
線維腫	1 (<1)	2 (<1)	1 (<1)	0
線維性組織球腫	0	0	0	1 (<1)
泌尿生殖器新生物	0	0	1 (<1)	0
血管腫	1 (<1)	0	1 (<1)	0
肝臓血管腫	0	0	1 (<1)	0
脂肪腫	0	3 (<1)	4 (<1)	1 (<1)
肺新生物	0	1 (<1)	1 (<1)	0
モートン神経腫	1 (<1)	0	0	0
皮膚の新生物	1 (<1)	0	0	0
神経鞘腫	0	1 (<1)	0	0
口腔新生物	1 (<1)	0	0	0
良性副甲状腺腫瘍	1 (<1)	0	0	0
腎新生物	0	1 (<1)	0	0
脂漏性角化症	0	0	1 (<1)	0
皮膚乳頭腫	1 (<1)	5 (<1)	4 (<1)	0
転移性甲状腺癌	0	0	0	1 (<1)
甲状腺新生物	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 24 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳腺線維腺腫	0	0	0	0
線維腫	0	0	0	0
線維性組織球腫	0	0	0	0
泌尿生殖器新生物	0	0	0	0
血管腫	0	0	0	0
肝臓血管腫	0	0	0	0
脂肪腫	0	0	0	0
肺新生物	0	0	0	0
モートン神経腫	0	0	0	0
皮膚の新生物	0	0	0	0
神経鞘腫	0	0	0	0
口腔新生物	1 (<1)	0	0	0
良性副甲状腺腫瘍	0	0	0	0
腎新生物	0	1 (<1)	0	0
脂漏性角化症	0	0	0	0
皮膚乳頭腫	0	1 (<1)	0	0
転移性甲状腺癌	0	0	0	0
甲状腺新生物	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 25 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
移行上皮癌	0	1 (<1)	0	0
外陰膣ヒト乳頭腫ウイルス感染	0	1 (<1)	0	0
血液およびリンパ系障害	37 (5)	51 (7)	56 (7)	11 (3)
リンパ球減少症	2 (<1)	18 (2)	17 (2)	0
白血球減少症	1 (<1)	7 (<1)	11 (1)	0
好酸球増加症	1 (<1)	3 (<1)	5 (<1)	0
貧血	15 (2)	13 (2)	21 (3)	4 (1)
好中球増加症	5 (<1)	4 (<1)	6 (<1)	1 (<1)
好中球減少症	1 (<1)	1 (<1)	3 (<1)	0
妊娠貧血	1 (<1)	0	0	0
低色素性貧血	1 (<1)	0	0	1 (<1)
鉄欠乏性貧血	3 (<1)	3 (<1)	2 (<1)	0
白血球増加症	4 (<1)	8 (1)	1 (<1)	0
リンパ節炎	1 (<1)	0	0	0
リンパ節症	6 (<1)	4 (<1)	6 (<1)	4 (1)
小球性貧血	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 26 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
移行上皮癌	0	1 (<1)	0	0
外陰膣ヒト乳頭腫ウイルス感染	0	0	0	0
血液およびリンパ系障害	8 (1)	25 (3)	26 (3)	4 (1)
リンパ球減少症	2 (<1)	16 (2)	15 (2)	0
白血球減少症	1 (<1)	6 (<1)	10 (1)	0
好酸球増加症	1 (<1)	3 (<1)	5 (<1)	0
貧血	1 (<1)	1 (<1)	4 (<1)	1 (<1)
好中球増加症	3 (<1)	3 (<1)	4 (<1)	0
好中球減少症	1 (<1)	1 (<1)	3 (<1)	0
妊娠貧血	0	0	0	0
低色素性貧血	0	0	0	0
鉄欠乏性貧血	1 (<1)	1 (<1)	0	0
白血球増加症	1 (<1)	3 (<1)	0	0
リンパ節炎	0	0	0	0
リンパ節症	0	0	0	3 (<1)
小球性貧血	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 27 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
正色素性正球性貧血	0	0	1 (<1)	0
脾腫	0	0	1 (<1)	0
血小板減少症	0	2 (<1)	0	1 (<1)
血小板増加症	1 (<1)	0	0	0
免疫系障害	16 (2)	23 (3)	22 (3)	8 (2)
過敏症	2 (<1)	11 (1)	9 (1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	0
アナフィラキシー反応	0	0	0	2 (<1)
造影剤アレルギー	0	1 (<1)	1 (<1)	0
薬物過敏症	3 (<1)	2 (<1)	3 (<1)	2 (<1)
食物アレルギー	1 (<1)	5 (<1)	2 (<1)	1 (<1)
家塵アレルギー	2 (<1)	0	1 (<1)	0
免疫不全症	0	0	1 (<1)	0
季節性アレルギー	9 (1)	6 (<1)	7 (<1)	3 (<1)
続発性免疫不全症	0	0	1 (<1)	0
内分泌障害	8 (1)	7 (<1)	10 (1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 28 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
正色素性正球性貧血	0	0	0	0
脾腫	0	0	0	0
血小板減少症	0	0	0	0
血小板増加症	1 (<1)	0	0	0
免疫系障害	1 (<1)	8 (1)	7 (<1)	3 (<1)
過敏症	0	7 (<1)	6 (<1)	1 (<1)
アナフィラキシー様反応	0	0	1 (<1)	0
アナフィラキシー反応	0	0	0	2 (<1)
造影剤アレルギー	0	0	0	0
薬物過敏症	0	0	0	0
食物アレルギー	0	1 (<1)	0	0
家塵アレルギー	0	0	0	0
免疫不全症	0	0	0	0
季節性アレルギー	1 (<1)	0	0	0
続発性免疫不全症	0	0	0	0
内分泌障害	2 (<1)	3 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 29 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
甲状腺機能低下症	4 (<1)	1 (<1)	3 (<1)	2 (<1)
副腎腫瘤	1 (<1)	0	0	0
自己免疫性甲状腺炎	0	1 (<1)	0	0
間脳性内分泌障害	0	0	1 (<1)	0
甲状腺腫	0	3 (<1)	1 (<1)	1 (<1)
副甲状腺機能亢進症	1 (<1)	1 (<1)	1 (<1)	0
原発性副甲状腺機能亢進症	0	0	1 (<1)	0
続発性副甲状腺機能亢進症	0	1 (<1)	0	0
甲状腺機能亢進症	2 (<1)	0	1 (<1)	0
エストロゲン欠乏症	0	0	1 (<1)	0
甲状腺腫瘤	0	0	1 (<1)	0
代謝および栄養障害	59 (8)	50 (7)	51 (7)	20 (6)
食欲減退	13 (2)	17 (2)	14 (2)	4 (1)
高コレステロール血症	4 (<1)	7 (<1)	7 (<1)	2 (<1)
異常体重減少	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 30 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
甲状腺機能低下症	2 (<1)	0	1 (<1)	0
副腎腫瘤	0	0	0	0
自己免疫性甲状腺炎	0	0	0	0
間脳性内分泌障害	0	0	0	0
甲状腺腫	0	1 (<1)	0	0
副甲状腺機能亢進症	0	1 (<1)	0	0
原発性副甲状腺機能亢進症	0	0	0	0
続発性副甲状腺機能亢進症	0	1 (<1)	0	0
甲状腺機能亢進症	0	0	0	0
エストロゲン欠乏症	0	0	0	0
甲状腺腫瘤	0	0	0	0
代謝および栄養障害	11 (1)	17 (2)	15 (2)	5 (1)
食欲減退	4 (<1)	10 (1)	7 (<1)	4 (1)
高コレステロール血症	2 (<1)	2 (<1)	3 (<1)	0
異常体重減少	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 31 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脱水	1 (<1)	3 (<1)	3 (<1)	0
高血糖	7 (<1)	3 (<1)	5 (<1)	1 (<1)
高ナトリウム血症	0	0	1 (<1)	0
ビタミンＢ１２欠乏	0	0	3 (<1)	0
ビタミンD欠乏	7 (<1)	5 (<1)	8 (1)	3 (<1)
糖尿病	3 (<1)	1 (<1)	2 (<1)	2 (<1)
糖尿病性ケトアシドーシス	2 (<1)	0	1 (<1)	0
脂質異常症	0	0	3 (<1)	0
電解質失調	1 (<1)	0	0	0
葉酸欠乏	1 (<1)	0	0	0
妊娠糖尿病	1 (<1)	0	0	0
耐糖能障害	0	1 (<1)	3 (<1)	1 (<1)
痛風	1 (<1)	1 (<1)	0	0
高カルシウム血症	1 (<1)	0	0	0
高カリウム血症	1 (<1)	0	0	1 (<1)
高脂血症	5 (<1)	2 (<1)	3 (<1)	1 (<1)
高トリグリセリド血症	4 (<1)	1 (<1)	1 (<1)	4 (1)
高尿酸血症	0	1 (<1)	0	3 (<1)
ビタミンD過剰症	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 32 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脱水	0	0	1 (<1)	0
高血糖	0	1 (<1)	1 (<1)	0
高ナトリウム血症	0	0	1 (<1)	0
ビタミンＢ１２欠乏	0	0	1 (<1)	0
ビタミンＤ欠乏	0	1 (<1)	1 (<1)	0
糖尿病	0	0	0	0
糖尿病性ケトアシドーシス	0	0	0	0
脂質異常症	0	0	0	0
電解質失調	0	0	0	0
葉酸欠乏	0	0	0	0
妊娠糖尿病	0	0	0	0
耐糖能障害	0	0	0	0
痛風	0	0	0	0
高カルシウム血症	0	0	0	0
高カリウム血症	0	0	0	1 (<1)
高脂血症	0	0	0	0
高トリグリセリド血症	2 (<1)	0	0	0
高尿酸血症	0	0	0	0
ビタミンＤ過剰症	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 33 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
低血糖症	0	0	1 (<1)	0
低カリウム血症	1 (<1)	1 (<1)	1 (<1)	0
低ナトリウム血症	1 (<1)	0	0	0
過小食	0	0	1 (<1)	0
低リン酸血症	0	0	1 (<1)	0
ビタミン欠乏症	2 (<1)	2 (<1)	0	0
食欲亢進	3 (<1)	2 (<1)	0	0
鉄欠乏	1 (<1)	2 (<1)	1 (<1)	0
ケトーシス	0	0	1 (<1)	0
肥満	1 (<1)	0	0	1 (<1)
多飲症	1 (<1)	0	0	0
１型糖尿病	0	1 (<1)	0	0
２型糖尿病	0	2 (<1)	0	0
亜鉛欠乏	0	0	1 (<1)	0
精神障害	162 (21)	131 (17)	131 (17)	60 (17)
不眠症	37 (5)	35 (5)	30 (4)	13 (4)
うつ病	68 (9)	53 (7)	48 (6)	30 (9)
感情不安定	5 (<1)	0	2 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 34 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
低血糖症	0	0	0	0
低カリウム血症	0	1 (<1)	0	0
低ナトリウム血症	0	0	0	0
過小食	0	0	0	0
低リン酸血症	0	0	0	0
ビタミン欠乏症	0	0	0	0
食欲亢進	1 (<1)	2 (<1)	0	0
鉄欠乏	0	0	0	0
ケトーシス	0	0	0	0
肥満	0	0	0	0
多飲症	1 (<1)	0	0	0
１型糖尿病	0	0	0	0
２型糖尿病	0	1 (<1)	0	0
亜鉛欠乏	0	0	0	0
精神障害	18 (2)	16 (2)	18 (2)	4 (1
不眠症	4 (<1)	3 (<1)	8 (1)	1 (<1
うつ病	5 (<1)	5 (<1)	4 (<1)	2 (<1
感情不安定	1 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 35 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
不安	27 (4)	31 (4)	26 (3)	7 (2)
初期不眠症	0	0	3 (<1)	0
気分変化	0	2 (<1)	3 (<1)	0
異常行動	0	1 (<1)	0	0
異常な夢	1 (<1)	0	1 (<1)	0
適応障害	0	0	0	1 (<1)
抑うつ気分を伴う適応障害	0	1 (<1)	0	0
感情障害	3 (<1)	3 (<1)	3 (<1)	1 (<1)
攻撃性	1 (<1)	0	0	0
激越	1 (<1)	0	0	0
怒り	1 (<1)	0	0	0
不安障害	2 (<1)	1 (<1)	0	0
気晴らし食い	1 (<1)	0	0	0
双極１型障害	0	1 (<1)	0	0
精神緩慢	1 (<1)	0	0	0
歯ぎしり	1 (<1)	0	1 (<1)	0
燃え尽き症候群	0	1 (<1)	0	0
閉所恐怖症	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 36 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
不安	1 (<1)	6 (<1)	2 (<1)	1 (<1)
初期不眠症	0	0	1 (<1)	0
気分変化	0	0	1 (<1)	0
異常行動	0	1 (<1)	0	0
異常な夢	0	0	0	0
適応障害	0	0	0	0
抑うつ気分を伴う適応障害	0	0	0	0
感情障害	1 (<1)	0	0	0
攻撃性	0	0	0	0
激越	0	0	0	0
怒り	0	0	0	0
不安障害	0	0	0	0
気晴らし食い	0	0	0	0
双極１型障害	0	0	0	0
精神緩慢	0	0	0	0
歯ぎしり	0	0	0	0
燃え尽き症候群	0	0	0	0
閉所恐怖症	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 37 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
自殺既遂	0	0	0	1 (<1)
錯乱状態	1 (<1)	0	0	0
転換性障害	0	0	1 (<1)	0
抑うつ気分	17 (2)	12 (2)	7 (<1)	4 (1)
抑うつ症状	3 (<1)	1 (<1)	2 (<1)	0
性的興奮障害	1 (<1)	0	1 (<1)	0
不快気分	1 (<1)	0	0	0
情動障害	0	0	1 (<1)	0
多幸気分	1 (<1)	1 (<1)	0	0
全般性不安障害	0	1 (<1)	0	0
幻覚	1 (<1)	0	0	0
幻聴	0	1 (<1)	0	0
故意の自傷行為	0	0	0	1 (<1)
リビドー減退	1 (<1)	3 (<1)	1 (<1)	0
リビド消失	0	1 (<1)	0	0
大うつ病	0	0	2 (<1)	0
躁病	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 38 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
自殺既遂	0	0	0	0
錯乱状態	0	0	0	0
転換性障害	0	0	0	0
抑うつ気分	0	0	0	0
抑うつ症状	0	0	0	0
性的興奮障害	1 (<1)	0	0	0
不快気分	0	0	0	0
情動障害	0	0	0	0
多幸気分	0	1 (<1)	0	0
全般性不安障害	0	0	0	0
幻覚	1 (<1)	0	0	0
幻聴	0	0	0	0
故意の自傷行為	0	0	0	0
リビドー減退	0	0	0	0
リビド消失	0	0	0	0
大うつ病	0	0	0	0
躁病	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 39 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
精神障害	0	0	0	1 (<1)
中期不眠症	1 (<1)	0	0	0
気分動揺	5 (<1)	2 (<1)	5 (<1)	1 (<1)
自己愛性人格障害	0	1 (<1)	0	0
神経過敏	2 (<1)	2 (<1)	1 (<1)	1 (<1)
神経症	0	2 (<1)	1 (<1)	0
悪夢	1 (<1)	0	0	0
強迫性障害	1 (<1)	0	0	0
パニック発作	1 (<1)	0	5 (<1)	0
パニック障害	0	1 (<1)	0	0
人格変化	0	1 (<1)	0	0
人格障害	0	1 (<1)	0	0
精神症状	0	1 (<1)	0	0
精神病性障害	0	0	1 (<1)	0
落ち着きのなさ	0	2 (<1)	0	0
睡眠発作	0	0	1 (<1)	0
睡眠障害	12 (2)	8 (1)	7 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 40 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
精神障害	0	0	0	0
中期不眠症	0	0	0	0
気分動揺	1 (<1)	1 (<1)	0	0
自己愛性人格障害	0	0	0	0
神経過敏	1 (<1)	0	0	1 (<1)
神経症	0	0	0	0
悪夢	1 (<1)	0	0	0
強迫性障害	1 (<1)	0	0	0
パニック発作	0	0	0	0
パニック障害	0	0	0	0
人格変化	0	0	0	0
人格障害	0	0	0	0
精神症状	0	1 (<1)	0	0
精神病性障害	0	0	0	0
落ち着きのなさ	0	1 (<1)	0	0
睡眠発作	0	0	0	0
睡眠障害	1 (<1)	3 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 41 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
身体表現性障害	3 (<1)	1 (<1)	1 (<1)	1 (<1)
ストレス	4 (<1)	3 (<1)	3 (<1)	4 (1)
自殺念慮	1 (<1)	2 (<1)	1 (<1)	2 (<1)
自殺企図	0	0	1 (<1)	1 (<1)
緊張	1 (<1)	0	0	0
タバコ乱用	1 (<1)	0	0	0
神経系障害	511 (66)	414 (54)	389 (51)	178 (51)
頭痛	129 (17)	133 (17)	126 (17)	46 (13)
錯感覚	69 (9)	56 (7)	59 (8)	15 (4)
多発性硬化症再発	344 (45)	221 (29)	199 (26)	119 (34)
灼熱感	13 (2)	21 (3)	25 (3)	0
片頭痛	21 (3)	21 (3)	22 (3)	6 (2)
浮動性めまい	38 (5)	33 (4)	30 (4)	9 (3)
傾眠	8 (1)	6 (<1)	8 (1)	2 (<1)
異常感覚	5 (<1)	12 (2)	4 (<1)	0
味覚異常	1 (<1)	4 (<1)	5 (<1)	2 (<1)
感覚鈍麻	48 (6)	31 (4)	43 (6)	16 (5)
三叉神経痛	8 (1)	5 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 42 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
身体表現性障害	0	0	0	0
ストレス	0	0	0	0
自殺念慮	0	0	0	0
自殺企図	0	0	0	0
緊張	1 (<1)	0	0	0
タバコ乱用	0	0	0	0
神経系障害	93 (12)	103 (13)	100 (13)	25 (7)
頭痛	41 (5)	47 (6)	41 (5)	7 (2)
錯感覚	5 (<1)	10 (1)	16 (2)	1 (<1)
多発性硬化症再発	23 (3)	15 (2)	11 (1)	4 (1)
灼熱感	3 (<1)	11 (1)	10 (1)	0
片頭痛	4 (<1)	5 (<1)	8 (1)	0
浮動性めまい	10 (1)	12 (2)	7 (<1)	4 (1)
傾眠	1 (<1)	4 (<1)	3 (<1)	2 (<1)
異常感覚	1 (<1)	6 (<1)	2 (<1)	0
味覚異常	0	1 (<1)	2 (<1)	0
感覚鈍麻	2 (<1)	1 (<1)	2 (<1)	2 (<1)
三叉神経痛	0	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 43 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
味覚消失	0	1 (<1)	1 (<1)	0
平衡障害	9 (1)	10 (1)	11 (1)	2 (<1)
帯状感	0	1 (<1)	3 (<1)	0
認知障害	0	1 (<1)	4 (<1)	1 (<1)
構語障害	1 (<1)	3 (<1)	6 (<1)	0
蟻走感	0	0	1 (<1)	1 (<1)
不全片麻痺	2 (<1)	0	2 (<1)	1 (<1)
知覚過敏	5 (<1)	3 (<1)	2 (<1)	1 (<1)
嗜眠	0	0	1 (<1)	0
意識消失	2 (<1)	0	2 (<1)	1 (<1)
失神寸前の状態	4 (<1)	2 (<1)	3 (<1)	2 (<1)
感覚障害	10 (1)	9 (1)	9 (1)	1 (<1)
一過性全健忘	0	0	1 (<1)	0
一過性脳虚血発作	0	1 (<1)	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	0
振戦	11 (1)	11 (1)	5 (<1)	4 (1)
ウートホフ現象	4 (<1)	4 (<1)	4 (<1)	1 (<1)
失認症	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 44 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
味覚消失	0	1 (<1)	1 (<1)	0
平衡障害	0	0	1 (<1)	0
帯状感	0	0	1 (<1)	0
認知障害	0	0	1 (<1)	0
構語障害	0	0	1 (<1)	0
蟻走感	0	0	1 (<1)	0
不全片麻痺	0	0	1 (<1)	0
知覚過敏	2 (<1)	1 (<1)	1 (<1)	0
嗜眠	0	0	1 (<1)	0
意識消失	0	0	1 (<1)	0
失神寸前の状態	2 (<1)	0	1 (<1)	2 (<1)
感覚障害	1 (<1)	0	1 (<1)	0
一過性全健忘	0	0	1 (<1)	0
一過性脳虚血発作	0	0	1 (<1)	0
横静脈洞血栓症	0	0	1 (<1)	0
振戦	0	3 (<1)	1 (<1)	1 (<1)
ウートホフ現象	0	0	1 (<1)	1 (<1)
失認症	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 45 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
異痛症	1 (<1)	0	0	0
意識変容状態	0	0	1 (<1)	0
健忘	5 (<1)	4 (<1)	3 (<1)	0
失語症	1 (<1)	0	0	2 (<1)
運動失調	2 (<1)	1 (<1)	4 (<1)	0
自律神経失調	0	0	1 (<1)	0
良性頭蓋内圧亢進	0	0	1 (<1)	0
手根管症候群	6 (<1)	3 (<1)	1 (<1)	2 (<1)
中枢神経系病変	2 (<1)	0	0	0
中枢痛症候群	1 (<1)	0	0	0
小脳症候群	1 (<1)	0	1 (<1)	0
脳血管発作	1 (<1)	0	0	0
脳血管障害	0	0	0	1 (<1)
頚髄神経根痛	1 (<1)	0	2 (<1)	2 (<1)
頚腕症候群	2 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 46 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
異痛症	0	0	0	0
意識変容状態	0	0	0	0
健忘	1 (<1)	0	0	0
失語症	0	0	0	0
運動失調	0	0	0	0
自律神経失調	0	0	0	0
良性頭蓋内圧亢進	0	0	0	0
手根管症候群	1 (<1)	0	0	0
中枢神経系病変	1 (<1)	0	0	0
中枢痛症候群	0	0	0	0
小脳症候群	0	0	0	0
脳血管発作	0	0	0	0
脳血管障害	0	0	0	0
頚髄神経根痛	0	0	0	0
頚腕症候群	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 47 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頚原性頭痛	0	1 (<1)	1 (<1)	0
概日リズム睡眠障害	0	1 (<1)	0	0
不器用	1 (<1)	2 (<1)	0	1 (<1)
複雑部分発作	1 (<1)	0	0	0
痙攣	4 (<1)	1 (<1)	1 (<1)	0
協調運動異常	1 (<1)	1 (<1)	1 (<1)	0
泣き	0	0	1 (<1)	0
振動覚低下	2 (<1)	2 (<1)	0	0
注意力障害	0	3 (<1)	3 (<1)	2 (<1)
体位性めまい	0	1 (<1)	0	0
よだれ	1 (<1)	0	1 (<1)	0
ジスキネジー	0	1 (<1)	0	0
ジストニー	0	1 (<1)	0	1 (<1)
脳症	1 (<1)	0	0	0
てんかん	2 (<1)	2 (<1)	1 (<1)	1 (<1)
てんかんの前兆	0	1 (<1)	0	0
顔面神経障害	0	0	1 (<1)	0
顔面部神経痛	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 48 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頚原性頭痛	0	1 (<1)	0	0
概日リズム睡眠障害	0	0	0	0
不器用	0	0	0	0
複雑部分発作	1 (<1)	0	0	0
痙攣	2 (<1)	0	0	0
協調運動異常	0	0	0	0
泣き	0	0	0	0
振動覚低下	0	0	0	0
注意力障害	0	0	0	0
体位性めまい	0	0	0	0
よだれ	0	0	0	0
ジスキネジー	0	0	0	0
ジストニー	0	0	0	0
脳症	0	0	0	0
てんかん	1 (<1)	0	0	1 (<1)
てんかんの前兆	0	1 (<1)	0	0
顔面神経障害	0	0	0	0
顔面部神経痛	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 49 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
顔面不全麻痺	1 (<1)	1 (<1)	1 (<1)	1 (<1)
顔面痙攣	2 (<1)	0	0	2 (<1)
痙性歩行	1 (<1)	0	0	0
舌咽神経痛	0	1 (<1)	0	0
大発作痙攣	2 (<1)	0	2 (<1)	1 (<1)
頭部動揺	0	1 (<1)	1 (<1)	1 (<1)
片側頭痛	5 (<1)	1 (<1)	0	1 (<1)
ホルネル症候群	1 (<1)	0	0	0
反射亢進	5 (<1)	2 (<1)	1 (<1)	1 (<1)
過眠症	3 (<1)	2 (<1)	1 (<1)	0
筋緊張亢進	1 (<1)	0	0	0
筋緊張低下	1 (<1)	0	0	0
思考散乱	0	0	1 (<1)	0
肋間神経痛	2 (<1)	1 (<1)	1 (<1)	0
脳圧低下	0	0	1 (<1)	0
虚血性脳卒中	0	0	1 (<1)	0
レルミット徴候	8 (1)	3 (<1)	9 (1)	1 (<1)
腰髄神経根障害	1 (<1)	2 (<1)	0	0
仮面状顔貌	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 50 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
顔面不全麻痺	1 (<1)	0	0	0
顔面痙攣	0	0	0	0
痙性歩行	0	0	0	0
舌咽神経痛	0	0	0	0
大発作痙攣	1 (<1)	0	0	0
頭部動揺	0	0	0	0
片側頭痛	0	1 (<1)	0	0
ホルネル症候群	0	0	0	0
反射亢進	0	0	0	0
過眠症	0	1 (<1)	0	0
筋緊張亢進	1 (<1)	0	0	0
筋緊張低下	0	0	0	0
思考散乱	0	0	0	0
肋間神経痛	0	0	0	0
脳圧低下	0	0	0	0
虚血性脳卒中	0	0	0	0
レルミット徴候	1 (<1)	0	0	0
腰髄神経根障害	0	0	0	0
仮面状顔貌	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 51 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
記憶障害	6 (<1)	4 (<1)	1 (<1)	5 (1)
感覚異常性大腿神経痛	0	1 (<1)	1 (<1)	0
前兆を伴う片頭痛	2 (<1)	7 (<1)	1 (<1)	1 (<1)
不全単麻痺	1 (<1)	0	0	1 (<1)
単麻痺	1 (<1)	0	0	0
運動機能障害	0	1 (<1)	1 (<1)	0
多発性硬化症	15 (2)	8 (1)	8 (1)	7 (2)
不随意性筋収縮	0	3 (<1)	1 (<1)	1 (<1)
筋痙直	27 (4)	17 (2)	16 (2)	7 (2)
神経圧迫	1 (<1)	0	5 (<1)	0
神経痛	6 (<1)	7 (<1)	4 (<1)	1 (<1)
神経学的症状	0	1 (<1)	1 (<1)	0
末梢性ニューロパチー	3 (<1)	0	1 (<1)	1 (<1)
眼振	1 (<1)	1 (<1)	2 (<1)	0
後頭神経痛	1 (<1)	0	2 (<1)	1 (<1)
視神経炎	0	2 (<1)	1 (<1)	0
起立不耐性	0	0	0	1 (<1)
嗅覚錯誤	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 52 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
記憶障害	0	0	0	0
感覚異常性大腿神経痛	0	0	0	0
前兆を伴う片頭痛	0	0	0	0
不全単麻痺	0	0	0	0
単麻痺	0	0	0	0
運動機能障害	0	0	0	0
多発性硬化症	4 (<1)	0	0	1 (<1)
不随意性筋収縮	0	0	0	0
筋痙直	2 (<1)	1 (<1)	0	0
神経圧迫	0	0	0	0
神経痛	1 (<1)	1 (<1)	0	0
神経学的症状	0	0	0	0
末梢性ニューロパチー	0	0	0	0
眼振	0	1 (<1)	0	0
後頭神経痛	0	0	0	0
視神経炎	0	0	0	0
起立不耐性	0	0	0	0
嗅覚錯誤	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 53 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
部分発作	0	1 (<1)	0	1 (<1)
周期性四肢運動障害	0	0	0	1 (<1)
腓骨神経麻痺	0	1 (<1)	0	1 (<1)
睡眠の質低下	0	1 (<1)	0	1 (<1)
錐体路症候群	1 (<1)	0	0	0
神経根痛	0	1 (<1)	0	0
頚髄神経根炎	0	1 (<1)	0	0
下肢静止不能症候群	6 (<1)	2 (<1)	4 (<1)	4 (1)
逆行性健忘	0	1 (<1)	0	0
坐骨神経痛	8 (1)	9 (1)	7 (<1)	2 (<1)
二次性進行型多発性硬化症	0	0	1 (<1)	0
鎮静	0	0	1 (<1)	0
感覚消失	0	1 (<1)	0	1 (<1)
副鼻腔炎に伴う頭痛	3 (<1)	2 (<1)	4 (<1)	2 (<1)
会話障害	0	1 (<1)	0	0
片頭痛発作重積	1 (<1)	0	0	0
失神	4 (<1)	2 (<1)	7 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 54 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
部分発作	0	0	0	0
周期性四肢運動障害	0	0	0	0
腓骨神経麻痺	0	0	0	0
睡眠の質低下	0	1 (<1)	0	0
錐体路症候群	0	0	0	0
神経根痛	0	0	0	0
頚髄神経根炎	0	0	0	0
下肢静止不能症候群	0	0	0	1 (<1)
逆行性健忘	0	0	0	0
坐骨神経痛	0	0	0	0
二次性進行型多発性硬化症	0	0	0	0
鎮静	0	0	0	0
感覚消失	0	0	0	0
副鼻腔炎に伴う頭痛	2 (<1)	1 (<1)	0	0
会話障害	0	0	0	0
片頭痛発作重積	0	0	0	0
失神	0	1 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 55 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
足根管症候群	0	0	0	1 (<1)
緊張性頭痛	7 (<1)	5 (<1)	8 (1)	2 (<1)
温度覚鈍麻	1 (<1)	0	0	0
舌の麻痺	0	1 (<1)	0	0
尺骨神経管症候群	0	1 (<1)	0	0
血管性頭痛	0	0	1 (<1)	0
振動覚亢進	2 (<1)	0	0	1 (<1)
第７脳神経麻痺	1 (<1)	1 (<1)	0	0
視野欠損	1 (<1)	1 (<1)	0	0
第６脳神経麻痺	0	0	0	1 (<1)
眼障害	95 (12)	72 (9)	80 (11)	29 (8)
霧視	22 (3)	13 (2)	18 (2)	6 (2)
眼瞼痙攣	7 (<1)	4 (<1)	6 (<1)	0
失明	0	1 (<1)	2 (<1)	0
眼痛	14 (2)	13 (2)	16 (2)	6 (2)
眼そう痒症	2 (<1)	0	1 (<1)	0
流涙増加	2 (<1)	1 (<1)	2 (<1)	1 (<1)
視力低下	11 (1)	4 (<1)	4 (<1)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 56 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
足根管症候群	0	0	0	0
緊張性頭痛	0	2 (<1)	0	0
温度覚鈍麻	1 (<1)	0	0	0
舌の麻痺	0	0	0	0
尺骨神経管症候群	0	0	0	0
血管性頭痛	0	0	0	0
振動覚亢進	0	0	0	0
第７脳神経麻痺	0	0	0	0
視野欠損	0	0	0	0
第６脳神経麻痺	0	0	0	0
眼障害	11 (1)	6 (<1)	6 (<1)	2 (<1)
霧視	4 (<1)	1 (<1)	2 (<1)	0
眼瞼痙攣	0	0	1 (<1)	0
失明	0	1 (<1)	1 (<1)	0
眼痛	1 (<1)	0	1 (<1)	1 (<1)
眼そう痒症	0	0	1 (<1)	0
流涙増加	0	0	1 (<1)	0
視力低下	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 57 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼の異常感	1 (<1)	2 (<1)	1 (<1)	0
黒内障	0	1 (<1)	0	0
眼精疲労	1 (<1)	0	1 (<1)	0
両眼球運動障害	0	0	1 (<1)	0
眼瞼炎	1 (<1)	2 (<1)	2 (<1)	0
アレルギー性眼瞼炎	0	0	1 (<1)	0
一過性失明	1 (<1)	0	0	1 (<1)
片側失明	0	0	0	1 (<1)
白内障	1 (<1)	1 (<1)	2 (<1)	0
嚢下白内障	1 (<1)	0	0	0
霰粒腫	1 (<1)	2 (<1)	1 (<1)	0
結膜出血	1 (<1)	0	0	1 (<1)
結膜刺激	1 (<1)	0	0	0
結膜炎	6 (<1)	8 (1)	7 (<1)	3 (<1)
アレルギー性結膜炎	2 (<1)	2 (<1)	3 (<1)	1 (<1)
複視	12 (2)	5 (<1)	8 (1)	4 (1)
眼乾燥	4 (<1)	7 (<1)	2 (<1)	1 (<1)
眼瞼湿疹	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 58 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼の異常感	0	0	0	0
黒内障	0	0	0	0
眼精疲労	0	0	0	0
両眼球運動障害	0	0	0	0
眼瞼炎	0	0	0	0
アレルギー性眼瞼炎	0	0	0	0
一過性失明	0	0	0	0
片側失明	0	0	0	0
白内障	0	0	0	0
嚢下白内障	0	0	0	0
霰粒腫	0	0	0	0
結膜出血	0	0	0	1 (<1)
結膜刺激	0	0	0	0
結膜炎	1 (<1)	1 (<1)	0	1 (<1)
アレルギー性結膜炎	0	0	0	0
複視	0	1 (<1)	0	0
眼乾燥	1 (<1)	1 (<1)	0	0
眼瞼湿疹	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 59 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼瞼紅斑	2 (<1)	0	0	0
眼のアレルギー	0	0	0	1 (<1)
眼の障害	1 (<1)	0	0	0
眼出血	0	1 (<1)	1 (<1)	0
眼刺激	1 (<1)	0	2 (<1)	0
眼運動障害	0	0	1 (<1)	0
眼部腫脹	0	0	1 (<1)	1 (<1)
眼瞼嚢胞	0	1 (<1)	0	0
眼瞼障害	0	0	1 (<1)	0
眼瞼刺激	1 (<1)	0	0	0
眼瞼浮腫	0	0	1 (<1)	0
眼瞼下垂	0	1 (<1)	2 (<1)	0
眼瞼そう痒症	1 (<1)	0	0	0
緑内障	1 (<1)	0	2 (<1)	0
ホームズ・アディー瞳孔	1 (<1)	0	0	0
遠視	2 (<1)	1 (<1)	0	0
虹彩毛様体炎	0	0	0	1 (<1)
角膜炎	0	0	1 (<1)	0
黄斑浮腫	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 60 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
眼瞼紅斑	2 (<1)	0	0	0
眼のアレルギー	0	0	0	0
眼の障害	0	0	0	0
眼出血	0	0	0	0
眼刺激	0	0	0	0
眼運動障害	0	0	0	0
眼部腫脹	0	0	0	0
眼瞼嚢胞	0	0	0	0
眼瞼障害	0	0	0	0
眼瞼刺激	0	0	0	0
眼瞼浮腫	0	0	0	0
眼瞼下垂	0	0	0	0
眼瞼そう痒症	1 (<1)	0	0	0
緑内障	0	0	0	0
ホームズ・アディー瞳孔	0	0	0	0
遠視	0	0	0	0
虹彩毛様体炎	0	0	0	0
角膜炎	0	0	0	0
黄斑浮腫	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 61 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
瞼板腺炎	0	0	1 (<1)	0
近視	1 (<1)	0	0	1 (<1)
夜盲	0	0	1 (<1)	0
眼球運動失調	0	1 (<1)	0	0
眼充血	1 (<1)	3 (<1)	2 (<1)	1 (<1)
開放隅角緑内障	0	0	1 (<1)	0
眼筋麻痺	0	1 (<1)	1 (<1)	0
視神経萎縮	0	0	1 (<1)	0
動揺視	0	1 (<1)	0	0
全眼球炎	0	1 (<1)	0	0
羞明	2 (<1)	1 (<1)	1 (<1)	0
光視症	0	2 (<1)	1 (<1)	0
老視	0	1 (<1)	0	0
翼状片	1 (<1)	0	0	0
屈折障害	1 (<1)	2 (<1)	0	0
閃輝暗点	1 (<1)	0	0	0
強膜炎	0	1 (<1)	0	0
乾燥症候群	0	1 (<1)	0	0
ブドウ膜炎	0	1 (<1)	2 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 62 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
瞼板腺炎	0	0	0	0
近視	0	0	0	0
夜盲	0	0	0	0
眼球運動失調	0	0	0	0
眼充血	1 (<1)	1 (<1)	0	0
開放隅角緑内障	0	0	0	0
眼筋麻痺	0	0	0	0
視神経萎縮	0	0	0	0
動揺視	0	0	0	0
全眼球炎	0	0	0	0
羞明	0	0	0	0
光視症	0	0	0	0
老視	0	0	0	0
翼状片	0	0	0	0
屈折障害	0	0	0	0
閃輝暗点	0	0	0	0
強膜炎	0	0	0	0
乾燥症候群	0	0	0	0
ブドウ膜炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 63 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
視力障害	6 (<1)	7 (<1)	6 (<1)	1 (<1)
硝子体浮遊物	0	2 (<1)	1 (<1)	0
硝子体出血	1 (<1)	0	0	0
耳および迷路障害	56 (7)	45 (6)	65 (9)	24 (7)
回転性めまい	37 (5)	22 (3)	42 (6)	15 (4)
耳鳴	6 (<1)	6 (<1)	7 (<1)	2 (<1)
耳不快感	1 (<1)	1 (<1)	2 (<1)	2 (<1)
耳痛	4 (<1)	6 (<1)	8 (1)	1 (<1)
聴力低下	3 (<1)	0	3 (<1)	1 (<1)
耳垢栓塞	1 (<1)	1 (<1)	0	1 (<1)
難聴	2 (<1)	1 (<1)	0	0
感音性難聴	0	1 (<1)	0	0
外耳道紅斑	1 (<1)	0	0	0
耳閉	1 (<1)	0	3 (<1)	0
耳出血	0	1 (<1)	0	0
耳そう痒症	0	1 (<1)	0	0
耳管障害	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 64 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
視力障害	1 (<1)	0	0	0
硝子体浮遊物	0	0	0	0
硝子体出血	0	0	0	0
耳および迷路障害	6 (<1)	11 (1)	10 (1)	1 (<1)
回転性めまい	5 (<1)	8 (1)	8 (1)	1 (<1)
耳鳴	1 (<1)	0	2 (<1)	0
耳不快感	0	0	1 (<1)	0
耳痛	0	1 (<1)	1 (<1)	0
聴力低下	0	0	1 (<1)	0
耳垢栓塞	0	1 (<1)	0	0
難聴	0	0	0	0
感音性難聴	0	0	0	0
外耳道紅斑	0	0	0	0
耳閉	0	0	0	0
耳出血	0	0	0	0
耳そう痒症	0	0	0	0
耳管障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 65 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
耳管機能障害	0	0	1 (<1)	1 (<1)
外耳障害	0	0	1 (<1)	0
外耳痛	0	1 (<1)	0	0
聴覚過敏	0	1 (<1)	1 (<1)	0
中耳の炎症	1 (<1)	0	0	0
乗物酔い	2 (<1)	2 (<1)	1 (<1)	0
鼓膜充血	0	1 (<1)	0	0
頭位性回転性めまい	4 (<1)	2 (<1)	4 (<1)	1 (<1)
前庭性運動失調	0	0	0	1 (<1)
前庭障害	1 (<1)	0	0	0
心臓障害	37 (5)	40 (5)	47 (6)	19 (5)
頻脈	6 (<1)	8 (1)	8 (1)	6 (2)
動悸	10 (1)	9 (1)	6 (<1)	3 (<1)
徐脈	1 (<1)	0	5 (<1)	2 (<1)
狭心症	0	3 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 66 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
耳管機能障害	0	0	0	0
外耳障害	0	0	0	0
外耳痛	0	0	0	0
聴覚過敏	0	0	0	0
中耳の炎症	0	0	0	0
乗物酔い	0	1 (<1)	0	0
鼓膜充血	0	0	0	0
頭位性回転性めまい	0	0	0	0
前庭性運動失調	0	0	0	0
前庭障害	0	0	0	0
心臓障害	7 (<1)	14 (2)	16 (2)	11 (3)
頻脈	1 (<1)	3 (<1)	6 (<1)	4 (1)
動悸	5 (<1)	4 (<1)	4 (<1)	2 (<1)
徐脈	0	0	2 (<1)	2 (<1)
狭心症	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 67 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
第一度房室ブロック	1 (<1)	5 (<1)	3 (<1)	2 (<1)
期外収縮	1 (<1)	3 (<1)	1 (<1)	0
洞性徐脈	2 (<1)	2 (<1)	3 (<1)	0
上室性期外収縮	2 (<1)	5 (<1)	4 (<1)	1 (<1)
急性冠動脈症候群	0	0	1 (<1)	0
上室性不整脈	1 (<1)	0	0	0
心房細動	0	0	1 (<1)	1 (<1)
左脚ブロック	1 (<1)	0	2 (<1)	1 (<1)
右脚ブロック	0	1 (<1)	1 (<1)	1 (<1)
心臓瘤	0	1 (<1)	1 (<1)	0
心不全	0	0	1 (<1)	0
うっ血性心不全	0	0	1 (<1)	0
心筋症	0	1 (<1)	1 (<1)	0
伝導障害	3 (<1)	1 (<1)	0	1 (<1)
僧帽弁逸脱	0	1 (<1)	1 (<1)	0
心筋虚血	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 68 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
第一度房室ブロック	1 (<1)	3 (<1)	1 (<1)	1 (<1)
期外収縮	0	1 (<1)	1 (<1)	0
洞性徐脈	0	1 (<1)	1 (<1)	0
上室性期外収縮	0	1 (<1)	1 (<1)	0
急性冠動脈症候群	0	0	0	0
上室性不整脈	0	0	0	0
心房細動	0	0	0	1 (<1)
左脚ブロック	0	0	0	0
右脚ブロック	0	0	0	0
心臓瘤	0	0	0	0
心不全	0	0	0	0
うっ血性心不全	0	0	0	0
心筋症	0	0	0	0
伝導障害	0	1 (<1)	0	0
僧帽弁逸脱	0	0	0	0
心筋虚血	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 69 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心筋炎	0	0	0	1 (<1)
結節性調律	0	0	1 (<1)	0
洞性頻脈	3 (<1)	0	4 (<1)	0
上室性頻脈	1 (<1)	0	0	0
頻脈性不整脈	0	0	1 (<1)	0
発作性頻脈	1 (<1)	0	0	1 (<1)
心室性期外収縮	7 (<1)	2 (<1)	7 (<1)	0
ウォルフ・パーキンソン・ホワイト症候群	0	2 (<1)	0	0
血管障害	84 (11)	321 (42)	277 (36)	25 (7)
潮紅	33 (4)	264 (34)	215 (28)	6 (2)
ほてり	16 (2)	49 (6)	49 (6)	5 (1)
充血	0	2 (<1)	7 (<1)	0
高血圧	24 (3)	12 (2)	20 (3)	13 (4)
起立性低血圧	2 (<1)	0	2 (<1)	0
血管障害	0	0	1 (<1)	0
動脈障害	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 70 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心筋炎	0	0	0	1 (<1)
結節性調律	0	0	0	0
洞性頻脈	0	0	0	0
上室性頻脈	0	0	0	0
頻脈性不整脈	0	0	0	0
発作性頻脈	0	0	0	1 (<1)
心室性期外収縮	0	1 (<1)	0	0
ウォルフ・パーキンソン・ホワイト症候群	0	1 (<1)	0	0
血管障害	45 (6)	293 (38)	245 (32)	9 (3)
潮紅	29 (4)	252 (33)	208 (27)	6 (2)
ほてり	11 (1)	42 (5)	42 (6)	3 (<1)
充血	0	2 (<1)	7 (<1)	0
高血圧	4 (<1)	4 (<1)	1 (<1)	0
起立性低血圧	1 (<1)	0	1 (<1)	0
血管障害	0	0	0	0
動脈障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 71 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
動脈硬化症	0	0	1 (<1)	0
毛細血管脆弱	1 (<1)	0	0	0
深部静脈血栓症	0	0	1 (<1)	1 (<1)
血腫	5 (<1)	2 (<1)	2 (<1)	2 (<1)
高血圧クリーゼ	1 (<1)	0	1 (<1)	0
低血圧	3 (<1)	6 (<1)	1 (<1)	0
腹腔内血腫	0	0	0	1 (<1)
微小血管症	0	1 (<1)	0	0
蒼白	1 (<1)	0	0	0
末梢冷感	3 (<1)	1 (<1)	0	0
末梢性虚血	1 (<1)	1 (<1)	0	0
静脈炎	2 (<1)	0	2 (<1)	0
レイノー現象	2 (<1)	1 (<1)	1 (<1)	0
静脈瘤	0	4 (<1)	1 (<1)	0
静脈痛	0	1 (<1)	0	0
静脈不全	0	1 (<1)	1 (<1)	0
静脈狭窄	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 72 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
動脈硬化症	0	0	0	0
毛細血管脆弱	0	0	0	0
深部静脈血栓症	0	0	0	0
血腫	0	0	0	1 (<1)
高血圧クリーゼ	0	0	0	0
低血圧	0	1 (<1)	0	0
腹腔内血腫	0	0	0	1 (<1)
微小血管症	0	0	0	0
蒼白	1 (<1)	0	0	0
末梢冷感	1 (<1)	0	0	0
末梢性虚血	1 (<1)	0	0	0
静脈炎	1 (<1)	0	0	0
レイノー現象	0	0	0	0
静脈瘤	0	0	0	0
静脈痛	0	0	0	0
静脈不全	0	0	0	0
静脈狭窄	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 73 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
呼吸器、胸郭および縦隔障害	119 (15)	117 (15)	125 (16)	41 (12)
咳嗽	36 (5)	38 (5)	37 (5)	9 (3)
鼻漏	8 (1)	15 (2)	11 (1)	1 (<1)
発声障害	3 (<1)	0	2 (<1)	1 (<1)
呼吸困難	7 (<1)	6 (<1)	5 (<1)	7 (2)
鼻閉	8 (1)	9 (1)	4 (<1)	1 (<1)
口腔咽頭痛	33 (4)	37 (5)	42 (6)	15 (4)
上気道咳症候群	3 (<1)	2 (<1)	4 (<1)	0
鼻出血	7 (<1)	4 (<1)	4 (<1)	2 (<1)
鼻乾燥	2 (<1)	0	1 (<1)	0
気道うっ血	5 (<1)	1 (<1)	2 (<1)	1 (<1)
アレルギー性鼻炎	7 (<1)	3 (<1)	6 (<1)	2 (<1)
副鼻腔うっ血	2 (<1)	1 (<1)	8 (1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	0
アレルギー性気管支炎	0	0	1 (<1)	0
アレルギー性咳嗽	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 74 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
呼吸器、胸郭および縦隔障害	15 (2)	25 (3)	22 (3)	10 (3)
咳嗽	2 (<1)	4 (<1)	5 (<1)	0
鼻漏	1 (<1)	11 (1)	5 (<1)	1 (<1)
発声障害	1 (<1)	0	2 (<1)	0
呼吸困難	3 (<1)	1 (<1)	2 (<1)	5 (1)
鼻閉	1 (<1)	1 (<1)	2 (<1)	0
口腔咽頭痛	1 (<1)	2 (<1)	2 (<1)	2 (<1)
上気道咳症候群	0	1 (<1)	2 (<1)	0
鼻出血	1 (<1)	0	1 (<1)	0
鼻乾燥	2 (<1)	0	1 (<1)	0
気道うっ血	1 (<1)	0	1 (<1)	0
アレルギー性鼻炎	2 (<1)	1 (<1)	1 (<1)	0
副鼻腔うっ血	0	1 (<1)	1 (<1)	0
咽喉絞扼感	0	1 (<1)	1 (<1)	0
アレルギー性気管支炎	0	0	0	0
アレルギー性咳嗽	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 75 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
アレルギー性咽頭炎	2 (<1)	1 (<1)	1 (<1)	0
アレルギー性呼吸器疾患	1 (<1)	0	0	0
アレルギー性呼吸器症状	1 (<1)	0	0	0
アレルギー性副鼻腔炎	1 (<1)	1 (<1)	0	0
喘息	2 (<1)	6 (<1)	2 (<1)	2 (<1)
慢性気管支炎	1 (<1)	0	0	0
息詰まり	2 (<1)	0	3 (<1)	1 (<1)
息詰まり感	0	1 (<1)	0	0
咽喉乾燥	2 (<1)	2 (<1)	0	0
労作性呼吸困難	1 (<1)	1 (<1)	0	0
喀血	1 (<1)	0	0	0
しゃっくり	2 (<1)	1 (<1)	1 (<1)	0
過換気	1 (<1)	0	1 (<1)	0
低換気	0	0	0	1 (<1)
上気道分泌増加	1 (<1)	0	0	0
鼻部不快感	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 76 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
アレルギー性咽頭炎	0	0	0	0
アレルギー性呼吸器疾患	0	0	0	0
アレルギー性呼吸器症状	0	0	0	0
アレルギー性副鼻腔炎	0	0	0	0
喘息	0	2 (<1)	0	0
慢性気管支炎	0	0	0	0
息詰まり	1 (<1)	0	0	0
息詰まり感	0	0	0	0
咽喉乾燥	2 (<1)	0	0	0
労作性呼吸困難	0	0	0	0
喀血	0	0	0	0
しゃっくり	1 (<1)	0	0	0
過換気	0	0	0	0
低換気	0	0	0	1 (<1)
上気道分泌増加	0	0	0	0
鼻部不快感	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 77 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
鼻浮腫	0	0	1 (<1)	0
鼻茸	1 (<1)	0	0	0
鼻中隔弯曲	0	1 (<1)	0	0
鼻中隔穿孔	0	0	0	1 (<1)
口腔咽頭水疱形成	1 (<1)	0	0	0
口腔咽頭不快感	1 (<1)	1 (<1)	2 (<1)	1 (<1)
口腔咽頭プラーク	1 (<1)	1 (<1)	0	0
口腔咽頭腫脹	0	0	1 (<1)	0
呼吸時疼痛	0	0	1 (<1)	0
副鼻腔嚢胞	0	0	1 (<1)	0
副鼻腔分泌過多	0	0	1 (<1)	0
咽頭嚢腫	0	1 (<1)	0	0
咽頭紅斑	1 (<1)	1 (<1)	1 (<1)	0
咽頭腫瘤	0	0	1 (<1)	0
胸水	0	1 (<1)	0	0
胸膜炎	0	0	1 (<1)	0
誤嚥性肺炎	0	1 (<1)	0	0
気胸	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 78 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
鼻浮腫	0	0	0	0
鼻茸	0	0	0	0
鼻中隔弯曲	0	0	0	0
鼻中隔穿孔	0	0	0	0
口腔咽頭水疱形成	0	0	0	0
口腔咽頭不快感	0	0	0	0
口腔咽頭プラーク	0	0	0	0
口腔咽頭腫脹	0	0	0	0
呼吸時疼痛	0	0	0	0
副鼻腔嚢胞	0	0	0	0
副鼻腔分泌過多	0	0	0	0
咽頭嚢腫	0	0	0	0
咽頭紅斑	0	0	0	0
咽頭腫瘤	0	0	0	0
胸水	0	1 (<1)	0	0
胸膜炎	0	0	0	0
誤嚥性肺炎	0	0	0	0
気胸	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 79 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
湿性咳嗽	3 (<1)	2 (<1)	2 (<1)	0
ラ音	2 (<1)	0	1 (<1)	0
呼吸抑制	0	1 (<1)	0	0
呼吸障害	0	0	1 (<1)	0
気道の炎症	1 (<1)	0	1 (<1)	0
季節性鼻炎	0	0	0	1 (<1)
低音性連続性ラ音	3 (<1)	1 (<1)	0	0
副鼻腔障害	1 (<1)	0	1 (<1)	0
睡眠時無呼吸症候群	0	0	1 (<1)	2 (<1)
くしゃみ	1 (<1)	0	0	1 (<1)
咽喉刺激感	3 (<1)	3 (<1)	0	0
扁桃障害	1 (<1)	0	0	0
上気道うっ血	3 (<1)	0	4 (<1)	2 (<1)
上気道の炎症	1 (<1)	0	0	0
声帯の炎症	1 (<1)	0	1 (<1)	0
声帯ポリープ	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 80 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
湿性咳嗽	0	0	0	0
ラ音	1 (<1)	0	0	0
呼吸抑制	0	0	0	0
呼吸障害	0	0	0	0
気道の炎症	0	0	0	0
季節性鼻炎	0	0	0	0
低音性連続性ラ音	0	0	0	0
副鼻腔障害	0	0	0	0
睡眠時無呼吸症候群	0	0	0	0
くしゃみ	0	0	0	0
咽喉刺激感	0	2 (<1)	0	0
扁桃障害	0	0	0	0
上気道うっ血	1 (<1)	0	0	1 (<1)
上気道の炎症	0	0	0	0
声帯の炎症	0	0	0	0
声帯ポリープ	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 81 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
喘鳴	1 (<1)	3 (<1)	1 (<1)	0
胃腸障害	289 (37)	366 (48)	398 (52)	65 (19)
悪心	67 (9)	93 (12)	105 (14)	16 (5)
下痢	83 (11)	107 (14)	128 (17)	14 (4)
上腹部痛	45 (6)	76 (10)	85 (11)	4 (1)
腹痛	37 (5)	73 (9)	63 (8)	5 (1)
嘔吐	37 (5)	65 (8)	53 (7)	9 (3)
胃腸障害	8 (1)	18 (2)	34 (4)	2 (<1)
消化不良	20 (3)	35 (5)	40 (5)	6 (2)
胃食道逆流性疾患	14 (2)	15 (2)	18 (2)	2 (<1)
便秘	33 (4)	23 (3)	29 (4)	9 (3)
胃炎	11 (1)	22 (3)	20 (3)	4 (1)
腹部不快感	11 (1)	19 (2)	14 (2)	1 (<1)
腹部膨満	11 (1)	4 (<1)	14 (2)	0
鼓腸	13 (2)	11 (1)	9 (1)	2 (<1)
口内乾燥	6 (<1)	16 (2)	10 (1)	1 (<1)
便意切迫	0	1 (<1)	3 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 82 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
喘鳴	0	0	0	0
胃腸障害	137 (18)	243 (32)	265 (35)	14 (4)
悪心	42 (5)	73 (9)	83 (11)	8 (2)
下痢	38 (5)	64 (8)	82 (11)	1 (<1)
上腹部痛	30 (4)	62 (8)	69 (9)	2 (<1)
腹痛	22 (3)	48 (6)	42 (6)	2 (<1)
嘔吐	10 (1)	32 (4)	37 (5)	3 (<1)
胃腸障害	6 (<1)	17 (2)	30 (4)	0
消化不良	10 (1)	22 (3)	22 (3)	0
胃食道逆流性疾患	6 (<1)	8 (1)	13 (2)	0
便秘	8 (1)	9 (1)	11 (1)	0
胃炎	3 (<1)	11 (1)	11 (1)	1 (<1)
腹部不快感	7 (<1)	12 (2)	8 (1)	0
腹部膨満	6 (<1)	3 (<1)	8 (1)	0
鼓腸	7 (<1)	9 (1)	8 (1)	1 (<1)
口内乾燥	0	9 (1)	5 (<1)	0
便意切迫	0	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 83 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
おくび	0	2 (<1)	3 (<1)	0
便失禁	2 (<1)	3 (<1)	4 (<1)	0
排便回数増加	0	1 (<1)	2 (<1)	0
逆流性食道炎	2 (<1)	1 (<1)	3 (<1)	1 (<1)
下腹部痛	3 (<1)	3 (<1)	7 (<1)	0
腹部硬直	1 (<1)	1 (<1)	2 (<1)	0
便通不規則	1 (<1)	0	1 (<1)	0
十二指腸潰瘍	1 (<1)	1 (<1)	2 (<1)	0
十二指腸炎	0	0	1 (<1)	0
心窩部不快感	2 (<1)	2 (<1)	3 (<1)	0
食中毒	2 (<1)	4 (<1)	5 (<1)	1 (<1)
胃障害	3 (<1)	1 (<1)	2 (<1)	0
胃潰瘍	0	0	1 (<1)	0
胃腸出血	1 (<1)	0	1 (<1)	0
歯肉痛	1 (<1)	0	2 (<1)	0
歯肉炎	3 (<1)	2 (<1)	3 (<1)	1 (<1)
舌痛	1 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 84 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
おくび	0	2 (<1)	2 (<1)	0
便失禁	1 (<1)	1 (<1)	2 (<1)	0
排便回数増加	0	1 (<1)	2 (<1)	0
逆流性食道炎	1 (<1)	1 (<1)	2 (<1)	0
下腹部痛	2 (<1)	1 (<1)	1 (<1)	0
腹部硬直	0	0	1 (<1)	0
便通不規則	0	0	1 (<1)	0
十二指腸潰瘍	0	1 (<1)	1 (<1)	0
十二指腸炎	0	0	1 (<1)	0
心窩部不快感	2 (<1)	1 (<1)	1 (<1)	0
食中毒	0	0	1 (<1)	0
胃障害	2 (<1)	1 (<1)	1 (<1)	0
胃潰瘍	0	0	1 (<1)	0
胃腸出血	1 (<1)	0	1 (<1)	0
歯肉痛	1 (<1)	0	1 (<1)	0
歯肉炎	1 (<1)	0	1 (<1)	0
舌痛	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 85 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯周炎	3 (<1)	2 (<1)	10 (1)	0
舌苔	0	0	1 (<1)	0
舌障害	1 (<1)	0	1 (<1)	0
腹部ヘルニア	0	2 (<1)	0	0
腹部圧痛	2 (<1)	1 (<1)	2 (<1)	1 (<1)
異常便	1 (<1)	2 (<1)	0	0
裂肛	1 (<1)	0	0	0
アフタ性口内炎	1 (<1)	0	1 (<1)	0
根尖肉芽腫	0	0	0	1 (<1)
唾液欠乏	0	1 (<1)	0	0
呼気臭	1 (<1)	0	0	0
口腔灼熱感症候群	0	0	1 (<1)	0
便習慣変化	0	0	1 (<1)	0
口唇のひび割れ	1 (<1)	0	0	0
口唇炎	0	1 (<1)	0	0
大腸炎	2 (<1)	1 (<1)	2 (<1)	1 (<1)
潰瘍性大腸炎	1 (<1)	0	0	0
結腸ポリープ	2 (<1)	1 (<1)	1 (<1)	1 (<1)
クローン病	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 86 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
歯周炎	0	0	1 (<1)	0
舌苔	0	0	1 (<1)	0
舌障害	1 (<1)	0	1 (<1)	0
腹部ヘルニア	0	0	0	0
腹部圧痛	0	1 (<1)	0	0
異常便	1 (<1)	2 (<1)	0	0
裂肛	0	0	0	0
アフタ性口内炎	0	0	0	0
根尖肉芽腫	0	0	0	0
唾液欠乏	0	1 (<1)	0	0
呼気臭	0	0	0	0
口腔灼熱感症候群	0	0	0	0
便習慣変化	0	0	0	0
口唇のひび割れ	1 (<1)	0	0	0
口唇炎	0	0	0	0
大腸炎	2 (<1)	0	0	1 (<1)
潰瘍性大腸炎	0	0	0	0
結腸ポリープ	0	0	0	0
クローン病	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 87 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
齲歯	2 (<1)	4 (<1)	5 (<1)	3 (<1)
憩室穿孔	0	1 (<1)	0	0
腸憩室	0	0	2 (<1)	1 (<1)
十二指腸ポリープ	0	1 (<1)	0	0
十二指腸胃逆流	1 (<1)	0	0	0
嚥下障害	6 (<1)	5 (<1)	5 (<1)	2 (<1)
小腸炎	0	1 (<1)	3 (<1)	0
腸炎	1 (<1)	0	1 (<1)	0
変色便	0	0	1 (<1)	1 (<1)
胃ポリープ	1 (<1)	0	0	0
出血性胃炎	0	1 (<1)	0	1 (<1)
胃十二指腸炎	0	0	1 (<1)	0
消化器痛	3 (<1)	1 (<1)	0	1 (<1)
歯肉出血	1 (<1)	2 (<1)	0	1 (<1)
歯肉嚢胞	0	0	1 (<1)	0
歯肉障害	0	0	1 (<1)	0
歯肉紅斑	0	0	0	1 (<1)
歯肉腫脹	1 (<1)	1 (<1)	0	0
舌炎	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 88 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
齲歯	0	0	0	0
憩室穿孔	0	0	0	0
腸憩室	0	0	0	0
十二指腸ポリープ	0	0	0	0
十二指腸胃逆流	0	0	0	0
嚥下障害	0	0	0	0
小腸炎	0	1 (<1)	0	0
腸炎	0	0	0	0
変色便	0	0	0	0
胃ポリープ	0	0	0	0
出血性胃炎	0	0	0	0
胃十二指腸炎	0	0	0	0
消化器痛	0	0	0	0
歯肉出血	0	0	0	0
歯肉嚢胞	0	0	0	0
歯肉障害	0	0	0	0
歯肉紅斑	0	0	0	0
歯肉腫脹	0	0	0	0
舌炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 89 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
吐血	1 (<1)	1 (<1)	1 (<1)	0
血便排泄	2 (<1)	0	1 (<1)	0
痔出血	0	0	0	1 (<1)
痔核	7 (<1)	8 (1)	8 (1)	1 (<1)
裂孔ヘルニア	2 (<1)	4 (<1)	1 (<1)	0
胃酸過多	2 (<1)	5 (<1)	0	0
口の感覚鈍麻	1 (<1)	2 (<1)	2 (<1)	0
胃排出不全	0	1 (<1)	0	0
炎症性腸疾患	0	0	1 (<1)	0
腸閉塞	0	0	1 (<1)	0
腸管ポリープ	0	1 (<1)	0	0
過敏性腸症候群	2 (<1)	1 (<1)	1 (<1)	0
口唇水疱	0	1 (<1)	0	0
口唇乾燥	1 (<1)	0	0	0
弛緩歯	0	1 (<1)	0	0
腰ヘルニア	0	0	1 (<1)	0
マロリー・ワイス症候群	0	1 (<1)	0	0
口腔内潰瘍形成	4 (<1)	1 (<1)	1 (<1)	0
神経因性腸	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 90 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
吐血	0	0	0	0
血便排泄	0	0	0	0
痔出血	0	0	0	0
痔核	0	0	0	0
裂孔ヘルニア	0	0	0	0
胃酸過多	1 (<1)	2 (<1)	0	0
口の感覚鈍麻	0	2 (<1)	0	0
胃排出不全	0	1 (<1)	0	0
炎症性腸疾患	0	0	0	0
腸閉塞	0	0	0	0
腸管ポリープ	0	0	0	0
過敏性腸症候群	0	0	0	0
口唇水疱	0	0	0	0
口唇乾燥	1 (<1)	0	0	0
弛緩歯	0	0	0	0
腰ヘルニア	0	0	0	0
マロリー・ワイス症候群	0	0	0	0
口腔内潰瘍形成	0	0	0	0
神経因性腸	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 91 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嚥下痛	0	1 (<1)	1 (<1)	0
食道出血	0	1 (<1)	0	0
食道痙攣	0	0	1 (<1)	0
食道潰瘍	0	0	1 (<1)	0
食道炎	0	2 (<1)	0	0
口腔内痛	0	1 (<1)	1 (<1)	0
膵脂肪腫症	0	1 (<1)	0	0
膵臓障害	0	0	1 (<1)	0
膵機能不全	0	0	1 (<1)	0
膵炎	1 (<1)	1 (<1)	0	0
急性膵炎	1 (<1)	0	0	0
口の錯感覚	2 (<1)	2 (<1)	0	0
消化性潰瘍	0	0	1 (<1)	0
歯周病	0	1 (<1)	0	0
腹膜出血	1 (<1)	0	0	0
肛門周囲痛	2 (<1)	1 (<1)	0	0
直腸出血	1 (<1)	1 (<1)	0	0
直腸攣縮	0	0	0	1 (<1)
逆流性胃炎	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 92 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
嚥下痛	0	1 (<1)	0	0
食道出血	0	1 (<1)	0	0
食道痙攣	0	0	0	0
食道潰瘍	0	0	0	0
食道炎	0	0	0	0
口腔内痛	0	0	0	0
膵脂肪腫症	0	0	0	0
膵臓障害	0	0	0	0
膵機能不全	0	0	0	0
膵炎	1 (<1)	1 (<1)	0	0
急性膵炎	0	0	0	0
口の錯感覚	0	0	0	0
消化性潰瘍	0	0	0	0
歯周病	0	0	0	0
腹膜出血	0	0	0	0
肛門周囲痛	0	0	0	0
直腸出血	0	0	0	0
直腸攣縮	0	0	0	0
逆流性胃炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 93 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
唾液管閉塞	0	0	1 (<1)	0
流涎過多	0	3 (<1)	0	0
口内炎	3 (<1)	2 (<1)	1 (<1)	1 (<1)
舌腫脹	0	1 (<1)	0	0
脆弱歯	1 (<1)	0	0	0
舌乾燥	1 (<1)	0	0	0
地図状舌	0	1 (<1)	0	0
歯の発育障害	1 (<1)	0	0	0
歯の障害	1 (<1)	1 (<1)	0	0
歯の磨耗	0	1 (<1)	0	0
埋伏歯	1 (<1)	0	3 (<1)	1 (<1)
歯の脱落	1 (<1)	1 (<1)	0	0
歯痛	19 (2)	18 (2)	26 (3)	4 (1)
臍ヘルニア	1 (<1)	0	1 (<1)	0
肝胆道系障害	11 (1)	10 (1)	15 (2)	6 (2)
肝障害	1 (<1)	2 (<1)	6 (<1)	2 (<1)
肝細胞融解性肝炎	0	1 (<1)	2 (<1)	0
胆管結石	2 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 94 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
唾液管閉塞	0	0	0	0
流涎過多	0	2 (<1)	0	0
口内炎	2 (<1)	0	0	0
舌腫脹	0	0	0	0
脆弱歯	0	0	0	0
舌乾燥	0	0	0	0
地図状舌	0	0	0	0
歯の発育障害	0	0	0	0
歯の障害	0	0	0	0
歯の磨耗	0	0	0	0
埋伏歯	0	0	0	0
歯の脱落	0	0	0	0
歯痛	1 (<1)	1 (<1)	0	0
臍ヘルニア	0	0	0	0
肝胆道系障害	4 (<1)	5 (<1)	8 (1)	0
肝障害	0	1 (<1)	4 (<1)	0
肝細胞融解性肝炎	0	1 (<1)	2 (<1)	0
胆管結石	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 95 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
肝炎	1 (<1)	0	1 (<1)	0
胆道ジスキネジー	0	1 (<1)	1 (<1)	1 (<1)
胆石症	3 (<1)	1 (<1)	2 (<1)	3 (<1)
胆嚢浮腫	0	0	1 (<1)	0
肝嚢胞	1 (<1)	1 (<1)	1 (<1)	0
脂肪肝	1 (<1)	2 (<1)	0	0
胆汁うっ滞性肝炎	0	1 (<1)	0	0
中毒性肝炎	1 (<1)	0	0	0
高ビリルビン血症	2 (<1)	0	1 (<1)	0
高トランスアミナーゼ血症	0	1 (<1)	0	0
皮膚および皮下組織障害	157 (20)	245 (32)	247 (33)	60 (17)
紅斑	10 (1)	36 (5)	54 (7)	6 (2)
そう痒症	30 (4)	62 (8)	58 (8)	7 (2)
発疹	26 (3)	58 (8)	55 (7)	9 (3)
多汗症	10 (1)	17 (2)	26 (3)	5 (1)
蕁麻疹	9 (1)	11 (1)	13 (2)	2 (<1)
全身性そう痒症	3 (<1)	9 (1)	9 (1)	3 (<1)
寝汗	8 (1)	13 (2)	14 (2)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 96 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
肝炎	0	0	1 (<1)	0
胆道ジスキネジー	0	1 (<1)	0	0
胆石症	1 (<1)	0	0	0
胆嚢浮腫	0	0	0	0
肝嚢胞	0	0	0	0
脂肪肝	0	0	0	0
胆汁うっ滞性肝炎	0	1 (<1)	0	0
中毒性肝炎	1 (<1)	0	0	0
高ビリルビン血症	2 (<1)	0	0	0
高トランスアミナーゼ血症	0	1 (<1)	0	0
皮膚および皮下組織障害	69 (9)	172 (22)	174 (23)	24 (7)
紅斑	4 (<1)	31 (4)	46 (6)	5 (1)
そう痒症	18 (2)	52 (7)	46 (6)	3 (<1)
発疹	10 (1)	41 (5)	33 (4)	4 (1)
多汗症	6 (<1)	14 (2)	17 (2)	3 (<1)
蕁麻疹	1 (<1)	8 (1)	10 (1)	0
全身性そう痒症	3 (<1)	9 (1)	8 (1)	2 (<1)
寝汗	3 (<1)	7 (<1)	7 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 97 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
皮膚灼熱感	0	6 (<1)	7 (<1)	0
脱毛症	19 (2)	17 (2)	11 (1)	7 (2)
そう痒性皮疹	2 (<1)	8 (1)	5 (<1)	0
アレルギー性皮膚炎	5 (<1)	13 (2)	8 (1)	1 (<1)
全身紅斑	0	4 (<1)	4 (<1)	0
全身性皮疹	0	4 (<1)	4 (<1)	0
斑状皮疹	1 (<1)	1 (<1)	9 (1)	0
皮膚乾燥	6 (<1)	7 (<1)	7 (<1)	1 (<1)
光線過敏性反応	1 (<1)	4 (<1)	4 (<1)	1 (<1)
紅斑性皮疹	0	2 (<1)	3 (<1)	0
皮膚炎	4 (<1)	4 (<1)	6 (<1)	1 (<1)
皮膚反応	0	1 (<1)	2 (<1)	2 (<1)
ざ瘡	13 (2)	7 (<1)	8 (1)	4 (1)
紅色症	0	0	1 (<1)	0
顔面感覚鈍麻	7 (<1)	2 (<1)	4 (<1)	1 (<1)
毛孔性角化症	0	0	1 (<1)	0
皮膚疼痛	0	0	2 (<1)	0
痒疹	0	3 (<1)	1 (<1)	0
アレルギー性そう痒症	2 (<1)	2 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 98 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
皮膚灼熱感	0	5 (<1)	7 (<1)	0
脱毛症	9 (1)	8 (1)	5 (<1)	1 (<1)
そう痒性皮疹	1 (<1)	6 (<1)	5 (<1)	0
アレルギー性皮膚炎	2 (<1)	6 (<1)	4 (<1)	0
全身紅斑	0	4 (<1)	4 (<1)	0
全身性皮疹	0	4 (<1)	4 (<1)	0
斑状皮疹	1 (<1)	0	4 (<1)	0
皮膚乾燥	2 (<1)	5 (<1)	3 (<1)	0
光線過敏性反応	1 (<1)	2 (<1)	3 (<1)	1 (<1)
紅斑性皮疹	0	2 (<1)	3 (<1)	0
皮膚炎	3 (<1)	2 (<1)	2 (<1)	0
皮膚反応	0	1 (<1)	2 (<1)	1 (<1)
ざ瘡	6 (<1)	2 (<1)	1 (<1)	0
紅色症	0	0	1 (<1)	0
顔面感覚鈍麻	0	0	1 (<1)	0
毛孔性角化症	0	0	1 (<1)	0
皮膚疼痛	0	0	1 (<1)	0
痒疹	0	1 (<1)	1 (<1)	0
アレルギー性そう痒症	1 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 99 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乾癬	5 (<1)	1 (<1)	3 (<1)	1 (<1)
丘疹性皮疹	0	1 (<1)	3 (<1)	0
皮膚色素脱失	0	0	1 (<1)	0
皮膚刺激	1 (<1)	2 (<1)	2 (<1)	1 (<1)
皮膚のつっぱり感	0	1 (<1)	3 (<1)	0
皮膚熱感	0	1 (<1)	1 (<1)	0
一過性棘融解性皮膚症	0	0	1 (<1)	0
日光性角化症	0	0	1 (<1)	0
血管浮腫	0	0	0	1 (<1)
水疱	1 (<1)	3 (<1)	0	0
冷汗	2 (<1)	0	1 (<1)	0
皮膚弛緩症	0	1 (<1)	0	0
頭部粃糠疹	0	0	0	1 (<1)
皮膚嚢腫	3 (<1)	1 (<1)	1 (<1)	1 (<1)
ざ瘡様皮膚炎	1 (<1)	2 (<1)	0	0
アトピー性皮膚炎	1 (<1)	1 (<1)	0	0
接触性皮膚炎	3 (<1)	2 (<1)	1 (<1)	3 (<1)
薬疹	0	1 (<1)	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 100 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乾癬	2 (<1)	0	1 (<1)	1 (<1)
丘疹性皮疹	0	1 (<1)	1 (<1)	0
皮膚色素脱失	0	0	1 (<1)	0
皮膚刺激	1 (<1)	0	1 (<1)	0
皮膚のつっぱり感	0	1 (<1)	1 (<1)	0
皮膚熱感	0	1 (<1)	1 (<1)	0
一過性棘融解性皮膚症	0	0	1 (<1)	0
日光性角化症	0	0	0	0
血管浮腫	0	0	0	0
水疱	0	0	0	0
冷汗	0	0	0	0
皮膚弛緩症	0	0	0	0
頭部粃糠疹	0	0	0	0
皮膚嚢腫	0	0	0	0
ざ瘡様皮膚炎	0	1 (<1)	0	0
アトピー性皮膚炎	0	0	0	0
接触性皮膚炎	0	1 (<1)	0	0
薬疹	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 101 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
発汗障害	1 (<1)	0	0	0
斑状出血	4 (<1)	1 (<1)	2 (<1)	1 (<1)
湿疹	4 (<1)	7 (<1)	5 (<1)	2 (<1)
多形紅斑	1 (<1)	0	0	0
剥脱性発疹	1 (<1)	1 (<1)	0	0
皮膚肉芽腫	1 (<1)	0	0	0
皮下出血	0	0	0	1 (<1)
毛質異常	1 (<1)	0	0	0
紅色汗疹	1 (<1)	1 (<1)	0	0
過角化	0	2 (<1)	2 (<1)	0
掌蹠角化症	0	1 (<1)	0	0
特発性蕁麻疹	0	1 (<1)	0	0
内出血発生の増加傾向	0	0	1 (<1)	1 (<1)
嵌入爪	1 (<1)	0	1 (<1)	1 (<1)
黒子	1 (<1)	0	0	0
脂肪組織萎縮症	0	0	0	1 (<1)
後天性リポジストロフィー	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 102 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
発汗障害	0	0	0	0
斑状出血	1 (<1)	0	0	1 (<1)
湿疹	1 (<1)	2 (<1)	0	0
多形紅斑	1 (<1)	0	0	0
剥脱性発疹	1 (<1)	0	0	0
皮膚肉芽腫	0	0	0	0
皮下出血	0	0	0	0
毛質異常	1 (<1)	0	0	0
紅色汗疹	0	1 (<1)	0	0
過角化	0	0	0	0
掌蹠角化症	0	0	0	0
特発性蕁麻疹	0	0	0	0
内出血発生の増加傾向	0	0	0	1 (<1)
嵌入爪	0	0	0	0
黒子	0	0	0	0
脂肪組織萎縮症	0	0	0	1 (<1)
後天性リポジストロフィー	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 103 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
網状皮斑	0	1 (<1)	1 (<1)	1 (<1)
睫毛眉毛脱落症	0	1 (<1)	0	0
爪床障害	1 (<1)	0	0	0
爪床の炎症	1 (<1)	0	0	0
爪変色	1 (<1)	1 (<1)	0	0
爪の障害	0	0	1 (<1)	0
神経皮膚炎	0	0	0	1 (<1)
爪破損	1 (<1)	2 (<1)	0	0
点状出血	3 (<1)	0	0	0
光線性皮膚症	1 (<1)	0	0	0
色素沈着障害	3 (<1)	1 (<1)	0	0
ばら色粃糠疹	3 (<1)	0	0	0
前癌性皮膚病変	1 (<1)	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0
猩紅熱様発疹	1 (<1)	0	0	0
小水疱性皮疹	1 (<1)	0	0	0
酒さ	3 (<1)	6 (<1)	0	0
瘢痕	1 (<1)	1 (<1)	0	1 (<1)
脂腺障害	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 104 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
網状皮斑	0	1 (<1)	0	0
睫毛眉毛脱落症	0	0	0	0
爪床障害	0	0	0	0
爪床の炎症	0	0	0	0
爪変色	0	0	0	0
爪の障害	0	0	0	0
神経皮膚炎	0	0	0	0
爪破損	1 (<1)	2 (<1)	0	0
点状出血	1 (<1)	0	0	0
光線性皮膚症	1 (<1)	0	0	0
色素沈着障害	0	0	0	0
ばら色粃糠疹	0	0	0	0
前癌性皮膚病変	0	0	0	0
斑状丘疹状皮疹	1 (<1)	0	0	0
猩紅熱様発疹	0	0	0	0
小水疱性皮疹	0	0	0	0
酒さ	1 (<1)	2 (<1)	0	0
瘢痕	0	0	0	0
脂腺障害	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 105 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脂漏	0	1 (<1)	0	0
脂漏性皮膚炎	0	0	0	1 (<1)
皮膚変色	1 (<1)	0	1 (<1)	0
皮膚障害	1 (<1)	0	0	0
皮膚剥脱	1 (<1)	2 (<1)	1 (<1)	0
皮膚色素過剰	2 (<1)	3 (<1)	1 (<1)	2 (<1)
皮膚色素減少	0	1 (<1)	0	0
皮膚硬結	1 (<1)	1 (<1)	1 (<1)	2 (<1)
皮膚病変	3 (<1)	3 (<1)	0	0
皮膚小結節	0	0	0	1 (<1)
皮膚潰瘍	0	0	1 (<1)	0
スティーブンス・ジョンソン症候群	0	1 (<1)	0	0
皮下結節	1 (<1)	1 (<1)	0	1 (<1)
顔面腫脹	1 (<1)	1 (<1)	2 (<1)	4 (1)
毛細血管拡張症	1 (<1)	1 (<1)	0	0
裂毛	1 (<1)	0	0	0
乾皮症	1 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 106 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
脂漏	0	0	0	0
脂漏性皮膚炎	0	0	0	0
皮膚変色	0	0	0	0
皮膚障害	1 (<1)	0	0	0
皮膚剥脱	0	1 (<1)	0	0
皮膚色素過剰	1 (<1)	3 (<1)	0	1 (<1)
皮膚色素減少	0	0	0	0
皮膚硬結	1 (<1)	0	0	1 (<1)
皮膚病変	2 (<1)	0	0	0
皮膚小結節	0	0	0	1 (<1)
皮膚潰瘍	0	0	0	0
スティーブンス・ジョンソン症候群	0	0	0	0
皮下結節	1 (<1)	1 (<1)	0	1 (<1)
顔面腫脹	1 (<1)	0	0	2 (<1)
毛細血管拡張症	1 (<1)	0	0	0
裂毛	1 (<1)	0	0	0
乾皮症	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 107 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
筋骨格系および結合組織障害	261 (34)	246 (32)	246 (32)	82 (23)
関節痛	65 (8)	66 (9)	64 (8)	17 (5)
筋痙縮	34 (4)	27 (4)	49 (6)	8 (2)
背部痛	90 (12)	94 (12)	82 (11)	32 (9)
筋肉痛	26 (3)	13 (2)	13 (2)	4 (1)
四肢痛	58 (8)	58 (8)	55 (7)	21 (6)
頚部痛	22 (3)	27 (4)	20 (3)	5 (1)
筋力低下	36 (5)	18 (2)	24 (3)	6 (2)
関節炎	1 (<1)	4 (<1)	6 (<1)	2 (<1)
骨痛	4 (<1)	3 (<1)	4 (<1)	0
側腹部痛	1 (<1)	0	4 (<1)	2 (<1)
四肢不快感	1 (<1)	0	1 (<1)	0
筋緊張	2 (<1)	2 (<1)	3 (<1)	0
筋骨格系胸痛	6 (<1)	3 (<1)	5 (<1)	1 (<1)
筋骨格硬直	11 (1)	7 (<1)	4 (<1)	9 (3)
四肢の結節	0	0	2 (<1)	0
関節障害	0	1 (<1)	2 (<1)	0
腋窩腫瘤	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 108 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
筋骨格系および結合組織障害	24 (3)	21 (3)	33 (4)	6 (2)
関節痛	5 (<1)	7 (<1)	7 (<1)	0
筋痙縮	3 (<1)	5 (<1)	6 (<1)	1 (<1)
背部痛	3 (<1)	2 (<1)	5 (<1)	2 (<1)
筋肉痛	8 (1)	2 (<1)	5 (<1)	1 (<1)
四肢痛	3 (<1)	4 (<1)	5 (<1)	0
頚部痛	0	2 (<1)	3 (<1)	1 (<1)
筋力低下	3 (<1)	0	2 (<1)	1 (<1)
関節炎	0	0	1 (<1)	0
骨痛	0	0	1 (<1)	0
側腹部痛	1 (<1)	0	1 (<1)	0
四肢不快感	0	0	1 (<1)	0
筋緊張	1 (<1)	0	1 (<1)	0
筋骨格系胸痛	0	0	1 (<1)	0
筋骨格硬直	1 (<1)	1 (<1)	1 (<1)	1 (<1)
四肢の結節	0	0	1 (<1)	0
関節障害	0	0	0	0
腋窩腫瘤	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 109 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
滑液包炎	3 (<1)	5 (<1)	6 (<1)	0
軟骨炎	0	1 (<1)	0	0
尾骨痛	2 (<1)	0	3 (<1)	0
腱付着部症	0	1 (<1)	0	0
外骨腫	0	0	1 (<1)	2 (<1)
四肢拘縮	0	1 (<1)	0	0
線維筋痛	2 (<1)	0	0	0
肛径部痛	1 (<1)	2 (<1)	0	0
成長痛	0	0	1 (<1)	1 (<1)
椎間板圧迫	0	1 (<1)	0	0
椎間板変性症	0	0	1 (<1)	0
椎間板障害	0	2 (<1)	1 (<1)	0
椎間板突出	2 (<1)	3 (<1)	2 (<1)	0
関節滲出液	0	0	2 (<1)	0
関節硬直	0	2 (<1)	5 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 110 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
滑液包炎	0	0	0	0
軟骨炎	0	0	0	0
尾骨痛	0	0	0	0
腱付着部症	0	0	0	0
外骨腫	0	0	0	0
四肢拘縮	0	0	0	0
線維筋痛	1 (<1)	0	0	0
肛径部痛	0	0	0	0
成長痛	0	0	0	1 (<1)
椎間板圧迫	0	0	0	0
椎間板変性症	0	0	0	0
椎間板障害	0	0	0	0
椎間板突出	0	0	0	0
関節滲出液	0	0	0	0
関節硬直	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 111 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
関節腫脹	3 (<1)	5 (<1)	4 (<1)	2 (<1)
下肢腫瘤	0	0	1 (<1)	0
中足骨痛	0	1 (<1)	0	0
運動性低下	1 (<1)	0	0	1 (<1)
筋拘縮	1 (<1)	0	2 (<1)	1 (<1)
筋肉疲労	1 (<1)	0	0	0
筋肉内出血	0	0	1 (<1)	0
筋固縮	0	0	0	1 (<1)
筋腫脹	0	1 (<1)	0	0
筋攣縮	4 (<1)	2 (<1)	0	1 (<1)
筋骨格不快感	3 (<1)	1 (<1)	2 (<1)	0
筋骨格痛	26 (3)	14 (2)	21 (3)	8 (2)
ミオキミア	0	1 (<1)	1 (<1)	0
筋硬化症	1 (<1)	1 (<1)	0	0
筋炎	1 (<1)	0	1 (<1)	0
結節性変形性関節症	1 (<1)	0	0	0
変形性関節症	5 (<1)	4 (<1)	4 (<1)	0
骨端症	0	0	1 (<1)	0
骨壊死	1 (<1)	2 (<1)	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 112 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
関節腫脹	1 (<1)	1 (<1)	0	0
下肢腫瘤	0	0	0	0
中足骨痛	0	1 (<1)	0	0
運動性低下	0	0	0	0
筋拘縮	1 (<1)	0	0	0
筋肉疲労	0	0	0	0
筋肉内出血	0	0	0	0
筋固縮	0	0	0	0
筋腫脹	0	0	0	0
筋攣縮	1 (<1)	0	0	0
筋骨格不快感	0	0	0	0
筋骨格痛	1 (<1)	0	0	0
ミオキミア	0	0	0	0
筋硬化症	0	0	0	0
筋炎	0	0	0	0
結節性変形性関節症	0	0	0	0
変形性関節症	0	0	0	0
骨端症	0	0	0	0
骨壊死	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 113 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨減少症	1 (<1)	2 (<1)	2 (<1)	1 (<1)
骨粗鬆症	4 (<1)	3 (<1)	1 (<1)	0
顎痛	4 (<1)	1 (<1)	0	1 (<1)
回帰性リウマチ	1 (<1)	0	0	0
膝蓋大腿部痛症候群	0	1 (<1)	1 (<1)	0
関節周囲炎	4 (<1)	1 (<1)	3 (<1)	0
足底筋膜炎	1 (<1)	0	0	0
多発性関節炎	1 (<1)	0	0	0
乾癬性関節症	0	0	1 (<1)	0
関節リウマチ	2 (<1)	0	0	0
肩回旋筋腱板症候群	2 (<1)	0	2 (<1)	0
重感	4 (<1)	7 (<1)	2 (<1)	2 (<1)
足根洞症候群	0	1 (<1)	0	0
シェーグレン症候群	0	2 (<1)	0	0
脊柱変形	1 (<1)	0	0	0
脊椎障害	0	1 (<1)	0	0
変形性脊椎症	2 (<1)	2 (<1)	2 (<1)	0
脊椎分離	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 114 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨減少症	0	1 (<1)	0	0
骨粗鬆症	0	0	0	0
顎痛	0	0	0	0
回帰性リウマチ	0	0	0	0
膝蓋大腿部痛症候群	0	0	0	0
関節周囲炎	0	0	0	0
足底筋膜炎	0	0	0	0
多発性関節炎	1 (<1)	0	0	0
乾癬性関節症	0	0	0	0
関節リウマチ	0	0	0	0
肩回旋筋腱板症候群	0	0	0	0
重感	1 (<1)	1 (<1)	0	0
足根洞症候群	0	0	0	0
シェーグレン症候群	0	0	0	0
脊柱変形	0	0	0	0
脊椎障害	0	0	0	0
変形性脊椎症	0	0	0	0
脊椎分離	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 115 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
滑液嚢腫	2 (<1)	2 (<1)	2 (<1)	0
滑膜障害	0	1 (<1)	0	0
滑膜炎	1 (<1)	0	0	0
腱障害	1 (<1)	1 (<1)	0	0
腱痛	1 (<1)	0	0	0
腱炎	9 (1)	3 (<1)	3 (<1)	0
腱鞘炎	2 (<1)	2 (<1)	2 (<1)	0
斜頚	1 (<1)	0	1 (<1)	0
弾発指	0	1 (<1)	1 (<1)	0
腎および尿路障害	151 (20)	146 (19)	176 (23)	58 (17)
蛋白尿	59 (8)	67 (9)	85 (11)	30 (9)
ミクロアルブミン尿	24 (3)	35 (5)	36 (5)	15 (4)
血尿	34 (4)	33 (4)	41 (5)	10 (3)
ケトン尿	6 (<1)	7 (<1)	15 (2)	1 (<1)
排尿困難	11 (1)	7 (<1)	13 (2)	1 (<1)
アルブミン尿	0	2 (<1)	2 (<1)	2 (<1)
着色尿	0	0	1 (<1)	0
腎結石症	8 (1)	5 (<1)	8 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 116 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
滑液嚢腫	0	0	0	0
滑膜障害	0	0	0	0
滑膜炎	0	0	0	0
腱障害	0	0	0	0
腱痛	0	0	0	0
腱炎	0	0	0	0
腱鞘炎	0	0	0	0
斜頚	0	0	0	0
弾発指	0	0	0	0
腎および尿路障害	50 (6)	60 (8)	62 (8)	11 (3)
蛋白尿	27 (4)	30 (4)	35 (5)	5 (1)
ミクロアルブミン尿	9 (1)	19 (2)	14 (2)	3 (<1)
血尿	12 (2)	11 (1)	12 (2)	2 (<1)
ケトン尿	3 (<1)	5 (<1)	7 (<1)	0
排尿困難	0	1 (<1)	3 (<1)	0
アルブミン尿	0	1 (<1)	1 (<1)	1 (<1)
着色尿	0	0	1 (<1)	0
腎結石症	2 (<1)	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 117 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頻尿	12 (2)	7 (<1)	6 (<1)	3 (<1)
慢性腎不全	0	0	1 (<1)	0
腎機能障害	0	0	1 (<1)	0
腎臓痛	1 (<1)	2 (<1)	2 (<1)	0
腎尿細管性アシドーシス	0	0	1 (<1)	0
尿失禁	7 (<1)	8 (1)	5 (<1)	3 (<1)
膀胱憩室	1 (<1)	0	0	0
膀胱機能障害	1 (<1)	2 (<1)	1 (<1)	0
膀胱刺激症状	0	1 (<1)	1 (<1)	0
膀胱痛	0	1 (<1)	0	0
膀胱穿孔	0	0	1 (<1)	0
膀胱痙縮	1 (<1)	0	0	0
尿路結石	1 (<1)	0	0	0
肋骨脊柱角圧痛	1 (<1)	0	0	0
出血性膀胱炎	0	1 (<1)	0	0
非感染性膀胱炎	3 (<1)	1 (<1)	1 (<1)	0
グロブリン尿	0	2 (<1)	0	0
慢性糸球体腎炎	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 118 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
頻尿	1 (<1)	1 (<1)	1 (<1)	0
慢性腎不全	0	0	1 (<1)	0
腎機能障害	0	0	1 (<1)	0
腎臓痛	1 (<1)	0	1 (<1)	0
腎尿細管性アシドーシス	0	0	1 (<1)	0
尿失禁	0	1 (<1)	1 (<1)	0
膀胱憩室	0	0	0	0
膀胱機能障害	0	0	0	0
膀胱刺激症状	0	0	0	0
膀胱痛	0	0	0	0
膀胱穿孔	0	0	0	0
膀胱痙縮	0	0	0	0
尿路結石	0	0	0	0
肋骨脊柱角圧痛	1 (<1)	0	0	0
出血性膀胱炎	0	1 (<1)	0	0
非感染性膀胱炎	0	0	0	0
グロブリン尿	0	0	0	0
慢性糸球体腎炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 119 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
糖尿	9 (1)	4 (<1)	3 (<1)	2 (<1)
高血圧性腎症	0	0	0	1 (<1)
緊張性膀胱	0	1 (<1)	1 (<1)	0
失禁	0	0	1 (<1)	1 (<1)
白血球尿	2 (<1)	0	3 (<1)	1 (<1)
排尿異常	0	1 (<1)	0	0
尿意切迫	11 (1)	10 (1)	9 (1)	5 (1)
腎下垂症	1 (<1)	1 (<1)	0	0
ネフローゼ症候群	0	0	0	1 (<1)
神経因性膀胱	2 (<1)	2 (<1)	1 (<1)	0
夜間頻尿	1 (<1)	0	0	1 (<1)
起立性蛋白尿症	0	1 (<1)	1 (<1)	0
膿尿	0	0	0	1 (<1)
腎仙痛	1 (<1)	1 (<1)	2 (<1)	0
腎嚢胞	1 (<1)	2 (<1)	0	0
腎障害	0	1 (<1)	0	0
有痛性排尿困難	0	1 (<1)	0	0
腹圧性尿失禁	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 120 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
糖尿	3 (<1)	1 (<1)	0	0
高血圧性腎症	0	0	0	0
緊張性膀胱	0	0	0	0
失禁	0	0	0	0
白血球尿	2 (<1)	0	0	0
排尿異常	0	0	0	0
尿意切迫	0	0	0	0
腎下垂症	0	0	0	0
ネフローゼ症候群	0	0	0	1 (<1)
神経因性膀胱	0	0	0	0
夜間頻尿	0	0	0	0
起立性蛋白尿症	0	0	0	0
膿尿	0	0	0	0
腎仙痛	0	0	0	0
腎嚢胞	0	0	0	0
腎障害	0	0	0	0
有痛性排尿困難	0	0	0	0
腹圧性尿失禁	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 121 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
尿管瘤	0	1 (<1)	0	0
切迫性尿失禁	0	2 (<1)	4 (<1)	1 (<1)
排尿躊躇	5 (<1)	1 (<1)	5 (<1)	1 (<1)
尿閉	4 (<1)	4 (<1)	4 (<1)	1 (<1)
尿路の炎症	1 (<1)	0	0	0
尿路痛	1 (<1)	1 (<1)	0	1 (<1)
尿臭異常	1 (<1)	1 (<1)	3 (<1)	0
妊娠、産褥および周産期の状態	3 (<1)	1 (<1)	0	0
自然流産	2 (<1)	0	0	0
妊娠浮腫	1 (<1)	0	0	0
妊娠	0	1 (<1)	0	0
生殖系および乳房障害	74 (10)	76 (10)	76 (10)	26 (7)
不規則月経	9 (1)	5 (<1)	10 (1)	5 (1)
無月経	5 (<1)	3 (<1)	5 (<1)	3 (<1)
月経障害	2 (<1)	1 (<1)	3 (<1)	1 (<1)
勃起不全	4 (<1)	5 (<1)	5 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 122 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
尿管瘤	0	0	0	0
切迫性尿失禁	0	0	0	0
排尿躊躇	2 (<1)	0	0	0
尿閉	0	1 (<1)	0	0
尿路の炎症	0	0	0	0
尿路痛	0	0	0	0
尿臭異常	0	1 (<1)	0	0
妊娠、産褥および周産期の状態	1 (<1)	0	0	0
自然流産	1 (<1)	0	0	0
妊娠浮腫	0	0	0	0
妊娠	0	0	0	0
生殖系および乳房障害	14 (2)	10 (1)	16 (2)	4 (1)
不規則月経	2 (<1)	0	4 (<1)	0
無月経	2 (<1)	0	3 (<1)	0
月経障害	0	0	3 (<1)	0
勃起不全	3 (<1)	0	2 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 123 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
バルトリン腺炎	0	0	1 (<1)	0
乳房腫瘤	1 (<1)	1 (<1)	1 (<1)	0
乳房痛	1 (<1)	2 (<1)	6 (<1)	0
月経過多	6 (<1)	5 (<1)	6 (<1)	3 (<1)
月経遅延	3 (<1)	2 (<1)	1 (<1)	1 (<1)
頻発月経	2 (<1)	2 (<1)	3 (<1)	1 (<1)
閉経後出血	2 (<1)	0	1 (<1)	0
腺筋症	0	0	1 (<1)	0
萎縮性外陰腟炎	0	0	2 (<1)	0
バルトリン嚢腫	2 (<1)	0	0	0
良性前立腺肥大症	1 (<1)	1 (<1)	0	0
乳房嚢胞	1 (<1)	2 (<1)	1 (<1)	1 (<1)
乳房分泌	0	0	1 (<1)	0
乳房不快感	0	1 (<1)	0	0
乳房障害	0	1 (<1)	0	1 (<1)
乳房腫大	0	0	0	1 (<1)
乳房出血	0	1 (<1)	0	0
乳房硬結	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 124 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
バルトリン腺炎	0	0	1 (<1)	0
乳房腫瘤	0	0	1 (<1)	0
乳房痛	0	1 (<1)	1 (<1)	0
月経過多	0	0	1 (<1)	0
月経遅延	0	1 (<1)	1 (<1)	1 (<1)
頻発月経	0	2 (<1)	1 (<1)	1 (<1)
閉経後出血	1 (<1)	0	1 (<1)	0
腺筋症	0	0	0	0
萎縮性外陰腟炎	0	0	0	0
バルトリン嚢腫	0	0	0	0
良性前立腺肥大症	0	0	0	0
乳房嚢胞	0	1 (<1)	0	0
乳房分泌	0	0	0	0
乳房不快感	0	0	0	0
乳房障害	0	0	0	0
乳房腫大	0	0	0	1 (<1)
乳房出血	0	0	0	0
乳房硬結	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 125 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房圧痛	0	0	2 (<1)	0
子宮頚部上皮異形成	1 (<1)	2 (<1)	0	0
子宮頚管ポリープ	0	0	0	1 (<1)
子宮頚部の炎症	0	1 (<1)	0	0
月経困難症	9 (1)	12 (2)	11 (1)	3 (<1)
性交困難	0	0	1 (<1)	0
射精障害	0	1 (<1)	0	0
子宮内膜増殖症	0	1 (<1)	0	0
子宮内膜症	0	1 (<1)	0	0
線維嚢胞性乳腺疾患	3 (<1)	0	1 (<1)	0
乳汁漏出症	0	1 (<1)	0	0
生殖器病変	1 (<1)	0	0	0
機能性子宮出血	1 (<1)	0	0	1 (<1)
閉経期症状	1 (<1)	1 (<1)	1 (<1)	0
不正子宮出血	6 (<1)	8 (1)	7 (<1)	5 (1)
乳頭障害	0	1 (<1)	0	0
希発月経	1 (<1)	1 (<1)	0	0
卵巣嚢胞	5 (<1)	9 (1)	4 (<1)	3 (<1)
卵巣嚢胞破裂	1 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 126 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房圧痛	0	0	0	0
子宮頚部上皮異形成	1 (<1)	0	0	0
子宮頚管ポリープ	0	0	0	0
子宮頚部の炎症	0	0	0	0
月経困難症	2 (<1)	2 (<1)	0	0
性交困難	0	0	0	0
射精障害	0	1 (<1)	0	0
子宮内膜増殖症	0	0	0	0
子宮内膜症	0	0	0	0
線維嚢胞性乳腺疾患	0	0	0	0
乳汁漏出症	0	0	0	0
生殖器病変	1 (<1)	0	0	0
機能性子宮出血	0	0	0	0
閉経期症状	0	0	0	0
不正子宮出血	0	1 (<1)	0	2 (<1)
乳頭障害	0	0	0	0
希発月経	1 (<1)	1 (<1)	0	0
卵巣嚢胞	0	1 (<1)	0	0
卵巣嚢胞破裂	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 127 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨盤痛	4 (<1)	3 (<1)	3 (<1)	0
多嚢胞性卵巣	0	1 (<1)	1 (<1)	0
早発閉経	0	1 (<1)	0	0
前立腺炎	0	1 (<1)	1 (<1)	0
前立腺腫大	0	0	1 (<1)	1 (<1)
性機能不全	2 (<1)	1 (<1)	2 (<1)	0
精巣障害	0	0	1 (<1)	0
精巣痛	3 (<1)	1 (<1)	0	0
子宮頚部びらん	1 (<1)	0	0	0
子宮出血	2 (<1)	1 (<1)	3 (<1)	1 (<1)
子宮の炎症	0	1 (<1)	0	0
子宮ポリープ	1 (<1)	1 (<1)	0	0
子宮腟脱	0	1 (<1)	0	0
腟分泌物	1 (<1)	0	1 (<1)	0
腟出血	3 (<1)	4 (<1)	3 (<1)	0
外陰腟乾燥	0	1 (<1)	1 (<1)	0
外陰腟痛	1 (<1)	0	0	0
外陰腟そう痒症	0	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 128 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨盤痛	1 (<1)	0	0	0
多嚢胞性卵巣	0	0	0	0
早発閉経	0	0	0	0
前立腺炎	0	0	0	0
前立腺腫大	0	0	0	0
性機能不全	0	0	0	0
精巣障害	0	0	0	0
精巣痛	0	0	0	0
子宮頚部びらん	0	0	0	0
子宮出血	0	0	0	0
子宮の炎症	0	0	0	0
子宮ポリープ	0	0	0	0
子宮腟脱	0	0	0	0
腟分泌物	0	0	0	0
腟出血	0	1 (<1)	0	0
外陰腟乾燥	0	0	0	0
外陰腟痛	0	0	0	0
外陰腟そう痒症	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 129 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
先天性、家族性および遺伝性障害	1 (<1)	2 (<1)	4 (<1)	1 (<1)
角膜ジストロフィー	0	0	1 (<1)	0
異形成母斑症候群	0	1 (<1)	1 (<1)	0
ジルベール症候群	1 (<1)	0	0	0
過誤腫	0	0	0	1 (<1)
先天性心臓疾患	0	1 (<1)	0	0
陰嚢水瘤	0	0	1 (<1)	0
ラウン・ギャノン・レバイン症候群	0	0	1 (<1)	0
一般・全身障害および投与部位の状態	194 (25)	178 (23)	215 (28)	133 (38)
疲労	87 (11)	94 (12)	96 (13)	30 (9)
熱感	2 (<1)	15 (2)	12 (2)	4 (1)
発熱	40 (5)	27 (4)	44 (6)	17 (5)
無力症	20 (3)	24 (3)	17 (2)	15 (4)
インフルエンザ様疾患	11 (1)	10 (1)	15 (2)	3 (<1)
胸痛	10 (1)	9 (1)	14 (2)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 130 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
先天性、家族性および遺伝性障害	0	0	0	0
角膜ジストロフィー	0	0	0	0
異形成母斑症候群	0	0	0	0
ジルベール症候群	0	0	0	0
過誤腫	0	0	0	0
先天性心臓疾患	0	0	0	0
陰嚢水瘤	0	0	0	0
ラウン・ギャノン・レバイン症候群	0	0	0	0
一般・全身障害および投与部位の状態	37 (5)	54 (7)	58 (8)	98 (28)
疲労	17 (2)	26 (3)	23 (3)	6 (2)
熱感	2 (<1)	10 (1)	11 (1)	4 (1)
発熱	3 (<1)	2 (<1)	6 (<1)	6 (2)
無力症	3 (<1)	9 (1)	4 (<1)	5 (1)
インフルエンザ様疾患	4 (<1)	1 (<1)	4 (<1)	2 (<1)
胸痛	0	1 (<1)	3 (<1)	3 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 131 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
倦怠感	1 (<1)	2 (<1)	5 (<1)	2 (<1)
胸部不快感	5 (<1)	4 (<1)	4 (<1)	1 (<1)
悪寒	7 (<1)	4 (<1)	4 (<1)	4 (1)
不快感	0	0	1 (<1)	0
顔面痛	3 (<1)	2 (<1)	4 (<1)	2 (<1)
冷感	1 (<1)	0	2 (<1)	0
びくびく感	0	0	1 (<1)	0
歩行障害	10 (1)	8 (1)	11 (1)	6 (2)
重力性浮腫	0	0	1 (<1)	0
易刺激性	5 (<1)	4 (<1)	3 (<1)	2 (<1)
粘膜乾燥	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	0
疼痛	11 (1)	15 (2)	15 (2)	5 (1)
圧痛	0	0	3 (<1)	0
口渇	1 (<1)	0	1 (<1)	0
適用部位浮腫	0	0	0	1 (<1)
腋窩痛	0	0	1 (<1)	0
嚢胞	1 (<1)	0	4 (<1)	0
嚢胞破裂	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 132 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
倦怠感	0	1 (<1)	3 (<1)	0
胸部不快感	1 (<1)	2 (<1)	2 (<1)	0
悪寒	1 (<1)	1 (<1)	2 (<1)	2 (<1)
不快感	0	0	1 (<1)	0
顔面痛	0	0	1 (<1)	0
冷感	0	0	1 (<1)	0
びくびく感	0	0	1 (<1)	0
歩行障害	1 (<1)	1 (<1)	1 (<1)	0
重力性浮腫	0	0	1 (<1)	0
易刺激性	1 (<1)	0	1 (<1)	1 (<1)
粘膜乾燥	0	1 (<1)	1 (<1)	0
粘膜の炎症	0	0	1 (<1)	0
疼痛	0	1 (<1)	1 (<1)	3 (<1)
圧痛	0	0	1 (<1)	0
口渇	1 (<1)	0	1 (<1)	0
適用部位浮腫	0	0	0	1 (<1)
腋窩痛	0	0	0	0
嚢胞	0	0	0	0
嚢胞破裂	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 133 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
医療機器不具合	0	1 (<1)	0	0
医療機器関連眼合併症	1 (<1)	1 (<1)	0	0
脂肪壊死	0	1 (<1)	0	0
異常感	1 (<1)	0	1 (<1)	1 (<1)
体温変動感	1 (<1)	0	0	0
全身症状	1 (<1)	0	0	0
全身性浮腫	0	1 (<1)	0	0
閉塞性ヘルニア	0	0	1 (<1)	0
ヘルニア痛	1 (<1)	0	0	0
空腹	1 (<1)	0	0	0
高熱	1 (<1)	2 (<1)	1 (<1)	0
注射直後反応	0	0	0	4 (1)
炎症	0	0	2 (<1)	0
注入部位血腫	0	1 (<1)	0	0
注射部位変色	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 134 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
医療機器不具合	0	0	0	0
医療機器関連眼合併症	0	0	0	0
脂肪壊死	0	0	0	0
異常感	1 (<1)	0	0	0
体温変動感	0	0	0	0
全身症状	0	0	0	0
全身性浮腫	0	0	0	0
閉塞性ヘルニア	0	0	0	0
ヘルニア痛	1 (<1)	0	0	0
空腹	1 (<1)	0	0	0
高熱	0	2 (<1)	0	0
注射直後反応	0	0	0	4 (1)
炎症	0	0	0	0
注入部位血腫	0	0	0	0
注射部位変色	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 135 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位乾燥	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	1 (<1)
注射部位紅斑	0	0	0	31 (9)
注射部位血管外漏出	0	0	0	1 (<1)
注射部位血腫	0	0	1 (<1)	5 (1)
注射部位出血	0	0	0	2 (<1)
注射部位過敏反応	0	0	0	1 (<1)
注射部位肥厚	0	0	0	3 (<1)
注射部位硬結	0	0	1 (<1)	7 (2)
注射部位炎症	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	7 (2)
注射部位結節	0	0	0	1 (<1)
注射部位浮腫	0	0	0	3 (<1)
注射部位疼痛	0	0	0	29 (8)
注射部位そう痒感	0	0	0	13 (4)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 136 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位乾燥	0	0	0	1 (<1)
注射部位知覚不全	0	0	0	1 (<1)
注射部位紅斑	0	0	0	30 (9)
注射部位血管外漏出	0	0	0	1 (<1)
注射部位血腫	0	0	0	5 (1)
注射部位出血	0	0	0	2 (<1)
注射部位過敏反応	0	0	0	1 (<1)
注射部位肥厚	0	0	0	3 (<1)
注射部位硬結	0	0	0	7 (2)
注射部位炎症	0	0	0	1 (<1)
注射部位腫瘤	0	0	0	6 (2)
注射部位結節	0	0	0	1 (<1)
注射部位浮腫	0	0	0	3 (<1)
注射部位疼痛	0	0	0	27 (8)
注射部位そう痒感	0	0	0	13 (4)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 137 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位発疹	0	0	0	3 (<1)
注射部位反応	0	0	0	5 (1)
注射部位瘢痕	0	0	0	1 (<1)
注射部位腫脹	0	0	0	10 (3)
注射部位蕁麻疹	0	0	0	3 (<1)
注射部位熱感	0	0	0	3 (<1)
局所腫脹	0	1 (<1)	0	0
足のもつれ	1 (<1)	1 (<1)	0	0
腫瘤	0	1 (<1)	0	0
医療機器による疼痛	0	0	2 (<1)	0
微石症	0	0	0	1 (<1)
壊死	0	0	0	1 (<1)
非心臓性胸痛	2 (<1)	3 (<1)	7 (<1)	3 (<1)
浮腫	1 (<1)	2 (<1)	1 (<1)	1 (<1)
末梢性浮腫	19 (2)	7 (<1)	16 (2)	4 (1)
骨盤腔内腫瘤	1 (<1)	0	0	0
不活発	0	0	1 (<1)	0
軟部組織の炎症	0	1 (<1)	0	0
腫脹	0	2 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 138 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
注射部位発疹	0	0	0	3 (<1)
注射部位反応	0	0	0	5 (1)
注射部位瘢痕	0	0	0	1 (<1)
注射部位腫脹	0	0	0	10 (3)
注射部位蕁麻疹	0	0	0	3 (<1)
注射部位熱感	0	0	0	3 (<1)
局所腫脹	0	0	0	0
足のもつれ	0	0	0	0
腫瘤	0	0	0	0
医療機器による疼痛	0	0	0	0
微石症	0	0	0	0
壊死	0	0	0	1 (<1)
非心臓性胸痛	0	0	0	2 (<1)
浮腫	0	0	0	1 (<1)
末梢性浮腫	5 (<1)	3 (<1)	0	1 (<1)
骨盤腔内腫瘤	0	0	0	0
不活発	0	0	0	0
軟部組織の炎症	0	0	0	0
腫脹	0	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 139 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
温度変化不耐症	0	1 (<1)	0	0
ワクチン接種部位疼痛	1 (<1)	0	0	0
血管穿刺部位血腫	0	0	1 (<1)	0
血管穿刺部位出血	0	1 (<1)	0	0
血管穿刺部位疼痛	0	1 (<1)	0	0
血管穿刺部位反応	0	1 (<1)	0	0
臨床検査	199 (26)	212 (28)	216 (28)	106 (30)
アラニン・アミノトランスフェラーゼ増加	38 (5)	45 (6)	49 (6)	20 (6)
尿中アルブミン陽性	27 (4)	46 (6)	36 (5)	18 (5)
アスパラギン酸アミノトランスフェラーゼ増加	18 (2)	33 (4)	29 (4)	14 (4)
尿中蛋白陽性	22 (3)	28 (4)	20 (3)	15 (4)
白血球数減少	1 (<1)	13 (2)	12 (2)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 140 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
温度変化不耐症	0	0	0	0
ワクチン接種部位疼痛	0	0	0	0
血管穿刺部位血腫	0	0	0	0
血管穿刺部位出血	0	0	0	0
血管穿刺部位疼痛	0	0	0	0
血管穿刺部位反応	0	0	0	0
臨床検査	87 (11)	101 (13)	124 (16)	31 (9)
アラニン・アミノトランスフェラーゼ増加	25 (3)	28 (4)	34 (4)	10 (3)
尿中アルブミン陽性	12 (2)	17 (2)	19 (3)	5 (1)
アスパラギン酸アミノトランスフェラーゼ増加	9 (1)	18 (2)	18 (2)	9 (3)
尿中蛋白陽性	12 (2)	9 (1)	12 (2)	2 (<1)
白血球数減少	0	7 (<1)	10 (1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 141 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
γ－グルタミルトランスフェラーゼ増加	19 (2)	20 (3)	12 (2)	8 (2)
尿中β２ミクログロブリン増加	14 (2)	12 (2)	15 (2)	5 (1)
血中副甲状腺ホルモン増加	6 (<1)	15 (2)	17 (2)	2 (<1)
尿中血陽性	7 (<1)	16 (2)	18 (2)	4 (1)
リンパ球数減少	1 (<1)	8 (1)	8 (1)	1 (<1)
尿中ケトン体陽性	2 (<1)	7 (<1)	10 (1)	2 (<1)
肝酵素上昇	10 (1)	7 (<1)	7 (<1)	7 (2)
β２ミクログロブリン増加	2 (<1)	4 (<1)	7 (<1)	0
体重減少	3 (<1)	11 (1)	10 (1)	3 (<1)
体重増加	11 (1)	5 (<1)	11 (1)	4 (1)
血中クレアチニン増加	5 (<1)	6 (<1)	5 (<1)	6 (2)
体温上昇	1 (<1)	2 (<1)	3 (<1)	1 (<1)
肝機能検査異常	2 (<1)	3 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 142 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
γ－グルタミルトランスフェラーゼ増加	7 (<1)	12 (2)	9 (1)	3 (<1)
尿中β２ミクログロブリン増加	5 (<1)	4 (<1)	8 (1)	1 (<1)
血中副甲状腺ホルモン増加	3 (<1)	4 (<1)	7 (<1)	0
尿中血陽性	2 (<1)	5 (<1)	7 (<1)	0
リンパ球数減少	0	5 (<1)	6 (<1)	1 (<1)
尿中ケトン体陽性	0	2 (<1)	6 (<1)	1 (<1)
肝酵素上昇	6 (<1)	4 (<1)	5 (<1)	3 (<1)
β２ミクログロブリン増加	2 (<1)	3 (<1)	4 (<1)	0
体重減少	1 (<1)	6 (<1)	4 (<1)	1 (<1)
体重増加	3 (<1)	1 (<1)	4 (<1)	1 (<1)
血中クレアチニン増加	1 (<1)	2 (<1)	3 (<1)	1 (<1)
体温上昇	0	1 (<1)	3 (<1)	0
肝機能検査異常	2 (<1)	3 (<1)	3 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 143 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中コレステロール増加	2 (<1)	2 (<1)	4 (<1)	1 (<1)
血中ブドウ糖増加	7 (<1)	10 (1)	18 (2)	7 (2)
血圧上昇	1 (<1)	2 (<1)	2 (<1)	1 (<1)
血中尿素増加	2 (<1)	0	4 (<1)	1 (<1)
血液学的検査異常	1 (<1)	2 (<1)	2 (<1)	0
ヘモグロビン減少	5 (<1)	8 (1)	6 (<1)	1 (<1)
リンパ球形態異常	1 (<1)	2 (<1)	2 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	0
血中ビリルビン増加	9 (1)	2 (<1)	3 (<1)	1 (<1)
血中クレアチン増加	0	2 (<1)	1 (<1)	0
血中ブドウ糖減少	1 (<1)	0	1 (<1)	1 (<1)
血中副甲状腺ホルモン異常	0	0	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	0
尿中結晶陽性	6 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 144 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中コレステロール増加	0	0	2 (<1)	0
血中ブドウ糖増加	2 (<1)	1 (<1)	2 (<1)	0
血圧上昇	0	0	2 (<1)	0
血中尿素増加	1 (<1)	0	2 (<1)	0
血液学的検査異常	1 (<1)	1 (<1)	2 (<1)	0
ヘモグロビン減少	0	1 (<1)	2 (<1)	0
リンパ球形態異常	1 (<1)	1 (<1)	2 (<1)	0
抗痙攣剤濃度減少	0	0	1 (<1)	0
血中ビリルビン増加	4 (<1)	1 (<1)	1 (<1)	1 (<1)
血中クレアチン増加	0	2 (<1)	1 (<1)	0
血中ブドウ糖減少	1 (<1)	0	1 (<1)	0
血中副甲状腺ホルモン異常	0	0	1 (<1)	0
血中ナトリウム減少	0	0	1 (<1)	0
尿中結晶陽性	1 (<1)	1 (<1)	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 145 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
白血球百分率数異常	0	0	1 (<1)	0
心電図ＱＴ延長	7 (<1)	1 (<1)	5 (<1)	5 (1)
好酸球数異常	1 (<1)	0	1 (<1)	0
尿中ブドウ糖陽性	3 (<1)	3 (<1)	3 (<1)	3 (<1)
ヘマトクリット減少	4 (<1)	6 (<1)	3 (<1)	1 (<1)
高比重リポ蛋白増加	1 (<1)	0	3 (<1)	0
低比重リポ蛋白増加	0	1 (<1)	3 (<1)	1 (<1)
尿中赤血球陽性	6 (<1)	8 (1)	5 (<1)	2 (<1)
呼吸数増加	0	0	1 (<1)	0
尿円柱	0	0	1 (<1)	0
尿中白血球陽性	13 (2)	14 (2)	15 (2)	9 (3)
アラニン・アミノトランスフェラーゼ異常	0	1 (<1)	1 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 146 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
白血球百分率数異常	0	0	1 (<1)	0
心電図ＱＴ延長	4 (<1)	1 (<1)	1 (<1)	3 (<1)
好酸球数異常	0	0	1 (<1)	0
尿中ブドウ糖陽性	1 (<1)	1 (<1)	1 (<1)	0
ヘマトクリット減少	1 (<1)	1 (<1)	1 (<1)	0
高比重リポ蛋白増加	1 (<1)	0	1 (<1)	0
低比重リポ蛋白増加	0	0	1 (<1)	0
尿中赤血球陽性	1 (<1)	3 (<1)	1 (<1)	0
呼吸数増加	0	0	1 (<1)	0
尿円柱	0	0	1 (<1)	0
尿中白血球陽性	0	2 (<1)	1 (<1)	0
アラニン・アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 147 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
アレルギー検査	0	0	1 (<1)	0
抗ＳＳＡ抗体陽性	0	1 (<1)	0	0
抗甲状腺抗体陽性	1 (<1)	0	0	0
抗核抗体増加	1 (<1)	0	0	0
動脈雑音	1 (<1)	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	1 (<1)	0	1 (<1)
細菌検査	2 (<1)	0	0	0
細菌検査陽性	2 (<1)	0	2 (<1)	2 (<1)
血中アルカリホスファターゼ異常	0	1 (<1)	0	1 (<1)
血中アルカリホスファターゼ増加	7 (<1)	4 (<1)	2 (<1)	1 (<1)
血中重炭酸塩減少	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 148 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
アレルギー検査	0	0	0	0
抗ＳＳＡ抗体陽性	0	0	0	0
抗甲状腺抗体陽性	1 (<1)	0	0	0
抗核抗体増加	0	0	0	0
動脈雑音	0	0	0	0
アスパラギン酸アミノトランスフェラーゼ異常	0	1 (<1)	0	0
細菌検査	0	0	0	0
細菌検査陽性	1 (<1)	0	0	0
血中アルカリホスファターゼ異常	0	1 (<1)	0	1 (<1)
血中アルカリホスファターゼ増加	2 (<1)	2 (<1)	0	0
血中重炭酸塩減少	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 149 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中重炭酸塩増加	0	1 (<1)	0	0
血中ビリルビン異常	0	0	0	1 (<1)
血中ビリルビン減少	1 (<1)	0	0	0
血中カルシウム減少	1 (<1)	1 (<1)	0	1 (<1)
血中カルシウム増加	2 (<1)	0	1 (<1)	1 (<1)
血中クロール減少	1 (<1)	0	0	0
血中クロール増加	0	0	2 (<1)	0
血中クレアチン異常	1 (<1)	0	0	0
血中クレアチニン異常	0	1 (<1)	0	0
血中葉酸減少	0	1 (<1)	1 (<1)	0
血中免疫グロブリンM増加	0	0	1 (<1)	0
血中鉄減少	1 (<1)	1 (<1)	0	0
血中ケトン体増加	0	1 (<1)	1 (<1)	1 (<1)
血中乳酸脱水素酵素異常	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 150 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中重炭酸塩増加	0	1 (<1)	0	0
血中ビリルビン異常	0	0	0	0
血中ビリルビン減少	0	0	0	0
血中カルシウム減少	0	0	0	0
血中カルシウム増加	1 (<1)	0	0	0
血中クロール減少	0	0	0	0
血中クロール増加	0	0	0	0
血中クレアチン異常	0	0	0	0
血中クレアチニン異常	0	0	0	0
血中葉酸減少	0	0	0	0
血中免疫グロブリンM増加	0	0	0	0
血中鉄減少	0	0	0	0
血中ケトン体増加	0	0	0	0
血中乳酸脱水素酵素異常	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 151 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中乳酸脱水素酵素増加	4 (<1)	5 (<1)	0	0
血中副甲状腺ホルモン減少	1 (<1)	0	0	0
血中リン減少	1 (<1)	0	0	0
血中リン増加	1 (<1)	0	0	0
血中カリウム減少	2 (<1)	0	1 (<1)	0
血中カリウム増加	0	4 (<1)	3 (<1)	1 (<1)
血圧低下	1 (<1)	1 (<1)	0	0
拡張期血圧上昇	0	0	1 (<1)	0
収縮期血圧上昇	1 (<1)	0	0	0
血中ナトリウム増加	0	1 (<1)	2 (<1)	2 (<1)
血中甲状腺刺激ホルモン増加	0	0	1 (<1)	0
血中トリグリセリド増加	5 (<1)	6 (<1)	3 (<1)	6 (2)
血中尿酸増加	2 (<1)	0	2 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 152 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
血中乳酸脱水素酵素増加	1 (<1)	4 (<1)	0	0
血中副甲状腺ホルモン減少	0	0	0	0
血中リン減少	1 (<1)	0	0	0
血中リン増加	0	0	0	0
血中カリウム減少	0	0	0	0
血中カリウム増加	0	0	0	0
血圧低下	0	0	0	0
拡張期血圧上昇	0	0	0	0
収縮期血圧上昇	0	0	0	0
血中ナトリウム増加	0	0	0	0
血中甲状腺刺激ホルモン増加	0	0	0	0
血中トリグリセリド増加	1 (<1)	0	0	0
血中尿酸増加	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 153 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
体温低下	0	1 (<1)	0	0
呼吸音異常	0	1 (<1)	0	0
心雑音	2 (<1)	1 (<1)	0	0
中枢神経系機能検査異常	1 (<1)	0	0	0
結腸内視鏡検査	0	1 (<1)	0	0
心筋虚血の心電図所見	0	1 (<1)	0	0
心電図異常	4 (<1)	0	3 (<1)	0
心電図ＰＲ延長	1 (<1)	0	0	0
心電図異常ＱＲＳ群	1 (<1)	0	0	0
心電図ＱＲＳ群延長	1 (<1)	0	0	0
心電図ＳＴ部分下降	1 (<1)	2 (<1)	1 (<1)	2 (<1)
心電図Ｔ波振幅減少	1 (<1)	0	1 (<1)	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 154 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
体温低下	0	0	0	0
呼吸音異常	0	0	0	0
心雑音	0	0	0	0
中枢神経系機能検査異常	1 (<1)	0	0	0
結腸内視鏡検査	0	0	0	0
心筋虚血の心電図所見	0	1 (<1)	0	0
心電図異常	0	0	0	0
心電図ＰＲ延長	1 (<1)	0	0	0
心電図異常ＱＲＳ群	0	0	0	0
心電図ＱＲＳ群延長	0	0	0	0
心電図ＳＴ部分下降	0	0	0	0
心電図Ｔ波振幅減少	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 155 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心電図２相性Ｔ波	0	0	0	1 (<1)
心電図Ｔ波逆転	1 (<1)	1 (<1)	0	2 (<1)
好酸球数増加	2 (<1)	2 (<1)	2 (<1)	0
好酸球百分率増加	0	1 (<1)	0	0
エプスタイン・バーウイルス抗体陽性	0	0	1 (<1)	0
大腸菌検査陽性	0	1 (<1)	0	0
全血球数異常	1 (<1)	0	0	0
γ－グルタミルトランスフェラーゼ異常	1 (<1)	1 (<1)	1 (<1)	0
γ－グルタミルトランスフェラーゼ減少	0	1 (<1)	0	0
胃内ｐＨ上昇	0	0	1 (<1)	0
握力低下	0	0	0	2 (<1)
心拍数減少	0	0	1 (<1)	0
心拍数増加	2 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 156 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心電図２相性Ｔ波	0	0	0	0
心電図Ｔ波逆転	0	0	0	1 (<1)
好酸球数増加	2 (<1)	1 (<1)	0	0
好酸球百分率増加	0	1 (<1)	0	0
エプスタイン・バーウイルス抗体陽性	0	0	0	0
大腸菌検査陽性	0	0	0	0
全血球数異常	0	0	0	0
γ－グルタミルトランスフェラーゼ異常	0	1 (<1)	0	0
γ－グルタミルトランスフェラーゼ減少	0	0	0	0
胃内ｐＨ上昇	0	0	0	0
握力低下	0	0	0	0
心拍数減少	0	0	0	0
心拍数増加	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 157 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心音異常	1 (<1)	0	0	0
ヒト乳頭腫ウイルス検査陽性	0	1 (<1)	0	0
ヒステロスコピー	0	1 (<1)	0	0
A型インフルエンザウイルス検査陽性	1 (<1)	0	0	0
眼圧上昇	0	1 (<1)	0	0
検査	0	0	1 (<1)	0
リンパ節触知	0	0	1 (<1)	0
リンパ球数異常	0	0	0	1 (<1)
リンパ球数増加	2 (<1)	2 (<1)	1 (<1)	0
リンパ球百分率減少	1 (<1)	1 (<1)	0	0
医学的観察	0	0	1 (<1)	0
後骨髄球百分率増加	1 (<1)	0	0	0
単球数減少	0	0	1 (<1)	1 (<1)
単球数増加	0	0	1 (<1)	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 158 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
心音異常	1 (<1)	0	0	0
ヒト乳頭腫ウイルス検査陽性	0	0	0	0
ヒステロスコピー	0	0	0	0
A型インフルエンザウイルス検査陽性	0	0	0	0
眼圧上昇	0	0	0	0
検査	0	0	0	0
リンパ節触知	0	0	0	0
リンパ球数異常	0	0	0	0
リンパ球数増加	0	1 (<1)	0	0
リンパ球百分率減少	0	1 (<1)	0	0
医学的観察	0	0	0	0
後骨髄球百分率増加	0	0	0	0
単球数減少	0	0	0	0
単球数増加	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 159 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨髄球数増加	1 (<1)	0	0	0
骨髄球百分率増加	1 (<1)	0	0	0
神経学的検査異常	0	1 (<1)	0	0
好中球数異常	0	0	0	1 (<1)
好中球数減少	2 (<1)	6 (<1)	1 (<1)	1 (<1)
好中球数増加	12 (2)	7 (<1)	6 (<1)	2 (<1)
好中球百分率異常	1 (<1)	0	0	0
好中球百分率増加	1 (<1)	1 (<1)	0	0
脳核磁気共鳴画像異常	1 (<1)	1 (<1)	0	0
便潜血陽性	0	0	0	1 (<1)
血小板数	0	1 (<1)	0	0
血小板数減少	2 (<1)	4 (<1)	0	3 (<1)
血小板数増加	3 (<1)	1 (<1)	1 (<1)	1 (<1)
ロンベルグ徴候陽性	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 160 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
骨髄球数増加	0	0	0	0
骨髄球百分率増加	0	0	0	0
神経学的検査異常	0	0	0	0
好中球数異常	0	0	0	0
好中球数減少	0	3 (<1)	0	1 (<1)
好中球数増加	1 (<1)	4 (<1)	0	0
好中球百分率異常	0	0	0	0
好中球百分率増加	0	1 (<1)	0	0
脳核磁気共鳴画像異常	1 (<1)	0	0	0
便潜血陽性	0	0	0	0
血小板数	0	1 (<1)	0	0
血小板数減少	0	2 (<1)	0	0
血小板数増加	0	0	0	0
ロンベルグ徴候陽性	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 161 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ＱＲＳ軸異常	2 (<1)	0	0	0
赤血球数減少	3 (<1)	4 (<1)	2 (<1)	0
赤血球数増加	1 (<1)	1 (<1)	1 (<1)	0
腎機能検査異常	0	1 (<1)	0	0
残尿量増加	0	1 (<1)	0	0
血清フェリチン減少	0	0	1 (<1)	0
子宮頚部スミア異常	1 (<1)	0	1 (<1)	0
つぎ足歩行検査異常	0	1 (<1)	0	0
トランスアミナーゼ上昇	2 (<1)	0	0	1 (<1)
膀胱超音波検査異常	1 (<1)	0	0	0
尿細胞診異常	1 (<1)	0	0	0
前庭機能検査異常	0	0	0	1 (<1)
ビタミンＢ１２減少	2 (<1)	2 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 162 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ＱＲＳ軸異常	0	0	0	0
赤血球数減少	1 (<1)	2 (<1)	0	0
赤血球数増加	0	0	0	0
腎機能検査異常	0	1 (<1)	0	0
残尿量増加	0	0	0	0
血清フェリチン減少	0	0	0	0
子宮頚部スミア異常	0	0	0	0
つぎ足歩行検査異常	0	0	0	0
トランスアミナーゼ上昇	0	0	0	1 (<1)
膀胱超音波検査異常	1 (<1)	0	0	0
尿細胞診異常	0	0	0	0
前庭機能検査異常	0	0	0	0
ビタミンＢ１２減少	0	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 163 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ビタミンD減少	2 (<1)	5 (<1)	2 (<1)	1 (<1)
ビタミンD増加	2 (<1)	0	4 (<1)	0
白血球数異常	0	0	0	1 (<1)
白血球数増加	14 (2)	8 (1)	6 (<1)	5 (1)
傷害、中毒および処置合併症	140 (18)	103 (13)	119 (16)	41 (12)
サンバーン	4 (<1)	2 (<1)	3 (<1)	1 (<1)
労働災害	1 (<1)	0	0	0
偶発的過量投与	0	1 (<1)	0	0
アルコール中毒	0	0	1 (<1)	0
動物咬傷	2 (<1)	2 (<1)	0	1 (<1)
動物による引っかき傷	0	0	0	1 (<1)
足関節部骨折	0	2 (<1)	3 (<1)	1 (<1)
節足動物咬傷	9 (1)	4 (<1)	7 (<1)	2 (<1)
節足動物刺傷	3 (<1)	2 (<1)	2 (<1)	0
気圧性中耳炎	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 164 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
ビタミンD減少	0	0	0	0
ビタミンD増加	0	0	0	0
白血球数異常	0	0	0	0
白血球数増加	2 (<1)	2 (<1)	0	0
傷害、中毒および処置合併症	4 (<1)	1 (<1)	1 (<1)	0
サンバーン	0	0	1 (<1)	0
労働災害	0	0	0	0
偶発的過量投与	0	1 (<1)	0	0
アルコール中毒	0	0	0	0
動物咬傷	0	0	0	0
動物による引っかき傷	0	0	0	0
足関節部骨折	0	0	0	0
節足動物咬傷	0	0	0	0
節足動物刺傷	0	0	0	0
気圧性中耳炎	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 165 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
第２度熱傷	1 (<1)	0	0	0
眼部化学的損傷	1 (<1)	0	0	0
凍瘡	1 (<1)	1 (<1)	0	0
鎖骨骨折	0	1 (<1)	1 (<1)	0
脳振盪	1 (<1)	2 (<1)	0	2 (<1)
造影剤反応	0	0	1 (<1)	0
挫傷	19 (2)	21 (3)	25 (3)	5 (1)
角膜擦過傷	1 (<1)	0	0	0
上顆炎	2 (<1)	1 (<1)	2 (<1)	1 (<1)
擦過傷	4 (<1)	2 (<1)	6 (<1)	2 (<1)
眼外傷	3 (<1)	1 (<1)	1 (<1)	1 (<1)
眼瞼損傷	0	1 (<1)	0	0
顔面損傷	0	1 (<1)	1 (<1)	1 (<1)
顔面骨骨折	0	1 (<1)	0	0
転倒	22 (3)	22 (3)	22 (3)	14 (4)
大腿骨頚部骨折	1 (<1)	0	0	0
大腿骨骨折	0	1 (<1)	1 (<1)	1 (<1)
腓骨骨折	1 (<1)	0	0	0
足骨折	4 (<1)	7 (<1)	6 (<1)	2 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 166 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
第２度熱傷	0	0	0	0
眼部化学的損傷	0	0	0	0
凍瘡	0	0	0	0
鎖骨骨折	0	0	0	0
脳振盪	0	0	0	0
造影剤反応	0	0	0	0
挫傷	2 (<1)	0	0	0
角膜擦過傷	0	0	0	0
上顆炎	0	0	0	0
擦過傷	0	0	0	0
眼外傷	0	0	0	0
眼瞼損傷	0	0	0	0
顔面損傷	0	0	0	0
顔面骨骨折	0	0	0	0
転倒	1 (<1)	0	0	0
大腿骨頚部骨折	0	0	0	0
大腿骨骨折	0	0	0	0
腓骨骨折	0	0	0	0
足骨折	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 167 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
前腕骨折	0	0	0	1 (<1)
眼内異物	1 (<1)	0	0	0
尾骨骨折	1 (<1)	0	1 (<1)	0
手骨折	2 (<1)	1 (<1)	0	4 (1)
頭部損傷	3 (<1)	1 (<1)	0	1 (<1)
腸脛靭帯症候群	0	0	1 (<1)	0
切開部位痛	0	1 (<1)	0	0
瘢痕ヘルニア	1 (<1)	1 (<1)	0	0
閉塞性瘢痕ヘルニア	0	0	1 (<1)	0
損傷	0	0	2 (<1)	1 (<1)
関節脱臼	1 (<1)	3 (<1)	0	0
関節損傷	6 (<1)	1 (<1)	2 (<1)	0
関節捻挫	16 (2)	13 (2)	13 (2)	3 (<1)
靭帯損傷	1 (<1)	0	1 (<1)	0
靭帯断裂	4 (<1)	1 (<1)	4 (<1)	0
靭帯捻挫	0	0	1 (<1)	0
四肢損傷	5 (<1)	5 (<1)	6 (<1)	3 (<1)
口唇損傷	0	0	0	1 (<1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 168 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
前腕骨折	0	0	0	0
眼内異物	0	0	0	0
尾骨骨折	0	0	0	0
手骨折	0	0	0	0
頭部損傷	0	0	0	0
腸脛靱帯症候群	0	0	0	0
切開部位痛	0	0	0	0
瘢痕ヘルニア	0	0	0	0
閉塞性瘢痕ヘルニア	0	0	0	0
損傷	0	0	0	0
関節脱臼	0	0	0	0
関節損傷	0	0	0	0
関節捻挫	0	0	0	0
靱帯損傷	0	0	0	0
靱帯断裂	0	0	0	0
靱帯捻挫	0	0	0	0
四肢損傷	0	0	0	0
口唇損傷	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 169 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
下肢骨折	0	0	1 (<1)	0
半月板障害	3 (<1)	4 (<1)	3 (<1)	1 (<1)
筋損傷	2 (<1)	0	0	0
筋断裂	0	2 (<1)	0	0
肉離れ	5 (<1)	5 (<1)	8 (1)	1 (<1)
頚部損傷	0	1 (<1)	1 (<1)	1 (<1)
神経損傷	0	0	1 (<1)	0
過量投与	0	1 (<1)	0	0
処置後合併症	2 (<1)	0	0	1 (<1)
処置後出血	1 (<1)	1 (<1)	0	0
処置後浮腫	0	0	1 (<1)	0
外傷後疼痛	2 (<1)	0	0	2 (<1)
術後発熱	0	2 (<1)	0	0
術後創合併症	0	0	0	1 (<1)
処置による低血圧	0	1 (<1)	0	0
処置による悪心	1 (<1)	1 (<1)	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 170 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
下肢骨折	0	0	0	0
半月板障害	0	0	0	0
筋損傷	0	0	0	0
筋断裂	0	0	0	0
肉離れ	0	0	0	0
頚部損傷	0	0	0	0
神経損傷	0	0	0	0
過量投与	0	0	0	0
処置後合併症	0	0	0	0
処置後出血	0	0	0	0
処置後浮腫	0	0	0	0
外傷後疼痛	0	0	0	0
術後発熱	0	0	0	0
術後創合併症	0	0	0	0
処置による低血圧	0	0	0	0
処置による悪心	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 171 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
処置による疼痛	3 (<1)	4 (<1)	6 (<1)	2 (<1)
処置による嘔吐	0	1 (<1)	0	0
放射線皮膚損傷	0	0	1 (<1)	0
橈骨骨折	1 (<1)	1 (<1)	2 (<1)	2 (<1)
反復性挫傷	1 (<1)	1 (<1)	0	0
網膜損傷	1 (<1)	1 (<1)	0	0
肋骨骨折	0	0	1 (<1)	0
交通事故	5 (<1)	3 (<1)	5 (<1)	3 (<1)
引っかき傷	0	0	1 (<1)	0
骨格損傷	6 (<1)	2 (<1)	2 (<1)	1 (<1)
皮膚裂傷	7 (<1)	5 (<1)	3 (<1)	1 (<1)
軟部組織損傷	0	1 (<1)	0	0
脊椎圧迫骨折	0	2 (<1)	0	0
ストレス骨折	0	0	0	1 (<1)
滑膜断裂	0	0	1 (<1)	0
腱損傷	1 (<1)	0	0	0
腱断裂	3 (<1)	0	0	1 (<1)
治療薬毒性	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 172 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
処置による疼痛	0	0	0	0
処置による嘔吐	0	0	0	0
放射線皮膚損傷	0	0	0	0
橈骨骨折	0	0	0	0
反復性挫傷	1 (<1)	0	0	0
網膜損傷	0	0	0	0
肋骨骨折	0	0	0	0
交通事故	0	0	0	0
引っかき傷	0	0	0	0
骨格損傷	0	0	0	0
皮膚裂傷	0	0	0	0
軟部組織損傷	0	0	0	0
脊椎圧迫骨折	0	0	0	0
ストレス骨折	0	0	0	0
滑膜断裂	0	0	0	0
腱損傷	0	0	0	0
腱断裂	0	0	0	0
治療薬毒性	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 173 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
熱傷	8 (1)	2 (<1)	4 (<1)	1 (<1)
脛骨骨折	2 (<1)	0	0	0
舌損傷	0	1 (<1)	0	0
歯の完全脱臼	1 (<1)	0	0	0
歯牙破折	2 (<1)	3 (<1)	2 (<1)	0
外傷性脳損傷	0	1 (<1)	0	0
外傷性骨折	0	0	1 (<1)	0
外傷性血腫	0	3 (<1)	1 (<1)	1 (<1)
上肢骨折	1 (<1)	0	1 (<1)	1 (<1)
ワクチン接種合併症	1 (<1)	0	1 (<1)	0
有毒性刺傷	2 (<1)	0	0	0
第７神経損傷	0	0	0	1 (<1)
むち打ち損傷	2 (<1)	4 (<1)	0	3 (<1)
創傷	3 (<1)	2 (<1)	1 (<1)	0
創し開	0	0	1 (<1)	0
創傷出血	1 (<1)	0	0	0
手首関節骨折	2 (<1)	0	2 (<1)	0
外科および内科処置	7 (<1)	9 (1)	4 (<1)	4 (1)

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 174 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
熱傷	0	0	0	0
脛骨骨折	0	0	0	0
舌損傷	0	0	0	0
歯の完全脱臼	0	0	0	0
歯牙破折	0	0	0	0
外傷性脳損傷	0	0	0	0
外傷性骨折	0	0	0	0
外傷性血腫	0	0	0	0
上肢骨折	0	0	0	0
ワクチン接種合併症	0	0	0	0
有毒性刺傷	0	0	0	0
第７神経損傷	0	0	0	0
むち打ち損傷	0	0	0	0
創傷	0	0	0	0
創し開	0	0	0	0
創傷出血	0	0	0	0
手首関節骨折	0	0	0	0
外科および内科処置	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 175 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房腫瘤摘除	0	1 (<1)	0	0
子宮頚部円錐切除	1 (<1)	0	0	0
嚢胞ドレナージ	1 (<1)	0	0	0
デンタルケア	0	0	1 (<1)	0
女性不妊手術	0	1 (<1)	0	0
ヘルニア修復	0	1 (<1)	0	0
入院	0	0	0	1 (<1)
子宮摘出	0	1 (<1)	1 (<1)	0
椎間板手術	0	0	1 (<1)	0
治療食	0	1 (<1)	0	0
色素性母斑切除	1 (<1)	0	0	0
不妊手術	0	0	0	1 (<1)
抜歯	3 (<1)	4 (<1)	0	2 (<1)
鼻甲介切除	1 (<1)	0	0	0
静脈ステント挿入	0	0	1 (<1)	0
社会環境	3 (<1)	1 (<1)	0	0
元タバコ使用者	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 176 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
乳房腫瘤摘除	0	0	0	0
子宮頚部円錐切除	0	0	0	0
嚢胞ドレナージ	0	0	0	0
デンタルケア	0	0	0	0
女性不妊手術	0	0	0	0
ヘルニア修復	0	0	0	0
入院	0	0	0	0
子宮摘出	0	0	0	0
椎間板手術	0	0	0	0
治療食	0	0	0	0
色素性母斑切除	0	0	0	0
不妊手術	0	0	0	0
抜歯	0	0	0	0
鼻甲介切除	0	0	0	0
静脈ステント挿入	0	0	0	0
社会環境	0	0	0	0
元タバコ使用者	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 177 of 178

	Irrespective of causal association			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
閉経	0	1 (<1)	0	0
社会問題	1 (<1)	0	0	0
職場でのストレス	1 (<1)	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015

Incidence of adverse events by system organ class and preferred term and causal association to study drug:
Studies 109MS301 and 109MS302
Page 178 of 178

	Causal association cannot be ruled out			
	Placebo (N=771)	BG00012 240 mg BID (N=769)	BG00012 240 mg TID (N=760)	GA (N=351)
閉経	0	0	0	0
社会問題	0	0	0	0
職場でのストレス	0	0	0	0

NOTE 1: Numbers in parentheses are percentages.
2: Data after subjects switched to alternative MS medications are excluded.
3: A subject was counted only once within each system organ class or preferred term.

SOURCE: BG12MS/JAPAN/ISS/T-AE-SOCPT-CAUS-A.SAS DATE: 02DEC2015